PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	COX, LS; MIDGLEY, CA; LANE, DP				COX, LS; MIDGLEY, CA; LANE, DP			XENOPUS P53 IS BIOCHEMICALLY SIMILAR TO THE HUMAN TUMOR-SUPPRESSOR PROTEIN P53 AND IS INDUCED UPON DNA-DAMAGE IN SOMATIC-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CASEIN KINASE-II; LARGE T-ANTIGEN; PURIFIED DNA; FREE-EXTRACT; SV40-TRANSFORMED CELLS; REPLICATION OCCURS; GENE AMPLIFICATION; NUCLEAR-ENVELOPE; BINDING FUNCTION	Xenopus p53 cDNA, homologous to the human tumour suppressor p53, has previously been cloned from oocyte and gastrula libraries. In this report, we describe a polyclonal antibody 2674 raised against Xenopus p53 (Xp53) expressed in bacteria, that recognises proteins of approximately 52, 46 and 35 kDa present in Xenopus oocytes, parthenogenically activated eggs and in somatic tissue culture cells. We report here purification of Xp53 from insect cells infected with XpS3-baculovirus, and this protein is shown to be phosphorylated by casein kinase II but has low sequence-specific DNA binding activity. Using similar purification conditions, we have isolated endogenous Xp53, shelving that Xenopus eggs contain high levels of p53 protein. Xp53 from eggs binds to the p53-specific DNA-binding consensus sequence. Two dimensional gel analysis indicates that Xp53 from eggs may exist in various states of phosphorylation. u.v.-induced DNA damage of somatic Xenopus cells results in accumulation of Xp53. We suggest that the high levels of putative Xp53 detected in eggs may represent maternal stockpiles of a protein necessary to protect rapidly dividing cells from the effects of DNA damage.			COX, LS (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Cox, Lynne/AAT-2047-2021; Lane, David P/C-4920-2008	Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545				BACHVAROVA R, 1966, J EXP ZOOL, V163, P285, DOI 10.1002/jez.1401630307; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1992, J CELL SCI, V101, P43; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1990, J CELL SCI, V97, P177; Davidson E. H., 1986, GENE ACTIVITY EARLY; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARVEY M, 1993, ONCOGENE, V8, P2457; HOEVER M, 1994, ONCOGENE, V9, P109; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLS AD, 1989, J CELL SCI, V94, P471; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2951	2959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084598				2022-12-25	WOS:A1994PG82200021
J	CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR				CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR			EXPRESSION OF LINEAGE RESTRICTED TRANSCRIPTION FACTORS PRECEDES LINEAGE-SPECIFIC DIFFERENTIATION IN A MULTIPOTENT HEMATOPOIETIC PROGENITOR-CELL LINE	ONCOGENE			English	Note							LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL LOCALIZATION; ERYTHROLEUKEMIA CELLS; STEM-CELLS; SCL GENE; GATA-1; ONCOGENE; CLONING; GROWTH	Lineage commitment and differentiation are likely to be coordinated by the combined effects of multiple transcription factors acting on numerous different target genes. The mechanisms by which lineage-restricted patterns of transcription factor expression are established are therefore of particular relevance to our understanding of the role of transcription factors both in normal development and in oncogenesis. Here, we report that the genes for the lineage-restricted transcription factors SCL, GATA-1 and GATA-2 are expressed in all multipotent, IL-3-dependent, haemopoietic progenitor cell lines tested. Moreover, a liquid differentiation assay has been used to demonstrate down regulation of SCL, GATA-1, GATA-2 and PU-1 during differentiation into non-expressing lineages. These data support the concept that multiple lineage-restricted transcription factors are expressed prior to lineage commitment.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge	CROSS, MA (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND.			Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218; Cross, Michael/0000-0002-8815-7621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HARRISON PR, 1978, EXP CELL RES, V115, P395, DOI 10.1016/0014-4827(78)90293-8; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEONARD M, 1993, BLOOD, V82, P1071; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3013	3016						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084606				2022-12-25	WOS:A1994PG82200029
J	NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M				NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M			RAS-DEPENDENT AND RAF-DEPENDENT ACTIVATION OF C-JUN TRANSCRIPTIONAL ACTIVITY BY THE HEPATITIS-B VIRUS TRANSACTIVATOR PX	ONCOGENE			English	Article							X-GENE PRODUCT; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; CELLS; PHOSPHORYLATION; EXPRESSION; PROTOONCOGENE; PROMOTERS; SERINE-63; GROWTH	The mechanisms by which pX, the transactivator of the Hepatitis B Virus (HBV), exerts its effects on transcription of viral and cellular genes have not yet been fully clarified. While previous reports suggested the possibility of a direct interaction of pX, which lacks intrinsic DNA-binding activity, with components of the cellular transcription machinery, more recent investigations support the hypothesis that pX might activate cellular kinases involved in transcriptional regulation and growth control. We analysed the mechanisms of c-Jun transcription factor activation by pX and in particular the role of cellular proteins involved in the transduction of mitogenic signals (namely Ha-Ras and Raf-1). In both HeLa and undifferentiated F9 cells pX was able to increase the activity of exogenous transfected c-Jun but not of c-Jun proteins bearing mutations in the serine residues located in the amino-terminal transcriptional activation domain. We show by use of Ha-Ras and Raf-1 dominant negative mutants that both Ha-Ras and Raf-1 are required for pX-induced activation of c-Jun transcriptional activity. In addition we show that pX is able to cooperate with Raf-1 in c-Jun activation. Our results are consistent with the hypothesis that at least one site of action of pX is peripheral and is located upstream of the Ras genes products.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of Cagliari; University of L'Aquila	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,IST CLIN MED 1,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095; Levrero, Massimo/0000-0002-4978-0875				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1994, IN PRESS J HEPATOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEASLEY RP, 1981, LANCET, V2, P1129; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEITELSON MA, 1993, ONCOGENE, V8, P1109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEE TH, 1991, J VIROL, V65, P5939; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; SCHEK N, 1991, ONCOGENE, V6, P1735; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TAKADA S, 1994, ONCOGENE, V9, P341; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	46	127	128	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2837	2843						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084589				2022-12-25	WOS:A1994PG82200009
J	NEMERE, I; DORMANEN, MC; HAMMOND, MW; OKAMURA, WH; NORMAN, AW				NEMERE, I; DORMANEN, MC; HAMMOND, MW; OKAMURA, WH; NORMAN, AW			IDENTIFICATION OF A SPECIFIC BINDING-PROTEIN FOR 1-ALPHA,25-DIHYDROXYVITAMIN D-3 IN BASAL-LATERAL MEMBRANES OF CHICK INTESTINAL EPITHELIUM AND RELATIONSHIP TO TRANSCALTACHIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLITES; CALCIUM-TRANSPORT; PARATHYROID-HORMONE; RAPID STIMULATION; ALKALINE-PHOSPHATASE; PERFUSED DUODENA; GENE-EXPRESSION; RAT INTESTINE; 1,25-DIHYDROXYVITAMIN-D3; CELLS	The steroid hormone 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25-(OH)(2)D-3) elicits biological responses by both genomic and nongenomic pathways. This report describes purification of a receptor for 1 alpha,25-(OH)(2)D-3 (VDR) located in the basal-lateral membrane (BLM) of vitamin D-replete chick intestinal epithelium, which is implicated in the nongenomic stimulation of calcium transport (transcaltachia). The BLM-VDR exhibited saturable binding for [H-3]1,25-(OH)(2)D-3 (K-D = 0.72 x 10(-9) M, B-max = 0.24 pmol/mg of protein). A 4500-fold purification of the BLM-VDR receptor was achieved. In addition, saturable binding was observed for [H-3]24R,25-(OH)(2)D-3 at physiologically relevant levels (K-D = 19 x 10(-9) M, B-max = 2.4 pmol/mg of protein) to a component apparently distinct from the 1 alpha 25-(OH)(2)D-3 BLM-VDR. A functional correlation between the BLM-VDR and transcaltachia was observed in three experimental situations: (i) vitamin D deficiency, which suppresses transcaltachia, resulted in reduced specific [H-3]1 alpha,25-(OH)(2)D-3 binding in the BLM-VDR, relative to corresponding fractions from vitamin D-replete chicks; (ii) the BLM-VDR exhibited down-regulation of specific [H-3]1 alpha,25-(OH)(2)D-3 binding following exposure to nonradioactive 1 alpha,25-(OH)(2)D-3; and (iii) the relative potencies of two ''6-s-cis'' analogs of 1 alpha,25-(OH)(2)D-3 to initiate transcaltachia and their ability to compete with [H-3]1 alpha,25-(OH)(2)D-3 for binding to the BLM-VDR were parallel. The combined results support the existence of a plasmalemmal 1 alpha,25-(OH)(2)D-3 receptor which is a prime candidate for signal transduction in transcaltachia.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside			Nemere, Ilka/A-7077-2008		NIDDK NIH HHS [DK 09012-28, DK 16-595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016595, R37DK009012, R01DK009012] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAN DT, 1990, J BONE MINER RES, V5, P517, DOI 10.1002/jbmr.5650050514; BARSONY J, 1991, P NATL ACAD SCI USA, V88, P1436, DOI 10.1073/pnas.88.4.1436; BENNASR L, 1988, ENDOCRINOLOGY, V123, P1778, DOI 10.1210/endo-123-4-1778; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2783; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; DEBOLAND AR, 1987, ENDOCRINOLOGY, V120, P1858, DOI 10.1210/endo-120-5-1858; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P39, DOI 10.1210/endo-127-1-39; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P2475, DOI 10.1210/endo-127-5-2475; Desai S S, 1986, J Bone Miner Res, V1, P497; DORMANEN MC, 1994, BIOCHEM BIOPH RES CO, V201, P394, DOI 10.1006/bbrc.1994.1714; HENRY HL, 1978, SCIENCE, V201, P835, DOI 10.1126/science.684411; HORST RL, 1981, ANAL BIOCHEM, V116, P189, DOI 10.1016/0003-2697(81)90344-4; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; NEMERE I, 1993, RECEPTOR, V3, P277; NEMERE I, 1981, ENDOCRINOLOGY, V109, P2180, DOI 10.1210/endo-109-6-2180; NEMERE I, 1981, ENDOCRINOLOGY, V108, P1450, DOI 10.1210/endo-108-4-1450; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; NEMERE I, 1986, J BIOL CHEM, V261, P6106; NEMERE I, 1986, ENDOCRINOLOGY, V119, P1406, DOI 10.1210/endo-119-3-1406; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V123, P2878, DOI 10.1210/endo-123-6-2878; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; SOMJEN D, 1983, BIOCHEM J, V214, P263; THEOFAN G, 1986, J BIOL CHEM, V261, P6943; WALI RK, 1992, AM J PHYSIOL, V262, pG945, DOI 10.1152/ajpgi.1992.262.6.G945; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X; WILHELM F, 1985, J BIOL CHEM, V260, P87; YOSHIMOTO Y, 1986, J STEROID BIOCHEM, V25, P905, DOI 10.1016/0022-4731(86)90322-5; ZHOU LX, 1992, J BONE MINER RES, V7, P457	31	276	283	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23750	23756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089147				2022-12-25	WOS:A1994PQ34500056
J	DAVIS, R; THELANDER, M; MANN, GJ; BEHRAVAN, G; SOUCY, F; BEAULIEU, P; LAVALLEE, P; GRASLUND, A; THELANDER, L				DAVIS, R; THELANDER, M; MANN, GJ; BEHRAVAN, G; SOUCY, F; BEAULIEU, P; LAVALLEE, P; GRASLUND, A; THELANDER, L			PURIFICATION, CHARACTERIZATION, AND LOCALIZATION OF SUBUNIT INTERACTION AREA OF RECOMBINANT MOUSE RIBONUCLEOTIDE REDUCTASE R1 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ESCHERICHIA-COLI; CARBOXYL TERMINUS; CALF THYMUS; PROTEIN R2; IRON; ENZYME; QUANTITIES; INHIBITION; SEPARATION	Mammalian ribonucleotide reductase is a heterotetramer formed by the two non-identical homodimers proteins R1 and R2. We have succeeded in expressing the 90-kDa mouse R1 protein in Escherichia coli in an active, soluble form using the T7 RNA polymerase pET vector system. To avoid inclusion bodies, the bacteria were grown at 15 degrees C with minimal concentration of the inducer isopropyl-1-thio-beta-D-galactopyranoside. After a rapid purification procedure, approximately 20 mg of pure R1 protein were obtained per liter of bacterial culture. The concentrated R1 protein solution had a pinkish red color. Spectroscopy in combination with iron and labile sulfur analyses demonstrated that the color originated from an iron-sulfur complex. However, all attempts to demonstrate a function of this complex have been inconclusive. A comparison of the recombinant R1 protein with the corresponding protein purified from calf thymus showed no evidence for glycosylation. Circular dichroism spectroscopy indicated an alpha-helical content of 50%. A flexible COOH-terminal tail of 7 residues in the R2 protein was earlier shown to be essential for binding to the R1 protein. Using a peptide protection assay and photoaffinity labeling, we now show that the R2 protein tail interacts with a region close to the carboxyl terminus of the R1 protein.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; BIOMEGA INC,BOEHRINGER INGELHEIM RES INC,LAVAL H7S 2G5,PQ,CANADA	Umea University; Boehringer Ingelheim			Mann, Graham J/G-4758-2014	Mann, Graham J/0000-0003-1301-405X				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1985, J BIOL CHEM, V260, P7015; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; CONNER J, 1993, BIOCHEMISTRY-US, V32, P13673, DOI 10.1021/bi00212a036; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FILATOV D, 1992, J BIOL CHEM, V267, P15816; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P251; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KROGSRUD RL, 1993, ANAL BIOCHEM, V213, P386, DOI 10.1006/abio.1993.1436; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCLEMENTS W, 1988, VIROLOGY, V162, P270, DOI 10.1016/0042-6822(88)90421-7; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; PALMER G, 1973, IRON SULFUR PROTEINS, V2, P285; PARADIS H, 1991, J BIOL CHEM, V266, P9647; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SALEM JS, 1993, FEBS LETT, V323, P93, DOI 10.1016/0014-5793(93)81455-9; Sambrook J, 1989, MOL CLONING LABORATO; SIKORSKA M, 1990, BIOCHEM CELL BIOL, V68, P880, DOI 10.1139/o90-130; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1980, J BIOL CHEM, V255, P7426; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER M, 1985, J BIOL CHEM, V260, P2737; UHLIN U, 1994, IN PRESS NATURE; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	37	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23171	23176						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083221				2022-12-25	WOS:A1994PQ16400043
J	MACK, MM; MOLINSKI, TF; BUCK, ED; PESSAH, IN				MACK, MM; MOLINSKI, TF; BUCK, ED; PESSAH, IN			NOVEL MODULATORS OF SKELETAL-MUSCLE FKBP12 CALCIUM-CHANNEL COMPLEX FROM IANTHELLA-BASTA - ROLE OF FKBP12 IN CHANNEL GATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE CHANNEL; RYANODINE BINDING-SITES; SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; MOLECULAR-CLONING; H-3 RYANODINE; RECEPTOR; SENSITIVITY; BRAIN; CDNA	Macrocyclic natural products derived from bromotyrosine isolated from the sponge Ianthella basta are shown to selectively modulate the skeletal isoform of the ryanodine-sensitive sarcoplasmic reticulum calcium channel by a novel mechanism involving the FKBP12/ RyR-1 complex. Bastadins 5, 7, and the newly identified isomer of bastadin 5, bastadin 19, show marked differences in potency and efficacy toward activation of the binding of [H-3]ryanodine. In physiological salt, bastadin 5 (5 mu M) increases the [H-3]ryanodine binding capacity of SR membranes 5-fold, by stabilizing the high affinity conformation of RyR-1 for ryanodine without shifting the affinity of the activator site for Ca2+ or altering the response to caffeine or adenine nucleotides. Bastadin 5 decreases the inhibitory potency of Mg2+ 8-fold and high (> 100 mu M) Ca2+ 5-fold. Bastadin 5 inhibits Ca2+ uptake into SR vesicles and enhances Ca2+-induced Ca2+ release 8-fold. Bastadin 5 increases single-channel open dwell time, tau(1) and tau(2) 65- and 92-fold, respectively, without changing unitary conductance for Cs+ (450 picosiemans) or open probability. Most significant is the finding that the unique actions of bastadin 5 on [H-3]ryanodine binding and Ca2+ transport are antagonized by the immunosuppressant FK506. FK506 alone weakly enhances the binding of [H-3]ryanodine, compared to bastadin 5. However, FK506 diminishes bastadin 5-induced changes in [H-3]ryanodine binding and Ca2+ transport without altering the efficacy of adenine nucleotides. Unlike FK506, bastadin 5 does not directly promote the dissociation of FKBP12 from the RyR-1 membrane complex; however, it markedly enhances the release of FKBP12 induced by FK506, These results suggest that the bastadin 5 effector site is a novel modulatory domain on FKBP12. Bastadins represent a new class of compounds to gain insight into the functional interactions between FKBP12 and RyR-1.	UNIV CALIF DAVIS, SCH VET MED, DEPT MOLEC BIOSCI, DIV PHARMACOL & TOXICOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis			Pessah, Isaac N/K-7985-2017; Molinski, Tadeusz F/P-2125-2018	Pessah, Isaac N/0000-0002-8149-588X; 	NIEHS NIH HHS [ES07059, ES05002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005002, R01ES005002, T32ES007059] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CARNEY JR, 1993, J NAT PROD, V56, P153, DOI 10.1021/np50091a025; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; DEXTER AF, 1993, J NAT PROD, V56, P782, DOI 10.1021/np50095a020; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; KAZLAUSKAS R, 1981, AUST J CHEM, V34, P765, DOI 10.1071/CH9810765; KUPCHAN SM, 1973, J ORG CHEM, V38, P178, DOI 10.1021/jo00941a049; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAI FA, 1989, J BIOL CHEM, V264, P16776; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MIAO S, 1990, J NAT PROD, V53, P1441, DOI 10.1021/np50072a007; MICKELSON JR, 1992, FEBS LETT, V301, P49, DOI 10.1016/0014-5793(92)80208-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; PORDESIMO EO, 1990, J ORG CHEM, V55, P4704, DOI 10.1021/jo00302a041; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WANG JP, 1993, J BIOL CHEM, V268, P20974; WATERHOUSE AL, 1984, J CHEM SOC CHEM COMM, P1265, DOI 10.1039/c39840001265; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	48	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23236	23249						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083229				2022-12-25	WOS:A1994PQ16400052
J	MISRAPRESS, A; COOKE, NE; LIEBHABER, SA				MISRAPRESS, A; COOKE, NE; LIEBHABER, SA			COMPLEX ALTERNATIVE SPLICING PARTIALLY INACTIVATES THE HUMAN CHORIONIC SOMATOMAMMOTROPIN-LIKE (HCS-L) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE-VARIANT; PLACENTAL-LACTOGEN GENES; MESSENGER-RNA; EXPRESSION; EVOLUTION; DISTINCT; DELETION; PREDICT; CLUSTER; CLONING	The human growth hormone/human chorionic somatomammotropin (hGH/hCS) gene cluster contains five genes: hGH-N, hGH-V, hCS-A, hCS-B, and hCS-L. The expression of the first four genes has been well documented. In contrast, the hCS-L gene has been considered a pseudogene inactivated by loss of the normal intron 2 splice donor site. Previously our laboratory has shown that hCS-L transcripts are present in human placenta and that their levels are induced during the second trimester. More detailed studies of hCS-L transcript processing and mRNA structure are hindered by overwhelming levels of the structurally similar hCS-A and hCS-B transcripts in the placenta. To circumvent this problem, we have established stably transfected cell lines selectively expressing the hCS-L gene. Analysis of hCS-L mRNA from these cell lines demonstrates at least five major alternative splicing pathways, four of which could be confirmed qualitatively by parallel analysis of placental RNA. This analysis reveals an unexpectedly high frequency of exon 2 skipping (73%) as well as utilization of three competing exon 3 splice acceptor sites. Since exon 2 encodes the signal peptide, the majority of hCS-L transcripts are unable to express a secreted protein. Three of the defined hCS-L mRNAs contain an extended open reading frame similar to that present in the functional GH and CS genes. All three of these hCS-L transcripts are of minor abundance and only two, hCS-L(L) and hCS-L(L'), contain exon 2. In vitro translation and signal peptide processing of hCS-L(L) mRNA yields a 20-kDa hCS-L isoform in vitro. These data confirm the placental expression of the hCS-L gene, demonstrate surprising complexity in the splicing of its transcripts, predict that the majority of processed hCS-L mRNAs are nonfunctional, and identify specific, low abundance mRNAs that may encode novel gestational hormones.	UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania					PHS HHS [R01 25147] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRERASALDANA HA, 1983, J BIOL CHEM, V258, P3787; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; COOKE NE, 1988, J BIOL CHEM, V263, P9001; COOKE NE, 1988, J CLIN INVEST, V82, P270, DOI 10.1172/JCI113582; COOKE NE, 1992, TROPHOBLAST CELLS PA, P222; FRANKENNE F, 1988, J CLIN ENDOCR METAB, V66, P1171, DOI 10.1210/jcem-66-6-1171; GEORGE DL, 1981, HUM GENET, V57, P138; GOLOS TG, 1993, ENDOCRINOLOGY, V133, P1744, DOI 10.1210/en.133.4.1744; GOOSSENS M, 1986, J CLIN ENDOCR METAB, V62, P712, DOI 10.1210/jcem-62-4-712; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; LIEBHABER SA, 1984, J BIOL CHEM, V259, P5597; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; MACLEOD JN, 1991, ENDOCRINOLOGY, V128, P1298, DOI 10.1210/endo-128-3-1298; PRESS RD, 1989, CANCER RES, V49, P2914; RAY J, 1990, J BIOL CHEM, V265, P7939; RESENDEZPEREZ D, 1990, NUCLEIC ACIDS RES, V18, P4665, DOI 10.1093/nar/18.16.4665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELVANAYAGAM CS, 1984, J BIOL CHEM, V259, P4642; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WURZEL JM, 1982, DNA-J MOLEC CELL BIO, V1, P251, DOI 10.1089/dna.1.1982.1.251	24	34	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23220	23229						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083227				2022-12-25	WOS:A1994PQ16400050
J	ZWERSCHKE, W; ROTTJAKOB, HW; KUNTZEL, H				ZWERSCHKE, W; ROTTJAKOB, HW; KUNTZEL, H			THE SACCHAROMYCES-CEREVISIAE CDC6 GENE IS TRANSCRIBED AT LATE MITOSIS AND ENCODES A ATP/GTPASE CONTROLLING S-PHASE INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; SIGNAL-TRANSDUCTION PATHWAY; DNA-REPLICATION GENES; CELL-CYCLE CONTROL; BUDDING YEAST; SUBCELLULAR-LOCALIZATION; MATING PHEROMONE; PROTEIN-KINASE; CALF THYMUS; PURIFICATION	We have compared the periodic fluctuation of mRNAs encoded by CDC6, a cell cycle gene controlling initiation of DNA replication, and CLN1, a G(1), cyclin gene expressed at late G(1). The maxima of CDC6 mRNA precede those of CLN1 mRNA by about 15 min in cells synchronized by release from pheromone arrest or from a cdc15 thermal arrest. CDC6 mRNA accumulates in cdc15-arrested telophase cells, decays around cell separation, and reappears during telophase and nuclear division of the next cycle. CDC6 transcription at late mitosis is not affected by the pheromone signaling pathway. The CDC6 mRNA fluctuation pattern is imposed to a CLN1-derived reporter gene if fused to the CDC6 promoter. The CDC6 gene was expressed in Escherichia coli as a glutathione-S-transferase fusion protein and purified by affinity chromatography. The Cdc6 protein binds rATP and rGTP upon UV cross-linking and catalyzes the DNA-independent hydrolysis of purine nucleoside triphosphates, but does not appear to interact directly with DNA. The Cdc6 protein may control the ATP-dependent initiation of replication by conferring ATPase activity to an origin-recognizing complex.	MAX PLANCK INST EXPTL MED,D-37075 GOTTINGEN,GERMANY	Max Planck Society				Zwerschke, Werner/0000-0003-1137-2953				ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; DEWET JR, 1986, METHOD ENZYMOL, V133, P3; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KUNTZEL H, 1994, IN PRESS PROGR NUCLE, V48; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LISZIEWICZ J, 1987, J BIOL CHEM, V262, P2549; LISZIEWICZ J, 1989, NARES, V16, P11507; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MOIR D, 1982, GENETICS, V100, P547; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PALMER RE, 1990, GENETICS, V125, P763; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE D, 1990, METHODS YEAST GENETI; ROTTJAKOB HW, 1993, THESIS U GOTTINGEN G; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAYERS J, 1988, GENETIC ENG, P109; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; ZHOU C, 1993, DNA CELL BIOL, V12, P363, DOI 10.1089/dna.1993.12.363; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZWERSCHKE W, 1994, THESIS GOTTINGEN	51	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23351	23356						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083240				2022-12-25	WOS:A1994PQ16400068
J	ARTIGUES, A; IRIARTE, A; MARTINEZCARRION, M				ARTIGUES, A; IRIARTE, A; MARTINEZCARRION, M			ACID-INDUCED REVERSIBLE UNFOLDING OF MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CONFORMATIONAL STATES; FERRICYTOCHROME-C; FOLDING REACTIONS; SMALL PROTEINS; PRECURSOR; FORMS; PH; INTERMEDIATE; SPECTROSCOPY	The acid-induced reversible unfolding of several forms of the mitochondrial isoenzyme of mammalian aspartate aminotransferase, including its precursor form, has been characterized under equilibrium conditions. A minimum of two transitions can be detected for the holoenzyme (pyridoxal form). One transition takes place at pH 3.6 and corresponds to the monomerization of the dimeric protein. The second transition is centered at pH 3.3 and represents the disappearance of much of the tertiary and secondary structures. The presequence peptide in the precursor protein does not affect the equilibria nor the rate of unfolding in the pH range from 7.5 to 2.0, The presence of the cofactor, pyridoxal 5'-phosphate, stabilizes the protein against acid denaturation. At pH 2.0, the protein retains significant amounts of secondary structure (26% alpha-helix, 20% beta-structure). Increasing the ionic strength at pH 2.0 results in significant changes in the secondary structure of the unfolded protein that acquires some of the characteristics ascribed to a compact molten globule. According to the circular dichroism spectra these changes are characterized by an increase in beta-structure, although Fourier transform infrared spectroscopy analysis indicates that this increase in beta-structure is due mostly to the formation of intermolecular beta-sheet as a consequence of protein aggregation. The formation of high molecular weight aggregates has been confirmed by analytical ultracentrifugation, Following neutralization of the acid-unfolded state at low ionic strength both mature and precursor proteins refold to their native active state (> 80% yield). By contrast the compact state present at pH 2.0 and high ionic strength is unable to recover its activity following neutralization. Thus, this compact state does not appear to represent an intermediate in the folding pathway of the protein, but rather a dead end product of aggregation, which may reflect the intrinsic tendencies of the unfolded protein to oligomerize at intracellular salt con centrations unless controlled by factors such as chaperones present in the cellular environment.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038184, R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38184, GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARAKAWA T, 1987, BIOCHEMISTRY-US, V26, P5428, DOI 10.1021/bi00391a032; AUNE KC, 1967, J BIOL CHEM, V242, P4486; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BISMUTO E, 1992, ARCH BIOCHEM BIOPHYS, V298, P624, DOI 10.1016/0003-9861(92)90458-9; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; BYLER DM, 1988, J IND MICROBIOL, V3, P73, DOI 10.1007/BF01569549; CHEN HM, 1992, BIOCHEMISTRY-US, V31, P12369, DOI 10.1021/bi00164a011; CHENG S, 1972, J BIOL CHEM, V247, P6597; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DYSON HJ, 1982, J BIOL CHEM, V257, P2267; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FELISS N, 1970, BIOCHEM BIOPH RES CO, V40, P932, DOI 10.1016/0006-291X(70)90993-9; FINK AL, 1991, CONFORMATIONS FORCES, P169; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P107; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JOHNSTON JP, 1946, T FARADAY SOC, V42, P789, DOI 10.1039/tf9464200789; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MARTINEZ, 1970, J BIOL CHEM, V245, P799; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MARTINEZCARRION M, 1970, BIOCHEMISTRY-US, V9, P2574, DOI 10.1021/bi00815a004; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; RALSTON G, 1993, INTRO ANAL ULTRACENT, P23; RAMALIGAN K, 1992, BIOPOLYMERS, V32, P9881; REYES AM, 1993, J BIOL CHEM, V268, P22281; SADLER PJ, 1993, EUR J BIOCHEM, V212, P811, DOI 10.1111/j.1432-1033.1993.tb17722.x; SANCHEZRUIZ JM, 1986, BIOCHEMISTRY-US, V25, P2915, DOI 10.1021/bi00358a027; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P3338, DOI 10.1021/bi00409a033; SANCHEZRUIZ JM, 1991, ARCH BIOCHEM BIOPHYS, V286, P38, DOI 10.1016/0003-9861(91)90006-5; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHACHMAN UK, 1959, ULTRACENTRIFUGATION; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P4604, DOI 10.1021/bi00068a017; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; STELLWAGEN E, 1975, BIOCHEMISTRY-US, V14, P5135, DOI 10.1021/bi00694a018; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TANFORD C, 1967, PHYSICAL CHEM MACROM, P364; WEST SM, 1989, BIOCHEM J, V261, P189, DOI 10.1042/bj2610189	58	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21990	21999						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071319				2022-12-25	WOS:A1994PE09800013
J	BANVILLE, D; AHMAD, S; STOCCO, R; SHEN, SH				BANVILLE, D; AHMAD, S; STOCCO, R; SHEN, SH			NOVEL PROTEIN-TYROSINE-PHOSPHATASE WITH HOMOLOGY TO BOTH THE CYTOSKELETAL PROTEINS OF THE BAND-4.1 FAMILY AND JUNCTION-ASSOCIATED GUANYLATE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; PHOSPHOTYROSINE PHOSPHATASE; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; SH2 DOMAIN; EZRIN-LIKE; EXPRESSION; DROSOPHILA; IDENTIFICATION	Reversible phosphorylation of proteins on tyrosine residues is critical in several cellular activities. The removal of the phosphate groups from tyrosine-phosphorylated proteins is accomplished by a class of enzymes which constitute a large family of related proteins, the protein tyrosine phosphatases. We report here the isolation of a complementary DNA encoding a novel protein tyrosine phosphatase, which we termed hPTP1E. Several overlapping cDNA clones were isolated to reconstruct a sequence of 8301 nucleotides. Northern blot analysis of poly(A)(+) RNA from different human tissues revealed the presence of a mRNA of 8.2-8.5 kilobases suggesting the near full-length sequence had been cloned. The composite hPTP1E cDNA contains an open reading frame encoding 2490 amino acid residues, The predicted protein (M(r) = 277,567) does not contain a signal peptide or a membrane-spanning region and possesses a single catalytic domain (amino acids 2241-2470). The recombinant phosphatase domain has been expressed in Escherichia coli, purified to near homogeneity and showed to possess specific protein tyrosine phosphatase activity. The primary structure of hPTP1E also displays homology to cytoskeleton- and membrane junction-associated proteins. Thus, the region encompassing amino acids 568-1053 is related to the cytoskeletal proteins of the band 4.1 family. In addition, hPTP1E contains five imperfect repeats possessing significant homology to the GLGF repeats of the junction-associated guanylate kinases such as the Drosophila discs-large tumor suppressor gene (dlg-1). The structural features of hPTP1E suggest that it localizes at the junction between the plasma membrane and the cytoskeleton where it may regulate signal transduction and cytoskeletal integrity.	UNIV CALGARY, DEPT PHARMACOL & THERAPEUT, CALGARY T2N 4N1, AB, CANADA	University of Calgary	BANVILLE, D (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, PHARMACEUT BIOTECHNOL SECTOR, 6100 ROYALMOUNT AVE, MONTREAL H4P 2R2, PQ, CANADA.							AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DUNSTER LM, 1994, VIROLOGY, V198, P265, DOI 10.1006/viro.1994.1029; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1989, ONCOGENES MOL ORIGIN, P147; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NEGRINI M, 1994, CANCER RES, V54, P1331; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO N, 1992, J CELL SCI, V103, P131; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; THOMAS ML, 1985, CELL, V41, P83, DOI 10.1016/0092-8674(85)90063-7; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHAO Z, 1993, P NATL ACAD SCI USA, V268, P2816	57	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22320	22327						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071359				2022-12-25	WOS:A1994PE09800060
J	WILLIAMS, ME; MARUBIO, LM; DEAL, CR; HANS, M; BRUST, PF; PHILIPSON, LH; MILLER, RJ; JOHNSON, EC; HARPOLD, MM; ELLIS, SB				WILLIAMS, ME; MARUBIO, LM; DEAL, CR; HANS, M; BRUST, PF; PHILIPSON, LH; MILLER, RJ; JOHNSON, EC; HARPOLD, MM; ELLIS, SB			STRUCTURE AND FUNCTIONAL-CHARACTERIZATION OF NEURONAL ALPHA(1E) CALCIUM-CHANNEL SUBTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; P-TYPE; MOLECULAR DIVERSITY; SKELETAL-MUSCLE; BETA-SUBUNIT; PHARMACOLOGICAL PROPERTIES; PERIPHERAL NEURONS; OMEGA-CONOTOXIN; PITUITARY-CELLS; CDNA LIBRARIES	We have cloned overlapping cDNAs encoding alpha(1E) Ca2+ channel subunits from mouse and human brain. We observed that these alpha(1E) transcripts were widely distributed in the central nervous system. We also demonstrated the existence of two variants of the human alpha(1E) subunit. Comparison of the sequence of these alpha(1E) subunits to those from other species suggests that at least four alternatively spliced variants of alpha(1E) exist. Expression of human alpha(1E) in HEK293 cells and Xenopus oocytes produced high voltage activated Ca2+ currents that inactivated rapidly (tau similar to 20 ms at 0 mV). The size of the currents obtained were enhanced similar to 40-fold by co-expression with human neuronal alpha(2) and beta Ca2+ channel subunits. alpha(1E) currents were insensitive to the drugs and toxins previously used to define other classes of voltage-activated Ca2+ channels. Thus, alpha(1E)-mediated Ca2+ channels appear to be a pharmacologically distinct class of voltage-activated Ca2+ channels.	UNIV CHICAGO, DEPT PHYSIOL & PHARMACOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	WILLIAMS, ME (corresponding author), SIBIA INC, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040165, R37MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-02121] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NIMH NIH HHS [MH-40165] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Battey, 1986, BASIC METHODS MOL BI; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL WA, 1993, ANN NY ACAD SCI, V681, P342, DOI 10.1111/j.1749-6632.1993.tb22913.x; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V456, P107, DOI 10.1113/jphysiol.1992.sp019329; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERRINGTON J, 1992, J NEUROPHYSIOL, V68, P213, DOI 10.1152/jn.1992.68.1.213; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Innis MA, 1990, PCR PROTOCOLS GUIDE; LAPEYRE B, 1985, GENE, V37, P215, DOI 10.1016/0378-1119(85)90275-6; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MILLER RJ, 1993, CURR BIOL, V3, P481, DOI 10.1016/0960-9822(93)90364-T; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	38	246	266	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22347	22357						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071363				2022-12-25	WOS:A1994PE09800064
J	CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH				CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH			A STUDY OF STABILIZATION OF P53 PROTEIN VERSUS POINT MUTATION IN COLORECTAL-CARCINOMA	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; MONOCLONAL-ANTIBODIES; TISSUE-SECTIONS; BREAST-CANCER; WILD-TYPE; EXPRESSION; ANTIGEN	Abnormalities of the p53 tumour suppressor gene occur in many types of cancer including approximately 60% of colorectal carcinomas. This study investigates in 47 colorectal carcinomas the relationship between stabilised p53 protein detected by immunocytochemistry (ICC), and p53 mutation. 27 cases stained positively with the antibody PAb1801. Sequencing of exons 5-8 revealed 19 mutations in 18 of these cases (one tumour contained two different mutations). A rapid, non-radioactive method was developed to screen for mutations in this region of the gene involving Single Strand Conformational Polymorphism analysis (SSCP) and a MspI restriction digestion. This screen detected 17/19 (89%) of the sequenced mutations, and a further four mutations in 20 PAb1801 negative cases that were confirmed by sequencing. Reproducibility of ICC in detecting stabilised protein was assessed by restaining the 47 cases with the antibody DO7 after pre-treatment to optimise detection. Fewer cases were negative with DO7 although overall concordance with PAb1801 was good. A substantial proportion of carcinomas with stabilised p53 as detected by ICC do not contain mutations in exons 5-8, whilst some mutations (the majority in exon 6) are not associated with stabilisation.			CRIPPS, KJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			Purdie, Colin/0000-0002-1258-4010				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUNN JM, 1993, BRIT J SURG, V80, P1410, DOI 10.1002/bjs.1800801118; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1993, ONCOGENE, V8, P203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PURDIE CA, 1991, AM J PATHOL, V138, P807; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUEZ NR, 1990, P NATL ACAD SCI USA, V89, P12028; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SOUSSI T, 1990, ONCOGENE, V5, P945; TENERIELLO MG, 1993, CANCER RES, V53, P3101; TOMINAGA O, 1993, ONCOGENE, V8, P2653; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	35	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2739	2743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058340				2022-12-25	WOS:A1994PC05400038
J	SEWING, A; MULLER, R				SEWING, A; MULLER, R			PROTEIN-KINASE-A PHOSPHORYLATES CYCLIN D1 AT 3 DISTINCT SITES WITHIN THE CYCLIN BOX AND AT THE C-TERMINUS	ONCOGENE			English	Note							RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; CELL-CYCLE; BINDING; ACTIVATION; SEQUENCES; PHASE; G(1)	Cyclin D1 is a nuclear phosphoprotein that is thought to play a major role in the control of G(0)/G(1)-->S progression. The fact that its expression is not tightly regulated during cell cycle progression suggests that its activity might be modulated by post-translational mechanisms. In the present study, we show that out of five serine-threonine kinases tested only protein kinase A (PKA) was able to phosphorylate cyclin D1 in vitro. In agreement with this observation, forskolin treatment, but not TPA stimulation, led to increased phosphorylation of cyclin D1 in vivo. Phosphoamino acid analysis and two-dimensional phosphopeptide mapping of wild-type and truncated cyclin D1 proteins showed that PKA phosphorylates three distinct serine residues in cyclin D1 at positions 90, 197 and 234. Serine-90 is located within the cyclin box, raising the possibility that phosphorylation of cyclin D1 might play a role in regulating the interaction with other proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO J, 1993, GENE DEV, V7, P331; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2733	2736						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058338				2022-12-25	WOS:A1994PC05400036
J	CZUBAYKO, F; RIEGEL, AT; WELLSTEIN, A				CZUBAYKO, F; RIEGEL, AT; WELLSTEIN, A			RIBOZYME-TARGETING ELUCIDATES A DIRECT ROLE OF PLEIOTROPHIN IN TUMOR-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MESSENGER-RNA; DEVELOPING BRAIN; FACTOR GENE; ADULT-RAT; CELLS; PROTEIN; EXPRESSION; CANCER; FAMILY	The growth and metastasis of solid tumors rely on the activities of polypeptide growth factors. However, numerous growth factors are expressed in tumors, and it is difficult to decipher which are essential for tumor progression. We found the secreted growth factor pleiotrophin (PTN) expressed at high levels in a number of human tumor cell lines as well as in tumor samples. To assess the role of PTN in tumor growth, we inactivated the PTN gene with PTN-targeted hammerhead ribozyme constructs. Cotransfection of PTN and of the ribozymes inhibited PTN-induced colony formation of PTN-responsive cells whereas a point mutant, catalytically inactive ribozyme was ineffective. Colony formation induced by transfections with a closely related growth factor (mid-kine) was not affected by the ribozymes. In human melanoma cells that express high levels of PTN mRNA, stable transfection with PTN-targeted ribozymes quenched production of PTN, inhibited colony formation of the cells, and prevented their tumor growth in mice. This demonstrates that expression of a growth factor can be a rate-limiting step for malignant progression and suggests that ribozymes could be used therapeutically to target tumor growth factors.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University				Wellstein, Anton/0000-0002-0570-4950				BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; KOVESDI I, 1990, BIOCHEM BIOPH RES CO, V172, P850, DOI 10.1016/0006-291X(90)90753-A; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUO MD, 1990, J BIOL CHEM, V265, P18749; LAI SP, 1992, BIOCHEM BIOPH RES CO, V187, P1113, DOI 10.1016/0006-291X(92)91312-E; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TOMOMURA M, 1990, BIOCHEM BIOPH RES CO, V171, P603, DOI 10.1016/0006-291X(90)91189-Y; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	82	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21358	21363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063762				2022-12-25	WOS:A1994PC40300080
J	KUBOHARA, Y; OKAMOTO, K				KUBOHARA, Y; OKAMOTO, K			CYTOPLASMIC CA2+ AND H+ CONCENTRATIONS DETERMINE CELL FATE IN DICTYOSTELIUM-DISCOIDEUM	FASEB JOURNAL			English	Article						THAPSIGARGIN; CALCIUM; DIFFERENTIATION-INDUCING FACTOR; STALK DIFFERENTIATION	PRESPORE-SPECIFIC GENE; INTRACELLULAR PH; FREE CALCIUM; PRESTALK CELLS; CYCLIC-AMP; TUMOR PROMOTER; SLIME-MOLD; ACID LOAD; DIFFERENTIATION; THAPSIGARGIN	A putative morphogen, called differentiation-inducing factor (DIF), is essential for stalk cell differentiation in the cellular slime mold, Dictyostelium discoideum. To investigate the relationship between the signal molecule (DIF) and the concentrations of cytoplasmic calcium ions and proton, we have examined the effects of thapsigargin (Tg) and 5,5-dimethyl-2,4-oxazolidinedione (DMO) on cell differentiation of a mutant strain HM44, which is defective in DIF production. Tg is a specific inhibitor of the Ca2+-ATPase present in endoplasmic and sarcoplasmic reticula, and raises the cytoplasmic calcium concentration. DMO is a reagent that decreases intracellular pH. When HM44 cells were incubated with Tg or DMO in the absence of DIF, a fraction of the cells was induced to stalk cells. If added together, these reagents induced stalk cell differentiation at high efficiency (70-80%), comparable to that attained with exogenous DIF. In the presence of the reagents, the efficiency was not much affected by lowering cell density, which suggests that the effect (stalk induction) of these reagents was not exerted through the stimulation of DIF production. Thus, these results indicate that a rise in cytoplasmic calcium and proton concentrations triggers stalk cell differentiation possibly by mimicking the roles of DIF.	KYOTO UNIV, FAC SCI, DEPT BOT, KYOTO 60601, JAPAN	Kyoto University								ABE T, 1989, PROTOPLASMA, V151, P175, DOI 10.1007/BF01403457; AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; BEATTY DM, 1993, ENDOCRINOLOGY, V133, P972, DOI 10.1210/en.133.3.972; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BONNER JT, 1970, P NATL ACAD SCI USA, V65, P110; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; EARLY AE, 1988, DEVELOPMENT, V103, P519; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRIDOLF T, 1992, BIOCHEM BIOPH RES CO, V184, P878, DOI 10.1016/0006-291X(92)90672-8; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.bi.56.070187.004225; GERSON DF, 1977, J CELL PHYSIOL, V91, P297, DOI 10.1002/jcp.1040910214; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HORN F, 1993, P INT DICTYOSTELIUM; INOUYE K, 1988, J CELL SCI, V91, P109; INOUYE K, 1988, DEVELOPMENT, V104, P669; INOUYE K, 1985, J CELL SCI, V76, P235; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JEMYN KA, 1987, DEVELOPMENT, V100, P745; KAY RR, 1986, J CELL SCI, V83, P165; KAY RR, 1989, DEVELOPMENT, V107, P81; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KUBOHARA Y, 1993, EXP CELL RES, V204, P382, DOI 10.1006/excr.1993.1047; KUBOHARA Y, 1993, FEBS LETT, V322, P73, DOI 10.1016/0014-5793(93)81114-F; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MAEDA Y, 1989, DIFFERENTIATION, V41, P169, DOI 10.1111/j.1432-0436.1989.tb00744.x; MAEDA Y, 1973, EXP CELL RES, V82, P125, DOI 10.1016/0014-4827(73)90253-X; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MORLEY P, 1992, CELL CALCIUM, V13, P263, DOI 10.1016/0143-4160(92)90014-J; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; NUCCITELLI R, 1982, INTRACELLULAR PH ITS, P1; RAMESH KW, 1990, J CLIN INVEST, V85, P1296; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SARAN S, 1994, IN PRESS FEBS LETT; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SHEN SS, 1978, NATURE, V272, P253, DOI 10.1038/272253a0; SOBOLEWSKI A, 1988, DEV BIOL, V127, P296, DOI 10.1016/0012-1606(88)90316-8; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIRLAPUR UK, 1991, DIFFERENTIATION, V48, P137, DOI 10.1111/j.1432-0436.1991.tb00252.x; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VANDUIJN B, 1991, P NATL ACAD SCI USA, V88, P4951, DOI 10.1073/pnas.88.11.4951; WANG M, 1989, DEVELOPMENT, V105, P569; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WEIJER CJ, 1984, J CELL SCI, V70, P133; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WILLIAMS JG, 1989, DEVELOPMENT, V107, P91; YAMADA Y, 1992, DEV BIOL, V149, P235, DOI 10.1016/0012-1606(92)90280-T; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119	66	83	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					869	874		10.1096/fasebj.8.11.8070636	http://dx.doi.org/10.1096/fasebj.8.11.8070636			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070636				2022-12-25	WOS:A1994PC88500010
J	MURAKAMI, Y; HURWITZ, J				MURAKAMI, Y; HURWITZ, J			FUNCTIONAL INTERACTIONS BETWEEN SV40 T-ANTIGEN AND OTHER REPLICATION PROTEINS AT THE REPLICATION FORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; LAGGING STRAND SYNTHESIS; POLYMERASE-ALPHA; INVITRO REPLICATION; PURIFIED PROTEINS; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-SYNTHESIS; INITIATION; ORIGIN	The functional interaction of simian virus 40 (SV40) large tumor antigen (T antigen) with DNA polymerase alpha (pol alpha)-primase complex, human single-stranded DNA binding protein (HSSB), and DNA polymerase delta (pol delta) holoenzyme, which includes pol delta, activator I (also called replication factor C), and proliferating cell nuclear antigen, at the replication fork was examined using the purified components that support SV40 DNA replication. Dilution of reaction mixtures during RNA primer synthesis revealed that T antigen remained associated continuously with the fork, while the pol alpha-primase complex dissociated from the complex during oligoribonucleotide synthesis. T antigen unwound duplex DNA from the SV40 core origin at a rate of 200 base pairs/min. Pol alpha-primase complex inhibited the rate of the unwinding reaction, and HSSB, pol alpha, and primase were all required for this effect. These requirements are the same as those essential for DNA primase-catalyzed oligoribonucleotide synthesis (Matsumoto, T., Eki, T., and Hurwitz, J. (1990) Proc. NatL Acad. Sci. U. S. A. 87, 9712-9716). This result suggests that the pol alpha-primase complex interacts with T antigen and HSSB during the unwinding reaction to synthesize RNA primers and that the interaction decreases the rate of T antigen movement. While pol delta holoenzyme can elongate primed DNA chains at a rate of 400-600 nucleotides/min on singly primed phiX174 DNA, the rate of the leading strand synthesis catalyzed by pol delta holoenzyme in the SV40 replication system in vitro was about 200 nucleotides/min. This rate was similar to the unwinding rate catalyzed by T antigen. Thus, the rate of leading strand synthesis catalyzed by pol delta holoenzyme in vitro appears to be limited by the unwinding reaction catalyzed by T antigen.			MURAKAMI, Y (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MOLEC BIOL,NEW YORK,NY 10021, USA.							AMIN AA, 1992, J BIOL CHEM, V267, P18612; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Baker T. A., 1992, DNA REPLICATION; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EDENBRG HJ, 1975, ANNU REV GENET, V9, P4077; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1992, J BIOL CHEM, V267, P7284; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GRONOSTAJSKI RM, 1984, J BIOL CHEM, V259, P9479; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TAPPER DP, 1979, BIOCHIM BIOPHYS ACTA, V565, P84, DOI 10.1016/0005-2787(79)90084-4; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P2869; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WU CA, 1992, J BIOL CHEM, V267, P4030; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	50	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11008	11017						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098707				2022-12-25	WOS:A1993LD46600047
J	SCHINKEL, AH; KEMP, S; DOLLE, M; RUDENKO, G; WAGENAAR, E				SCHINKEL, AH; KEMP, S; DOLLE, M; RUDENKO, G; WAGENAAR, E			N-GLYCOSYLATION AND DELETION MUTANTS OF THE HUMAN MDR1 P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PHENOTYPE; MONOCLONAL-ANTIBODIES; COMPLEMENTARY-DNA; GENE FAMILY; HUMAN-CELLS; EXPRESSION; TRANSPORTER; MUTATIONS; PROTEINS; MELANOMA	P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell. To investigate the significance of the conserved N-glycosylation sites present in the putative first extracellular loop of P-glycoproteins, we mutated one, two, or all three of these sites present in the human MDR1 P-glycoprotein. We also deleted a stretch of 20 amino acids, containing two of the three N-glycosylation sites. The effects of these mutations were studied by transfection into drug-sensitive cells. In vincristine-resistant transfected clones selected for similar steady state levels of membrane-bound P-glycoprotein, the absence of N-glycosylation did not alter the level or pattern of (cross-)resistance. However, the absence of N-glycosylation sites drastically reduced the efficiency with which drug-resistant clones could be generated. These findings suggest that N-glycosylation contributes to proper routing or stability of P-glycoprotein but not to drug transport per se. The deletion mutants demonstrated a clearly decreased and altered drug resistance pattern, even with a high level of P-glycoprotein in the plasma membrane. This, and possibly the observed lack of glycosylation of the remaining intact glycosylation sequence, suggests a constrained P-glycoprotein structure. Our findings support the current model for P-glycoprotein structure.			SCHINKEL, AH (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Rudenko, Gabrielle (Gabby)/O-7938-2018; Kemp, Stephan/A-3935-2008	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530; Kemp, Stephan/0000-0003-2023-064X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BECK WT, 1982, CANCER RES, V42, P184; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CROOP JM, 1988, J CLIN INVEST, V81, P1303, DOI 10.1172/JCI113455; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENDICOTT JA, 1991, SEQUENCING MAPPING, V2, P89; GEENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERGER LM, 1989, FEBS LETT, V257, P419, DOI 10.1016/0014-5793(89)81586-8; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; LINCKE CR, 1990, CANCER RES, V50, P1779; LING V, 1983, CANCER TREAT REP, V67, P869; LOCKSHIN A, 1985, CANCER RES, V45, P345; Parekh RB, 1991, CURR OPIN STRUC BIOL, V1, P750, DOI 10.1016/0959-440X(91)90174-R; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SILVERMAN JA, 1991, GENE, V106, P229, DOI 10.1016/0378-1119(91)90203-N; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	41	169	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7474	7481						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096511				2022-12-25	WOS:A1993KV14100093
J	TEWARI, R; MACGREGOR, JI; IKEDA, T; LITTLE, JR; HULTGREN, SJ; ABRAHAM, SN				TEWARI, R; MACGREGOR, JI; IKEDA, T; LITTLE, JR; HULTGREN, SJ; ABRAHAM, SN			NEUTROPHIL ACTIVATION BY NASCENT FIMH SUBUNITS OF TYPE-1 FIMBRIAE PURIFIED FROM THE PERIPLASM OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-SPECIFIC ADHESIN; PILI; IDENTIFICATION; INFECTION; PROTEIN; PHAGOCYTOSIS; ORGANIZATION; STIMULATION; MACROPHAGES; LEUKOCYTES	Previous studies of type 1 fimbriae of Escherichia coli have implicated FimH, a minor subunit, as the determinant of its mannose binding property. Structure-function analysis of FimH has not been possible because of the difficulty in obtaining adequate amounts of the subunit from type 1 fimbriae. We have obtained nascent FimH that has not been incorporated into the fimbrial structure from the periplasm of an E. coli strain expressing the cloned fimH gene. Nascently translocated FimH was initially degraded in the periplasm; however, when co-expressed with FimC, a putative fimbrial chaperone, the FimH molecules were stabilized and readily isolated from the periplasmic extract by fractionation on a sodium dodecyl sulfate-polyacrylamide gel followed by electroelution of the FimH band from the gel. The eluted protein was purified to homogeneity by affinity chromatography on a mannose-Sepharose column. Purified FimH displayed the same mannose-inhibitable binding to human neutrophils as type 1 fimbriated bacteria, including triggering an oxidative burst with concomitant release of reactive oxygen metabolites. In addition, inert microspheres coated with FimH, but not those coated with bovine serum albumin, were phagocytosed by neutrophils. These data provide direct evidence that FimH is the determinant on type 1 fimbriae which is responsible for mediating mannose-specific adherence and that isolated FimH is a potent activator of human neutrophils.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, DEPT MED, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital				Tewari, Prof. (Dr.) Rupinder/0000-0002-9049-837X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029549, R01AI027466, R01AI029549, R01AI013550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-13550, AI-27466, AI-29549] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; Beachey, 1980, BACTERIAL ADHERENC B, V6, P1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CLEGG S, 1987, J BACTERIOL, V169, P934, DOI 10.1128/jb.169.3.934-938.1987; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; FIRON N, 1987, INFECT IMMUN, V55, P472, DOI 10.1128/IAI.55.2.472-476.1987; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GOETZ MB, 1987, INFECT IMMUN, V55, P534, DOI 10.1128/IAI.55.3.534-540.1987; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HORWITZ MA, 1982, REV INFECT DIS, V4, P104; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1985, MOL GEN GENET, V199, P410, DOI 10.1007/BF00330751; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; NEU HC, 1965, J BIOL CHEM, V240, P3685; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; PONNIAH S, 1991, J BACTERIOL, V173, P4195, DOI 10.1128/jb.173.13.4195-4202.1991; PONNIAH S, 1989, J IMMUNOL, V142, P992; PONNIAH S, 1992, INFECT IMMUN, V60, P5197, DOI 10.1128/IAI.60.12.5197-5203.1992; RODRIGUEZORTEGA M, 1987, INFECT IMMUN, V55, P968, DOI 10.1128/IAI.55.4.968-973.1987; ROOT RK, 1981, REV INFECT DIS, V3, P565; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; STEADMAN R, 1990, BIOCHIM BIOPHYS ACTA, V1053, P37, DOI 10.1016/0167-4889(90)90023-7; STENDAHL O, 1981, MONOGR ALLERGY, V17, P12; STOSSEL TP, 1974, NEW ENGL J MED, V290, P774, DOI 10.1056/NEJM197404042901405; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF JE, 1987, J IMMUNOL, V138, P582	42	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					3009	3015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8094080				2022-12-25	WOS:A1993KK81500110
J	BAUTISTA, DS; XUAN, JW; HOTA, C; CHAMBERS, AF; HARRIS, JF				BAUTISTA, DS; XUAN, JW; HOTA, C; CHAMBERS, AF; HARRIS, JF			INHIBITION OF ARG-GLY-ASP (RGD)-MEDIATED CELL-ADHESION TO OSTEOPONTIN BY A MONOCLONAL-ANTIBODY AGAINST OSTEOPONTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED MAMMALIAN-CELLS; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; NEOPLASTIC TRANSFORMATION; RAT BONE; PHOSPHORYLATED GLYCOPROTEIN; ENHANCED EXPRESSION; METASTATIC ABILITY; RNA DISTRIBUTION; MESSENGER-RNA	Osteopontin (OPN), a secreted phosphoprotein, has been implicated in various biological phenomena (e.g. bone development, sepsis, tumor progression, and metastasis). Its role in any context is poorly understood. OPN contains a conserved Gly-Arg-Gly-Asp-Ser (GRGDS) sequence, and binds to cells via integrin-mediated mechanisms. Using recombinant human osteopontin-glutathione S-transferase fusion protein and our improved hybridoma fusion partner (Sp2/mIL6), we raised murine monoclonal antibodies against osteopontin. We characterized two antibodies that recognize not only recombinant but also native human osteopontin. These antibodies do not cross-react with mouse osteopontin (recombinant protein or that secreted by ras-transformed NM 3T3 cells), or bovine bone osteopontin, suggesting that they recognize epitopes unique to human OPN. One antibody specifically inhibited adhesion of MDA-MB-435 human breast cancer cells and ras-transformed NIH 3T3 cells to human osteopontin. This antibody failed to recognize osteopontin cleaved by thrombin, which cleaves adjacent to the cell binding domain. We previously showed that thrombin cleavage reduces osteopontin cell binding activity. Thus we postulate that this monoclonal antibody recognizes and interferes with the function of the RGD/thrombin cleavage region of human OPN.	LONDON REG CANC CTR, LONDON N6A 4L6, ON, CANADA; UNIV WESTERN ONTARIO, DEPT ONCOL, LONDON N6A 4L6, ON, CANADA; UNIV WESTERN ONTARIO, DEPT IMMUNOL & MICROBIOL, LONDON N6A 4L6, ON, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CARTIER M, 1990, GENE, V95, P223, DOI 10.1016/0378-1119(90)90365-X; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHAMBERS AF, 1990, INVAS METAST, V10, P225; CHANG PL, 1991, CANCER RES, V51, P2144; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FUJISAWA R, 1993, J DENT RES, V72, P1222, DOI 10.1177/00220345930720081001; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HARRIS JF, 1992, J IMMUNOL METHODS, V148, P199, DOI 10.1016/0022-1759(92)90173-Q; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; KERR JM, 1991, GENE, V108, P237, DOI 10.1016/0378-1119(91)90439-I; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KUBOTA T, 1993, ARCH ORAL BIOL, V38, P23, DOI 10.1016/0003-9969(93)90150-K; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LOPEZ CA, 1993, LAB INVEST, V69, P355; MAOR G, 1989, ENDOCRINOLOGY, V125, P1239, DOI 10.1210/endo-125-3-1239; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MCKEE MD, 1993, J BONE MINER RES, V8, P485; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MOORE MA, 1991, BIOCHEMISTRY-US, V30, P2501, DOI 10.1021/bi00223a029; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PRICE JE, 1990, CANCER RES, V50, P717; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Sambrook J, 1989, MOL CLONING LABORATO; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SINGH K, 1990, J BIOL CHEM, V265, P18696; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; WORCESTER EM, 1992, J BONE MINER RES, V7, P1029; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; YOKOTA M, 1992, BIOCHEM BIOPH RES CO, V189, P892, DOI 10.1016/0006-291X(92)92287-8; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZHANG R, 1990, J BIOL CHEM, V265, P15375	54	83	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23280	23285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083234				2022-12-25	WOS:A1994PQ16400058
J	TONETTI, DA; HENNINGCHUBB, C; YAMANISHI, DT; HUBERMAN, E				TONETTI, DA; HENNINGCHUBB, C; YAMANISHI, DT; HUBERMAN, E			PROTEIN-KINASE C-BETA IS REQUIRED FOR MACROPHAGE DIFFERENTIATION OF HUMAN HL-60 LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; GENE-EXPRESSION; RETINOIC ACID; INDUCTION; RESISTANT; PHORBOL-12-MYRISTATE-13-ACETATE; TRANSLOCATION; DIESTER	The requirement for protein kinase C (PKC)-beta in phorbol 12-myristate 13-acetate (PMA)-induced macrophage differentiation of human HL-60 promyelocytic leukemia cells was studied by using the variant HL-525, which is deficient in PKC-beta and is resistant to PMA-induced differentiation. Transfecting these resistant HL-525 cells with expression vectors containing either PKC-beta I or PKC-beta II cDNA resulted in clones that displayed PKC-beta transcript levels similar to or higher than those of the parental HL-60 cells or cells from a PMA-susceptible HL 60 clone, HL-205. These productive transfectants also exhibited PMA-induced cell attachment and spreading, inhibition of cell replication, reactivity to the OKM1 monoclonal antibody, and the ability to phagocytize opsinized beads, which are all characteristic macrophage markers. No PMA-induced differentiation markers were observed in any of the PKC-beta I or PKC-beta II transfectants that did not exhibit an increased PKC-beta RNA level or in cells transfected with control plasmids. These results indicate that restoration of the PKC-beta isozyme deficiency by productive gene transfection causes HL-525 cells to revert to a phenotype like that of the parental HL-60 cells, which is characterized by susceptibility to PMA-induced macrophage differentiation. Therefore, we can conclude that PKC-beta is one of the essential elements in the PMA-induced signal transduction pathway which leads to macrophage differentiation in HL-60 cells and perhaps in other related cell types,	ARGONNE NATL LAB,CTR MECHANIST BIOL & BIOTECHNOL,ARGONNE,IL 60439; UNIV CALIF IRVINE,DEPT MED,DIV HEMATOL ONCOL,IRVINE,CA 92717	United States Department of Energy (DOE); Argonne National Laboratory; University of California System; University of California Irvine								AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ANDERSON NL, 1985, CANCER RES, V45, P4955; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BLAIR OC, 1986, CYTOMETRY, V7, P171, DOI 10.1002/cyto.990070208; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; EDASHIGE K, 1992, ARCH BIOCHEM BIOPHYS, V299, P200, DOI 10.1016/0003-9861(92)90264-W; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FOON KA, 1982, BLOOD, V60, P1; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOMMA Y, 1988, CANCER RES, V48, P2744; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HOOPER WC, 1989, BIOCHIM BIOPHYS ACTA, V1013, P47, DOI 10.1016/0167-4889(89)90126-2; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUBERMAN E, 1982, CARCINOGENESIS, V3, P111, DOI 10.1093/carcin/3.1.111; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; MURAO S, 1983, CANCER RES, V43, P4989; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIKAWA M, 1990, CANCER RES, V50, P621; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SLAPAK CA, 1993, J BIOL CHEM, V268, P12267; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YANG KD, 1994, BLOOD, V83, P490	43	113	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23230	23235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083228				2022-12-25	WOS:A1994PQ16400051
J	LOUDON, RP; BENOVIC, JL				LOUDON, RP; BENOVIC, JL			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE G-PROTEIN-COUPLED RECEPTOR KINASE-GRK6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; RHODOPSIN KINASE; BETA-2-ADRENERGIC RECEPTOR; CATALYTIC SUBUNIT; FAMILY; DESENSITIZATION; CLONING; MEMBER; IDENTIFICATION; ISOPRENYLATION	G protein-coupled receptor kinases (GRKs), such as rhodopsin kinase and beta-adrenergic receptor kinase (beta ARK), are involved in mediating agonist-specific phosphorylation and desensitization of G protein-coupled receptors. GRK6 is the most recently identified member of the GRK family and displays higher homology with GRK5 (70.1% amino acid identity) and IT11 (68.5%) compared to beta ARK (37.4%) and rhodopsin kinase (47.1%). To further characterize GRK6, it has been overexpressed in Sf9 cells and purified to homogeneity by sequential chromatography on SP-Sepharose and heparin-Sepharose columns. GRK6 shares a number of in vitro characteristics with GRK5, including potent inhibition by heparin and dextran sulfate (IC50 values of similar to 15 and similar to 7 nM, respectively), hyperstimulation by polycations, and preference for phosphorylation of non-acidic peptides. Rhodopsin and the beta(2)-adrenergic and m2 muscarinic cholinergic receptors serve as stimulus-dependent substrates for GRK6, but with stoichiometries significantly lower than achieved by GRK5 and beta ARK. Additionally, GRK6 does not undergo significant autophosphorylation even though it contains residues identical to those that are autophosphorylated in GRK5 and rhodopsin kinase. These data extend our knowledge of a growing family of receptor specific kinases and suggest that GRK6 has a substrate specificity distinct from beta ARK, rhodopsin kinase, and GRK5.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SHICHI H, 1978, J BIOL CHEM, V253, P7040; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	40	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22691	22697						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077221				2022-12-25	WOS:A1994PQ16300038
J	IYER, SS; PEARSON, DW; NAUSEEF, WM; CLARK, RA				IYER, SS; PEARSON, DW; NAUSEEF, WM; CLARK, RA			EVIDENCE FOR A READILY DISSOCIABLE COMPLEX OF P47PHOX AND P67PHOX IN CYTOSOL OF UNSTIMULATED HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; GENERATING NADPH OXIDASE; GTP-BINDING PROTEIN; MICROBICIDAL OXIDASE; PARTIAL-PURIFICATION; GUANINE-NUCLEOTIDES; FUNCTIONAL DOMAIN; PLASMA-MEMBRANE	We explored the association between two cytosolic components of the phagocyte respiratory burst oxidase, p47phox and p67phox. Both of these proteins bound to immobilized GTP or 2',5'-ADP, but not to GDP or ATP. Similarly, triazine dye-ligand chromatography demonstrated coisolation of p47phox and p67phox. Binding of p67phox to GTP was less avid than that of p47phox. Each of the proteins in whole neutrophil cytosol bound separately to GTP in the absence of the other, whereas studies with recombinant proteins showed binding of p47phox but not p67phox. These data suggest that p47phox and p67phox exist as a complex that very likely involves at least one additional cytosolic protein. Sequential precipitation in graded concentrations of ammonium sulfate demonstrated similar profiles for p47phox and p67phox. Charge-based separations using either an anion or cation exchange resin resulted in coelution of the two cytosolic oxidase components, in spite of their widely differing charges as shown by separate analysis of the recombinant proteins. Moreover, preparative isoelectric focusing showed that a portion of the p47phox and p67phox in cytosol coisolated at a pi (7.3-8.3) midway between those of the separate proteins. Despite this, each protein sedimented independently in sucrose density gradients. The data indicate that the complex of p47phox and p67phox was dissociated by increased temperature, high osmolarity, or prolonged incubation. We suggest that under the physiologic conditions in the cytosol of intact phagocytes p47phox, p67phox and probably other proteins exist as a macromolecular complex, the function of which may be to permit en bloc translocation of oxidase components to the plasma membrane.	UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System				Nauseef, William/0000-0003-4032-757X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, P01AI028412, R01AI020866] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020866, R37 AI020866, AI28412, AI20866] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1991, AM J HEMATOL, V37, P263, DOI 10.1002/ajh.2830370410; BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CASIMIR C, 1992, EUR J CLIN INVEST, V22, P403, DOI 10.1111/j.1365-2362.1992.tb01481.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1979, J IMMUNOL, V122, P2605; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; Ezekowitz R A, 1992, Curr Top Microbiol Immunol, V181, P283; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QUINN MT, 1992, J BIOL CHEM, V267, P7303; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; SHAAG D, 1988, BIOCHIM BIOPHYS ACTA, V952, P213, DOI 10.1016/0167-4838(88)90118-5; SMITH RM, 1991, BLOOD, V77, P673; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; TURNER AJ, 1981, TRENDS BIOCHEM SCI, V6, P171, DOI 10.1016/0968-0004(81)90063-3; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	58	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22405	22411						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071369				2022-12-25	WOS:A1994PE09800072
J	BECK, SC; DEMAIO, A				BECK, SC; DEMAIO, A			STABILIZATION OF PROTEIN-SYNTHESIS IN THERMOTOLERANT CELLS DURING HEAT-SHOCK - ASSOCIATION OF HEAT-SHOCK PROTEIN-72 WITH RIBOSOMAL-SUBUNITS OF POLYSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSLATIONAL THERMOTOLERANCE; RAT FIBROBLASTS; RNA-POLYMERASE; STRESS; BINDING; HSP70; LIVER; PHOSPHORYLATION	Thermotolerance is defined as the capacity of cells, following a cycle of stress and recovery, to survive a second stress which would otherwise be lethal. Whereas this is a well-documented phenomenon, the mechanisms underlying this protective event remain to be elucidated. Protection of protein synthesis appears to be one of the components in the induction of thermotolerance termed ''translational thermotolerance.'' In the present study we show that translational thermotolerance is not the result of an increase in the concentration of cellular transcripts or the stabilization of preexisting messages, nor the preservation of the rate of amino acid uptake, synthesis of aminoacyl-tRNA, or protection from degradation of newly synthesized polypeptides. These results suggest that translational thermotolerance is the consequence of stabilization of translational initiation and/or polypeptide chain elongation during heat shock. We found that heat shock protein (hsp)-72, the major inducible form of the hsp-70 family of heat shock proteins, is associated with ribosomal subunits in polysomes of thermotolerant cells during heat shock, We hypothesize that such interaction is responsible for rescuing translational initiation and/or polypeptide chain elongation in thermotolerant cells during a subsequent stress, It is possible that hsp-72 on the ribosome is ''waiting'' for the nascent polypeptide to emerge from the ribosome. Such interaction may maintain the growing polypeptide in solution during stress, allowing elongation to continue, and maintaining a constant rate of translation during the stress.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BALLINGER DG, 1983, CELL, V33, P103, DOI 10.1016/0092-8674(83)90339-2; BANSAL GS, 1991, EXP CELL RES, V195, P303, DOI 10.1016/0014-4827(91)90377-7; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DEMAIO A, 1993, CIRC SHOCK, V40, P177; DEMAIO A, 1993, EUR J BIOCHEM, V218, P413; DEMAIO A, 1991, CIRC SHOCK, V34, P329; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KASSENBROCK CK, 1989, SCIENCE, V242, P1551; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LANDRY J, 1983, CAN J BIOCHEM CELL B, V61, P428, DOI 10.1139/o83-058; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P316; MCCORMICK W, 1969, J MOL BIOL, V39, P315, DOI 10.1016/0022-2836(69)90320-9; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH JD, 1965, J MOL BIOL, V13, P617, DOI 10.1016/S0022-2836(65)80130-9; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	57	82	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21803	21811						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063823				2022-12-25	WOS:A1994PK97300063
J	REZAIE, AR; ESMON, CT				REZAIE, AR; ESMON, CT			ASP-70-]LYS MUTANT OF FACTOR-X LACKS HIGH-AFFINITY CA2+ BINDING-SITE YET RETAINS FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; ACTIVATED FACTOR-V; CALCIUM-BINDING; PROTEIN-C; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; FACTOR-VII; FACTOR-IX; THROMBIN; PROTHROMBIN	To study the role of a putative high affinity Ca2+ binding site in the protease domain of factor X, we prepared a deletion mutant (E2FX) lacking the G1a and first epidermal growth factor-like domains. E2FX possesses a single high affinity Ca2+ binding site (K-d = 154 mu M). Asp-70 or Glu-80 (chymotrypsin numbering system) was then converted to Lys. These mutants, E2FXD70K and E2FXE80K, allow examination of the Ca2+-dependent assembly of activation complexes involving substrate and enzyme forms of factor X that do not bind Ca2+ E2FXD70K and E2FXE80K share similar properties. They retain functional activity, but the D70K mutant no longer binds Ca2+, and neither mutant exhibits a Ca2+-dependent increase in peptide chromogenic substrate activity. Activation of E2FXD70K by the soluble tissue factor-factor VIIa complex was still Ca2+-dependent (K-d(app) = 133 +/- 38 mu M), but the K-d(app) for Ca2+ was decreased relative to E2FX (K-d(app) = 205 +/- 53 mu M). Prothrombin or prethrombin 1 activation by the E2FXaD70K in the presence of factor Va was also Ca2+-dependent (K-d(app) = 124 +/- 47 mu M and 102 +/- 38 mu M, respectively), and the K-d(app) was again lower than that of E2FXa (272 +/- 79 mu M and 179 +/- 54 mu M, respectively). In the absence of factor Va, activation of prethrombin 1 by E2FXaD70K was not influenced by Ca2+, but activation by E2FXa was enhanced (K-d(app) = 161 +/- 32 mu M). The results suggest the presence of functionally important Ca2+ binding sites in components of the factor X and prothrombin activation complexes that do not involve factor X. Furthermore, the Ca2+ binding sites in factor X and trypsin appear to be structurally similar. The Asp or Glu --> Lys mutations within this site may create an internal salt bridge that conserves factor X (Xa) function even in the absence of Ca2+.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute					NHLBI NIH HHS [HL29807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1992, PROTEIN SCI, V1, P426; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, THESIS WASHINGTON U; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1990, BLOOD, V76, P1; MORITA T, 1984, J BIOL CHEM, V259, P5698; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; OWEN WG, 1974, J BIOL CHEM, V249, P594; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; STENFLO J, 1991, BLOOD, V78, P1637; SUGO T, 1984, J BIOL CHEM, V259, P5705; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016	32	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21495	21499						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063784				2022-12-25	WOS:A1994PK97300019
J	ROMEIS, T; HOLTJE, JV				ROMEIS, T; HOLTJE, JV			SPECIFIC INTERACTION OF PENICILLIN-BINDING PROTEIN-3 AND PROTEIN-7/8 WITH SOLUBLE LYTIC TRANSGLYCOSYLASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MUREIN-METABOLIZING ENZYMES; SLT GENE; DIVISION; MUTANTS; OVEREXPRESSION; ENDOPEPTIDASE; SEPARATION; BACTERIA; CLONING	Soluble lytic transglycosylase 70 (Slt70), one of the better characterized murein hydrolases of Escherichia coli, was covalently bound to CNBr-activated Sepharose and used as a specific tool to screen for proteins showing an affinity for Slt70. Several proteins were specifically enriched by Slt-Sepharose affinity chromatography. Two of them were identified as the penicillin-binding proteins (PBP)3 and PBP7/8. Thus, the bifunctional synthase PBP3, specifically involved in septum formation, and PBP7/8, recently shown to be a DD-endopeptidase, bind to Slt70 in vitro. In addition, PBP7/8 was found not only to stabilize but also to stimulate the enzymatic activity of Slt70 by a protein-protein interaction. It is concluded that Slt70, PBP7/8, and PBP3 may form a multienzyme complex in vivo.	MAX PLANCK INST ENTWICKLUNGSBIOL, BIOCHEM ABT, D-72076 TUBINGEN, GERMANY	Max Planck Society								BETZNER AS, 1989, MOL GEN GENET, V219, P489, DOI 10.1007/BF00259625; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; ENGEL H, 1992, J BACTERIOL, V174, P6394, DOI 10.1128/JB.174.20.6394-6403.1992; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HARTMANN R, 1972, NATURE, V235, P426, DOI 10.1038/235426a0; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HENDERSON TA, 1994, J BACTERIOL, V176, P256, DOI 10.1128/JB.176.1.256-259.1994; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1993, FEMS SYMP, P419; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; HOLTJE JV, 1974, MODE ACTION ANTIBIOT, P294; KECK W, 1990, MOL MICROBIOL, V4, P209, DOI 10.1111/j.1365-2958.1990.tb00588.x; KITANO K, 1986, J BACTERIOL, V167, P759, DOI 10.1128/jb.167.3.759-765.1986; KOCH AL, 1990, RES MICROBIOL, V141, P529, DOI 10.1016/0923-2508(90)90017-K; KOCH AL, 1985, J THEOR BIOL, V117, P137, DOI 10.1016/S0022-5193(85)80169-7; KOHLRAUSCH U, 1991, J BACTERIOL, V173, P3425, DOI 10.1128/jb.173.11.3425-3431.1991; KUSSER W, 1980, EUR J BIOCHEM, V103, P277, DOI 10.1111/j.1432-1033.1980.tb04312.x; LEDUC M, 1989, FEMS MICROBIOL LETT, V60, P11, DOI 10.1016/0378-1097(89)90068-2; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MATSUHASHI M, 1981, BETA LACTAM ANTIBIOT, P203; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEU HC, 1965, J BIOL CHEM, V240, P3685; ROMEIS T, 1993, FEMS MICROBIOL LETT, V111, P141; SCHMIDT LS, 1981, J BACTERIOL, V145, P632, DOI 10.1128/JB.145.1.632-637.1981; SCHWARZ U, 1969, J MOL BIOL, V41, P419, DOI 10.1016/0022-2836(69)90285-X; SCHWARZ U, 1981, FEMS MICROBIOL LETT, V10, P107, DOI 10.1111/j.1574-6968.1981.tb06217.x; SHOCKMAN GD, 1965, BACTERIOL REV, V29, P345, DOI 10.1128/MMBR.29.3.345-358.1965; Shockman GD, 1994, NEW COMPREHENSIVE BI, P131; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; SPRATT BG, 1977, J BACTERIOL, V131, P293, DOI 10.1128/JB.131.1.293-305.1977; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; TUOMANEN E, 1987, J BACTERIOL, V169, P4912, DOI 10.1128/jb.169.11.4912-4915.1987; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	38	89	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21603	21607						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063800				2022-12-25	WOS:A1994PK97300035
J	CHAO, QM; ETZLER, ME				CHAO, QM; ETZLER, ME			INCORRECT TARGETING OF PLANT VACUOLAR LECTINS IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFLORUS SEED LECTIN; DOLICHOS-BIFLORUS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SECRETORY VESICLES; PLASMA-MEMBRANE; CDNA CLONING; PROTEIN; TRANSPORT; PHYTOHEMAGGLUTININ	Two soluble vacuolar lectins, seed lectin and DB58, from the legume, Dolichos biflorus, were expressed in Saccharomyces cerevisiae using both low and high copy number plasmids under the control of the GAL1 promoter. When expressed at low levels, these lectins were each secreted by the yeast at all stages of growth. Expression of the lectins at high levels resulted in the retention of most of the lectins in the cell. Cell fractionation studies showed that this retained lectin was not associated with the yeast vacuoles. The differential COOH-terminal processing of these lectins, that results in the production of heteroligomers in plants, did not occur in yeast. Site-directed mutagenesis was employed to produce a construct encoding the shorter subunit of the seed lectin. Expression of this truncated subunit in yeast produced the same results as found with the larger subunit, thus indicating that this modification does not provide the vacuolar targeting signal. The inability of these two vacuolar proteins from different plant tissues to be transported to the yeast vacuole suggests that plants and yeast utilize different signals for targeting soluble vacuolar proteins.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21882] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WN, 1972, J BIOL CHEM, V247, P1161; BJERRUM OJ, 1986, HDB IMMUNOBLOTTING P; BOLLER T, 1986, ANNU REV PLANT PHYS, V37, P137, DOI 10.1146/annurev.pp.37.060186.001033; BUNKER TW, 1994, PLANTA, V192, P144; CARTER WG, 1975, BIOCHEMISTRY-US, V14, P5118, DOI 10.1021/bi00694a015; CARTER WG, 1975, J BIOL CHEM, V250, P2756; CHRISPEELS MJ, 1984, PHILOS T R SOC B, V304, P309, DOI 10.1098/rstb.1984.0026; DOREL C, 1989, J CELL BIOL, V108, P327, DOI 10.1083/jcb.108.2.327; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ETZLER ME, 1984, PLANT PHYSIOL, V76, P871, DOI 10.1104/pp.76.4.871; ETZLER ME, 1981, J BIOL CHEM, V256, P2367; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOLDSTEIN IJ, 1986, LECTINS PROPERTIES F, P235; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALVORSON H, 1958, BIOCHIM BIOPHYS ACTA, V30, P28, DOI 10.1016/0006-3002(58)90237-3; HARADA JJ, 1990, J BIOL CHEM, V265, P4997; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1977, GENETICS, V85, P23; KARP DR, 1982, J BIOL CHEM, V257, P7330; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KUZURUZINSKA MA, 1987, ANN REV BIOCH, V56, P915; MANEN JF, 1982, PLANTA, V155, P328, DOI 10.1007/BF00429460; Maniatis T., 1982, MOL CLONING; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MATSUOKA K, 1992, PLANT CELL PHYSIOL, V33, P453; NEILL JD, 1987, GENE, V55, P303, DOI 10.1016/0378-1119(87)90290-3; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; QUINN JM, 1989, PLANT PHYSIOL, V91, P1382, DOI 10.1104/pp.91.4.1382; ROBERTS DM, 1982, ARCH BIOCHEM BIOPHYS, V218, P213, DOI 10.1016/0003-9861(82)90338-1; ROBERTS DM, 1984, PLANT PHYSIOL, V76, P879, DOI 10.1104/pp.76.4.879; ROTHMAN JH, 1989, TRENDS BIOCHEM SCI, V14, P347, DOI 10.1016/0968-0004(89)90170-9; Rubin G M, 1975, Methods Cell Biol, V12, P45; RUOHOLA H, 1987, P NATL ACAD SCI USA, V84, P8468, DOI 10.1073/pnas.84.23.8468; SAALBACH G, 1991, PLANT CELL, V3, P695, DOI 10.1105/tpc.3.7.695; SCHEKMAN R, 1982, MOL BIOL YEAST SACCH; SCHNELL DJ, 1987, EUR J BIOCHEM, V167, P227, DOI 10.1111/j.1432-1033.1987.tb13327.x; SCHNELL DJ, 1987, J BIOL CHEM, V262, P7220; SCHNELL DJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P229, DOI 10.1006/abbi.1994.1161; SCHNELL DJ, 1988, J BIOL CHEM, V263, P14648; Sherman F, 1979, METHODS YEAST GENETI; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TAGUE BW, 1987, J CELL BIOL, V105, P1971, DOI 10.1083/jcb.105.5.1971; TAGUE BW, 1990, PLANT CELL, V2, P533, DOI 10.1105/tpc.2.6.533; TALBOT CF, 1978, PLANT PHYSIOL, V61, P847, DOI 10.1104/pp.61.5.847; TALBOT CF, 1978, BIOCHEMISTRY-US, V17, P1474, DOI 10.1021/bi00601a018; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOELKER TA, 1989, PLANT CELL, V1, P95, DOI 10.1105/tpc.1.1.95; VONSCHAEWEN A, 1993, J EXP BOT, V44, P339; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	54	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20866	20871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063703				2022-12-25	WOS:A1994PC40300012
J	HAJJAR, KA; JACOVINA, AT; CHACKO, J				HAJJAR, KA; JACOVINA, AT; CHACKO, J			AN ENDOTHELIAL-CELL RECEPTOR FOR PLASMINOGEN TISSUE-PLASMINOGEN ACTIVATOR .1. IDENTITY WITH ANNEXIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT PROTEIN-I; SEQUENCE-ANALYSIS; PHOSPHATIDYLSERINE EXPOSURE; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; ESCHERICHIA-COLI; CALPACTIN FAMILY; T-PA; EXPRESSION; SURFACE	Sequencing of two internal peptides from the putative human endothelial cell tissue plasminogen activator (t-PA) receptor identified an analog of the calcium- and phospholipid-binding protein, annexin II (Ann-II). The polymerase chain reaction-derived, full-length cDNA revealed complete sequence identity with the heavy chain of Ann-II, and ligand-precipitated receptor protein immunoreacted specifically with a monoclonal antibody to Ann-II. Transfected 293 cells bound plasminogen (K-d = 114 nM; B-max = 347,000) as well as t-PA (K-d = 48 nM; B-max = 380,000). Antisense oligonucleotides directed against endothelial cell Ann-II mRNA inhibited binding of both t-PA and plasminogen by 49% and 38%, respectively. The K307T mutant of Ann-II expressed on 293 cells failed to bind plasminogen, while the K328I mutant bound this ligand in a manner equivalent to the wild-type. Binding of plasminogen to both the wild-type and the K328I mutant was blocked by pretreatment of 293 cells with carboxypeptidase B. These data suggest a novel mechanism whereby a plasmin-like serine protease may cleave Ann-II at Lys(307)-Arg(308), exposing a new carboxyl-terminal lysine residue (Lys(307)) for binding and efficient activation of plasminogen.	CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University	HAJJAR, KA (corresponding author), CORNELL UNIV,COLL MED,DEPT PEDIAT,DIV HEMATOL ONCOL,1300 YORK AVE,BOX 45,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL 46403, HL 18828, HL 42493] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042493, P50HL018828, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNATHAN ES, 1990, BLOOD, V76, P1795; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BEEBE DP, 1987, THROMB RES, V46, P241, DOI 10.1016/0049-3848(87)90286-6; BEEBE DP, 1989, BLOOD, V74, P2034; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUDANI AK, 1991, MOL CELL BIOCHEM, V108, P133; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KWAAN HC, 1984, SEMIN THROMB HEMOST, V10, P71, DOI 10.1055/s-2007-1004409; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MILES LA, 1986, J CLIN INVEST, V77, P2001, DOI 10.1172/JCI112529; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, BLOOD, V72, P628; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGUYEN G, 1992, J BIOL CHEM, V267, P6249; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; OTTER M, 1991, J BIOL CHEM, V266, P13931; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; SANZO MA, 1990, BIOCHEM J, V269, P475, DOI 10.1042/bj2690475; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHAFER AI, 1989, BLOOD, V74, P1015; SHIH GC, 1993, P SOC EXP BIOL MED, V202, P258; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; WENG XW, 1993, PROTEIN SCI, V2, P448; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; YE RD, 1987, J BIOL CHEM, V262, P3718; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	58	443	455	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21191	21197						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063740				2022-12-25	WOS:A1994PC40300057
J	DOHI, DF; SUTTON, RC; FRAZIER, ML; NAKAMORI, S; MCISAAC, AM; IRIMURA, T				DOHI, DF; SUTTON, RC; FRAZIER, ML; NAKAMORI, S; MCISAAC, AM; IRIMURA, T			REGULATION OF SIALOMUCIN PRODUCTION IN COLON-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; HUMAN COLORECTAL-CARCINOMA; HUMAN SEMINAL PLASMA; MONOCLONAL-ANTIBODIES; MOLECULAR-WEIGHT; MUCUS GLYCOPROTEINS; DIFFERENTIATION ANTIGENS; N-ACETYLGALACTOSAMINE; EXPRESSION; METASTASES	In this study, we investigated the biochemical basis for the induction of sialomucin production in HT-29 LMM human colon carcinoma cells. Previous studies showed that conditioned medium from organ cultures of normal human colonic connective tissues (NCCM) stimulated the biosynthesis of high molecular weight sialoglycoproteins (M(r) 740,000 and 450,000) by colon carcinoma cells in vitro. Using monoclonal antibodies specific for human milk mucin, we determined that the polypeptide core of these sialomucins was the polymorphic epithelial mucin core peptide coded by the MUC1 gene. Northern analysis showed that cells treated with NCCM expressed a higher level of MUC1 poly(A)+ mRNA than untreated cells. The UDP-GalNAC: polypeptide N-acetylgalactosaminyltransferase activity in microsomal fractions from these cells did not change upon NCCM treatment. The ratios of oligosaccharides with various negative charges secreted by HT-29 LMM cells in the presence of benzyl-alpha-D-N-acetylgalactosaminide were not affected by NCCM treatment indicating that the degree of sialylation of O-linked carbohydrate chains is not influenced by NCCM treatment. [H-3]Glucosamine pulse-chase labeling studies using antibodies specific for a COOH-terminal unglycosylated region of the MUC1 mucin core peptides suggested that NCCM treatment of HT-29 LMM cells did not change the rate of MUC1-related sialomucin processing.	UNIV TOKYO, FAC PHARMACEUT SCI,DIV CHEM TOXICOL & IMMUNOCHEM, HONGO 7-3-1,BUNKYO KU, TOKYO 113, JAPAN; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED ONCOL, HOUSTON, TX 77030 USA	University of Tokyo; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA050231, R01CA039319] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA50231, R01-CA39319] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARKLIE J, 1981, INT J CANCER, V28, P23, DOI 10.1002/ijc.2910280105; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; DEVINE PL, 1991, BIOCHEM BIOPH RES CO, V178, P593, DOI 10.1016/0006-291X(91)90149-2; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1986, EUR J BIOCHEM, V155, P239, DOI 10.1111/j.1432-1033.1986.tb09482.x; HANISCH FG, 1985, EUR J BIOCHEM, V152, P343, DOI 10.1111/j.1432-1033.1985.tb09204.x; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HOFF SD, 1989, CANCER RES, V49, P6883; IRIMURA T, 1991, CANCER RES, V51, P5728; IRIMURA T, 1987, CANCER RES, V47, P881; IRIMURA T, 1988, CANCER RES, V48, P2353; IRIMURA T, 1990, CANCER RES, V50, P3331; Irimura T, 1991, Semin Cancer Biol, V2, P129; IRIMURA T, 1988, J CELL BIOCHEM, V37, P1, DOI 10.1002/jcb.240370102; KITAGAWA H, 1991, BIOCHEM BIOPH RES CO, V178, P1429, DOI 10.1016/0006-291X(91)91053-F; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAN MS, 1990, J BIOL CHEM, V265, P15294; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MATSUSHITA Y, 1990, LAB INVEST, V63, P780; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; PEAT N, 1992, CANCER RES, V52, P1954; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRICE JE, 1989, CLIN EXP METASTAS, V7, P55, DOI 10.1007/BF02057181; Sambrook J, 1989, MOL CLONING LABORATO; SMITH AC, 1987, J CLIN INVEST, V80, P300, DOI 10.1172/JCI113073; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1983, METHOD ENZYMOL, V98, P47; UEMURA M, 1988, CANCER RES, V48, P5335; YAMORI T, 1987, CANCER RES, V47, P2741; YAMORI T, 1989, CANCER RES, V49, P887; YUREWICZ EC, 1987, J BIOL CHEM, V262, P4733; ZOTTER S, 1985, VIRCHOWS ARCH A, V406, P237, DOI 10.1007/BF00737089; ZOTTER S, 1987, LAB INVEST, V57, P193	46	25	26	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10133	10138						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098036				2022-12-25	WOS:A1993LB80000031
J	CAIRNS, P; SHAW, ME; KNOWLES, MA				CAIRNS, P; SHAW, ME; KNOWLES, MA			INITIATION OF BLADDER-CANCER MAY INVOLVE DELETION OF A TUMOR-SUPPRESSOR GENE ON CHROMOSOME-9	ONCOGENE			English	Note							TRANSITIONAL CELL-CARCINOMA; INTERFERON GENES	Although many genetic lesions including suppressor gene inactivation have been identified in sporadic tumours, the identity of the common initiating or early genetic events in most cases remains obscure. We have analysed tumour and leucocyte DNA from a series of 252 primary human bladder tumours of all grades and stages for deletions of chromosome 9. Probes from four polymorphic loci were used to detect loss of heterozygosity (LOH) in tumour specimens. Fifty-nine per cent of tumours from patients informative at one or more of these loci showed LOH. A comparison of LOH for markers on 9p and 9q indicated that proximal 9p or 9q is the likely site for a candidate bladder tumour-suppressor gene. Most strikingly, LOH was observed not only in tumours of high grade or stage but also in > 50% of grade 1 and 2 superficial (pTa) tumours. This is the first change to be identified at significant frequency in such tumours. Inactivation of a tumour-suppressor gene on chromosome 9 may therefore be an early genetic event in the development of bladder cancer.			CAIRNS, P (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,OXTED RHS 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIBAS Z, 1984, CANCER RES, V44, P1257; JAMES CD, 1991, CANCER RES, V51, P1684; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LATHROP GM, 1988, GENOMICS, V3, P361; MOSTOFI FK, 1988, DIAGNOSIS MANAGEMENT, P83; Mostofi FK, 1973, INT CLASSIFICATION T; OLUMI AF, 1990, CANCER RES, V50, P7081; PRESTI JC, 1991, CANCER RES, V51, P5405; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; Sambrook J, 1989, MOL CLONING LABORATO; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; TSAI YC, 1990, CANCER RES, V50, P44; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1988, HMSO CANCER STATISTI; 1978, TNM CLASSIFICAITON M	24	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1083	1085						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096074				2022-12-25	WOS:A1993KT22000034
J	TAGUCHI, H; YOSHIDA, M				TAGUCHI, H; YOSHIDA, M			CHAPERONIN FROM THERMUS-THERMOPHILUS CAN PROTECT SEVERAL ENZYMES FROM IRREVERSIBLE HEAT DENATURATION BY CAPTURING DENATURATION INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; ATP HYDROLYSIS; GROEL; RECONSTITUTION; CARBOXYLASE; AGGREGATION; INVITRO; BINDING	Chaperonin isolated from Thermus thermophilus is stable up to 80-degrees-C. Taking advantage of this heat stability, we have studied the effects of chaperonin on heat denaturation of several relatively heat labile enzymes. When the enzymes are incubated at their denaturating temperatures, the presence of T. thermophilus chaperonin in the solution has little effect on the rate of apparent inactivation of the enzyme. However, this inactivation is not irreversible since most activity is recovered when the solution is shifted to the second incubation at a moderate temperature with concomitant addition of MgATP. When the chaperonin is omitted from the solution, no recovery is observed. Recovery of the activity is also dependent on MgATP in the second incubation and 50% of recovery is attained at 5 muM MgATP. When the chaperonin is added after starting the incubation at a denaturing temperature, recovery of the activity becomes poorer as the delay of chaperonin addition increases. The critical temperature of the incubation at which irreversible denaturation occurs to the enzymes is elevated 8-15-degrees-C by inclusion of T. thermophilus chaperonin in the solution. The heat stability of captured proteins by the chaperonin, assessed as retention of the ability to resume productive folding under optimal conditions, is measured more accurately using chemically produced folding intermediate-chaperonin complexes. The ability is lost at about 78-degrees-C being irrespective of variable heat stability of individual enzymes. These results indicate that during heat denaturation proteins assume a common structure which is recognizable by the chaperonin. Once a protein with this structure is captured by T. thermophilus chaperonin, it retains the ability to resume productive folding even after exposure to the otherwise denaturing high temperature. Its heat stability seems to be limited solely by heat stability of chaperonin.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,4259 NAGATSUTA,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology			Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	21	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5371	5375						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095496				2022-12-25	WOS:A1993KR82200008
J	GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG				GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG			ENHANCEMENT OF PANCREATIC TUMOR-METASTASIS IN TRANSGENIC IMMUNODEFICIENT MICE	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; T-ANTIGEN; ACINAR-CELLS; MOUSE MODEL; NUDE-MICE; SCID MICE; GROWTH; GENE; EXPRESSION; NK	Metastatic pancreatic cancer presents a bleak prognosis. Typically, human tumor development has been modelled in animals by generating transgenic mice carrying an oncogene, and metastasis studied by engrafting human tumor cells into immunodeficient mice. We derived mouse lines that spontaneously develop metastatic pancreatic cancer by crossing a transgenic line that develops primary pancreatic adenocarcinomas with lines that are deficient for different lymphocyte components of the immune system. We obtained transgenics carrying the SCID mutation resulting in loss of B and T cell function, those carrying the beige mutation resulting in impaired NK cell and macrophage activity, and those carrying both mutations. Although human graft studies indicated that the SCID mutation permits metastasis of different types of tumor cells, in our mice its effect on metastasis of the pancreatic tumor was minimal. In contrast, the beige mutation resulted in metastasis in almost 90% of the animals. The SCID and beige mutations synergistically resulted in faster growing tumors. Both primary tumors and metastases contained undifferentiated and differentiated cell types. The tissue distribution of metastases was similar to that recorded from human patients with pancreatic cancer, suggesting that mechanisms underlying metastasis in these mice could be similar to those involved in human disease.	UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT PATHOL, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT BIOMED SCI, GUELPH N1G 2W1, ON, CANADA	University of Guelph; University of Guelph; University of Guelph								ALOSCO T, 1993, CANCER IMMUNOL IMMUN, V36, P364, DOI 10.1007/BF01742252; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CECI JD, 1991, ONCOGENE, V6, P323; CONNELLY CS, 1989, EXP CELL RES, V183, P257, DOI 10.1016/0014-4827(89)90387-X; CROY BA, 1990, J REPROD FERTIL, V88, P231, DOI 10.1530/jrf.0.0880231; CROY BA, 1982, J REPROD IMMUNOL, V4, P277; DECKHUT AM, 1992, J VIROL, V66, P440, DOI 10.1128/JVI.66.1.440-447.1992; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; FODSTAD O, 1984, CANCER RES, V44, P4403; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GLASNER S, 1992, AM J PATHOL, V140, P1237; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNING R, 1981, VIROLOGY, V108, P325, DOI 10.1016/0042-6822(81)90441-4; HILL LL, 1991, CANCER RES, V51, P4937; HOGAN B, 1986, MANIPULATING MOUSE E; HOWARD JM, 1977, CURR PROBL CANCER, V2, P1; INOHARA H, 1992, CARCINOGENESIS, V13, P845, DOI 10.1093/carcin/13.5.845; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KERBEL RS, 1991, CANCER METAST REV, V10, P201, DOI 10.1007/BF00050792; KIM YB, 1980, J IMMUNOL, V125, P755; LANIER LL, 1992, CURR OPIN IMMUNOL, V4, P38, DOI 10.1016/0952-7915(92)90121-T; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; NOMURA T, 1990, J RADIAT RES, V31, P288, DOI 10.1269/jrr.31.288; NOMURA T, 1991, JPN J CANCER RES, V82, P701, DOI 10.1111/j.1349-7006.1991.tb01906.x; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PHILLIPS RA, 1989, CURR TOP MICROBIOL, V152, P259; PROSS HF, 1993, NAT IMMUN, V12, P279; QIAN JH, 1991, J IMMUNOL, V146, P3250; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDDY S, 1987, CANCER RES, V47, P2456; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STUTMAN O, 1981, NATURE, V290, P254, DOI 10.1038/290254a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TANAKA Y, 1989, VIROLOGY, V171, P205, DOI 10.1016/0042-6822(89)90527-8; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TEVETHIA SS, 1980, VIRAL ONCOLOGY, P581; WEINER LM, 1993, CANCER RES, V53, P94; WILLIAMS SS, 1993, LAB ANIM SCI, V43, P139; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2983	2990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084602				2022-12-25	WOS:A1994PG82200025
J	STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J				STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J			GERM-LINE EXCLUSION OF A SINGLE P53 ALLELE BY PREMATURE TERMINATION OF TRANSLATION IN A LI-FRAUMENI SYNDROME FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; NONSENSE MUTATIONS; BREAST-CANCER; DEFICIENT; NEOPLASMS; CHILDREN; MICE	Germline p53 mutations have been detected in approximately half of the families affected by the Li-Fraumeni syndrome (LFS), in which they are believed to represent the genetic status predisposing to multiple cancers. Failure to detect mutations in the other half of LFS families suggests that sequence analysis, which has been limited to the p53 gene coding region, have overlooked other genetic events lying outside of this region or/and that alterations in other gene(s) than p53 may also lead to the syndrome. In this report, we present the evidence that a single base pair deletion in the p53 coding sequence, leading to premature signal termination of translation, generates a null allele by preventing transport of mutant allele mRNAs into the cytoplasm. This allelic exclusion which confers a status of unizygote vis-a-vis the wild-type p53 gene to individuals who carry the mutant allele, leads to predisposition to multiple cancers in a Li-Fraumeni family. Thus, the loss of the wild-type p53 allele appears as the rate limiting step in tumor induction.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PEDIAT ONCOL,F-94805 VILLEJUIF,FRANCE; INSERM,U155,UNITE RECH EPIDEMIOL GENET,F-75016 PARIS,FRANCE; INST GUSTAVE ROUSSY,UNITE DIAGNOST MOLEC,F-94805 VILLEJUIF,FRANCE; INT AGCY RES CANC,F-69372 LYON 08,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; World Health Organization; International Agency for Research on Cancer (IARC)			Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018; Stolzenberg, Marie-Claude/I-6281-2017	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Stolzenberg, Marie-Claude/0000-0001-8026-0360; Feunteun, Jean/0000-0003-1212-9189				BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BIRCH JM, 1994, CANCER RES, V54, P1298; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRUGIERES L, 1993, CANCER RES, V53, P452; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORIO Y, 1994, ONCOGENE, V9, P1231; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LI FP, 1988, CANCER RES, V48, P5358; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MCINTOSH I, 1993, NAT GENET, V4, P219, DOI 10.1038/ng0793-219; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2799	2804						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084585				2022-12-25	WOS:A1994PG82200005
J	EVANS, GA; GARCIA, GG; ERWIN, R; HOWARD, OMZ; FARRAR, WL				EVANS, GA; GARCIA, GG; ERWIN, R; HOWARD, OMZ; FARRAR, WL			PERVANADATE SIMULATES THE EFFECTS OF INTERLEUKIN-2 (IL-2) IN HUMAN T-CELLS AND PROVIDES EVIDENCE FOR THE ACTIVATION OF 2 DISTINCT TYROSINE KINASE PATHWAYS BY IL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70-75 BETA-SUBUNIT; SIGNAL TRANSDUCTION; RECEPTOR COMPLEX; PROTEIN-KINASE; LYMPHOCYTES-T; PHOSPHORYLATION; ASSOCIATION	Pervanadate has been shown to rapidly increase the level of tyrosine phosphorylation in intact cells. Because one of the most rapidly detectable events following treatment of human T cells with interleukin-2 (IL-2) is tyrosine kinase activation, we were interested to determine whether pervanadate could act to induce IL-2-associated events. We show here that pervanadate does act to induce IL-2 signal transduction pathways as determined by induction of mitogenesis and interferon gamma production in normal human T cells and the factor independent T cell line YT. Analysis of signal transduction events shows that pervanadate induces the activity of the src family of tyrosine kinases lck and fyn and the tyrosine phosphorylation of a major IL-2 responsive protein of 97 kDa. Pervanadate does not, however, induce the activity of tyrosine kinases associated with the IL-2 receptor or the phosphorylation of a major IL-2 responsive protein of 116 kDa (Jak-3). Together these data suggest that src family kinase activation is a down stream event following IL-2 stimulation and is not directly associated with the activation of the IL-2 receptor-associated tyrosine kinase. The data also imply that tyrosine phosphorylation of p116/Jak-3 is strictly associated with activation of tyrosine kinases associated with the IL-2 receptor. With the use of pervanadate as a tool, we have established a dissociation of src family kinases with IL-2 receptor activation and imply the involvement of two distinct tyrosine kinase pathways, a receptor-associated pathway closely coupled with Jak-3 phosphorylation and a downstream pathway involving src family kinase activation.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, CYTOKINE MECHANISMS SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	EVANS, GA (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA.		Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052				COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FERRIS DK, 1989, J IMMUNOL, V143, P870; FUNG MR, 1991, J IMMUNOL, V147, P1253; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; MILLS GB, 1985, J BIOL CHEM, V260, P2500; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RUI H, 1992, J BIOL CHEM, V267, P24076; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	29	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23407	23412						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089104				2022-12-25	WOS:A1994PQ34500007
J	JONES, LG; ELLA, KM; BRADSHAW, CD; GAUSE, KC; DEY, M; WISEHARTJOHNSON, AE; SPIVEY, EC; MEIER, KE				JONES, LG; ELLA, KM; BRADSHAW, CD; GAUSE, KC; DEY, M; WISEHARTJOHNSON, AE; SPIVEY, EC; MEIER, KE			ACTIVATIONS OF MITOGEN-ACTIVATED PROTEIN-KINASES AND PHOSPHOLIPASE-D IN A7R5 VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EL4 THYMOMA CELLS; SWISS 3T3 CELLS; GROWTH-FACTOR; MAP KINASE; PHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION; PHORBOL ESTER; PHOSPHATIDYLCHOLINE BREAKDOWN; FREE SYSTEM; WILD-TYPE	Activation of mitogen-activated protein kinases (MAPKs) was examined in the A7r5 rat vascular smooth muscle cell line. Treatment of A7r5 cells with vasopressin, phorbol ester (PMA), or serum resulted in activation of two MAPKs, Erk-1 and Erk-2. Phosphatidylinositol-specific phospholipase C was activated in response to vasopressin but not to PMA. Vasopressin and PMA both caused maximal activation of PLD within 5 minutes. Application of bacterial phospholipase D (PLD) to A7r5 cells increased phosphatidic acid to levels similar to those seen with vasopressin or PMA. Acute exposure of the cells to vasopressin, PMA, or PLD increased phosphorylation of many of the same cytosolic and membrane proteins. However, bacterial PLD did not promote significant activation of Erk-1 and Erk-2. Phosphatidic acid and lysophosphatidic acid (LPA) likewise did not stimulate MAPK activity in A7r5 cells. Serum and vasopressin stimulated DNA synthesis when present for more than 30 min, while PLD, PMA, phosphatidic acid, and LPA were not mitogenic. These data suggest that activations of MAPKs and PLD are concurrent but independent responses to vasopressin in A7r5 cells. Acute activation of these enzymes is not sufficient to simulate DNA synthesis.	MED UNIV S CAROLINA, DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT, CHARLESTON, SC 29425 USA	Medical University of South Carolina					NHLBI NIH HHS [HL 07260-16] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CHEN RH, 1992, MOL CELL BIOL, V12, P925; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELDAR H, 1993, J BIOL CHEM, V268, P12560; ELLA KM, 1994, ANAL BIOCHEM, V218, P136, DOI 10.1006/abio.1994.1152; EXTON JH, 1990, J BIOL CHEM, V265, P1; EXTON JH, 1992, CIBA F SYMP, V164, P36; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; JONES LG, 1992, AM J PHYSIOL, V263, pH1447, DOI 10.1152/ajpheart.1992.263.5.H1447; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KONDO T, 1992, J BIOL CHEM, V267, P23609; KONISHI F, 1991, BIOCHEM BIOPH RES CO, V179, P1070, DOI 10.1016/0006-291X(91)91928-6; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; LUBINUS MAD, 1994, J BIOL CHEM, V269, P1994; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MEIER KE, 1992, FASEB J, V6, pA1851; MOEHREN G, 1994, J BIOL CHEM, V269, P838; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OHANIAN J, 1990, J BIOL CHEM, V265, P8921; OLSON SC, 1991, J BIOL CHEM, V266, P17236; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1992, J BIOL CHEM, V267, P24796; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKI T, 1979, J BIOL CHEM, V254, P9761; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG P, 1991, J BIOL CHEM, V266, P14877; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZHANG H, 1990, J BIOL CHEM, V265, P21309	75	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23790	23799						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089151				2022-12-25	WOS:A1994PQ34500062
J	MILLS, RG; RALSTON, GB; KING, GF				MILLS, RG; RALSTON, GB; KING, GF			THE SOLUTION STRUCTURE OF SARAFOTOXIN-C - IMPLICATIONS FOR LIGAND RECOGNITION BY ENDOTHELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DISTANCE GEOMETRY CALCULATIONS; RAT ISOLATED AORTA; SOLUTION CONFORMATION; NMR-SPECTROSCOPY; PROTEIN STRUCTURES; RECEPTOR SUBTYPES; ANALOGS; ANTAGONIST; CLONING	The solution structure of sarafotoxin-c has been determined using NMR spectroscopy. A total of 112 interproton distance constraints derived from two-dimensional MMR spectra were used to calculate a family of structures using a combination of distance geometry and dynamical simulated annealing calculations. The structures reveal a well defined cu helix extending from Glu(9) to Cys(15) and an N-terminal region (Cys(1)-Asp(8)) that is tightly constrained by disulfide bands to Cys residues in the central helix. In contrast, the C-terminal region (His(16)-Trp(21)) does not adopt a defined conformation in the final family of structures. This is consistent with the paucity of NMR-derived structural constraints obtained for this region and leads to the suggestion that the C-terminal region oscillates rapidly between a number of substantially different conformers. It is proposed that differences between the central helix of the endothelin and sarafotoxin isopeptides might be important in binding of these ligands by the G protein-coupled endothelin receptors.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200				ANDERSEN NH, 1992, BIOCHEMISTRY-US, V31, P1280, DOI 10.1021/bi00120a003; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BENEDETTI E, 1992, BIOPOLYMERS, V32, P453, DOI 10.1002/bip.360320424; BENNES R, 1990, FEBS LETT, V276, P21, DOI 10.1016/0014-5793(90)80497-7; BORTMANN P, 1991, NEUROCHEM INT, V18, P491, DOI 10.1016/0197-0186(91)90145-4; BRUNGER AT, 1990, X PLOR VERSION 2 1 U; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ENDO S, 1989, FEBS LETT, V257, P149, DOI 10.1016/0014-5793(89)81808-3; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULATI A, 1991, LIFE SCI, V48, P1207, DOI 10.1016/0024-3205(91)90460-S; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HIRATA Y, 1989, BIOCHEM BIOPH RES CO, V160, P228, DOI 10.1016/0006-291X(89)91645-8; IHARA M, 1992, LIFE SCI, V51, P47; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KARNE S, 1993, J BIOL CHEM, V268, P19126; KIMURA S, 1988, BIOCHEM BIOPH RES CO, V156, P1182, DOI 10.1016/S0006-291X(88)80757-5; KOCHVA E, 1993, TOXICON, V31, P541, DOI 10.1016/0041-0101(93)90111-U; KOCHVA E, 1982, TOXICON, V20, P581, DOI 10.1016/0041-0101(82)90052-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDAN G, 1991, TOXICON, V29, P237, DOI 10.1016/0041-0101(91)90108-4; MILLS RG, 1991, FEBS LETT, V282, P247, DOI 10.1016/0014-5793(91)80488-O; MILLS RG, 1992, BIOCHEMISTRY-US, V31, P5640, DOI 10.1021/bi00139a030; MILLS RG, 1994, THESIS U SYDNEY; MIYAUCHI T, 1991, J CARDIOVASC PHAR S7, V17, P394; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ODONOGHUE SI, 1993, PROTEIN ENG, V6, P557, DOI 10.1093/protein/6.6.557; RANDALL MD, 1989, BRIT J PHARMACOL, V98, P685, DOI 10.1111/j.1476-5381.1989.tb12644.x; SAEKI T, 1991, BIOCHEM BIOPH RES CO, V179, P286, DOI 10.1016/0006-291X(91)91367-L; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAUDEK V, 1991, INT J PEPT PROT RES, V37, P174; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SOKOLOVSKY M, 1992, J NEUROCHEM, V59, P809, DOI 10.1111/j.1471-4159.1992.tb08318.x; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAKEMORI AE, 1992, ANNU REV PHARMACOL, V32, P239, DOI 10.1146/annurev.pa.32.040192.001323; TAMAOKI H, 1992, BIOPOLYMERS, V32, P353, DOI 10.1002/bip.360320410; TAMAOKI H, 1991, PROTEIN ENG, V4, P509, DOI 10.1093/protein/4.5.509; TOPOUZIS S, 1991, BRIT J PHARMACOL, V102, P545, DOI 10.1111/j.1476-5381.1991.tb12208.x; TOPOUZIS S, 1989, BRIT J PHARMACOL, V98, P669, DOI 10.1111/j.1476-5381.1989.tb12642.x; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; TOTA MR, 1990, J BIOL CHEM, V265, P16891; URADE Y, 1992, FEBS LETT, V311, P12, DOI 10.1016/0014-5793(92)81355-P; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V180, P475, DOI 10.1016/S0006-291X(05)81089-7; WILLIAMS RJP, 1977, ANGEW CHEM INT EDIT, V16, P766, DOI 10.1002/anie.197707661; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	58	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23413	23419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089105				2022-12-25	WOS:A1994PQ34500008
J	XU, XM; BARRY, DC; SETTLEMAN, J; SCHWARTZ, MA; BOKOCH, GM				XU, XM; BARRY, DC; SETTLEMAN, J; SCHWARTZ, MA; BOKOCH, GM			DIFFERING STRUCTURAL REQUIREMENTS FOR GTPASE-ACTIVATING PROTEIN RESPONSIVENESS AND NADPH OXIDASE ACTIVATION BY RAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BINDING PROTEIN; GAP; IDENTIFICATION; EFFECTOR; RHO; P21; DOMAIN; COMPONENTS; P21RAC1	The Rac GTP-binding proteins regulate the actin cytoskeleton and the superoxide-forming NADPH oxidase of phagocytic leukocytes. These functions of Rac are determined by the GTP/GDP state of the protein, which can be modulated by GTPase-activating proteins (GAPs). The interaction of Ras with both downstream signaling targets and GAPs is mediated via an ''effector'' domain (amino acids 3(9-40). We demonstrate that the effector domain of Rac2 is required for both NADPH oxidase activation and actin assembly, but that mutations in this region do not decrease the responsiveness of Rac to GAPs. In contrast, mutations of residues 12 (Gly --> Val) or 61 (Gln --> Leu) inhibit both intrinsic- and GAP-stimulated GTP hydrolysis by Rac2. A double mutation in which both the effector domain and Q61L were modified restored NADPH oxidase activation and membrane ruffling, while the equivalent effector domain and G12V double mutation did not. The Rac2 Q61L mutant had an increased ''affinity'' for NADPH oxidase activation and for GAP binding as compared to the wild type or G12V proteins. These experiments suggest that Rac contains at least two ''effector'' interaction sites, and that changes in binding interactions at one of these sites may influence the function of the other.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, BOSTON, MA 02129 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital				schwartz, martin/0000-0002-2071-1243; xu, xuemin/0000-0002-7426-272X	NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MORII N, 1993, J BIOL CHEM, V268, P27160; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WITTINGHOFER A, 1992, CANCER BIOL, V3, P189; WOOD DR, 1994, J BIOL CHEM, V269, P5322; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	36	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23569	23574						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089125				2022-12-25	WOS:A1994PQ34500030
J	ZHANG, FL; MOOMAW, JF; CASEY, PJ				ZHANG, FL; MOOMAW, JF; CASEY, PJ			PROPERTIES AND KINETIC MECHANISM OF RECOMBINANT MAMMALIAN PROTEIN GERANYLGERANYLTRANSFERASE TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE SYNTHASE; BOVINE BRAIN; FARNESYLTRANSFERASE; TRANSFERASE; INHIBITION; BINDING; ZINC; CYS; PRENYLATION; FARNESYL	Protein geranylgeranyltransferase type I (GGTase I) catalyzes the prenylation of a number of proteins that play important roles in cellular signaling The recent cDNA cloning of this enzyme (Zhang, F. L., Diehl, R. E., Kohl, N. E., Gibbs, J. B., Giros, B., Casey, P.J., and Omer, C. A. (1994) J, Biol. Chem. 269, 3175-3180) has allowed us to develop an expression system for obtaining large quantities of the enzyme. Co-infection of insect cells with recombinant baculoviruses encoding the two subunits of the enzyme results in GGTase I accumulation within the cells to levels of >20% of cytosolic protein. The recombinant enzyme could be readily purified by ion-exchange chromatography and is shown to possess the activity and specificity of the enzyme obtained from mammalian tissues. Production of the recombinant enzyme allowed us to confirm its identity as a zinc metalloenzyme by direct identification of the metal using atomic absorption spectroscopy. We also identify two substrate analogs that are competitive inhibitors of GGTase I. One is a novel isoprenoid analog, 3-aza-GGPP, which inhibits the enzyme with a K-i of 15 nM. The second inhibitor is the tetrapeptide Cys-Val-Phe-Leu, which exhibits a K-i of 50 nM. The use of these inhibitors, coupled with a steady-state kinetic analysis of the enzyme, reveals that the reaction catalyzed by GGTase I proceeds through a random ordered sequential mechanism.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM 46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; ERICSSON J, 1993, J BIOL CHEM, V268, P832; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FROMM HJ, 1975, INITIAL RATE ENZYME, P83; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KOHL NE, 1991, J BIOL CHEM, V266, P18884; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUELBACHER M, 1988, BIOCHEMISTRY-US, V27, P7315; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RAHIER A, 1990, BIOCHEM SOC T, V18, P48, DOI 10.1042/bst0180048; REARDON JE, 1986, BIOCHEMISTRY-US, V25, P5609, DOI 10.1021/bi00367a040; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REISS Y, 1991, METHODS SAN DIEGO, V1, P241; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGEL IH, 1975, ENZYME KINETICS, P506; STEIGER A, 1992, J ORG CHEM, V57, P3444, DOI 10.1021/jo00038a038; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P29; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	38	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23465	23470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089111				2022-12-25	WOS:A1994PQ34500016
J	CALABRO, A; HASCALL, VC				CALABRO, A; HASCALL, VC			DIFFERENTIAL-EFFECTS OF BREFELDIN-A ON CHONDROITIN SULFATE AND HYALURONAN SYNTHESIS IN RAT CHONDROSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROTEOGLYCAN CORE PROTEIN; ENDOPLASMIC-RETICULUM; CULTURED CHONDROCYTES; EMBRYONIC CHICKEN; GRANULOSA-CELLS; LINKAGE REGION; BIOSYNTHESIS; CARTILAGE; OLIGOSACCHARIDES	Brefeldin A, a fungal metabolite, interferes with vesicular transport causing disassembly of the Golgi complex with redistribution of Golgi components to the endoplasmic reticulum, and isolation of the trans-Golgi cisternae from the trans-Golgi network. We examined the effects of brefeldin A on the synthesis of hyaluronan and chondroitin sulfate by chondrocytes from the Swarm rat chondrosarcoma. Hyaluronan synthesis continues at a constant rate in the presence of brefeldin A for at least 8 h, and is therefore independent of vesicular transport. By contrast, chondroitin sulfate synthesis is rapidly inhibited (to <1% within 15 min) by brefeldin A indicating that addition of chondroitin sulfate chains to the aggrecan core protein precursor requires vesicular transport. Removal of brefeldin A rapidly restored chondroitin sulfate chain elongation and sulfation on the aggrecan core protein precursor reaching 100% of control in 2 h and consistently establishing a higher steady state rate (up to 120%) by 4 h. Addition of p-nitrophenyl-beta-D-xylopyranoside, an exogenous acceptor for the synthesis of chondroitin sulfate chains, does not reverse the brefeldin A block. This suggests that xyloside-initiated synthesis of chondroitin sulfate depends on transport vesicles as might occur if the enzymes for synthesizing the Linkage tetrasaccharide (i.e. galactosyltransferases) reside in the Golgi, while those required to elongate the chains reside in the trans-Golgi network. Recovery of chondroitin sulfate synthesis from brefeldin A treatment occurred efficiently in the presence of cycloheximide, indicating that the machinery for chondroitin sulfate synthesis reassembles from previously existing proteins. The results are consistent with the current model that hyaluronan synthesis occurs at the plasma membrane and is independent of vesicular transport, and with the hypothesis that the enzyme complex for chondroitin sulfate elongation and sulfation resides within the trans-Golgi network, and therefore isolated from the aggrecan core protein precursor in the presence of brefeldin A.	NIDR, BONE RES BRANCH, PROTEOGLYCAN CHEM SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BERNSTEIN RE, 1987, ADV CLIN CHEM, V26, P1, DOI 10.1016/S0065-2423(08)60321-2; CALABRO A, 1994, J BIOL CHEM, V269, P22771; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FELLINI SA, 1984, J BIOL CHEM, V259, P4634; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HASCALL VC, 1988, ISI ATLAS-BIOCHEM, V1, P189; HIDALGO J, 1992, EUR J CELL BIOL, V58, P214; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; KIMURA JH, 1981, J BIOL CHEM, V256, P7890; KIMURA JH, 1981, J BIOL CHEM, V256, P4368; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; MASON RM, 1982, BIOCHEM J, V207, P445, DOI 10.1042/bj2070445; MCQUILLAN DJ, 1984, BIOCHEM J, V224, P977, DOI 10.1042/bj2240977; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MITCHELL D, 1981, BIOCHEM J, V196, P521, DOI 10.1042/bj1960521; NILSSON B, 1982, J BIOL CHEM, V257, P920; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Prehm P., 1989, CIBA F SYMP, V143, P281; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; RODEN L, 1966, J BIOL CHEM, V241, P5949; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; THONAR EJMA, 1983, J BIOL CHEM, V258, P1564; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22764	22770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077228				2022-12-25	WOS:A1994PQ16300048
J	KITAZUME, S; KITAJIMA, K; INOUE, S; TROY, FA; CHO, JW; LENNARZ, WJ; INOUE, Y				KITAZUME, S; KITAJIMA, K; INOUE, S; TROY, FA; CHO, JW; LENNARZ, WJ; INOUE, Y			IDENTIFICATION OF POLYSIALIC ACID-CONTAINING GLYCOPROTEIN IN THE JELLY COAT OF SEA-URCHIN EGGS - OCCURRENCE OF A NOVEL TYPE OF POLYSIALIC ACID STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; LIQUID-CHROMATOGRAPHY; CARBOHYDRATE UNITS; POLY(SIALIC ACID); ACROSOME REACTION; RAINBOW-TROUT; CHAINS; PURIFICATION; SIALOGLYCOPROTEIN; INDUCTION	Sea urchin eggs are surrounded by a gelatinous layer (called the jelly coat) that consists of mixture of fucose-rich polysaccharides and sialic acid-rich glycoproteins. Chemical and 500 MHz H-1 NMR spectroscopic studies revealed for the first time the presence of a novel polysialic acid (polySia) structure in the jelly coat glycoproteins isolated from Hemicentrotus pulcherrimus (designated polySia-gp(H)). The structure of the polySia chains was thoroughly characterized as (-->5-O-glycolyl-Neu5Gc alpha 2-->)(n), where n ranges from 4 to more than 40 Neu5Gc residues. The polyNeu5Gc chains were attached to core oligosaccharides that were O-glycosidically linked to threonine residues on a core polypeptide. Each polypeptide contained about 17 O-linked polysialylglycan chains. The apparent molecular weight of polySia-gp(H) was 180,000. The expression of this new polySia structure in place of alpha 2-->8-linked polySia is the main structural feature that distinguishes polySia-gp from other known polysialylated glycoproteins. The (-->5-O-glycolyl-Neu5Gc alpha 2-->)(n), chains were resistant to exo- and endosialidases from Arthrobacter ureafaciens and bacteriophage K1F, respectively. Discovery of these (-->5-O-glycolyl-Neu5Gc alpha 2-->)(n) chains adds a new class of naturally occurring polySia to the structurally diverse family of polysialylated glycoproteins. The structure of a polySia-gp hom a different sea urchin species, Strongylocentrotus purpuratus (designated polySia-gp(S)), was also determined to ascertain if there were any species-specific differences. The 500 MHz H-1 NMR spectra of the two polySia-gps were identical, indicating that at this level of molecular detail the structures were the same. The molecular weight of polySia-gp(S) was larger, however (250,000), and it contained about 25 polySia chains O-glycosidically linked to both threonine (two-thirds) and serine (one-third) residues.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; UNIV TOKYO,GRAD SCH SCI,DEPT BIOCHEM & BIOPHYS,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of California System; University of California Davis; University of Tokyo; Showa University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184, R01GM033185, R37GM033185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09352] Funding Source: Medline; NIGMS NIH HHS [GM 33185, GM 33184] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BERGWERFF AA, 1993, POLYSIALIC ACID, P201; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; GROGAN T, 1994, LAB INVEST, V70, pA110; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE S, 1980, BIOCHEM BIOPH RES CO, V93, P162, DOI 10.1016/S0006-291X(80)80260-9; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; IRIE A, 1990, 15TH INT CARB S YOK, P200; ISAKA S, 1970, EXP CELL RES, V59, P37, DOI 10.1016/0014-4827(70)90621-X; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SATO C, 1993, J BIOL CHEM, V268, P23675; SCOTT AA, 1994, LAB INVEST, V70, pA120; SEGALL GK, 1981, DEV BIOL, V86, P87, DOI 10.1016/0012-1606(81)90318-3; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHIMIZU T, 1990, DEV GROWTH DIFFER, V32, P473; SHIMODA Y, 1994, BIOCHEMISTRY-US, V33, P1202, DOI 10.1021/bi00171a020; SMIRNOVA GP, 1987, BIOCHIM BIOPHYS ACTA, V920, P47, DOI 10.1016/0005-2760(87)90309-2; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; ZUBER C, 1992, J BIOL CHEM, V267, P9965	43	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22712	22718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077223				2022-12-25	WOS:A1994PQ16300041
J	LEVITSKY, DO; NICOLL, DA; PHILIPSON, KD				LEVITSKY, DO; NICOLL, DA; PHILIPSON, KD			IDENTIFICATION OF THE HIGH-AFFINITY CA2+-BINDING DOMAIN OF THE CARDIAC NA+-CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SODIUM DODECYL-SULFATE; SARCOPLASMIC-RETICULUM; MEMBRANE; RELEASE; CELL; NA; CA	The cardiac sarcolemmal Na+-Ca2+ exchanger transports Na+ and Ca2+ but is also regulated by Ca2+ at a high affinity binding site. A large intracellular, hydrophilic loop of the exchanger has been suggested to contain the Ca2+-binding regulatory domain (Matsuoka S., Nicoll, D. A., Reilly, R. F., Hilgemann, D. W., and Philipson, K. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3870-3874). To localize the Ca2+-binding site(s), we expressed portions of the exchanger loop as fusion proteins and measured binding by Ca-45(2+) overlay. The high affinity binding domain is located near the center of the loop and binds Ca2+ in a cooperative manner. K-0.5 ranges from 0.3 to 3 mu M in the presence of 0.2-5 mM Mg2+. The binding region (amino acids 371-508) has two highly acidic sequences, each characterized by 3 consecutive aspartic acid residues. Ca2+ affinity markedly decreases when these aspartates are mutated. The Ca2+-binding region does not contain an EF-hand motif. The mobilities during SDS-polyacrylamide gel electrophoresis of fusion proteins with high Ca2+ affinity differ depending on the presence or absence of Ca2+ in the gel loading buffer. The high affinity Ca2+-binding domain is probably responsible for the secondary Ca2+ regulation of the Na+-Ca2+ exchanger.	UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER PF, 1976, J PHYSL, V259, P104; BRAR SK, 1993, J BIOL CHEM, V268, P24902; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HRYSHKO LV, 1994, BIOPHYS J, V66, pA331; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P262; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Sambrook J, 1989, MOL CLONING LABORATO; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	21	162	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22847	22852						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077237				2022-12-25	WOS:A1994PQ16300059
J	HANSEN, SK; GUERRINI, L; BLASI, F				HANSEN, SK; GUERRINI, L; BLASI, F			DIFFERENTIAL DNA-SEQUENCE SPECIFICITY AND REGULATION OF HIV-1 ENHANCER ACTIVITY BY CREL-RELA TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; P65 SUBUNIT; CHLORAMPHENICOL ACETYLTRANSFERASE; BINDING SUBUNIT; RNA-POLYMERASE; 65-KD SUBUNIT; GENE; PROTEIN; P50	The cRel-RelA and NF-kappa B (p50-RelA) transcription factors bind to a kappa B-like sequence termed Rel-related proteins binding element localized in the regulatory region of the human urokinase plasminogen activator (uPA) gene. This sequence is highly conserved in murine and porcine uPA genes where it retained the ability to associate with cRel-RelA. On the other hand, NF-kappa B binding was obtained with the human and porcine elements only. Methylation interference analysis showed that NF-kappa B and cRel-RelA had identical interference patterns. Mutational analysis showed that DNA binding was highly sensitive to mutations within the decameric Rel-related proteins binding element core site. However, alterations of nucleotides flanking the decameric IgK-kappa B motif, which preferentially associated with NF-kappa B, resulted in high affinity cRel-RelA binding both in vitro and in vivo. These data demonstrate that NF-kappa B and cRel-RelA have overlapping but distinct DNA sequence specificities. Bandshift analysis with HeLa and Jurkat cell extracts or with in vitro translated proteins revealed that the SV40-, HIV-1-, and interleukin-2 receptor alpha subunit kappa B elements efficiently associated with cRel-RelA, suggesting that this heterodimer may be involved in the regulation of several genes. Cotransfection studies of HIV-1 long terminal repeat-chloramphenicol acetyltransferase reporter DNA with RelA, cRel, and p50 expression vectors were performed in COS7 and U293 cells to analyze the ability of cRel-RelA to regulate HIV-1 enhancer activity. In vivo formation of the cRel-RelA complex resulted in specific stimulation of the viral enhancer at a level comparable with that obtained with NF-kappa B. These data suggest that activation of cellular cRel-RelA may play a critical role in the regulation of HIV-1 enhancer activity.	DIBIT HS RAFFAELE SCI INST,MOLEC GENET UNIT,I-20132 MILAN,ITALY; UNIV MILAN,DEPT GENET & MICROBIAL BIOL,I-20132 MILAN,ITALY; UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN K,DENMARK	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Milan; University of Copenhagen				Blasi, Francesco/0000-0001-9406-1784	Telethon [168] Funding Source: Medline	Telethon(Fondazione Telethon)		BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHIOU HC, 1993, CURR OPIN CELL BIOL, V5, P477; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERLOV C, 1991, ONCOGENE, V6, P583; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; ZABEL U, 1991, J BIOL CHEM, V266, P252	36	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22230	22237						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071349				2022-12-25	WOS:A1994PE09800049
J	KLINE, PC; SCHRAMM, VL				KLINE, PC; SCHRAMM, VL			ELECTROSTATIC POTENTIAL SURFACES OF THE TRANSITION-STATE FOR AMP-DEAMINASE AND FOR (R)-COFORMYCIN, A TRANSITION-STATE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DEAMINASE; AQUEOUS-SOLUTION; YEAST; ENZYME; MECHANISM; 2'-DEOXYCOFORMYCIN; STABILIZATION; HYDROLYSIS; SEQUENCE; BINDING	The transition state for the hydrolysis of AMP by AMP deaminase has been characterized by heavy atom kinetic isotope effects (Merkler, D. J., Kline, P. C., Weiss, P., and Schramm, V. L. (1993) Biochemistry 32, 12993-13001). The experimentally established transition state includes a bond order of 0.8 to the attacking water nucleophile, a full bond order to the exocyclic 6-amino group, rehybridization of C-6 of the purine ring to sp(3) and protonation of N-1 by Glu(633). The transition state is on the path to formation of an unstable tetrahedral intermediate in which the exocyclic amine undergoes rapid protonation followed by its departure. In this mechanism, the highest energetic barrier on the reaction coordinate is the attack of the zinc activated water. In a further test of this transition state structure, the electrostatic potential surface for the purine ring of the transition state has been determined by molecular orbital calculations and compared to that of the base of (R)-coformycin 5'-monophosphate, a slow onset, tight binding inhibitor of AMP deaminase that binds with an overall dissociation constant of 10-(11) M. The electrostatic potential surfaces of the aglycones of the transition state and (R)-coformycin are compared to the adenine ring of the substrate and to an alternative transition state structure in which the transition state is late, with fully bonded hydroxyl and fully protonated exocyclic amine. The results indicate a near-match of the electrostatic potential surfaces for the early transition state and (R)-coformycin. The electrostatic nature of the late transition state with a protonated amine leaving group differs both from the transition state determined by kinetic isotope effects and from that of (R)-coformycin analogues. The results provide evidence that the nature of the enzyme-stabilized transition state for adenine deamination involves an early transition state with a partially bonded hydroxyl group. The observed tight binding inhibition by (R)-coformycin analogues as transition state inhibitors results from the similarity of the partial charges on the inhibitors to that of the enzymatic transition state stabilized by AM[P deaminase.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021083, R37GM041916, R01GM041916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21083, GM41916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COX MB, 1990, J BIOMOL STRUCT DYN, V8, P199, DOI 10.1080/07391102.1990.10507798; CRAMER CJ, 1992, CHEM PHYS LETT, V198, P74, DOI 10.1016/0009-2614(92)90051-N; CRAMER CJ, 1992, J COMPUT AID MOL DES, V6, P629, DOI 10.1007/BF00126219; ERLICH J, 1994, IN PRESS BIOCHEMISTR, V33; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; FRIEDEN C, 1979, BIOCHEM BIOPH RES CO, V91, P278, DOI 10.1016/0006-291X(79)90614-4; Frisch M.J., 1992, GAUSSIAN 92 REVISION; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P9917, DOI 10.1021/bi00089a007; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; JONES W, 1989, BIOCHEMISTRY-US, V28, P1242, DOI 10.1021/bi00429a043; KATI WM, 1989, BIOCHEMISTRY-US, V28, P7919, DOI 10.1021/bi00445a055; LAI TF, 1972, ACTA CRYSTALL B-STRU, VB 28, P1982, DOI 10.1107/S0567740872005394; LAMOTTEBRASSEUR J, 1990, J THEOR BIOL, V145, P183, DOI 10.1016/S0022-5193(05)80124-9; MARCH J, 1984, ADV ORG CHEM, P576; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MERKLER DJ, 1993, BIOCHEMISTRY-US, V32, P5792, DOI 10.1021/bi00073a011; MERKLER DJ, 1990, BIOCHEMISTRY-US, V29, P8358, DOI 10.1021/bi00488a023; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1993, BIOCHEMISTRY-US, V32, P12993, DOI 10.1021/bi00211a007; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MERZ KM, 1990, 589 IND U QUANT CHEM; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PARKIN D, 1991, BIOCHEMISTRY-US, V30, P921; Pauling L., 1960, NATURE CHEM BOND, V3rd; POLITZER P, 1981, CHEM APPLICATIONS AT; SABINA RL, 1987, J BIOL CHEM, V262, P12397; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; SIGGEL MRF, 1988, J AM CHEM SOC, V110, P8022, DOI 10.1021/ja00232a011; SIMS LB, 1977, QUANTUM CHEM PROGRAM, V337; SIMS LB, 1984, ISOTOPES ORGANIC CHE, V6, P161; SIMS LB, 1974, SPECIAL PUBLICATION, V1; SJOBERG P, 1990, J PHYS CHEM-US, V94, P3959, DOI 10.1021/j100373a017; SREBRENI.S, 1973, CHEM PHYS LETT, V20, P419, DOI 10.1016/0009-2614(73)85188-7; STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208; VENANZI CA, 1992, J MED CHEM, V35, P1643, DOI 10.1021/jm00087a022; WILSON DK, 1993, BIOCHEMISTRY-US, V32, P1689, DOI 10.1021/bi00058a001; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Wilson E. B., 1955, MOL VIBRATIONS; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002; YEUNG CY, 1985, J BIOL CHEM, V260, P299	42	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22385	22390						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071366				2022-12-25	WOS:A1994PE09800069
J	LACRAZ, S; ISLER, P; VEY, E; WELGUS, HG; DAYER, JM				LACRAZ, S; ISLER, P; VEY, E; WELGUS, HG; DAYER, JM			DIRECT-CONTACT BETWEEN T-LYMPHOCYTES AND MONOCYTES IS A MAJOR PATHWAY FOR INDUCTION OF METALLOPROTEINASE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE; MACROPHAGE ACTIVATION; INTERFERON-GAMMA; SYNOVIAL-CELLS; COGNATE; INTERLEUKIN-1-BETA; INHIBITOR; BIOSYNTHESIS; SUPPRESSION; CACHECTIN	Monocytes and macrophages can modulate the turnover of extracellular matrix by producing metalloproteinases such as interstitial collagenase and 92-kDa gelatinase as well as tissue inhibitor of metalloproteinases. To study mechanisms of metalloproteinase induction in human mononuclear phagocytes, the effects of direct cell-cell contact between activated T lymphocytes and the human monocytic cell line THP-1 were determined. T cells were first activated with phorbol 12-myristate 13-acetate and phytohemagglutinin for 24 h, fixed with paraformaldehyde, and then exposed to THP-1 cells for 48 h. Upon contact with fixed activated T lymphocytes, a massive induction in the expression of both proteinases and tissue inhibitor of metalloproteinases was observed, whereas unstimulated T cells had no effect. Stimulation of metalloproteinase biosynthesis by THP-1 cells was mimiked by a membrane preparation derived from activated T cell lines, whereas cytosol and nuclear fractions of the T cells were ineffective. Furthermore, activated T lymphocytes exposed to trypsin, tunicamycin, or cycloheximide lost the capacity to stimulate THP-1 cells upon subsequent contact, implying the involvement of cell-surface glycoproteins. Similar induction of metalloproteinases by direct contact with activated T cells was also observed using normal blood monocytes as the target cells, and stimulation of monocyte metalloproteinases by T cell contact occurs at a pretranslational level. Consequently, cell cell contact may represent an important biological mechanism for potentiating the inflammatory response that leads to extracellular matrix destruction.	UNIV HOSP GENEVA,DEPT MED,DIV IMMUNOL & ALLERGY,HANS WILSDORF LAB,CH-1211 GENEVA 14,SWITZERLAND; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	University of Geneva; Barnes-Jewish Hospital; Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P5151; DAYER J-M, 1978, Clinics in Rheumatic Diseases, V4, P517; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRASSI J, 1989, J IMMUNOL METHODS, V123, P193, DOI 10.1016/0022-1759(89)90223-8; HAYNES BF, 1988, ARTHRITIS RHEUM, V31, P947, DOI 10.1002/art.1780310802; ISLER P, 1993, EUR CYTOKINE NETW, V4, P15; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KRZESICKI RF, 1991, ARTHRITIS RHEUM-US, V34, P1245, DOI 10.1002/art.1780341007; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LIU CC, 1989, P NATL ACAD SCI USA, V86, P3286, DOI 10.1073/pnas.86.9.3286; LONDEI M, 1988, SCAND J IMMUNOL, V27, P35, DOI 10.1111/j.1365-3083.1988.tb02321.x; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; STOUT RD, 1993, CURR OPIN IMMUNOL, V5, P398, DOI 10.1016/0952-7915(93)90059-2; STOUT RD, 1993, J IMMUNOL, V150, P5330; TAO X, 1993, EUR J IMMUNOL, V23, P2916, DOI 10.1002/eji.1830231128; VANKOOTEN C, 1991, J IMMUNOL, V146, P2654; VEY E, 1992, J IMMUNOL, V149, P2040; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINGFIELD P, 1986, EUR J BIOCHEM, V160, P491, DOI 10.1111/j.1432-1033.1986.tb10066.x; ZHANG JH, 1992, J IMMUNOL, V148, P177	31	165	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22027	22033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071324				2022-12-25	WOS:A1994PE09800018
J	OJCIUS, DM; GAPIN, L; KANELLOPOULOS, JM; KOURILSKY, P				OJCIUS, DM; GAPIN, L; KANELLOPOULOS, JM; KOURILSKY, P			IS ANTIGEN-PROCESSING GUIDED BY MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES	FASEB JOURNAL			English	Article						ANTIGEN PRESENTATION; IMMUNODOMINANCE; T LYMPHOCYTES; PROTEASES; PEPTIDES; MHC LOADING	T-CELL RECOGNITION; CLASS-I MOLECULES; PEPTIDE BINDING-PROTEIN; IMMUNOGENIC PEPTIDES; DISULFIDE BONDS; SELF-PEPTIDES; MHC MOLECULES; RMA-S; DETERMINANT; TRANSPORTER	Major histocompatibility complex class I (MHC-1) molecules bind peptide fragments derived from cytosolic antigens, and class II (MHC-2) molecules bind fragments of proteins that enter the endocytic pathway. How peptides of the right affinity and size are generated in vivo is still the focus of intense research. Current data are consistent with the view that precursor peptides of varying length are produced in the cytosol and transported into the endoplasmic reticulum lumen where nascent MHC-1 could sample the peptides for their affinity. High-affinity peptides would form stable complexes with MHC-1, which are resistant to proteolysis by luminal enzymes; peptides unable to bind to MHC-1 presumably undergo proteolysis in the lumen. On the other hand, multiple mechanisms are probably used to load MHC-2. Some proteins denatured in the acidic and reducing environment of the endosomes most likely bind to MHC-2 through the antigen's immunodominant region, and the exposed portions of the antigen are degraded by endosomal proteases. Other antigens must first be proteolysed into peptide fragments, which compete among themselves for binding to MHC-2, whereas heat shock proteins could also contribute peptides for MHC-2 loading. Because of their respective loading modes, there is a partial correlation between the MHC-2 binding affinity of the protein fragments and their in vivo immunodominance, which may not necessarily be the case for MHC-1.			OJCIUS, DM (corresponding author), INST PASTEUR, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; COGSWELL JP, 1988, ANTIGEN PRESENTING C, P115; COLLINS DS, 1991, J IMMUNOL, V147, P4054; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARDING CV, 1993, J IMMUNOL, V151, P3988; HOWARD JC, 1993, NATURE, V365, P211, DOI 10.1038/365211a0; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; JENSEN PE, 1993, J IMMUNOL, V150, P3347; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LAKEY EK, 1987, P NATL ACAD SCI USA, V84, P1659, DOI 10.1073/pnas.84.6.1659; LAMB JR, 1987, EMBO J, V6, P1245, DOI 10.1002/j.1460-2075.1987.tb02360.x; LEE P, 1988, J IMMUNOL, V140, P1063; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OJCIUS DM, 1994, J IMMUNOL, V152, P2798; OJCIUS DM, 1993, J IMMUNOL, V151, P6020; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; ROTZSCHKE O, 1994, CURR OPIN IMMUNOL, V6, P45, DOI 10.1016/0952-7915(94)90032-9; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; ROUAS N, 1992, MOL IMMUNOL, V29, P883, DOI 10.1016/0161-5890(92)90126-I; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1992, J IMMUNOL, V148, P844; SHASTRI N, 1986, J IMMUNOL, V137, P911; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; VANNOORT JM, 1991, EUR J IMMUNOL, V21, P1989, DOI 10.1002/eji.1830210904; WALLNY HJ, 1992, EUR J IMMUNOL, V22, P655, DOI 10.1002/eji.1830220307; WRAITH DC, 1992, J AUTOIMMUN, V5, P103, DOI 10.1016/0896-8411(92)90025-L; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; ZHUORU L, 1991, J IMMUNOL, V146, P438; ZISMAN E, 1991, P NATL ACAD SCI USA, V88, P9738, DOI 10.1073/pnas.88.21.9738	61	8	9	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1994	8	12					974	978		10.1096/fasebj.8.12.8088463	http://dx.doi.org/10.1096/fasebj.8.12.8088463			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088463				2022-12-25	WOS:A1994PG29300010
J	YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M				YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M			A NEW COMMUNICATION-SYSTEM BETWEEN HEPATOCYTES AND SINUSOIDAL ENDOTHELIAL-CELLS IN LIVER THROUGH VASCULAR ENDOTHELIAL GROWTH-FACTOR AND FLT TYROSINE KINASE RECEPTOR FAMILY (FLT-1 AND KDR/FLK-1)	ONCOGENE			English	Article							C-MET PROTOONCOGENE; MOLECULAR-CLONING; RAT-TISSUES; EXPRESSION; BINDING; GENE; IDENTIFICATION; PURIFICATION; SEQUENCE; MITOGEN	Hepatocyte Growth Factor (HGF)/Scatter Factor secreted from sinusoidal endothelial cells and Kupffer cells in liver activates the c-Met tyrosine kinase receptor expressed on hepatocytes. Here we report yet another possible communication system through a different ligand and tyrosine kinase receptor in an opposite direction. We isolated and determined the primary structure of the entire coding region of rat flt-1 (fms-like tyrosine kinase), a receptor for Vascular Endothelial Growth Factor (VEGF). Using rat flt-1 cDNA as a probe we found that the flt-1 mRNA was expressed at very high levels in sinusoidal endothelial cells in normal rat liver, but was hardly detectable in hepatocytes. The transcripts of another VEGF receptor KDR/Flk-1 structurally related to Flt-1 was also expressed specifically in sinusoidal endothelial cells. On the other hand, VEGF mRNA was expressed weakly in hepatocytes, but not in the nonparenchymal cell fraction. Furthermore, in an in vitro culture system, VEGF demonstrated a remarkably specific growth-stimulatory activity as well as maintenance activity on the sinusoidal endothelial cells. These results suggest that hepatocytes regulate the proliferation and survival of the sinusoidal endothelial cells in liver in a paracrine manner. Therefore two reciprocal communication systems, VEGF-Flt receptor family and HGF-Met receptor, may exist in hepatic tissue.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	University of Tokyo; Technion Israel Institute of Technology			GOTOH, Noriko/D-8430-2015; Neufeld, Gera/F-1524-2019					APRELIKOVA O, 1992, CANCER RES, V52, P746; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ECIHMANN A, 1993, MECH DEVELOP, V42, P33; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TERMAN BI, 1991, ONCOGENE, V6, P1677; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; YASMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	41	244	256	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058332				2022-12-25	WOS:A1994PC05400029
J	BALAGURUMOORTHY, P; BRAHMACHARI, SK				BALAGURUMOORTHY, P; BRAHMACHARI, SK			STRUCTURE AND STABILITY OF HUMAN TELOMERIC SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSFERASE-ACTIVITY; QUADRUPLEX STRUCTURE; Z-DNA; 5'-GUANOSINE MONOPHOSPHATE; POLYINOSINIC ACID; POLYGUANYLIC ACID; GUANINE; TETRAHYMENA; COMPLEXES; TETRAPLEX	Telomeric DNA of a variety of vertebrates including humans contains the tandem repeat d(TTAGGG)(n). We have investigated the structural properties of the human telomeric repeat oligonucleotide models d(T(2)AG(3))(4), d(G(3)T(2)A)(3)G(3), and d(G(3)T(2)AG(3)) using CD, gel electrophoresis, and chemical probing techniques. The sequences d(G(3)T(2)A)(3)G(3) and d(T(2)AG(3))(4) assume an antiparallel G quartet structure by intramolecular folding, while the sequence d(G(3)T(2)AG(3)) also adopts an antiparallel G quartet structure but by dimerization of hairpins. In all the above cases, adenines are in the loop. The TTA loops are oriented at the same end of the G tetrad stem in the case of hairpin dimer. Further, the oligonucleotide D(G(3)T(2)AG(3)) forms a higher order structure by the association of two hairpin dimers via stacking of G tetrad planes. Here we show that N-7 of adenine in the hairpin dimer is Hoogsteen hydrogen-bonded. The partial reactivity of loop adenines with DEPC in d(T(2)AG(3))(4) suggests that the intramolecular G quartet structure is highly polymorphic and structures with different loop orientations and topologies are formed in solution. Intra- and interloop hydrogen bonding schemes for the TTA loops are proposed to account for the observed diethyl pyrocarbonate reactivities of adenines. Sodium-induced G quartet structures differ from their potassium-induced counterparts not only in stability but also in loop conformation and interactions. Thus, the overall structure and stability of telomeric sequences are modulated by the cation present, loop sequence, and the number of G tracts, which might be important for the telomere function.	INDIAN INST SCI, MOLEC BIOPHYS UNIT, BANGALORE 560012, KARNATAKA, INDIA; INDIAN INST SCI, CTR GENET ENGN, BANGALORE 560012, KARNATAKA, INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								ALBERGO DD, 1981, BIOCHEMISTRY-US, V20, P1409, DOI 10.1021/bi00509a001; ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1991, J BIOMOL STRUCT DYN, V8, P15; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BRAHMACHARI SK, 1989, NUCLEIC ACIDS RES, V17, P7273, DOI 10.1093/nar/17.18.7273; BURTON K, 1966, BIOCHEM J, V98, P70, DOI 10.1042/bj0980070; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; CHERRY JM, 1985, CELL, V43, P747, DOI 10.1016/0092-8674(85)90248-X; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FRIEDMANN T, 1978, NUCLEIC ACIDS RES, V5, P615, DOI 10.1093/nar/5.2.615; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GRAY DM, 1974, BIOPOLYMERS, V13, P2087, DOI 10.1002/bip.1974.360131011; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUO Q, 1992, J BIOL CHEM, V267, P15293; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HERRICK G, 1985, CELL, V43, P759, DOI 10.1016/0092-8674(85)90249-1; HOLLIDAY R, 1989, TRENDS GENET, V5, P355, DOI 10.1016/0168-9525(89)90150-9; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; JOHNSTON BH, 1992, METHOD ENZYMOL, V211, P127; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MOHANTY D, 1993, NUCLEIC ACIDS RES, V21, P1767, DOI 10.1093/nar/21.8.1767; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; OKA Y, 1980, GENE, V10, P301; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1975, J AM CHEM SOC, V97, P7198, DOI 10.1021/ja00857a059; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; SASISEKHARAN V, 1975, J MOL BIOL, V92, P171, DOI 10.1016/0022-2836(75)90221-1; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	58	343	348	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21858	21869						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063830				2022-12-25	WOS:A1994PK97300070
J	LECAM, A; PANTESCU, V; PAQUEREAU, L; LEGRAVEREND, C; FAUCONNIER, G; ASINS, G				LECAM, A; PANTESCU, V; PAQUEREAU, L; LEGRAVEREND, C; FAUCONNIER, G; ASINS, G			CIS-ACTING ELEMENTS CONTROLLING TRANSCRIPTION FROM RAT SERINE-PROTEASE INHIBITOR 2.1 GENE PROMOTER - CHARACTERIZATION OF 2 GROWTH-HORMONE RESPONSE SITES AND A DOMINANT PURINE-RICH ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; ZINC-FINGER PROTEIN; NUCLEAR FACTOR; C-FOS; REGULATORY ELEMENTS; CDNA CLONING; C/EBP FAMILY; EXPRESSION; HEPATOCYTES; DNA	The cis-acting elements that are functionally important for the basal, the growth hormone (GH), and the glucocorticoid hormone (GC) regulation of expression of the rat serine protease inhibitor 2.1 gene (spi 2.1) were mapped. Normal rat hepatocytes were transiently transfected with constructs harboring deleted or mutated versions of the spi 2.1 proximal promoter region fused to the chloramphenicol acetyltransferase gene. A purine-rich sequence (GAGA box, nucleotides -57 to -45), whose mutation or deletion almost completely knocks out both basal and hormone-stimulated promoter activities, plays the role of a key control element. A positive GC response element, spanning nucleotides -88 to -74, confers GC responsiveness to a heterologous promoter. Two structurally unrelated GH-response elements (GHRE) were identified. GHRE-II (nucleotides -138 to -104) contains a CCAAT enhancer binding protein binding site whose mutation completely abolishes its GB-dependent enhancer function. GHRE-I, which spans nucleotides -61 to +8, is not an enhancer element. Its GH-dependent activity depends on the preservation of the distance separating the GAGA box and elements of the basic transcriptional machinery. Taken together these results have revealed the existence of an apparently new type of promoter functioning that strictly depends on the integrity of a key regulatory (G + A) motif.	UNIV BARCELONA,FAC PHARM,DEPT BIOCHEM,E-08034 BARCELONA,SPAIN	University of Barcelona	LECAM, A (corresponding author), INSERM,U376,CTR PHARMACOL ENDOCRINOL,RUE CARDONILLE,F-34094 MONTPELLIER 05,FRANCE.		Paquereau, Laurent/A-8781-2010	PAQUEREAU, Laurent/0000-0002-6158-0155				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BILLESTRUP N, 1993, J CELL BIOCH S, V17, P101; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1475; GAGNE D, 1985, J STEROID BIOCHEM, V23, P247, DOI 10.1016/0022-4731(85)90401-7; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PAQUEREAU L, 1992, ANAL BIOCHEM, V204, P147, DOI 10.1016/0003-2697(92)90154-Y; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1283; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WESTIN S, 1990, MOL PHARMACOL, V38, P192; YOON JB, 1990, J BIOL CHEM, V265, P19947	38	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21532	21539						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063790				2022-12-25	WOS:A1994PK97300025
J	REDMOND, T; TARDIFF, M; ZIGMOND, SH				REDMOND, T; TARDIFF, M; ZIGMOND, SH			INDUCTION OF ACTIN POLYMERIZATION IN PERMEABILIZED NEUTROPHILS - ROLE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PHOSPHOLIPASE-D; F-ACTIN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PROTEIN-KINASE; NADPH OXIDASE; ACTIVATION; GTP; TRISPHOSPHATE; CYTOSKELETON	We have used streptolysin-O (SO) permeabilized neutrophils to investigate the signal transduction pathway through which chemoattractants induce actin polymerization. Chemoattractants stimulate phosphorylation of various proteins and lipids but whether these phosphorylations are required for actin polymerization is not known. Addition of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) to SO-permeabilized neutrophils induced a doubling of the F-actin. This induction of F-actin, assayed by TRITC-labeled phalloidin binding, did not require the addition of ATP. Neither addition of apyrase to deplete residual ATP nor addition of ADP or UDP to compete with residual endogenous ATP inhibited significantly the GTP gamma S-induced polymerization. Addition of ATP on its own caused no increase in F-actin and did not affect the time course or concentration dependence of GTP gamma S-induced F-actin. Addition of ATP did increase the maximal amount of F-actin induced by GTP gamma S by about 20%. N-Formylnorleucylleucylphenalanine (formyl-pep tide) in the presence of GTP, but not in its absence, also stimulated an increase in F-actin in SO-permeabilized cells. The F-actin induced by formyl-peptide plus GTP was inhibited by pertussis toxin. The induction did not require addition of ATP and addition of ADP to compete with residual ATP only slightly decreased the level of actin. However, addition of UDP significantly reduced the response to formyl-peptide plus GTP. Addition of ATP enhanced the increase in F-actin induced by optimal concentrations of GTP with formyl-peptide. ATP also lowered the apparent K-m for GTP, but not for N-formyl peptide. The non-hydrolyzable ATP analog, adenosine 5'-(beta,gamma-imino)triphosphate, did not enhance the actin polymerization. Rather its presence inhibited the response induced by formyl-peptide plus GTP. The data suggest that actin polymerization can be induced by GTP gamma S in an manner that is largely ATP-independent. A role for ATP cannot be ruled out in the induction of actin polymerization by formyl-peptide plus GTP.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Tardif, Marianne/AAA-5357-2019	Tardif, Marianne/0000-0003-4438-8281	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019883, R37AI019883] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19883] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BHAKDI S, 1988, PROG ALLERGY, V40, P1; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARSON M, 1986, J CELL BIOL, V103, P2702; COCKCROFT S, 1991, BIOCHEM J, V275, P127, DOI 10.1042/bj2750127; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HENSON PM, 1971, J IMMUNOL, V107, P1535; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; NACCACHE PH, 1990, BLOOD, V76, P2098; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STUTCHFIELD J, 1991, EUR J BIOCHEM, V197, P119, DOI 10.1111/j.1432-1033.1991.tb15889.x; SVITKINA TM, 1986, J CELL SCI, V82, P235; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21657	21663						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063808				2022-12-25	WOS:A1994PK97300044
J	SLICE, LW; WONG, HC; STERNINI, C; GRADY, EF; BUNNETT, NW; WALSH, JH				SLICE, LW; WONG, HC; STERNINI, C; GRADY, EF; BUNNETT, NW; WALSH, JH			THE CONSERVED NPX(N)Y MOTIF PRESENT IN THE GASTRIN-RELEASING PEPTIDE RECEPTOR IS NOT A GENERAL SEQUESTRATION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; BETA-ADRENERGIC-RECEPTOR; MEDIATED INTERNALIZATION; DOWN-REGULATION; BOMBESIN; RAT; BINDING; IMMUNOREACTIVITY; DESENSITIZATION; PHOSPHORYLATION	Exposure of the gastrin-releasing peptide (GRP) receptor to agonists causes a rapid desensitization of the receptor-stimulated mobilization of intracellular calcium. Homologous desensitization occurs by uncoupling the G-proteins from the receptor and by ligand induced internalization. The molecular determinants of desensitization of the GRP receptor are not well known. The importance of tyrosine 324 which is located in a highly conserved NPX(2-3)Y motif of the GRP receptor was investigated. Kirsten murine sarcoma virus-transformed rat kidney (KNRK) cells were transfected with expression vectors encoding either the wild type or the mutant (tyrosine 324 to alanine 324) rat GRP receptor. The wild type and mutant GRP receptors were expressed at a high level in the KNRK cells, 2.0 x 10(6) and 0.5 x 10(6) receptors per cell, respectively. The wild type and mutant GRP receptors bound GRP with the same affinity (K-d = 6-7 nM). KNRK cells expressing the wild type or mutant GRP receptor had similar [Ca2+](i) dose response to GRP. KNRK cells expressing the GRP receptor rapidly internalized bound I-125-GRP at 37 degrees C. Internalization was inhibited at 4 degrees C and by 0.45 nl sucrose. The internalization of bound I-125-GRP by the mutant GRP receptor was identical to the wild type receptor. Fluorescent microscopy was used to directly observe the GRP receptor expressed on the surface of the KNRK cells and to visualize its ligand induced internalization. There was no difference in the pattern of internalization between the wild type and mutant GRP receptors expressed in KNRK cells. Therefore, the highly conserved tyrosine 324 does not have a role in GRP binding, receptor-G-protein interaction, or initial events of ligand induced receptor internalization. The NPX(n)Y motif is not a general sequestration sequence for seven transmembrane G-protein linked receptors.	UNIV CALIF LOS ANGELES,W LOS ANGELES VET AFFAIRS MED CTR,CTR GASTROENTER BIOL,DEPT PHYSIOL,LOS ANGELES,CA 90073; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SLICE, LW (corresponding author), UNIV CALIF LOS ANGELES,W LOS ANGELES VET AFFAIRS MED CTR,CTR GASTROENTER BIOL,DEPT MED,LOS ANGELES,CA 90073, USA.			Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK 17294, DK 35740, DK 39957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017294, R01DK035740, R37DK039957, R37DK017294, R01DK039957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1990, J BIOL CHEM, V265, P16450; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DOCKRAY GJ, 1979, NEUROSCIENCE, V4, P1561, DOI 10.1016/0306-4522(79)90019-8; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GREELEY GH, 1986, P SOC EXP BIOL MED, V183, P136; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HEYMANNMONNIKES I, 1990, BRAIN RES, V533, P309, DOI 10.1016/0006-8993(90)91354-J; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MAYER EA, 1986, AM J PHYSIOL, V250, pG581, DOI 10.1152/ajpgi.1986.250.5.G581; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; STERNINI C, 1986, GASTROENTEROLOGY, V90, P1155, DOI 10.1016/0016-5085(86)90380-X; TACHE Y, 1981, GASTROENTEROLOGY, V81, P298; THIES RS, 1990, J BIOL CHEM, V265, P10132; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	25	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21755	21761						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063819				2022-12-25	WOS:A1994PK97300057
J	DEMARTINO, GN; MOOMAW, CR; ZAGNITKO, OP; PROSKE, RJ; CHUPING, M; AFENDIS, SJ; SWAFFIELD, JC; SLAUGHTER, CA				DEMARTINO, GN; MOOMAW, CR; ZAGNITKO, OP; PROSKE, RJ; CHUPING, M; AFENDIS, SJ; SWAFFIELD, JC; SLAUGHTER, CA			PA700, AN ATP-DEPENDENT ACTIVATOR OF THE 20-S-PROTEASOME, IS AN ATPASE CONTAINING MULTIPLE MEMBERS OF A NUCLEOTIDE-BINDING PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEASE; MULTICATALYTIC PROTEINASE; ENDOGENOUS INHIBITOR; PROTEOLYTIC PATHWAY; SOLUBLE EXTRACTS; 26-S PROTEASE; LATENT FORM; COMPLEX; UBIQUITIN; GENE	PA700 is a 700,000-dalton multisubunit protein that activates multiple proteolytic activities of the 20 S proteasome by a mechanism dependent upon ATP hydrolysis (Ma, C.-P., Vu, J. H., Proske, R. J., Slaughter, C. A., and DeMartino, G. N. (1994) J. Biol. Chem. 269, 3539-3547). In order to determine the identities of and structural relationships among the subunits of PA700, individual PA700 subunits were isolated by a combination of reverse phase high performance liquid chromatography (HPLC) and SDS-polyacrylamide gel electrophoresis. Seven of the 16 subunits of PA700 so isolated were subjected to solid phase protease digestion followed by reverse phase HPLC. Selected peptides from each protein were sequenced by automated Edman degradation. Comparison of the resulting amino acid sequences with those in current data bases indicated that three of the subunits represented novel proteins, whereas four subunits were homologous to previously described proteins. Three subunits of the latter group were, in turn, homologous to one another and are members of a large family of proteins containing a consensus sequence for ATP binding. Purified PA700 demonstrated ATPase activity. Treatment of PA700 with alkylating agents, such as N-ethylmaleimide, inhibited with similar kinetics both proteasome activation and ATPase activity, suggesting that these two activities are functionally Linked. Thus, PA700 is composed of multiple members of a protein family that may function in the ATP-dependent regulation of proteasome activity.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DEMARTINO, GN (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1990, New Biologist, V2, P227; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P299, DOI 10.1016/0304-4165(91)90135-4; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P273, DOI 10.1016/0003-9861(88)90189-0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PENTZ ES, 1991, GENE, V103, P239, DOI 10.1016/0378-1119(91)90279-K; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XIE XS, 1988, METHOD ENZYMOL, V157, P634; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	47	187	195	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20878	20884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063704				2022-12-25	WOS:A1994PC40300014
J	LEI, JY; TANG, XX; CHAMBERS, TC; POHL, J; BENIAN, GM				LEI, JY; TANG, XX; CHAMBERS, TC; POHL, J; BENIAN, GM			PROTEIN-KINASE DOMAIN OF TWITCHIN HAS PROTEIN-KINASE ACTIVITY AND AN AUTOINHIBITORY REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; CALMODULIN-BINDING DOMAIN; BOVINE CARDIAC-MUSCLE; CAENORHABDITIS-ELEGANS; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; CYCLIC-AMP; RAT-BRAIN	Twitchin is a 753-kDa polypeptide located in the muscle A-bands of the nematode, Caenorhabditis elegans. It consists of multiple copies of both fibronectin m and immunoglobulin C2 domains and, near the C terminus, a protein kinase domain with greatest homology to the catalytic domains of myosin light chain kinases. We have expressed and purified from Escherichia coli twitchin's protein kinase catalytic core and flanking sequences that do not include fibronectin III and immunoglobulin C2 domains. The protein was shown to phosphorylate a model substrate and to undergo autophosphorylation. The autophosphorylation occurs at a slow rate, attaining a maximum at 3 h with a stoichiometry of about 1.0 mol of phosphate/mol of protein, probably through an intramolecular mechanism. Sequence analysis of proteolytically derived phosphopeptides revealed that autophosphorylation occurred N-terminal to the catalytic core, predominantly at Thr-5910, with possible minor sites at Ser-5912 and/or Ser-5913. This portion of twitchin (residues 5890-6268) was also phosphorylated in vitro by protein kinase C in the absence of calcium and phosphotidylserine, but not by cAMP-dependent protein kinase. By comparing the activities of three twitchin segments, the enzyme appears to be inhibited by the 60-amino acid residues lying just C-terminal to the kinase catalytic core. Thus, Like a number of other protein kinases including myosin Light chain kinases, the twitchin kinase appears to be autoregulated.	EMORY UNIV, DEPT PATHOL, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT PHARMACOL, ATLANTA, GA 30322 USA; EMORY UNIV, MICROCHEM FACIL, ATLANTA, GA 30322 USA	Emory University; Emory University; Emory University								ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; ADELSTEIN RS, 1982, FED PROC, V41, P2873; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BENIAN GM, 1993, GENETICS, V134, P1097; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BHALLA RC, 1982, BIOCHEM J, V203, P583, DOI 10.1042/bj2030583; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CONTI MA, 1981, J BIOL CHEM, V256, P3178; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; DELANGE RJ, 1968, J BIOL CHEM, V243, P2200; EDELMAN AM, 1982, FEBS LETT, V138, P293, DOI 10.1016/0014-5793(82)80464-X; FOYT HL, 1985, J CYCLIC NUCL PROT, V10, P143; FYRBERG CC, 1992, P ROY SOC B-BIOL SCI, V249, P33, DOI 10.1098/rspb.1992.0080; GAO ZH, 1992, BIOCHEMISTRY-US, V31, P6126, DOI 10.1021/bi00141a024; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HARRIS HE, 1977, BIOCHEMISTRY-US, V16, P859, DOI 10.1021/bi00624a008; HATHAWAY DR, 1981, NATURE, V291, P252, DOI 10.1038/291252a0; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HIGASHI K, 1983, BIOCHIM BIOPHYS ACTA, V747, P232, DOI 10.1016/0167-4838(83)90102-4; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKEBE M, 1985, J BIOL CHEM, V260, P4547; INOUE M, 1977, J BIOL CHEM, V252, P7610; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1988, CALMODULIN, P195; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KIKKAWA U, 1986, ENZYMES A, V17, P167; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; MAROTO M, 1992, J MOL BIOL, V224, P287, DOI 10.1016/0022-2836(92)90994-U; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MOERMAN DG, 1982, CELL, V29, P773, DOI 10.1016/0092-8674(82)90439-1; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; MOERMAN DG, 1980, THESIS S FRASER U BU; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; SELLERS JR, 1987, ENZYMES, V18, P382; SHAFER WM, 1991, J BIOL CHEM, V266, P112; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Stull J, 1988, CALMODULIN, P91; STULL JT, 1986, ENZYMES, V17, P113; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKANOOHMURO H, 1992, BIOCHEM BIOPH RES CO, V183, P31, DOI 10.1016/0006-291X(92)91604-O; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TAN JL, 1990, J BIOL CHEM, V265, P13818; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VALLET B, 1981, BIOCHIM BIOPHYS ACTA, V674, P256, DOI 10.1016/0304-4165(81)90383-4; WALSH MP, 1981, ADV CYCL NUCL RES<D>, V14, P375; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; Waterston R., 1988, NEMATODE C ELEGANS, P281; WATERSTON RH, 1980, DEV BIOL, V77, P271, DOI 10.1016/0012-1606(80)90475-3; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; WOLF H, 1980, P NATL ACAD SCI-BIOL, V77, P5852, DOI 10.1073/pnas.77.10.5852	69	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21078	21085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063727				2022-12-25	WOS:A1994PC40300042
J	LOBIE, PE; MERTANI, H; MOREL, G; MORALESBUSTOS, O; NORSTEDT, G; WATERS, MJ				LOBIE, PE; MERTANI, H; MOREL, G; MORALESBUSTOS, O; NORSTEDT, G; WATERS, MJ			RECEPTOR-MEDIATED NUCLEAR TRANSLOCATION OF GROWTH-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM BINDING-PROTEIN; RAT PITUITARY-GLAND; GH RECEPTOR; CYTOSKELETAL NETWORKS; INSULIN-RECEPTORS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; NEUROPEPTIDE-Y; LYMPHOCYTES-T; TARGET-CELLS	We have previously shown that the growth hormone (GH) receptor-binding protein is associated with the nucleus. me show here both by electron microscopy and nuclear isolation that GIT is subject to rapid nuclear translocation. The intracellular fate of intravenously injected I-125-bovine growth hormone (bGH) was examined in the rat hepatocyte by electron microscopic autoradiography. The hormone appeared rapidly at the plasma membrane, then sequentially in lysosomal and multivesicular bodies and/or the nuclear membrane before final translocation to the nuclear matrix. Maximal translocation to the nuclear matrix occurred within 30 min of injection. Nuclear translocation of I-125-hGH was also studied by isolation of nuclei from cells stably transfected with cDNAs encoding the GH receptor, GH-binding protein, and a membrane bound but cytoplasmic domain-deficient receptor. Specific internalization and nuclear translocation of hormone only occurred in cells transfected with the full-length receptor. The translocation was rapid and became saturated within 1 h after addition of hormone to the culture media. SDS-polyacrylamide gel electrophoresis of isolated nuclei showed that GH is transported to the nucleus as the intact molecule. Pretreatment of cells with lysosomotropic agents (chloroquine, ammonium chloride, and bacitracin) decreased hormone degradation and increased nuclear translocation of GH. The nuclear translocation of GH was achieved independent of the cytoskeletal system (microtubular, microfilament, and intermediate filament networks). Thus, GH is subject to rapid receptor-dependent nuclear translocation via the endosomal pathway.	FAC MED LYON SUD,CNRS,URA 1454,OULLINS,FRANCE; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA	Centre National de la Recherche Scientifique (CNRS); University of Queensland	LOBIE, PE (corresponding author), KAROLINSKA INST,NOVUM,INST MED NARINGSLARA,CTR BIOTEKN,S-14157 HUDDINGE,SWEDEN.		MERTANI, Hichem-Claude/AAR-6415-2020; waters, michael j/C-9582-2014					AKNER G, 1992, EUR J CELL BIOL, V58, P356; AMIT T, 1993, MOL CELL ENDOCRINOL, V94, P149, DOI 10.1016/0303-7207(93)90163-E; BARRAZONE P, 1980, J CELL BIOL, V87, P360; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BICK T, 1989, ENDOCRINOLOGY, V125, P1718, DOI 10.1210/endo-125-3-1718; BONIFACINO JS, 1983, BIOCHEM J, V214, P121, DOI 10.1042/bj2140121; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CHABOT JG, 1988, AM J PHYSIOL, V254, pE301, DOI 10.1152/ajpendo.1988.254.3.E301; CHABOT JG, 1988, NEUROENDOCRINOLOGY, V47, P511, DOI 10.1159/000124963; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; FRANCIS SM, 1993, MOL ENDOCRINOL, V7, P972, DOI 10.1210/me.7.8.972; FRASER RA, 1992, ENDOCRINOLOGY, V130, P3593, DOI 10.1210/en.130.6.3593; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GISS BJ, 1985, MOL CELL ENDOCRINOL, V42, P259, DOI 10.1016/0303-7207(85)90057-7; GOLDFINE ID, 1978, SCIENCE, V202, P760, DOI 10.1126/science.715440; GORIN E, 1984, ENDOCRINOLOGY, V115, P467, DOI 10.1210/endo-115-2-467; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HIZUKA N, 1981, J BIOL CHEM, V256, P4591; HORIUCHI R, 1982, J BIOL CHEM, V257, P3139; HUSMAN B, 1988, MOL CELL ENDOCRINOL, V59, P13, DOI 10.1016/0303-7207(88)90191-8; HYNES RO, 1978, CELL, V13, P151, DOI 10.1016/0092-8674(78)90146-0; ILONDO MM, 1992, ENDOCRINOLOGY, V130, P2037, DOI 10.1210/en.130.4.2037; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; JOHNSON LK, 1980, NATURE, V287, P340, DOI 10.1038/287340a0; KUNO K, 1993, J BIOL CHEM, V268, P13510; LEHTO VP, 1978, NATURE, V272, P175, DOI 10.1038/272175a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; LOBIE PE, 1992, ENDOCRINOLOGY, V130, P3057, DOI 10.1210/en.130.5.3057; LOMEDICO PT, 1986, COLD SPRING HARB SYM, V51, P631, DOI 10.1101/SQB.1986.051.01.075; MACDONALD HS, 1986, BIOCHEM BIOPH RES CO, V138, P254, DOI 10.1016/0006-291X(86)90273-1; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MARCHISIO PC, 1980, P NATL ACAD SCI-BIOL, V77, P1656, DOI 10.1073/pnas.77.3.1656; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MERTANI HC, 1994, IN PRESS NEUROENDOCR; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOLLER C, 1993, MOL CELL ENDOCRINOL, V99, P111; MOREL G, 1986, ENDOCRINOLOGY, V119, P1972, DOI 10.1210/endo-119-5-1972; MOREL G, 1985, PEPTIDES, V6, P1085, DOI 10.1016/0196-9781(85)90432-2; MOREL G, 1994, BIOCHEM PHARMACOL, V47, P63, DOI 10.1016/0006-2952(94)90438-3; MOREL G, 1991, ENDOCRINOLOGY, V129, P1497, DOI 10.1210/endo-129-3-1497; MOREL G, 1985, NEUROENDOCRINOLOGY, V41, P312, DOI 10.1159/000124195; MOREL G, 1987, CELL TISSUE RES, V248, P531; MOREL G, 1991, ELECTRON MICROS, P83; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; Nadler N J, 1971, J Cell Biol, V49, P877; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERROTAPPLANAT M, 1992, J CELL BIOL, V119, P337, DOI 10.1083/jcb.119.2.337; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; POSTELVINAY MC, 1982, ENDOCRINOLOGY, V111, P244, DOI 10.1210/endo-111-1-244; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; REZVANI I, 1973, BIOCHEM MED METAB B, V7, P432, DOI 10.1016/0006-2944(73)90064-1; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SALPETER MM, 1973, ADV TECHNIQUES BIOL, P113; SAVION N, 1981, J BIOL CHEM, V256, P1149; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH RM, 1987, P NATL ACAD SCI USA, V84, P459, DOI 10.1073/pnas.84.2.459; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; WELCH WJ, 1985, MOL CELL BIOL, V5, P1571, DOI 10.1128/MCB.5.7.1571; WONG KY, 1988, BIOCHEMISTRY-US, V27, P375, DOI 10.1021/bi00401a056; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269	81	110	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21330	21339						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063758				2022-12-25	WOS:A1994PC40300076
J	MURPHY, JE; HANOVER, JA; FROEHLICH, M; DUBOIS, G; KEEN, JH				MURPHY, JE; HANOVER, JA; FROEHLICH, M; DUBOIS, G; KEEN, JH			CLATHRIN ASSEMBLY PROTEIN AP-3 IS PHOSPHORYLATED AND GLYCOSYLATED ON THE 50-KDA STRUCTURAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; NUCLEAR-PORE; O-GLCNAC; CYTOPLASMIC GLYCOPROTEINS; MONOCLONAL-ANTIBODIES; INTACT NEURONS; CONTAIN; IDENTIFICATION; RESIDUES; CLONING	AP-3 (AP180) in rat sympathetic neurons maintained in culture was analyzed by pulse-chase labeling with [S-35]methionine to look for post-translational modifications. At early times, two lower molecular weight precursors of the mature species were detected. By 10 min, all of the AP-3 was found in the mature form which is stable for at least 9 h. me show here that at least one of these processing events is due to the addition of O-linked N-acetylglucosamine (GlcNAc) which is present on the mature form of the protein. Wheat germ agglutinin, a GlcNAc-specific probe, bound to AP-3 and the binding was blocked by excess GlcNAc but not by excess mannose. Purified AP-3, and AP-3 in coated vesicles derived from bovine brain. served as substrates for beta-D-galactosyltransferase which is specific for terminal GlcNAc residues. Analysis of the disaccharide released by beta-elimination indicated that single GlcNAc residues are attached to AP-3 through an O-glycosidic linkage to threonine or serine residues. In vivo P-32-labeled AP-3, the result of serine phosphorylation (Keen J. H., and Black, M. M. (1986) J. Cell Biol. 102, 1325-1333), bound to wheat germ agglutinin-Sepharose indicating that phosphorylation and glycosylation can occur simultaneously on the same molecule. Both modifications have been mapped to the central 50-kDa structural domain that is responsible for the anomalous migration of AP-3. Consistent with localization to the nonclathrin binding domain, the O-GlcNAc modification does not play a discernible role in the interaction of AP-3 with clathrin.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; BERLIN W, 1994, GLYCOBIOLOGY PRACTIC, P329; BLACK MM, 1991, J NEUROSCI, V11, P1163; BRYAN J, 1989, SCIENCE, V242, P1396; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; CHOU C-F, 1991, Journal of Cell Biology, V115, p353A; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MOZDZANOWSKI J, 1992, ANAL BIOCHEM, V207, P11, DOI 10.1016/0003-2697(92)90492-P; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NYAME K, 1987, J BIOL CHEM, V262, P7990; PENG I, 1985, BRAIN RES, V361, P200, DOI 10.1016/0006-8993(85)91290-9; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; REASON AJ, 1992, J BIOL CHEM, V267, P16911; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TURNER JR, 1990, P NATL ACAD SCI USA, V87, P5608, DOI 10.1073/pnas.87.15.5608; UNGEWICKELL E, 1989, ANAL BIOCHEM, V179, P352, DOI 10.1016/0003-2697(89)90143-7; ZHOU SB, 1992, J NEUROSCI, V12, P2144	37	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21346	21352						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063760				2022-12-25	WOS:A1994PC40300078
J	CHRISMAN, TD; SCHULZ, S; POTTER, LR; GARBERS, DL				CHRISMAN, TD; SCHULZ, S; POTTER, LR; GARBERS, DL			SEMINAL PLASMA FACTORS THAT CAUSE LARGE ELEVATIONS IN CELLULAR CYCLIC-GMP ARE C-TYPE NATRIURETIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; PORCINE BRAIN; RECEPTOR; CNP; PURIFICATION; EXPRESSION; SEQUENCE; FAMILY	Seminal plasma (porcine) was shown to elevate cyclic GMP in Balb/3T3 cells (235-fold), NIH/3T3, Rat-2, but not in human T84 cells. Seminal plasma and C-type natriuretic peptide (CNP) markedly elevated cyclic GMP of 293 cells stably transfected with the guanylyl cyclase-B (GC-B) receptor, but failed to elevate cyclic GMP concentrations of 293 cells stably transfected with the guanylyl cyclase-A receptor. The seminal plasma activity was analyzed by reverse-phase high performance liquid chromatography; two major fractions were obtained and the amino acid sequence of one matched that of proCNP-103. For the second peak of activity, sequence could not be obtained but the purified material bound to antibody specific for CNP. CNP concentrations in seminal plasma and seminal vesicle fluid were shown to be 2,000- and 100,000-fold greater than those found in porcine brain, respectively. Significant amounts of immunoreactive CNP also were detected in tracheal mucosa and uterus suggesting a general signaling role for the peptide. That seminal plasma CNP serves a function during fertilization was suggested by finding expression of GC-B mRNA in the uterus/oviduct and CNP-stimulatable GC-B in the intact uterus. Therefore, some or all of the GC-B receptor appears to exist on the apical membrane of uterine epithelial cells.	UNIV TEXAS,SW MED CTR DALLAS,DEPT PHARMACOL,DALLAS,TX 75235; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University	CHRISMAN, TD (corresponding author), UNIV TEXAS,SW MED CTR DALLAS,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.							ARIMURA JJ, 1991, BIOCHEM BIOPH RES CO, V174, P142, DOI 10.1016/0006-291X(91)90497-U; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CASEY ML, 1992, J CLIN ENDOCR METAB, V74, P223, DOI 10.1210/jc.74.1.223; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; FULLER F, 1988, J BIOL CHEM, V263, P9395; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V236, P30; IIDA T, 1990, FEBS LETT, V260, P98, DOI 10.1016/0014-5793(90)80076-U; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; LIN MQ, 1992, AM J PHYSIOL, V262, pC1304, DOI 10.1152/ajpcell.1992.262.5.C1304; MANN T, 1974, BIOCH SEMEN MALE REP, P1; MARUMO F, 1992, J ENDOCRINOL, V132, P101, DOI 10.1677/joe.0.1320101; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; NESBITT JA, 1976, J BIOL CHEM, V251, P2344; POTTER LR, 1992, J BIOL CHEM, V267, P14531; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; RUFO GA, 1982, J BIOL CHEM, V257, P4627; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SOFKIKITIS N, 1992, J ANDROL, V15, P54; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; TAWARAGI Y, 1990, BIOCHEM BIOPH RES CO, V172, P627, DOI 10.1016/0006-291X(90)90720-8; THOMPSON MR, 1987, PATHOL IMMUNOPATH R, V6, P103, DOI 10.1159/000157052; UEDA S, 1991, BIOCHEM BIOPH RES CO, V175, P759, DOI 10.1016/0006-291X(91)91631-L; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	31	100	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3698	3703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8094083				2022-12-25	WOS:A1993KM16100101
J	WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S				WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S			INDUCTION OF GENOMIC INSTABILITY IN SV40-TRANSFORMED HUMAN-CELLS - SUFFICIENCY OF THE N-TERMINAL-147 AMINO-ACIDS OF LARGE T-ANTIGEN AND ROLE OF PRB AND P53	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; WILD-TYPE P53; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; CYCLE CHECKPOINT; DNA-SYNTHESIS; CHROMOSOMAL-ABERRATIONS; MONOCLONAL-ANTIBODIES	Genomic instability is an early event in the transformation of human cells by SV40 and may contribute, as a mutagenic process, to the generation of the rare cells which survive crisis and yield immortal populations. We have previously reported that expression of large T antigen is responsible for induction of chromosome aberrations and aneuploidy. In the present study we have demonstrated that the amino terminal 147 amino acids of the protein are as proficient as full length T antigen for this destabilization of the cell genome. Analysis of mutants within this region indicated that T antigens defective for binding to pRB or lacking the first 127 amino acids are significantly reduced in their ability to induce aneuploidy and/or aberrations, whereas a cytoplasmic T antigen is less severely impaired. In addition, we have shown that binding of T antigen to p53 is dispensable for genome destabilization but may be required for continued proliferation of genetically aberrant cells.	MCMASTER UNIV,DEPT PATHOL,MOLEC VIROL & IMMUNOL PROGRAMME,HAMILTON L8N 3Z5,ON,CANADA	McMaster University								ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; ANDERSON RW, 1988, J VIROL, V62, P285, DOI 10.1128/JVI.62.1.285-296.1988; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; BOND JA, 1994, ONCOGENE, V9, P1885; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARNDEN DG, 1985, ISCN; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYFLICK L, 1965, EXP CELL RES, V37, P617; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RASHEED D, 1974, CANCER, V33, P1033; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAY FA, 1993, CARCINOGENESIS, V14, P1511, DOI 10.1093/carcin/14.8.1511; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	78	52	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2943	2950						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084597				2022-12-25	WOS:A1994PG82200020
J	GALINIER, A; GARNERONE, AM; REYRAT, JM; KAHN, D; BATUT, J; BOISTARD, P				GALINIER, A; GARNERONE, AM; REYRAT, JM; KAHN, D; BATUT, J; BOISTARD, P			PHOSPHORYLATION OF THE RHIZOBIUM-MELILOTI FIXJ PROTEIN INDUCES ITS BINDING TO A COMPOUND REGULATORY REGION AT THE FIXK PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MODULAR STRUCTURE; SIGMA-70 SUBUNIT; RNA-POLYMERASE; MALT PROTEIN; TRANSCRIPTION; DOMAIN; NIFA; SPECIFICITY; ACTIVATION	The FixJ protein is a member of the regulator class of two-component systems involved in the transcriptional activation of nitrogen fixation genes in Rhizobium meliloti. Phosphorylation of FixJ was previously demonstrated to dramatically enhance its transcriptional activity at the nifA and fixK promoters. Here we show that the isolated carboxyl-terminal domain of FixJ, FixJC, binds the fixK promoter, whereas binding of the full-length FixJ protein requires its phosphorylation. By analyzing the DNase I and Exonuclease III protection patterns of the wild-type and a mutant fixK promoter, we have identified two overlapping binding regions for both phosphorylated FixJ and FixJC. A higher affinity region is located between positions -69 and -44 relative to the transcription start site, and a lower affinity region, between positions -57 and -31, overlaps the -35 region of the promoter.	INRA,CNRS,BIOL MOLEC RELAT PLANTES MICROORGANISMES LAB,F-31326 CASTANET TOLOSAN,FRANCE	INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)			BATUT, Jacques/B-6506-2008; Kahn, Daniel/B-9393-2013	Kahn, Daniel/0000-0001-8093-0854				AGRON PG, 1992, J BACTERIOL, V174, P4120, DOI 10.1128/jb.174.12.4120-4129.1992; AGRON PG, 1993, P NATL ACAD SCI USA, V90, P3506, DOI 10.1073/pnas.90.8.3506; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATUT J, 1989, EMBO J, V8, P1279, DOI 10.1002/j.1460-2075.1989.tb03502.x; DARE S, 1994, NUCLEIC ACIDS RES, V22, P1555; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEPHILIP P, 1992, MOL GEN GENET, V235, P49, DOI 10.1007/BF00286180; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; REYRAT JM, 1993, J BACTERIOL, V175, P6867, DOI 10.1128/jb.175.21.6867-6872.1993; RICHET E, 1987, J BIOL CHEM, V262, P12647; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; Sambrook J, 1989, MOL CLONING LABORATO; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; VIDALINGIGLIARDI D, 1993, J BIOL CHEM, V268, P24527; WAELKENS F, 1992, MOL MICROBIOL, V6, P1447, DOI 10.1111/j.1365-2958.1992.tb00865.x; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; ZHAN L, 1992, J MOL BIOL, V226, P1037	28	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23784	23789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089150				2022-12-25	WOS:A1994PQ34500061
J	KAPUS, A; GRINSTEIN, S; WASAN, S; KANDASAMY, R; ORLOWSKI, J				KAPUS, A; GRINSTEIN, S; WASAN, S; KANDASAMY, R; ORLOWSKI, J			FUNCTIONAL-CHARACTERIZATION OF 3 ISOFORMS OF THE NA+/H+ EXCHANGER STABLY EXPRESSED IN CHINESE-HAMSTER OVARY CELLS - ATP DEPENDENCE, OSMOTIC SENSITIVITY, AND ROLE IN CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; VOLUME REGULATION; INTRACELLULAR PH; H+ EXCHANGER; MOLECULAR-CLONING; PLASMA-MEMBRANE; GROWTH-FACTORS; GENE FAMILY; ANTIPORTER; ACTIVATION	Four distinct isoforms of the mammalian Na+/H+ exchanger (NHE) have been identified by molecular cloning. Three of these (NHE-1, NHE-2, and NHE-3) have been shown to be functionally active by heterologous expression. Their kinetic and pharmacological proper ties are well documented, yet comparatively little is known about their regulation. In this report, rat NHE-1, NHE-2, and NHE-3 were stably transfected into antiporter-deficient Chinese hamster ovary cells to study their role in cellular proliferation and their regulation by nucleotides and cell volume. Their ability to influence cell proliferation was assessed by measuring the growth of antiporter-deficient cells and of the different transfectants in media of varying pH. While antiporter-deficient cells were unable to grow at acidic pH levels, all three isoforms supported proliferation under these conditions. Therefore, while the epithelia-specific isoforms (NHE-2 and NHE-3) are thought to play primarily a role in transcellular ion transport, they can also contribute to intracellular pH (pH(i)) homeostasis and have a permissive role in cell growth. The activity of the three isoforms was markedly inhibited by depletion of cellular ATP. In the pH(i) 6.0-7.2 range, decreases in the affinity for internal H+ and/or the maximal rate of transport accounted for the inhibitory effect, depending on the isoform. The osmotic responsiveness of the three isoforms was also compared. As reported earlier NHE-1 was stimulated by hypertonicity. Under similar conditions, NHE-2 was also stimulated to a comparable extent. Conversely, both isoforms were inhibited in hypotonic media. In contrast, NHE-3 was markedly inhibited by hypertonic cell shrinking but was unaffected by hypotonicity. Osmotic inhibition of NHE-3 was rapid, reversible, and apparent throughout the pH range studied. Osmotic inhibition of NHE-3 may play a role in the physiology and pathophysiology of epithelia.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,PQ,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University				Orlowski, John/0000-0001-7371-175X				ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; CALA PM, 1980, J GEN PHYSIOL, V76, P683, DOI 10.1085/jgp.76.6.683; CASSEL D, 1986, J BIOL CHEM, V261, P5460; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PONYSSEGUR J, 1984, P NATL ACAD SCI USA, V81, P4833; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, AM J PHYSIOL, V257, pC1148; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; TAKAICHI K, 1993, AM J PHYSIOL, V264, pC944, DOI 10.1152/ajpcell.1993.264.4.C944; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; TSE M, 1993, J MEMBRANE BIOL, V135, P93; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925; YU FH, 1993, J BIOL CHEM, V268, P25536	36	239	241	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23544	23552						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089122				2022-12-25	WOS:A1994PQ34500027
J	LEONDELRIO, A; GRAVEL, RA				LEONDELRIO, A; GRAVEL, RA			SEQUENCE REQUIREMENTS FOR THE BIOTINYLATION OF CARBOXYL-TERMINAL FRAGMENTS OF HUMAN PROPIONYL-COA CARBOXYLASE ALPHA-SUBUNIT EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOTIN OPERON REPRESSOR; DNA-BINDING; PROTEIN; SYNTHETASE; ENZYME; TRANSCARBOXYLASE; MUTAGENESIS; PREDICTION; DOMAINS; BIRA	Biotin-dependent enzymes play an essential role in the metabolism of all organisms. Their biotinylation is catalyzed by holoenzyme synthetases, which attach a biotin molecule to a specific lysine residue on the apoenzymes. The sequence flanking the biotin binding site is highly conserved among biotin-dependent enzymes. This sequence conservation might be related to the extensive cross-species activity showed by holoenzyme synthetases. In this study, we have expressed carboxyl-terminal fragments of the alpha subunit of human propionyl-CoA carboxylase (PCC-alpha) in Escherichia coli and used site-directed mutagenesis to determine the sequence requirements for biotinylation by the bacterial holoenzyme synthetase. We show that the carboxyl-terminal 67 amino acids of PCC-alpha act as an independent domain in the biotinylation reaction. Mutations that affect several conserved Gly residues and a Pro-Met-Pro sequence near the biotin binding site are critical for biotinylation. Substitution of the amino acids that flank the biotin acceptor Lys residue or elimination of the last 3 amino acids of the PCC-alpha peptides had little or no effect on their biotinylation despite their high conservation in biotin enzymes.	MCGILL UNIV,DEPT BIOL,MONTREAL H3H 1P3,PQ,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL H3H 1P3,PQ,CANADA	McGill University; McGill University	LEONDELRIO, A (corresponding author), MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,2300 TUPPER ST,MONTREAL H3H 1P3,PQ,CANADA.		Leon-Del-Rio, Alfonso/L-5932-2019					BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; BUONCRISTIANI MR, 1986, GENE, V44, P255, DOI 10.1016/0378-1119(86)90189-7; BURRI BJ, 1981, J CLIN INVEST, V68, P1491, DOI 10.1172/JCI110402; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; EISENBERG MA, 1982, J BIOL CHEM, V257, P5167; GRAVEL RA, 1980, ARCH BIOCHEM BIOPHYS, V201, P669, DOI 10.1016/0003-9861(80)90557-3; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; KALOUSEK F, 1980, J BIOL CHEM, V255, P60; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KONDO H, 1984, INT J PEPT PROT RES, V23, P559; KOSOW DP, 1962, J BIOL CHEM, V237, P3633; LAMHONWAH AM, 1989, NUCLEIC ACIDS RES, V17, P4396, DOI 10.1093/nar/17.11.4396; LANE MD, 1964, J BIOL CHEM, V239, P2858; LI SJ, 1992, J BIOL CHEM, V267, P855; MCALLISTER HC, 1966, J BIOL CHEM, V241, P2855; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SHENOY BC, 1988, FASEB J, V2, P2505, DOI 10.1096/fasebj.2.9.3131174; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; WOOD HG, 1987, FASEB J, V46, P2124	26	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22964	22968						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083196				2022-12-25	WOS:A1994PQ16400012
J	TAKAHASHI, N; MORISHIGE, KI; JAHANGIR, A; YAMADA, M; FINDLAY, I; KOYAMA, H; KURACHI, Y				TAKAHASHI, N; MORISHIGE, KI; JAHANGIR, A; YAMADA, M; FINDLAY, I; KOYAMA, H; KURACHI, Y			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF CDNA-ENCODING A 2ND CLASS OF INWARD RECTIFIER POTASSIUM CHANNELS IN THE MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; GUINEA-PIG HEART; PROTEIN; MEMBRANE; CELLS	We have cloned a second class of inward rectifier potassium channels, designated MB-IRK2, from a mouse brain cDNA library. The amino acid sequence of this clone shares 70% identity with the mouse IRIK1. Xenopus oocytes injected with cRNA derived from MB-IRIK2 expressed a K+ current, which showed inward rectifying channel characteristics similar to the MB-IRK1 current. In contrast to the MB-IRK1 current, however, the MB-IRK2 current exhibited significant inactivation during hyperpolarizing pulses. In patch clamp experiments with 140 mM K+ in the pipette, the single channel conductance of MB-IRK2 was 34.2 +/- 2.1 picosiemens (n = 5), a value significantly larger than that of MB-IRK1 (22.2 +/- 3.0 picosiemens, n = 5). Consistent with the whole cell current, the steady-state open probability (P-o) of the MB-IRK2 channel decreased with hyperpolarization, whereas that of the MB-IRK1 remained constant. Northern blot analysis revealed the mRNA for MB-IRK2 to be expressed in forebrain, cerebellum, heart, kidney, and skeletal muscle. In the brain, the abundance of mRNA for MB-IRK2 was much higher in cerebellum than in forebrain and vice versa in the case of MB-IRK1. These results demonstrate that the IRK family is composed of multiple genes, which may play heterogenous functional roles in various organs, including the central nervous system.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; UNIV TOURS,CNRS,EP 21,F-37200 TOURS,FRANCE	Osaka University; Mayo Clinic; Mayo Clinic; Centre National de la Recherche Scientifique (CNRS); Universite de Tours			Findlay, Ian/P-5049-2016	Findlay, Ian/0000-0003-0650-2602	NHLBI NIH HHS [R01 HL47360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN FH, 1991, J MOL CELL CARDIOL, V23, P259, DOI 10.1016/0022-2828(91)90062-Q; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FLETCHER GH, 1992, BRAIN RES, V575, P103, DOI 10.1016/0006-8993(92)90429-D; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISHIKAWA T, 1993, J MEMBRANE BIOL, V131, P193, DOI 10.1007/BF02260108; JOSEPHSON IR, 1989, CIRCULATION, V80, P144; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MORISHIGE K, 1993, FEBS LETT, V336, P375, DOI 10.1016/0014-5793(93)80840-Q; PONGS O, 1992, PHYSIOL REV, V72, P61; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; WAHLER G, 1990, BIOPHYS J, V57, pA512; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0	24	110	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23274	23279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083233				2022-12-25	WOS:A1994PQ16400057
J	KESTER, M; CORONEOS, E; THOMAS, PJ; DUNN, MJ				KESTER, M; CORONEOS, E; THOMAS, PJ; DUNN, MJ			ENDOTHELIN STIMULATES PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 MESSENGER-RNA EXPRESSION AND PROTEIN-SYNTHESIS THROUGH A TYROSINE KINASE-SIGNALING PATHWAY IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT MECHANISM; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; MESSENGER-RNA; GENE-EXPRESSION; GROWTH-FACTOR; PHORBOL ESTER; G/H SYNTHASE; CYCLOOXYGENASE; PEPTIDES	We evaluated the role of endothelin-1 (ET-1), a vasoconstrictor peptide, to regulate prostaglandin endoperoxide synthase (PGHS)-1 and -2 gene expression and protein synthesis in cultured rat mesangial cells (MC). ET-1 induced mRNA for PGHS-2 but not PGHS-1 and also stimulated protein accumulation of PGHS-2 but not PGHS-1 in MC. ET-1 induction of PGHS-2 protein was accompanied by a sustained enhancement of enzymatic activity assessed by conversion of arachidonic acid to prostaglandin E(2). The ET-1-stimulated PGHS-2 expression was reduced with protein tyrosine kinase but not with protein kinase C inhibitors or in protein kinase C-depleted cells. Both dexamethasone and heparin reduced ET-1-activated PGHS-2 mRNA expression and protein formation. We conclude that in MC, ET-1 induces PGHS-2 through a protein tyrosine kinase-dependent pathway.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	KESTER, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22563] Funding Source: Medline; NIDDK NIH HHS [DK31684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAIRD NR, 1993, AM J KIDNEY DIS, V21, P557, DOI 10.1016/S0272-6386(12)80405-7; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FORCE T, 1992, Journal of the American Society of Nephrology, V3, P491; GLASSER KB, 1992, BIOCHEM PHARMACOL, V45, P711; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HLA T, 1991, J BIOL CHEM, V266, P24059; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUWILER A, 1993, EXP NEPHROL, V1, P19; KESTER M, 1992, J CELL PHYSIOL, V153, P244, DOI 10.1002/jcp.1041530204; KESTER M, 1992, J CELL PHYSIOL, V150, P578, DOI 10.1002/jcp.1041500319; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; LIN AH, 1989, J BIOL CHEM, V264, P17379; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MENE P, 1990, KIDNEY INT, V37, P1256, DOI 10.1038/ki.1990.109; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSULLIVAN MG, 1993, BIOCHEM BIOPH RES CO, V191, P1294, DOI 10.1006/bbrc.1993.1358; RESINK TJ, 1989, BIOCHEM BIOPH RES CO, V158, P279, DOI 10.1016/S0006-291X(89)80209-8; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SCHRAMEK H, 1994, BIOCHEM BIOPH RES CO, V199, P992, DOI 10.1006/bbrc.1994.1327; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SIMONSON MS, 1993, ANNU REV PHYSIOL, V55, P249, DOI 10.1146/annurev.physiol.55.1.249; SIMONSON MS, 1991, EXP CELL RES, V192, P148, DOI 10.1016/0014-4827(91)90169-U; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Srivastava S. K., 1993, Journal of the American Society of Nephrology, V4, P501; STRIKER LJ, 1991, LAB INVEST, V64, P446; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; THOMAS C P, 1991, Journal of the American Society of Nephrology, V2, P419; VEHERA Y, 1989, CANCER RES, V49, P780; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	43	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22574	22580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077206				2022-12-25	WOS:A1994PQ16300021
J	DENNIS, MS; LAZARUS, RA				DENNIS, MS; LAZARUS, RA			KUNITZ DOMAIN INHIBITORS OF TISSUE FACTOR-FACTOR VIIA .2. POTENT AND SPECIFIC INHIBITORS BY COMPETITIVE PHAGE SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR; ANTITHROMBIN-III; COAGULATION CASCADE; PROTEIN; COMPLEX; INITIATION; PROTEASES; HEPARIN; DISPLAY; SYSTEM	Active-site inhibitors of the human tissue factor-Factor VIIa complex (TF.FVIIa) that are both potent and specific have been selected from Alzheimer's amyloid beta-protein precursor inhibitor (APPI) Kunitz domain libraries using a strategy termed competitive phage selection. Phage display Libraries I-III, previously sorted by direct selection, were sorted by competitive selection against immobilized TF.FVIIa in which increasing amounts of Factor XIa (FXIa) were added to the selection buffer to remove phage with high affinity for FXIa. The most striking difference in the selected Kunitz domain sequences was at the P-4' position where Lys was highly preferred instead of Leu which was found here by direct selection (Dennis, M. S., and Lazarus, R. A. (1994) J. Biol. Chem. 269, 22129-22136). In addition, both Lys and Arg were selected in the P, position as opposed to Arg alone. A new library (Library IV) was constructed which contained all previously observed amino acids at 9 positions in the primary and secondary binding loops of APPI, Comparable results were obtained by sorting Library IV against immobilized TF.FVIIa in the presence of either FXIa alone or FXIa, plasma kallikrein, and plasmin. The Kunitz domains obtained by either competitive selection strategy potently inhibited TF.FVIIa, with K-i* values ranging from about 2 to 20 nM; the K-i* values were generally >1 mu M for FXIa and plasma kallikrein and ranged from 4 to 200 mM for plasmin. Variants selective for TF.FVIIa were assayed for free FVIIa and FXa inhibitory activity and characterized in coagulation assays. A rationale for the selection of Lys at both the P-4' and P-1 positions based upon comparison of sequences and structures of relevant serine proteases and inhibitors is presented.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Roche Holding; Genentech								BODE W, 1984, EUR J BIOCHEM, V144, P185, DOI 10.1111/j.1432-1033.1984.tb08447.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1986, MOL CELLULAR BASIS D, P213; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1993, BLOOD, V82, P1679; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MANN KG, 1993, BLOOD, V82, P1680; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; RAO LVM, 1993, BLOOD, V81, P2600; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT CF, 1987, BLOOD, V69, P1431; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011	31	69	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22137	22144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071338				2022-12-25	WOS:A1994PE09800034
J	GALLO, ML; PERGOLA, F; DANIELS, GA; LIEBER, MR				GALLO, ML; PERGOLA, F; DANIELS, GA; LIEBER, MR			DISTINCT ROLES FOR RAG-1 IN THE INITIATION OF V(D)J RECOMBINATION AND IN THE RESOLUTION OF CODING ENDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROKEN DNA-MOLECULES; STRAND BREAK REPAIR; SCID MUTATION; MOUSE THYMOCYTES; GENE; MICE; REARRANGEMENT; LYMPHOCYTES; EXPRESSION; RADIATION	Although RAG-1 and RAG-2 have been shown to be indispensible for V(D)J recombination, their exact role in this reaction remains unclear. Co-transfecting RAG-1 and RAG-2 expression vectors into NIH3T3 fibroblasts confers V(D)J recombination activity to these otherwise recombinationally inactive cells. In this report we have found that in transient transfections of mouse NIH3T3 fibroblasts with RAG-1 and RAG-2 and the appropriate recombination substrates, one RAG-1 expression vector, pRAG-1A, is capable of yielding both signal joints and coding joints, while another RAG-1 expression vector, pRAG-1B, yields only signal joints. The RAG-1 open reading frame for these two expression vectors is interchangeable, indicating that the inability to resolve coding joints is due to the 45-base pair difference found in the 5'-untranslated regions of these constructs. Differences in this region result in a 15-fold difference in gene expression when the luciferase coding region is substituted for the RAG-1 cDNA. This report provides evidence that RAG-1 may have a role in both the initiation of V(D)J recombination as well as the resolution of coding ends. The data also suggest that these RAG-1 activities may be dependent on different levels of RAG-1 expression.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM, ST LOUIS, MO 63110 USA; STANFORD UNIV, DEPT PATHOL, STANFORD, CA 94306 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Stanford University				Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909	NATIONAL CANCER INSTITUTE [T32CA009302, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09151-20, 5T32CA09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HSIEH C, 1991, MOL CELL BIOL, V11; HSIEH CL, 1992, J BIOL CHEM, V267, P15613; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PHILLIPS RA, 1989, CURR TOP MICROBIOL, V152, P11; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WANG LC, 1993, MOL CELL BIOL, V13, P3890, DOI 10.1128/MCB.13.7.3890	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22188	22192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071342				2022-12-25	WOS:A1994PE09800042
J	ZHOU, H; MANJI, SS; FINDLAY, DM; MARTIN, TJ; HEATH, JK; NG, KW				ZHOU, H; MANJI, SS; FINDLAY, DM; MARTIN, TJ; HEATH, JK; NG, KW			NOVEL ACTION OF RETINOIC ACID - STABILIZATION OF NEWLY SYNTHESIZED ALKALINE-PHOSPHATASE TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN MATRIX; ENVELOPE NUCLEOSIDE TRIPHOSPHATASE; MESSENGER-RNA TRANSLOCATION; GENE-EXPRESSION; RAT; CELLS; TRANSPORT; LIVER; DNA; RIBONUCLEOPROTEIN	Several observations led us to investigate the possibility that retinoic acid achieved its marked induction of alkaline phosphatase gene expression through a post-transcriptional effect in the nuclei of clonal rat pre-osteoblastic UMR 201 cells. The steady-state level of alkaline phosphatase mRNA was significantly stimulated by retinoic acid. Although nuclear run-on analysis showed that 10(-6) M retinoic acid caused an increase in alkaline phosphatase gene transcription, this was transient compared with the rise in alkaline phosphatase mRNA which continued to accumulate for many hours after retinoic acid stimulation of gene transcription had ceased. Moreover, the modest increase in transcriptional rate (similar to 2-fold) was not sufficient to account for the magnitude of the rise in mRNA level. In order, therefore, to examine the influence of retinoic acid on nuclear processing events, a cellular subfractionation method was applied. By nuclease protection analysis, and also by using reverse transcription-polymerase chain reaction, sequences corresponding to intron 2 and intron 4, respectively, were demonstrated specifically in the nuclear matrix fraction of both control and retinoic acid treated cells. Mature (spliced) alkaline phosphatase mRNA accumulated in the non-matrix (DNase I/salt eluate, nuclear membrane) and cytoplasmic fractions of retinoic acid-treated cells at more than 100-fold greater levels than in control cells. This implies that nuclear processing of the primary RNA transcript occurred only in cells treated with retinoic acid. The post-transcriptional action of retinoic acid was inhibited by cotreatment with 10 mu g/ml cycloheximide. Transforming growth factor beta (TGF beta) (1 ng/ml) did not influence whole cell alkaline phosphatase levels in UMR 201 cells. Nevertheless, TGF beta increased the transcriptional rate of the alkaline phosphatase gene. Although precursor mRNA was detected in the nuclear matrix fraction of TGF beta treated cells, there was no evidence of fur ther mRNA nuclear processing. The data are consistent with stabilization of nascent alkaline phosphatase mRNA chains by retinoic acid treatment and suggests that regulation of mRNA processing can be independent of gene transcription. This study demonstrates a novel post-transcriptional action of retinoic acid which plays an important, if not a dominant role, in determining the steady-state level of alkaline phosphatase mRNA.	UNIV MELBOURNE, ST VINCENTS HOSP, DEPT MED, FITZROY, VIC 3065, AUSTRALIA	St Vincent's Hospital Melbourne; University of Melbourne			Heath, Joan/D-3054-2012	Heath, Joan/0000-0001-6955-232X; Zhou, Hong/0000-0001-5899-9660				ALBERTS B, 1989, MOL BIOL CELL, P483; [Anonymous], METABOLIC BASIS INHE; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERND A, 1982, EUR J BIOCHEM, V129, P43, DOI 10.1111/j.1432-1033.1982.tb07018.x; CALLAN HG, 1982, PROC R SOC SER B-BIO, V214, P417, DOI 10.1098/rspb.1982.0020; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; COCHRANE AW, 1988, J MOL BIOL, V203, P555, DOI 10.1016/0022-2836(88)90192-1; COMERFORD SA, 1987, NUCLEAR STRUCTURE TH, P1; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAIFERMAN I, 1975, BIOCHEMISTRY-US, V14, P3808, DOI 10.1021/bi00688a013; Favaloro J, 1980, Methods Enzymol, V65, P718; GIANNI M, 1991, BIOCHEM J, V274, P673, DOI 10.1042/bj2740673; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HEATH JK, 1989, ENDOCRINOLOGY, V124, P3060; HEATH JK, 1992, MOL ENDOCRINOL, V6, P636, DOI 10.1210/me.6.4.636; HODGE LD, 1977, J CELL BIOL, V72, P194, DOI 10.1083/jcb.72.1.194; JACKSON DA, 1981, NATURE, V292, P552, DOI 10.1038/292552a0; JACOBS H, 1982, EUR J BIOCHEM, V121, P597, DOI 10.1111/j.1432-1033.1982.tb05828.x; KILEDJIAN M, 1991, J BIOL CHEM, V266, P4207; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LEWIN B, 1985, GENES, V2, P429; LONG BH, 1979, CELL, V18, P1079, DOI 10.1016/0092-8674(79)90221-6; MARIMAN E, 1982, NUCLEIC ACIDS RES, V10, P6131, DOI 10.1093/nar/10.19.6131; MARIMAN ECM, 1982, J MOL BIOL, V154, P103, DOI 10.1016/0022-2836(82)90420-X; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MILLER TE, 1978, J CELL BIOL, V76, P675, DOI 10.1083/jcb.76.3.675; NG KW, 1988, J BONE MINER RES, V3, P53; NG KW, 1989, J MOL ENDOCRINOL, V3, P57, DOI 10.1677/jme.0.0030057; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; Rodan GA, 1983, BONE MINERAL RES ANN, V2, P244; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHRODER HC, 1990, BIOCHEMISTRY-US, V29, P2368, DOI 10.1021/bi00461a022; SCHRODER HC, 1984, CANCER RES, V44, P3812; SCHRODER HC, 1988, BIOCHEM J, V252, P777, DOI 10.1042/bj2520777; SCHRODER HC, 1987, J BIOL CHEM, V262, P8917; SCHRODER HC, 1987, PROG NUCLEIC ACID RE, V34, P89, DOI 10.1016/S0079-6603(08)60494-8; SMITH HC, 1980, BIOCHEM BIOPH RES CO, V97, P1541, DOI 10.1016/S0006-291X(80)80041-6; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; TOH Y, 1989, EUR J BIOCHEM, V182, P231, DOI 10.1111/j.1432-1033.1989.tb14822.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANEEKELEN CAG, 1981, J CELL BIOL, V88, P554, DOI 10.1083/jcb.88.3.554; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WEISS MJ, 1988, P NATL ACAD SCI USA, V85, P7666, DOI 10.1073/pnas.85.20.7666; ZHOU H, 1991, J BONE MINER RES, V6, P767	60	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22433	22439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071372				2022-12-25	WOS:A1994PE09800076
J	JBILO, O; TOUTANT, JP; VATSIS, KP; CHATONNET, A; LOCKRIDGE, O				JBILO, O; TOUTANT, JP; VATSIS, KP; CHATONNET, A; LOCKRIDGE, O			PROMOTER AND TRANSCRIPTION START SITE OF HUMAN AND RABBIT BUTYRYLCHOLINESTERASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINESTERASE GENE; MOUSE ACETYLCHOLINESTERASE; TISSUE DISTRIBUTION; SECONDARY STRUCTURE; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION; CHOLINESTERASES; INITIATOR; PROTEINS	Two kilobase segments of the 5'-untranslated regions of the human and rabbit butyrylcholinesterase (BCHE) genes were characterized. The sequences shared extensive identity except for a 333-base pair (bp) Alu repeat present only in human BCHE. One single transcription start site was found in both genes with the techniques of primer extension, amplification of the 5'-end of mRNA, and RNase protection. Cap sites in human and rabbit BCHE genes were found in strictly homologous positions. In human BCHE, the transcription start site was found 157 bp upstream of Met(-28), the translation start site. Potential regulatory elements in both promoters included one AP1 site and multiple sites for topoisomerase, Oct-1 and PEA-3. Transient expression of BCHE-reporter gene constructs showed that a 194-bp fragment of the 5'-flanking region of human BCHE and a 570-bp fragment of rabbit BCHE were sufficient for promoting chloramphenicol acetyltransferase activity in HeLa cells. No consensus TATA and CAAT boxes were found. However, the sequence around the transcription start site exhibited homology with initiator elements found in other TATA-less promoters in developmentally regulated genes.	UNIV NEBRASKA,MED CTR,EPPLEY INST,OMAHA,NE 68198; INRA,F-34060 MONTPELLIER,FRANCE; UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; INRAE; University of Michigan System; University of Michigan			Chatonnet, Arnaud/AAM-5569-2021; Chatonnet, Arnaud/E-2190-2017	Chatonnet, Arnaud/0000-0002-4057-3896	NCI NIH HHS [P30 CA 36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER M, 1990, FEBS LETT, V267, P107, DOI 10.1016/0014-5793(90)80300-8; ALLDERDICE PW, 1991, GENOMICS, V11, P452, DOI 10.1016/0888-7543(91)90154-7; ARPAGAUS M, 1991, J BIOL CHEM, V266, P6966; ARPAGAUS M, 1990, BIOCHEMISTRY-US, V29, P124, DOI 10.1021/bi00453a015; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EDWARDS JA, 1982, J NEUROCHEM, V38, P1393, DOI 10.1111/j.1471-4159.1982.tb07918.x; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAUGHAN G, 1991, GENOMICS, V11, P455, DOI 10.1016/0888-7543(91)90155-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HSIANG YH, 1988, CANCER RES, V48, P3230; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JBILO O, 1992, FASEB J, V6, pA484; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KRIS M, 1994, IN PRESS IN VITRO CE; LAPIDOTLIFSON Y, 1989, P NATL ACAD SCI USA, V86, P4715, DOI 10.1073/pnas.86.12.4715; LAYER PG, 1988, DEVELOPMENT, V102, P387; LAYER PG, 1987, P NATL ACAD SCI USA, V84, P284, DOI 10.1073/pnas.84.1.284; LAYER PG, 1993, CELL TISSUE RES, V273, P219, DOI 10.1007/BF00312823; LAYER PG, 1990, BIOESSAYS, V12, P415, DOI 10.1002/bies.950120904; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LI Y, 1993, J BIOL CHEM, V268, P3563; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MASSOULIE J, 1988, HDB EXP PHARM, V86, P167; MCTIERNAN C, 1987, P NATL ACAD SCI USA, V84, P6682, DOI 10.1073/pnas.84.19.6682; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NUEDA A, 1993, J BIOL CHEM, V268, P19305; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TOUTANT JP, 1985, J NEUROCHEM, V44, P580, DOI 10.1111/j.1471-4159.1985.tb05452.x; van der Eb A J, 1980, Methods Enzymol, V65, P826; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453; VIGNERON P, 1994, NEUROMUSCULAR DISORD, V3, P447; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	57	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20829	20837						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063698				2022-12-25	WOS:A1994PC40300007
J	PRATHER, PL; MCGINN, TM; ERICKSON, LJ; EVANS, CJ; LOH, HH; LAW, PY				PRATHER, PL; MCGINN, TM; ERICKSON, LJ; EVANS, CJ; LOH, HH; LAW, PY			ABILITY OF DELTA-OPIOID RECEPTORS TO INTERACT WITH MULTIPLE G-PROTEINS IS INDEPENDENT OF RECEPTOR DENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG108-15 HYBRID-CELLS; GTP-BINDING PROTEIN; ADENYLYL-CYCLASE; FUNCTIONAL EXPRESSION; MEDIATED INHIBITION; INTRINSIC ACTIVITY; MOLECULAR-CLONING; COMPLEMENTARY-DNA; GAMMA-SUBUNITS; BETA-SUBUNIT	To determine whether the previously demonstrated ability of delta-opioid receptors to interact simultaneously with multiple G-proteins was a function of high receptor levels, this interaction was investigated in Chinese hamster ovary cells stably expressing 10 different levels of cloned delta-opioid receptors, ranging from 18,000 to 1.6 x 10(6) receptors/cell. The opioid agonist D-Ala(2), D-Leu(5)-enkephalin (DADLE) inhibited forskolin-stimulated adenylyl cyclase activity in all 10 clones with variable maximal inhibitory levels. Furthermore, opioid agonists altered incorporation of [alpha-P-32]azidoanilido-GTP into at least four G-protein alpha-subunits in all 10 clones, three of which were determined to be G(i3 alpha), G(i2 alpha) and G(o2 alpha). This effect was concentration-dependent, naloxone-reversible, and delta-opioid agonist-specific and was blocked by pretreatment with pertussis toxin. Although DADLE induced an increase in the incorporation of [alpha-P-32]azidoanilido-GTP into three of the four G alpha proteins that was independent of receptor density, the magnitude of this response was greater as receptor density increased. In addition, concentrations of DADLE required to promote 50% maximal labeling were similar for all four G(alpha) proteins within each clone and did not appear to be affected by receptor density. Therefore, the ability of delta-opioid receptors to interact with multiple G-proteins is independent of receptor density and there is also no apparent correlation between the amount of G-protein activated and the maximal effect of an agonist.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PRATHER, PL (corresponding author), UNIV MINNESOTA, SCH MED, DEPT PHARMACOL, 3-249 MILLARD HALL, MINNEAPOLIS, MN 55455 USA.			Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA07339, DA05695, DA07234-07, P50 DA005010] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695, P50DA005010, R01DA007339] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ASHKENAZI A, 1988, COLD SPRING HARB SYM, V53, P263, DOI 10.1101/SQB.1988.053.01.033; BERGSBAKEN CL, 1993, J PHARMACOL EXP THER, V264, P1474; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BRASS LF, 1988, J BIOL CHEM, V263, P5348; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN Y, 1993, MOL PHARMACOL, V44, P8; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; EASON MG, 1992, J BIOL CHEM, V267, P15795; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; ISOM LL, 1987, J BIOL CHEM, V262, P17504; JIN WZ, 1992, MOL PHARMACOL, V42, P1083; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAW PY, 1993, MOL PHARMACOL, V43, P684; LAW PY, 1982, MOL PHARMACOL, V21, P483; LAW PY, 1992, DRUGS ABUSE NEUROBIO, P39; LAW SF, 1993, J BIOL CHEM, V268, P10721; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA H, 1990, FEBS LETT, V266, P178, DOI 10.1016/0014-5793(90)81534-U; UEDA H, 1990, J NEUROCHEM, V54, P841, DOI 10.1111/j.1471-4159.1990.tb02328.x; UEDA H, 1988, P NATL ACAD SCI USA, V85, P7013, DOI 10.1073/pnas.85.18.7013; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	45	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21293	21302						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063754				2022-12-25	WOS:A1994PC40300072
J	SEEDORF, U; BRYSCH, P; ENGEL, T; SCHRAGE, K; ASSMANN, G				SEEDORF, U; BRYSCH, P; ENGEL, T; SCHRAGE, K; ASSMANN, G			STEROL CARRIER PROTEIN-X IS PEROXISOMAL 3-OXOACYL COENZYME-A THIOLASE WITH INTRINSIC STEROL CARRIER AND LIPID TRANSFER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TRIGLYCERIDE TRANSFER PROTEIN; RAT-LIVER; 3-KETOACYL-COA THIOLASE; CLONING; PURIFICATION; CHOLESTEROL; EXPRESSION; BIOSYNTHESIS; CDNAS	Sterol carrier protein 2 (SCP2; also called nonspecific lipid transfer protein) is a small basic sterol carrier and lipid transfer protein assumed to participate in the intracellular transport of sterols and certain other lipids. Upon cloning and sequencing SCPS-encoding cDNAs, we and others found cDNAs containing unexpected inframe 5'-extensions of up to 1,250 nucleotides upstream of the initiator ATG of the cDNA encoding pre-SCPB. The corresponding transcripts are primarily expressed in the liver and are predicted to encode a previously undescribed fusion protein containing a 143-amino acid C-terminal domain completely identical to pre-SCP2 and a 404-amino acid N-terminal domain with unknown biochemical activity or function (named sterol carrier protein x, SCPx). Here, we show that purified recombinant SCPx cleaves 3-oxoacyl((n))-CoA to yield acetyl-CoA and acyl((n-2))-CoA. Like SCPS, recombinant SCPx also stimulates the microsomal conversion of 7-dehydrocholesterol to cholesterol and transfers phosphatidylcholine and 7-dehydrocholesterol from small unilamellar vesicles to acceptor membranes in vitro. Furthermore, SCPx epitopes are primarily detected within peroxisomes. These findings suggest that SCPx is a previously undescribed peroxisomal 3-ketoacyl-CoA thiolase (EC 2.8.1.16) with intrinsic sterol carrier and lipid transfer activity (suggested name: SCP2/3-oxoacyl-CoA thiolase).	UNIV MUNSTER, ZENT LAB, INST MIKROBIOL, D-48149 MUNSTER, GERMANY; UNIV MUNSTER, ZENT LAB, INST BIOCHEM, D-48149 MUNSTER, GERMANY; UNIV MUNSTER, ZENT LAB, INST KLIN CHEM & LAB MED, D-48149 MUNSTER, GERMANY	University of Munster; University of Munster; University of Munster	SEEDORF, U (corresponding author), UNIV MUNSTER, ZENT LAB, INST ARTERIOSKLEROSEFORSCH, DOMAGKSTR 3, D-48149 MUNSTER, GERMANY.							BILLHEIMER JT, 1990, DNA CELL BIOL, V9, P154; BLOJ B, 1978, FEBS LETT, V96, P87, DOI 10.1016/0014-5793(78)81068-0; CHANDERBHAN R, 1983, BIOCHEM BIOPH RES CO, V117, P702, DOI 10.1016/0006-291X(83)91654-6; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN R, 1983, J BIOL CHEM, V258, P11731; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HE ZG, 1991, DNA CELL BIOL, V10, P559, DOI 10.1089/dna.1991.10.559; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; LEIGHTON F, 1987, PEROXISOMES BIOL MED, P177; LIDSTROMOLSSON B, 1986, BIOCHEM J, V238, P879, DOI 10.1042/bj2380879; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; OSSENDORP BC, 1990, BIOCHEM BIOPH RES CO, V168, P631, DOI 10.1016/0006-291X(90)92367-9; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PETERS TJ, 1975, CLIN SCI MOL MED, V48, P259, DOI 10.1042/cs0480259; POORTHUIS BJHM, 1981, BIOCHIM BIOPHYS ACTA, V665, P256, DOI 10.1016/0005-2760(81)90010-2; POORTHUIS BJHM, 1982, BIOCHIM BIOPHYS ACTA, V710, P99, DOI 10.1016/0005-2760(82)90195-3; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEEDORF U, 1994, J BIOL CHEM, V269, P2613; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SEEDORF U, 1993, GENE, V123, P165, DOI 10.1016/0378-1119(93)90120-R; SELTMAN H, 1985, BIOCHEM J, V230, P19, DOI 10.1042/bj2300019; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; VAHOUNY GV, 1984, BIOCHEM BIOPH RES CO, V122, P509, DOI 10.1016/S0006-291X(84)80062-5; WETTERAU JR, 1992, SCIENCE, V258, P999; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	42	150	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21277	21283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063752				2022-12-25	WOS:A1994PC40300070
J	TRYBUS, KM				TRYBUS, KM			REGULATION OF EXPRESSED TRUNCATED SMOOTH-MUSCLE MYOSINS - ROLE OF THE ESSENTIAL LIGHT-CHAIN AND TAIL LENGTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CONFORMATIONAL STATES; HEAVY-MEROMYOSIN; PHOSPHORYLATION; MECHANISM; SEQUENCE	Regulatory Light chain (RLC) phosphorylation controls smooth muscle myosin's ability to act as a molecular motor. If thick filament-regulated myosins share a common structural basis for the ''on off'' switch, then the interface between the RLC and essential light chain (ELC) should be as important in smooth muscle myosin as it is for calcium-dependent regulation in molluscan myosin (Xie, X., Harrison, D. H., Schlichting, I., Sweet, R. M., Kalabokis, V. N., Szent-Gyorgyi, A. G., and Cohen, C. (1994) Nature 368, 306-312). To test this hypothesis, a baculovirus expression system was used to obtain a truncated smooth muscle myosin that contained its native RLC and either smooth ELC, skeletal ELC, or no ELC. Movement of actin in a motility assay by heavy meromyosin (HMM) containing either skeletal or smooth ELC occurred at the same rate and in a phosphorylation-dependent manner. In contrast, substitution of skeletal RLC for smooth RLC produced an inactive molecule. HMM without an ELC moved actin at 25% the rate of control HMM, but the movement was phosphorylation-dependent even without an RLC/ELC interface. Poor regulation was observed, however, when the tail was truncated from 72 to 27 nm even though this species was primarily double headed. These results suggest that the molecular changes induced at the active site by phosphorylation can occur independent of the ELC, but critically depend upon a stable coiled-coil tail that determines how the RLCs interact at the head/rod junction.			TRYBUS, KM (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CRAIG R, 1980, J MOL BIOL, V140, P35, DOI 10.1016/0022-2836(80)90355-1; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MALMQVIST U, 1991, PFLUG ARCH EUR J PHY, V418, P523, DOI 10.1007/BF00370566; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; NYITRAY L, 1991, J BIOL CHEM, V266, P18469; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PRESTON YA, 1993, MOL BIOL CELL, V4, P41; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SWEENEY HL, 1993, J BIOL CHEM, V269, P1603; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TRYBUS KM, 1985, J BIOL CHEM, V260, P5988; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	21	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20819	20822						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063695				2022-12-25	WOS:A1994PC40300004
J	XIAO, S; ROSE, DW; SASAOKA, T; MAEGAWA, H; BURKE, TR; ROLLER, PP; SHOELSON, SE; OLEFSKY, JM				XIAO, S; ROSE, DW; SASAOKA, T; MAEGAWA, H; BURKE, TR; ROLLER, PP; SHOELSON, SE; OLEFSKY, JM			SYP (SH-PTP2) IS A POSITIVE MEDIATOR OF GROWTH FACTOR-STIMULATED MITOGENIC SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR; KINASE; SH2; PHOSPHORYLATION; CORKSCREW; BINDING; ASSOCIATION; ACTIVATION	Syp (SH-PTP2) was recently identified as a phosphotyrosine phosphatase containing two SH2 domains within its primary structure. In response to appropriate growth factor stimulation, Syp becomes phosphorylated on tyrosine residues and associates with insulin receptor substrate 1 (IRS-1) and/or the corresponding growth factor receptor via its SH2 domains, leading to increased Syp activity. To assess the importance of Syp in mitogenic signaling, we microinjected mammalian fibroblasts with several reagents designed to interfere with Syp SH2/phosphotyrosine interaction in vivo. Insulin-, insulin-like growth factor-1-, and epidermal growth factor-stimulated DNA synthesis, indicated by bromodeoxyuridine (BrdUrd) incorporation, was dramatically decreased following microinjection of a Syp antibody (Ab) (65-85%) or a Syp GST-SH2 fusion protein (similar to 90%) in comparison with cells microinjected with control IgG or glutathione S-transferase (GST), respectively. In addition, microinjection of an IRS-1-derived phosphonopeptide, which inhibits in vitro binding of Syp-SH2 to IRS-1 with an ED(50) value of similar to 23 mu M, also decreased BrdUrd incorporation in vivo by approximately 50-75%. Microinjection of the Syp Ab, Syp GST-SH2 fusion protein, or the phosphonopeptide had no effect on serum-stimulated BrdUrd incorporation. In conclusion, disruption of Syp function in living cells inhibited cell cycle progression in response to growth factor stimulation, indicating that Syp is a critical positive regulator of mitogenic signal transduction.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA; VET ADM MED CTR, MED RES SERV, SAN DIEGO, CA 92126 USA; SHIGA UNIV MED SCI, DEPT MED 3, OTSU, SHIGA 52021, JAPAN; NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, MED CHEM LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Shiga University of Medical Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Burke, Terrence R/N-2601-2014	Burke, Terrence/0000-0001-9925-8586; Maegawa, Hiroshi/0000-0002-4611-8149	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; CASE RD, 1994, J BIOL CHEM, V269, P10467; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE GM, 1989, J CELL SCI, V94, P443; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, IN PRESS J BIOL CHEM; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	254	264	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21244	21248						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063747				2022-12-25	WOS:A1994PC40300065
J	LEE, EB; BEUG, H; HAYMAN, MJ				LEE, EB; BEUG, H; HAYMAN, MJ			MUTATIONAL ANALYSIS OF THE ROLE OF THE CARBOXY-TERMINAL REGION OF THE V-ERBB PROTEIN IN ERYTHROID CELL-TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; SINGLE POINT MUTATION; EGF RECEPTOR; TYROSINE KINASES; GENE-PRODUCT; C-ERBB; IDENTIFICATION; EXPRESSION; MUTANTS	The v-erbB protein encoded by the avian erythroblastosis virus AEV-H is responsible for the transformation of fibroblasts and erythroblasts by this virus. Deletion of amino acids 961-1102, which lie carboxy terminal to the kinase domain of the v-erbB protein, destroys the ability of the virus to transform erythroid cells without severely affecting fibroblast transformation. This region is termed the E-domain and has been postulated to contain a region important for erythroid cell transformation. In-frame deletions of approximately 23 amino acids were introduced throughout the E-domain in an attempt to locate a specific region that was essential for erythroid cell transformation. Several of the deletions gave rise to a partial transformed phenotype, although no single deletion that completely abolished erythroid cell transformation was found. Interestingly, deletion of amino acids 1031-1055 resulted in a superactivated v-erbB protein that was more active for erythroid cell transformation than the wild-type AEV-H v-erbB protein. This indicates that there is a negative regulatory region located within this region that normally partially suppresses the transforming activity of the v-erbB protein for erythroid cells. These data suggest that the E-domain contains both negative and positive regulatory regions that function in erythroid cells, and complete deletion of the region is necessary to abolish erythroid cell transformation.	SUNY STONY BROOK, DEPT IRON STEEL & OTHER MET, STONY BROOK, NY 11794 USA; INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN J, 1992, ONCOGENE, V7, P1903; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1992, ONCOGENE, V7, P2025; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROYERPOKORA B, 1979, NATURE, V282, P750, DOI 10.1038/282750a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; THEROUX SJ, 1992, IN PRESS J BIOL CHEM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	43	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1317	1327						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097581				2022-12-25	WOS:A1993KY32800025
J	HERZOG, H; BAUMGARTNER, M; VIVERO, C; SELBIE, LA; AUER, B; SHINE, J				HERZOG, H; BAUMGARTNER, M; VIVERO, C; SELBIE, LA; AUER, B; SHINE, J			GENOMIC ORGANIZATION, LOCALIZATION, AND ALLELIC DIFFERENCES IN THE GENE FOR THE HUMAN NEUROPEPTIDE-Y Y1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; EXPRESSION; INDUCTION; PROTEINS	A 14-kilobase pair (kb) region of genomic DNA encoding the human neuropeptide Y Y1-receptor gene including 3'- and 5'-flanking sequences has been cloned and the human gene localized to chromosome 4q(31.3-32). In contrast to the contiguous structure of most G protein-coupled receptor genes, the NPY Y1 receptor gene is divided into three exons. A small 5'-exon of the mRNA untranslated region is separated by a 6-kb intron from the second exon. The coding region of the receptor is interrupted by a small intron, containing an in-frame stop codon, shortly after the proposed fifth transmembrane domain. In the 5'-flanking region a potential cAMP-response element and an AP-2 site, in addition to a TATA-like sequence and a typical CAAT, box are present. A single point mutation within the 6-kb intron generates a PstI polymorphic site with a highly informative allele frequency of 54:46% in the population.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	HERZOG, H (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Herzog, Herbert/B-8294-2008					AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BECKSICKINGER AG, 1992, EUR J BIOCHEM, V206, P957, DOI 10.1111/j.1432-1033.1992.tb17006.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DUMANT Y, 1992, PROG NEUROBIOL, V38, P125; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORRISON N, 1990, HUM GENET, V85, P130; NAHON JL, 1987, P NATL ACAD SCI USA, V84, P2135, DOI 10.1073/pnas.84.8.2135; POTTER EK, 1991, EUR J PHARMACOL, V193, P15, DOI 10.1016/0014-2999(91)90194-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; TERMAN BI, 1992, CYTOGENET CELL GENET, V60, P214, DOI 10.1159/000133341; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WHARTON J, 1993, IN PRESS P NATL ACAD	24	72	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6703	6707						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8095935				2022-12-25	WOS:A1993KT36800089
J	FACCHIANO, F; BENFENATI, F; VALTORTA, F; LUINI, A				FACCHIANO, F; BENFENATI, F; VALTORTA, F; LUINI, A			COVALENT MODIFICATION OF SYNAPSIN-I BY A TETANUS TOXIN-ACTIVATED TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENAL CHROMAFFIN CELLS; F-ACTIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; RAT-BRAIN; PHOSPHORYLATION; CLEAVAGE; PROTEINS; BINDING; FAMILY	The synapsins are neuronal phosphoproteins that bind to small synaptic vesicles and to actin filaments and are believed to play a regulatory role in neurotransmitter release. Here we show that synapsin I is covalently modified with remarkable affinity and selectivity by the enzyme transglutaminase. Transglutaminase catalyzes the formation of covalent bonds between protein glutamine residues and primary amines and has been found recently to be potently activated by tetanus toxin, a dichain clostridial protein that selectively blocks neurotransmitter secretion. We also report the presence of two species of immunoreactive transglutaminases in nerve endings, one cytosolic and one located on synaptic vesicles; they are potently activated by tetanus toxin and, when activated, covalently modify synaptic vesicle-bound synapsin I. These results suggest a role for transglutaminase in the control of neurotransmitter secretion and provide evidence for synapsin I being a molecular target of tetanus toxin.	UNIV MILAN,S RAFFAELE SCI INST,NATL RES COUNCIL,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY; UNIV MODENA,INST HUMAN PHYSIOL,I-41100 MODENA,ITALY	University of Milan; Universita di Modena e Reggio Emilia	FACCHIANO, F (corresponding author), IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY.		Flavia, Valtorta/F-3450-2012; Facchiano, Francesco/K-8716-2016; Luini, Alberto/L-1372-2013	Flavia, Valtorta/0000-0001-9556-4746; Facchiano, Francesco/0000-0003-4313-0617; Luini, Alberto/0000-0002-8729-2549	Telethon [112] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; FACCHIANO F, 1992, J BIOL CHEM, V267, P13267; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAYCOCK JW, 1988, P NATL ACAD SCI USA, V85, P1677, DOI 10.1073/pnas.85.5.1677; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KATZ B, 1969, J PHYSIOL-LONDON, V203, P459, DOI 10.1113/jphysiol.1969.sp008875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PRESEK P, 1992, J NEUROCHEM, V59, P1336, DOI 10.1111/j.1471-4159.1992.tb08445.x; REICHELT KL, 1992, J NEUROCHEM, V59, P500, DOI 10.1111/j.1471-4159.1992.tb09398.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TALLARIDA RJ, 1981, MANUAL PHARM CALCULA, P1; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0	31	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4588	4591						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095260				2022-12-25	WOS:A1993KP88400006
J	LEHEL, C; LOS, D; WADA, H; GYORGYEI, J; HORVATH, I; KOVACS, E; MURATA, N; VIGH, L				LEHEL, C; LOS, D; WADA, H; GYORGYEI, J; HORVATH, I; KOVACS, E; MURATA, N; VIGH, L			A 2ND GROEL-LIKE GENE, ORGANIZED IN A GROESL OPERON IS PRESENT IN THE GENOME OF SYNECHOCYSTIS SP PCC-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; ESCHERICHIA-COLI; PROTEINS; CHAPERONIN; SEQUENCE; PLANT	Using a groEL gene of Synechococcus sp. PCC 7942 as a DNA probe, a 4.8-kilobase pair (kbp) BamHI fragment of chromosomal DNA of Synechocystis sp. PCC 6803 was cloned. Sequencing of 3.25 kbp of the BamHI fragment revealed three open reading frames. The amino acid sequences deduced from the nucleotide sequences of the two open reading frames are identical to those gained from N-terminal sequencing of purified groEL and groES proteins. This finding demonstrates that these two open reading frames correspond to groEL and groES genes of Synechocystis sp. PCC 6803. groEL of Synechocystis sp. PCC 6803 is remarkably homologous to groEL proteins of other organisms. Southern blot analysis indicates that only one groESL operon is present in the genomic DNA of Synechocystis sp. PCC 6803, whereas the existence of at least two copies of groEL-analogous genes are anticipated. The level of the bicistronic, 2.2-kb transcript of groESL operon increased 100-fold within 1.5 min upon heat stress. A 9-base pair inverted repeat revealed around the groESL promoter might be involved in regulation of the heat shock response.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST BIOCHEM, POB 521, H-6701 SZEGED, HUNGARY; HUNGARIAN ACAD SCI, INST PLANT PHYSIOL, H-6701 SZEGED, HUNGARY; NATL INST BASIC BIOL, OKAZAKI, AICHI 444, JAPAN	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Wada, Hajime/K-2186-2015; LOS, Dmitry A./C-6608-2013; Murata, Norio/E-6569-2010	LOS, Dmitry A./0000-0002-0142-7853; 				ANG D, 1991, J BIOL CHEM, V266, P24233; ARNOSTI DN, 1986, J BACTERIOL, V168, P1243, DOI 10.1128/jb.168.3.1243-1249.1986; CHITNIS PR, 1991, J BIOL CHEM, V266, P58; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Gross C. A., 1990, STRESS PROTEINS BIOL, P166; GUPTA RS, 1989, BIOCHEM BIOPH RES CO, V163, P780, DOI 10.1016/0006-291X(89)92290-0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; LEHEL C, 1992, PLANT MOL BIOL, V18, P327, DOI 10.1007/BF00034959; LEHEL C, 1993, IN PRESS PLANT PHYSL; LING M, 1992, J BACTERIOL, V174, P3981; MAZODIER P, 1991, J BACTERIOL, V173, P7382, DOI 10.1128/jb.173.22.7382-7386.1991; MCFADDEN BA, 1989, PLANTA, V178, P297, DOI 10.1007/BF00391857; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NARBERHAUS F, 1992, J BACTERIOL, V174, P3290, DOI 10.1128/jb.174.10.3290-3299.1992; NARBERHAUS F, 1992, J BACTERIOL, V174, P3282, DOI 10.1128/jb.174.10.3282-3289.1992; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PRASAD TK, 1992, PLANT MOL BIOL, V18, P873, DOI 10.1007/BF00019202; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, J BACTERIOL, V174, P3993, DOI 10.1128/jb.174.12.3993-3999.1992; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; TORRESRUIZ JA, 1992, ARCH BIOCHEM BIOPHYS, V295, P172, DOI 10.1016/0003-9861(92)90503-O; VIGH L, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P373; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	28	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1799	1804						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093614				2022-12-25	WOS:A1993KH62000047
J	ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K				ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K			STRUCTURE OF THE HUMAN LC-PTP (HEPTP) GENE - SIMILARITY IN GENOMIC ORGANIZATION WITHIN PROTEIN-TYROSINE-PHOSPHATASE GENES	ONCOGENE			English	Note							MOLECULAR-CLONING; PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOTH-EATEN; EXPRESSION; MUTATIONS; DOMAINS; KINASES; FAMILY; EXONS	Recently, various cDNA sequences coding protein-tyrosine phosphatases (PTPs) have been reported and their extensive similarities in the catalytic domains clarified, but knowledge of the structures and organizations of their genes is still limited. In this study, a detailed structure and organization of the human intracellular LC-PTP (also called HePTP) gene is reported. The 13 to 18.5 kb genomic clones encoding human LC-PTP have been isolated. The LC-PTP gene is organized into 11 exons, including the 5'-noncoding first exon and the 3'-noncoding exon. Splicing sites for exons 4 to 10, which encode the conserved catalytic PTP domain, arise almost at the same position as for the CD45 gene. This elucidation of the LC-PTP gene structure provides insight into the domain evolution of intracellular LC-PTP and transmembrane CD45, which may be generated by gene duplications of an ancestral gene.			ADACHI, M (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,JAPAN.							ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOKKEL E, 1992, ONCOGENE, V7, P1423; HALL LR, 1988, J IMMUNOL, V141, P2781; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISOBE M, 1994, ONCOGENE, V9, P1751; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1994, ONCOGENE, V9, P877; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3031	3035						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084610				2022-12-25	WOS:A1994PG82200033
J	HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF				HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF			MOLECULAR-CLONING, SEQUENCING, CHROMOSOMAL LOCALIZATION AND EXPRESSION OF MOUSE P21 (WAF1)	ONCOGENE			English	Note							GENE; INHIBITOR; PROTEIN; KINASES	The recent discovery that expression of Waf1 (p21), an inhibitor of cyclin-dependent kinases, is induced by the tumor suppressor p53 provides an important linkage between growth suppression and the cell cycle. We report here the cloning and sequencing of a mouse p21 cDNA that contains the entire coding region. Hybridization of the mouse p21 probe in Southern blot analyses confirms that p21 is a single-copy gene and that the corresponding locus, Waf1, lies proximal to H-2 on mouse chromosome 17. In northern analyses, the expression of p21 is found in most normal mouse tissues, but a surprising lack of correlation is found. between mRNA levels of p21 and p53. In order to determine which regions of p21 are most evolutionarily conserved, we have compared the cDNA sequences for the entire p21 coding region in 13 different mouse strains or species and the human p21 sequence. We conclude that two regions (corresponding to human codons 21-60 and 130-164) are strongly conserved in p21 and that these regions may represent domains that are especially critical to a functional p21 protein.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUPPI, K (corresponding author), NCI, GENET LAB, BLDG 37, BETHESDA, MD 20892 USA.		Mock, Beverly A/B-3110-2015; Michieli, Paolo/A-2588-2011	Mock, Beverly A/0000-0003-2479-4549; Michieli, Paolo/0000-0002-3093-8871				CHEDID M, 1994, ONCOGENE, V9, P3021; DIETRICH W, 1992, GENETICS, V131, P423; DOSIK JK, IN PRESS MAMMALIAN G; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HIMMELBAUER H, 1993, MAMM GENOME, V4, pS230, DOI 10.1007/BF00360843; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; MOCK BA, 1993, MAMM GENOME, V4, P461, DOI 10.1007/BF00296823; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUSSI T, 1990, ONCOGENE, V5, P945; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	18	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3017	3020						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084607				2022-12-25	WOS:A1994PG82200030
J	METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP				METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP			MURINE A-MYB - EVIDENCE FOR DIFFERENTIAL SPLICING AND TISSUE-SPECIFIC EXPRESSION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; C-MYB; B-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; FUNCTIONAL DOMAINS; MYELOID-LEUKEMIA	The myb gene family consists of three members, A-myb, B-myb and c-myb. The proteins encoded by these genes bind DNA in a sequence-specific manner and regulate transcription of target genes. In this communication, we report the nucleotide sequence of murine A-myb cDNA. This gene encodes a protein of 751 amino acids with an estimated molecular weight of 83 kDa. cDNA sequence analysis of multiple independent cDNA clones reveals the presence of alternatively spliced mRNAs that encode smaller proteins. Northern blot analysis of adult mouse tissue RNAs reveals A-myb expression predominantly in the testis, with very low levels of expression in the ovaries, spleen and brain. In situ hybridization analysis of adult mouse testis shows that this gene is expressed at high levels in type A spermatogonia (stem cells), and preleptotene and pachytene spermatocytes, with concomitant downregulation of expression upon terminal differentiation of these cells into mature spermatozoa. This pattern of expression suggests that A-myb is involved in the control of proliferation and differentiation of spermatogonia. This potential function of A-myb in spermatogenesis is reminiscent of the role of c-myb in hematopoiesis.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [5-P30-CA12227, CA-52009] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUER KH, 1987, EMBO J, V6, P2719; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIDENKAPP H, 1988, NATURE, V355, P835; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; LAM EWF, 1992, ONCOGENE, V7, P1885; MCMAHON J, 1988, ONCOGENE, V3, P717; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PAULES RS, 1988, ONCOGENE, V3, P59; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Russel D. L., 1990, HISTOLOGICAL HISTOPA; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILLIAMS DL, 1987, BIOTECHNIQUES, V5, P718; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	43	73	75	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3077	3086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084617				2022-12-25	WOS:A1994PG82200041
J	ELBENNA, J; FAUST, LP; BABIOR, BM				ELBENNA, J; FAUST, LP; BABIOR, BM			THE PHOSPHORYLATION OF THE RESPIRATORY BURST OXIDASE COMPONENT P47(PHOX) DURING NEUTROPHIL ACTIVATION - PHOSPHORYLATION OF SITES RECOGNIZED BY PROTEIN-KINASE-C AND BY PROLINE-DIRECTED KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SERINE THREONINE KINASES; 47-KDA PROTEIN; SUBSTRATE RECOGNITION; PLASMA-MEMBRANE; CYTOCHROME-B; IDENTIFICATION; ASSOCIATION; CLONING; PEPTIDE	The respiratory burst oxidase catalyzes the production of O-2(radical anion) from oxygen and NADPH. It is dormant in resting cells but becomes active when the cells are stimulated, Activation is accompanied by the phosphorylation of multiple serines in the cytosolic oxidase component p47(phox), which moves from cytosol to the membrane during oxidase activation. Using immunopurified p47(phox) isolated from P-32(i)-loaded neutrophils activated with phorbol myristate acetate, we showed that all the P-32 was in the C-terminal CNBr fragment of the protein, and that in that fragment, Ser-303, Ser-304, Ser-320, Ser328, Ser-345, and Ser-348 and at least one of the three serines, Ser-359, Ser-370, and Ser-379, were phosphorylated, while Ser-282, Ser-287, Ser-381, and Ser-388 were not, Of the phosphorylated serines, Ser-303, Ser-304, Ser320, and Ser-328 are located in protein kinase C substrate sequences. Ser-345 and Ser-348, however, are located in sequences recognized by mitogen-activated protein (MAP) kinase (-PXSP-). This finding suggests that MAP kinase or a related proline-directed kinase may participate in the regulation of O-2(radical anion) production by activated neutrophils. The tryptic peptide map of p47(phox) phosphopeptides from neutrophils activated by N-formyl-methionyl-leucyl-phenylalanine closely resembled that of p47(phox) phosphopeptides from phorbol-activated cells, suggesting that the same serines were phosphorylated in response to each agent.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIAID NIH HHS [AI-30742, AI-28479, AI-24227] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI130742, R01AI028479, R37AI024227, R01AI024227, R01AI030742, R21AI128479] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1993, J BIOL CHEM, V268, P17326; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRAMER IM, 1988, BIOCHIM BIOPHYS ACTA, V971, P189; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUO K, 1990, ONCOGENE, V5, P921; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1981, BIOCHEM J, V196, P363, DOI 10.1042/bj1960363; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WOLFSON M, 1985, J IMMUNOL, V135, P2057	36	296	299	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23431	23436						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089108				2022-12-25	WOS:A1994PQ34500011
J	SAKAI, H; TAKEGUCHI, N				SAKAI, H; TAKEGUCHI, N			A GTP-BINDING PROTEIN INHIBITS A GASTRIC HOUSEKEEPING CHLORIDE CHANNEL VIA INTRACELLULAR PRODUCTION OF SUPEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PARIETAL-CELLS; CONDUCTANCE CL CHANNELS; BOVINE CHROMAFFIN CELLS; OXYGEN RADICALS; NADPH OXIDASE; GAMMA-S; BASOLATERAL MEMBRANE; HYDROGEN-PEROXIDE; ARACHIDONIC-ACID; EPITHELIAL-CELLS	A housekeeping basolateral Cl- channel of rabbit gastric parietal cells, the single channel conductance of which is about 0.3 picosiemens, is opened by prostaglandin E(2) and closed by intracellular application of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). In the present patch clamp study, we found a novel GTP gamma S-dependent regulatory mechanism of the Cl- channel. GTP gamma S significantly decreased the open probability of the single Cl- channel without altering unit conductance. An intracellular application of superoxide dismutase (SOD; 100 units/ml) inhibited the GTP gamma S (50 mu M)-induced closure of the Cl- channel. SOD plus catalase (100 units/ml) also inhibited the GTP gamma S-induced effect, while catalase alone did not inhibit it. In the absence of GTP gamma S, an intracellular application of hydrogen peroxide (H2O2; 30 mu M) did not affect the Cl- channel current. Desferrioxamine (50 mu M) which inhibits hydroxyl radical (.OH) production was without effect on the GTP gamma S-induced closure. These results suggest that the GTP gamma S-induced closure of the Cl- channel was due to intracellular production of superoxide (O-2(radical anion)), but not due to .OH or H2O2. Furthermore, an artificial production of O-2(radical anion) inside the cell by lumazine (50-100 mu M) plus xanthine oxidase (0.5-1 milliunit/ml) in the absence of GTP gamma S also closed the channel. The lumazine/xanthine oxidase-induced closure of the channel was inhibited by SOD, but not by catalase or desferrioxamine. We conclude hom these results that GTP-binding protein-coupled production of O-2(radical anion) leads to closure of the Cl- channel in rabbit gastric parietal cells.			SAKAI, H (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,DEPT PHARMACEUT PHYSIOL,TOYAMA 93001,JAPAN.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BACON BR, 1984, SEMIN LIVER DIS, V4, P181, DOI 10.1055/s-2008-1041769; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAUER ML, 1992, BIOCHIM BIOPHYS ACTA, V1104, P87, DOI 10.1016/0005-2736(92)90135-9; BERGLINDH T, 1980, AM J PHYSIOL, V239, pG90, DOI 10.1152/ajpgi.1980.239.2.G90; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BRITIGAN BE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P213, DOI 10.1016/0304-4165(91)90269-M; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DORNAND J, 1989, IMMUNOLOGY, V68, P384; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P711, DOI 10.1113/jphysiol.1991.sp018575; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P725, DOI 10.1113/jphysiol.1991.sp018576; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HIRAISHI H, 1992, J BIOL CHEM, V267, P14812; HIRAISHI H, 1987, AM J PHYSIOL, V253, pG40, DOI 10.1152/ajpgi.1987.253.1.G40; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KEYSER DO, 1990, NEURON, V5, P545, DOI 10.1016/0896-6273(90)90092-T; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOTERA T, 1994, AM J PHYSIOL, V266, pC536, DOI 10.1152/ajpcell.1994.266.2.C536; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P176; MARTIN DK, 1993, BIOCHEM BIOPH RES CO, V192, P1266, DOI 10.1006/bbrc.1993.1553; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCGILL JM, 1993, J MEMBRANE BIOL, V133, P253; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; NAITO Y, 1992, J CLIN GASTROENTEROL, V14, pS131, DOI 10.1097/00004836-199206001-00023; PEETERSJORIS C, 1975, BIOCHEM J, V150, P31, DOI 10.1042/bj1500031; PERRY MA, 1986, GASTROENTEROLOGY, V90, P362, DOI 10.1016/0016-5085(86)90933-9; ROBERT A, 1992, GUT, V33, P444, DOI 10.1136/gut.33.4.444; SAKAI H, 1992, J PHYSIOL-LONDON, V448, P293, DOI 10.1113/jphysiol.1992.sp019042; SAKAI H, 1993, J PHYSIOL-LONDON, V461, P201, DOI 10.1113/jphysiol.1993.sp019509; SAKAI H, 1989, PFLUG ARCH EUR J PHY, V414, P185, DOI 10.1007/BF00580962; SATOH S, 1992, J HISTOCHEM CYTOCHEM, V40, P1157, DOI 10.1177/40.8.1619279; SCHWARTZ RD, 1988, J NEUROCHEM, V50, P565, DOI 10.1111/j.1471-4159.1988.tb02948.x; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1990, J BIOL CHEM, V265, P7725; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; THAETE LG, 1985, J HISTOCHEM CYTOCHEM, V33, P803, DOI 10.1177/33.8.3894498; TILLY BC, 1991, J BIOL CHEM, V266, P2036; Varma S D, 1987, Free Radic Res Commun, V4, P77, DOI 10.3109/10715768709088091	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23426	23430						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089107				2022-12-25	WOS:A1994PQ34500010
J	KOUTEK, B; PRESTWICH, GD; HOWLETT, AC; CHIN, SA; SALEHANI, D; AKHAVAN, N; DEUTSCH, DG				KOUTEK, B; PRESTWICH, GD; HOWLETT, AC; CHIN, SA; SALEHANI, D; AKHAVAN, N; DEUTSCH, DG			INHIBITORS OF ARACHIDONOYL ETHANOLAMIDE HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-KETO ESTERS; CANNABINOID RECEPTOR AGONIST; TRIFLUOROMETHYL KETONE; FLUOROMETHYL KETONES; BRAIN CONSTITUENT; ANANDAMIDE; PEPTIDYL; ACIDS; DERIVATIVES; ENZYMES	Arachidonoyl ethanolamide (anandamide) is a naturally occurring brain constituent that binds to a specific brain cannabinoid receptor (CBR1). An amidase activity (anandamide amidase) in membrane fractions of brain and in cultured neuroblastoma cells rapidly degrades anandamide to arachidonic acid (Deutsch, D. G., and Chin, S. (1993) Biochem. Pharmacol. 46, 791-796). In the current study, analogs of anandamide representing three classes of putative transition-state inhibitor (trifluoromethyl ketones, alpha-keto esters, and alpha-keto amides) were synthesized and tested as inhibitors of anandamide hydrolysis in vitro and as ligands for CBR1. The trifluoromethyl ketones and alpha-keto esters showed nearly 100% inhibition of anandamide hydrolysis in vitro at 7.5 mu M inhibitor and 27.7 mu M anandamide. Arachidonyl trifluoromethyl ketone was the only synthetic compound in the series of fatty acid derivatives able to displace [H-3]CP-55940 binding to CBR1 with a K-i of 0.65 mu M. It was also the most effective inhibitor in intact neuroblastoma cells, leading to a 12-fold increase of cellular anandamide levels at 12 mu M. From the action of these inhibitors on this hydrolytic enzyme, it seems likely that anandamide is cleaved by a mechanism that involves an active-site serine hydroxyl group. These inhibitors may serve as useful tools to elucidate the role anandamide plays in vivo.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Saint Louis University				Howlett, Allyn/0000-0002-2810-0164; Koutek, Bohumir/0000-0002-0779-4953	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003690, K05DA000182] Funding Source: NIH RePORTER; NIDA NIH HHS [K05-DA00182, R01-DA06912, R01-DA03690] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLEN KN, 1989, BIOCHEMISTRY-US, V28, P8466, DOI 10.1021/bi00447a029; ANGELASTRO MR, 1990, J MED CHEM, V33, P11, DOI 10.1021/jm00163a002; BOIVIN J, 1992, TETRAHEDRON LETT, V33, P1285, DOI 10.1016/S0040-4039(00)91602-2; BRADY K, 1989, BIOCHEMISTRY-US, V28, P9066, DOI 10.1021/bi00449a017; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; ELIEL EL, 1972, J ORG CHEM, V37, P505, DOI 10.1021/jo00968a043; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001; HAMMOCK BD, 1982, PESTIC BIOCHEM PHYS, V17, P76, DOI 10.1016/0048-3575(82)90128-6; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HU LY, 1990, ARCH BIOCHEM BIOPHYS, V281, P271, DOI 10.1016/0003-9861(90)90443-3; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mechoulam R., 1986, CANNABINOIDS THERAPE, DOI [10.1201/9780429260667, DOI 10.1201/9780429260667]; MEHDI S, 1993, BIOORG CHEM, V21, P249, DOI 10.1006/bioo.1993.1021; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OCAIN TD, 1992, J MED CHEM, V35, P451, DOI 10.1021/jm00081a005; OTTENHEIM HJC, 1978, ORG SYNTH, V61, P1; PEET NP, 1990, J MED CHEM, V33, P394, DOI 10.1021/jm00163a063; PRESTWICH GD, 1984, ARCH BIOCHEM BIOPHYS, V228, P639, DOI 10.1016/0003-9861(84)90033-X; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SHIOTSUKI T, 1994, PROTEIN EXPRES PURIF, V5, P296, DOI 10.1006/prep.1994.1045; SOLLADIE G, 1993, J ORG CHEM, V58, P2181, DOI 10.1021/jo00060a038; STEGLICH W, 1978, SYNTHESIS-STUTTGART, P622; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SZEKACS A, 1990, CHEM RES TOXICOL, V3, P325, DOI 10.1021/tx00016a009; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; VOGEL Z, 1993, J NEUROCHEM, V61, P353	35	195	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22937	22940						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083191				2022-12-25	WOS:A1994PQ16400007
J	FENG, GH; LEE, DN; WANG, DG; CHAN, CL; LANDICK, R				FENG, GH; LEE, DN; WANG, DG; CHAN, CL; LANDICK, R			GREA-INDUCED TRANSCRIPT CLEAVAGE IN TRANSCRIPTION COMPLEXES CONTAINING ESCHERICHIA-COLI RNA-POLYMERASE IS CONTROLLED BY MULTIPLE FACTORS, INCLUDING NASCENT TRANSCRIPT LOCATION AND STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEXES; ELONGATION-FACTOR; PAUSE SITE; DNA; TERMINATION; PROMOTER; PROTEINS; SII; CHROMATOGRAPHY; EXPRESSION	The Escherichia coli GreA and GreB proteins induce cleavage of 3' fragments from nascent transcripts in halted transcription complexes. We have overproduced and purified the GreA protein and tested how it affects initiation, pausing, and termination by E. coli RNA po lymerase. Recombinant GreA induced cleavage of two to three nucleotide fragments in two promoter-proximal complexes, whereas an apparently endogenous cleavage removed a single larger fragment. Both types of cleavage stopped once the transcript was shortened to similar to 10 nucleotides. However, during initiation, GreA induced cleavage of transcripts as short as four nucleotides, inhibiting their release as abortive products and stimulating both productive initiation and ''primer-shifting'' at a weak promoter. GreA induced repetitive cleavage over a long distance in complexes containing a long G-less nascent transcript, However, reverse translocation was inhibited in transcription complexes that contained a G-rich, C-less nascent transcript. Substituting IMP for GRIP in the transcript relieved inhibition. Finally, GreA had little effect on transcription through the his and trp leader pause sites or on termination at nine different rho-independent terminators. We propose that transcript cleavage and reverse translocation are controlled in part by backsliding of the nascent transcript through an RNA-binding site.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038660, R01GM038660, R29GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIVAZASHVILI VA, 1982, MOL BIOL, V15, P711; ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JOHNSON T, 1994, CELL, V77, P212; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KRUMMEL B, 1990, THESIS U CALIFORNIA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDICK R, 1990, J MOL BIOL, V216, P25, DOI 10.1016/S0022-2836(05)80058-0; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; REINES D, 1992, J BIOL CHEM, V267, P3795; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1991, P NATL ACAD SCI USA, V88, P1245; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WYATT JR, 1993, RNA WORLD, P465; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	54	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22282	22294						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071355				2022-12-25	WOS:A1994PE09800056
J	GERENDASY, DD; HERRON, SR; WATSON, JB; SUTCLIFFE, JG				GERENDASY, DD; HERRON, SR; WATSON, JB; SUTCLIFFE, JG			MUTATIONAL AND BIOPHYSICAL STUDIES SUGGEST RC3/NEUROGRANIN REGULATES CALMODULIN AVAILABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; BINDING DOMAIN; NITROCELLULOSE SHEETS; PHOSPHORYLATION SITE; MESSENGER-RNA; BOVINE BRAIN; RAT-BRAIN; PROTEIN; NEUROMODULIN; IDENTIFICATION	RC3/neurogranin is a forebrain-enriched, postnatal-onset, thyroid hormone-dependent, protein kinase C substrate of dendritic spines that interacts with calmodulin. These characteristics suggest a prominent role within the Ca2+-mediated second messenger cascades associated with neonatal synaptogenesis and adult neural plasticity. To understand the molecular interactions between RC3 and calmodulin, we characterized recombinant RC3 and four sequence variants: Ser-36 --> Ala, Ser-36 --> Asp, Ser-36 --> Lys, and Phe-37 --> Trp. Interactions between CaM and variant Phe-37 --> Trp can be monitored by fluorescence spectroscopy, allowing us to determine, by competitive assays, the relative affinities of the wild-type and variant proteins for calmodulin. The effects of salt and Ca2+ on the rank order of these affinities permit partial dissection of hydrophobic, ionic, and structural components of the RC3-CaM interaction and suggest that it is bimodal. We demonstrate that RC3 binds preferentially to CaM when Ca2+ is absent and that the addition of a negative charge to residue 36 is sufficient to disrupt all detectable RC3-CaM interactions. We propose a model wherein a Ca2+-''sensitive,'' bimodal interaction between RC3 and CaM regulates the transduction of postsynaptic Ca2+ fluxes into physiological responses through the modulation of Ca2+/ CaM availability.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, SCH MED, MENTAL RETARDAT RES CTR, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN RES INST, LOS ANGELES, CA 90024 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NINDS NIH HHS [NS22347, NS2211] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN SJ, 1993, 23RD P ANN SOC NEUR; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; INIGUEZ MA, 1992, J CLIN INVEST, V90, P554, DOI 10.1172/JCI115894; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTZEN MR, 1994, IN PRESS J NEUROCHEM; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; Morreale de Escobar G, 1983, CONGENITAL HYPOTHYRO, P85; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WOJTKOWIAK Z, 1983, ANAL BIOCHEM, V129, P486, DOI 10.1016/0003-2697(83)90581-X	31	84	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22420	22426						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071370				2022-12-25	WOS:A1994PE09800074
J	GOOD, L; ELELA, SA; NAZAR, RN				GOOD, L; ELELA, SA; NAZAR, RN			TETRAHYMENA RIBOZYME DISRUPTS RIBOSOMAL-RNA PROCESSING IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA INTERVENING SEQUENCE; GROUP-I INTRONS; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; PHYSARUM-POLYCEPHALUM; THERMOPHILA; CLEAVAGE; GENES; MODEL; RDNA	The intervening sequence (IVS) of Tetrahymena thermophila nucleolar DNA interrupts a highly conserved sequence in the RNA core structure of the large ribosomal subunit. This location in nuclear DNA is unusual as most group I introns are in mitochondrial and chloroplast DNA. To examine the effect of a ribozyme insertion in another nuclear genome, the Tetrahymena NS was introduced into the analogous position in a cloned Schizosaccharomyces pombe ribosomal gene, and the mutant rDNA was expressed in vivo. RNA analyses indicated that mature 5.8 S rRNA was not formed from the mutant gene transcript and the amount of 27 S nRNA was significantly reduced. In contrast, hybridization analyses indicated that RNA splicing continued, and normal forms of free ribozyme were present. The results show that the TVS sequence can interfere with rRNA processing and suggest that the unusual amplification of a single rDNA repeat may have forced Tetrahymena to accommodate its ribozyme.			GOOD, L (corresponding author), UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH N1G 2W1, ON, CANADA.							CECH TR, 1983, P NATL ACAD SCI-BIOL, V80, P3903, DOI 10.1073/pnas.80.13.3903; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1979, P NATL ACAD SCI USA, V76, P5051, DOI 10.1073/pnas.76.10.5051; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DIN N, 1979, CELL, V18, P525, DOI 10.1016/0092-8674(79)90069-2; DINGMAN CW, 1968, BIOCHEMISTRY-US, V7, P659, DOI 10.1021/bi00842a022; DOVER GA, 1988, NATURE, V336, P623, DOI 10.1038/336623a0; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; ELELA SA, 1994, NUCLEIC ACIDS RES, V22, P686, DOI 10.1093/nar/22.4.686; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRIS PJ, 1983, MOL CELL BIOL, V3, P635, DOI 10.1128/MCB.3.4.635; Gerbi S. A., 1985, MOL EVOLUTIONARY GEN, P419, DOI DOI 10.1007/978-1-4684-4988-4_7; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; GRABOWSKI PJ, 1981, CELL, V23, P467, DOI 10.1016/0092-8674(81)90142-2; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JOHANSEN S, 1992, CURR GENET, V22, P297, DOI 10.1007/BF00317925; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; Maniatis T., 1982, MOL CLONING; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NAZAR RN, 1987, J BIOL CHEM, V262, P7523; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; ROGERS SO, 1993, CURR GENET, V23, P338, DOI 10.1007/BF00310896; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAK J, 1982, NUCLEIC ACIDS RES, V10, P2851, DOI 10.1093/nar/10.9.2851; STEELE WJ, 1965, J BIOL CHEM, V240, P1742; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; VANRYK DI, 1992, J BIOL CHEM, V267, P16177; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	41	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22169	22172						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071340				2022-12-25	WOS:A1994PE09800039
J	HUANG, SL; CHEUNG, WY				HUANG, SL; CHEUNG, WY			H+ IS INVOLVED IN THE ACTIVATION OF CALCINEURIN BY CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN PHOSPHATASE; DIVALENT METAL-IONS; LIGHT CHAIN KINASE; LIMITED PROTEOLYSIS; BINDING; CALCIUM; DOMAIN; MECHANISM; ENZYMES	We have studied recently the surface hydrophobic properties of several calmodulin (CaM) target enzymes and found that a certain amphipathic domain(s) of the enzyme was exposed in response to a H+ increase within the neutral pH range. The exposed domain appeared to be related to their CaM-binding domains and associated with their activation by CaM (Huang, S., Carlson, G. M., and Cheung, W,Y. (1994) J. Biol. Chem. 269, 7631-7638). In this paper, the involvement of H+ in the activation of calcineurin (CaN), one of the CaM target enzymes, was further studied. Using dansylated CaM to monitor its conformational change, we found that the binding of Ca2+ to CaM occurred at a lower range of Ca2+ concentrations (pCa from 7 to 6) than the formation of CaM CaN complex (pCa from 6 to 5). However, addition of H+ within the neutral pH range shifted the formation of CaM CaN complex to the lower range of Ca2+ concen trations. Similarly, the addition of H+ shifted the Ca2+ requirement for enzyme activation to a lower Ca2+ range. These results show that the interaction of CaM with CaN could be initiated either by Ca2+ or by H+ in the presence of suboptimal Ca2+, suggesting a positive cooperative effect between Ca2+ and H+. The CaM-stimulated activity of CaN was accompanied by a time-dependent autoinactivation. Kinetic analysis showed that the autoinactivation initiated by Ca2+ or by H+ was biphasic and that the decay rate constants were comparable, In heavy water (D2O), the Ca2+-induced formation of CaM CaN complex as well as the activity of CaN were decreased, indicating a solvent deuterium isotope effect. The same solvent isotope effect was observed in the H+-induced formation of CaM CaN complex and in the H+-induced enzyme activity. When the enzyme was rendered CaM-independent by limited proteolysis, the isotope effect was abolished, suggesting that H+ was involved in the CaM-dependent and not the CAM-independent activity. Collectively, these data suggest that the interaction of CaM with CaN depends on the two cations: Ca2+ exposes an amphipathic domain on CaM, and H+ exposes the CaM-binding domain on the target enzyme.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 36734] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFAI T, 1979, ADV CYCLIC NUCLEOTID, V10, P219; BESSEY OA, 1952, J BIOL CHEM, V196, P175; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; EVANS JS, 1989, CALMODULIN, P57; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; HUANG SL, 1994, J BIOL CHEM, V269, P7631; HUANG SL, 1993, FASEB J, V7, pA1158; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KENNELLY PJ, 1990, J BIOL CHEM, V265, P1742; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KING MM, 1984, J BIOL CHEM, V259, P8847; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; RODAN GA, 1976, P NATL ACAD SCI USA, V73, P1829, DOI 10.1073/pnas.73.6.1829; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TALLANT EA, 1984, BIOCHEMISTRY-US, V23, P973, DOI 10.1021/bi00300a027; WALLACE RW, 1980, CALCIUM CELL FUNCTIO, V1, P33; [No title captured]	30	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22067	22074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071329				2022-12-25	WOS:A1994PE09800024
J	KIHARA, H; SIRAGANIAN, RP				KIHARA, H; SIRAGANIAN, RP			SRC HOMOLOGY-2 DOMAINS OF SYK AND LYN BIND TO TYROSINE-PHOSPHORYLATED SUBUNITS OF THE HIGH-AFFINITY IGE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; T-CELL; SIGNAL TRANSDUCTION; IMMUNOGLOBULIN-E; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; CYTOPLASMIC DOMAINS; HISTAMINE-RELEASE; BETA-SUBUNIT	Aggregation of the high affinity IgE receptor (Fc epsilon RI) on rat basophilic leukemia RBL-2H3 cells results in activation of the protein tyrosine kinases Syk and Lyn. Here, we report that fusion proteins containing the Src homology 2 (SH2) domains of Syk and Lyn precipitated tyrosine-phosphorylated proteins from RBL-2H3 cell lysates. There was no detectable precipitation with the N-terminal Syk SH2 domain, minimal with the C-terminal Syk SH2, and strong when the two SH2 domains were expressed in tandem. The Syk SH2 domains showed pronounced selectivity in the binding of tyrosine-phosphorylated proteins. Thus, Syk SH2 precipitated only three phosphoproteins, two of which were the beta and gamma subunits of Fc epsilon RI. In contrast, the fusion protein with Lyn SH2, in addition to precipitating the same Fc epsilon RI components, bound to many other phosphoproteins. Tyrosine phosphorylation of the beta and gamma subunits of Fc epsilon RI was essential for their precipitation with the SH2 fusion proteins. By direct binding studies, there was more binding of Syk SH2 to Fc epsilon RI gamma than to Fc epsilon RI beta, whereas Lyn SH2 bound only to Fc epsilon RI beta. The Syk SH2 fusion protein competitively inhibited the association of gamma and beta with Syk in lysates of activated cells. The SH2-mediated association of these two protein tyrosine kinases with Fc epsilon RI could play an important role in recep tor signaling.			KIHARA, H (corresponding author), NIDR, IMMUNOL LAB, BLDG 10, RM 1N106, BETHESDA, MD 20892 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sambrook J, 1989, MOL CLONING LABORATO; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	188	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22427	22432						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071371				2022-12-25	WOS:A1994PE09800075
J	SINGH, BN; LUCAS, JJ; BEACH, DH; COSTELLO, CE				SINGH, BN; LUCAS, JJ; BEACH, DH; COSTELLO, CE			EXPRESSION OF A NOVEL CELL-SURFACE LIPOPHOSPHOGLYCAN-LIKE GLYCOCONJUGATE IN TRYPANOSOMA-CRUZI EPIMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI LIPOPHOSPHOGLYCAN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; WHEAT-GERM-AGGLUTININ; TRANS-SIALIDASE; GLYCOPROTEIN; PROTEINS; ACID; LIPOPEPTIDOPHOSPHOGLYCAN; OLIGOSACCHARIDES; MOIETY	The lipophosphoglycan (LPG)-like glycoconjugate expressed on the cell surface of Trypanosoma cruzi epimastigotes was isolated, purified, and partially characterized. The glycoconjugate migrated as a homogeneous band (42 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Matrix-assisted laser desorption ionization mass spectral analysis of the native molecule indicated the presence of two major components whose molecular masses were about 18.4 and 22.5 kDa. The LPG could be metabolically labeled with [H-3]galactose, [H-3]mannose, [C-14]glucose, or [H-3]palmitic acid. Monosaccharide compositional analysis of the LPG indicated that galactose, glucosamine, and sialic acid predominate over mannose, galactosamine, and inositol. A peptide associated with the LPG molecule contained about 40 amino acid residues per inositol and had threonine as the predominant amino acid. The LPG showed strong binding to Ricinus communis agglutinin-1 and Tritium vulgare wheat germ agglutinin, indicating the presence of terminal beta 1,4-linked galactosyl residue(s) and N-acetylglucosamine, respectively. Lectin binding studies also suggested the presence of a terminal beta-galactose and GlcNAc in the glycan-inositol lipid core of LPG. Virtually all of the sialic acids appeared to be located in the saccharide portion of the molecule. Treatment of the LPG with phosphatidylinositol-specific phospholipase C liberated an alkylacylglycerol. Structural analysis of the alkylacylglycerol and its acidic methanolysis products by gas-liquid chromatography/ mass spectrometry indicated that the glycerol substituents were primarily the C-16 1-alkyl group and C-16 2-acyl group. The ratio of inositol to 1-O-alkyl-2-O-acylglycerol was 1:1. Treatment of the glycoconjugate with nitrous acid released a major phospholipid product that migrated close to the phosphatidylinositol standard on thin layer chromatography. This result implied that phosphatidylinositol was glycosidically linked to the nonacetylated amino sugar. Furthermore, the LPG was found to contain phosphate and was labile to mild acid hydrolysis, strongly suggesting that the intact molecule is related to Leishmania LPG. The most striking and unique feature of T. cruzi LPG is the presence of large amounts of glucosamine and sialic acid as well as galactosamine. These results indicate that the glycoconjugate expressed on the T. cruzi cell surface is a new type of LPG-like molecule anchored on the cell surface via an alkylacylphosphatidylinositol.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210; MIT,DEPT CHEM,MASS SPECTROMETRY FACIL,CAMBRIDGE,MA 02139	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Massachusetts Institute of Technology (MIT)	SINGH, BN (corresponding author), SUNY HLTH SCI CTR,DEPT IMMUNOL & MICROBIOL,750 E ADAMS ST,SYRACUSE,NY 13210, USA.			Costello, Catherine/0000-0003-1594-5122	NCRR NIH HHS [RR-00317] Funding Source: Medline; NIAID NIH HHS [NIAID AI-05802] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDREWS NW, 1988, J EXP MED, V167, P300, DOI 10.1084/jem.167.2.300; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CASTELLANI O, 1967, J PROTOZOOL, V14, P447, DOI 10.1111/j.1550-7408.1967.tb02024.x; COHEN SA, 1984, AM LAB FAIRFIELD AUG, P48; CUATRECASAS P, 1972, METHOD ENZYMOL, V28, P897; DEEG MA, 1992, J BIOL CHEM, V267, P18581; Defaye J., 1970, ADV CARBOHYD CHEM BI, V25, P181; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAHMBERG CG, 1976, METHODS MEMBR BIOL, V7, P179; GROSS GAM, 1990, ANN REV CELL BIOL, V6, P1; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JARDIM A, 1991, J IMMUNOL, V147, P3538; KORN ED, 1973, J BIOL CHEM, V248, P439; KUMAR R, 1983, J LIPID RES, V24, P930; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCHANKMAN S, 1993, PARASITOL TODAY, V9, P218; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SINGH BN, 1994, ARCH BIOCHEM BIOPHYS, V309, P273, DOI 10.1006/abbi.1994.1113; SINGH BN, 1991, ARCH BIOCHEM BIOPHYS, V286, P409, DOI 10.1016/0003-9861(91)90059-R; SINGH BN, MOL BIOCHEM PARASIT, V42, P225; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037	43	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21972	21982						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071317				2022-12-25	WOS:A1994PE09800011
J	WANG, H; CAPPS, GG; ROBINSON, BE; ZUNIGA, MC				WANG, H; CAPPS, GG; ROBINSON, BE; ZUNIGA, MC			AB-INITIO ASSOCIATION WITH BETA(2)-MICROGLOBULIN DURING BIOSYNTHESIS OF THE H-2L(D) CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX HEAVY-CHAIN PROMOTES PROPER DISULFIDE BOND FORMATION AND STABLE PEPTIDE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; TOXIC LYMPHOCYTES-T; CIS-TRANS-ISOMERASE; CELL-SURFACE; TRANSPLANTATION ANTIGENS; INFLUENZA NUCLEOPROTEIN; SYNTHETIC PEPTIDES; MOLECULES; EXPRESSION; BETA-2-MICROGLOBULIN	In vitro translation studies indicate that the beta(2)-microglobulin (beta(2)-m) light chain influences the formation of intrachain disulfide bonds in class I major histocompatibility complex (MHC) molecules during their biosynthesis. We now have examined the influence of beta(2)-m on class I MHC intrachain disulfide bond formation in vivo. Using beta(2)-m(+) and beta(2)-m(-) derivatives of a cell line transfected with the mouse H-2L(d) gene, we show that all of the H-2L(d) molecules from beta(2)-m(-) cells have both the alpha(2) and alpha(3) intrachain disulfide bonds, whereas about 50% of the H-2L(d) molecules from beta(2)-m(-) cells have only one of these bonds. All of the free H-2L(d) heavy chains from beta(2)-m(+) cells can undergo a peptide-induced conformational change and can bind exogenous peptide and beta(2)-m stably in vitro. Only those H-2L(d) molecules from beta(2)-m(-) cells, which have both intrachain disulfide bonds, undergo a peptide- and beta(2)-m-induced conformational change in vitro. These H-2L(d) molecules do not bind beta(2)-m and peptide stably in vitro. From these results emerges a greater understanding of the role of beta(2)-m at the time of class I MHC molecule synthesis: beta(2)-m promotes intrachain disulfide bond formation in the class I MHC molecule and additionally affects class I MHC structure to render it competent to form stable trimolecular complexes with peptide and beta(2)-m.	UNIV CALIF SANTA CRUZ,DEPT BIOL,SINSHEIMER LABS,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BURSHTYN DN, 1993, J IMMUNOL, V151, P3082; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GATTONICELLI S, 1992, CANCER RES, V52, P1201; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; KIMBALL ES, 1983, CONTEMP TOP MOLEC IM, V9, P1; KORDEL J, 1990, FEBS LETT, V263, P27, DOI 10.1016/0014-5793(90)80697-H; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; MURRE C, 1984, J EXP MED, V160, P167, DOI 10.1084/jem.160.1.167; PULLEN JK, 1992, J IMMUNOL, V148, P953; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SHIROISHI T, 1985, J IMMUNOL, V134, P623; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0; ZUNIGA MC, 1986, J CELL BIOL, V102, P1, DOI 10.1083/jcb.102.1.1	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22276	22281						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071354				2022-12-25	WOS:A1994PE09800055
J	ARCINAS, M; BOXER, LM				ARCINAS, M; BOXER, LM			DIFFERENTIAL PROTEIN-BINDING TO THE C-MYC PROMOTER DURING DIFFERENTIATION OF HEMATOPOIETIC-CELL LINES	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ZINC-FINGER PROTEIN; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; INDUCIBLE PROTEIN; DNA INTERACTIONS; HEAT-SHOCK; 1ST EXON	In vivo footprinting has been used to examine protein binding sites in the c-myc promoter during differentiation cell lines. The c-myc gene is proliferating cells, but c-myc levels decrease dramatically during differentiation. A number of potential protein binding sites have been identified from in vitro studies of the c-myc promoter, but very little is known about occupancy of these sites in vivo. We have identified in vivo footprints at DNase hypersensitive sites II2 and III1 which disappear during differentiation, while a footprint at site IV is present only in differentiated cells. Footprints at DNase hypersensitive sites I and II1 do not change with differentiation. A protected region near DNase hypersensitive site III2 is present in both undifferentiated and differentiated cells, but it extends further 5' in undifferentiated cells. From the protected sequences we have been able to identify candidate transcription factors likely to be involved in the control of c-myc expression. By electrophoretic mobility shift assay we have demonstrated that a protein binds to the sequence at site IV. We have also examined the 3' end of the first exon and the 5' end of intron I and do not find any evidence for protein binding sites in this region that was thought to be important for the block to transcription elongation during differentiation.	VET ADM MED CTR, CTR MOLEC BIOL MED, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BORNKAMM GW, 1988, C MYC DEGREGULATION; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; CONKLIN KF, 1984, DNA METHYLATION; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIBACH E, 1983, CANCER RES, V43, P4136; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LANG JC, 1991, ONCOGENE, V6, P2067; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MOBERG KH, 1992, ONCOGENE, V7, P411; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PLET A, 1992, ONCOGENE, V7, P1847; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SALUZ HP, 1987, LABORATORY GUIDE GEN; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	62	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2699	2706						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058334				2022-12-25	WOS:A1994PC05400031
J	DALY, RJ; BINDER, MD; SUTHERLAND, RL				DALY, RJ; BINDER, MD; SUTHERLAND, RL			OVEREXPRESSION OF THE GRB2 GENE IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; MITOGENIC SIGNAL TRANSDUCTION; RETINOIC ACID RECEPTOR; PHOSPHOLIPASE-C; ADAPTER PROTEIN; TRANSGENIC MICE; EGF RECEPTOR; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING	A receptor blotting technique was used to detect SH2 domain containing epidermal growth factor receptor (EGFR) substrates that exhibited differential expression either between normal breast epithelial cells and breast cancer cells or between different human breast cancer cell lines. This identified a 25 kD protein, subsequently identified as Grb2, which was markedly overexpressed in three breast cancer cell lines (MCF-7, MDA-MB-361 and -453) relative to both normal breast epithelial cells and the majority of breast cancer cell lines. Northern blot analysis revealed that 7/19 breast cancer cell lines exhibited more than twofold overexpression of Grb2 mRNA, with overexpression correlating with high expression of erbB receptors. In MCF-7, MDA-MB-361 and -453 cells the overexpression of Grb2 mRNA and protein was accompanied by a small amplification of the Grb2 gene locus. Overexpression of Grb2 correlated with increased complex formation between Grb2 and the hSos-1 Ras GDP-GTP exchange protein. This upregulation of the Ras signalling pathway might modulate the growth factor sensitivity of human breast cancer cells and therefore play a role in tumour progression.			DALY, RJ (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Binder, Michele/0000-0002-4494-6717; Daly, Roger/0000-0002-5739-8027				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BOS JL, 1989, CANCER RES, V49, P4682; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUCKLEY MF, 1993, ONCOGENE, V8, P5127; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1988, GROWTH FACTORS ONCOG, P119; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN E, 1993, NAT GENET, V5, P242, DOI 10.1038/ng1193-242; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HARLOW E, 1988, ANTIBODIES LABORATOR; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KOGA M, 1990, CANCER RES, V50, P4849; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500	47	92	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2723	2727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058337				2022-12-25	WOS:A1994PC05400034
J	MOTTO, DG; ROSS, SE; JACKMAN, JK; SUN, QM; OLSON, AL; FINDELL, PR; KORETZKY, GA				MOTTO, DG; ROSS, SE; JACKMAN, JK; SUN, QM; OLSON, AL; FINDELL, PR; KORETZKY, GA			IN-VIVO ASSOCIATION OF GRB2 WITH PP116, A SUBSTRATE OF THE T-CELL ANTIGEN RECEPTOR-ACTIVATED PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; SH3 DOMAIN; ZETA-CHAIN; RAS; PHOSPHORYLATION; STIMULATION; COMPLEX; SEVENLESS	Numerous recent studies have implicated the src homology 2 and 3 domain-containing protein, Grb2, in coupling protein tyrosine kinase signaling pathways with the Res signaling pathway. Ligation of the T cell antigen receptor results in the activation of both a PTK, and Ras; therefore, we investigated whether Grb2 may serve a similar function in T cells. Here we report that a GST/Grb2 fusion protein associates with several tyrosine phosphoproteins from lysates of T cell antigen receptor-stimulated Jurkat T cells. Two of these proteins, pp36 and pp116, bind to the Grb2 fusion protein with high affinity. Through the use of mutated Grb2 fusion proteins, we demonstrate that pp116 binds the amino-terminal src homology 3 domain of Grb2, the same domain of Grb2 thought to be primarily responsible for its inter action with SOS. We demonstrate further that pp116 associates with Grb2 in vivo, and we provide evidence that in the Jurkat T cell line Grb2 may exist complexed with either pp116 or with SOS.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; SYNTEX INC, DISCOVERY RES, DEPT LEUKOCYTE BIOL, PALO ALTO, CA 95304 USA	University of Iowa; University of Iowa; Syntex Corporation			Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [CA56050, CA56843] Funding Source: Medline; NHLBI NIH HHS [HL07638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056050, R29CA056843] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EGERTON M, 1992, J IMMUNOL, V149, P1847; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, J IMMUNOL, V144, P1591; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALEK SN, 1993, J BIOL CHEM, V268, P22557; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	79	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21608	21613						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063801				2022-12-25	WOS:A1994PK97300036
J	XU, Q; JUNG, YS; CHITNIS, VP; GUIKEMA, JA; GOLBECK, JH; CHITNIS, PR				XU, Q; JUNG, YS; CHITNIS, VP; GUIKEMA, JA; GOLBECK, JH; CHITNIS, PR			MUTATIONAL ANALYSIS OF PHOTOSYSTEM-I POLYPEPTIDES IN SYNECHOCYSTIS SP PCC-6803 - SUBUNIT REQUIREMENTS FOR REDUCTION OF NADP(+) MEDIATED BY FERREDOXIN AND FLAVODOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP PCC-6301; CHEMICAL CROSS-LINKING; SP PCC-6803; CORE PROTEIN; TARGETED MUTAGENESIS; MOLECULAR-CLONING; GENE-PRODUCT; PSAE GENE; CYANOBACTERIUM; COMPLEX	The subunit requirements NADP(+) reduction by photosystem I were assessed in mutants of Synechocystis sp PCC 6803 created by targeted inactivation of the psaD, psaE, psaF, and psaL genes. The PsaE-less, PsaF-PsaJ-less, and PsaL-less mutants showed normal photoautotrophic growth, while the growth of PsaD-less mutants was slower without glucose. In isolated wild-type membranes, the rate of flavodoxin reduction and flavodoxin-mediated NADP(+) reduction were 800 and 480 mu mol/mg of chlorophyll/h, respectively. The rate of ferredoxin-mediated NADP(+) photoreduction was 460 mu mol/mg of chlorophyll/h. There was no diminution in NADP(+) photoreduction in membranes isolated from the PsaF-less and PsaL-less mutants. The rates of ferredoxin-mediated NADP(+) photoreduction in membranes of the PsaE-less mutants were 25 mu mol/mg of chlorophyll/h. However, the rate of flavodoxin reduction was 380 mu mol/mg of chlorophyll/h, and that of flavodoxin-mediated NADP(+) photoreduction was 170 mu mol/mg of chlorophyll/h. PsaD-less membranes showed <20% of the wild-type rates of flavodoxin-mediated NADP(+) photoreduction, but were completely deficient in ferredoxin-mediated NADP(+) photoreduction. Therefore, the roles of PsaE and PsaD are more crucial for ''docking'' of ferredoxin than of flavodoxin. Proteolysis studies showed that while PsaD was susceptible to rapid in vitro degradation by thermolysin, the number and sizes of protease-resistant fragments were not affected by the absence of PsaE. Protease accessibility studies further indicated that the C-terminal domain of PsaD is surface-exposed on the n-side. These results suggest that PsaE and the C-terminal domain of PsaD generate the docking site for the electron acceptors of photosystem I.	KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, MANHATTAN, KS 66506 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA	Kansas State University; University of Nebraska System; University of Nebraska Lincoln								BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; COHEN Y, 1993, PLANT MOL BIOL, V23, P895, DOI 10.1007/BF00021544; FUKUYAMA K, 1992, J MOL BIOL, V225, P775, DOI 10.1016/0022-2836(92)90400-E; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; IKEUCHI M, 1992, PLANT CELL PHYSIOL, V33, P1057; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KRUIP J, 1993, J BIOL CHEM, V268, P23353; LELONG C, 1994, J BIOL CHEM, V269, P10034; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU QA, 1994, J BIOL CHEM, V269, P3205; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHANG LL, 1994, J BIOL CHEM, V269, P5036; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	39	83	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21512	21518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063787				2022-12-25	WOS:A1994PK97300022
J	DEREWENDA, U; SWENSON, L; GREEN, R; WEI, YY; MOROSOLI, R; SHARECK, F; KLUEPFEL, D; DEREWENDA, ZS				DEREWENDA, U; SWENSON, L; GREEN, R; WEI, YY; MOROSOLI, R; SHARECK, F; KLUEPFEL, D; DEREWENDA, ZS			CRYSTAL-STRUCTURE, AT 2.6-ANGSTROM RESOLUTION, OF THE STREPTOMYCES-LIVIDANS XYLANASE-A, A MEMBER OF THE F-FAMILY OF BETA-1,4-D-GLYCANASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYTIC DOMAIN; CLOSTRIDIUM-THERMOCELLUM; 3-DIMENSIONAL STRUCTURE; REFINED STRUCTURE; SEQUENCE; CRYSTALLIZATION; PURIFICATION; PRINCIPLES; CELLULASE; PROTEINS	The crystal structure of the 32-kDa catalytic domain of the Streptomyces lividans xylanase A was solved by molecular isomorphous replacement methods and subsequently refined at 2.6-Angstrom resolution to a conventional crystallographic R factor of 0.21. This is the first successful structure determination of a member of the F family of endo-beta-1,4-D-glycanases. Unlike the recently determined xylanases of the G family (Wakarchuk, W. W., Campbell, R. L., Sung, W. L., Davoodi, J., and Yaguchi, M. (1994) Protein Sci. 3, 467-475), where the catalytic domains have a unique beta-sheet structure, the 32-kDa domain of the S. lividans xylanase A is folded into a complete (alpha/beta)(8) barrel, the first such fold observed among beta-1,4-D-glycanases. The active site is located at the carbonyl end of the beta barrel. The crystal structure supports the earlier assignment of Glu-128 and Glu-236 as the catalytic amino acids (Moreau, A., Roberge, M., Manin, C., Shareck, F., Kluepfel, D., and Morosoli, R. (1994) Biochem. J., in press).	UNIV QUEBEC, INST ARMAND FRAPPIER, CTR RECH MICROBIOL APPL, LAVAL H7N 4Z3, PQ, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, AB, CANADA	University of Quebec; University of Alberta								BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BEDARKAR S, 1992, J MOL BIOL, V228, P693, DOI 10.1016/0022-2836(92)90852-B; BIELY P, 1985, ANAL BIOCHEM, V144, P142, DOI 10.1016/0003-2697(85)90095-8; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRUNGER AT, 1988, X PLOR MANUAL; CAMPBELL RL, 1993, FDN BIOTECHNICAL IND, V8, P63; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FAURE E, 1989, GENE, V84, P39, DOI 10.1016/0378-1119(89)90137-6; GEBLER J, 1992, J BIOL CHEM, V267, P12549; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; HALL J, 1988, GENE, V69, P29, DOI 10.1016/0378-1119(88)90375-7; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hopwood D. A., 1985, GENETIC MANIPULATION; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KATSUBE Y, 1990, 2ND P INT C PROT ENG, P91; KLEUPFEL D, 1992, APPL MICROBIOL BIOT, V36, P626; KLUEPFEL D, 1990, BIOCHEM J, V267, P45, DOI 10.1042/bj2670045; KLUEPFEL D, 1988, METHOD ENZYMOL, V160, P180; LASKOWSKI RA, 1992, PROCHECK VERSION 2 P; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LAWSON DM, 1994, ACTA CRYSTALLOGR D, V50, P332, DOI 10.1107/S0907444993013113; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MOREAU A, 1994, EUR J BIOCHEM, V219, P261, DOI 10.1111/j.1432-1033.1994.tb19937.x; MOREAU A, 1994, IN PRESS BIOCH J; MOROSOLI R, 1986, BIOCHEM J, V239, P587, DOI 10.1042/bj2390587; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; PICKERSGILL RW, 1993, J MOL BIOL, V229, P246, DOI 10.1006/jmbi.1993.1023; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SENIOR DJ, 1992, TAPPI J, V75, P125; SHARECK F, 1991, GENE, V107, P75, DOI 10.1016/0378-1119(91)90299-Q; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SOUCHON H, 1994, J MOL BIOL, V235, P1348, DOI 10.1006/jmbi.1994.1089; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; STEC B, 1990, J MOL BIOL, V211, P235, DOI 10.1016/0022-2836(90)90023-F; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	47	157	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20811	20814						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063693				2022-12-25	WOS:A1994PC40300002
J	HOPE, JN; CHEN, HC; HEJTMANCIK, JF				HOPE, JN; CHEN, HC; HEJTMANCIK, JF			AGGREGATION OF BETA-A3-CRYSTALLIN IS INDEPENDENT OF THE SPECIFIC SEQUENCE OF THE DOMAIN CONNECTING PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLIN GENE FAMILY; MONOMERIC GAMMA-CRYSTALLIN; LENS BETA-CRYSTALLIN; X-RAY-ANALYSIS; EYE-LENS; EVOLUTIONARY RELATIONSHIPS; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; CIRCULAR-DICHROISM; BP CHAIN	The beta- and gamma-crystallins are structural proteins whose high concentration and close packing are important in maintaining transparency of the eye lens. The beta gamma-crystallin superfamily includes proteins with similar core structures consisting of two compact domains linked by a short connecting peptide. In gamma-crystallins, the connecting peptide folds back on itself, allowing the amino and carboxyl domains to participate in close interactions. The beta-crystallin connecting peptide is extended so that dimerization of two beta-crystallin monomers is required for similar interdomain interactions. In order to examine the role of the sequence of the connecting peptide in determining the extended beta-crystallin conformation and hence their association into dimers, we have exchanged the 10 residues of the beta A3-crystallin connecting peptide with the 9-residue connecting peptide sequence of mouse gamma B-crystallin by site-directed mutagenesis. Unaltered and modified recombinant beta A3-crystallins were expressed in a baculovirus system and purified by sequential anion exchange chromatography and gel filtration. Integrity of the recombinant crystallins was confirmed by NH2-terminal sequence analysis, immunoblots, and CD spectrometry. Reconstitution of the mutant recombinant protein with crystallins from mouse lens soluble extract resulted in aggregates of identical size distribution as normal beta A3-crystallin. We conclude that the sequence of the connecting peptide is not critical for the association of beta A3-crystallin into dimers and higher order aggregates as had been postulated.	NEI,MECHANISMS OCULAR DIS LAB,BETHESDA,MD 20892; NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AARTS HJM, 1989, EUR J BIOCHEM, V183, P31, DOI 10.1111/j.1432-1033.1989.tb14892.x; AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BERBERS GAM, 1983, BIOCHIM BIOPHYS ACTA, V748, P213, DOI 10.1016/0167-4838(83)90297-2; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BHAT SP, 1984, DNA-J MOLEC CELL BIO, V3, P287, DOI 10.1089/dna.1.1984.3.287; BLOEMENDAL H, 1975, EXP EYE RES, V20, P463, DOI 10.1016/0014-4835(75)90087-1; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CHAMBERS C, 1993, GENE, V133, P295, DOI 10.1016/0378-1119(93)90655-M; CHAMBERS C, 1991, J BIOL CHEM, V266, P6742; DENDUNNEN JT, 1986, J MOL BIOL, V189, P37, DOI 10.1016/0022-2836(86)90379-7; DENDUNNEN JT, 1985, GENE, V38, P197, DOI 10.1016/0378-1119(85)90218-5; DRIESSEN HP, 1981, EUR J BIOCHEM, V121, P83, DOI 10.1111/j.1432-1033.1981.tb06433.x; GORIN MB, 1984, CURR EYE RES, V3, P939, DOI 10.3109/02713688409167211; GRAW J, 1991, GENE, V104, P265, DOI 10.1016/0378-1119(91)90260-I; HEJTMANCIK JF, 1986, J BIOL CHEM, V261, P982; HOGG D, 1986, J BIOL CHEM, V261, P2420; HOPE JN, 1994, PROTEIN ENG, V7, P445, DOI 10.1093/protein/7.3.445; INANA G, 1983, NATURE, V302, P310, DOI 10.1038/302310a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; LOK S, 1984, NUCLEIC ACIDS RES, V12, P4517, DOI 10.1093/nar/12.11.4517; LUCHIN SV, 1987, BIOCHIM BIOPHYS ACTA, V916, P163, DOI 10.1016/0167-4838(87)90104-X; MAYR EM, 1994, J MOL BIOL, V235, P84, DOI 10.1016/S0022-2836(05)80017-8; MEAKIN SO, 1985, MOL CELL BIOL, V5, P1408, DOI 10.1128/MCB.5.6.1408; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PETERSON CA, 1986, GENE, V45, P139, DOI 10.1016/0378-1119(86)90248-9; SLINGSBY C, 1985, TRENDS BIOCHEM SCI, V10, P281, DOI 10.1016/0968-0004(85)90088-X; WHITE HE, 1989, J MOL BIOL, V207, P217, DOI 10.1016/0022-2836(89)90452-X; WISTOW G, 1981, FEBS LETT, V133, P9, DOI 10.1016/0014-5793(81)80460-7; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; YANG JT, 1986, METHOD ENZYMOL, V130, P208	32	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21141	21145						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063735				2022-12-25	WOS:A1994PC40300051
J	KULIOPULOS, A; NELSON, NP; YAMADA, M; WALSH, CT; FURIE, B; FURIE, BC; ROTH, DK				KULIOPULOS, A; NELSON, NP; YAMADA, M; WALSH, CT; FURIE, B; FURIE, BC; ROTH, DK			LOCALIZATION OF THE AFFINITY PEPTIDE-SUBSTRATE INACTIVATOR SITE ON RECOMBINANT VITAMIN-K-DEPENDENT CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL CARBOXYLASE; RECOGNITION SITE; FACTOR-IX; PROPEPTIDE; INVITRO; MECHANISM; IDENTIFICATION; COAGULATION; PROTHROMBIN; EXPRESSION	A recombinant His(6)-tagged vitamin K-dependent gamma-glutamyl carboxylase has been produced in baculovirus-infected insect cells. The His(6)-carboxylase shares nearly identical kinetic properties with the wild-type enzyme from bovine liver microsomes. The His(6)-carboxylase was irreversibly inactivated by the N-bromoacetyl-FLEEL-I-125-Y peptide substrate/affinity label under pseudo-first order conditions. This inactivation could be abolished by coincubation with a high affinity peptide substrate consistent with an active site-directed inactivation. The inactivated His(6)-carboxylase-Ac-FLEEL-I-125-Y, purified under denaturing conditions by Ni-chelation chromatography followed by preparative polyacrylamide gel electrophoresis, was subjected to proteolytic digestions with either Glu-C or Lys-C endoproteinases. The resulting polypeptide fragments were probed with three regiospecific antibodies which recognized epitopes present at the extreme N terminus (residues -23 to -13), at the hydrophobic N-terminal region (residues 86-99), and at the hydrophilic C-terminal region (residues 661-673). The site of attachment to the I-125-affinity label is located within the first 218 amino acid residues of the 758-residue carboxylase. This is the first evidence for the involvement of either the putative membrane-anchoring hydrophobic region (residues 50-314) or possibly the N-terminal hydrophilic region (residues 1-50) in gamma-carboxylation of glutamate-peptide substrates.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; TUFTS UNIV NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,CTR THROMBOSIS & HEMOSTASIS,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Harvard University; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443, K11HL002574, F32HL008882] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL08882-01, HL02574, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNETT EM, 1992, J AM CHEM SOC, V114, P9209, DOI 10.1021/ja00049a075; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DOWD P, 1992, J AM CHEM SOC, V114, P7613, DOI 10.1021/ja00046a001; DOWD P, 1991, J AM CHEM SOC, V113, P7734, DOI 10.1021/ja00020a041; DUBOIS J, 1991, BIOCHEMISTRY-US, V30, P10506, DOI 10.1021/bi00107a020; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAM SW, 1990, J AM CHEM SOC, V112, P1660, DOI 10.1021/ja00160a073; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBER P, 1990, J BIOL CHEM, V265, P12467; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P7722, DOI 10.1021/bi00148a037; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	24	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21364	21370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063763				2022-12-25	WOS:A1994PC40300081
J	YU, W; SANTHANAGOPALAN, V; SEWELL, AK; JENSEN, LT; WINGE, DR				YU, W; SANTHANAGOPALAN, V; SEWELL, AK; JENSEN, LT; WINGE, DR			DOMINANCE OF METALLOTHIONEIN IN METAL-ION BUFFERING IN YEAST CAPABLE OF SYNTHESIS OF (GAMMA-EC)(N)G ISOPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE CELLS; GLUTAMYL-TRANSFERASE PEPTIDES; CADMIUM-SULFIDE CRYSTALLITES; DNA-BINDING PROTEIN; CUP2 GENE-PRODUCT; CANDIDA-GLABRATA; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; EXPRESSION; PHYTOCHELATINS	The relationship of yeast metallothionein (MT) and (gamma EC)(n)G isopeptides (phytochelatins) in metal ion buffering was assessed. The effect of constitutive expression of yeast metallothionein (MT) genes on accumulation of metal-(gamma EC)(n)G isopeptide (phytochelatin) complexes was analyzed in Candida glabrata and Schizosaccharomyces pombe cultures incubated in the presence of cadmium salts. Constitutive expression of the Saccharomyces cerevisiae MT (CUP1) gene inhibited the accumulation of metal-phytochelatin complexes in both C. glabrata and S. pombe. Intracellular Cd(II) sequestration occurred by formation of CdMT complexes. Phytochelatin (gamma EC)(n)G complexes appear 60 function in metal buffering in cells when MT genes are not present or expressed. A third condition in which metal-(gamma EC)(n)G complexes are observed is when constitutively expressed MTT does not accumulate. We observed that C. glabrata lacking the AMT1 gene necessary for copper induction of the MT genes expressed MTII constitutively, but this expression does not lead to CdMTII accumulation. Only Cd-(gamma EC)(n)G complexes accumulate. Likewise, metal exposed cultures of S. cerevisiae (cup1) transformed with C. glabrata MTII under the constitutive ADH1 promoter resulted in constitutive expression of MTII and accumulation of CuMTII complexes but no CdMTII complexes. The inability of constitutively expressed C. glabrata MTII to buffer Cd(II) ions may arise in part from an inherent kinetic lability of CdMTII complexes. Incubation of ZnMTII with a metallochromic chelator, 4-(2-pyridylazo)resorcinol resulted in greater Zn(II) loss than Zn(II) complexes with CUP1 MT or C. glabrata MTI. C. glabrata MTII appears 60 be the first MT described which forms an unstable Cd(II) complex.	UNIV UTAH, HLTH SCI CTR, DEPT MED, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135; Jensen, Laran/0000-0003-3199-1743	NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARBAS J, 1992, J INORG BIOCHEM, V48, P95, DOI 10.1016/0162-0134(92)80019-R; BROKER M, 1987, BIOTECHNIQUES, V5, P516; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; DAMERON CT, 1989, NATURE, V338, P596, DOI 10.1038/338596a0; DAMERON CT, 1989, J BIOL CHEM, V264, P17355; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; ECKER DJ, 1986, J BIOL CHEM, V261, P6895; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GRILL E, 1986, FEBS LETT, V197, P115, DOI 10.1016/0014-5793(86)80309-X; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAYASHI Y, 1986, ENVIRON HEALTH PERSP, V65, P13, DOI 10.2307/3430156; HUNT JB, 1984, J BIOL CHEM, V259, P4793; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KNEER R, 1992, ARCH MICROBIOL, V157, P305, DOI 10.1007/BF00248673; MACREADIE IG, 1992, BIOTECHNOL LETT, V14, P639, DOI 10.1007/BF01021634; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; MEHRA RK, 1992, GENE, V114, P75, DOI 10.1016/0378-1119(92)90709-X; MEHRA RK, 1990, J BIOL CHEM, V265, P6369; MEHRA RK, 1989, J BIOL CHEM, V264, P19747; MEHRA RK, 1988, ARCH BIOCHEM BIOPHYS, V265, P381, DOI 10.1016/0003-9861(88)90141-5; MEHRA RK, 1988, P NATL ACAD SCI USA, V85, P8815, DOI 10.1073/pnas.85.23.8815; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MIRANDA JR, 1990, FEBS LETT, V260, P277; NAKAGAWA KH, 1991, J AM CHEM SOC, V113, P3621, DOI 10.1021/ja00009a075; NARULA SS, 1991, J AM CHEM SOC, V113, P9354, DOI 10.1021/ja00024a045; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; Palmiter R D, 1987, Experientia Suppl, V52, P63; RAUSER WE, 1990, ANNU REV BIOCHEM, V59, P61, DOI 10.1146/annurev.bi.59.070190.000425; REESE RN, 1988, J BIOL CHEM, V263, P4186; RUSSELL PR, 1983, NATURE, V301, P167, DOI 10.1038/301167a0; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WINGE DR, 1985, J BIOL CHEM, V260, P4464; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	39	14	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21010	21015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063718				2022-12-25	WOS:A1994PC40300032
J	BEDELLHOGAN, D; TRACKMAN, P; ABRAMS, W; ROSENBLOOM, J; KAGAN, H				BEDELLHOGAN, D; TRACKMAN, P; ABRAMS, W; ROSENBLOOM, J; KAGAN, H			OXIDATION, CROSS-LINKING, AND INSOLUBILIZATION OF RECOMBINANT TROPOELASTIN BY PURIFIED LYSYL OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS	The use of recombinant human tropoelastin (rTE) and selected variants thereof as substrates for the assay of lysyl oxidase activity in vitro was explored. The possibility was also assessed that an insoluble elastin-like product could be generated from this elastin precursor in the absence of other macromolecules found associated with elastin in vivo. rTE was more efficiently oxidized by lysyl oxidase than the insoluble chick aorta elastin substrate conventionally used. Anionic amphiphilic elastin ligands strongly inhibited rTE oxidation consistent with the importance of electrostatic enzyme-substrate interactions previously noted with the insoluble elastin substrate. An rTE variant, rTEDELTA26A, lacking the hydrophilic sequence coded by exon 26A, was a less effective substrate than rTE, largely due to an increase in K(m), while the kinetic parameters for the oxidation of rTEDELTA36, lacking the C-terminal polybasic sequence coded by exon 36, were quite similar to those for rTE. Incubation of rTEDELTA26A with lysyl oxidase not only resulted in the generation of peptidyl alpha-aminoadipic-delta-semialdehyde and lysine-derived cross-linkages, but also yielded a product insoluble in hot 0.1 N NaOH, consistent with the properties of insoluble elastin. Thus, oxidation, cross-linking and insolubilization of elastin substrates by lysyl oxidase can occur in the absence of other macromolecules implicated as being involved in this process in vivo, although such macromolecules may be essential to obtain the proper alignment between tropoelastin units for specifically placed cross-linkages and optimally functional elastic fibers.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH DENT MED,ORAL BIOL RES CTR,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania; University of Pennsylvania				Trackman, Philip/0000-0001-5064-614X	NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NIAMS NIH HHS [AR 18880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902, P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018880, R37AR018880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; DIEDRICH DL, 1978, P NATL ACAD SCI USA, V75, P3708, DOI 10.1073/pnas.75.8.3708; FORNIERI C, 1987, J CELL BIOL, V105, P1463, DOI 10.1083/jcb.105.3.1463; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1981, J BIOL CHEM, V256, P5417; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING AI, 1952, ANAT REC, V114, P55; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MIRELMAN D, 1979, J BIOL CHEM, V254, P571; NARAYANAN AS, 1972, BIOCHIM BIOPHYS ACTA, V35, P126; RICH CB, 1982, METHOD ENZYMOL, V82, P665; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9	18	132	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10345	10350						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098038				2022-12-25	WOS:A1993LB80000056
J	BUTTA, N; URCELAY, E; GONZALEZMANCHON, C; PARRILLA, R; AYUSO, MS				BUTTA, N; URCELAY, E; GONZALEZMANCHON, C; PARRILLA, R; AYUSO, MS			PERTUSSIS TOXIN INHIBITION OF ALPHA-1-ADRENERGIC OR VASOPRESSIN-INDUCED CA2+ FLUXES IN RAT-LIVER - SELECTIVE-INHIBITION OF THE ALPHA-1-ADRENERGIC RECEPTOR-COUPLED METABOLIC-ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEMBRANE CA-2+ INFLOW; PHOSPHOLIPASE-C; CA-2+-MOBILIZING HORMONES; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; REGULATORY PROTEIN; ADENYLATE-CYCLASE; BINDING-PROTEINS; 2ND MESSENGERS	Pretreatment with pertussis toxin produced a impairment of the response to the alpha-adrenergic agonist phenylephrine in perfused isolated rat livers. The sustained phases of phenylephrine-induced increases in respiration, glucose mobilization, gluconeogenesis, vascular resistance, and efflux of H+ and Ca2+ were inhibited to variable degrees in livers from pertussis toxin-treated animals. The susceptibility of such a diversity of receptor-mediated effects suggests that a common, most likely early step(s) of the alpha1-receptor-coupled signaling pathway may be regulated by a pertussis toxin-sensitive G(i) protein(s) that appears to be involved in the control of the rate of these processes. The most significant effect of pertussis toxin has been to almost entirely prevent the phenylephrine-induced sustained release of Ca2+. Pertussis toxin also inhibited the vasopressin-mediated influx of Ca2+. These findings indicate that G proteins associated with receptor-operated calcium channels are a site of interaction of pertussis toxin. The following observations support the conclusion that pertussis toxin per se does not perturb the hepatic metabolism. Its effects are specifically linked to functional responses mediated by alpha1-type adrenergic receptors: 1) polypeptide receptor-mediated metabolic effects, as those induced by vasopressin, were not affected by pertussis toxin; 2) non-receptor-mediated effects, such as fatty acid-induced stimulation of respiration and gluconeogenesis, were not impaired by pertussis toxin; and 3) neither the hepatic responses to alpha2-(clonidine) nor to beta-(isoproterenol) adrenergic receptor agonists were altered in livers from pertussis toxin-treated rats. The differential effects of pertussis toxin in the metabolic actions of phenylephrine and vasopressin, in spite of apparently similar effects in perturbing their actions on Ca2+ fluxes, suggest that pertussis toxin-sensitive alpha1-receptor-associated G protein(s) other than those controlling Ca2+ channels, were also specifically affected in the alpha1-agonist-signaling pathway. The finding that increasing concentrations of phenylephrine were capable of overcoming these pertussis toxin actions indicates that alpha1-adrenoreceptors' ligand affinity is controlled by G(i) proteins.	CSIC, CTR INVEST BIOL, ENDOCRINE PHYSIOL UNIT, VELAZQUEZ 144, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Gonzalez-Manchon, Consuelo/H-9257-2015; Milagros Rodriguez, Biblioteca-CIB/H-7697-2015; Ayuso, Matilde Sánchez/B-2777-2008; Parrilla, Roberto/B-6307-2008	Gonzalez-Manchon, Consuelo/0000-0002-3081-0253; Ayuso, Matilde Sánchez/0000-0003-2504-0925; Urcelay, Elena/0000-0001-8470-8396				AIYAR N, 1989, BIOCHEM J, V261, P63, DOI 10.1042/bj2610063; ALTHAUSSALZMANN M, 1980, EUR J BIOCHEM, V106, P241; ALTIN JG, 1986, BIOCHEM J, V238, P653, DOI 10.1042/bj2380653; ALTIN JG, 1987, BIOCHEM J, V242, P43, DOI 10.1042/bj2420043; Bergmeyer H.U., 1975, METHODS ENZYMATIC AN; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOYER JL, 1984, J BIOL CHEM, V259, P8076; BUTTA N, 1991, 4 PORT SPAN BIOCH C; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GONZALEZMANCHON C, 1988, ARCH BIOCHEM BIOPHYS, V265, P258, DOI 10.1016/0003-9861(88)90126-9; HALLAM TJ, 1989, TRENDS PHARMACOL SCI, V10, P8, DOI 10.1016/0165-6147(89)90092-8; HUGHES BP, 1987, BIOCHEM J, V245, P41, DOI 10.1042/bj2450041; HUGHES BP, 1987, BIOCHEM J, V248, P911, DOI 10.1042/bj2480911; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; MENAYA J, 1987, BIOCHEM J, V248, P903, DOI 10.1042/bj2480903; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; POBINER BF, 1985, J BIOL CHEM, V260, P6200; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RASHED SM, 1991, EUR J BIOCHEM, V197, P805, DOI 10.1111/j.1432-1033.1991.tb15975.x; REINHART PH, 1984, BIOCHEM J, V220, P35, DOI 10.1042/bj2200035; REQUERO AM, 1986, ARCH BIOCHEM BIOPHYS, V246, P114; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SAZ JM, 1989, BIOCHEM BIOPH RES CO, V160, P480, DOI 10.1016/0006-291X(89)92458-3; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; TAYLOR WM, 1986, HORMONAL CONTROL GLU, V2, P147; TOHKIN M, 1990, EUR J BIOCHEM, V194, P81, DOI 10.1111/j.1432-1033.1990.tb19430.x; UHING RJ, 1985, FEBS LETT, V188, P317, DOI 10.1016/0014-5793(85)80394-X; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203; YANG LJ, 1991, J BIOL CHEM, V266, P22451	39	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6081	6089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8095934				2022-12-25	WOS:A1993KT36800005
J	DEGUCHI, Y; AGUS, D; KEHRL, JH				DEGUCHI, Y; AGUS, D; KEHRL, JH			A HUMAN HOMEOBOX GENE, HB24, INHIBITS DEVELOPMENT OF CD4+ T-CELLS AND IMPAIRS THYMIC INVOLUTION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BONE-MARROW; B-CELLS; EXPRESSION; LYMPHOCYTES; HOX-1.1; REGION; BOX	The HB24 gene encodes a diverged human homeodomain-containing protein known to be expressed in hematopoietic progenitors and activated lymphocytes. We have generated transgenic mice that express HB24 under the control of the T cell receptor beta chain promoter/enhancer. Analysis of T cells and thymocytes from the transgenic mice revealed a marked increase in activated cells as assessed by cell size profiles and interleukin-2 receptor expression. Within the thymus these changes were most pronounced in the CD4+CD8- subset. Strikingly, the normal development of CD4+ T cells in the transgenic mice was impaired. Single positive CD4 cells were reduced 35% in the thymus, and CD4+ T cells were reduced 90% in the spleen and lymph nodes compared to the controls. Similar findings were found both in young mice (6 weeks old) and in more elderly mice (1 y old). However, the thymuses of the elderly mice failed to undergo normal involution. Sera from HB24 transgenic mice had levels of IgG1 10-100-fold lower than sera from matched controls, most likely as a consequence of the decrease in CD4+ T cells. These transgenic mice provide a useful model for studying the role of HB24 in lymphocyte activation as well as for understanding the effects of abnormal T cell activation on thymic and T cell development.	NIAID, IMMUNOREGULAT LAB, BLDG 10, RM 11B-13, BETHESDA, MD 20892 USA; NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NICHD NIH HHS [N01-HD-02911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ARONSON M, 1991, THYMUS, V18, P7; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BRUCE J, 1981, J IMMUNOL, V127, P2496; Carbone F. R., 1989, Fundamental immunology., P541; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DEGUCHI Y, 1991, NEW BIOL, V3, P353; DEGUCHI Y, 1991, BLOOD, V78, P323; DEGUCHI Y, 1992, J BIOL CHEM, V267, P8222; DEGUCHI Y, 1992, IN PRESS BLOOD; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FORMAN J, 1982, J EXP MED, V155, P749, DOI 10.1084/jem.155.3.749; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRUNSBY MJ, 1991, SCIENCE, V253, P1417; HENDRICK SM, 1984, NATURE, V308, P149; HIROKAWA K, 1989, MECH AGEING DEV, V49, P49, DOI 10.1016/0047-6374(89)90067-5; HIROKAWA K, 1990, VIRCHOWS ARCH B, V59, P38, DOI 10.1007/BF02899385; HODES RJ, 1989, FUNDAMENTAL IMMUNOLO, P587; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAPPLER JW, 1978, J EXP MED, V148, P1510, DOI 10.1084/jem.148.6.1510; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; MANIATIS T, 1988, MOL CLONING; MANLEY JL, 1985, CELL, V43, P1, DOI 10.1016/0092-8674(85)90002-9; MARX LJ, 1988, SCIENCE, V1008, P242; MATSUYAMA M, 1972, GANN, V63, P209; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Robinson M. A., 1989, Fundamental immunology., P489; SCHUURMAN HJ, 1991, THYMUS, V18, P1; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; YAMADA S, 1973, GANN, V64, P287; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	38	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3646	3653						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8094082				2022-12-25	WOS:A1993KM16100094
J	HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M				HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M			V-ERBA REQUIRES AUXILIARY PROTEINS FOR DOMINANT NEGATIVE ACTIVITY	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; ACID-RESPONSIVE ELEMENT; DNA-BINDING DOMAIN; RETINOIC-ACID; C-ERBA; CELL-TRANSFORMATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; ALPHA-MYOSIN	The avian v-erbA protein is an important example of a dominant negative oncogene. It has been identified as a highly mutated form of its cellular homolog, the thyroid hormone receptor alpha (TR-alpha), and its biological activity has been correlated with its repressor function on certain receptor-regulated genes. Although v-erbA has lost the hormone responsiveness of its cellular homolog, it has retained DNA-binding activity, and it has been implied that this function is required for repression and transformation. Here we demonstrate that v-erbA forms heterodimers with the retinoid X receptor (RXR-alpha). Only heteromeric v-erbA-RXR-alpha complexes show DNA-binding strong enough to account for its potent repressor function. In addition, v-erbA-RXR-alpha heterodimers specifically bind natural thyroid hormone-responsive elements (TREs) but not retinoic acid-responsive elements (RAREs). Repression of TRE-controlled gene expression by v-erbA requires the presence of RXR-alpha with the natural TREs tested. In contrast, natural RAREs investigated here do not bind the v-erbA-RXR-alpha heterodimer and also are not significantly repressed by v-erbA. Carboxy-terminal mutations that abolish verbA-RXR-alpha heterodimer formation also abolish v-erbA repressor activity. These data suggest that interaction of v-erbA with RXRs or similar auxiliary receptors is essential for the dominant negative activity of the v-erbA oncogene.	LA JOLLA CANC RES FDN, CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, J MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					55	65						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093812				2022-12-25	WOS:A1993KN00500007
J	WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A				WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A			SMOOTH-MUSCLE AND BONE NEOPLASMS IN TRANSGENIC MICE EXPRESSING SV40 T-ANTIGEN	ONCOGENE			English	Article							SOFT-TISSUE SARCOMAS; LARGE TUMOR-ANTIGEN; HEAT-SHOCK PROTEIN; CHOROID-PLEXUS; P53 GENE; SIMIAN VIRUS-40; HYBRID GENE; GERM-LINE; RETINOBLASTOMA; MUTATION	Transgenic mice carrying the SV40 early region fused to the Drosophila hsp70 promoter developed smooth muscle and bone neoplasms. The smooth muscle tumors appeared in aged mice and were preferentially located on the muzzle or eyelids. Multiple neoplasms were often present and each appeared to be an independent proliferation. In contrast, the bone tumors typically developed in the petrous ridge and had all the features of osteogenic sarcomas, displaying distant metastasis and invasion of the brain. Cells in both types of tumors exhibited nuclear expression of SV40 T antigen. Mice homozygous for the transgene had a shorter latency for appearance of smooth muscle tumors and developed osteosarcomas more frequently than hemizygous mice. This model system implicates the cellular T antigen-binding proteins, such as Rb and p53, in the pathogenesis of bone and soft tissue neoplasms in mice.	UNIV WASHINGTON,HOSP PATHOL RC72,SEATTLE,WA 98195; BIOTRANSPLANT INC,BOSTON,MA 02129; UNIV WISCONSIN,SCH VET MED,MADISON,WI 53706	University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison	WILKIE, TM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75325, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11576] Funding Source: Medline; NINDS NIH HHS [NS-22475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARTAVANISTSAKONAS S, 1979, CELL, V17, P9, DOI 10.1016/0092-8674(79)90290-3; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHEN JD, 1992, ONCOGENE, V7, P1167; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P646; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KNOWLES BB, 1990, AM J PATHOL, V137, P259; KOTHARY R, 1989, DEVELOPMENT, V105, P707; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI H, 1991, JPN J CANCER RES, V82, P4, DOI 10.1111/j.1349-7006.1991.tb01736.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MESSING A, 1988, ONCOGENE RES, V3, P87; MILLER CW, 1990, CANCER RES, V50, P7950; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMAR RA, 1984, CANCER RES, V44, P3976; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PORTER PL, 1992, AM J PATHOL, V140, P145; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1989, ONCOGENE, V4, P715; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRAUSS PG, 1992, INT J CANCER, V50, P252, DOI 10.1002/ijc.2910500215; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; TOGUCHIDA J, 1992, CANCER RES, V52, P6194	47	20	21	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2889	2895						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084593				2022-12-25	WOS:A1994PG82200014
J	BUHR, A; FLUKIGER, K; ERNI, B				BUHR, A; FLUKIGER, K; ERNI, B			THE GLUCOSE-TRANSPORTER OF ESCHERICHIA-COLI - OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SIGNAL-TRANSDUCING PROTEIN; 3-DIMENSIONAL NMR-SPECTROSCOPY; BACILLUS-SUBTILIS; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; ENZYME-II; SECONDARY STRUCTURE; MANNITOL TRANSPORT; PHOSPHORYLATING SUBUNIT	The glucose transporter of the bacterial phosphotransferase system couples vectorial translocation to phosphorylation of the transported sugar. It consists of a transmembrane subunit (IICE(Glc)) and a hydrophilic subunit (IIA(Glc)). The IICBGlc subunit consists of two domains. The NH2-terminal IIC domain (residues 1-386) spans the membrane eight times and contains the substrate binding site. The COOH-terminal hydrophilic IIB domain (residues 391-476) is accessible from the cytoplasmic side of the membrane. It contains the phosphorylation site (Cys(421)) and together with the IIC domain catalyzes the transfer of phosphoryl groups from the IIA(Glc) subunit to the transported solute. Starting from a plasmid vector containing ptsG under an inducible promoter, the IIB and the IIC domains have been subcloned separately, overexpressed in Escherichia coli, and purified by Ni2+ chelate affinity chromatography. Approximately 40 mg of IIBGlc-6H and 4 mg of IICGlc-6H could be purified from 1 liter of culture. Cells expressing IIBGlc-6H and IICGlc-6H separately have a three times longer generation time on glucose minimal medium than cells expressing wild-type IICBGlc. The rate of IIBGlc-6H phosphorylation determined in a nitrocellulose filter binding assay is indistinguishable from wild-type IICBGlc. The in vitro specific activity of IICGlc-6H in the presence of excess IIBGlc-6H is 2% of the control. IIBGlc-6H also complements the activity of a IICBGlc mutant with an inactive IIB domain (C421S) indicating that IIC and IIB are flexibly linked such that a free IIB domain can displace an inactive IIB domain from its contact site on the IIC domain. Based on this work, the secondary structure of the IIBGlc domain has been determined by isotope-edited NMR spectroscopy (Golic Grdadolnik, S., Eberstadt, M., Gemmecker, G., Kessler, H., Buhr, A., and Erni, B. (1994) Eur. J. Biochem. 219, 945-952).	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND	University of Bern								ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BUHR A, 1993, J BIOL CHEM, V268, P11599; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN Y, 1993, J CELL BIOCHEM, V51, P75, DOI 10.1002/jcb.240510114; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; ELLIOTT J, 1978, MOL GEN GENET, V161, P1, DOI 10.1007/BF00266608; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1982, J BIOL CHEM, V257, P13726; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; ERNI B, 1989, J BIOL CHEM, V264, P18733; FAIRBROTHER WJ, 1992, BIOCHEMISTRY-US, V31, P4413, DOI 10.1021/bi00133a005; FAIRBROTHER WJ, 1991, BIOCHEMISTRY-US, V30, P6896, DOI 10.1021/bi00242a013; FAIRBROTHER WJ, 1992, FEBS LETT, V296, P148, DOI 10.1016/0014-5793(92)80367-P; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENOVESIOTAVERNE JC, 1990, J MOL BIOL, V216, P515, DOI 10.1016/0022-2836(90)90379-Z; GRDADOLNIK SG, 1994, EUR J BIOCHEM, V219, P945; HERZBERG O, 1992, J BIOL CHEM, V267, P24819; HUMMEL U, 1992, PROTEIN SCI, V1, P356; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; KROON GJA, 1993, PROTEIN SCI, V2, P1331, DOI 10.1002/pro.5560020816; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LAI XK, 1993, J BACTERIOL, V175, P6441, DOI 10.1128/jb.175.20.6441-6450.1993; LAMMERS LA, 1992, J MOL BIOL, V228, P310, DOI 10.1016/0022-2836(92)90511-H; LEE CA, 1983, J BIOL CHEM, V258, P761; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; MEINS M, 1993, J BIOL CHEM, V268, P11604; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, 1993, PROTEIN SCI, V2, P543; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POSTMA PW, 1987, ESCHERICHIA COLI SAL, V1, P127; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1990, RES MICROBIOL, V141, P1061, DOI 10.1016/0923-2508(90)90079-6; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROBILLARD GT, 1993, BIOCHEMISTRY-US, V32, P9553, DOI 10.1021/bi00088a006; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLTE BJ, 1981, J BACTERIOL, V148, P257, DOI 10.1128/JB.148.1.257-264.1981; SCHUNK T, 1992, DEVEL BIOCH, V29, P87; SEIP S, 1994, BIOCHEMISTRY-US, V33, P7174, DOI 10.1021/bi00189a021; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAGOREC M, 1992, MOL GEN GENET, V234, P325, DOI 10.1007/BF00283853	70	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23437	23443						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089109				2022-12-25	WOS:A1994PQ34500012
J	PAPP, PP; MUKHOPADHYAY, G; CHATTORAJ, DK				PAPP, PP; MUKHOPADHYAY, G; CHATTORAJ, DK			NEGATIVE CONTROL OF PLASMID DNA-REPLICATION BY ITERONS - CORRELATION WITH INITIATOR BINDING-AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS DNAJ; P1-PLASMID REPLICATION; P1 REPLICATION; REPA PROTEIN; ORIGIN; SEQUESTRATION; SEQUENCES; GENE	Initiation of DNA replication and negative control of initiation frequency in many bacterial plasmids are mediated by multiple binding sites (iterons) for the replicon-encoded initiator protein. Here we show that a single iteron of plasmid P1, when cloned in a multicopy vector, pUC19, can control replication of a miniP1 plasmid effectively. Using this assay system, several iterons with single point mutations were analyzed. The degree of control was directly correlated with the binding affinity of the iterons for the initiator protein in vitro. The control was also unaffected whether or not a wild type iteron was flanked with strong transcription terminators. We conclude that initiator binding is the only activity of p1 iteron sequences relevant to replication control.	NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Papp, Peter P/A-6907-2013					ABELES AL, 1991, P NATL ACAD SCI USA, V88, P9011, DOI 10.1073/pnas.88.20.9011; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; CHATTORAJ DK, 1985, P NATL ACAD SCI USA, V82, P2588, DOI 10.1073/pnas.82.9.2588; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; DASGUPTA S, 1993, J MOL BIOL, V232, P23, DOI 10.1006/jmbi.1993.1367; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; INGMER H, 1993, J BACTERIOL, V175, P7834, DOI 10.1128/JB.175.24.7834-7841.1993; Kittell B. L., 1993, BACTERIAL CONJUGATIO, P223, DOI 10.1007/978-1-4757-9357-4_8; MATHEWS CK, 1993, J BACTERIOL, V175, P6377, DOI 10.1128/jb.175.20.6377-6381.1993; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; MUKHOPADHYAY G, 1993, J MOL BIOL, V231, P19, DOI 10.1006/jmbi.1993.1253; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; MUKHOPADHYAY G, 1994, EMBO J, V13, P2089, DOI 10.1002/j.1460-2075.1994.tb06484.x; MURAISO K, 1990, J BACTERIOL, V172, P4441, DOI 10.1128/jb.172.8.4441-4447.1990; PAL SK, 1986, J MOL BIOL, V192, P275, DOI 10.1016/0022-2836(86)90364-5; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PAPP PP, 1994, NUCLEIC ACIDS RES, V22, P152, DOI 10.1093/nar/22.2.152; PAPP PP, 1993, J MOL BIOL, V233, P219, DOI 10.1006/jmbi.1993.1501; PATEL I, 1987, CELL, V51, P455, DOI 10.1016/0092-8674(87)90641-6; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; STERNBERG N, 1983, J BACTERIOL, V153, P800, DOI 10.1128/JB.153.2.800-812.1983; WEICKERT MJ, 1992, J MOL BIOL, V226, P69, DOI 10.1016/0022-2836(92)90125-4	25	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23563	23568						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089124				2022-12-25	WOS:A1994PQ34500029
J	TIKOO, A; VARGA, M; RAMESH, V; GUSELLA, J; MARUTA, H				TIKOO, A; VARGA, M; RAMESH, V; GUSELLA, J; MARUTA, H			AN ANTI-RAS FUNCTION OF NEUROFIBROMATOSIS TYPE-2 GENE-PRODUCT (NF2/MERLIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAP; CDNA; CLONING; GTPASE; CELLS; EXPRESSION; PROTEINS; P190; RHO	Previously, we have cloned a candidate for the 595-amino acid neurofibromatosis type 2 tumor suppressor called NF2 or Merlin, with striking sequence similarity in its N-terminal half to an F-actin-binding protein family called TERM, which includes talin, ezrin, radixin, and moesin (Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Parry, D. M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, It, Haase, V. H., Ambrose, C. M., Munro, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. E., Seizinger, B. R., Short, M. P., Buckler, A. J., and Gusella, J. F. (1993) Cell 72, 791-800). In an attempt to determine whether NF2 serves as a tumor suppressor and if so whether its N terminal half is involved in its anti-oncogenicity, both fall-length NF2 and its N-terminal half (NF2-N, residues 9-359) have been expressed in v-Ha-Ras-transformed NIH/3T3 cells. Like neurofibromatosis type 1 (NF1) fragments (Nur-E-Kamal, M. S. A., Varga, M., and Maruta, H. (1993) J. Biol. Chem. 268, 22331-22337), full-length NF2 can reverse the Ras-induced malignant phenotype, i.e. anchorage-independent growth in a soft agar, and restore contact inhibition of cell growth, indicating that NF2 is indeed a tumor suppressor. Furthermore, NF2-N also suppresses the Ras-induced malignant phenotype, although it appears to be less effective than the full-length NF2. These observations indicate that the anti-Ras function of NF2 resides in part in its N-terminal half, Thus, NF2 appears to be a new member of the tumor suppressor family of actin-cytoskeleton-associated proteins, which includes vinculin, alpha-actinin, tropomyosin-1, gelsolin, and tensin.	ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE, VIC 3050, AUSTRALIA; MASSACHUSETTS GEN HOSP E, CTR NEUROSCI, MOLEC NEUROGENET UNIT, BOSTON, MA 02129 USA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BOS JL, 1989, CANCER RES, V49, P4682; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUECK U, 1993, P NATL ACAD SCI USA, V90, P383; HAASE VH, 1994, HUM MOL GENET, V3, P407, DOI 10.1093/hmg/3.3.407; HARA T, 1994, CANCER RES, V54, P330; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARUTA H, 1989, NATO ADV SCI I A-LIF, V170, P255; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MORII N, 1993, J BIOL CHEM, V268, P27160; MUELLAUER L, 1993, ONCOGENE, V8, P2531; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PATTERSON HF, 1990, J CELL BIOL, V111, P1001; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; ROULEAU GA, 1993, NATURE, V363, P615; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEBER K, 1974, COLD SPRING HARB SYM, V39, P363, DOI 10.1101/SQB.1974.039.01.047; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	31	128	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23387	23390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089100				2022-12-25	WOS:A1994PQ34500002
J	VENKATACHALAM, KV; HUANG, WZ; LAROCCO, M; PALZKILL, T				VENKATACHALAM, KV; HUANG, WZ; LAROCCO, M; PALZKILL, T			CHARACTERIZATION OF TEM-1 BETA-LACTAMASE MUTANTS FROM POSITION-238 TO POSITION-241 WITH INCREASED CATALYTIC EFFICIENCY FOR CEFTAZIDIME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SUBSTITUTIONS; SUBSTRATE-SPECIFICITY; CEPHALOSPORINS; HYDROLYSIS	Recently, TEM beta-lactamase variants with amino acid substitutions in the active-site pocket of the enzyme have been identified in natural isolates with increased resistance to extended-spectrum cephalosporins such as cefotaxime and ceftazidime. To identify other amino acid substitutions that alter the activity of TEM-1 toward extended-spectrum cephalosporins, a random library was constructed that contained all possible amino acid substitutions over the 3-residue window of 238-241 (ABL numbering). Mutants were selected for 100-fold greater ceftazidime resistance than wild-type. Ah mutants had a serine substitution at position 238, a lysine or arginine at position 240, and a small amino acid at position 241. The role of each substitution was investigated by constructing individual G238S, E240K, and R241G substitutions as well as the G238S:E240K double mutant. Each enzyme was purified to homogeneity and the kinetic parameters k(cat) and K-m were determined using several substrates. The G238S substitution increases catalytic efficiency for both ceftazidime and cefotaxime. However, to achieve large increases in catalytic efficiency, both G238S and the E240K substitutions are required. The R241G substitution results in a small increase in catalytic efficiency for only ceftazidime. The contribution of each residue to the transition state stabilization energy was found to be additive indicating that the substitutions act independently to change the catalytic properties of the enzyme.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; ST LUKES EPISCOPAL HOSP, TEXAS MED CTR, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Saint Lukes Episcopal Hospital				Venkatachalam, K.V./0000-0001-6692-9099	NIAID NIH HHS [R01-AI32956] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BARTHELEMY M, 1988, FEBS LETT, V231, P217, DOI 10.1016/0014-5793(88)80734-8; Bevington PR, 1969, DATA REDUCTION ERROR; BUSH K, 1986, ANTIMICROB AGENTS CH, V30, P6, DOI 10.1128/AAC.30.1.6; BUSH K, 1989, INFECTION, V17, P429, DOI 10.1007/BF01645566; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; LEE KY, 1991, PROTEINS, V11, P45, DOI 10.1002/prot.340110106; MEDEIROS AA, 1984, BRIT MED BULL, V40, P18, DOI 10.1093/oxfordjournals.bmb.a071942; NEU HC, 1965, J BIOL CHEM, V240, P3685; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; ROY C, 1985, EUR J CLIN MICROBIOL, V4, P146, DOI 10.1007/BF02013586; Sambrook J, 1989, MOL CLONING LABORATO; SHLAES DM, 1990, ANTIMICROB AGENTS CH, V34, P1570, DOI 10.1128/AAC.34.8.1570; SHLAES DM, 1992, BIOCHEM J, V284, P411, DOI 10.1042/bj2840411; SOUGAKOFF W, 1988, FEMS MICROBIOL LETT, V56, P343, DOI 10.1111/j.1574-6968.1988.tb03204.x; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	27	55	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23444	23450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089110				2022-12-25	WOS:A1994PQ34500013
J	KAUR, KJ; RUBEN, L				KAUR, KJ; RUBEN, L			PROTEIN TRANSLATION ELONGATION FACTOR-1-ALPHA FROM TRYPANOSOMA-BRUCEI BINDS CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM FORMS; FACTOR EF-1-ALPHA; ACCOMPANIES DIFFERENTIATION; RABBIT RETICULOCYTES; CALCIUM HOMEOSTASIS; ADENYLATE-CYCLASE; PROCYCLIC FORMS; MAMMALIAN-CELLS; FACTOR-TU	The following study examines the calmodulin (CaM) branch of the calcium signal pathway in the protozoan parasite Trypanosoma brucei. To accomplish this goal, a subset of cytosolic CaM-binding proteins (CaMBPs) was partially purified by a combination of DE52 and CaM-Sepharose affinity chromatography. Monoclonal antibodies (CBP-KK1) were used to clone the cDNA for a 53-kDa CaMBP from a lambda ZAP expression library of the metacyclic stage of T. brucei. The deduced amino acid sequence of clone CaMBP-12B had 81% overall amino acid identity to the translation elongation factor-1 alpha (EF-1 alpha) from Euglena gracilis and 76% identity to the rabbit EF-1 alpha. Rabbit EF-1 alpha was recognized by CBP-KK1 and was shown to bind to CaM-Sepharose in a calcium-dependent manner. By contrast, the complex of EF-1 alpha beta gamma did not bind CaM Sepharose. A heterobifunctional sulfhydryl derivative of CaM (N-succinimydyl 3-(2-pyridyldithio)propionate-CaM) formed reducible cross-links with EF-1 alpha in solution but not with the complex of EF-1 alpha beta gamma. Biotinylated CaM bound weakly to trypanosome and rabbit EF-1 alpha in a gel overlay assay. This report demonstrates the direct interaction between CaM and the translation elongation factor EF-1 alpha.	SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA	Southern Methodist University			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024627] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24627] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BASS KE, 1992, MOL BIOCHEM PARASIT, V56, P129, DOI 10.1016/0166-6851(92)90160-L; BEC G, 1989, J BIOL CHEM, V264, P21131; BILLINGSLEY ML, 1987, BIOTECHNIQUES, V5, P22; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; CAVALLIUS J, 1992, NUCLEIC ACIDS RES, V20, P1422, DOI 10.1093/nar/20.6.1422; DAMPER D, 1976, J PROTOZOOL, V23, P349, DOI 10.1111/j.1550-7408.1976.tb03787.x; DEMEESTER F, 1991, MOL BIOCHEM PARASIT, V44, P23, DOI 10.1016/0166-6851(91)90217-T; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; EID JE, 1991, GENE DEV, V5, P2024, DOI 10.1101/gad.5.11.2024; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GORELICK FS, 1983, J CELL BIOL, V97, P1294, DOI 10.1083/jcb.97.4.1294; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; HAGHIGHAT NG, 1992, MOL BIOCHEM PARASIT, V51, P99, DOI 10.1016/0166-6851(92)90205-X; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR RV, 1991, EUR J BIOCHEM, V195, P313, DOI 10.1111/j.1432-1033.1991.tb15708.x; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LENSTRA JA, 1986, EUR J BIOCHEM, V155, P475, DOI 10.1111/j.1432-1033.1986.tb09514.x; LINZ JE, 1987, MOL CELL BIOL, V7, P1925, DOI 10.1128/MCB.7.5.1925; MARCHESI VT, 1993, P NATL ACAD SCI USA, V90, P3028, DOI 10.1073/pnas.90.7.3028; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MONTANDON PE, 1990, NUCLEIC ACIDS RES, V18, P75, DOI 10.1093/nar/18.1.75; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; ORR GA, 1992, EXP PARASITOL, V74, P127, DOI 10.1016/0014-4894(92)90039-D; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; RUBEN L, 1985, MOL BIOCHEM PARASIT, V17, P331, DOI 10.1016/0166-6851(85)90007-6; RUBEN L, 1991, MOL BIOCHEM PARASIT, V46, P123, DOI 10.1016/0166-6851(91)90206-L; RUBEN L, 1990, EXP PARASITOL, V70, P144, DOI 10.1016/0014-4894(90)90095-T; RUBEN L, 1987, J PROTOZOOL, V34, P367, DOI 10.1111/j.1550-7408.1987.tb03193.x; RUBEN L, 1983, BIOCHIM BIOPHYS ACTA, V758, P104, DOI 10.1016/0304-4165(83)90290-8; RUBEN L, 1985, IMMUNOLOGY, V56, P227; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; RUBEN L, 1991, J BIOL CHEM, V266, P24351; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SLOBIN LI, 1980, EUR J BIOCHEM, V110, P555, DOI 10.1111/j.1432-1033.1980.tb04898.x; SONNEMANN J, 1993, FEBS LETT, V329, P183, DOI 10.1016/0014-5793(93)80218-J; SONNEMANN J, 1991, J BIOL CHEM, V266, P23091; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; WHITEHEART SW, 1989, J BIOL CHEM, V264, P14334; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207; WU YM, 1992, BIOCHEM J, V287, P187, DOI 10.1042/bj2870187; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG WN, 1993, J BIOL CHEM, V268, P392	54	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23045	23050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083206				2022-12-25	WOS:A1994PQ16400025
J	WILSON, BA; BLANKE, SR; REICH, KA; COLLIER, RJ				WILSON, BA; BLANKE, SR; REICH, KA; COLLIER, RJ			ACTIVE-SITE MUTATIONS OF DIPHTHERIA-TOXIN - TRYPTOPHAN-50 IA A MAJOR DETERMINANT OF NAD AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; ASPARTIC-ACID; BINDING-SITE; FRAGMENT-A; MECHANISM; MUTAGENESIS; SYNTHETASE; FLUORESCENCE; GLUTAMINE	The two active-site trytophans of diphtheria toxin, Trp-50 and Trp-153, were individually or jointly replaced with phenylalanine or alanine by directed mutagenesis of a synthetic gene for the toxin's catalytic A fragment. Substitution of Trp-50 with alanine (W50A) decreased the ADP-ribosyltransferase activity by nearly 10(5)-fold and reduced NAD-glycohydrolase activity beyond the limits of our detection. Effects of the W153A mutation on these activities were less dramatic, <40-fold decrease in ADP-ribosylation and <10-fold decrease in NAD glycohydrolysis. The W50F and W153F substitutions caused only minimal reductions (<2-fold) in enzyme activities and NAD affinity. Decreases in affinity for NAD in the initial, ground state complex, as measured by intrinsic protein fluorescence, correlated well with the reductions in enzyme activity. None of the mutations caused greater than a 10-fold decrease in NAD affinity for the ternary Michaelis complex in the ADP-ribosylation reaction; and none caused significant increase in susceptibility to proteolytic digestion by trypsin. The results indicate that Trp-50 is a major determinant of NAD affinity. Also, they identify this residue as a candidate for modification in the development of inactive forms of the toxin for use in vaccine development.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; SHIPLEY INST MED,BOSTON,MA 02115	Harvard University; Harvard Medical School				Collier, R John/0000-0002-2427-4239	NIAID NIH HHS [AI08315, AI22021, AI22848] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021, R01AI022848, F32AI008315] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1992, CURR TOP MICROBIOL I, V175, P1; ATKINS WM, 1991, BIOCHEMISTRY-US, V30, P3406, DOI 10.1021/bi00228a008; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BLANKE SR, 1992, BACTERIAL PROTEIN TO, P349; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P433; CARROLL S F, 1985, P544; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHOTHIA C, 1985, J MOL BIOL, V182, P151, DOI 10.1016/0022-2836(85)90033-6; CHUNG DW, 1977, BIOCHIM BIOPHYS ACTA, V483, P248, DOI 10.1016/0005-2744(77)90053-5; COLLIER RJ, 1974, DHEW NIH74477 PUBL, P287; Collier RJ, 1982, ADP RIBOSYLATION REA, P575; Collier RJ, 1980, MULTIFUNCTIONAL PROT, P261; COLLIER RJ, 1986, PROTEIN CARBOHYDRATE, P399; DESERRANO VS, 1994, BIOCHEMISTRY-US, V33, P1340, DOI 10.1021/bi00172a008; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; FERSHT A, 1987, ENZYME STRUCTURE MEC; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; GILARDI G, 1994, BIOCHEMISTRY-US, V33, P1425, DOI 10.1021/bi00172a020; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; MATSUI I, 1994, BIOCHEMISTRY-US, V33, P451, DOI 10.1021/bi00168a009; MAYER RJ, 1986, P NATL ACAD SCI USA, V83, P7718, DOI 10.1073/pnas.83.20.7718; MICHEL A, 1977, BIOCHIM BIOPHYS ACTA, V491, P286, DOI 10.1016/0005-2795(77)90064-2; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Moss J, 1990, ADP RIBOSYLATING TOX; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PJURA P, 1993, PROTEINS, V15, P401, DOI 10.1002/prot.340150407; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2272, DOI 10.1073/pnas.82.8.2272; TWETEN RK, 1985, J BIOL CHEM, V260, P392; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; [No title captured]	43	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23296	23301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083236				2022-12-25	WOS:A1994PQ16400061
J	KUO, WL; GEHM, BD; ROSNER, MR; LI, WL; KELLER, G				KUO, WL; GEHM, BD; ROSNER, MR; LI, WL; KELLER, G			INDUCIBLE EXPRESSION AND CELLULAR-LOCALIZATION OF INSULIN-DEGRADING ENZYME IN A STABLY TRANSFECTED CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-ALPHA; TARGETING SIGNAL; RAT-LIVER; METALLOENDOPROTEASE INHIBITORS; MONOCLONAL-ANTIBODIES; DEGRADATION PRODUCTS; ZELLWEGER SYNDROME; MAMMALIAN-CELLS; HEPATOMA-CELLS; PEROXISOMES	Insulin degrading enzyme (IDE) is an evolutionarily conserved, nonlysosomal metalloprotease that has been implicated in the cellular degradation and processing of insulin. However, the site and the mode of the action of this enzyme are unclear. We have addressed these questions by establishing several Ltk(-) cell Lines that can overexpress human insulin-degrading enzyme (hIDE) upon glucocorticoid induction. The level of overexpression of hIDE protein and transcripts in these lines correlates well with an increase in insulin degradation in both cell lysates and intact cells. Comparison of the deduced amino acid sequences of mammalian and Drosophila IDEs reveals a conserved carboxyl-terminal peroxisomal targeting sequence (A/S-K-L), suggesting that IDE may be localized in peroxisomes. To test this possibility, we determined the cellular location of the stably transfected hIDE by both immunofluorescence and immunocryoelectron microscopy. The overexpressed hIDE predominantly colocalized with catalase in peroxisomes, although IDE was also found in the cytosol at a much lower concentration. These results demonstrate that stably transfected IDE catalyzes a rate-limiting step in cellular insulin degradation and is localized predominantly in peroxisomes.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; GENENTECH INC,DEPT PHARMACOL,SAN FRANCISCO,CA 94080	University of Chicago; Roche Holding; Genentech	KUO, WL (corresponding author), UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637, USA.							ABRAHAMSEN MS, 1993, MOL BIOCHEM PARASIT, V57, P1, DOI 10.1016/0166-6851(93)90239-T; AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AKIYAMA H, 1988, BIOCHEM BIOPH RES CO, V155, P914, DOI 10.1016/S0006-291X(88)80583-7; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BONDAR AG, 1990, GENE AMST, V91, P193; CHOWDHARY BK, 1985, BIOCHIM BIOPHYS ACTA, V840, P180, DOI 10.1016/0304-4165(85)90117-5; CORPAS FJ, 1993, EUR J CELL BIOL, V61, P81; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1990, J BIOL CHEM, V265, P2984; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GEHM BD, 1993, J BIOL CHEM, V268, P7943; GOLDFINE ID, 1981, ENDOCRINOLOGY, V108, P1821, DOI 10.1210/endo-108-5-1821; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MISBIN RI, 1983, ENDOCRINOLOGY, V113, P1525, DOI 10.1210/endo-113-4-1525; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIURA S, 1992, J BIOL CHEM, V267, P14405; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PEASE RJ, 1987, EUR J BIOCHEM, V164, P251, DOI 10.1111/j.1432-1033.1987.tb11018.x; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1632; SANTOS MJ, 1985, P NATL ACAD SCI USA, V82, P6556, DOI 10.1073/pnas.82.19.6556; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; TOOHEY MG, 1986, MOL CELL BIOL, V6, P4526, DOI 10.1128/MCB.6.12.4526; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WANDERS RJA, 1984, BIOCHEM BIOPH RES CO, V123, P1054, DOI 10.1016/S0006-291X(84)80240-5	50	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22599	22606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077210				2022-12-25	WOS:A1994PQ16300025
J	HARADA, M; INOHARA, M; NAKAO, M; NAKAYAMA, T; KAKUDO, A; SHIBANO, Y; AMACHI, T				HARADA, M; INOHARA, M; NAKAO, M; NAKAYAMA, T; KAKUDO, A; SHIBANO, Y; AMACHI, T			DIVALENT METAL-ION REQUIREMENTS OF A THERMOSTABLE MULTIMETAL BETA-GALACTOSIDASE FROM SACCHAROPOLYSPORA-RECTIVIRGULA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTANTS; ESCHERICHIA-COLI; BINDING; CONSTANTS; ENZYMES; GLU-461; MG2+	To understand the roles of metal ions on the catalytic properties and thermostability of the thermostable beta-galactosidase of Saccharopolyspora rectivirgula, a thermophilic actinomycete, we have investigated the binding kinetics and requirements of divalent metal ions by equilibrium dialysis, titration, and metal ion buffer techniques. We found that the monomeric multimetal enzyme (M(r) 136,977) had eight specific binding sites for divalent metal ions. These sites were classified as follows: a very tight (class I) site for Ca2+, three tight (class II) sites consisting of two Ca2+-specific sites (class II,,) and one Mn2+-specific site (class IIMn; K-d for Mn2+, 2.0 nM), and four loose (class III) sites for Mn2+ (K-d, 1.2 mu M) and Mg2+ (K-d, 2 mu M). Removal of metal ions bound to class II and III sites of the holoenzyme (Ca3Mn5 species; relative V-max (V-rel), 100%) by a chelating resin at 4 degrees C yielded a less thermostable Ca-1 species (V-rel, 1.7%) with a class I Ca2+ ion, removal of which by a chelating resin at 50 degrees C caused a complete irreversible inactivation of the enzyme, Titration studies revealed that stoichiometric binding of Mn2+ to a class IIMn site of the Ca-1 species caused a 33-fold activation whereas binding of Ca2+ to class IICa sites had no effect on enzyme activity. Ca-1 species could be also activated 8-fold by heating at 60 degrees C for 20 min, suggesting that the catalytically important class II Mn2+ plays important roles in maintaining the native structure essential for activity, Occupation of class III sites by Mg2+ or Mn2+ was of physiological importance to attain sufficient thermostability by which this extracellular beta-galactosidase remained active for a prolonged time at elevated temperatures as was observed during growth of S. rectivirgula.	SUNTORY LTD,INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN; SUNTORY LTD,INST FUNDAMENTAL RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd; Suntory Holdings Ltd								AGARWAL RP, 1987, J BIOL CHEM, V262, P2568; ANDEREGG G, 1982, PURE APPL CHEM, V54, P2693, DOI 10.1351/pac198254122693; AULD DS, 1988, METHOD ENZYMOL, V158, P13, DOI 10.1016/0076-6879(88)58043-6; BAKER JO, 1988, METHOD ENZYMOL, V158, P33, DOI 10.1016/0076-6879(88)58046-1; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; CASE GS, 1973, BIOCHEM J, V133, P99, DOI 10.1042/bj1330099; CLARK CR, 1970, CHEM COMMUN, P794; CLARK CR, 1970, J CHEM SOC P2, V2, P1943; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; EDWARDS RA, 1990, BIOCHEMISTRY-US, V29, P11001, DOI 10.1021/bi00501a019; EDWARDS RA, 1990, BIOCHEM BIOPH RES CO, V171, P33, DOI 10.1016/0006-291X(90)91352-S; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; FUKADA H, 1983, J BIOL CHEM, V258, P3193; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; LEAHY M, 1991, BIOCHEM SOC T, V19, pS19, DOI 10.1042/bst019019s; LEGLER G, 1983, CARBOHYD RES, V116, P95, DOI 10.1016/S0008-6215(00)90957-1; MARET W, 1988, METHOD ENZYMOL, V158, P79, DOI 10.1016/0076-6879(88)58049-7; NAKAO M, 1994, APPL MICROBIOL BIOT, V40, P657, DOI [10.1007/s002530050046, 10.1007/BF00173325]; Perrin D. D., 2012, BUFFERS PH METAL ION; RAAFLAUB J, 1956, METHOD BIOCHEM ANAL, V3, P301; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SELLIN S, 1984, J BIOL CHEM, V259, P1426; SELWOOD T, 1990, BIOCHEM J, V268, P317, DOI 10.1042/bj2680317; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; Wallenfels K., 1972, ENZYMES, V7, P617	27	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22021	22026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071323				2022-12-25	WOS:A1994PE09800017
J	OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S				OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S			COMPLEX-FORMATION BETWEEN LAMIN-A AND THE RETINOBLASTOMA GENE-PRODUCT - IDENTIFICATION OF THE DOMAIN ON LAMIN-A REQUIRED FOR ITS INTERACTION	ONCOGENE			English	Article							LARGE T-ANTIGEN; INTERMEDIATE FILAMENT PROTEINS; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; NUCLEAR-ENVELOPE; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB GENE; BINDING	The retinoblastoma susceptibility gene product (pRB) has been known to function as a negative regulator of cell growth. Recent observations suggest that its biological activity might be modulated by an interaction with nuclear structures. By using in vitro binding assays, we have found that pRB can associate with lamin A, which has been known to be one of the major nuclear matrix proteins. A series of GST-lamin A deletion mutants was constructed to define the amino acid sequence required for binding to pRB. A GST-lamin A (247-355) contained an activity to associate with pRB, while the other constructs, such as GST-lamin A (37-244) or GST-lamin A (356-571), could not bind to pRB. Within the pRB-binding domain of lamin A, there exists the short amino acid sequence which is also present in the pRB-binding region of the transcription factor E2F-1. The similar experiments using a set of GST-RB deletion mutants revealed that a region containing the E1A-binding pocket B and the carboxy-terminal portion of pRB was responsible for binding to lamin A.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUOH KU,TOKYO 104,JAPAN	Chiba Cancer Center; National Cancer Center - Japan								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P153; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4297; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OZAKI T, 1992, FEBS LETT, V312, P165, DOI 10.1016/0014-5793(92)80927-9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	46	177	180	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2649	2653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058329				2022-12-25	WOS:A1994PC05400025
J	FRIGUET, B; STADTMAN, ER; SZWEDA, LI				FRIGUET, B; STADTMAN, ER; SZWEDA, LI			MODIFICATION OF GLUCOSE-6-PHOSPHATE-DEHYDROGENASE BY 4-HYDROXY-2-NONENAL - FORMATION OF CROSS-LINKED PROTEIN THAT INHIBITS THE MULTICATALYTIC PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPOFUSCIN-LIKE SUBSTANCES; GLUTAMINE-SYNTHETASE; APOLIPOPROTEIN-B; OXIDATIVE STRESS; OXIDIZED LDL; MACROPHAGES; DEGRADATION; COMPLEX; LIVER	Incubation of glucose-6-phosphate dehydrogenase (Glu-6-PDH) from Leuconostoc mesenteroides with the lipid peroxidation product 4-hydroxy-2-nonenal leads to the formation of cross-linked protein. This is accompanied by the appearance of protein-associated fluorescence with excitation and emission maxima of 340 and 415 nm, respectively, and with the disappearance of histidine and lysine residues. Cross-linked protein is less susceptible than native Glu-6-PDH to proteolysis by the multicatalytic protease, a multienzymic proteolytic complex involved in the intracellular degradation of damaged proteins. In addition, 4-hydroxy-2-nonenal-modified Glu-6-PDH inhibits the multicatalytic protease and can therefore prevent the efficient degradation of oxidized protein. These findings may have important implications for the accumulation of altered protein and fluorescent material in vivo, processes that are believed to be involved in age- and disease-related impairment of cellular function.	NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Friguet, Bertrand/0000-0001-8085-1961				AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; BRUNK UT, 1992, MUTAT RES, V275, P395, DOI 10.1016/0921-8734(92)90042-N; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; DEMONTARBY L, 1989, B SOC CHIM FR, P419; ESTERBAUER H, 1986, BIOCHEM J, V239, P405, DOI 10.1042/bj2390405; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1990, LIPOFUSCIN CEROID PI, P3; HOFF HF, 1993, J LIPID RES, V34, P1919; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; ISHAQUE A, 1974, BIOCHEM BIOPH RES CO, V59, P894, DOI 10.1016/S0006-291X(74)80063-X; IVY GO, 1991, MECH AGEING DEV, V57, P213, DOI 10.1016/0047-6374(91)90048-5; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; KIKUGAWA K, 1987, CHEM PHYS LIPIDS, V44, P277, DOI 10.1016/0009-3084(87)90054-5; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROMA P, 1992, J LIPID RES, V33, P819; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SKILTON HE, 1991, FEBS LETT, V279, P351, DOI 10.1016/0014-5793(91)80185-6; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; TAPPEL AL, 1980, FREE RADICALS BIOL, V4, P2; TSUCHIDA M, 1987, CHEM PHYS LIPIDS, V44, P297, DOI 10.1016/0009-3084(87)90055-7	39	288	294	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21639	21643						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063806				2022-12-25	WOS:A1994PK97300041
J	EISSENBERG, JC; GE, YW; HARTNETT, T				EISSENBERG, JC; GE, YW; HARTNETT, T			INCREASED PHOSPHORYLATION OF HP1, A HETEROCHROMATIN-ASSOCIATED PROTEIN OF DROSOPHILA, IS CORRELATED WITH HETEROCHROMATIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; OKADAIC ACID; MELANOGASTER; CHROMATIN; GENE; DEPHOSPHORYLATION; TRANSFORMATION; TRANSCRIPTION; EMBRYOGENESIS	The heterochromatin-associated nonhistone chromosomal protein HP1 exerts dosage-dependent effects on the silencing of genes juxtaposed to pericentric heterochromatin in Drosophila melanogaster. Here, we report that HP1 is multiply phosphorylated in Drosophila tissue, predominantly at serine and threonine residues. Pulse-labeling studies of explanted Drosophila tissues suggest that phosphorylation is relatively rapid and that phosphate is incorporated into existing protein. Maternally synthesized HP1 is underphosphorylated. The appearance of more highly phosphorylated HP1 isoforms at 1.5-2 h of development coincides with the embryonic stage at which cytologically visible heterochromatin appears and HP1 concentrates in heterochromatin. The extent of HP1 phosphorylation is lower in polytene tissue, where heterochromatin is underrepresented. These results are consistent with a role for phosphorylation of HP1 in the assembly and maintenance of heterochromatin in Drosophila.			EISSENBERG, JC (corresponding author), ST LOUIS UNIV,HLTH SCI CTR,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040732] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40732] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BILLINGS PC, 1979, NUCLEIC ACIDS RES, V6, P2151, DOI 10.1093/nar/6.6.2151; BLUMENFELD M, 1978, P NATL ACAD SCI USA, V75, P866, DOI 10.1073/pnas.75.2.866; CLARK RF, 1992, NUCLEIC ACIDS RES, V20, P6067, DOI 10.1093/nar/20.22.6067; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1993, MOL GEN GENET, V240, P333, DOI 10.1007/BF00280383; ENDOW SA, 1975, CHROMOSOMA BERL, V50; FRIDELL YWC, 1991, NUCLEIC ACIDS RES, V19, P5082, DOI 10.1093/nar/19.18.5082; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KALOUS J, 1993, DEV BIOL, V157, P448, DOI 10.1006/dbio.1993.1148; LOCKE J, 1988, GENETICS, V120, P181; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHOWALD AP, 1985, ANNU REV GENET, V19, P149, DOI 10.1146/annurev.ge.19.120185.001053; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MIKLOS GLG, 1990, BIOESSAYS, V12, P1, DOI 10.1002/bies.950120102; NEIL JC, 1981, NATURE, V291, P675, DOI 10.1038/291675a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SINCLAIR DAR, 1983, MOL GEN GENET, V191, P326, DOI 10.1007/BF00334834; SUNG MT, 1977, BIOCHEMISTRY-US, V16, P286, DOI 10.1021/bi00621a020; VANHOLDE KE, 1988, CHROMATIN, P111; VLASSOVA IE, 1991, MOL GEN GENET, V229, P316, DOI 10.1007/BF00272172; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WUSTMANN G, 1989, MOL GEN GENET, V217, P520, DOI 10.1007/BF02464926	35	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21315	21321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063756				2022-12-25	WOS:A1994PC40300074
J	XU, HE; JOHNSTON, SA				XU, HE; JOHNSTON, SA			YEAST BLEOMYCIN HYDROLASE IS A DNA-BINDING CYSTEINE PROTEASE - IDENTIFICATION, PURIFICATION, BIOCHEMICAL, CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL4; CLONING; AMINOPEPTIDASE; SPECIFICITY; RESISTANCE; PROTEINASE; MECHANISM; CARCINOMA; CLEAVAGE; COMPLEX	Bleomycin (BLM) is a DNA binding and damaging antibiotic produced by Streptomyces verticillus that has been used as an anti-tumor drug for various human cancers. The mammalian BLM hydrolase is a cysteine protease that inactivates BLM to relieve the toxicity of BLM to normal and tumor cells. The normal physiological function of BLM hydrolase is not known, but its activity limits the use of BLM in cancer chemotherapy. We have discovered a DNA binding activity for the yeast homolog of the mammalian BLM hydrolase in the course of studying the interaction of GAL4, a DNA-binding transcription factor, with its DNA recognition sites. Using gel mobility shift assays, we have purified a protein from yeast that binds specifically to the GAL4 DNA-binding sites. The purified protein is a tetramer of a 48-kDa polypeptide. The gene encoding the 48-kDa polypeptide was cloned and has a high homology to rabbit ELM hydrolase. The purified protein was confirmed to have a cysteine protease activity that can hydrolyze and inactivate BLM in vitro. We have established the optimal conditions for the protease activity of this protein and biochemically characterized its DNA binding activity. This protein binds both single- and double-stranded forms of the GAL4 DNA-binding sites with high affinity (10 nM to single strand and 1 mu M to double strand). Its DNA binding activity is heat stable and resistant to various detergents. This protein may represent the first example of a eukaryotic DNA-binding protease. The discovery of a DNA binding activity for BLM hydrolase suggests an in vivo interaction between it and BLM on DNA.	UNIV TEXAS,SW MED CTR,DEPT MED,GRAD PROGRAM MOLEC BIOL & BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	XU, HE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,GRAD PROGRAM MOLEC BIOL & BIOCHEM,DALLAS,TX 75235, USA.			Xu, H. Eric/0000-0002-6829-8144				AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Carter S.K., 1985, BLEOMYCIN CHEMOTHERA, P3; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; HOLMES CE, 1993, J BIOL CHEM, V268, P25909; JANI JP, 1992, CANCER RES, V52, P2931; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; LAZO JS, 1987, METABOLISM ACTION AN, P194; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MISTRY JS, 1993, BIOCHEM BIOPH RES CO, V191, P420, DOI 10.1006/bbrc.1993.1234; MORRIS G, 1992, MOL PHARMACOL, V42, P57; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ROY SN, 1981, CANCER RES, V41, P4471; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUZUKI H, 1968, J ANTIBIOT, V21, P379, DOI 10.7164/antibiotics.21.379; UMEZAWA H, 1971, Pure and Applied Chemistry, V28, P665, DOI 10.1351/pac197128040665; UMEZAWA H, 1972, J ANTIBIOT, V25, P409, DOI 10.7164/antibiotics.25.409; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; VASHEE S, 1993, J BIOL CHEM, V268, P24699; MKR137 SIGM CHEM CO	33	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21177	21183						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063738				2022-12-25	WOS:A1994PC40300055
J	AHMED, M; BORSCH, CM; NEYFAKH, AA; SCHULDINER, S				AHMED, M; BORSCH, CM; NEYFAKH, AA; SCHULDINER, S			MUTANTS OF THE BACILLUS-SUBTILIS MULTIDRUG TRANSPORTER BMR WITH ALTERED SENSITIVITY TO THE ANTIHYPERTENSIVE ALKALOID RESERPINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MUTAGENESIS; RESISTANCE; BINDING	The Bacillus subtilis multidrug transporter Bmr effluxes structurally diverse toxic compounds out of bacterial cells. Antihypertensive alkaloid reserpine reverses Bmr-mediated multidrug resistance by inhibiting drug transport. We have obtained a mutant of the bmr gene that provides a normal level of multidrug resistance, which can, however, only be reversed by very high concentrations of reserpine. Reduction of Bmr sensitivity to reserpine has been caused by the substitution of Leu for Val286 in the Bmr molecule. This mutation also led to a dramatic decrease of [H-3]reserpine binding to membrane vesicles prepared from the Bmr-overexpressing bacteria. Leucine is larger than valine by one methylene group. Substitution of Val286 with a smaller residue, glycine, had an opposite effect. It led to increased sensitivity of Bmr to reserpine and increased affinity of reserpine binding to the membranes prepared from Bmr-overexpressing bacteria. Neither of the mutations significantly changed the sensitivity of Bmr to rescinnamine, a structural analog of reserpine. The results suggest that Val286 is involved in the formation of the reserpine-binding site of the Bmr molecule.	UNIV ILLINOIS,DEPT MED CHEM & PHARMACOGNOSY MC 781,CHICAGO,IL 60680; HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERINO E, 1992, BIOTECHNIQUES, V12, P508; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0	19	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11086	11089						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098708				2022-12-25	WOS:A1993LD46600056
J	CHEN, CY; DION, SB; KIM, CM; BENOVIC, JL				CHEN, CY; DION, SB; KIM, CM; BENOVIC, JL			BETA-ADRENERGIC-RECEPTOR KINASE - AGONIST-DEPENDENT RECEPTOR-BINDING PROMOTES KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; SYNTHETIC PEPTIDES; PROTEIN-KINASE; PHOTOEXCITED RHODOPSIN; PHOSPHORYLATION; PURIFICATION; MECHANISM; SUBSTRATE; FAMILY; TRANSLOCATION	The beta-adrenergic receptor kinase (betaARK) specifically phosphorylates the activated form of multiple receptors such as the beta2-adrenergic receptor (beta2AR) and rhodopsin. betaARK also phosphorylates synthetic peptides, albeit with an approximately 10(4)-10(7)-fold lower V(max)/K(m) ratio as compared to receptors, with a clear preference for peptides containing acidic residues on the aminoterminal side of a serine or threonine. To further characterize the mechanism of substrate phosphorylation by betaARK, we designed a series of analogue peptides containing a single amino acid change (serine, glutamic acid, or phosphoserine) situated 2 or 4 residues amino-terminal to the target serine. While betaARK weakly phosphorylated peptides lacking an acidic residue, peptides containing either a single phosphoserine or glutamic acid were substantially better substrates with a 3.5- to 8-fold increase in V(max). Additional studies demonstrated that the interaction of betaARK with an activated receptor (beta2AR* or Rho*) also significantly enhanced peptide phosphorylation. Both Rho* and a truncated rhodopsin lacking its carboxyl-terminal phosphorylation sites activated peptide phosphorylation to a similar extent with EC50 values for activation of 0.65 and 1.34 muM, respectively. In contrast, the agonist-occupied beta2AR activated peptide phosphorylation by betaARK with a substantially higher affinity (EC50 of 0.012 muM) compared to Rho*. The V(max)/K(m) ratio for betaARK phosphorylation of a poor peptide substrate such as RRRASAAASAA was increased up to approximately 200-fold by the activated receptor while the phosphorylation of a good peptide substrate (RRREEEEESAAA) was increased only up to approximately 8-fold. Our results suggest that acidic residues (glutamic acid or phosphoserine) localized on the amino-terminal side of target serines are important but not essential determinants in directing peptide phosphorylation. The substrate specificity of betaARK appears to rely more strongly on the overall topological structure of the activated receptor which promotes the specific binding and activation of betaARK.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	37	122	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7825	7831						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096517				2022-12-25	WOS:A1993KW97900039
J	GOLDSMITH, ME; MADDEN, MJ; MORROW, CS; COWAN, KH				GOLDSMITH, ME; MADDEN, MJ; MORROW, CS; COWAN, KH			A Y-BOX CONSENSUS SEQUENCE IS REQUIRED FOR BASAL EXPRESSION OF THE HUMAN MULTIDRUG RESISTANCE (MDR1) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; DNA-BINDING PROTEINS; P-GLYCOPROTEIN; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; CP-1/CBF SUBUNITS; CHINESE-HAMSTER; CDNA CLONING; HUMAN-TUMORS; CELL-LINES	Basal transcription of the human multidrug resistance (mdr1) promoter was studied by chloramphenicol acetyltransferase (CAT) reporter fusion gene analysis in two parental and doxorubicin-resistant human tumor cell lines. Deletion of mdr1 DNA sequences to -89 relative to the start of transcription (at +1) had little effect on expression. Deletion of nucleotide sequences from -89 to -70, however, resulted in a 5-10-fold reduction in mdrCAT expression. DNase I footprint analysis demonstrated that the region from -85 to -70 was protected from nuclease digestion using nuclear extracts from these cell lines. The sequence between -82 and -73 is perfectly homologous with the 10-base pair Y-box consensus sequence found in the promoters of all major histocompatibility complex class-II (MHC II) genes. The Y-box sequence in MHC II genes is required for accurate and efficient transcription and contains the sequence CCAAT in the reverse orientation (Dorn, A., Durand, B., Marfing, C., Le Meur, M., Benoist, C., and Mathis, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6249-6253). Mutations in the reverse CCAAT sequence of the Y-box consensus substantially reduced expression of an mdrCAT vector and eliminated nucleoprotein binding in an electrophoretic mobility shift assay. These results suggest that proteins which bind to the putative Y-box consensus sequence are critical for basal transcriptional regulation of the human mdr1 gene.			GOLDSMITH, ME (corresponding author), NCI,MED BRANCH,BLDG 10,RM 12N226,BETHESDA,MD 20892, USA.							ABRAHAM I, 1990, EXP CELL RES, V189, P133, DOI 10.1016/0014-4827(90)90265-C; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN D, 1991, J BIOL CHEM, V266, P2239; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LOUIE KG, 1986, BIOCHEM PHARMACOL, V35, P467, DOI 10.1016/0006-2952(86)90221-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; OGURA M, 1991, JPN J CANCER RES, V82, P1151, DOI 10.1111/j.1349-7006.1991.tb01770.x; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RICHTER A, 1972, J NATL CANCER I, V49, P1705, DOI 10.1093/jnci/49.6.1705; SAKURA H, 1988, GENE, V73, P499; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VICKERS PP, 1989, TRENDS PHARMACOL SCI, V10, P443; WOLFFE AP, 1992, NEW BIOL, V4, P290	56	112	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5856	5860						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095499				2022-12-25	WOS:A1993KR82200075
J	SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG				SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG			FORMATION OF SHC-GRB2 COMPLEXES IS NECESSARY TO INDUCE NEOPLASTIC TRANSFORMATION BY OVEREXPRESSION OF SHC PROTEINS	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; EGF RECEPTOR; RAS; DOMAINS; ACTIVATION; SEVENLESS	The mammalian SHC gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. Shc proteins are phosphorylated on tyrosine by a variety of receptor and cytoplasmic tyrosine kinases. Phosphorylated Shc proteins form a complex with the SH2-SH3 containing Grb2 protein which is implicated in the regulation of Ras, suggesting that Shc is involved in the intracellular transmission of growth signals from activated tyrosine kinases to Ras. Overexpression of Shc proteins in cultured fibroblasts induces a transformed phenotype. We now report that, in vitro, the high affinity binding of Grb2 to Shc proteins requires phosphorylation of Shc at Tyr317, which lies within the high affinity binding motif for the Grb2 SH2 domain, pYVNV, where Asn at the +2 position is crucial for complex formation. In vivo, Tyr317 is the major, but not the only, site for Shc phosphorylation, and is the sole Shc high affinity binding site for Grb2. Mutant Shc proteins with substitution of the Tyr317 by Phe lose the capacity to be highly phosphorylated on tyrosine upon growth factor receptor activation, to bind Grb2 and to induce neoplastic transformation. In contrast, Shc proteins that have an extensive aminoterminal deletion, but retain the Tyr317 site and the SH2 domain conserve the capacity to be phosphorylated, to bind to Grb2 and to induce cell transformation. These data indicate that the formation of the Shc-Grb2 complex is a crucial event in the transformation induced by overexpression of Shc and support the notion that Shc proteins can deliver activation signals to RAS.	UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Perugia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013; Salcini, Anna Elisabetta/G-4472-2017; Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWMAN S, 1990, TECHNIQUE, V5, P254; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	210	215	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2827	2836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084588				2022-12-25	WOS:A1994PG82200008
J	KRUDY, GA; KLEEREKOPER, Q; GUO, XD; HOWARTH, JW; SOLARO, RJ; ROSEVEAR, PR				KRUDY, GA; KLEEREKOPER, Q; GUO, XD; HOWARTH, JW; SOLARO, RJ; ROSEVEAR, PR			NMR-STUDIES DELINEATING SPATIAL RELATIONSHIPS WITHIN THE CARDIAC TROPONIN-I TROPONIN-C COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RABBIT SKELETAL-MUSCLE; CALCIUM-BINDING SITES; AMINO-ACID SEQUENCE; BIOLOGICAL-ACTIVITY; CONTRACTION; PROTEIN; RESOLUTION; MUTATION; EXPRESSION	NMR spectroscopy and selective isotope labeling of both recombinant cardiac troponin C (cTnC3) and a truncated cardiac troponin I (cTnI/NH2) lacking the N-terminal 32-amino acid cardiac-specific sequence have been used to probe protein-protein interactions central to muscle contraction. Using [methyl-C-13]Met-labeled cTnC3, all 10 cTnC Met residues of Ca2+-saturated cTnC3 could be resolved in the two-dimensional heteronuclear single- and multiple-quantum coherence spectrum of the cTnI.cTnC complex. Based on the known Met assignments in cTnC3, the largest chemical shift changes were observed for Met(81), Met(120), Met(137), and Met(157). Methionines 120, 137, and 157 are all located in the C-terminal domain of cTnC. Methionine 81 is located at the N terminus of the central helix. Minimal chemical shift changes were observed for Met(45), Met(47), and Met(103) of cTnC3 in the cTnI.cTnC complex. All 6 Met residues in [methyl-C-13]Met-labeled cTnI/NH2 could be resolved in the cTnI.cTnC complex, suggesting that both cTnI and cTnC form a stable homogeneous binary complex under the conditions of the MMR experiment. In the absence of added protease inhibitors in the cTnI.cTnC complex, cTnI/NR(2) was found to undergo selective proteolysis to yield a 5.5-kDa N-terminal fragment corresponding to residues 33-80. Judging from the NMR spectra of [methyl-C-13]Met-labeled cTnC3, cTnI-(33-80) was sufficient for interaction with the C-terminal domain of cTnC in a manner identical to that observed for native cTnI/NH2. However, in the presence of the proteolytic fragment cTnI-(33-80), the chemical shift of Met(81) was not perturbed from its position in free cTnC3. Thus, residues located C-terminal to Arg(80) in cTnI appear to be responsible for interaction with the N-terminal half of cTnC, Taken together these results provide strong evidence for an antiparallel arrangement for the two proteins in the troponin complex such that the N-terminal portion of cTnI interacts with the C-terminal domain of cTnC. This interaction likely plays a role in maintaining the stability of the TnI.TnC complex.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	University of Texas System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022231, R37HL022231, R01HL045724, R01HL049934] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45724, HL49934, HL22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GUO X, 1992, Biophysical Journal, V61, pA158; GUO XD, 1994, J BIOL CHEM, V269, P15210; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; NEGELE JC, 1992, J BIOL CHEM, V267, P825; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROSEVEAR PR, 1988, BIOCHEMISTRY-US, V27, P7931, DOI 10.1021/bi00420a052; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; WATTANAPERMPOOL J, 1994, BIOPHYS J, V66, pW338; XU B, 1993, J BIOL CHEM, V268, P16259; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P346, DOI 10.1016/0022-2364(90)90265-B	29	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23731	23735						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089144				2022-12-25	WOS:A1994PQ34500053
J	WANG, ZQ; LIN, HN; LI, SS; HUANG, CH				WANG, ZQ; LIN, HN; LI, SS; HUANG, CH			CALORIMETRIC STUDIES AND MOLECULAR MECHANICS SIMULATIONS OF MONOUNSATURATED PHOSPHATIDYLETHANOLAMINE BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; MIXED-CHAIN PHOSPHATIDYLCHOLINES; PACKING; PHASE; PHOSPHOLIPIDS; CONFORMATION; SERIES	This investigation was designed to determine how information about the lipid chain melting and structural characteristics of sn-1 saturated/sn-2 monounsaturated phosphatidylethanolamines, a subclass of naturally occurring phospholipids, can be generalized among these lipid molecules. Specifically, 30 molecular species of sn-1 saturated/sn-2 unsaturated monoenoic phosphatidylethanolamines were semi-synthesized. The phase transition behavior of these monoenoic lipids in excess water was studied calorimetrically. The computer-based molecular mechanics approach was used to simulate the energy-minimized structures and to calculate steric energies for the diglyceride moieties of some of the 30 monoenoic lipid molecules, at T < T-m, in various aggregated states. These combined calorimetric and computational studies led to the following results and conclusions. 1) For a homologous series of monoenoic lipids with a common molecular weight and with a cis-double band at various positions along the sn-2 acyl chain, the characteristic reduction of the main phase transition temperature (T-m) is proposed to be a result of an entropy-driven phenomenon. 2) The maximal decrease in the T-m for bilayers prepared from four series of monoenoic phosphatidylethanolamines containing a sn-2 octadecenoyl chain is shown by interpolation of calorimetric data to occur uniquely when the cis double bond is located commonly between C(10) and C(11) positions from the carboxyl end. 3) Monoenoic phosphatidylethanolamines can be divided into two groups. The T-m values obtained with bilayers of monoenoic lipids within each group can be systematically correlated with their structural parameters, leading to the derivation of two general T-m- structure relationships.	UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIGMS GM-17452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001; BARTON PG, 1975, J BIOL CHEM, V250, P4470; CHANG H, 1983, BIOCHIM BIOPHYS ACTA, V728, P319, DOI 10.1016/0005-2736(83)90501-1; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; EPAND RM, 1988, CHEM PHYS LIPIDS, V49, P101, DOI 10.1016/0009-3084(88)90070-9; GAO Q, 1986, J LIPID RES, V27, P1214; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; KEOUGH KMW, 1987, BIOCHIM BIOPHYS ACTA, V902, P1, DOI 10.1016/0005-2736(87)90129-5; KOYNOVA R, 1990, CHEM PHYS LIPIDS, V54, P677; LAFLEUR M, 1990, EUR BIOPHYS J, V19, P55, DOI 10.1007/BF00185086; LI SS, 1993, BIOPHYS J, V65, P1415, DOI 10.1016/S0006-3495(93)81205-0; LI SS, 1994, BIOPHYS J, V66, P2005, DOI 10.1016/S0006-3495(94)80993-2; LIN HN, 1990, BIOCHEMISTRY-US, V29, P7063, DOI 10.1021/bi00482a017; MENA PL, 1985, CHEM PHYS LIPIDS, V37, P257, DOI 10.1016/0009-3084(85)90014-3; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P507; XU H, 1988, BIOCHIM BIOPHYS ACTA, V943, P63, DOI 10.1016/0005-2736(88)90347-1; Yeagle P.L, 2016, MEMBRANES CELLS	20	27	27	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23491	23499						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089115				2022-12-25	WOS:A1994PQ34500020
J	DAVIDSON, WS; LUNDKATZ, S; JOHNSON, WJ; ANANTHARAMAIAH, GM; PALGUNACHARI, MN; SEGREST, JP; ROTHBLAT, GH; PHILLIPS, MC				DAVIDSON, WS; LUNDKATZ, S; JOHNSON, WJ; ANANTHARAMAIAH, GM; PALGUNACHARI, MN; SEGREST, JP; ROTHBLAT, GH; PHILLIPS, MC			THE INFLUENCE OF APOLIPOPROTEIN STRUCTURE ON THE EFFLUX OF CELLULAR FREE-CHOLESTEROL TO HIGH-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE ANALOGS; A-I; AMPHIPATHIC HELIX; EXCHANGEABLE APOLIPOPROTEINS; LYSOSOMAL CHOLESTEROL; CELLS; PARTICLES; MEMBRANE; STEROL; CHROMATOGRAPHY	The influence of apolipoprotein conformation on the ability of high density lipoprotein (HDL) to remove cellular free cholesterol (FC) has not been studied in detail. To address the effects of amphipathic cu-helix structure on cellular FC efflux, three class A helical peptides and apolipoprotein (ape) All were complexed to dimyristoyl phosphatidylcholine (DMPC) to make discoidal complexes that were used as accepters of cell cholesterol. The peptides consisted of an 18-amino acid, amphipathic, alpha-helical peptide with the sequence DWL-KAFYDKVAEKLKEAF (18A), a dimer of 18A covalently linked by a proline residue (37pA), and acetyl-18A-amide (Ac-18A-NH2) that has a higher alpha-helix content than the unblocked 18A molecule. The three peptides strongly mimic the lipid-binding characteristics of the amphipathic segments of apolipoproteins and form discoidal complexes with DMPC that are similar in diameter (11-12 nm) to those formed by human apoAI when reconstituted at a 2.5:1 (w:w) phospholipid to protein ratio. The abilities of these complexes to remove radiolabeled FC were compared in experiments using cultured mouse L-cell fibroblasts; efflux of FC from both the plasma membrane and the lysosomal pools was examined. For each of the accepters, the removal of cholesterol from the plasma membrane and lysosomal pools was equally efficient. All four discoidal complexes were equally efficient cell membrane FC accepters when compared at saturating acceptor concentrations of >200 mu g of DMPC/ml of medium. However, at the same lipid concentration, protein-free DMPC small unilamellar vesicles (SUV) were significantly less efficient. The initial rates of FC removal from cells at saturating concentrations of acceptor particles (V-max) were 12, 10, 10, and 11% per h, respectively, for the complexes containing either 18A, Ac-18A-NH2, 37pA, or apoAI, but only 1% cellular FC per h for the DMPC SUV. The 10-fold higher V-max for the apoprotein/peptide containing accepters was likely due to a reversible interaction of apoprotein or peptide with the plasma membrane that changed the lipid packing characteristics in such a way as to increase the rate of FC desorption from the cell surface. This interaction required amphipathic alpha-helical segments, but it was not affected by the length, number, or lipid-binding affinity of the helices. Furthermore, the efflux efficiency was not dependent on the amino acid sequence of the helical segments which suggests that this interaction is not mediated by a specific cell surface binding site. At lower acceptor concentrations of <100 mu g of DMPC/ml of medium, differences in efflux efficiency were seen between the peptide-containing particles as a group and the apoAI-containing particle demonstrating that cu-helix structure can affect the ability of acceptor particles to either sequester or retain cholesterol molecules.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; UNIV ALABAMA,SCH MED,ATHEROSCLEROSIS RES UNIT,BIRMINGHAM,AL 35294	Drexel University; University of Alabama System; University of Alabama Birmingham				Phillips, Michael/0000-0002-7147-8007; Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, T32HL007443, P01HL034343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34343, HL22633, HL07443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BOCKRIS JO, 1963, PROC R SOC LON SER-A, V274, P55, DOI 10.1098/rspa.1963.0114; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHRISTENSEN HN, 1974, ENZYME KINETICS, P50; CHUNG BH, 1985, J BIOL CHEM, V260, P256; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; FIEVET C, 1991, DIABETES METAB REV, V7, P155, DOI 10.1002/dmr.5610070304; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GARBER DW, 1992, ARTERIOSCLER THROMB, V12, P886, DOI 10.1161/01.ATV.12.8.886; HARA H, 1991, J BIOL CHEM, V266, P3080; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; LEROY A, 1993, J BIOL CHEM, V268, P4798; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; MAHLBERG F, 1993, DRUGS AFFECTING LIPI, P493; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; ORAM JF, 1990, CURR OPIN LIPIDOL, V1, P416; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RADER DJ, 1991, J LIPID RES, V32, P1849; ROTHBLAT GH, 1970, SCIENCE, V169, P880, DOI 10.1126/science.169.3948.880; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; VONEKARDSTEIN A, 1992, J BIOL CHEM, V268, P2616; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	47	69	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22975	22982						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083197				2022-12-25	WOS:A1994PQ16400014
J	DONOVAN, JA; WANGE, RL; LANGDON, WY; SAMELSON, LE				DONOVAN, JA; WANGE, RL; LANGDON, WY; SAMELSON, LE			THE PROTEIN PRODUCT OF THE C-CBL PROTOONCOGENE IS THE 120-KDA TYROSINE-PHOSPHORYLATED PROTEIN IN JURKAT CELLS ACTIVATED VIA THE T-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ZETA-CHAIN; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; V-CBL; KINASE; SH2; ASSOCIATION; ONCOGENE; BINDING; ZAP-70	Tyrosine phosphorylation of multiple cellular proteins is a critical event in T cell receptor (TCR)-mediated activation. This pathway has also been implicated in cellular transformation in multiple systems. The viral oncogene v-cbl is the transforming gene of a murine retrovirus that induces pre-B cell lymphomas and myelogenous leukemias. The product of its cellular homolog, p120(cbl), is a 120-kDa cytoplasmic protein that is nontransforming when overexpressed. Here we show that the 120-kDa protein tyrosine phosphorylated in Jurkat T cells upon TCR engagement is p120(cbl). Following stimulation through the TCR, this tyrosine phosphorylation is rapid and reversible. Tyrosine-phosphorylated p120(cbl) binds to glutathione S-transferase fusion proteins generated from SH2 domains of the Fyn, Lck, and Blk protein tyrosine kinases, GTPase-activating protein and phospholipase Cy. The p120(cbl) from unactivated and activated cells also binds to full-length glutathione S-transferase-Grb2 and the Grb2 N-terminal SH3 domain, but not to the Grb2 C-terminal SH3 domain. Additionally, p120(cbl) binds to SH3 domains of Fyn and Lck, but not Blk. These data expand our knowledge of protein tyro sine kinase signaling pathways in T cells by identifying a prominent tyrosine kinase substrate. This protein, the product of the cellular homolog of a transforming oncogene, can interact with several known signaling molecules.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; UNIV WESTERN AUSTRALIA, DEPT BIOCHEM, NEDLANDS, WA 6009, AUSTRALIA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Western Australia				Wange, Ronald/0000-0001-9593-3572				ANDONIOU CE, 1994, IN PRESS EMBO J; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P361; DONOVAN JA, 1993, J AM SOC NEPHROL, V4, P976; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; EGERTON M, 1992, J IMMUNOL, V149, P1847; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARVEL J, 1991, EUR J IMMUNOL, V21, P195, DOI 10.1002/eji.1830210129; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	35	305	310	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22921	22924						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083187				2022-12-25	WOS:A1994PQ16400003
J	JONES, KC; MANN, KG				JONES, KC; MANN, KG			A MODEL FOR THE TISSUE FACTOR PATHWAY TO THROMBIN .2. A MATHEMATICAL SIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; FACTOR-VIII; EXTRINSIC PATHWAY; FACTOR-IX; PHOSPHOLIPID-VESICLES; CATALYZED ACTIVATION; BLOOD-COAGULATION; FACTOR-XA; PROTHROMBINASE; KINETICS	A mathematical simulation of the tissue factor pathway to the generation of thrombin has been developed using a combination of empirical, estimated, and deduced rate constants for reactions involving the activation of factor IX X, V, and VIII, in the formation of thrombin, as well as rate constants for the assembly of the coagulation enzyme complexes which involve factor VIIIa-factor IXa (intrinsic tenase) and factor Va-Xa (prothrombinase) assembled on phospholipid membrane. Differential equations describing the fate of each species in the reaction were developed and solved using an interactive procedure based upon the Runge-Kutta technique. In addition to the theoretical considerations involving the reactions of the tissue factor pathway, a physical constraint associated with the stability of the factor VIIIa-factor IXa complex has been incorporated into the model based upon the empirical observations associated with the stability of this complex. The model system provides a realistic accounting of the fates of each of the proteins in the coagulation reaction through a range of initiator (factor VIIa-tissue factor) concentrations ranging from 5 pM to 5 nM. The model is responsive to alterations in the concentrations of factor VIII, factor V, and their respective activated species, factor VIIIa and factor Va, and overall provides a reasonable approximation of empirical data. The computer model permits the assessment of the reaction over a broad range of conditions and provides a useful tool for the develop ment and management of reaction studies.	UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIGGS R, 1961, THROMB DIATH HAEMOST, V6, P1; BOYCE WE, 1969, ELEMENTARY DIFFERENT, P345; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FASS DN, 1982, BLOOD, V59, P594; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; JESTY J, 1979, J BIOL CHEM, V254, P2337; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LEWIS SD, 1985, J BIOL CHEM, V260, P192; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; MANN KG, 1990, BLOOD, V76, P1; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OWEN CA, 1955, ARCH INTERN MED, V95, P194, DOI 10.1001/archinte.1955.00250080016003; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; ZUR M, 1980, J BIOL CHEM, V255, P5703	26	159	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23367	23373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083242				2022-12-25	WOS:A1994PQ16400070
J	MARIYAMA, M; LEINONEN, A; MOCHIZUKI, T; TRYGGVASON, K; REEDERS, ST				MARIYAMA, M; LEINONEN, A; MOCHIZUKI, T; TRYGGVASON, K; REEDERS, ST			COMPLETE PRIMARY STRUCTURE OF THE HUMAN ALPHA-3(IV) COLLAGEN CHAIN - COEXPRESSION OF THE ALPHA-3(IV) AND ALPHA-4(IV) COLLAGEN CHAINS IN HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; ALPORT SYNDROME; GOODPASTURE ANTIGEN; BIDIRECTIONAL PROMOTER; GENE; IDENTIFICATION; LOCALIZATION; SEQUENCE; ALPHA-5(IV)	We report the entire primary structure of the human alpha 3(IV) collagen chain determined from cDNA clones and polymerase chain reaction-amplified DNAs. The deduced amino acid sequence demonstrates that the complete translation product consists of 1670 amino acid residues and the mature alpha 3(IV) chain contains 1642 residues with a corresponding calculated molecular mass of 161,753. The full-length translated polypeptide has a signal peptide of 28 amino acids, a 1410-residue collagenous domain starting with a 14-residue noncollagenous sequence, and a 232-residue NC1 domain. There are 23 noncollagenous interruptions in the Gly-X-Y repeat sequence of the collagenous domain. The major transcription start site of the alpha 3(IV) chain gene was also determined from genomic DNA by primer extension and S1 nuclease protection assays. Northern analysis revealed coexpression of the alpha 3(IV) and alpha 4(IV) chains in tissues where expression was observed such as in kidney, muscle, and lung.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06536; UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND	Yale University; Yale University; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	MARIYAMA, M (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.							ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BERNAL D, 1993, J BIOL CHEM, V268, P12090; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; FENG LL, 1994, J BIOL CHEM, V269, P2342; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MOCHIZUKI T, 1994, IN PRESS NATURE GENE; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; OOHASHI T, 1994, J BIOL CHEM, V269, P7620; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; QUINONES S, 1992, J BIOL CHEM, V267, P19780; REDDY GK, 1993, BIOCHIM BIOPHYS ACTA, V1157, P241, DOI 10.1016/0304-4165(93)90106-I; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; SAUS J, 1988, J BIOL CHEM, V263, P13374; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	35	95	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23013	23017						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083201				2022-12-25	WOS:A1994PQ16400020
J	RAY, BK; GAO, X; RAY, A				RAY, BK; GAO, X; RAY, A			EXPRESSION AND STRUCTURAL-ANALYSIS OF A NOVEL HIGHLY INDUCIBLE GENE ENCODING ALPHA(1)-ANTITRYPSIN IN RABBIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; HUMAN ALPHA-1-PROTEINASE INHIBITOR; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; INVITRO SUPPRESSION; REPLACEMENT THERAPY; NUCLEOTIDE-SEQUENCE; REACTIVE SITE; DEFICIENCY; ELASTASE	alpha(1)-Antitrypsin is a major plasma proteinase inhibitor whose primary function is to control the proteolytic activity of neutrophil elastase that hydrolyzes structural proteins. This protein, in rabbit is expressed as three isoforms designated as F, S-1, and S-2. An inducible form of this protein has been cloned from an acute-phase cDNA library of rabbit liver. Structural study has revealed that the cloned cDNA is the S-2 isoform previously identified by partial peptide sequence analysis. The amino acid sequence of the reactive center of the S-2 form is not conserved and thus can be categorized as of unorthodox type. mRNA analysis has indicated that the transcription of the S-2 isoform which is normally present at a very low concentration increases more than 100-fold under inflammatory conditions while the expression of the F and S-1 isoforms changes about 1.5-fold under similar conditions. The S-2 isoform is biologically active and capable of inhibiting both elastase and chymotrypsin. The high level of induction of this active isoform of alpha(1)-antitrypsin under inflammatory conditions and its apparent resistance to oxidation-mediated inactivation, common to the orthodox forms of alpha(1)-antitrypsin, make the S-2 isoform suitable for gene therapy in diseases associated with alpha(1)-antitrypsin deficiency.	UNIV MISSOURI, DEPT VET MICROBIOL, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ARONSEN KF, 1972, SCAND J CLIN LAB INV, V29, P127, DOI 10.3109/00365517209102760; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; Birk Y, 1976, Methods Enzymol, V45, P716; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CARP H, 1978, AM REV RESPIR DIS, V118, P617; CARP H, 1979, J CLIN INVEST, V63, P793, DOI 10.1172/JCI109364; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHAO S, 1990, BIOCHEMISTRY-US, V29, P323, DOI 10.1021/bi00454a004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; DICKSON I, 1974, CLIN CHIM ACTA, V54, P381, DOI 10.1016/0009-8981(74)90257-5; FAGERHOL MK, 1978, SER HAEMATOL, V1, P153; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GADEK JE, 1981, J CLIN INVEST, V68, P1158, DOI 10.1172/JCI110360; GARVER RI, 1987, SCIENCE, V237, P762, DOI 10.1126/science.3497452; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KUEPPERS F, 1978, GENETIC DETERMINANTS, P23; Laurell C., 1975, PLASMA PROTEINS, P229; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; NUKIWA T, 1987, J BIOL CHEM, V262, P11999; OLSEN GN, 1975, J CLIN INVEST, V55, P427, DOI 10.1172/JCI107947; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; RAY BK, 1991, BIOCHEM BIOPH RES CO, V178, P507, DOI 10.1016/0006-291X(91)90136-U; RAY BK, 1993, EUR J BIOCHEM, V216, P127, DOI 10.1111/j.1432-1033.1993.tb18124.x; RAY BK, 1991, NUCLEIC ACIDS RES, V19, P4559, DOI 10.1093/nar/19.16.4559; RAY BK, 1991, BIOCHEM BIOPH RES CO, V178, P68, DOI 10.1016/0006-291X(91)91780-G; SAITO A, 1990, J BIOCHEM, V108, P80, DOI 10.1093/oxfordjournals.jbchem.a123167; SAITO A, 1991, J BIOCHEM, V109, P158, DOI 10.1093/oxfordjournals.jbchem.a123338; SAITO A, 1993, J BIOCHEM-TOKYO, V113, P456, DOI 10.1093/oxfordjournals.jbchem.a124066; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; TAKAHARA H, 1982, J BIOL CHEM, V257, P2438; TAKAHARA H, 1983, J BIOCHEM, V93, P1411, DOI 10.1093/oxfordjournals.jbchem.a134276; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	45	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22080	22086						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071331				2022-12-25	WOS:A1994PE09800026
J	SHAEFFER, JR				SHAEFFER, JR			MONOUBIQUITINATED ALPHA-GLOBIN IS AN INTERMEDIATE IN THE ATP-DEPENDENT PROTEOLYSIS OF ALPHA-GLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN SYSTEM; PROTEINS; CHAINS; DEGRADATION; PATHWAY; RETICULOCYTES; PURIFICATION; RECOGNITION; ENZYME	A dialyzed whole human reticulocyte (beta-thalassemic) lysate was incubated with human I-125-alpha globin at 37 degrees C for 15 min in a medium supporting proteolysis with ATP and added ubiquitin (Ub). Analysis of this reaction mixture by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that similar to 0.5% of the initial I-125-alpha globin substrate radioactivity (I-125 cpm) was in the conjugate (Ub(1)-alpha) of one Ub monomer with one I-125-alpha globin monomer and substantially less in the Ub(2)-alpha conjugate. When the reaction mixture contained 0.5 mu M ubiquitin aldehyde (Ubal) to inhibit endogenous isopeptidases, there was a 7-9-fold increase in the Ub(1)-alpha and Ub(2)-alpha conjugates and an appearance of higher molecular weight species including polyubiquitinated I-125-alpha globin (Ub(>10)-alpha). Purified fractions of Ub(1)-alpha, Ub(2)-alpha, Ub(3,4)-alpha, and Ub(>10)-alpha conjugates were isolated by preparative SDS PAGE, dialyzed and treated with triethylamine to remove SDS, and dissolved in 10 mM HCOO-(Na+), pH 4.0. Incubation of each of the conjugate fractions with Ubal-treated lysate in a proteolysis reaction mixture showed a progressive increase in the initial rate of degradation (conversion to acid-soluble I-125 cpm) with increase in molar amount of Ub from similar to 3 times that of the unconjugated I-125-alpha globin precursor for Ub(1)-alpha to similar to 6 times for Ub(>10)-alpha. Analytical SDS-PAGE of the Ub(1)-alpha mixture also showed a rapid conversion to higher M(r) conjugates. These results suggest that monoubiquitinated alpha globin, in addition to higher M(r) conjugates, is an intermediate in the ATP-dependent proteolysis of alpha globin. The finding that addition of Ubal enhances the amount of these conjugates suggests that isopeptidase activity contributes to the poor turnover of hemoglobin alpha chains observed in intact beta-thalassemic reticulocytes.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	SHAEFFER, JR (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, CTR BLOOD RES, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029379] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29379] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUNN HF, 1986, HEMOGLOBIN MOL GENET, P333; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; GARLICK RL, 1984, BIOCHIM BIOPHYS ACTA, V79, P29; GERACI G, 1969, J BIOL CHEM, V244, P4664; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GREGORI L, 1985, J BIOL CHEM, V260, P5232; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hershko A., 1978, PROTEIN TURNOVER LYS, P149; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1986, J BIOL CHEM, V261, P2391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MATSUI SI, 1982, P NATL ACAD SCI-BIOL, V79, P1535, DOI 10.1073/pnas.79.5.1535; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSE IA, 1988, UBIQUITIN, P148; SHAEFFER JR, 1978, NATURE, V276, P631, DOI 10.1038/276631a0; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILKINSON KD, 1988, UBIQUITIN, P5	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22205	22210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071345				2022-12-25	WOS:A1994PE09800045
J	FONTECILLACAMPS, JC; DELLORENS, R; LEDU, MH; CUCHILLO, CM				FONTECILLACAMPS, JC; DELLORENS, R; LEDU, MH; CUCHILLO, CM			CRYSTAL-STRUCTURE OF RIBONUCLEASE A-CENTER-DOT-D(APTPAPAPG) COMPLEX - DIRECT EVIDENCE FOR EXTENDED SUBSTRATE RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; ACTIVE-SITE; BINDING; RESOLUTION; ANALOG; RNASE; STEP	The crystal structure of the complex between ribonuclease A and d(ApTpApApG) has been solved by x-ray crystallography using the molecular replacement method. The model includes, besides the enzyme, the d(ApTpApA) 5'-segment (A(1)T(2)A(3)A(4)) and 68 solvent molecules. The R-factor for the strongest 87% of the measured data that partially extends to 2.3-Angstrom resolution is 0.207. The A(1) position is well defined; the 5'-O of the deoxyribose establishes a hydrogen bond with a solvent molecule that is, in turn, bonded to the epsilon-amino group of Lys(66). The base (B-0 site) is well ordered; it interacts with a symmetry-related enzyme molecule. In the crystal, the phosphate group at the p(0) site has no direct charge compensation. However, Lys(66) is not too far, and, in solution, it could bind to it. The T-2 (R(1)B(1)p(1)) Site is occupied as in other complex structures, and it is defined by very good electron density. The A(3) Site shows that the adenine moiety interacts with Asn(71) and Gln(69) and that the phosphate at p(2) forms a salt bridge with Lys(7). The most consistent model for the base of A(4) (B-3), both in terms of electron density and stereochemistry, shows that it forms a hydrogen bond with Gln(69) and a g(-)g(-) array with the base at B-2. The stacking of B-2 and B-3 may be a general feature of the binding of polyribonucleotides to ribonuclease A. The side chains of GLn(69), Asn(71), and Glu(111) may thus constitute a malleable binding site capable of establishing various hydrogen bonds depending on the nature of the stacked bases. There is no evidence for the 3' G(5) site in the electron density map.	UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL VICENT VILLAR PALASI, E-08193 BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona	FONTECILLACAMPS, JC (corresponding author), INST BIOL STRUCT, CRISTALLOG & CRISTALLOGENESE PROT LAB, 41 AVE MARTYRS, F-38027 GRENOBLE 1, FRANCE.							ARUS C, 1981, BIOCHIM BIOPHYS ACTA, V660, P117, DOI 10.1016/0005-2744(81)90116-9; AVEY HP, 1967, NATURE, V213, P557, DOI 10.1038/213557a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; Blackburn P, 1982, ENZYMES, VXV, P317; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; FINDLAY D, 1962, BIOCHEM J, V85, P152, DOI 10.1042/bj0850152; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IRIE M, 1986, J BIOCHEM-TOKYO, V100, P1057, DOI 10.1093/oxfordjournals.jbchem.a121785; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; IWAHASHI K, 1981, J BIOCHEM-TOKYO, V90, P1685, DOI 10.1093/oxfordjournals.jbchem.a133644; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; KARTHA G, 1967, NATURE, V213, P862, DOI 10.1038/213862a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MITSUI Y, 1978, BIOCHIM BIOPHYS ACTA, V535, P299, DOI 10.1016/0005-2795(78)90096-X; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; ROBERTS GCK, 1969, P NATL ACAD SCI USA, V62, P1151, DOI 10.1073/pnas.62.4.1151; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SARMA RH, 1980, NUCLEIC ACID GEOMETR, P25; SAUNDERS M, 1957, J AM CHEM SOC, V79, P3289, DOI 10.1021/ja01569a083; SMYTH DG, 1963, J BIOL CHEM, V238, P227; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WODAK SY, 1977, J MOL BIOL, V116, P855, DOI 10.1016/0022-2836(77)90275-3; WYCKOFF HW, 1967, J BIOL CHEM, V242, P3749; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	34	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21526	21531						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063789				2022-12-25	WOS:A1994PK97300024
J	WELHAM, MJ; DURONIO, V; LESLIE, KB; BOWTELL, D; SCHRADER, JW				WELHAM, MJ; DURONIO, V; LESLIE, KB; BOWTELL, D; SCHRADER, JW			MULTIPLE HEMOPOIETINS, WITH THE EXCEPTION OF INTERLEUKIN-4, INDUCE MODIFICATION OF SHC AND MSOS1, BUT NOT THEIR TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION PATHWAYS; RAS P21; REGULATED KINASE-2; INSULIN-RECEPTOR; ADAPTER PROTEIN; EGF RECEPTOR	She, grb2, and Son-of-sevenless (mSos1) proteins are potential upstream regulators of p21(ras). We show that p52(She) and p46(She) comprise a significant portion of two of the major protein substrates phosphorylated on tyrosine in response to interleukin-2 (IL-2), IL-3, granulocyte-macrophage colony stimulating factor (GM-CSF), Steel factor (SLF), and colony stimulating factor-1 (CSF-1). Once tyrosine phosphorylated, p52(She) and p46(She) associated with grb2. However, in contrast to published results with epidermal growth factor, treatment with GMCSF, IL-3, and SLF failed to induce significant biochemically detectable translocation of She, grb2, or mSos1 from the cytosol to the plasma membrane. In addition, we did not observe significant epidermal growth factor-induced translocation of Sos1 to the membrane in Rat-1 cells. Treatment with SLF or IL-3 did increase tyrosine phosphorylation of membrane-localized p52(She), which could then associate with grb2, although the majority of tyrosine-phosphorylated She was located in the cytosol. SLF, IL-3, and phorbol ester induced a decrease in the electrophoretic mobility of mSos1. This occurred with slower kinetics than p21(ras) activation and unlike hemopoietin-induced activation of p21(ras) was partially inhibited by a specific protein kinase C inhibitor. Thus, growth factor-induced modification of mSos1 may represent a downstream event, subsequent to p21(ras) activation. Significantly, IL-4, a cytokine that fails to activate p21(ras), also failed to induce significant tyrosine phosphorylation of She or a shift in mSos1 mobility for the first time correlating these events with the ability of a growth factor to activate p21(ras). Together, these data suggest that the current model for regulation of p21(ras), which proposes a stable association of She-grb2-Sos1 complexes at the plasma membrane, may be an oversimplification.	UNIV MELBOURNE,HOWARD FLOREY INST EXPTL PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; University of Melbourne	WELHAM, MJ (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA.		Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DURONIO V, 1992, J BIOL CHEM, V267, P21856; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HULI J, 1989, J IMMUNOL, V142, P800; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; OKUDA K, 1992, BLOOD, V79, P2880; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEDERGAST AM, 1993, CELL, V75, P175; PELICCI G, 1992, CELL, V70, P94; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAINES MA, 1992, BLOOD, V79, P3350; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	65	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21165	21176						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063737				2022-12-25	WOS:A1994PC40300054
J	BRAMBILLA, R; DRAETTA, G				BRAMBILLA, R; DRAETTA, G			MOLECULAR-CLONING OF PISSLRE, A NOVEL PUTATIVE MEMBER OF THE CDK FAMILY OF PROTEIN SERINE/THREONINE KINASES	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; CELL-DIVISION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GENE CDC2; P34(CDC2); HOMOLOGY; PHOSPHORYLATION; EXPRESSION; SEQUENCE	Several members of the cdk family of protein kinases are involved in the regulation of the eukaryotic cell cycle. Using a PCR-based strategy we have screened different human tumor cell lines for cdk-related cDNAs. One clone isolated from the bladder carcinoma cell line RT112 encodes a novel protein kinase named PISSLRE, based on its predicted sequence at the conserved PSTAIRE motif. PISSLRE showed 50% amino acid identity with the previously isolated p58(KGTA). PISSLRE contained all the structural elements featured by cyclin dependent kinases, including a proline in the PSTAIRE motif, which might be important for cyclin binding. PISSLRE was found expressed as 2.0 kb messenger RNA in a variety of human cell lines. Its expression was not restricted to tumor cells as it was detectable also in normal fibroblasts. In adult tissues, PISSLRE mRNA showed the highest expression in lung, liver and kidney. The broad expression pattern in adult tissues might suggest that PISSLRE could be involved in processes distinct from cell proliferation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Brambilla, Riccardo/A-6082-2010	Brambilla, Riccardo/0000-0003-3569-5706				BEN DY, 1991, EMBO J, V10, P317; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DE BH, 1993, NATURE, V363, P595; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; LAPIDOT LY, 1992, P NATL ACAD SCI USA, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SPURR NK, 1990, DNA SEQUENCE, V1, P48; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	42	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3037	3041						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084611				2022-12-25	WOS:A1994PG82200034
J	SHARP, JD; PICKARD, RT; CHIOU, XG; MANETTA, JV; KOVACEVIC, S; MILLER, JR; VARSHAVSKY, AD; ROBERTS, EF; STRIFLER, BA; BREMS, DN; KRAMER, RM				SHARP, JD; PICKARD, RT; CHIOU, XG; MANETTA, JV; KOVACEVIC, S; MILLER, JR; VARSHAVSKY, AD; ROBERTS, EF; STRIFLER, BA; BREMS, DN; KRAMER, RM			SOCIETY FOR SERINE-228 IS ESSENTIAL FOR CATALYTIC ACTIVITIES OF 85-KDA CYTOSOLIC PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LYSOPHOSPHOLIPASE ACTIVITY; CYSTEINE RESIDUES; ARACHIDONIC-ACID; MECHANISM; BINDING; PROTEIN	The Ca2+-sensitive cytosolic phospholipase A(2) (cPLA(2)) displays both a phospholipase A(2) and a lysophospholipase activity. Numerous hydrolases, including lipases, catalyze the hydrolysis of ester bonds by means of an active site triad of amino acids that includes a serine or a cysteine residue, We have examined whether human cPLA(2) belongs to this class of enzymes by using site-directed mutagenesis. Although chemical inactivation of cPLA(2) by the sulfhydryl reagent N-ethylmaleimide made it appear that cysteine(s) may be essential for catalysis, all 9 cysteine residues of cPLA(2) proved dispensable, allowing near-normal enzyme activity when substituted by alanine. We noted that cPLA(2) contains a 110-amino-acid region with sequence homology to phospholipase B (PLB) from Penicillium notatum. Interestingly, one of the conserved serines of cPLA(2), Ser-228, within this domain aligns with the lipase consensus sequence Gly-X(Leu)-Ser(137)-X(Gly)-Gly of PLB. Replacement of Ser-228 by alanine (or threonine or cysteine) yielded catalytically inactive cPLA(2), even though the native conformation was maintained as determined by CD spectroscopy. Likewise, the lysophospholipase activity was completely abolished by the Ser-228 mutations. In contrast, substitution by alanine of three different serines of cPLA(2) (Ser-195, Ser-215, or Ser-577) that also aligned with the PLB sequence allowed for substantial enzymatic activity of cPLA(2). Our findings provide evidence that 1) Ser-228 participates in the catalytic mechanism of cPLA(2) and that 2) both the phospholipase A(2) and the lysophospholipase activities of cPLA(2) are catalyzed by the same active site residue(s).			SHARP, JD (corresponding author), ELI LILLY & CO, LILLY RES LABS, INDIANAPOLIS, IN 46285 USA.							ABELES RH, 1992, BIOCHEMISTRY-US, P154; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; JAUHIAINEN M, 1986, J BIOL CHEM, V267, P13418; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1993, ADV SEC MESS PHOSPH, V28, P81; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWE ME, 1992, J BIOL CHEM, V267, P17069; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROBERTSON DL, 1994, J BIOL CHEM, V269, P2146; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N	35	113	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23250	23254						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083230				2022-12-25	WOS:A1994PQ16400053
J	LUTHRA, M; RANGANATHAN, D; RANGANATHAN, S; BALASUBRAMANIAN, D				LUTHRA, M; RANGANATHAN, D; RANGANATHAN, S; BALASUBRAMANIAN, D			RACEMIZATION OF TYROSINE IN THE INSOLUBLE PROTEIN-FRACTION OF BRUNESCENT AGING HUMAN LENSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC-ACID RACEMIZATION; CATARACT FORMATION; AMINO-ACIDS; SPECTROSCOPY	With increase in age, proteins of the eye lens undergo covalent modifications associated with interprotein cross-linking, loss of protein solubility, generation of protein-associated pigments, and racemization of some optically active residues. Precipitated protein aggregates localized in the nucleus of brunescent lenses are modified to such an extent that they become resistant to the commonly used methods of extraction by reducing agents or detergents. Thus, little information is available on the types of protein modifications that occur in the nuclear region of the lens. Here we report the simultaneous solubilization and digestion of the entire nuclear pellet of brunescent human cataract lenses into constituent amino acids and their derivatives through protease action at neutral pH. Fractionation of the resulting hydrolyzate by reverse phase chromatography, followed by spectroscopic and biochemical analysis of one of the purified fractions, showed the presence of racemic tyrosine in the amino acid mixture. Racemization of L-amino acid residues in protein chains is associated with the aging process. This is the first report of racemization of tyrosine in any system studied so far.	CTR CELLULAR & MOLEC BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA; CSIR, REG RES LAB, TRIVANDRUM 695019, KERALA, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Institute Interdisciplinary Science & Technology (NIIST)			Luthra-Guptasarma, Manni/A-7558-2011	Luthra-Guptasarma, Manni/0000-0002-2740-887X				ANGLE SR, 1989, J AM CHEM SOC, V111, P1136, DOI 10.1021/ja00185a058; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BADA JL, 1973, P NATL ACAD SCI USA, V70, P1331, DOI 10.1073/pnas.70.5.1331; GARNER WH, 1978, P NATL ACAD SCI USA, V75, P3618, DOI 10.1073/pnas.75.8.3618; GOTTLIEB OR, 1978, PROG CHEM ORG NAT PR, V35, P1; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; KRIAUSAKUL N, 1978, SCIENCE, V201, P1011, DOI 10.1126/science.201.4360.1011; LIGHT A, 1967, METHOD ENZYMOL, V11, P426; MASTERS PM, 1978, P NATL ACAD SCI USA, V75, P1204, DOI 10.1073/pnas.75.3.1204; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; Michaelis L, 1944, J AM CHEM SOC, V66, P1023, DOI 10.1021/ja01234a057; NEUBERGER A, 1948, ADV PROTEIN CHEM, V4, P297, DOI 10.1016/S0065-3233(08)60009-1; NOLL BW, 1974, BIOCHEMISTRY-US, V13, P5164, DOI 10.1021/bi00722a018; NOMOTO M, 1960, J BIOCHEM-TOKYO, V48, P906, DOI 10.1093/oxfordjournals.jbchem.a127244; ORTWERTH BJ, 1992, EXP EYE RES, V55, P777, DOI 10.1016/0014-4835(92)90004-C; Patai S, 1988, CHEM QUINONOID COMPO, V2; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; POUCHERT CJ, 1983, ALDRICH LIBRARY NMR, P254; RAO CM, 1991, BIOCHEM BIOPH RES CO, V176, P1351, DOI 10.1016/0006-291X(91)90435-A; SMITH EL, 1955, J BIOL CHEM, V212, P271; SMITH GG, 1980, SCIENCE, V207, P765, DOI 10.1126/science.207.4432.765; SNYDER EI, 1963, J AM CHEM SOC, V85, P2624, DOI 10.1021/ja00900a023; TANNENBAUM HP, 1975, ANAL CHEM, V47, P49, DOI 10.1021/ac60351a027; TRUSCOTT RJW, 1977, EXP EYE RES, V25, P139, DOI 10.1016/0014-4835(77)90126-9; VAIRAMANI M, 1988, BIOMED ENVIRON MASS, V17, P299, DOI 10.1002/bms.1200170412; VOIGT D, 1978, BIOMED MASS SPECTROM, V5, P44, DOI 10.1002/bms.1200050109; WHITESIDES GM, 1964, J AM CHEM SOC, V86, P2628, DOI 10.1021/ja01067a022	28	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22678	22682						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077220				2022-12-25	WOS:A1994PQ16300036
J	SHIN, JM; KAJIMURA, M; ARGUELLO, JM; KAPLAN, JH; SACHS, G				SHIN, JM; KAJIMURA, M; ARGUELLO, JM; KAPLAN, JH; SACHS, G			BIOCHEMICAL-IDENTIFICATION OF TRANSMEMBRANE SEGMENTS OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SODIUM DODECYL-SULFATE; AMINO-ACID-SEQUENCE; COMPLEMENTARY-DNA; MEMBRANE TOPOLOGY; ATPASE; ORGANIZATION; INHIBITOR; PROTEINS; LOCATION	The transmembrane segments of sarcoplasmic reticulum Ca2+-ATPase were determined by trypsinization of cytoplasmic side out intact sarcoplasmic reticulum vesicles. The membrane portion of tryptic digest comprising the transmembrane fragments, joined by the intravesicular segments, was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis after labeling with fluorescein 5-maleimide in the presence of sodium dodecyl sulfate. In this way, seven fluorescent bands of tryptic fragments below 11 kDa were observed which were derived from 4 pairs of membrane spanning segments and one hydrophobic sequence at the C-terminal end. Two peptides of 10.8 and 10.6 kDa had the identical N-terminal sequence beginning at Glu(826), representing the transmembrane segments M7 and M8 and their connecting loop. A band at 8.1 kDa contained one peptide beginning at Tyr(36) (M1/loop/M2). A 7.7-kDa peptide starting at Leu(253) (M3/loop/M4) and a 7.3-kDa peptide beginning at Ala(752) (M5/loop/M6) were also observed. A band at 6.7 kDa contained two peptides, one beginning at Ser(48) (M1/loop/M2) and another beginning at Tyr(763) (M5/loop/M6). In addition, a 4-kDa peptide beginning at Met(925) was observed. The size of this peptide did not allow for a complete pair of transmembrane segments, but this peptide could have been derived from trypsinolysis between the last pair of membrane spanning segments. These data therefore provide biochemical evidence for at least 8 transmembrane segments and perhaps two more at the C-terminal end of the enzyme.	VET ADM WADSWORTH MED CTR, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, DEPT PHYSIOL & MED, LOS ANGELES, CA 90073 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of California System; University of California Los Angeles; University of Pennsylvania			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297; Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014752, R01DK040615, P30DK041301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40615, DK 41301, DK 14752] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHU A, 1988, METHOD ENZYMOL, V157, P36; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; INESI G, 1980, J BIOL CHEM, V255, P3025; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MEISSNER G, 1971, BIOCHIM BIOPHYS ACTA, V241, P356, DOI 10.1016/0005-2736(71)90036-8; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q	25	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22533	22537						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077201				2022-12-25	WOS:A1994PQ16300016
J	ASTROM, A; PETTERSSON, U; CHAMBON, P; VOORHEES, JJ				ASTROM, A; PETTERSSON, U; CHAMBON, P; VOORHEES, JJ			RETINOIC ACID INDUCTION OF HUMAN CELLULAR RETINOIC ACID-BINDING PROTEIN-II GENE-TRANSCRIPTION IS MEDIATED BY RETINOIC ACID RECEPTOR RETINOID-X RECEPTOR HETERODIMERS BOUND TO ONE FAR UPSTREAM RETINOIC ACID-RESPONSIVE ELEMENT WITH 5-BASE PAIR SPACING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; THYROID-HORMONE; REGULATORY ELEMENTS; MOLECULAR-CLONING; HUMAN SKIN; BETA-GENE; RXR; IDENTIFICATION; PROMOTER; ALPHA	We previously cloned the human cellular retinoic acid-binding protein-II (CRABPII) gene and demonstrated a rapid and transient increase in retinoic acid (RA) dependent transcription in cultured human skin fibroblasts, To determine whether retinoid receptors could regulate CRABPII gene transcription, cotransfection experiments were performed. When RAR alpha was cotransfected in Cos-1 cells with a reporter construct containing -8.0 kilobases of the upstream region, an 18-fold RA induction was obtained. By deletion analysis, a region essential for RA induction located approximately -5.6 kilobases upstream from the human CRABPII gene start site was identified. Sequencing and mutational analysis identified a direct repeat (GGGTCAttggaAGGACA) with 5-base pair spacing (DR-5) that is critical for RA-mediated induction of human CRABPII gene transcription. This is different from the mouse CRABPII gene in which two RAREs (DR-1 and DR-2) are required for full activation. To determine whether RAR and RXR can bind to the human CRABPII RARE, gel retardation assays were performed. In these assays, in vitro translated RAR alpha and RXR alpha were found to bind efficiently as heterodimers in gel retardation assays; weak binding of RAR alpha homodimers was observed. These data demonstrate that the human CRABPII gene is regulated by a far upstream RARE that most efficiently binds RAR-RXR heterodimers.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,ANN ARBOR,MI 48109; FAC MED STRASBOURG,INST CHIM BIOL,CNRS,UNITE BIOL MOLEC 184,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE; FAC MED STRASBOURG,INST CHIM BIOL,INSERM,F-67085 STRASBOURG,FRANCE	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; ASTROM A, 1992, J BIOL CHEM, V267, P25251; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; FOGH K, 1993, ARCH BIOCHEM BIOPHYS, V300, P751, DOI 10.1006/abbi.1993.1104; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPORN MB, 1983, CANCER RES, V43, P3034; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	45	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22334	22339						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071361				2022-12-25	WOS:A1994PE09800062
J	CHOU, KC; ZHANG, CT				CHOU, KC; ZHANG, CT			PREDICTING PROTEIN-FOLDING TYPES BY DISTANCE FUNCTIONS THAT MAKE ALLOWANCES FOR AMINO-ACID INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CLASS; GLOBULAR-PROTEINS	Given the amino acid composition of a protein, how may one predict its folding type? Although around this problem a number of methods have been proposed, none of them has taken into account the correlative effect among different amino acids, and hence the accuracy of prediction could not be improved to the extent that it should have. In view of this, a new method has been developed in which the similarity between two protein molecules is based on the scale of Mahalanobis distance rather than on the ordinary intuitive geometric distances, such as Minkowski's distance and Euclidian distance. By introducing the Mahalanobis distance, the correlative effect among different amino acids can be automatically incorporated. Predictions have been performed for 131 real proteins consisting of alpha, beta, alpha + beta, and alpha/beta proteins. The results indicate that the rates of correct prediction for both alpha and beta proteins are 100%, and those for alpha + beta and alpha/beta are 88.9 and 89.7%, respectively, with an average accuracy of 94,7%. Predictions have also been performed for 10,000 simulated proteins generated by Monte Carlo sampling for each of the above four folding types, yielding an average accuracy of 95.9%. The accuracy thus obtained for the simulated proteins can avoid the bias due to the limited number of testing proteins selected arbitrarily by different investigators and hence can be regarded as an objective accuracy. It is anticipated that a method with such a high objective accuracy should become a reliable tool in predicting the protein folding type and a useful tool for improving the prediction of secondary structure as well.			CHOU, KC (corresponding author), UPJOHN LABS,COMP AIDED DRUG DISCOVERY,7247-267-1,KALAMAZOO,MI 49007, USA.		Chou, Kuo-Chen/A-8340-2009					CHOU KC, 1993, J PROTEIN CHEM, V12, P169, DOI 10.1007/BF01026038; CHOU PY, 1989, PREDICTION PROTEIN S, P549; CHOU PY, 1980, 2 CHEM C N AM CONT; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DEGROOT MH, 1986, PROBABILITY STATISTI, P267; DELEAGE G, 1989, PREDICTION PROTEIN S, P587; DUBCHAK I, 1993, PROTEINS, V16, P79, DOI 10.1002/prot.340160109; KIKUCHI T, 1993, J PROTEIN CHEM, V12, P515, DOI 10.1007/BF01025116; KLEIN P, 1986, BIOCHIM BIOPHYS ACTA, V874, P205, DOI 10.1016/0167-4838(86)90119-6; KLEIN P, 1986, BIOPOLYMERS, V25, P1659, DOI 10.1002/bip.360250909; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; Mahalanobis P.C., 1936, P NAT I SCI INDIA, V2, P49; MAO BY, 1994, PROTEIN ENG, V7, P319, DOI 10.1093/protein/7.3.319; METFESSEL BA, 1993, PROTEIN SCI, V2, P1171, DOI 10.1002/pro.5560020712; MUSKAL SM, 1992, J MOL BIOL, V225, P713, DOI 10.1016/0022-2836(92)90396-2; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; Pillai KCS, 1985, ENCY STATISTICAL SCI, P176; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ZHANG CT, 1992, BIOPHYS J, V63, P1523, DOI 10.1016/S0006-3495(92)81728-9; ZHANG CT, 1992, PROTEIN SCI, V1, P401	20	212	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22014	22020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071322				2022-12-25	WOS:A1994PE09800016
J	LO, SH; AN, Q; BAO, SD; WONG, WK; LIU, Y; JANMEY, PA; HARTWIG, JH; CHEN, LB				LO, SH; AN, Q; BAO, SD; WONG, WK; LIU, Y; JANMEY, PA; HARTWIG, JH; CHEN, LB			MOLECULAR-CLONING OF CHICK CARDIAC-MUSCLE TENSIN - FULL-LENGTH CDNA SEQUENCE, EXPRESSION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENS-TYPE JUNCTIONS; PHOSPHOTYROSINE-CONTAINING PROTEINS; CRK ONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; SMOOTH-MUSCLE; EXTRACELLULAR-MATRIX; ACTIN POLYMERIZATION; ELECTRON-MICROSCOPY; DEPENDENT MANNER	Here we describe the molecular cloning of 7.1-kilobase cDNA encoding chick cardiac muscle tensin. It contains an open reading frame of 1,744 amino acid (aa) residues. Sequence analysis reveals that, in addition to the previously noted SH2 domain (Davis, S., Lu, M. L., Lo, S. H., Lin, S., Butler, J. A., Druker, B. J., Roberts, T. M., An, Q., and Chen, L. B. (1991) Science 252, 712-715), tensin contains virtually all of the known sequence (362 aa) of insertin, an actin-capping protein that allows actin monomer to be ''inserted'' (Schroer, E., and Wegner, A. (1985) Eur. J. Biochem. 153, 515-520). Moreover, tensin shares partial homology with actin (46.7% identity in 30 aa), beta-spectrin's actin-binding consensus (40% identity in 26 aa), BCR (40% identity in 25 aa), catenin alpha (35% identity in 45 aa), synapsin Ia (25.6% identity in 156 aa), IL-3 receptor (20.2% identity in 384 aa), and IL-2/EPO receptors (14% identity in 20 aa). Recombinant full-length tensin, tagged with an influenza-derived epitope, was overexpressed by a baculovirus system and purified to apparent homogeneity. It migrates as a 200-kDa protein in SDS-polyacrylamide gel electrophoresis, similar to the native tensin. The structure of the tensin molecule has been characterized by light scattering, electron microscopy, and gel filtration. Nine monoclonal antibodies recognizing different regions of tensin have been prepared and characterized. The epitope-tagged recombinant tensin gene was subcloned into a pRcCMV vector and transfected into NIH3T3 cells. Immunofluorescence stainings with monoclonal antibodies specific for chick tensin (not cross-reactive with mouse tensin) showed that the expressed protein is indeed localized at focal contacts, as that of native tensin.			LO, SH (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47874] Funding Source: Medline; NIDDK NIH HHS [DK 38452] Funding Source: Medline; NIGMS NIH HHS [GM 38318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOCKHOLT SM, 1992, EXP CELL RES, V203, P39, DOI 10.1016/0014-4827(92)90037-9; BRESNICK AR, 1991, J BIOL CHEM, V266, P12989; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; COSSETTE LJ, 1992, MOL BIOL CELL, V3, pA147; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; EVANS RR, 1984, J BIOL CHEM, V259, P3916; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HARLOW E, 1988, ANTIBODIES LABORATOR; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; OLLO R, 1987, P NATL ACAD SCI USA, V84, P5700, DOI 10.1073/pnas.84.16.5700; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROCCO M, 1983, J BIOL CHEM, V258, P4545; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; RUHNAU K, 1989, J MOL BIOL, V210, P141, DOI 10.1016/0022-2836(89)90296-9; SABE H, 1991, INT IMMUNOL, V3, P1137, DOI 10.1093/intimm/3.11.1137; SCHROER E, 1985, EUR J BIOCHEM, V153, P515, DOI 10.1111/j.1432-1033.1985.tb09332.x; SMALL JV, 1985, EMBO J, V4, P45, DOI 10.1002/j.1460-2075.1985.tb02315.x; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TIABALL JG, 1986, J CELL BIOL, V98, P1961; TOKUYASU KT, 1981, P NATL ACAD SCI-BIOL, V78, P7619, DOI 10.1073/pnas.78.12.7619; TYLER JM, 1980, J CELL BIOL, V85, P489, DOI 10.1083/jcb.85.2.489; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOODS A, 1992, J CELL SCI, V101, P277; [No title captured]	58	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22310	22319						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071358				2022-12-25	WOS:A1994PE09800059
J	LORENZ, B; MULLER, WEG; KULAEV, IS; SCHRODER, HC				LORENZ, B; MULLER, WEG; KULAEV, IS; SCHRODER, HC			PURIFICATION AND CHARACTERIZATION OF AN EXOPOLYPHOSPHATASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE KINASE; ESCHERICHIA-COLI; PROPIONIBACTERIUM-SHERMANII; MECHANISM; PROTEINS; YEAST; VACUOLES; ENZYMES; GENE	An exopolyphosphatase (polyphosphate phosphohydrolase; EC 3.6.1.11) activity that cleaves inorganic polyphosphates to orthophosphate has been purified to apparent homogeneity (>95% pure) from Saccharomyces cerevisiae, The exopolyphosphatase is a monomeric protein with a polypeptide molecular mass of 28 kDa. The enzyme, which can be stabilized in the presence of Triton X-100, has a pH optimum of 7.5 and requires, for maximal activity, Co2+ or Mg2+ ions. In the absence of these ions, the exopolyphosphatase binds to polyphosphate but does not degrade it, allowing affinity purification of the enzyme on a polyphosphate-modified zirconia support. o-Vanadate, Cu2+, and Ca2+ are effective inhibitors of the exopolyphosphatase. The enzyme preferentially hydrolyzes linear polyphosphates in a nonprocessive manner; pyrophosphate as well as cyclic tri- and tetrametaphosphate are degraded only at very low rates, whereas ATP is not split by the exopolyphosphatase. The only product formed by the action of the enzyme is orthophosphate.	UNIV MAINZ,INST PHYSIOL CHEM,D-55099 MAINZ,GERMANY; RUSSIAN ACAD SCI,INST BIOCHEM & PHYSIOL MICROORGANISMS,PUSHCHINO 142292,RUSSIA	Johannes Gutenberg University of Mainz; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences			Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; ANDREEVA N A, 1990, Biokhimiya, V55, P1094; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; ANDREEVA NA, 1990, BIOKHIMIYA, V55, P2286; AVAEVA SM, 1985, USP BIOL KHIM, V26, P42; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BORGLUND E, 1978, UPSALA J MED SCI, V83, P81, DOI 10.3109/03009737809179116; BURTON K, 1951, BIOCHEM J, V48, P458, DOI 10.1042/bj0480458; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; Cooper T., 1981, BIOCH ARBEITSMETHODE; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DIRHEIMER G, 1965, CR HEBD ACAD SCI, V260, P3787; FELTER S, 1973, BIOCHIMIE, V55, P245, DOI 10.1016/S0300-9084(73)80122-1; FELTER S, 1970, B SOC CHIM BIOL, V52, P75; FELTER S, 1970, B SOC CHIM BIOL, V52, P433; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GRIFFIN JB, 1965, J BIOL CHEM, V240, P427; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HEPPEL LA, 1955, METHOD ENZYMOL, V2, P570, DOI 10.1016/S0076-6879(55)02255-6; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KRITSKII MS, 1972, IOKHIMIYA, V37, P983; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; Kulaev IS, 1979, BIOCH INORGANIC POLY; KUNITZ M, 1950, J GEN PHYSIOL, V33, P349, DOI 10.1085/jgp.33.4.349; KUNITZ M., 1940, JOUR GEN PHYSIOL, V24, P15, DOI 10.1085/jgp.24.1.15; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISS E, 1960, BIOCHEM Z, V333, P193; LORENZ B, 1994, ANAL BIOCHEM, V216, P118, DOI 10.1006/abio.1994.1015; MATTENHEIMER H, 1956, HOPPESEYLERS Z PHYSL, V303, P565; MUHAMMED A, 1959, J GEN MICROBIOL, V20, P482, DOI 10.1099/00221287-20-3-482; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; PICK U, 1990, FEBS LETT, V274, P15, DOI 10.1016/0014-5793(90)81318-I; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; ROBINSON NA, 1984, BIOCHEM INT, V8, P757; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; SCHRODER HC, 1986, J BIOL CHEM, V261, P663; SZYMONA M, 1964, BIOCHIM BIOPHYS ACTA, V85, P283, DOI 10.1016/0926-6569(64)90249-4; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WINDER FG, 1957, J GEN MICROBIOL, V17, P573, DOI 10.1099/00221287-17-3-573; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; YOSHIDA A, 1955, J BIOCHEM-TOKYO, V42, P163, DOI 10.1093/oxfordjournals.jbchem.a126518	45	55	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22198	22204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071344				2022-12-25	WOS:A1994PE09800044
J	SCHEFFLER, JE; WAUGH, DS; BEKESI, E; KIEFER, SE; LOSARDO, JE; NERI, A; PRINZO, KM; TSAO, KL; WEGRZYNSKI, B; EMERSON, SD; FRY, DC				SCHEFFLER, JE; WAUGH, DS; BEKESI, E; KIEFER, SE; LOSARDO, JE; NERI, A; PRINZO, KM; TSAO, KL; WEGRZYNSKI, B; EMERSON, SD; FRY, DC			CHARACTERIZATION OF A 78-RESIDUE FRAGMENT OF C-RAF-1 THAT COMPRISES A MINIMAL BINDING DOMAIN FOR THE INTERACTION WITH RAS-GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COMPARATIVE BIOCHEMICAL-PROPERTIES; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; GROWTH-FACTORS; GENE-PRODUCT; RAF-1 KINASE; P21 PROTEIN; ONCOGENIC P21(RAS)	Four overlapping peptide fragments of human c-Raf-1 (residues 55-132, 55-117, 77-132, and 77-117) were expressed in Escherichia coli as carboxyl-terminal extensions of maltose binding protein (MBP). The MBP-Raf fusions were purified by affinity chromatography on amylose resin and tested for binding to Ras GTP indirectly by measuring their ability to inhibit the stimulation of has GTPase activity by GTPase activating protein (GAP120) in vitro. MBP-Raf(55-132) was a potent inhibitor in this assay (50% inhibition at 100 nM concentration), but the other fusion proteins had no measurable effect. The fusion partners were cleaved with Factor Xa protease and separated by gel filtration. The 8960-dalton Raf(55-132) fragment retained full activity as a competitive inhibitor of GAP120. It also blocked Ras-stimulated germinal vesicle breakdown in frog oocytes. Raf(55-132) was further characterized by circular dichroism and nuclear magnetic resonance spectroscopy. The results indicate that this fragment of c-Raf-1 adopts a highly structured, monomeric conformation in solution.	HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT CHEM PHYS, NUTLEY, NJ 07110 USA	Roche Holding	SCHEFFLER, JE (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT ONCOL, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AHN NG, 1991, J BIOL CHEM, V266, P4220; BARANY G, 1980, PEPTIDES ANAL SYNTHE, VZ, P1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEWLEY TA, 1969, BIOCHEMISTRY-US, V8, P4701, DOI 10.1021/bi00840a007; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAYL, 1993, CELL, V73, P611; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CHUNG DL, 1991, BIOCHEM BIOPH RES CO, V181, P1378, DOI 10.1016/0006-291X(91)92091-W; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EGAN SE, 1993, SCIENCE, V365, P781; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FABIAN JR, 1994, IN PRESS P NATL ACAD; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1988, J BIOL CHEM, V263, P11792; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KRENGEL U, 1990, CELL, V62, P529; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MALLER JL, 1980, CURR TOP CELL REGUL, V16, P272; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ORITA S, 1993, J BIOL CHEM, V268, P25542; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUBINFELD B, 1991, INT J PEPT PROT RES, V38, P47; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; STUDIER FW, 1991, METHOD ENZYMOL, V186, P60; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	86	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22340	22346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071362				2022-12-25	WOS:A1994PE09800063
J	MARSTON, NJ; CROOK, T; VOUSDEN, KH				MARSTON, NJ; CROOK, T; VOUSDEN, KH			INTERACTION OF P53 WITH MDM2 IS INDEPENDENT OF E6 AND DOES NOT MEDIATE WILD-TYPE TRANSFORMATION SUPPRESSOR FUNCTION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CASEIN KINASE-II; MUTANT P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; MONOCLONAL-ANTIBODIES; TUMOR SUPPRESSION; GENE-EXPRESSION; CELL-GROWTH	Using a new series of p53 mutants targeting the conserved regions we have analysed the relationship of various activities of the protein. Mdm-2 and human papillomavirus (HPV) E6, two proteins which interact with and abrogate p53 function, were shown to bind independently. Deletion of the conserved regions of the protein in which most of the naturally occurring mutations are found (boxes II-V) abrogated transcriptional activity and the ability to interact with E6, supporting the importance of this DNA binding domain to these activities. Nevertheless, these mutants retained the ability to interact with mdm2. One mutant, deleted of all the C-terminal sequences, showed loss of mdm2 binding, E6 binding and transcriptional activity. More subtle mutations within the C-terminus of the protein, including alterations of the cdc2 and CKII phosphorylation sites, had no effect on the transcriptional trans-activation, mdm-2 or E6 binding functions, indicating that phosphorylation of these sites is not essential for these activities. Deletion of conserved box I sequences abolished the interaction with mdm-2 without loss of transcriptional activation or transformation suppressor activity, suggesting that mdm-2 is not a downstream effector of p53 function.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, IN PRESS J VIROL; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P81; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1993, MOL CELL BIOL, V12, P2789; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P275; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	90	71	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058335				2022-12-25	WOS:A1994PC05400032
J	VANDERKUUR, JA; WANG, XY; ZHANG, LY; CAMPBELL, GS; ALLEVATO, G; BILLESTRUP, N; NORSTED, G; CARTERSU, C				VANDERKUUR, JA; WANG, XY; ZHANG, LY; CAMPBELL, GS; ALLEVATO, G; BILLESTRUP, N; NORSTED, G; CARTERSU, C			DOMAINS OF THE GROWTH-HORMONE RECEPTOR REQUIRED FOR ASSOCIATION AND ACTIVATION OF JAK2 TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR RECEPTOR; RAT INSULINOMA CELLS; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; 3T3-F442A FIBROBLASTS; MOLECULAR-CLONING; MESSENGER-RNA; PHOSPHORYLATION; EXPRESSION	Growth hormone (GH) has recently been shown to activate the GH receptor (GHR)-associated tyrosine kinase JAK2. In the present study, regions of the GHR required for JAK2 association with GHR were identified. GH-dependent JAK2 association with GHR was detected in Chinese hamster ovary (CHO) cells expressing wild-type GHR (GHR(1-638)) or GHR truncated at amino acid 454 (GHR(1-454)) or 380 (GHR(1-380)). JAK2 did not associate with GHR in cells expressing GHR truncated at amino acid 294 (GHR(1-294)) or when amino acids 297-311 containing a proline-rich motif were deleted (GHR(Delta P)) or prolines 300, 301, 303, and 305 in the proline-rich motif were mutated to alanines (GHR(4P-->A)). Cross-linking I-125-human GH to GHR demonstrated that GHR mutants migrated with the appropriate molecular weight, with the exception of GHR(4P-->A) which migrated as a protein similar in size to GHR(1-294). In studies performed in CHO and RIN-5AH cells, the ability of JAK2 to associate with the mutated GHR was found to correlate with GH-dependent activation of JAK2, tyrosyl phosphorylation of GHR (in the case of GHR(1-638) and GHR(1-454)), and the ability of the GHR to copurify with tyrosine kinase activity. In CHO cells expressing mutated GHR, GH dependent tyrosyl phosphorylation of cellular proteins (p121, p97, p42, and p39) was dependent on the ability to activate JAK2. No proteins showed increased tyrosyl phosphorylation in CHO cells expressing GHR(1-294) GHR(4P-->A) or GHR(Delta P). Deletion of the C-terminal half (amino acids 455-638) of the GHR ablated GH-dependent tyrosyl phosphorylation of p97. Taken together, these results provide strong evidence that the N-terminal quarter of the cytoplasmic domain of GHR and within this region, the proline-rich motif, is required for association of JAK2 with GHR and GH-dependent activation of JAK2, and that tyrosines in the N-terminal half of the cytoplasmic domain of the GHR are phosphorylated by JAK2. The finding that a specific interaction with the C-terminal half of GHR appears to be necessary for p97 phosphorylation indicates that while JAK2 activation may be necessary far a full biological response to GH, it appears not to be sufficient.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN	University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute; Karolinska Institutet				Billestrup, Nils/0000-0002-4968-8067	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, T32DK007245] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NIDDK NIH HHS [R01-DK34171, 5T32-DK07245, R01 DK034171] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BURNSIDE J, 1991, ENDOCRINOLOGY, V128, P3183, DOI 10.1210/endo-128-6-3183; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1994, IN PRESS P NATL ACAD; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOLLER C, 1992, THESIS KAROLINSKA I; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	162	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21709	21717						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063815				2022-12-25	WOS:A1994PK97300051
J	BRESNICK, EH; FELSENFELD, G				BRESNICK, EH; FELSENFELD, G			THE LEUCINE-ZIPPER IS NECESSARY FOR STABILIZING A DIMER OF THE HELIX-LOOP-HELIX TRANSCRIPTION FACTOR USF BUT NOT FOR MAINTENANCE OF AN ELONGATED CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; MAJOR LATE PROMOTER; DOMINANT CONTROL REGION; DNA-BINDING; UPSTREAM ELEMENT; TRANSGENIC MICE; GLOBIN GENE; PROTEINS; DOMAIN; OLIGOMERIZATION	The basic helix-loop-helix transcription factor USF43 binds to E box motifs on certain promoters and enhancers, as well as the beta-globin locus control region. We have used gel filtration chromatography, velocity centrifugation, and chemical cross-linking methods to investigate the stoichiometry and shape of USF43 in solution and when bound to DNA. USF43 has a very large Stokes' radius (44 Angstrom) and a high frictional ratio (1.64), consistent with an asymmetric elongated oligomer. Under a variety of conditions, the only detectible USF43 species in solution and bound to DNA is a dimer. The carboxyl-terminal leucine zipper is absolutely essential for a stable dimer but not for the elongated conformation. We used a protease footprinting assay to demonstrate that, when USF43 binds to DNA, a approximate to 15-kDa USF43 domain becomes resistant to cleavage with trypsin. This domain includes sequences that are not expected to interact with the DNA helix, suggesting that trypsin cleavage sites are masked by a conformational change. Our results show that the oligomerization state of USF43 does not change upon binding to DNA, and the helix-loop-helix oligomerization motif of USF43 is not itself sufficient to form a high affinity dimerization interface.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EISENBERG H, 1989, LANDOLTBORNSTEIN, P257; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; FARMER K, 1992, J BIOL CHEM, V267, P5631; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIEGEL LM, 1965, BIOCHIM BIOPHYS ACTA, V45, P346; SOBER HA, 1970, HDB BIOCH, pC10; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VINSON CR, 1992, NEW BIOL, V4, P396; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109; 1984, GEL FILTRATION THEOR, P25	39	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21110	21116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063730				2022-12-25	WOS:A1994PC40300046
J	GOPALAKRISHNAN, V; BENKOVIC, SJ				GOPALAKRISHNAN, V; BENKOVIC, SJ			SPATIAL RELATIONSHIP BETWEEN POLYMERASE AND EXONUCLEASE ACTIVE-SITES OF PHAGE-T4 DNA-POLYMERASE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; MUTATOR MUTANTS; BACTERIOPHAGE-T4; TEMPLATE; FRAGMENT	The spatial relationship between the polymerase and exonuclease active sites of bacteriophage T4 DNA polymerase enzyme has been examined using a bulky biotin-streptavidin block at a specified position in an oligonucleotide (Fig. 1). The idea was to monitor the closest distance of approach of the T4 enzyme before being blocked by the bulky biotin-streptavidin complex while performing either of its activities. The results indicated a distance of 4-5 nucleotides between the biotin-streptavidin probe and the exonuclease site and a distance requirement of at least 7 nucleotides between the bulky probe and the 3'-primer terminus for efficient polymerization by the T4 enzyme. The difference in the two distances suggested a separation of 2-3 nucleotides between the two active sites of the T4 enzyme.	PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM13306-23] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1986, J MOL BIOL, V189, P261, DOI 10.1016/0022-2836(86)90508-5; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STEITZ TA, 1987, PROTEIN ENG, P227; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	15	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21123	21126						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063732				2022-12-25	WOS:A1994PC40300048
J	HUANG, XF; ARVAN, P				HUANG, XF; ARVAN, P			FORMATION OF THE INSULIN-CONTAINING SECRETORY GRANULE CORE OCCURS WITHIN IMMATURE BETA-GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; BREFELDIN-A; HUMAN PROINSULIN; ATT20 CELLS; ENDOPROTEOLYTIC CLEAVAGE; SELECTIVE-INHIBITION; PERMEABILIZED CELLS; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; ATT-20 CELLS	Contrasting with earlier immunocytochemical studies of pancreatic islet beta-cells, several recent reports describe polypeptide prohormone processing within the trans-Golgi network (TGN). Such a concern is relevant to beta-cells, wherein cleavage of the connecting polypeptide from soluble proinsulin triggers insulin condensation. Two distinct models describe how hormone condensation might enhance efficiency of storage in secretory granules: sorting for entry into granules would be favored if insulin condensed in the TGN; sorting by retention within granules would be favored if insulin condensed after proinsulin entry into immature granules (IGs). To distinguish these possibilities, we utilized Brefeldin A (BFA) to prevent protein export from the TGN. BFA did not inhibit the activity of proinsulin-processing enzymes, nor did it alter the behavior of the TGN by fractionation on Percoll density gradients. Moreover, BFA did not inhibit constitutive-like protein traffic originating from IGs. However, BFA blocked proinsulin transfer from the TGN to IGs. As long as proinsulin resided in the TGN, conversion to insulin did not occur. Washout of BFA restored granule formation and subsequent insulin production, These data provide biochemical confirmation that the generation of insulin, which is crucial for its passive condensation, occurs within IGs rather than in the TGN.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215	University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK48280, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P89443; CHANAT E, 1991, J CELL BIOL, V115, P1491; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FRANK BH, 1968, BIOCHEM BIOPH RES CO, V32, P155, DOI 10.1016/0006-291X(68)90362-8; GRANT PT, 1972, BIOCHEM J, V126, P433, DOI 10.1042/bj1260433; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IRMINGER JC, 1994, J BIOL CHEM, V269, P1756; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MOORE HPH, 1989, SECRETION ITS CONTRO, P189; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1991, CELL, V64, P1183; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STEINER DF, 1987, P NATL ACAD SCI USA, V84, P6184, DOI 10.1073/pnas.84.17.6184; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1972, ENDOCRINE PANCREAS, P175; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; WONG JG, 1991, AM J PHYSIOL, V261, pC1033, DOI 10.1152/ajpcell.1991.261.6.C1033; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	64	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20838	20844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063699				2022-12-25	WOS:A1994PC40300008
J	NAGASE, H; FIELDS, CG; FIELDS, GB				NAGASE, H; FIELDS, CG; FIELDS, GB			DESIGN AND CHARACTERIZATION OF A FLUOROGENIC SUBSTRATE SELECTIVELY HYDROLYZED BY STROMELYSIN-1 (MATRIX METALLOPROTEINASE-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; CLEAVAGE SITE; SEQUENCE SPECIFICITIES; VERTEBRATE COLLAGENASE; ENDOGENOUS ACTIVATOR; SECONDARY STRUCTURE; HUMAN FIBROBLAST; HUMAN AGGRECAN; PROCOLLAGENASE; PURIFICATION	Members of the matrix metalloproteinase (MMP) family have been implicated in disease states such as arthritis, periodontal disease, and tumor cell invasion and metastasis. Stromelysin 1 (MMP-3) has a broad substrate specificity and participates in the activation of several MMP zymogens. We examined known sequences of MMP-3 cleavage sites in natural peptides and proteins and compared sequence specificities of MMP-3 and interstitial collagenase (MMP-1) in order to design fluorogenic substrates that (i) would be hydrolyzed rapidly by MMP-3, (ii) would discriminate between MMP-3 and MMP-1, and (iii) could be monitored continuously without interference from MMP amino acid residues. Designed substrates were then screened for activity toward MMP-1, gelatinase A (MMP-2), MMP-3, and gelatinase B (MMP-9). The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (K-cat/K-m similar to 11,000 S-1 M(-1)) MMP-1 had 25% of the activity of MMP-3 toward NFF-1. The second substrate, NEFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp- Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (k(cat)/K-m = 59,400 s(-1) M(-1)) than MMP-1. Unfortunately, NFF-2 showed little discrimination between MMP-3, MMP-2 (k(cat)/K-m = 54,000 s(-1) M(-1)), and MMP-9 (k(cat)/K-m = 55,300 s(-1) M(-1)). The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (K-cat/K-m = 218,000 s(-1) M(-1)) and very slowly by MMP-9 (k(cat)/K-m = 10,100 s(-1) M(-1)), but there was no significant hydrolysis by MMP-1 and MMP-2. NFF-3 is the first documented synthetic substrate hydrolyzed by only certain members of the MMP family and thus has important application for the discrimination of MMP-3 activity from that of other MMPs. Although NFF-3 was designed by assuming that substrate subsites were independent and hence free energy changes derived from single mutation experiments were additive, we found discrepancies between predicted and experimental k(cat)/K-m values, one on the order of 2000-5000. Thus, the design of additional discriminatory MMP substrates may require approaches other than assuming additive free energy changes, such as screening synthetic libraries and consideration of secondary and tertiary structures of substrates and the enzyme.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA; UNIV MINNESOTA, CTR BIOMED ENGN, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Kansas; University of Kansas Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIAMS NIH HHS [AR 40994, AR 39189] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189, R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZZO W, 1986, J BIOL CHEM, V261, P5434; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BICKETT DM, 1993, ANAL BIOCHEM, V212, P58, DOI 10.1006/abio.1993.1291; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FIELDS C G, 1991, Peptide Research, V4, P95; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FIELDS CG, 1992, ANAL BIOCHEM, V203, P245, DOI 10.1016/0003-2697(92)90309-U; FIELDS CG, 1993, PEPTIDES 1992, P447; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FIELDS GB, 1988, APPLICATION SOLID PH, P136; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FURCHT LT, 1994, LAB INVEST, V70, P781; GEOGHEGAN KF, 1993, BIOCONJUGATE CHEM, V4, P537, DOI 10.1021/bc00024a017; GOLDBERG GI, 1990, ANN NY ACAD SCI, V580, P375, DOI 10.1111/j.1749-6632.1990.tb17945.x; GOOLEY PR, 1993, BIOCHEMISTRY-US, V32, P13098, DOI 10.1021/bi00211a020; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; HASSELL AM, 1994, J MOL BIOL, V236, P1410, DOI 10.1016/0022-2836(94)90068-X; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NETZELARNETT S, 1991, J BIOL CHEM, V266, P21326; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; POE M, 1992, ARCH BIOCHEM BIOPHYS, V298, P757, DOI 10.1016/0003-9861(92)90477-E; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; RUBEN GC, 1988, J BIOL CHEM, V263, P2861; STACK MS, 1989, J BIOL CHEM, V264, P4277; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P13109, DOI 10.1021/bi00211a021; VATER CA, 1983, J BIOL CHEM, V258, P9374; WEINGARTEN H, 1985, BIOCHEMISTRY-US, V24, P6730, DOI 10.1021/bi00344a064; WEINGARTEN H, 1986, BIOCHEM BIOPH RES CO, V139, P1184, DOI 10.1016/S0006-291X(86)80302-3; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU JJ, 1991, J BIOL CHEM, V266, P5625	60	224	253	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20952	20957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063713				2022-12-25	WOS:A1994PC40300024
J	WALSH, JP; SUEN, R; LEMAITRE, RN; GLOMSET, JA				WALSH, JP; SUEN, R; LEMAITRE, RN; GLOMSET, JA			ARACHIDONOYL-DIACYLGLYCEROL KINASE FROM BOVINE TESTIS - PURIFICATION AND PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; DIGLYCERIDE KINASE; PROTEIN-KINASE; ESCHERICHIA-COLI; PHOSPHOLIPASE-C; HUMAN-PLATELETS; INDUCED TRANSLOCATION; RECEPTOR ACTIVATION; BICINCHONINIC ACID; PHASE-SEPARATION	Previous work in our laboratory demonstrated the existence of a membrane-bound diacylglycerol kinase highly selective for diacylglycerols containing arachidonate as the sn-2 fatty acyl moiety (MacDonald, M. L., Mack K. F., Richardson, C. N., and Glomset, J. A. (1988) J. Biol. Chem. 263, 1575-1583). We now report the purification of arachidonoyl-diacylglycerol kinase 34,400-fold to apparent homogeneity from bovine testis. High concentrations of both salt and detergent were required to extract the enzyme from membranes and stabilize its activity, suggesting that in. vivo the enzyme is part of a complex with other membrane or cytoskeletal proteins. Arachidonoyl-diacylglycerol kinase had an apparent M(r) of 58,000 both on SDS-polyacrylamide gels and by size exclusion chromatography. The enzyme appeared to be an integral membrane protein. In a mixed micellar assay, arachidonoyl-diacylglycerol kinase followed surface dilution kinetics with respect to diacylglycerol. The purified enzyme retained the arachidonate selectivity observed previously in membranes. Kinetic analyses indicated a K-m for sn-1-stearoyl-2-arachidonoylglycerol of 2.4 mol %, as compared to 43 mol % for sn-1-palmitoyl-2-oleoylglycerol. Calcium, an activator of some other diacylglycerol kinases, had no apparent effect on the arachidonate-specific enzyme. Guanosine triphosphate could effectively substitute for ATP as the phosphoryl donor and Mg2+ could be replaced by Mn2+ or Ca2+. Phosphatidylserine and, to a lesser extent, phosphatidylinositol inhibited the purified enzyme. Phosphatidylcholine and phosphatidylethanolamine had only small effects.	UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCRR NIH HHS [RR00166] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BECHER P, 1967, NONIONIC SURFACTANTS, P468; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP HH, 1980, LIPIDS, V15, P285, DOI 10.1007/BF02533542; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; BROWN W, 1989, J PHYS CHEM-US, V93, P2512, DOI 10.1021/j100343a055; CALL FL, 1973, J LIPID RES, V14, P466; CHEN Q, 1993, J NEUROCHEM, V60, P1212, DOI 10.1111/j.1471-4159.1993.tb03279.x; DALEO GR, 1976, EUR J BIOCHEM, V68, P339, DOI 10.1111/j.1432-1033.1976.tb10820.x; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; FORD DA, 1990, J BIOL CHEM, V265, P12280; GANONG BR, 1991, ANAL BIOCHEM, V193, P35, DOI 10.1016/0003-2697(91)90039-V; GAREWAL HS, 1973, ANAL BIOCHEM, V54, P319, DOI 10.1016/0003-2697(73)90359-X; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HEECHEONG M, 1985, BIOCHIM BIOPHYS ACTA, V833, P59, DOI 10.1016/0005-2760(85)90253-X; Holub B J, 1978, Adv Lipid Res, V16, P1; HOLUB BJ, 1978, J NEUROCHEM, V31, P903, DOI 10.1111/j.1471-4159.1978.tb00126.x; HOLUB BJ, 1979, LIPIDS, V14, P308; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; ITABE H, 1992, J BIOL CHEM, V267, P15319; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; KANOH H, 1978, EUR J BIOCHEM, V85, P225, DOI 10.1111/j.1432-1033.1978.tb12230.x; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KATO M, 1990, J BIOL CHEM, V265, P794; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1971, BIOCHEM J, V122, P171, DOI 10.1042/bj1220171; LEE C, 1991, J BIOL CHEM, V266, P22837; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIN CH, 1986, LIPIDS, V21, P206, DOI 10.1007/BF02534823; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MILDVAN AS, 1981, PHILOS T ROY SOC B, V293, P65, DOI 10.1098/rstb.1981.0061; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SEVERSON DL, 1986, BIOCHEM CELL BIOL, V64, P976, DOI 10.1139/o86-130; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; SHIM YH, 1989, BIOCHEM CELL BIOL, V67, P233, DOI 10.1139/o89-035; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SOLING HD, 1989, J BIOL CHEM, V264, P10643; STATHOPOULOS VM, 1990, BIOCHEM J, V272, P569, DOI 10.1042/bj2720569; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; TANFORD C, 1977, J PHYS CHEM-US, V81, P1555, DOI 10.1021/j100531a007; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YAMADA K, 1988, BIOCHEM J, V255, P601; [No title captured]	73	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21155	21164						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063736				2022-12-25	WOS:A1994PC40300053
J	SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA				SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA			ONCOGENIC ACTIVATION OF HUMAN R-RAS BY POINT MUTATIONS ANALOGOUS TO THOSE OF PROTOTYPE H-RAS ONCOGENES	ONCOGENE			English	Article							GROWTH-FACTOR; NIH3T3 FIBROBLASTS; GENE-PRODUCT; KINASE; RAF-1; TRANSFORMATION; EXPRESSION; CELLS; PROTEINS	R-ras, K-rev-1/rap and TC21, are more closely related to prototype H-vas than any other known members of the vas superfamily. We recently isolated a mutationally activated TC21 oncogene from a human ovarian carcinoma cell line. Based upon these observations, we sought to re-examine the transforming potential of R-ras, which was reported earlier to lack transforming capacity. Mutations were introduced into the R-uas gene at codons 38 or 87, analogous to positions 12 and 61, respectively, responsible for H-ras oncogene activation. While both mutations resulted in acquisition of R-ras transforming capacity for NIH3T3 cells the position 61 was shown to be more active. Transfectants expressing either R-ras mutant formed colonies in soft agar and were tumorigenic in vivo. As has been reported for H-ras, R-ras cooperated with c-raf-1 in inducing transformation of NIH3T3 cells. These results imply interactions in R-ras and c-raf-1 signaling pathways. We observed R-ras transcripts of 4.6 and 1.2 kb ubiquitously expressed in each of a variety of tissues examined. All these findings raise the possibility that R-ras, like prototype vas genes, may be mutationally activated as an oncogene in some human malignancies.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHAN AML, 1994, IN PRESS P NATL ACAD; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2977	2982						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084601				2022-12-25	WOS:A1994PG82200024
J	BRODE, PF; ERWIN, CR; RAUCH, DS; LUCAS, DS; RUBINGH, DN				BRODE, PF; ERWIN, CR; RAUCH, DS; LUCAS, DS; RUBINGH, DN			ENZYME BEHAVIOR AT SURFACES - SITE-SPECIFIC VARIANTS OF SUBTILISIN BPN' WITH ENHANCED SURFACE STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ADSORPTION; BACILLUS-SUBTILIS; DISULFIDE BONDS; SUBSTRATE; MUTAGENESIS; EFFICIENT; LYSOZYME; CLONING; MODEL	Enzyme adsorption and inactivation at the solid/ liquid interface for subtilisin BPN' show a strong dependence on the nature of the solid surface. Adsorption of BPN' at the solid/liquid interface is considerably greater for a hydrophobic surface than for a hydrophilic one. Likewise, the rate of inactivation of the wild-type BPN' is over five times greater when equilibrated with a hydrophobic surface than with a hydrophilic surface. The rate data from these enzyme inactivation experiments performed at 50 degrees C are best fit by a second-order kinetic equation, suggesting a bimolecular pathway to inactivation. The role of increased surface adsorption on this bimolecular inactivation is discussed in terms of two different mechanisms. Several site-specific variants of subtilisin BPN' have been made in an attempt to alter the surface-inactivation of the wild-type enzyme. The extent of adsorption on the model surfaces is significantly lowered by certain lysine to phenylalanine changes in BPN'. Consequently, the surface autolytic stability shows a 4-fold improvement. The change in surface autolytic stability is achieved even though the basic kinetic parameters (k(cat) and K-M) of the variant enzymes are not significantly different on a soluble substrate. The results provide insights into the use of mutagenesis to probe the mechanism of protein interactions with surfaces.			BRODE, PF (corresponding author), PROCTER & GAMBLE CO, MIAMI VALLEY LABS, CINCINNATI, OH 45239 USA.							ANDRADE JD, 1985, SURFACE INTERFACIAL, V2; BARROUG A, 1989, COLLOID SURFACE, V37, P339, DOI 10.1016/0166-6622(89)80130-1; Brockman H.L., 1984, P3; BRODE PF, 1992, LANGMUIR, V8, P1325, DOI 10.1021/la00041a014; CORNISHBOWDEN A, 1975, PRINCIPLES ENZYME KI, P142; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; ERWIN CR, 1990, PROTEIN ENG, V4, P87, DOI 10.1093/protein/4.1.87; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GHOSH S, 1962, ARCH BIOCHEM BIOPHYS, V99, P121, DOI 10.1016/0003-9861(62)90253-9; KATO A, 1988, PROTEIN ENG, V2, P153, DOI 10.1093/protein/2.2.153; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V754, P227, DOI 10.1016/0005-2760(83)90165-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MATSUBAR.H, 1965, J BIOL CHEM, V240, P1125; MCLAREN DA, 1970, ADV ENZYMOL REL S BI, V33, P245; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; MURAKI M, 1988, PROTEIN ENG, V2, P49, DOI 10.1093/protein/2.1.49; NORDE W, 1986, J COLLOID INTERF SCI, V112, P447, DOI 10.1016/0021-9797(86)90113-X; PANTOLIANO MW, 1987, BIOCHEMISTRY-US, V26, P2077, DOI 10.1021/bi00382a002; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; Robson B., 1986, INTRO PROTEINS PROTE, Vsecond; RUBINGH DN, 1992, STUD POLYM SCI, V11, P445; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; STORY GM, 1991, ACS SYM SER, V447, P225; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984; YUCKENBERG PD, 1991, DIRECTED MUTAGENESIS, P27; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	29	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23538	23543						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089121				2022-12-25	WOS:A1994PQ34500026
J	MULLER, A; HINRICHS, W; WOLF, WM; SAENGER, W				MULLER, A; HINRICHS, W; WOLF, WM; SAENGER, W			CRYSTAL-STRUCTURE OF CALCIUM-FREE PROTEINASE-K AT 1.5-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; CHLOROMETHYL KETONE; X-RAY; PROGRAM; SITES	Proteinase K from the fungus Tritirachium album Limber binds two Ca2+ ions, one strongly (Ca 1) and the other weakly (Ca 2). Removal of these cations reduces the stability of proteinase K as shown by thermal denaturation, but the proteolytic activity is unchanged, The x-ray structures of native and Ca2+-free proteinase K at 1.5-Angstrom resolution show that there are no cuts in the polypeptide backbone (i.e. no autolysis), Ca 1 has been replaced by Na+, while Ca 2 has been substituted by a water associated with a larger but locally confined structural change at that site. A small but concerted geometrical shift is transmitted from the Ca 1 site via eight secondary structure elements to the substrate recognition site (Gly(100)-Tyr(104), and Ser(132)-Gly(136)) but not to the catalytic triad (Asp(39), His(69), Ser(224)). This is accompanied by positional changes of localized waters.	FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY; SERC,DARESBURY LAB,WARRINGTON WA4 4AD,CHESHIRE,ENGLAND	Free University of Berlin; STFC Daresbury Laboratory				Hinrichs, Winfried/0000-0002-0435-4565; Wolf, Wojciech/0000-0002-9162-9933				BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BAJORATH J, 1988, EUR J BIOCHEM, V176, P441, DOI 10.1111/j.1432-1033.1988.tb14301.x; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1986, FEBS LETT, V197, P105, DOI 10.1016/0014-5793(86)80307-6; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P404; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HUBBARD R, 1990, FRODO VERSION E 4 4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUS E, 1981, BIOCHEM BIOPH RES CO, V44, P513; LAVERY R, 1981, INT J QUANTUM CHEM, V20, P49, DOI 10.1002/qua.560200106; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MULLER A, 1993, J BIOL CHEM, V268, P26150; PAHLER A, 1984, EMBO J, V3, P1311, DOI 10.1002/j.1460-2075.1984.tb01968.x; PAPIZ M, 1987, P DARESBURY STUDY WE; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WOLF WM, 1991, J BIOL CHEM, V266, P17695	20	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23108	23111						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083213				2022-12-25	WOS:A1994PQ16400034
J	GAIDDON, C; BOUTILLIER, AL; MONNIER, D; MERCKEN, L; LOEFFLER, JP				GAIDDON, C; BOUTILLIER, AL; MONNIER, D; MERCKEN, L; LOEFFLER, JP			GENOMIC EFFECTS OF THE PUTATIVE ONCOGENE G-ALPHA-S - CHRONIC TRANSCRIPTIONAL ACTIVATION OF THE C-FOS PROTOONCOGENE IN ENDOCRINE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PITUITARY-TUMORS; G-PROTEINS; NEURONAL DIFFERENTIATION; FUNCTIONAL-ANALYSIS; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; ADENYLYL CYCLASE; MESSENGER-RNA; PC12 CELLS; CAMP	Somatic mutations of the a subunit of Gs (G alpha s) have been detected in a variety of endocrine tumors. To test whether G alpha s is an oncogene, we investigated the genomic effects of G alpha s protein in which the GTPase activity had been inactivated. Results from transient transfection studies show that such proteins increase 1) transcription of a reporter gene driven by the minimal cAMP-responsive element (TGACGTCA) and 2) c-fos transcription in several endocrine cell lines (GH3, AtT20, and PC12). By promoter deletion analyses and genetic inactivation of cAMP-dependent protein kinase, we show that this transcriptional stimulation by G alpha s impinges on several regulatory elements within the c-fos promoter and operates within the protein kinase A pathways. Stable PC12 cell lines were established to analyze long-term effects of constitutively active G alpha s. Cell lines expressing mutated G alpha s have elevated cAMP levels and increased AP1 binding activity. Transcription of a variety of genes, including c-fos, c-jun, and junB, is increased in these cells. The strong and permanent effects of G alpha s on early immediate genes, and c-fos in particular, may be responsible for the oncogenic potential of G alpha s in endocrine cells.	INST PHYSIOL & CHIM BIOL,CNRS,URA 1446,F-67084 STRASBOURG,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,RECH DEV,F-94403 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis			LOEFFLER, Jean-Philippe/AAS-4401-2020; Gaiddon, Christian/F-7321-2012	Gaiddon, Christian/0000-0003-4315-3851				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CLEMENTI E, 1990, ONCOGENE, V5, P1059; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE E, 1992, J BIOL CHEM, V267, P1212; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MERCKEN L, 1990, NUCLEIC ACIDS RES, V18, P662, DOI 10.1093/nar/18.3.662; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; RIVERA V M, 1990, New Biologist, V2, P751; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Treisman R, 1990, Semin Cancer Biol, V1, P47; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	53	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22663	22671						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077218				2022-12-25	WOS:A1994PQ16300034
J	KESSLER, E; SAFRIN, M				KESSLER, E; SAFRIN, M			THE PROPEPTIDE OF PSEUDOMONAS-AERUGINOSA ELASTASE ACTS AS AN ELASTASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCELLULAR PROTEASE; ESCHERICHIA-COLI; PRO-REGION; ALKALINE-PHOSPHATASE; POLYACRYLAMIDE GELS; INACTIVE PRECURSOR; CARBOXYPEPTIDASE-Y; STRUCTURAL GENE; SEQUENCE; ACTIVATION	Elastase, an extracellular protease of Pseudomonas aeruginosa, is synthesized as a preproenzyme containing a large amino-terminal propeptide. The propeptide is cleaved within the periplasm to form a noncovalent complex with the elastase moiety. The propeptide-elastase complex was purified from the cell extract of P. aeruginosa by affinity chromatography on Gly(3)-D-Phe-Sepharose. The purified fraction was proteolytically inactive and contained the propeptide-elastase complex as the major protein component. Activation by Limited proteolysis with trypsin was associated with the disappearance of the propeptide. To correlate individual proteins in the preparation with proteolytic activity, the purified fraction was subjected to polyacrylamide gel electrophoresis under nondenaturing conditions and subsequent incubation of the separation gel over a skim milk-agarose-indicator gel. Clearing zones due to proteolysis were produced either by mature elastase (control) or the free processed periplasmic enzyme, a low level of which was present in the purified propeptide-elastase complex preparation. No clearing was evident with the propeptide-elastase complex, indicating inhibition by the bound propeptide. Proteolytic activity of mature elastase was inhibited by various Pseudomonas cell fractions. This inhibition was abolished by antipropeptide antibodies, and, as evident from immunoblotting analysis, was consistent with propeptide presence in the effective fraction, whole cell extract, cytosol, and one of the two periplasmic fractions obtained upon conversion of P. aeruginosa cells to spheroplasts. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotting of the various cell fi actions onto nitrocellulose membranes followed by incubation of the membranes with elastase and subsequent probing with antielastase antibodies revealed elastase propeptide binding. This binding of mature elastase to the propeptide was prevented by antibodies to the propeptide but not by inhibitors of elastase activity. Thermolysin, a neutral metalloprotease homologous to elastase, was not recognized by the elastase propeptide. In addition, propeptide containing P. aeruginosa fractions that were inhibitory to elastase had no effect on thermolysin activity. We conclude that elastase propeptide functions as an elastase inhibitor. Inhibition is specific, effective against both periplasmic and mature elastase, and depends on enzyme propeptide binding.			KESSLER, E (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,SACKLER FAC MED,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL.							BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLUMBERG S, 1975, BIOCHEMISTRY-US, V14, P2410, DOI 10.1021/bi00682a022; BLUMBERG S, 1983, EUR J BIOCHEM, V136, P151, DOI 10.1111/j.1432-1033.1983.tb07719.x; CHENG KJ, 1971, J BACTERIOL, V107, P325, DOI 10.1128/JB.107.1.325-336.1971; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DORING G, 1981, ZBL BAKT-INT J MED M, V249, P89, DOI 10.1016/S0174-3031(81)80045-5; FECYCZ IT, 1985, EUR J BIOCHEM, V146, P35, DOI 10.1111/j.1432-1033.1985.tb08616.x; FUKUSHIMA J, 1989, J BACTERIOL, V171, P1698, DOI 10.1128/jb.171.3.1698-1704.1989; GOLDBERG JB, 1987, J BACTERIOL, V169, P4532, DOI 10.1128/jb.169.10.4532-4539.1987; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HECK LW, 1986, INFECT IMMUN, V54, P149, DOI 10.1128/IAI.54.1.149-153.1986; HECK LW, 1986, J IMMUNOL, V6, P2253; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JENSEN SE, 1980, CAN J MICROBIOL, V26, P87, DOI 10.1139/m80-013; JENSEN SE, 1980, J BACTERIOL, V144, P844, DOI 10.1128/JB.144.2.844-847.1980; KAWAMOTO S, 1993, INFECT IMMUN, V61, P1400, DOI 10.1128/IAI.61.4.1400-1405.1993; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; KESSLER E, 1992, FEBS LETT, V299, P291, DOI 10.1016/0014-5793(92)80134-3; KESSLER E, 1993, J BIOL CHEM, V268, P7503; KESSLER E, 1982, INFECT IMMUN, V38, P716, DOI 10.1128/IAI.38.2.716-723.1982; KESSLER E, 1977, INVEST OPHTH VIS SCI, V16, P488; KESSLER E, 1988, J BACTERIOL, V170, P1215, DOI 10.1128/jb.170.3.1215-1219.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALAMY MH, 1964, BIOCHEMISTRY-US, V3, P1889, DOI 10.1021/bi00900a017; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; MORIHARA K, 1979, INFECT IMMUN, V24, P188, DOI 10.1128/IAI.24.1.188-193.1979; NICAS TI, 1985, CAN J MICROBIOL, V31, P387, DOI 10.1139/m85-074; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHTA Y, 1991, MOL MICROBIOL, V5, P1506; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; THAYER MM, 1991, J BIOL CHEM, V266, P2864; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	42	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22726	22731						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077225				2022-12-25	WOS:A1994PQ16300043
J	CHANG, JY; CANALS, F; SCHINDLER, P; QUEROL, E; AVILES, FX				CHANG, JY; CANALS, F; SCHINDLER, P; QUEROL, E; AVILES, FX			THE DISULFIDE FOLDING PATHWAY OF POTATO CARBOXYPEPTIDASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; CONTAINING PROTEINS; CRYSTAL-STRUCTURE; RESOLUTION; ISOMERASE; STATE	Potato carboxypeptidase inhibitor (PCI) contains 39 amino acids and three disulfides. Reduced and denatured PCI refolds spontaneously in vitro to regain its native structure. The folding pathway of a recombinant form of this protein has been elucidated by structural analysis and stop/go folding experiments of both acid and iodoacetate-trapped intermediates. The results reveal that folding of PCI proceeds through an initial stage of nonspecific disulfide formation (packing), followed by disulfide reshuffling (consolidation) of partially packed intermediates to acquire the native struc ture. The process of nonspecific packing involves a sequential flow of fully reduced PCI through 1- and 2-disulfide intermediates and leads to the formation of scrambled 3-sulfide species. All three classes of intermediates are highly heterogeneous, Disulfide reshuffling occurs at the final stage which refines and consolidates the scrambled species to acquire the native conformation. The efficiencies of disulfide formation and disulfide reshuffling can be selectively regulated by redox poten tial. Disulfide formation is promoted by cystine or oxidized glutathione, whereas disulfide reshuffling requires free thiols, such as cysteine, reduced glutathione, or beta-mercaptoethanol. Consolidation of scrambled species to form the native PCI represents the major rate-limiting step. When folding of PCI was carried out in the presence of cystine (2 mM) alone, more than 98% of the intermediates accumulate as the scrambled species after 1 min of folding. Furthermore, denaturant (5 M GdmCl or 8 M urea) mainly disrupts the final stage of PCI folding and exerts no apparent influence on the early stage of nonspecific packing. The compositions of 1- and 2-disulfide intermediates, according td their high performance liquid chromatography patterns, remain indistinguishable regardless of whether folding is performed in the absence or presence of denaturant.	UNIV AUTONOMA BARCELONA,DEPT BIOQUIM,E-08193 BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,INST BIOL FONAMENTAL,E-01893 BARCELONA,SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona	CHANG, JY (corresponding author), CIBA GEIGY LTD,PHARMACEUT RES LABS,CH-4002 BASEL,SWITZERLAND.		Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019	Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789				ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BOERNSEN KO, 1990, CHIMIA, V44, P412; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; HABER E, 1962, J BIOL CHEM, V237, P1839; HANTGAN RR, 1974, BIOCHEMISTRY-US, V13, P3421, DOI 10.1021/bi00714a001; HASS GM, 1981, METHOD ENZYMOL, V80, P778; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P964; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEARY TR, 1979, BIOCHEMISTRY-US, V18, P2252, DOI 10.1021/bi00578a018; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARINOBUSLJE C, 1994, IN PRESS APPL MICROB; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; Pace C N, 1986, Methods Enzymol, V131, P266; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; RYAN CA, 1974, J BIOL CHEM, V249, P5495; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEXENA P, 1970, BIOCHEMISTRY-US, V9, P5015; VENDRELL J, 1986, J CHROMATOGR, V358, P401, DOI 10.1016/S0021-9673(01)90354-1; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	37	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22087	22094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071332				2022-12-25	WOS:A1994PE09800027
J	ERCAN, N; GANNON, MC; NUTTALL, FQ				ERCAN, N; GANNON, MC; NUTTALL, FQ			INCORPORATION OF GLYCOGENIN INTO A HEPATIC PROTEOGLYCOGEN AFTER ORAL GLUCOSE-ADMINISTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SUBSTRATE-SPECIFICITY; PROTEIN; LIVER; PHOSPHORYLASE; BIOGENESIS; INITIATION; SYNTHASE; LINKAGE; FORM	Glycogenin is a 37-kDa protein upon which new glycogen molecules are considered to be constructed. Therefore, we were interested in determining its role in liver glycogen synthesis following glucose administration. Twenty-four-hour fasted rats were given 4 g/kg glucose orally. Glycogenin and synthase R activities and glycogen were determined over the subsequent 24 h. In fasted rats given just water, glycogenin activity was present and did not change over the subsequent 24 h. Following glucose, glycogenin activity also was not differ ent for 1 h, i.e. the glycogenin was not incorporated into glycogen even though the glycogen concentration had increased. Subsequently, the glycogenin activity became unmeasurable. Presumably, the glycogenin was incorporated into a proteoglycan product since after amylase treatment, glycogenin activity was again present and was quantitatively unchanged. Free glycogenin activity remained unmeasurable until after 12 h. At this time, glycogen began to decrease, and, by 15 h, free glycogenin activity again appeared. The results indicate that in fasted rats, essentially all of the glycogenin was free. Following administration of oral glucose, glycogenin was incorporated into a proteoglycan product but only 60 min after glycogen synthesis had begun. Free glycogenin did not reappear until the 15(th) h after glucose was given and after the glycogen concentration had decreased by similar to 60%.	VET AFFAIRS MED CTR,ENDOCRINE SECT 111G,METAB RES LAB,MINNEAPOLIS,MN 55417; VET AFFAIRS MED CTR,ENDOCRINOL METAB & NUTR SECT,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,DEPT FOOD SCI & NUTR,MINNEAPOLIS,MN 55417	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Gannon, Mary Carol/L-7092-2016	Gannon, Mary Carol/0000-0001-5460-2478	NIDDK NIH HHS [DK43018-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO YJ, 1993, J BIOL CHEM, V268, P21717; Kennedy L., 1985, MEMBRANES MUSCLE, P65; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; NIEWOEHNER CB, 1984, AM J PHYSIOL, V246, pE89, DOI 10.1152/ajpendo.1984.246.1.E89; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P194; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759	19	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22328	22333						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071360				2022-12-25	WOS:A1994PE09800061
J	MULLOY, B; RIBEIRO, AC; ALVES, AP; VIEIRA, RP; MOURAO, PAS				MULLOY, B; RIBEIRO, AC; ALVES, AP; VIEIRA, RP; MOURAO, PAS			SULFATED FUCANS FROM ECHINODERMS HAVE A REGULAR TETRASACCHARIDE REPEATING UNIT DEFINED BY SPECIFIC PATTERNS OF SULFATION AT THE O-2 AND O-4 POSITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEAWEED ECKLONIA-KUROME; BRANCHED CHONDROITIN SULFATE; ACROSOME REACTION; SEA-CUCUMBER; MOLECULAR-WEIGHT; JELLY COAT; BODY WALL; POLYSACCHARIDES; ANTICOAGULANT; SPERM	Sulfated fucans from echinoderms (sea cucumber and sea urchin) have a linear backbone of 1-->3-linked alpha-L-fucopyranose with some sulfate substitution at the 2- and 4-positions, NMR spectroscopy indicates that both polysaccharides have a tetrasaccharide repeat unit in which the separate residues differ only in the extent and position of their sulfate substitution. The sea urchin fucan has the structure, (Eq.1): [3-alpha-L-Fucp-2(OSO3-)-1-->3-alpha-L-Fucp-4(OSO3-)-1--> 3-alpha-L-Fucp-2,4(OSO3-)1-->3-alpha-L-Fucp-2(OSO3-)]n and the sea cucumber has the structure, (Eq.2): 3-alpha-L-Fucp-2,4(OSO3-)-1-->-3-alpha-L-Fucp-1-->3-alpha-L-Fucp-2(OSO3-)-1-->3-alpha-L-Fucp-2(OSO3-)-1]n This type of regular structure has not previously been described, and is in contrast with the random arrangement of substituents on the similar 1-->3-linked alpha-L-fucopyranose backbone of the fucoidans from brown algae.	UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, BR-21941590 RIO DE JANEIRO, BRAZIL; NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND	Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control			Mourao, Paulo/AAA-5386-2020					AHUJA KK, 1982, EXP CELL RES, V140, P353, DOI 10.1016/0014-4827(82)90124-0; ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BOLWELL GP, 1979, J CELL SCI, V36, P19; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARK GF, 1992, FASEB J, V6, pA233; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; DANISHEFSKY I, 1969, J BIOL CHEM, V244, P1741; DELL A, 1988, CARBOHYD RES, V179, P7, DOI 10.1016/0008-6215(88)84105-3; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DISCHE Z, 1948, J BIOL CHEM, V175, P595; DISCHE Z, 1947, J BIOL CHEM, V167, P189; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GLABE CG, 1982, J CELL BIOL, V94, P123, DOI 10.1083/jcb.94.1.123; HAHNENBERGER R, 1991, GLYCOCONJUGATE J, V8, P350, DOI 10.1007/BF00731347; HUANG TTF, 1982, GAMETE RES, V5, P355, DOI 10.1002/mrd.1120050406; JUNQUEIRA LCU, 1980, REV CAN BIOL EXPTL, V39, P157; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; MAHONY MC, 1991, CONTRACEPTION, V44, P657, DOI 10.1016/0010-7824(91)90085-T; MCCLURE MO, 1992, AIDS RES HUM RETROV, V8, P19, DOI 10.1089/aid.1992.8.19; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P639, DOI 10.1111/j.1432-1033.1987.tb13561.x; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NISHINO T, 1994, CARBOHYD RES, V255, P213, DOI 10.1016/S0008-6215(00)90980-7; NISHINO T, 1991, PHYTOCHEMISTRY, V30, P535, DOI 10.1016/0031-9422(91)83722-W; NISHINO T, 1991, AGR BIOL CHEM TOKYO, V55, P791, DOI 10.1080/00021369.1991.10870645; NISHINO T, 1992, CARBOHYD RES, V229, P355, DOI 10.1016/S0008-6215(00)90581-0; NISHINO T, 1991, CARBOHYD RES, V211, P77, DOI 10.1016/0008-6215(91)84147-7; NISHINO T, 1991, THROMB RES, V64, P723, DOI 10.1016/0049-3848(91)90072-5; OEHNINGER S, 1992, J ANDROL, V13, P519; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; Percival E., 1967, CHEM ENZYMOLOGY MARI, P157; PETERSON RN, 1984, J EXP ZOOL, V231, P137, DOI 10.1002/jez.1402310118; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCHACHTER H, 1969, J BIOL CHEM, V244, P4785; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; SEGALL GK, 1981, DEV BIOL, V86, P87, DOI 10.1016/0012-1606(81)90318-3; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHALGI R, 1986, BIOL REPROD, V34, P446, DOI 10.1095/biolreprod34.3.446; SINNIGER V, 1993, J CHROMATOGR-BIOMED, V615, P215, DOI 10.1016/0378-4347(93)80335-2; VIEIRA RP, 1993, BIOCHEMISTRY-US, V32, P2254, DOI 10.1021/bi00060a018; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WARREN L, 1959, J BIOL CHEM, V234, P1971	55	160	175	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22113	22123						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071336				2022-12-25	WOS:A1994PE09800031
J	FEE, JA; MONSEY, JD; HANDLER, RJ; LEONIS, MA; MULLANEY, SR; HOPE, HMR; SILBERT, DF				FEE, JA; MONSEY, JD; HANDLER, RJ; LEONIS, MA; MULLANEY, SR; HOPE, HMR; SILBERT, DF			A CHINESE-HAMSTER FIBROBLAST MUTANT DEFECTIVE IN THROMBIN-INDUCED SIGNALING HAS A LOW-LEVEL OF PHOSPHOLIPASE C-BETA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; ALPHA-SUBUNITS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; INDUCED MITOGENESIS; GQ-ALPHA; ACTIVATION	A mutant fibroblast, 2A4b, was isolated from the Chinese hamster lung cell line CCL39 by a previously described selection (Rath, H. M., Doyle, G. A. R., and Silbert, D. F. (1989) J. Biol. Chem. 264, 13387-13390) for cells deficient in thrombin-induced signaling. Although the antiporter activation by thrombin in 2A4b is only similar to 60% that in CCL39, the stimulation by serum is not significantly impaired, indicating that the defect in 2A4b lies upstream of the antiporter in the signaling pathway. The addition of thrombin to serum-starved 2A4b cells causes blunted responses both in production of inositol phosphates and in the cytosolic [Ca2+] transient, particularly when no Ca2+ is added to the external medium. The in vitro inositol phospholipid-specific phospholipase C (PLC) activity of 2A4b cytosol plus membrane extracts exceeds that in CCL39. However, im munoblots with antibodies to PLC isozymes show that although the levels of PLC-delta(1), PLC-gamma(1), and PLC-beta(3) are at least as great as those in CCL39, the amount of PLC-beta(1) in 2A4b is markedly deficient (less than or equal to 10%). PLC-beta(1) is found primarily in the nucleus and in non nuclear membranes of CCL39 and is proportionately low in these subcellular locations of 2A4b. Thrombin activation of phospholipases D and A, is impaired in 2A4b. We postulate that the deficiency in PLC-beta(1) causes defective targeting of protein kinase C cu to specific membrane sites, which may be required for activation of these downstream phospholipases.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)								Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BAFFY G, 1994, J BIOL CHEM, V269, P8483; Bell R M, 1986, Methods Enzymol, V124, P353; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLANK JL, 1993, J BIOL CHEM, V268, P25184; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CHO YS, 1993, FEBS LETT, V334, P257, DOI 10.1016/0014-5793(93)80689-R; COUNILLON L, 1993, BIOCHIM BIOPHYS ACTA, V1172, P343, DOI 10.1016/0167-4781(93)90228-6; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HA KS, 1993, J BIOL CHEM, V268, P10534; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEONIS MA, 1993, J BIOL CHEM, V268, P9416; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; Markwell M A, 1981, Methods Enzymol, V72, P296; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MCKENZIE FR, 1959, J BIOL CHEM, V267, P227; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARK DG, 1993, J BIOL CHEM, V268, P4573; POUYSSEGUR J, 1988, PHILOS T ROY SOC B, V320, P427, DOI 10.1098/rstb.1988.0086; RABEN DM, 1987, J CELL PHYSIOL, V130, P466, DOI 10.1002/jcp.1041300322; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RATH HM, 1989, J BIOL CHEM, V264, P13387; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WU DQ, 1992, J BIOL CHEM, V267, P1811; YANG SF, 1967, J BIOL CHEM, V242, P477	70	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21699	21708						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063814				2022-12-25	WOS:A1994PK97300050
J	SANDLER, MA; ZHANG, JN; WESTERHAUSEN, DR; BILLADELLO, JJ				SANDLER, MA; ZHANG, JN; WESTERHAUSEN, DR; BILLADELLO, JJ			A NOVEL PROTEIN INTERACTS WITH THE MAJOR TRANSFORMING GROWTH-FACTOR-BETA RESPONSIVE ELEMENT IN THE PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; NUCLEAR FACTOR-I; NF-KAPPA-B; TGF-BETA; EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; EXPRESSION CLONING; RECEPTOR; CELLS; KINASE	Multiple transforming growth factor-beta (TGF-beta) responsive elements have been identified within the 5'-flanking region of the plasminagen activator inhibitor type-1 (PAI-1) gene. This study was designed to characterize the major TGF-beta responsive element (-804 to -546). DNA footprint assays showed that the region of protein contact (-726 to -703) did not include consensus sequences for any known transacting factors. The results of UV cross-linking and Southwestern blot experiments Showed that a protein of M(r) 100,000 specifically binds to the TGF-beta responsive element and that this protein undergoes post-transcriptional activation within 5 min after stimulaltion sf Hep G2 cells by TGF-beta resulting in a marked increase in affinity for the target DNA sequence. These results show that stimulation of Hep G2 dells with TGF-beta increases the affinity of a novel 100-kDa protein for the major TGF-beta responsive element within the PAI-1 gene.	WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL)								AMBROSE BJB, 1987, METHOD ENZYMOL, V152, P522; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRABLETZ T, 1993, MOL CELL BIOL, V13, P1155, DOI 10.1128/MCB.13.2.1155; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1481; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FUJII S, 1991, CIRCULATION, V83, P645, DOI 10.1161/01.CIR.83.2.645; HARLINE MC, 1992, BIOTECHNIQUES, V13, P388; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MARDER VJ, 1992, CIRCULATION, V85, P386, DOI 10.1161/01.CIR.85.1.386; MARIMAN ECM, 1989, NUCLEIC ACIDS RES, V17, P6385, DOI 10.1093/nar/17.15.6385; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIMURO J, 1989, J BIOL CHEM, V264, P936; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SALO T, 1991, J BIOL CHEM, V266, P11436; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SINGH H, 1989, BIOTECHNIQUES, V7, P252; TABIBZADEH S, 1991, NUCLEIC ACIDS RES, V19, P2783, DOI 10.1093/nar/19.10.2783; TEGERNILSSON AC, 1991, CIRCULATION, V84, P72; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	45	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21500	21504						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063785				2022-12-25	WOS:A1994PK97300020
J	MILARSKI, KL; SALTIEL, AR				MILARSKI, KL; SALTIEL, AR			EXPRESSION OF CATALYTICALLY INACTIVE SYP PHOSPHATASE IN 3T3 CELLS BLOCKS STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TYROSINE-PHOSPHATASE; PHOSPHOLIPASE-C; SH3 DOMAINS; IRS-1; PHOSPHORYLATION; ASSOCIATION; SUBSTRATE-1; CORKSCREW	To explore the role of the protein tyrosine phosphatase Syp in insulin signaling, a catalytically inert mutant Syp protein was expressed under an inducible promoter in cells transfected with the human insulin receptor. Expression of the mutant phosphatase significantly reduced the stimulation of mitogenesis by insulin; indicating that the mutation produced a dominant negative phenotype. Tyrosine phosphorylation of both the insulin receptor and its major substrates, She and insulin receptor substrate-1, were unaffected by the mutant phosphatase. However, both the insulin-dependent tyrosine phosphorylation and activation of mitogenactivated protein kinase were markedly attenuated. Expression of the mutant phosphatase allowed the detection of a 120-kDa protein phosphorylated in response to insulin that associated with the src homology (SH) 2 domains of the phosphatase, suggesting a possible regulatory role for this protein. These results indicate that the activity of Syp plays a critical part in the mitogenic actions of insulin.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT SIGNAL TRANSDUC,ANN ARBOR,MI 48105	Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLEMIS J, 1993, P NATL ACAD SCI USA, V90, P5889; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOBE K, 1993, J BIOL CHEM, V268, P11167; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	29	293	298	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21239	21243						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063746				2022-12-25	WOS:A1994PC40300064
J	MURRAY, NR; BURNS, DJ; FIELDS, AP				MURRAY, NR; BURNS, DJ; FIELDS, AP			PRESENCE OF A BETA(II) PROTEIN-KINASE C-SELECTIVE NUCLEAR-MEMBRANE ACTIVATION FACTOR IN HUMAN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PHORBOL ESTERS; LAMIN-B; PROLIFERATION; ALPHA; PKC; DIFFERENTIATION; PHOSPHORYLATION; DIACYLGLYCEROL; FAMILY	In human promyelocytic (HL60) leukemia cells beta(II) protein kinase C (PKC) is selectively translocated to the nucleus in response to proliferative stimuli. At the nucleus, beta(II) PKC directly phosphorylates the nuclear envelope polypeptide lamin B at two consensus PKC phosphorylation sites, Ser(395) and Ser(405). Phosphorylation of these sites by beta(II) PKC leads to solubilization of lamin B indicative of mitotic nuclear envelope breakdown in vitro (Hocevar, B. A., Burns, D. J., and Fields, A. P. (1993) J. Biol. Chem. 268, 7545-7552). We have now investigated the molecular basis for beta(II) PKC-selective nuclear translocation and lamin B phosphorylation using an in vitro reconstitution system. We find that beta(II) PKC phosphorylates nuclear envelope lamin B at 10-20 times the rate of alpha PKC, whereas both kinases phosphorylate soluble lamin B at similar rates. Comparative tryptic phosphopeptide analysis demonstrates that alpha PKC and beta(II) PKC phosphorylate identical sites, Ser(395) and Ser(405), on soluble lamin B. These data suggest that a component(s) of the nuclear envelope confers beta(II) PKC-selective nuclear activation and lamin B phosphorylation. Extraction of nuclear envelopes with either non-ionic detergent (2% n-octyl glucoside) or organic solvent (CHCl3/ CH3OH/H2O; 10:10:3) abolishes beta(II) PKC-selective phosphorylation of nuclear lamin B. Nuclear membrane extracts reconstitute beta(II) PKC-selective phosphorylation, indicating the presence of a beta(II) PKC-selective nuclear membrane activation factor (NMAF). NMAF selectively activates beta(II) PKC histone H1 kinase activity 3-4-fold above the level achieved with optimal concentrations of Ca2+, diacylglycerol, and phosphatidylserine. Finally, NMAF activity is not affected by exhaustive protease treatment, suggesting that it is a nuclear membrane lipid(s) or lipid metabolite. These data suggest that NMAF plays a physiologic role in the nuclear activation of beta(II) PKC.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; SPHINX PHARMACEUT INC, DURHAM, NC 27717 USA	Case Western Reserve University					NCI NIH HHS [CA-56869] Funding Source: Medline; NIGMS NIH HHS [GM-43186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BUHROW SA, 1982, J BIOL CHEM, V257, P4019; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GERACE L, 1984, J CELL SCI, P137; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEACH KL, 1992, J BIOL CHEM, V267, P21816; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	33	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21385	21390						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063766				2022-12-25	WOS:A1994PC40300084
J	PARRY, GCN; MACKMAN, N				PARRY, GCN; MACKMAN, N			A SET OF INDUCIBLE GENES EXPRESSED BY ACTIVATED HUMAN MONOCYTIC AND ENDOTHELIAL-CELLS CONTAIN KAPPA-B-LIKE SITES THAT SPECIFICALLY BIND C-REL-P65 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATING FACTOR GENE; TUMOR-NECROSIS-FACTOR; MEDIATED TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; C-REL; LIPOPOLYSACCHARIDE; INDUCTION; THP-1; DNA; INVOLVEMENT	NF-kappa B/Rel proteins regulate the inducible expression of many genes in activated monocytes and endothelial cells that contain decameric kappa B and kappa B-like binding sites. In this study, we examined the binding of c-Rel-p65 heterodimers to non-consensus kappa B-like sites from several genes that do not bind prototypic NF-kappa B(p50-p65). c-Rel-p65 heterodimers from both monocytic and endothelial cells bound to the kappa B-Like sites in the interleukin-8, granulocyte/macrophage colony-stimulating factor, intercellular adhesion molecule-1, and tissue factor genes but not to a closely related sequence in the granulocyte colony-stimulating factor gene. In contrast, kappa B sites in the endothelial-leukocyte adhesion molecule-1 and Ig kappa genes that match the kappa B consensus, 5'-GGGRN-NYYCC-3' (where R indicates A or G, Y indicates C or T, and N indicates any base), bound NF-kappa B(p50-p65). Comparison of the kappa B-like sites indicated that c-Rel-p65 heterodimers bound to a consensus sequence, 5'-HGGAR-NYYCC-3' (where R indicates A or G, Y indicates C or T, H indicates A, C, or T, and N indicates any base), which differs at position 1 from the kappa B consensus established for binding NF-kappa B(p50-p65) and other members of the NF-kappa B/Rel family. The selective binding of c-Rel-p65 heterodimers to kappa B-like sites in this set of genes may play a central role in regulating inducible gene expression in monocytes and endothelial cells.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL-48872, HL-16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLINS T, 1993, LAB INVEST, V68, P499; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Grilli Mariagrazia, 1993, V143, P1; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HIMES SR, 1993, ONCOGENE, V8, P3189; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1994, FASEB J, V8, P5902; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YAMADA H, 1991, BLOOD, V78, P1988	27	147	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20823	20825						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063696				2022-12-25	WOS:A1994PC40300005
J	GREENBERGER, LM				GREENBERGER, LM			MAJOR PHOTOAFFINITY DRUG LABELING SITES FOR IODOARYL AZIDOPRAZOSIN IN P-GLYCOPROTEIN ARE WITHIN, OR IMMEDIATELY C-TERMINAL TO, TRANSMEMBRANE DOMAIN-6 AND DOMAIN-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE GENE; CYSTIC-FIBROSIS GENE; CLASS-II REGION; BACTERIAL TRANSPORT PROTEINS; ALPHA-1 SUBUNIT; CA2+ CHANNELS; HUMAN-CELLS; EXPRESSION; BINDING; IDENTIFICATION	P-glycoprotein can mediate multidrug resistance in tumor cells and is hypothesized to be an energy-dependent drug efflux pump. The protein is composed of two cassettes; each cassette contains six transmembrane domains followed by a nucleotide binding fold. The [I-125]iodoaryl azidoprazosin photoaffinity drug binding sites in P-glycoprotein have been mapped by immunological analysis. After complete digestion of P-glycoprotein with trypsin, two major photolabeled fragments have been mapped. The 5- and 4-kDa fragments are located within, or immediately C-terminal to, the last transmembrane domain of each cassette: transmembranes 6 and 12 of P-glycoprotein, respectively. The 4-kDa fragment maximally extends up to, but not including, the Walker A motif of the second nucleotide binding fold, whereas the 5-kDa fragment maximally extends a few residues beyond the Walker A motif of the first nucleotide binding fold. A minor photolabeling domain is also found between transmembrane domain 4 and up to, but not including, transmembrane domain 6. These data suggest that a portion of the drug binding site in P-glycoprotein is in close proximity to ATP binding regions. Furthermore, symmetrical regions in each cassette of P-glycoprotein are likely to participate in drug efflux.			GREENBERGER, LM (corresponding author), AMER CYANAMID CO,LEDERLE LABS,ONCOL & IMMUNOL RES SECT,PEARL RIVER,NY 10965, USA.							AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSHCE R, 1989, EUR J BIOCHEM, V183, P189; BUSHE R, 1989, MOL PHARMACOL, V35, P414; BUSHMAN E, 1991, MOL CELL BIOL, V11, P595; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; FORD JM, 1990, PHARMACOL REV, V42, P155; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GREENBERGER IM, 1992, DRUG RESISTANCE BIOC, P63; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; PRATT WB, 1990, PRINCIPLES DRUG ACTI, P595; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; ROY SN, 1985, CANCER RES, V45, P3856; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7725; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WU JH, 1992, J BIOL CHEM, V267, P12570; Yang C. H., 1991, SYNERGISM ANTAGONISM, P311; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; Young R. C., 1989, DRUG RESISTANCE CANC, P1; ZEHEB R, 1987, BIOCHEM BIOPH RES CO, V143, P732, DOI 10.1016/0006-291X(87)91415-X	69	189	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11417	11425						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098711				2022-12-25	WOS:A1993LD46600101
J	GRIMM, R; DONALDSON, GK; VANDERVIES, SM; SCHAFER, E; GATENBY, AA				GRIMM, R; DONALDSON, GK; VANDERVIES, SM; SCHAFER, E; GATENBY, AA			CHAPERONIN-MEDIATED RECONSTITUTION OF THE PHYTOCHROME PHOTORECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVENA-SATIVA L; RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; GENE-EXPRESSION; HIGHER-PLANTS; PROTEINS; INVITRO; YEAST; GROE; CHROMOPHORE	The native phytochrome photoreceptor was purified to homogeneity from etiolated seedlings of oat (Avena sativa L.) and used for renaturation experiments. Light scattering measurements showed that the GroEL molecular chaperone interacts with non-native phytochrome to suppress aggregation of the refolding polypeptide, following its dilution from a chaotrope. The binary complex formed between non-native phytochrome and GroEL was stable and could be isolated by size exclusion chromatography. Discharge of the photoreceptor from GroEL was obtained with 2 mM MgATP, although 6 mM adenosine 5'-O-(3-thiotriphosphate) was also effective. Phytochrome released from GroEL with MgATP was found primarily in the form of 124-kDa monomers, as judged by size exclusion chromatography and nondenaturing gel electrophoresis, although dimers and other oligomeric forms were also observed. The reconstituted dimers, and other oligomeric forms, preferentially cross-reacted with a monoclonal antibody that recognizes native-like epitopes. In vitro folding reactions, using chemically denatured phytochrome, revealed that successful reconstitution of the photoreceptor required the presence of the GroEL chaperonin and MgATP under the conditions tested. Reconstitution in the presence of GroEL yielded phytochrome that could exhibit photoreversibility between the red-light absorbing and far-red absorbing forms.	DUPONT CO,CENT RES DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880; INST BIOL 2,W-7800 FREIBURG,GERMANY	DuPont								BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOI JK, 1990, BIOCHEMISTRY-US, V29, P6883, DOI 10.1021/bi00481a018; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Furuya M, 1989, Adv Biophys, V25, P133, DOI 10.1016/0065-227X(89)90006-3; FURUYA M, 1987, PHYTOCHROME PHOTOREG; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JONES AM, 1989, PHOTOCHEM PHOTOBIOL, V49, P479, DOI 10.1111/j.1751-1097.1989.tb09198.x; JONES AM, 1985, PLANTA, V164, P501, DOI 10.1007/BF00395966; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; KAUFMAN LS, 1984, SCIENCE, V226, P1447, DOI 10.1126/science.226.4681.1447; Kendrick RE., 2012, PHOTOMORPHOGENESIS P, P333; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; LAGARIAS JC, 1985, J BIOL CHEM, V260, P2415; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NAGATANI A, 1987, PHYTOCHROME PHOTOREG, P95; SONG PS, 1988, J PHOTOCH PHOTOBIO B, V2, P43, DOI 10.1016/1011-1344(88)85036-X; THOMAS B, 1984, PLANTA, V160, P382, DOI 10.1007/BF00393420; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIERSTRA RD, 1982, P NATL ACAD SCI-BIOL, V79, P5272, DOI 10.1073/pnas.79.17.5272; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WYNN RM, 1992, J BIOL CHEM, V267, P12400	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5220	5226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095267				2022-12-25	WOS:A1993KP88400094
J	ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S				ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S			IDENTIFICATION OF HUMAN DAN GENE, MAPPING TO THE PUTATIVE NEUROBLASTOMA TUMOR-SUPPRESSOR LOCUS	ONCOGENE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; N-MYC AMPLIFICATION; CELL-LINES; NEURO-BLASTOMA; SHORT ARM; DELETION; EXPRESSION; CHROMOSOME; TUMORIGENICITY; HETEROZYGOSITY	The expression of DAN gene (previously designated as N03 gene) is significantly reduced in a variety of transformed rat fibroblasts, including v-src- (SR-3Y1), SV40- and v-mos-transformed 3Y1 cells, compared with that in parental 3Y1 cells. Recently, DAN gene has been shown to possess a tumor suppressive activity when it is overexpressed in SR-3Y1 cells (Ozaki & Sakiyama, 1994). To assess the involvement of DAN gene,vith human neoplasms, we have isolated human DAN counterpart from a normal lung cDNA library by using rat DAN cDNA as a probe, and determined its chromosomal location. Human DAN gene mapped to chromosome 1p36.11-p36.13, which is well known to show highly significant linkage with the genesis and/or progression of human neuroblastoma. Southern blot analysis on tumor DNA from 26 patients with neuroblastoma has detected three patients showing genomic rearrangement or deletion within or closely linked to the DAN gene locus. Collectively, we propose that human DAN gene is a possible candidate for a tumor suppressor gene of human neuroblastoma.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHUOH KU,CHIBA 260,JAPAN; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KAWASAKI 211,KANAGAWA,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIGUSA KU,NAGOYA 464,JAPAN; KAZUSA DNA,RES INST,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center; Chiba University; National Institutes for Quantum Science & Technology; Nippon Medical School; Nagoya University; Kazusa DNA Research Institute								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIECHE I, 1993, CANCER RES, V53, P1990; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRANCKE U, 1978, BIRTH DEFECTS, V12, P131; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; GILBERT F, 1984, CANCER RES, V44, P5444; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIYAKE K, 1973, AUTONOM NERV SYST JP, V10, P115; MOLEY JF, 1992, CANCER RES, V52, P770; OZAKI T, 1994, CANCER RES, V54, P646; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGIMOTO T, 1986, CANCER RES, V46, P4765; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUCHIDA Y, 1990, FEBS LETT, V263, P191, DOI 10.1016/0014-5793(90)81370-4; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	58	79	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2785	2791						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084583				2022-12-25	WOS:A1994PG82200003
J	FAULKNER, KM; LIOCHEV, SI; FRIDOVICH, I				FAULKNER, KM; LIOCHEV, SI; FRIDOVICH, I			STABLE MN(III) PORPHYRINS MIMIC SUPEROXIDE-DISMUTASE IN-VITRO AND SUBSTITUTE FOR IT IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPERFUSION INJURY; MANGANESE; COMPLEXES; OXYGEN; DEHYDRATASE; INACTIVATION; PARAQUAT; COPPER; IRON	Several manganic porphyrins, with substituents on the methine bridge carbons, were prepared and examined for stability, redox behavior, catalysis of the dismutation of superoxide radical (O-2(-)), and the ability to protect a superoxide dismutase (SOD)-null strain E. coli against dissolved oxygen and a SOD competent strain against paraquat. All of the compounds tested exhibited reversible redox behavior and were stable to EDTA in both the oxidized and reduced states, and several were able to catalyze the dismutation of O-2(-) with the rate constants of similar to 10(7) M(-1) s(-1). The marked protective effects of some of these compounds exceeded that which could be anticipated on the basis of such rate constants. The tetrakis (1-methyl-4-pyridyl) compound was reduced enzymatically at the expense of NADPH and nonenzymatically by GSH and was kept in the reduced state within E. coli. Since the rate constant for reoxidation of the reduced form by O-2(-) is 4 x 10(9) M(-1) s(-1), it appears that this compound acts in vivo as an NADPH/GSH:O-2(-) oxidoreductase rather than as an SOD mimic. Its ability to facilitate aerobic growth of the SOD-null strain can be explained on this basis.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University								ARCHIBALD FS, 1981, J BACTERIOL, V145, P442, DOI 10.1128/JB.145.1.442-451.1981; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; ARCHIBALD FS, 1981, J BACTERIOL, V146, P928, DOI 10.1128/JB.146.3.928-936.1981; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BLOCH CA, 1986, J BACTERIOL, V168, P795, DOI 10.1128/jb.168.2.795-798.1986; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; COLLMAN JP, 1993, SCIENCE, V261, P1404, DOI 10.1126/science.8367724; CONCANNON MJ, 1991, MICROSURG, V12, P18, DOI 10.1002/micr.1920120105; ERLANSSON M, 1990, FREE RADICAL BIO MED, V9, P59, DOI 10.1016/0891-5849(90)90050-S; FARAGGI M, 1984, OXYGEN RADICALS CHEM, P419; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLOHE L, 1988, MOL CELL BIOCHEM, V84, P123, DOI 10.1007/BF00421046; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1958, J BIOL CHEM, V233, P1578; FUJITA T, 1992, BIOCHEM BIOPH RES CO, V189, P191, DOI 10.1016/0006-291X(92)91543-Y; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GORECKI M, 1991, FREE RADICAL RES COM, V12-3, P401, DOI 10.3109/10715769109145810; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1532, DOI 10.1039/f29797501532; HATORI N, 1992, FREE RADICAL BIO MED, V13, P137, DOI 10.1016/0891-5849(92)90075-R; HODGSON EK, 1973, ANAL BIOCHEM, V51, P470, DOI 10.1016/0003-2697(73)90502-2; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; KITAJIMA N, 1993, INORG CHEM, V32, P1879, DOI 10.1021/ic00062a001; KOPPENOL WH, 1984, ISR J CHEM, V24, P11; KUO CF, 1987, J BIOL CHEM, V262, P4724; LIOCHEV SI, 1991, J BIOL CHEM, V266, P8747; LIOCHEV SI, 1992, ARCH BIOCHEM BIOPHYS, V294, P138, DOI 10.1016/0003-9861(92)90147-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARZI I, 1993, J TRAUMA, V35, P110, DOI 10.1097/00005373-199307000-00018; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCLAUGHLIN VB, 1993, INORG CHEM, V32, P941, DOI 10.1021/ic00058a031; MELLOFILHO AC, 1991, MUTAT RES, V307, P109; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; NAKAE D, 1990, ARCH BIOCHEM BIOPHYS, V279, P315, DOI 10.1016/0003-9861(90)90497-M; NISHIKIMI M, 1975, ARCH BIOCHEM BIOPHYS, V166, P273, DOI 10.1016/0003-9861(75)90388-4; OYANAGUI Y, 1991, BIOCHEM PHARMACOL, V42, P991, DOI 10.1016/0006-2952(91)90280-I; PARIZADA B, 1991, FREE RADICAL RES COM, V15, P297, DOI 10.3109/10715769109105225; PASTERNACK RF, 1981, J INORG BIOCHEM, V15, P261, DOI 10.1016/S0162-0134(00)80161-0; PASTERNACK RF, 1979, J AM CHEM SOC, V101, P1026, DOI 10.1021/ja00498a038; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SAWADA Y, 1973, BIOCHIM BIOPHYS ACTA, V327, P257, DOI 10.1016/0005-2744(73)90408-7; SMITH JB, 1990, FREE RADICAL RES COM, V8, P101, DOI 10.3109/10715769009087980; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; SUTTON HC, 1989, FREE RADICAL BIO MED, V6, P53, DOI 10.1016/0891-5849(89)90160-3; TAKABATAKE T, 1992, CHEM PHARM BULL, V40, P1644; TIAN YP, 1993, BIOCHEM BIOPH RES CO, V191, P646, DOI 10.1006/bbrc.1993.1266; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; TRIANA JF, 1991, CIRC RES, V69, P731, DOI 10.1161/01.RES.69.3.731; TSANG PKS, 1990, INORG CHEM, V29, P2848, DOI 10.1021/ic00340a025; WADA K, 1994, ARCH BIOCHEM BIOPHYS, V310, P1, DOI 10.1006/abbi.1994.1132; WARD PA, 1988, FREE RADICAL BIO MED, V5, P403, DOI 10.1016/0891-5849(88)90114-1; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3	62	374	385	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23471	23476						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089112				2022-12-25	WOS:A1994PQ34500017
J	VALDEZ, BC; PERLAKY, L; HENNING, D; SAIJO, Y; CHAN, PK; BUSCH, H				VALDEZ, BC; PERLAKY, L; HENNING, D; SAIJO, Y; CHAN, PK; BUSCH, H			IDENTIFICATION OF THE NUCLEAR AND NUCLEOLAR LOCALIZATION SIGNALS OF THE PROTEIN P120 - INTERACTION WITH TRANSLOCATION PROTEIN B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SEQUENCES; CELLS; PROLIFERATION; PHOSPHOPROTEIN-B23; NUCLEOPHOSMIN; EXPRESSION; CONSTRUCT; ANTIGEN; SHUTTLE; DOMAINS	The human p120 nucleolar protein is a cell cycle-related protein that peaks during the S phase and has been shown to be associated with a beaded fibrillar structure. To study domains responsible for the nucleolar localization of protein p120, initially deletion mutants were made that defined sequences containing the localization signals; then, fusion genes that were composed of segments of the p120 molecule joined to the N-terminal end of the Escherichia coli beta-galactosidase were constructed. In the absence of the localization signals the beta-galactosidase remained in the cytoplasm. When the identified nuclear localization signal containing the amino acid sequence 99-110 (NAPRGKKRPAPG) was fused to the beta-galactosidase, the protein localized to the nucleus. When only the identified nucleolar localization signal containing the amino acid sequence 40-57 (SKRLSSRARKRAAKRRLG) was fused to the beta-galactosidase, the fusion protein remained in the cytoplasm. When both the nuclear and nucleolar localization signals were fused to the beta-galactosidase it localized predominantly to the nucleolus. Nucleolar protein B23, a putative ''shuttle protein,'' bound to amino acid sequence 24-56 of protein p120. Deletion analysis showed that amino acids 187-215 of protein B23 bound to protein p120. The results suggest that protein B23 may be part of the mechanism of protein targeting to the nucleolus.			VALDEZ, BC (corresponding author), BAYLOR COLL MED,DEPT PHARMACOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ABUELHEIGA L, 1992, CLIN IMMUNOL IMMUNOP, V64, P145, DOI 10.1016/0090-1229(92)90192-Q; ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BUSCH H, 1990, CANCER RES, V50, P4830; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CLACKSON T, 1991, GENERAL APPLICATIONS, P202; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIS FM, 1979, P NATL ACAD SCI USA, V76, P892, DOI 10.1073/pnas.76.2.892; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FREEMAN J W, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P261; FREEMAN JW, 1986, CANCER RES, V46, P3593; FREEMAN JW, 1991, CANCER RES, V51, P1973; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; HATANAKA M, 1992, 12TH P UOEH INT S ST, V15, P167; LAWRENCE CB, 1989, SOFTWARE PACKAGE NUC; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OLSON MOJ, 1981, EXP CELL RES, V135, P259, DOI 10.1016/0014-4827(81)90161-0; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PERLAKY L, 1992, CANCER RES, V52, P428; RICHTER JD, 1992, NUCLEAR TRAFFICKING, P89; SAIJO Y, 1993, CANCER LETT, V68, P95, DOI 10.1016/0304-3835(93)90134-U; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; TINLAND B, 1992, P NATL ACAD SCI USA, V89, P7442, DOI 10.1073/pnas.89.16.7442; VALDEZ BC, 1992, CANCER RES, V52, P5681; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; YAMASAKI L, 1992, NUCLEAR TRAFFICKING, P121	34	150	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23776	23783						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089149				2022-12-25	WOS:A1994PQ34500060
J	ZHANG, JM; FENG, Y; FORGAC, M				ZHANG, JM; FENG, Y; FORGAC, M			PROTON CONDUCTION AND BAFILOMYCIN BINDING BY THE V-0 DOMAIN OF THE COATED VESICLE V-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SUBUNIT COMPOSITION; PUMP; POLYPEPTIDE; RECONSTITUTION; PURIFICATION; INHIBITION; SYNTHASE; F0	We have previously demonstrated that the V-0 domain of the coated vesicle V-ATPase, a 250-kDa integral complex, does not form a functional proton channel (Zhang, J., Myers, M., and Forgac, M. (1992) J. Biol. Chem. 267, 9773-9778). In the present study we describe dissociation of the V-0 complex and separation of the V-0 subunits by gel filtration. Dicyclohexylcarbodiimide-inhibitable passive proton conductance of reconstituted Vesicles containing reassembled V-0 subunits was measured in response to a K+/valinomycin-generated membrane potential. We observed that reconstituted vesicles containing the 17/19-kDa subunits carried out passive proton transport, with the addition of the 38- and 100-kDa subunits increasing proton conductance. Reconstituted vesicles containing the 38- and/or 100-kDa subunits showed no proton transport. Partial separation of the 17- and 19-kDa subunits revealed that the 17-kDa subunit alone carried out proton transport, with increased conductance on the addition of the 19-kDa subunit. These results indicate that the V-0 domain possesses the information necessary to form a dicyclohexylcarbodiimide-inhibitable passive proton channel. Bafilomycin binding by native and reassembled V-0 complexes was also measured by their ability to protect V-ATPase activity against bafilomycin inhibition. The native V-0 domain, the isolated 100-kDa subunit and the 100/38-kDa subunits were able to protect against inhibition by bafilomycin, suggesting that the binding site for bafilomycin resides on the 100-kDa subunit.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1993, J BIOL CHEM, V268, P5649; BOWMAN BJ, 1989, J BIOL CHEM, V264, P1506; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FENG Y, 1992, J BIOL CHEM, V267, P5817; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FORGAC M, 1992, J EXP BIOL, V172, P155; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAI SP, 1988, J BIOL CHEM, V263, P16731; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PERIN MS, 1991, J BIOL CHEM, V266, P3877; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SUN SZ, 1987, J BIOL CHEM, V262, P14790; WANG SY, 1988, J BIOL CHEM, V263, P17638; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	27	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23518	23523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089118				2022-12-25	WOS:A1994PQ34500023
J	BUNTING, KD; LINDAHL, R; TOWNSEND, AJ				BUNTING, KD; LINDAHL, R; TOWNSEND, AJ			OXAZAPHOSPHORINE-SPECIFIC RESISTANCE IN HUMAN MCF-7 BREAST-CARCINOMA CELL-LINES EXPRESSING TRANSFECTED RAT CLASS-3 ALDEHYDE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CANCER-CELLS; CYCLOPHOSPHAMIDE; OXIDATION; IDENTIFICATION; SENSITIVITY; ALDOPHOSPHAMIDE; RETINALDEHYDE; METABOLISM; ACTIVATION	Overexpression of either class 1 or class 3 aldehyde dehydrogenase (ALDH) has been found in cell lines selected for resistance to the oxazaphosphorine (OAP) alkylating anticancer agent cyclophosphamide (CPA). Direct oxidation of the CPA metabolic intermediate aldophosphamide (ALDO) is catalyzed efficiently in vitro by the class 1 ALDH isozyme, but the involvement of the class 3 isozyme in OAP resistance is problematic since in vitro studies do not show efficient oxidation of ALDO. Cell lines were established that express stably transfected rat class 3 ALDH to model the potential role of this isozyme in OAF resistance. Clonogenic survival assay data indicated that even modest expression of rat class 3 ALDH was associated with resistance (2-4-fold) to the CPA analog mafosfamide and that the fold resistance was directly proportional to the class 3 ALDH activity expressed in clonal transfectants. Pretreatment of the highest activity cell line (3A1-31A) with 75 mu M diethyl-aminobenzaldehyde, an ALDH substrate and inhibitor of benzaldehyde oxidation, effectively reversed the 3.8-fold resistance in this line; drug sensitivity was unaffected by diethylaminobenzaldehyde in the control transfected cell line. The resistance conferred by ALDH to mafosfamide is OAP-specific since the 3A1-31A line is also resistant to 4-hydroperoxycyclophosphamide (2.9-fold) and 4-hydroperoxyifosfamide (3.2-fold) but not to the non-oxazaphosphorine drugs phosphoramide mustard and melphalan, which cannot be detoxified by aldehyde dehydrogenase enzymes.	WAKE FOREST UNIV,CTR COMPREHENS CANC,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069	Wake Forest University; Wake Forest Baptist Medical Center; University of South Dakota								CHANG TKH, 1993, CANCER RES, V53, P5629; CLARKE L, 1989, CANCER RES, V49, P2344; COLVIN M, 1990, CANCER CHEMOTHERAPY, P276; COX PJ, 1975, CANCER RES, V35, P3755; DEWYS WD, 1973, JNCI-J NATL CANCER I, V50, P783, DOI 10.1093/jnci/50.3.783; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; FREI E, 1988, CANCER RES, V48, P6417; GOEDDE HW, 1990, PHARMACOL THERAPEUT, V45, P345; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; HILTON J, 1984, CANCER RES, V44, P5156; HSU LC, 1992, J BIOL CHEM, V267, P3030; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; KOHN FR, 1985, BIOCHEM PHARMACOL, V34, P3465, DOI 10.1016/0006-2952(85)90719-1; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LINDAHL R, 1991, ADV EXP MED BIOL, V284, P1; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MANTHEY CL, 1988, BIOCHEM PHARMACOL, V37, P2781, DOI 10.1016/0006-2952(88)90041-X; MOREB J, 1992, CANCER RES, V52, P1770; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NIEMEYER U, 1989, PROGR CLIN BIOCH MED, V9, P35; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; SLADEK NE, 1991, ADV EXP MED BIOL, V284, P97; SLADEK NE, 1985, CANCER RES, V45, P1549; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SLADEK NE, 1989, DRUG METAB REV, V20, P697, DOI 10.3109/03602538909103572; SREERAMA L, 1993, BIOCHEM PHARMACOL, V45, P2487, DOI 10.1016/0006-2952(93)90231-K; SREERAMA L, 1993, ADV EXP MED BIOL, V328, P99; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; TOWNSEND AJ, 1989, J BIOL CHEM, V264, P21582; VICKERS PJ, 1988, DEV CANCER CHEMOTHER, V2, P117; YIN SJ, 1993, ADV EXP MED BIOL, V328, P87	33	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23197	23203						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083225				2022-12-25	WOS:A1994PQ16400047
J	LEFEBVRE, O; RUTH, J; SENTENAC, A				LEFEBVRE, O; RUTH, J; SENTENAC, A			A MUTATION IN THE LARGEST SUBUNIT OF YEAST TFIIIC AFFECTS TRANSFER-RNA AND 5-S RNA-SYNTHESIS - IDENTIFICATION OF 2 CLASSES OF SUPPRESSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; FACTOR-TAU; C III; 2ND-LARGEST SUBUNIT; GENE-TRANSCRIPTION; ESCHERICHIA-COLI; SHUTTLE VECTORS; DNA	We report the characterization of a mutation affecting tau(138), the largest subunit of yeast transcription factor IIIC (TFIIIC). A previously described thermosensitive mutation (tsv115), tightly linked to the centromere of chromosome I (Harris, S. D., and Pringle, J. R. (1991) Genetics 127, 279-285) is shown to lie in the TFC3 gene which encodes tau(138). The tau(138) subunit carrying this mutation bears a single substitution of Glu for Gly at position 349 (G349E). In extracts from mutant cells, both the level of TFIIIC and its affinity for tDNA were found to be reduced. The tDNA binding activity of mutant TFIIIC protein was very sensitive to mild heat treatments, and TFIIIC-DNA interaction was inhibited at moderate salt concentrations, as evidenced by gel shift assays. In addition, the tsv115 mutation affected 5 S RNA synthesis in vitro, suggesting that the tau(138) subunit also plays a role in recognition of the TFIIIA-5 S DNA complex. Multicopy suppressors of the TFIIIC defect were sought to reveal components participating in TFIIIC function. One class of suppressors encodes known components of the transcription machinery: two TFIIIC subunits, tau(95) and tau(131), the 70-kDa subunit of TFIIIB, TBP, and a shared subunit of RNA polymerase (pol) I, II, and III, ABC10 alpha; it also includes genes potentially related to pol III function, such as SRP40 which also suppresses a mutation in a subunit shared by RNA polymerases I and III. A second class of suppressors is not involved in transcription but alleviates the main physiological defects of mutant cells. It includes RPR1 and NOP1, required for the maturation of pre-tRNA and pre-rRNA, respectively.			LEFEBVRE, O (corresponding author), CTR ETUD SACLAY, CEA, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE.		LEFEBVRE, Olivier/C-3847-2014	LEFEBVRE, Olivier/0000-0002-3903-9450				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BELL GI, 1977, J BIOL CHEM, V252, P3082; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHIANNILKULCHAI N, 1992, MOL CELL BIOL, V12, P4433, DOI 10.1128/MCB.12.10.4433; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CONESA C, 1993, J BIOL CHEM, V268, P18047; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GUDENUS R, 1988, GENETICS, V119, P517; HARRIS SD, 1991, GENETICS, V127, P279; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1991, J BIOL CHEM, V266, P5616; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SEGALL J, 1986, J BIOL CHEM, V261, P1578; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STETTLER S, 1992, J BIOL CHEM, V267, P21390; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Treich Isabelle, 1992, Gene Expression, V2, P31; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; WILLIS I, 1989, EMBO J, V8, P4281, DOI 10.1002/j.1460-2075.1989.tb08614.x; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	73	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23374	23381						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083243				2022-12-25	WOS:A1994PQ16400071
J	POON, D; CAMPBELL, AM; BAI, Y; WEIL, PA				POON, D; CAMPBELL, AM; BAI, Y; WEIL, PA			YEAST TAF170 IS ENCODED BY MOT1 AND EXISTS IN A TATA BOX-BINDING PROTEIN (TBP)-TBP-ASSOCIATED FACTOR COMPLEX DISTINCT FROM TRANSCRIPTION FACTOR-IID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; GENE-TRANSCRIPTION; TBP; SUBUNIT; ACTIVATION; EXPRESSION; COACTIVATORS; STIMULATION; COMPONENTS	Our characterization of the Saccharomyces cerevisiae TATA box-binding protein (TBP) has led to the identification of nine specific yeast TBP-associated factors (TAFs) ranging in size from 170 to 25 kDa. The amino acid sequence derived from a purified TAF with an apparent M(r) of 170,000 indicates that yeast Taf170 is encoded by the essential yeast gene MOT1. We describe in this report a series of experiments that demonstrate that the protein encoded by MOT1 is a bona fide yeast TAF and that Taf170 forms a separate complex with TBP distinct from the RNA polymerase II-specific multisubunit transcription factor IID TBP-TAF complex. The significance of this unique TBP.Taf170 complex regarding transcriptional regulation is discussed.			POON, D (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232, USA.				NIDDK NIH HHS [DK42502] Funding Source: Medline; NIGMS NIH HHS [1F31 GM93003, 5T32 GM07347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; INOSTROZA JA, 1992, CELL, V70, P477; ISACSSON U, 1974, ANAL CHIM ACTA, V68, P339, DOI 10.1016/S0003-2670(01)82590-3; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; POON D, 1993, J BIOL CHEM, V268, P15325; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SIKORSKI RS, 1989, GENETICS, V122, P19; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23135	23140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083216				2022-12-25	WOS:A1994PQ16400038
J	BRATTON, DL				BRATTON, DL			POLYAMINE INHIBITION OF TRANSBILAYER MOVEMENT OF PLASMA-MEMBRANE PHOSPHOLIPIDS IN THE ERYTHROCYTE GHOST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; LIPID ASYMMETRY; AMINOPHOSPHOLIPID TRANSLOCASE; PLATELET ACTIVATION; BLOOD-PLATELETS; CROSS-LINKING; CELL-SURFACE; PROTEINS; SPERMINE; PHOSPHATIDYLSERINE	The resting plasma membrane of circulating blood cells demonstrates an asymmetric distribution of the phospholipid classes across the bilayer that is altered during cellular activation. To better understand the mechanisms governing transbilayer distribution of phospholipids, studies were conducted using the erythrocyte ghost, in which plasma membrane leaflet distribution of phospholipids can be readily probed. Preparation of ghosts by hypotonic lysis at increasingly high dilution markedly enhanced (up to 10-fold) calcium-induced (50-500 mu M) transbilayer movement of phospholipids. The enhanced transbilayer movement was assessed by translocation of exogenously added sn-2-[6[(7- nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl]-labeled phosphatidylcholine and phosphatidylserine from the plasma membrane outer leaflet to the inner leaflet and vice versa, as well as transbilayer movement of endogenous phosphatidylserine to the outer leaflet. It was found that phospholipid movement was bidirectional and also nonspecific with regard to polar head group. It was further demonstrated that preparation of ghosts at increasing dilution resulted in depletion of cellular polyamines and that physiologic replenishment of spermine, and to a lesser extent spermidine, resulted in significant inhibition (50 and 25%, respectively) of transbilayer movement of phospholipids. Replenishment of other di- and polyamines demonstrated that inhibition was not simply dependent on total cationic charge but rather on charge density and suggestive of specific interaction of the polyamines, particularly spermine, with the plasma membrane. As most cells demonstrate both a high degree of regulation in maintenance of polyamine levels and the means for facile shifts within cellular polyamine pools, it is suggested that loss of membrane asymmetry during cellular activation may be mediated in part through enhanced transbilayer movement of phospholipids due to altered polyamine-membrane associations.			BRATTON, DL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,D506,DENVER,CO 80206, USA.				NHLBI NIH HHS [HL34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BALLAS SK, 1983, P NATL ACAD SCI-BIOL, V80, P1942, DOI 10.1073/pnas.80.7.1942; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CHIU D, 1981, BLOOD, V58, P398; CHUNG L, 1985, BIOCHEMISTRY-US, V24, P442, DOI 10.1021/bi00323a030; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; COOPER KD, 1976, CLIN CHIM ACTA, V73, P71, DOI 10.1016/0009-8981(76)90307-7; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FARMER BT, 1985, BIOCHIM BIOPHYS ACTA, V821, P420, DOI 10.1016/0005-2736(85)90046-X; FESUS L, 1985, J BIOL CHEM, V260, P3771; GERRITSEN WJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P607, DOI 10.1016/0005-2736(80)90464-2; GRAMZINSKI RA, 1990, DIFFERENTIATION, V43, P59, DOI 10.1111/j.1432-0436.1990.tb00430.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAEST CWM, 1976, BIOCHIM BIOPHYS ACTA, V436, P353, DOI 10.1016/0005-2736(76)90199-1; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; LORAND L, 1987, BIOCHEMISTRY-US, V26, P308, DOI 10.1021/bi00375a043; LUCY JA, 1993, BIOCHEM SOC T, V21, P280, DOI 10.1042/bst0210280; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MEERS P, 1986, BIOCHEMISTRY-US, V25, P3109, DOI 10.1021/bi00359a007; MIDDELKOOP E, 1989, BIOCHIM BIOPHYS ACTA, V981, P151, DOI 10.1016/0005-2736(89)90093-X; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PALADE P, 1987, J BIOL CHEM, V262, P6149; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHINDLER M, 1980, P NATL ACAD SCI-BIOL, V77, P1457, DOI 10.1073/pnas.77.3.1457; SCHLEGEL RA, 1987, J CELL PHYSIOL, V132, P381, DOI 10.1002/jcp.1041320229; SEILER N, 1983, METHOD ENZYMOL, V94, P10; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHUBER F, 1989, BIOCHEM J, V260, P1; SHUKLA SD, 1982, ARCH BIOCHEM BIOPHYS, V214, P335, DOI 10.1016/0003-9861(82)90038-8; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; TILLY RHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P188, DOI 10.1016/0005-2736(90)90453-U; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; VANZOELEN EJJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P97, DOI 10.1016/0005-2736(78)90191-8; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; WYSE JW, 1988, BIOCHIM BIOPHYS ACTA, V941, P141, DOI 10.1016/0005-2736(88)90174-5; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046	53	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22517	22523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077200				2022-12-25	WOS:A1994PQ16300014
J	LATTION, AL; DIVIANI, D; COTECCHIA, S				LATTION, AL; DIVIANI, D; COTECCHIA, S			TRUNCATION OF THE RECEPTOR CARBOXYL-TERMINUS IMPAIRS AGONIST-DEPENDENT PHOSPHORYLATION AND DESENSITIZATION OF THE ALPHA(1B)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INOSITOL PHOSPHOLIPID-METABOLISM; ALPHA-1-ADRENERGIC RECEPTOR; HOMOLOGOUS DESENSITIZATION; PROMOTED DESENSITIZATION; PHOSPHATIDYLINOSITOL HYDROLYSIS; RAPID DESENSITIZATION; PHOSPHOINOSITIDASE-C; CELLS; INTERNALIZATION	The alpha(1B)-adrenergic receptor (alpha(1B)AR) and its truncated mutant T368 lacking the last 147 amino acids were stably expressed in Rat1 fibroblasts. The wild type alpha(1B)AR was rapidly phosphorylated upon exposure to the agonist epinephrine as well as to phorbol ester as assessed by immunoprecipitation of the receptor with antiserum raised against its amino-terminal portion. Exposure of cells expressing the wild type alpha(1B)AR to epinephrine resulted also in rapid homologous desensitization of receptor-mediated response on polyphosphoinositide hydrolysis. On the other hand, truncation of the serine- and threonine-rich carboxyl portion of the alpha(1B)AR abolished agonist-induced phosphorylation and greatly impaired homologous desensitization of the receptor. The truncated receptor T368 could undergo agonist-induced decrease of cell surface receptors but to a lesser extent, as compared with the wild type alpha(1B)AR. These results demonstrate that the carboxyl portion of the alpha(1B)AR plays a crucial role in the regulation of receptor function. They also suggest a strong relationship between agonist-induced phosphorylation and desensitization of the alpha(1B)AR, which were both insensitive to the inhibitor of protein kinase C RO-318220. Our findings support the emerging hypothesis that the biochemical mechanisms involved in rapid agonist dependent regulation of G protein-coupled receptors, which activate polyphosphoinositide hydrolysis, do not primarily involve protein kinase C.	UNIV LAUSANNE, FAC MED, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Geneva; University of Lausanne								BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DICKENSON JM, 1993, BRIT J PHARMACOL, V110, P1449, DOI 10.1111/j.1476-5381.1993.tb13984.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVA C, 1990, J PHARMACOL EXP THER, V253, P257; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MORRISON WJ, 1987, MOL PHARMACOL, V33, P58; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARIS S, 1988, J BIOL CHEM, V263, P11250; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WOLSING DH, 1993, J PHARMACOL EXP THER, V266, P253	39	129	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22887	22893						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077240				2022-12-25	WOS:A1994PQ16300065
J	LEE, DN; FENG, GH; LANDICK, R				LEE, DN; FENG, GH; LANDICK, R			GREA-INDUCED TRANSCRIPT CLEAVAGE IS ACCOMPANIED BY REVERSE TRANSLOCATION TO A DIFFERENT TRANSCRIPTION COMPLEX CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; ELONGATION-FACTOR; STRUCTURAL-ANALYSIS; DNA; SII; CHROMATOGRAPHY; TERMINATION; PROTEIN	GreA- and GreB-induced transcript cleavage drives reverse translocation of Escherichia coli RNA polymerase on a DNA template in the absence of NTPs (Feng, G;.-H., Lee, I). N., Wang, D., Chan, C. L., and Landick, R. (1994) J. Biol. Chem. 269, 22282-22294, accompanying report). During transcript elongation, the sizes of the DNA footprint and the single-stranded transcription bubble vary markedly among transcription complexes halted at different template positions. To test whether transcription complex intermediates formed during transcript cleavage-induced reverse translocation also display heterogeneous conformations at different template positions, we examined the structures of two different transcription complexes before and after GreA treatment. Transcription complexes halted at position +16 after initiation at the T7 A1 promoter or paused at the trpL pause site exhibited strong blocks to transcript cleavage after removal of 6 to 10 nucleotides. In both cases, the downstream contact between RNA polymerase and DNA moved little during transcript cleavage, thereby increasing its distance from the active site, whereas the upstream DNA contact and the borders of the transcription bubble moved in approximate register with the transcript 3'-end. The backward movements of halted E. coli RNA polymerase are similar to a recently postulated model for discontinuous translocation during transcription, but differ from those reported for arrested RNA polymerase II transcription complexes.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)					NIGMS NIH HHS [GM-38660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R29GM038660, R37GM038660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FENG GH, 1994, J BIOL CHEM, V269, P22282; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KRUMMEL B, 1990, THESIS U CALIFORNIA; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1987, RNA POLYM REGULATION, P441; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; REINES D, 1992, J BIOL CHEM, V267, P3795; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	38	23	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22295	22303						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071356				2022-12-25	WOS:A1994PE09800057
J	UHLINGER, DJ; TAYLOR, KL; LAMBETH, JD				UHLINGER, DJ; TAYLOR, KL; LAMBETH, JD			P67-PHOX ENHANCES THE BINDING OF P47-PHOX TO THE HUMAN NEUTROPHIL RESPIRATORY BURST OXIDASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE; PLASMA-MEMBRANE; CYTOSOLIC COMPONENTS; GUANINE-NUCLEOTIDES; CYTOCHROME-B; ACTIVATION; PROTEIN	The neutrophil respiratory burst oxidase consists of both the plasma membrane-associated flavocytochrome b(558) and cytosolic regulatory proteins including p47-phox, p67-phox, and a small GTP-binding protein (Rac1 and/or Rac2). Oxidase activation is thought to result from the assembly of the cytosolic components on the cytochrome. A model has been proposed in which p47-phox binds directly to the cytochrome, while p67-phox binding occurs indirectly by binding to p47-phox. We have carried out a steady state kinetic analysis using a cell free semirecombinant activation system (isolated plasma membrane plus recombinant cytosolic factors) to analyze the effects of p47-phox and p67-phox on one another's association in the active oxidase complex. As predicted from the model, increasing p47-phox concentration markedly lowered the EC(50) for p67-phox, indicating that p67-phox is dependent upon p47-phox for binding. Unexpectedly, increasing p67-phox concentration also produced a significant enhancement of p47-phox binding. Thus, a more complex binding model must be invoked in which p47-phox and p67-phox mutually enhance one another's binding.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NATIONAL CANCER INSTITUTE [R01CA022294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NCI NIH HHS [CA22294] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KRECK ML, 1994, J BIOL CHEM, V269, P4161; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIKI H, 1994, J BIOL CHEM, V269, P5489; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; QUINN MT, 1993, J BIOL CHEM, V268, P20983; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTROSEND, 1992, SCIENCE, V256, P1459; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; WYMAN J, 1964, ADVANCES PROTEIN CHE, V19, P224	31	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22095	22098						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071333				2022-12-25	WOS:A1994PE09800028
J	FILVAROFF, E; CALAUTTI, E; REISS, M; DOTTO, GP				FILVAROFF, E; CALAUTTI, E; REISS, M; DOTTO, GP			FUNCTIONAL EVIDENCE FOR AN EXTRACELLULAR CALCIUM RECEPTOR MECHANISM TRIGGERING TYROSINE KINASE ACTIVATION-ASSOCIATED WITH MOUSE KERATINOCYTE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TERMINAL DIFFERENTIATION; EPIDERMAL-CELLS; INTRACELLULAR CALCIUM; MURINE KERATINOCYTES; PARATHYROID CELLS; SIGNAL TRANSDUCTION; E-CADHERIN; PROTEIN; PHOSPHORYLATION; METABOLISM	Calcium-induced keratinocyte differentiation is associated with tyrosine phosphorylation of a p62 protein which associates with the ras-GTPase activating protein (GAP). We have examined the nature of the cal dum signal triggering p62 phosphorylation. EGTA, a specific chelator of calcium, was able to completely block calcium induced p62 phosphorylation, even after using conditioned medium from calcium-treated keratinocytes. Preventing calcium-induced cell-cell contacts by anti-cadherin antibodies did not inhibit tyrosine phosphorylation. Slight increases in extracellular calcium concentrations (0.15 or 0.30 mM) were already sufficient to induce p62 phosphorylation. Other divalent cations, such as magnesium, zinc, nickel, and cobalt, but not the trivalent cation lanthanum, induced p62 phosphorylation to a similar extent as calcium. There was no close correlation between the ability of the various ions to induce p62 phosphorylation and increase free intracellular calcium. Similarly, treatment of primary keratinocytes with the calcium ionophores A23187 or X537A did not induce p62 phosphorylation, although it increased free intracellular calcium levels. Finally, blockers of potassium uptake, which is induced by calcium, did not inhibit p62 phosphorylation. Thus, in keratinocyte differentiation, calcium is likely to provide the primary signal for p62 tyrosine phosphorylation and may act directly at the cell membrane through a ''cationic receptor mechanism'' analogous to that described in other cell types.	YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,DEPT PATHOL & BIOL,NEW HAVEN,CT 06510	Yale University; Yale University			Calautti, Enzo/M-8283-2018	Calautti, Enzo/0000-0002-4439-9709; Reiss, Michael/0000-0001-8543-8092	NATIONAL CANCER INSTITUTE [P01CA008341, R01CA045708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA08341, CA 45708] Funding Source: Medline; NIAMS NIH HHS [AR 39190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1990, CELL CALCIUM, V11, P333, DOI 10.1016/0143-4160(90)90035-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; GRAYSON S, 1985, J INVEST DERMATOL, V74, P508; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J INVEST DERMATOL, V81, pS50, DOI 10.1111/1523-1747.ep12540491; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; HENNINGS H, 1989, CARCINOGENESIS, V10, P777, DOI 10.1093/carcin/10.4.777; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; JUHLIN C, 1990, J BIOL CHEM, V265, P8275; JUHLIN C, 1987, BIOCHEM BIOPH RES CO, V143, P570, DOI 10.1016/0006-291X(87)91391-X; KAMPS MP, 1988, ONCOGENE, V2, P305; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LEE E, 1991, CARCINOGENESIS, V12, P1651, DOI 10.1093/carcin/12.9.1651; LI LW, 1993, J CELL PHYSIOL, V154, P643, DOI 10.1002/jcp.1041540324; MALMGUIST KG, 1904, NUCL INSTRUM METHODS, V3, P611; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; NEMETH EF, 1990, CELL CALCIUM, V11, P319, DOI 10.1016/0143-4160(90)90032-P; NYGREN P, 1988, BIOCHIM BIOPHYS ACTA, V968, P253, DOI 10.1016/0167-4889(88)90014-6; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; REED PW, 1972, J BIOL CHEM, V247, P6970; REISS M, 1991, J CELL PHYSIOL, V147, P281, DOI 10.1002/jcp.1041470213; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; WILLIAMLAU KH, 1989, BIOCHEM BIOPH RES CO, V257, P23; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHAO YH, 1993, MOL CELL BIOL, V13, P7507, DOI 10.1128/MCB.13.12.7507; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298; ZIBOH VA, 1984, BIOCHEM BIOPH RES CO, V122, P1234, DOI 10.1016/0006-291X(84)91224-5	40	43	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21735	21740						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063817				2022-12-25	WOS:A1994PK97300054
J	SHEIKH, MS; SHAO, ZM; LI, XS; DAWSON, M; JETTEN, AM; WU, SL; CONLEY, BA; GARCIA, M; ROCHEFORT, H; FONTANA, JA				SHEIKH, MS; SHAO, ZM; LI, XS; DAWSON, M; JETTEN, AM; WU, SL; CONLEY, BA; GARCIA, M; ROCHEFORT, H; FONTANA, JA			RETINOID-RESISTANT ESTROGEN RECEPTOR-NEGATIVE HUMAN BREAST-CARCINOMA CELLS TRANSFECTED WITH RETINOIC ACID RECEPTOR-ALPHA ACQUIRE SENSITIVITY TO GROWTH-INHIBITION BY RETINOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; X-RECEPTOR; CANCER CELLS; THYROID-HORMONE; GENE-EXPRESSION; GRANULOCYTIC DIFFERENTIATION; RAR-ALPHA; PROLIFERATION; IDENTIFICATION; SUPERFAMILY	Retinoids mediate their actions via RARs (retinoic acid receptors) and RXRs (retinoid X receptors). Each class of these nuclear retinoid receptors is further subdivided into three species, namely alpha, beta, and gamma. Recent studies demonstrate that estrogen receptor (ER)-positive human breast carcinoma (HBC) cell lines and tumor samples exhibit significantly higher levels of RAR alpha than their ER-negative counterparts. ER-positive HBC cell lines are sensitive to, and ER-negative cell Lines are resistant to, growth inhibitory effects of retinoic acid (RA). We previously demonstrated that the expression of functional ERs in an established ER-negative cell line resulted in higher levels of RAR alpha and sensitivity to growth inhibition by RA. To further investigate the major role of RAR alpha in retinoid-mediated inhibition of growth, we transfected RAR alpha cDNA in two RA-resistant ER-negative HBC cell lines. Analyses of different clonal populations of RAR alpha transfectants from each cell line revealed growth inhibition by retinoids. Utilizing RAR- and RXR-class selective retinoids, we further demonstrated that only the RAR alpha-selective retinoids mediated the growth inhibition in these cells, while the RXR-selective retinoids were biologically inert. We thus provide evidence that the molecular mechanisms of retinoid inhibition of HBC proliferation predominantly involve RAR alpha.	UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,DIV ONCOL,BALTIMORE,MD 21201; UNIV MONTPELLIER 1,FAC MED,INSERM,U148,F-34090 MONTPELLIER,FRANCE; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025; NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,RES TRIANGLE PK,NC 27709	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; SRI International; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445; Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [R01CA063335] Funding Source: NIH RePORTER; NCI NIH HHS [CA63335] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAWSON MI, 1989, J MED CHEM, V32, P1504, DOI 10.1021/jm00127a018; DAWSON MI, 1993, RETINOIDS NEW TRENDS; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1989, ANAL BIOCHEM, V132, P6; FONTANA JA, 1990, CANCER RES, V50, P1977; FONTANA JA, 1990, CANCER RES, V50, P1997; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GARCIA M, 1990, ONCOGENE, V5, P1809; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KIEFER MC, 1988, NUCLEIC ACIDS RES, V16, P5213, DOI 10.1093/nar/16.11.5213; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; LOHNES D, 1992, J CELL SCI S, V16, P69; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1993, J CELL BIOCH F S, V17, P176; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MAIGNAN J, 1988, Patent No. 2601670; MARSHALL JA, 1983, J AM CHEM SOC, V105, P5679, DOI 10.1021/ja00355a027; MARTH C, 1984, BIOCHEM PHARMACOL, V33, P2217, DOI 10.1016/0006-2952(84)90657-9; MOON RC, 1985, CIBA F SYMP, V113, P156; MOON RC, 1983, CANCER RES, V43, P2469; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; Sambrook J, 1989, MOL CLONING LABORATO; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SHAO ZM, 1994, INT J ONCOL, V4, P859; SHEIKH MS, 1993, MOL CELL ENDOCRINOL, V92, P153, DOI 10.1016/0303-7207(93)90002-2; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHEIKH MS, 1993, BIOCHEM BIOPH RES CO, V193, P1232, DOI 10.1006/bbrc.1993.1757; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	54	116	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21440	21447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063776				2022-12-25	WOS:A1994PK97300011
J	FITZGERALD, DJ; DRYDEN, GL; BRONSON, EC; WILLIAMS, JS; ANDERSON, JN				FITZGERALD, DJ; DRYDEN, GL; BRONSON, EC; WILLIAMS, JS; ANDERSON, JN			CONSERVED PATTERNS OF BENDING IN SATELLITE AND NUCLEOSOME POSITIONING RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-DIRECTED CURVATURE; HISTONE-DNA INTERACTIONS; CURVED DNA; DROSOPHILA-MELANOGASTER; KINETOPLAST DNA; CORE PARTICLE; W-CHROMOSOME; BENT DNA; CHROMATIN; TRANSCRIPTION	Intrinsic DNA curvature has previously been implicated in the condensation of satellite DNA in chromatin. In this article, electrophoretic methods and computer programs for predicting DNA structure from nucleotide sequence were used to determine if curvature is a conserved feature of satellite DNA The results revealed that satellite sequences display wide variation in magnitude of intrinsic bending. Less than half of the satellites examined were strongly bent when compared with control DNA. However, a conserved pattern of bending was seen in all 57 satellite sequences that were studied. The pattern consisted of repeating units of two 50-60-base pair bending elements which were separated by a 20-30-base pair region of low curvature. This pattern resembles qualitatively the bending of DNA in the nucleosome where the helix is folded approximately two turns around the histone octomer with the turns interrupted by a less bent segment in the center of the particle. The distance between successive pairs of bending elements was also similar to the average spacing of nucleosomes in chromatin. Thus, the conserved structures could play some role in the positioning of nucleosomes along satellite chromatin. In order to strengthen the correlation between DNA structure and nucleosome positioning, sequences were examined which have been shown to position nucleosomes at single major sites. This analysis revealed a conserved pattern of DNA structure resembling the two peak units seen in satellites. In addition, the nucleotide sequence patterns responsible for the conserved patterns of bending were similar in both satellite and nucleosome positioning DNA. Likewise, nucleotide sequence patterns that are thought to direct the rotational orientation of DNA in the nucleosome were similar in both sequence sets. These results are considered in terms of a general model for the role of DNA bending and nucleotide sequence in the control of nucleosome positioning and chromatin condensation in eukaryotes.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [1-T32-CA09634-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM41708-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BARSACCHIPILONE G, 1986, CHROMOSOMA, V93, P435, DOI 10.1007/BF00285826; BENFANTE R, 1989, NUCLEIC ACIDS RES, V17, P8273, DOI 10.1093/nar/17.20.8273; BIGOT Y, 1990, MOL BIOL EVOL, V7, P351; BOCK H, 1984, J MOL BIOL, V176, P131, DOI 10.1016/0022-2836(84)90385-1; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BUCKLAND RA, 1985, J MOL BIOL, V186, P25, DOI 10.1016/0022-2836(85)90253-0; CARRERA P, 1991, NUCLEIC ACIDS RES, V19, P5639, DOI 10.1093/nar/19.20.5639; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DAVIE JR, 1988, BIOCHEM CELL BIOL, V66, P256, DOI 10.1139/o88-034; DONG F, 1991, P NATL ACAD SCI USA, V229, P1109; DOSHI P, 1991, MOL BIOL EVOL, V8, P721; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; ECKDAHL TT, 1987, NUCLEIC ACIDS RES, V15, P8531; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HAUGHTPOWERS J, 1991, J MOL BIOL, V221, P795, DOI 10.1016/0022-2836(91)80176-U; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; INOKUCHI K, 1988, NUCLEIC ACIDS RES, V16, P6693, DOI 10.1093/nar/16.14.6693; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; John B, 1979, Int Rev Cytol, V58, P1, DOI 10.1016/S0074-7696(08)61473-4; KABSCH W, 1982, NUCLEIC ACIDS RES, V10, P1097, DOI 10.1093/nar/10.3.1097; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LINXWEILER W, 1985, CELL, V42, P281; LOCKLEAR L, 1990, NUCLEIC ACIDS RES, V18, P7015, DOI 10.1093/nar/18.23.7015; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MARTINEZBALBAS A, 1990, BIOCHEMISTRY-US, V29, P2342, DOI 10.1021/bi00461a019; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MIKLOS GLG, 1982, GENOME EVOLUTION, P41; Monckton Darren G., 1993, Current Opinion in Biotechnology, V4, P660, DOI 10.1016/0958-1669(93)90046-Y; MUSICH PR, 1977, COLD SPRING HARB SYM, V42, P1147; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NEUBAUER B, 1986, J MOL BIOL, V190, P639, DOI 10.1016/0022-2836(86)90249-4; NUSSINOV R, 1989, BIOCHIM BIOPHYS ACTA, V1008, P329, DOI 10.1016/0167-4781(89)90024-9; OMORI A, 1980, NUCLEIC ACIDS RES, V8, P5363, DOI 10.1093/nar/8.22.5363; PAGES M, 1988, EUR J BIOCHEM, V174, P391, DOI 10.1111/j.1432-1033.1988.tb14110.x; PLOHL M, 1990, BIOCHIMIE, V72, P665, DOI 10.1016/0300-9084(90)90049-M; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; PUHL HL, 1993, J MOL BIOL, V229, P827, DOI 10.1006/jmbi.1993.1089; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SAITOH Y, 1991, CHROMOSOMA, V101, P32, DOI 10.1007/BF00360684; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SATCHWELL SC, 1989, EMBO J, V8, P229, DOI 10.1002/j.1460-2075.1989.tb03368.x; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TALARICO D, 1988, MOL CELL BIOL, V8, P1336, DOI 10.1128/MCB.8.3.1336; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANWYE JD, 1991, NUCLEIC ACIDS RES, V19, P5253, DOI 10.1093/nar/19.19.5253; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0; ZHANG XY, 1984, J MOL BIOL, V176, P105, DOI 10.1016/0022-2836(84)90384-X	77	100	100	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21303	21314						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063755				2022-12-25	WOS:A1994PC40300073
J	KRUDE, T; KNIPPERS, R				KRUDE, T; KNIPPERS, R			MINICHROMOSOME REPLICATION IN-VITRO - INHIBITION OF RE-REPLICATION BY REPLICATIVELY ASSEMBLED NUCLEOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; LARGE-T-ANTIGEN; PARENTAL NUCLEOSOMES; MAMMALIAN-CELLS; INVITRO REPLICATION; XENOPUS EGGS; CHROMATIN; EXTRACTS; PROTEIN; INITIATION	Single-stranded circular DNA, containing the SV40 origin sequence, was used as a template for complementary DNA strand synthesis in cytosolic extracts from HeLa cells. In the presence of the replication-dependent chromatin assembly factor CAF-1, defined numbers of nucleosomes were assembled during complementary DNA strand synthesis. These minichromosomes were then induced to semiconservatively replicate by the addition of the SV40 initiator protein T antigen (re-replication). The results indicate that re-replication of minichromosomes appears to be inhibited by two independent mechanisms. One acts at the initiation of minichromosome re-replication, and the other affects replicative chain elongation. To directly demonstrate the inhibitory effect of replicatively assembled nucleosomes, two types of minichromosomes were prepared: (i) post-replicative minichromosomes were assembled in a reaction coupled to replication as above; (ii) pre-replicative minichromosomes were assembled independently of replication on double stranded DNA. Both types of minichromosomes were used as templates far DNA replication under identical conditions. Replicative fork movement was found to be impeded only on post-replicative minichromosome templates. In contrast, pre-replicative minichromosomes allowed one unconstrained replication cycle, but re-replication was inhibited due to a block in fork movement. Thus, replicatively assembled chromatin may have a profound influence on the re-replication of DNA.	UNIV KONSTANZ,FAK BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz				Krude, Torsten/0000-0002-1842-1933				ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1988, CANCER CELL, V6, P229; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; ISHIMI Y, 1992, J BIOL CHEM, V267, P10910; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; KRUDE T, 1993, J BIOL CHEM, V268, P14432; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; KRUDE T, 1993, MOL CELL BIOL, V13, P1059, DOI 10.1128/MCB.13.2.1059; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LASSLE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P1, DOI 10.1016/0167-4781(92)90045-2; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P343; MATHEWS JM, 1985, ENZYMOLOGY POST TRAN, V2, P125; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Sambrook J, 1989, MOL CLONING LABORATO; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; SUGASAWA K, 1992, P NATL ACAD SCI USA, V89, P1055, DOI 10.1073/pnas.89.3.1055; TACK LC, 1987, J BIOL CHEM, V262, P6339; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	57	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21021	21029						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063720				2022-12-25	WOS:A1994PC40300034
J	STRAWN, LM; MANN, E; ELLIGER, SS; CHU, LM; GERMAIN, LL; NIEDERFELLNER, G; ULLRICH, A; SHAWVER, LK				STRAWN, LM; MANN, E; ELLIGER, SS; CHU, LM; GERMAIN, LL; NIEDERFELLNER, G; ULLRICH, A; SHAWVER, LK			INHIBITION OF GLIOMA CELL-GROWTH BY A TRUNCATED PLATELET-DERIVED GROWTH-FACTOR-BETA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIMIAN SARCOMA-VIRUS; PDGF RECEPTOR; V-SIS; SIGNAL-TRANSDUCTION; B-CHAIN; AUTOCRINE TRANSFORMATION; LIGAND-BINDING; MESSENGER-RNA; CDNA CLONING	Abnormal expression of platelet-derived growth factor (PDGF) receptors has been observed in malignant glioma and other tumors such as osteosarcomas and malignant melanomas. However, their role in the development and maintenance of the tumors is not understood. Signaling through the PDGF receptors is activated by ligand-induced dimerization. Thus, introduction of mutant receptors that are kinase deficient but still dimerization competent is one strategy to study the importance of PDGF receptors in glioma cell growth. A truncated PDGF-beta receptor was introduced into C6 rat glioma cells and the PDGF-mediated signaling and subsequent cell growth studied. In clones expressing the mutant receptor, PDGF-BB-induced tyrosine phosphorylation of the endogenous receptor was significantly reduced. In addition, these cells grew to lower density in culture and formed smaller colonies in soft agar than the C6 parental cells. Furthermore, the ability of cells expressing the truncated receptor to grow as xenografts in nude mice was significantly impaired. These results support the important role for the PDGF-beta receptor in C6 glioma cell growth. They also demonstrate the usefulness of dominant-negative mutants of the PDGF receptor for the evaluation of the role of the receptor in tumorigenesis.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society	STRAWN, LM (corresponding author), SUGEN INC,REDWOOD CITY,CA 94063, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Deinhardt F., 1980, VIRAL ONCOLOGY, P359; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1989, BRIT MED BULL, V45, P453, DOI 10.1093/oxfordjournals.bmb.a072334; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JAMES CD, 1988, CANCER RES, V48, P5546; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1991, J BIOL CHEM, V266, P16755; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VASSBOTN FS, 1993, MOL CELL BIOL, V13, P4066, DOI 10.1128/MCB.13.7.4066; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WESTPHAL M, 1989, NEUROSURGERY, V25, P681, DOI 10.1227/00006123-198911000-00001; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	56	101	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21215	21222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063742				2022-12-25	WOS:A1994PC40300060
J	FINCH, RA; REVANKAR, GR; CHAN, PK				FINCH, RA; REVANKAR, GR; CHAN, PK			NUCLEOLAR LOCALIZATION OF NUCLEOPHOSMIN/B23 REQUIRES GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-INHIBITORY PROPERTIES; RIBOSOMAL-RNA SYNTHESIS; MURINE TUMOR-CELLS; IMP DEHYDROGENASE; HELA-CELLS; PROTEIN-B23 TRANSLOCATION; GENE-EXPRESSION; B23; 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE; NUCLEAR	Incubation of HeLa cells with the IMP dehydrogenase inhibitors: ribavirin (100 muM, 4 h), tiazofurin (100 muM, 4 h), selenazofurin (100 muM, 4 h), or mycophenolic acid (10 muM, 4 h) resulted in approximately 70% reduction in cellular GTP pools and shifting of nucleophosmin/B23 from nucleoli to nucleoplasm as detected by immunofluorescence (B23-translocation). Enzyme-linked immunosorbent assay and Western blot assay showed there is no loss or degradation of nucleophosmin/B23 protein during drug treatment. This translocation effect could be prevented by co-incubation with guanosine (100 muM) or reversed by addition of guanosine (100 muM) to the culture medium after B23-translocation had been induced by these inhibitors. Under these conditions of guanosine supplementation, cellular GTP pool concentrations were maintained at the control level. These results indicate that localization of nucleophosmin/B23 into the nucleolus is dependent, on the cellular GTP level.	BAYLOR COLL MED,DEPT PHARMACOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; TRIPLEX PHARMACEUT CORP,THE WOODLANDS,TX 77380	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA042476] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACS G, 1964, P NATL ACAD SCI USA, V52, P493, DOI 10.1073/pnas.52.2.493; BALLAL NR, 1974, LIFE SCI, V14, P1835; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Busch H., 1970, NUCLEOLUS; BUSCH RK, 1984, LIFE SCI, V35, P1777, DOI 10.1016/0024-3205(84)90275-3; CHAN PK, 1988, CANCER LETT, V40, P143, DOI 10.1016/0304-3835(88)90004-3; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN PK, 1987, CANCER RES, V47, P3798; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEVER TE, 1989, GUANINE NUCLEOTIDE B, P35; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FINCH RA, 1992, ONCOLOGY, V49, P223; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEBEYEHU G, 1985, J MED CHEM, V28, P99, DOI 10.1021/jm00379a018; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; JAYARAM HN, 1983, BIOCHEM PHARMACOL, V32, P2633, DOI 10.1016/0006-2952(83)90038-2; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2371, DOI 10.1016/0006-2952(82)90532-9; KHYM JX, 1975, CLIN CHEM, V21, P1245; KUTTAN R, 1982, BIOCHEM BIOPH RES CO, V107, P862, DOI 10.1016/0006-291X(82)90602-7; LOWE JK, 1977, CANCER RES, V37, P736; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MATSUMOTO SS, 1990, BIOCHEM PHARMACOL, V39, P455, DOI 10.1016/0006-2952(90)90050-U; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; SAUNDERS PP, 1983, MOL PHARMACOL, V23, P534; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SMITH CM, 1974, BIOCHEM PHARMACOL, V23, P2727, DOI 10.1016/0006-2952(74)90043-4; SMITH RA, 1984, CLIN APPLICATIONS RI; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SRIVASTAVA PC, 1983, J MED CHEM, V26, P445, DOI 10.1021/jm00357a024; SRIVASTAVA PC, 1977, J MED CHEM, V20, P256, DOI 10.1021/jm00212a014; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; SWEET P, 1989, CANCER RES, V49, P677; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; WEISS JW, 1974, CANCER RES, V34, P581; WELDON SL, 1990, J BIOL CHEM, V265, P7308; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1986, CANCER RES, V46, P922	51	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5823	5827						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095498				2022-12-25	WOS:A1993KR82200070
J	CHANG, CH; SONG, DL				CHANG, CH; SONG, DL			MELITTIN POTENTIATES GUANYLATE-CYCLASE ACTIVATION STIMULATED BY ATRIAL-NATRIURETIC-FACTOR AND ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT LUNG MEMBRANES; FACTOR RECEPTOR; PEPTIDE RECEPTOR; WASP VENOM; PROTEIN; PURIFICATION; MASTOPARAN; BINDING	The biologically relevant receptor for atrial natriuretic factor (ANF) has been shown to be membrane-bound guanylate cyclase. While guanylate cyclase is known to be activated by ANF and ATP, the molecular mechanism of the enzyme activation remains unclear. We now show that melittin, the main peptide toxin of bee venom, activates membrane-bound guanylate cyclase and potentiates ANF- and ATP-stimulated guanylate cyclase activity in rat lung membranes. Melittin stimulated basal guanylate cyclase activity by increasing the V(max) without significantly affecting the K(m) of the substrate, GTP. However, melittin enhances ANF- and ATP-stimulated enzyme activity by altering both the V(max) and the EC50 of ANF and ATP. Although melittin activates guanylate cyclase in crude membranes, it has little effect on the activity of the purified enzyme. The effect of melittin on guanylate cyclase activation in rat lung membranes is attenuated by the Ca2+ chelator, EGTA. These results suggest that the effects of melittin on guanylate cyclase activation may require the participation of accessory proteins or non-protein factors. Therefore, melittin would be a valuable tool for exploring the molecular mechanisms of ANF-mediated guanylate cyclase activation.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ON,CANADA	Case Western Reserve University; University of Toronto	CHANG, CH (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,DIV HYPERTENS & ENDOCRINOL,W165,CLEVELAND,OH 44106, USA.		Chang, Chung-Ho/B-1068-2010					BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BIANCHI C, 1985, HISTOCHEMISTRY, V82, P441, DOI 10.1007/BF02450479; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG CH, 1991, BIOCHIM BIOPHYS ACTA, V1093, P42, DOI 10.1016/0167-4889(91)90136-L; CHANG CH, 1990, EUR J PHARM-MOLEC PH, V189, P293, DOI 10.1016/0922-4106(90)90122-E; CHANG CH, 1991, FASEB J, V5, pA673; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COX JA, 1985, J BIOL CHEM, V260, P2527; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; GAZZANO H, 1991, BIOCHIM BIOPHYS ACTA, V1077, P99, DOI 10.1016/0167-4838(91)90531-4; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; IVANOVA K, 1990, EUR J PHARM-MOLEC PH, V189, P317, DOI 10.1016/0922-4106(90)90125-H; KUNO T, 1986, J BIOL CHEM, V261, P5817; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LEITMAN DC, 1987, ENDOCRIN METAB CLIN, V16, P79, DOI 10.1016/S0889-8529(18)30496-1; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; POTTER L R, 1992, Biophysical Journal, V61, pA79; QUIRION R, 1986, P NATL ACAD SCI USA, V83, P174, DOI 10.1073/pnas.83.1.174; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; WALDMAN SA, 1987, PHARMACOL REV, V39, P163	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4908	4911						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095264				2022-12-25	WOS:A1993KP88400053
J	BUSH, KT; STUART, RO; LI, SH; MOURA, LA; SHARP, AH; ROSS, CA; NIGAM, SK				BUSH, KT; STUART, RO; LI, SH; MOURA, LA; SHARP, AH; ROSS, CA; NIGAM, SK			EPITHELIAL INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS - MULTIPLICITY OF LOCALIZATION, SOLUBILITY, AND ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; SUBCELLULAR-DISTRIBUTION; ENDOPLASMIC-RETICULUM; PURKINJE-CELLS; MDCK CELLS; PROTEIN; CAVEOLAE; CALCIUM	In an earlier subcellular fractionation study of epithelial tissue (liver and pancreas), we demonstrated that the inositol 1,4,5-trisphosphate receptor (IP(3)R) is found in association with biochemically distinct cellular membranes, including the endoplasmic reticulum (ER) and plasma membrane (Sharp, A H., Snyder, S. H., and Nigam, S. K. (1992) J. Biol. Chem. 267, 7444-7449). To further characterize epithelial IP(3)Rs, we have now employed cultured Madin-Darby canine kidney (MDCK) cells, a well studied tight polarized epithelial cell type. Indirect immunofluorescence with an antiserum which specifically recognizes IP(3)R in MDCK cells by immunoblotting and immunoprecipitation gave an ER-like staining pattern as well as a basolateral plasma membrane like staining pattern, the latter being particularly evident in highly confluent monolayers. In sections of adult rat kidney tubules a similar staining pattern was observed. Interestingly, whereas known basolateral proteins (Na+,K+-ATPase and the facilitated glucose trans porter) gave a continuous basolateral staining pattern, that seen for IP(3)R was discontinuous (punctate). A highly similar staining pattern was observed for the caveolar protein, caveolin, suggesting that the punctate basolateral plasma membrane-like staining pattern observed for IP(3)R reflects its localization to basolateral caveolae. Biotinylation of non-permeabilized and permeabilized MDCK cells, followed by immunoprecipitation of IP(3)R and detection with streptavidin, indicated that while most IP(3)R is localized to biotin-inaccessible compartments (i.e. ER), a fraction (10-20%) of IP(3)R was accessible to externally added biotin primarily from the basolateral side. This result is compatible with the dual ER and basolateral caveolar localization suggested by immunocytochemistry, although it does not exclude the presence of some IP(3)R in the basolateral plasma membrane as well. Solubility studies revealed IP(3)R to be considerably more insoluble than the basolateral proteins, Na+,K+-ATPase and the liver cell adhesion molecule, as well as the cytoskeletal proteins, ankyrin and fodrin. In the most insoluble fraction, IP(3)R was found along with caveolin, further supporting the notion that part of the cellular IP(3)R pool associates with caveolae. Since multiple localizations of IP(3)R within a cell might reflect the existence of multiple isoforms, polymerase chain reaction amplification of first strand cDNA with primers specific for the three isotypes of IP(3)R was performed. All three isoforms of IP(3)R were expressed in the homogeneous population of MDCK cells. The existence of distinct membrane localizations and multiple isoforms of IP(3)R within the same cell type suggests an explanation for the complex spatiotemporal patterns of Ca2+ release from inositol 1,4,5-trisphosphate-sensitive Ca2+ pools in epithelial and other cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,RENAL DIV,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Nigam S K, 1992, Curr Opin Nephrol Hypertens, V1, P187, DOI 10.1097/00041552-199212000-00001; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHARP AH, 1992, J BIOL CHEM, V267, P7444; STUART RO, 1994, J CELL PHYSL, V159, P323; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x	33	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23694	23699						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089140				2022-12-25	WOS:A1994PQ34500048
J	BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW				BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW			ALTERATIONS OF THE GROWTH-CHARACTERISTICS OF THE FIBROBLAST CELL-LINE C3H 10T1/2 BY MEMBERS OF THE WNT GENE FAMILY	ONCOGENE			English	Article							MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; EXPRESSION INVITRO; PROTEIN; TRANSFORMATION; PROTOONCOGENE; GLAND; CONSTRUCTION; HYPERPLASIA; RETROVIRUS	Retroviral vectors were used to introduce members of the Wnt gene family into the embryonic fibroblast cell line C3H 10T1/2. In contrast to previous reports where no effect of Wnt genes on fibroblasts was seen, we found that the expression of Wnt-1, Wnt-6 and Wnt-7b altered the appearance of the cells when maintained at confluence. The cells were smaller and grew to a higher density than cells containing a control. retrovirus or cells expressing Wnt-4 or Wnt-5b. Detailed analysis of growth characteristics of polyclonally infected cultures demonstrated that the Wnt-1, Wnt-6 and Wnt-7b expressing cells grew to a higher density in 5% fetal calf serum than control or Wnt-5b expressing cells. Wnt-4 expressing cells grew to a marginally higher density than control cells. In 0.5% serum, growth of the Wnt-1, Wnt-6 and Wnt-7b containing cells appeared to be inhibited. No growth in soft agar was observed for either control cells or Wnt expressing cells. We conclude that at least some mesenchymal cells can respond to Wnt gene products. Our results are also the first report of biological effects of Wnt-6 and Wnt-7b.	INST CANC RES,HADDOW LABS,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	BRADBURY, JM (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014; Dale, Trevor C/D-3749-2009	Edwards, Paul A/0000-0002-4789-3374; Dale, Trevor C/0000-0002-4880-9963				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK FAM, 1986, NUCLEIC ACIDS RES, V14, P693, DOI 10.1093/nar/14.2.693; Sambrook J, 1989, MOL CLONING LABORATO; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WEBERHALL SJ, IN PRESS DIFFERENTIA	36	46	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2597	2603						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058323				2022-12-25	WOS:A1994PC05400019
J	CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S				CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S			RAS-15A PROTEIN SHARES HIGHLY SIMILAR DOMINANT-NEGATIVE BIOLOGICAL PROPERTIES WITH RAS-17N AND FORMS A STABLE, GUANINE-NUCLEOTIDE RESISTANT COMPLEX WITH CDC25 EXCHANGE FACTOR	ONCOGENE			English	Article							HA-RAS MUTATION; SACCHAROMYCES-CEREVISIAE; ACTIVATION; MUTANTS; BINDING; P21RAS; SIGNAL; KINASES; INHIBITION; CYTOSOL	We show that expression of Ras-15A, previously shown to be a dominant-negative mutant in yeast, is a potent inhibitor of endogenous Ras protein function in mammalian cells. Expression of Ras-15A did not inhibit the growth of cells containing an oncogenic ras gene nor did it interfere with the ability of transiently expressed oncogenic ras or raf genes to activate transcription from a Ras-responsive ets1/AP-1 promoter. In contrast, expression of Ras-15A completely blocked growth of normal cells and activation of the ets1/AP-1 promoter by transiently overexpressed SOS1 and normal Ras proteins. These results suggest that Ras-15A, like Ras-17N, blocks endogenous Ras function by interfering with upstream activation of Ras proteins rather than downstream effects. To test whether Ras-15A and Ras-17N interfere with Ras function by blocking GDP-GTP exchange proteins, we examined their physical interaction with the CDC25 exchange protein. All three proteins formed stable complexes with CDC25 in the absence of guanine-nucleotides, but only Ras-15A was not released from CDC25 by physiological concentrations of GDP or GTP. These results establish that Ras-15A blocks the activation of normal Ras proteins by sequestering GDP-GTP exchange factors into nonproductive complexes. In contrast, it would appear that the similar biological properties of Ras-17N are mediated by a reversible, competitive sequestration of exchange factors.	ONYX PHARMACEUT,RICHMOND,CA 94806; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,PISCATAWAY,NJ 08854; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Rutgers State University New Brunswick; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Powers, Scott/0000-0003-2769-1932; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DER CJ, 1988, ONCOGENE, V3, P105; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, IN PRESS MOL CELL BI; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; POWERS S, 1991, CELL, V65, P1255; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	28	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2691	2698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058333				2022-12-25	WOS:A1994PC05400030
J	DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW				DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW			AN E2F DOMINANT-NEGATIVE MUTANT BLOCKS E1A INDUCED CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING PROPERTIES; MURINE THYMIDINE KINASE; HUMAN MYC PROMOTER; ESCHERICHIA-COLI; GROWTH SUPPRESSION; FUNCTIONAL DOMAINS; TRANS-ACTIVATION; S-PHASE	E2F is a cellular transcription factor that is regulated during the cell cycle through interactions with the product of the retinoblastoma susceptibility gene (RB1) and the pRb-like p107 and p130 proteins. Analysis of mutations within both adenovirus E1A and pRb, which affected their ability to regulate cellular proliferation and alter E2F activity, suggested that E2F may play a role in cell cycle progression. Microinjection of a GST-E2F-1 fusion protein into quiescent Balb/c 3T3 cells induced DNA synthesis whereas co-injection of GST-E2F-1 and GST-E2F(95-191) protein, encoding only the DNA binding domain of E2F-1, blocked the induction of S-phase. While E1A likely targets multiple cellular pathways, co-injection of the GST-E2F(95-191) dominant inhibitory protein with 12S E1A protein blocked E1A-mediated induction of DNA synthesis, suggesting that the E2F-dependent pathway is dominant. Analysis of the interval required for microinjected quiescent cells to enter S-phase indicated that E2F-1 acted faster than either E1A or serum.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	St Jude Children's Research Hospital; Cleveland Clinic Foundation					NATIONAL CANCER INSTITUTE [R01CA053496, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765, CA53496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRUNER M, 1988, J BIOL CHEM, V263, P3984; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEVINS JR, 1990, UCLA SYM BI, V124, P417; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROUSSEL MF, 1994, ONCOGENE, V9, P405; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1993, IN PRESS EMBO J; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	64	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2605	2612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058324				2022-12-25	WOS:A1994PC05400020
J	QUINLAN, MP				QUINLAN, MP			ENHANCED PROLIFERATION, GROWTH-FACTOR INDUCTION AND IMMORTALIZATION BY ADENOVIRUS E1A 12S IN THE ABSENCE OF E1B	ONCOGENE			English	Article							PRIMARY EPITHELIAL-CELLS; TUMOR-ANTIGEN; MORPHOLOGICAL TRANSFORMATION; 19-KILODALTON PROTEIN; MOLECULAR MECHANISMS; GENE-EXPRESSION; E1A-12S PROTEIN; DNA-SYNTHESIS; P53; TYPE-5	Immortalization and transformation of primary epithelial cells requires expression of the adenovirus E1A and E1B genes, respectively. The E1A gene is involved in growth stimulatory processes. Little is known about the mechanism utilized by E1B, however, roles in growth stimulatory processes have also been implied. To determine whether there are any functional interactions between E1A 12S and the E1B 55K and 19K polypeptides, primary epithelial cells were infected with 12S viruses with different E1B regions. In the absence of both E1B proteins, there was an increase in 12S expression. This resulted in increased levels of DNA synthesis, entry into S-phase of the cell cycle and increased levels of proliferation, in the presence or absence of serum. There was also a higher induction of growth factor activity. In the presence of the 55K and absence of the 19K protein, there was a decrease in 12S expression. However, the highest induction of proliferative responses was observed. This suggests that expression of the 19K polypeptide inhibits 12S function directly. The lack of 19K expression also enabled the epithelial cells to have a much higher plating efficiency, achieve a greater cell density and reach the immortalized state faster. Although some modest differences in p53 expression were observed when compared to mock, they could not be correlated with any phenotype.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAIRNS J, 1978, CANCER SOC; DEPPERT W, 1990, ONCOGENE, V5, P1701; Flint S. J, 1981, DNA TUMOR VIRUSES; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P27; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SENEAR AW, 1986, MOL CELL BIOL, V6, P1253, DOI 10.1128/MCB.6.4.1253; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIMOJO H, 1968, VIROLOGY, V36, P422, DOI 10.1016/0042-6822(68)90167-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; Weinberg R. A., 1989, ONCOGENES MOL ORIGIN; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	53	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058328				2022-12-25	WOS:A1994PC05400024
J	KADOWAKI, T; YONEDA, M; OKAMOTO, K; MAEDA, K; YAMAMOTO, K				KADOWAKI, T; YONEDA, M; OKAMOTO, K; MAEDA, K; YAMAMOTO, K			PURIFICATION AND CHARACTERIZATION OF A NOVEL ARGININE-SPECIFIC CYSTEINE PROTEINASE (ARGINGIPAIN) INVOLVED IN THE PATHOGENESIS OF PERIODONTAL-DISEASE FROM THE CULTURE SUPERNATANT OF PORPHYROMONAS-GINGIVALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; TRYPSIN-LIKE PROTEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; EXTRACELLULAR MEMBRANE-VESICLES; COLLAGENOLYTIC ACTIVITY; BACTERICIDAL ACTIVITY; DEGRADATION; IMMUNOGLOBULINS; COMPONENTS; FIBRINOGEN	A novel arginine-specific cysteine proteinase, termed ''argingipain,'' was purified from culture supernatants of Porphyromonas gingivalis, an anaerobe commonly associated with progressive periodontal disease, by conventional chromatographic techniques. The purified enzyme was found to be composed of a single polypeptide of M(r) similar to 44,000. Analysis of the enzymatic properties revealed several distinctive features for this enzyme. The proteolytic activity is absolutely thiol-dependent, but the enzyme also has in part the characteristics of both metallo and serine endopeptidases, as shown by the inhibition of activity by metal chelators, chymostatin, and the chloromethyl ketones of tosyl-L-lysine and tosyl-L-phenylalanine. However, internal protease inhibitors, such as cystatins, tissue inhibitor of metalloproteinases, and alpha(1)-antichymotrypsin, have no effects on the activity, suggesting its evasion from normal host defense systems in vivo. Despite its narrow specificity for synthetic substrates containing Arg in the P1 site and hydrophobic amino acids in the P2 or P3 sites, the enzyme extensively degrades collagens (types I and IV) and immunoglobulin G. Most important, the enzyme has the ability to disrupt the functions of polymorphonuclear leukocytes, as shown by its inhibitory effect on the generation of active oxygen species from the activated cells. Further, the enzyme is found to be produced by all of the species of P. gingivalis examined, but not by other bacteria. These results suggests that argingipain plays a key role as a major virulence factor from P. gingivalis in the development of periodontal disease via the direct destruction of periodontal tissue components and the disruption of normal host defense mechanisms.	KYUSHU UNIV,FAC DENT,DEPT PHARMACOL,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC DENT,DEPT PERIODONT & ENDODONT,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University								ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARLSSON J, 1984, INFECT IMMUN, V43, P644, DOI 10.1128/IAI.43.2.644-648.1984; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; CURTIS MA, 1993, J GEN MICROBIOL, V139, P949, DOI 10.1099/00221287-139-5-949; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DZINK JL, 1988, J CLIN PERIODONTOL, V15, P316, DOI 10.1111/j.1600-051X.1988.tb01590.x; FUJIMURA S, 1987, INFECT IMMUN, V55, P716, DOI 10.1128/IAI.55.3.716-720.1987; GRENIER D, 1989, ORAL MICROBIOL IMMUN, V4, P12, DOI 10.1111/j.1399-302X.1989.tb00400.x; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; HINODE D, 1991, INFECT IMMUN, V59, P3060, DOI 10.1128/IAI.59.9.3060-3068.1991; HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774; KEIL B, 1986, CYSTEINE PROTEINASES, P147; KILIAN M, 1981, INFECT IMMUN, V34, P757, DOI 10.1128/IAI.34.3.757-765.1981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ MS, 1991, J BACTERIOL, V173, P495, DOI 10.1128/jb.173.2.495-504.1991; LAUGHON BE, 1982, J CLIN MICROBIOL, V15, P345, DOI 10.1128/JCM.15.2.345-346.1982; MAYRAND D, 1988, MICROBIOL REV, V52, P134, DOI 10.1128/MMBR.52.1.134-152.1988; OGLE JD, 1953, ARCH BIOCHEM BIOPHYS, V42, P327, DOI 10.1016/0003-9861(53)90362-2; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; ROBERTSON PB, 1982, J PERIODONTAL RES, V17, P275, DOI 10.1111/j.1600-0765.1982.tb01154.x; SAKAI H, 1989, BIOCHIM BIOPHYS ACTA, V991, P367, DOI 10.1016/0304-4165(89)90130-X; SATO M, 1987, ARCH ORAL BIOL, V32, P235, DOI 10.1016/0003-9969(87)90016-1; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; SINGH S, 1984, J PERIODONTOL, V55, P1; SMALLEY JW, 1988, ARCH ORAL BIOL, V33, P323, DOI 10.1016/0003-9969(88)90065-9; SMALLEY JW, 1987, J GEN MICROBIOL, V133, P2883; SOJAR HT, 1993, INFECT IMMUN, V61, P2369, DOI 10.1128/IAI.61.6.2369-2376.1993; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V3, P103, DOI 10.1111/j.1399-302X.1988.tb00093.x; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; TRUSH MA, 1978, METHOD ENZYMOL, V57, P462; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; UITTO VJ, 1989, INFECT IMMUN, V57, P213, DOI 10.1128/IAI.57.1.213-218.1989; VANDYKE TE, 1985, J ORAL PATHOL MED, V14, P95; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; WINKLER JR, 1988, J PERIODONTOL, V59, P40, DOI 10.1902/jop.1988.59.1.40; YAMAMOTO K, 1980, J BIOCHEM-TOKYO, V87, P511, DOI 10.1093/oxfordjournals.jbchem.a132772; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990; YOSHIMURA F, 1984, ARCH ORAL BIOL, V29, P559, DOI 10.1016/0003-9969(84)90078-5	47	158	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21371	21378						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063764				2022-12-25	WOS:A1994PC40300082
J	QUITSCHKE, WW				QUITSCHKE, WW			2 NUCLEAR FACTOR-BINDING DOMAINS ACTIVATE EXPRESSION FROM THE HUMAN AMYLOID BETA-PROTEIN PRECURSOR PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MESSENGER-RNA; REGULATORY REGION; GENE-EXPRESSION; CELLS; INTERLEUKIN-1; BRAIN; APP; CONTAINS; ELEMENTS	Amyloid beta-protein is derived from the amyloid beta-protein precursor (APP), and it is a major component of brain amyloid depositions in Alzheimer's disease and Down's syndrome. Overexpression of APP may be one of several factors contributing to amyloid formation. The APP promoter was therefore analyzed to determine the mechanism by which APP gene expression is regulated. Cell type-specific expression from the human APP promoter is accomplished with 94 base pairs upstream from the main transcriptional start site. This promoter region contains two nuclear factor binding domains, designated APB alpha and APB beta. The contribution of these binding domains to promoter activity was analyzed by transient transfection in HeLa and PC-12 cells. Under standard culture conditions, at least 70-90% of the total activity from the APP promoter can be attributed to binding domain APB beta. The recognition domain for this nuclear factor binding site is defined by the sequence GCCGCTAGGGGT (position -93 to -82). The contribution of binding site APB alpha to APP promoter activity is considerably lower and represents 10-30% of the total activity. The recognition site for the nuclear factor that binds to APB alpha is delineated by the sequence GGATCAGCTGAC (position -53 to -42). Elimination of both binding sites causes APP promoter activity in vivo to decline to near background levels.			QUITSCHKE, WW (corresponding author), SUNY STONY BROOK, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30994] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ADLER MJ, 1991, P NATL ACAD SCI USA, V88, P16, DOI 10.1073/pnas.88.1.16; BURGER PC, 1973, AM J PATHOL, V73, P457; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; ELLIS WG, 1974, NEUROLOGY, V24, P101, DOI 10.1212/WNL.24.2.101; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAY CW, 1993, MOL BRAIN RES, V19, P251, DOI 10.1016/0169-328X(93)90037-P; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; Maniatis T, 1989, MOL CLONING; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maxam A M, 1980, Methods Enzymol, V65, P499; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; POLLWEIN P, 1993, BIOCHEM BIOPH RES CO, V190, P637, DOI 10.1006/bbrc.1993.1096; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; QUON D, 1990, BIOCHEM BIOPH RES CO, V167, P96, DOI 10.1016/0006-291X(90)91735-B; ROBAKIS NK, 1987, LANCET, V1, P384; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21229	21233						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063744				2022-12-25	WOS:A1994PC40300062
J	STUMPO, DJ; HAUPT, DM; BLACKSHEAR, PJ				STUMPO, DJ; HAUPT, DM; BLACKSHEAR, PJ			PROTEIN-KINASE-C ISOZYME DISTRIBUTION AND DOWN-REGULATION IN RELATION TO INSULIN-STIMULATED C-FOS INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; GROWTH-FACTOR; PHORBOL ESTERS; BC3H-1 MYOCYTES; ZETA-ISOFORM; FACTOR-I; BETA-I; RECEPTOR; PHOSPHORYLATION; FIBROBLASTS	Insulin can stimulate the expression of c-fos and other immediate early genes in many insulin-sensitive cell types. We found previously that this effect of insulin was essentially normal in cells in which protein kinase C (PKC) was down-regulated by 16 h of exposure to 16 mu M phorbol 12-myristate 13-acetate (PMA). However, recent studies by other groups have suggested that much of the insulin response was lost in down-regulated cells and that at least part of the remaining response could be due to a species of PKC beta that is resistant to down-regulation. To resolve these discrepancies, we performed PKC enzyme assays and immunoblots on HIRc-B, H4IIEC3, and BC3H-1 cells before and after down-regulation with PMA. PKC enzyme activity was undetectable in the first two cell types after down-regulation; in addition, in all three cells the expressed PKC isozymes other than PKC zeta were completely down-regulated by the PMA exposure. Neither PKC beta(1) nor beta(2) was expressed in any of the cells, as determined by immunoblotting with isotype-specific antibodies. As in our previous studies, c-Fos mRNA accumulation in response to insulin was essentially normal in the down-regulated HIRc-B and H4IIEC3 cells, whereas the response to re-added PMA was completely abolished. PKC zeta was expressed in all three cell types and was not down-regulated by PMA; these and other considerations leave open the possibility that this and other ''atypical'' PKC isotypes could play a role in insulin action.	DUKE UNIV, MED CTR,DEPT MED,SARAH W STEDMAN CTR NUTR STUDIES, DIV ENDOCRINOL M, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ARITA Y, 1992, CANCER RES, V52, P4514; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1987, MOL ENDOCRINOL, V1, P44, DOI 10.1210/mend-1-1-44; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BORNER C, 1992, J BIOL CHEM, V267, P12900; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EXTON JH, 1991, DIABETES, V40, P521, DOI 10.2337/diabetes.40.5.521; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; KILEY S, 1990, J BIOL CHEM, V265, P15704; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; LAI WS, 1990, J BIOL CHEM, V265, P16556; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SHERR CJ, 1990, BLOOD, V75, P1; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TAUB R, 1987, J BIOL CHEM, V262, P10893; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	36	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21184	21190						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063739				2022-12-25	WOS:A1994PC40300056
J	HIMPENS, B; DESMEDT, H; BOLLEN, M				HIMPENS, B; DESMEDT, H; BOLLEN, M			MODULATION NUCLEOCYTOSOLIC [CA2+] GRADIENT IN SMOOTH-MUSCLE BY PROTEIN-PHOSPHORYLATION	FASEB JOURNAL			English	Article						CALCIUM; PROTEIN KINASE; PROTEIN PHOSPHATASE; NUCLEUS	NUCLEAR-PORE COMPLEX; CALCIUM GRADIENTS; CELL-NUCLEUS; KINASE-C; MOBILIZATION; HEPATOCYTES; VASOPRESSIN; MICROSCOPE; TRANSIENTS; INHIBITOR	In resting DDT(1)MF-2 smooth muscle cells, the cytosolic free Ca2+ concentration ([Ca2+](c)) was higher than the free Ca2+ concentration in the nucleus ([Ca2+](n)). However, this nucleocytosolic [Ca2+] gradient was reversed by Ca2+ agonists like ATP or, as is shown here, by the epidermal growth factor (EGF). The ATP-induced reversal of the nucleocytosolic [Ca2+] gradient was blocked by stimulation of protein kinase C with phorbol 12-myristate 13-acetate or with the diacylglycerol kinase inhibitor R59949, or by inhibition of the Ser/Thr-specific protein phosphatases-1 and -2A with okadaic acid or calyculin A. Moreover, the magnitude of the ATP-induced reversal of the [Ca2+] gradient diminished during prolonged culture of the cells. The EGF-induced [Ca2+] rise in the cytosol and nucleus was blocked by okadaic acid and by the tyrosine kinase inhibitors herbimycin A and psi-tectorigenin. Our data suggest that the nucleocytosolic [Ca2+] gradient is modulated by (de)phosphorylation processes catalyzed by tyrosine protein kinases, by protein kinase C, and by Ser/Thr protein phosphatases-1. and -2A.	KATHOLIEKE UNIV LEUVEN, FAC MED, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, FAC MED, BIOCHEM LAB, B-3000 LOUVAIN, BELGIUM	KU Leuven; KU Leuven								ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BOLLEN M, 1993, ADV PROTEIN PHOSPHAT, V7, P31; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V24, P69; BUSTAMANTE JO, 1993, BIOPHYS J, V64, P1735, DOI 10.1016/S0006-3495(93)81545-5; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHEN CS, 1993, J BIOL CHEM, V268, P15812; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DECOURCELLES DD, 1990, ADV SEC MESS PHOSPH, V24, P491; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1994, CELL CALCIUM, V15, P55, DOI 10.1016/0143-4160(94)90104-X; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KHALIL RA, 1992, NEWS PHYSIOL SCI, V7, P10; MEEK DW, 1992, BIOCHEM J, V287, P1; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NAKATO K, 1992, EUR J BIOCHEM, V209, P745, DOI 10.1111/j.1432-1033.1992.tb17343.x; OBERLEITHNER H, 1992, P NATL ACAD SCI USA, V89, P241, DOI 10.1073/pnas.89.1.241; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; STEHNOBITTEL L, 1994, BIOPHYS J, V66, pA119; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	31	20	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1994	8	11					879	883		10.1096/fasebj.8.11.8070638	http://dx.doi.org/10.1096/fasebj.8.11.8070638			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070638				2022-12-25	WOS:A1994PC88500012
J	SHAH, MA; TRACKMAN, PC; GALLOP, PM; KAGAN, HM				SHAH, MA; TRACKMAN, PC; GALLOP, PM; KAGAN, HM			REACTION OF LYSYL OXIDASE WITH TRANS-2-PHENYLCYCLOPROPYLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE-OXIDASE; AMINE OXIDASE; MECHANISM; INHIBITORS; QUINONE; TRANYLCYPROMINE; DEHYDROGENASE; INACTIVATION; COFACTOR; CLEAVAGE	trans-2-Phenylcyclopropylamine hydrochloride (tranylcypromine; TCP) was found to be both an inhibitor and a substrate of lysyl oxidase, the enzyme which oxidizes peptidyl lysine in elastin and collagen to initiate cross-linking in these proteins. The reaction of TCP with this enzyme was further characterized in view of the potential interference that chronic administration of this antidepressant compound may exert on the development and repair of connective tissues. In contrast to the irreversible and/or competitive inhibitors of lysyl oxidase previously described, TCP noncompetitively and reversibly inhibited the oxidation of both alkylamine and elastin substrates with K(i) values of 386 and 375 muM, respectively. The noncompetitive mode of interaction affected the accessibility of the active site to productive amine substrates since the reductive trapping of n-hexylamine to lysyl oxidase was largely prevented by the presence of TCP. It was of additional interest that lysyl oxidase catalyzed a limited degree of conversion of TCP to cinnamaldehyde accompanied by the production of hydrogen peroxide. The lack of significant incorporation of protein-bound tritium accompanying reduction of the enzyme-TCP complex with [H-3]NaBH4 argued against the formation of a Schiff base between the enzyme and the cinnamaldehyde product as the basis of the inhibitory effect. Spectral evidence was also obtained for an additional interaction between TCP and lysyl oxidase that was independent of the inhibitory effect of TCP. Cyclopropylamine, lacking the benzene moiety of TCP, inhibited lysyl oxidase irreversibly and competitively, and was not a substrate, pointing toward a defining role for the benzene moiety in the interaction of TCP with lysyl oxidase.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH DENT MED,DEPT ORAL BIOL,CAMBRIDGE,MA 02138	Boston University; Harvard University; Harvard Medical School; Harvard University; Harvard School of Dental Medicine			Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018880, R37AR018880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007723] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18880] Funding Source: Medline; NIA NIH HHS [AG-07723] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELES RH, 1978, ENZYME ACTIVATED IRR, P1; BRIGGS NC, 1990, J CLIN PSYCHIAT, V51, P426; CRABBE MJC, 1974, BIOCHEM PHARMACOL, V23, P2983; DAVIDSON VL, 1991, BIOCHEMISTRY-US, V30, P1924, DOI 10.1021/bi00221a027; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; ESTERBAUER H, 1976, TETRAHEDRON, V32, P285, DOI 10.1016/0040-4020(76)87015-9; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1989, PQQ AND QUINOPROTEINS, P317; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, P321; KECK PE, 1989, J CLIN PSYCHOPHARM, V9, P48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAECH C, 1980, J BIOL CHEM, V255, P2700; PARE CMB, 1976, CIBA F S, V39, P271; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; REMICK RA, 1989, PROG NEURO-PSYCHOPH, V13, P497, DOI 10.1016/0278-5846(89)90137-1; SAYRE LM, 1991, J ORG CHEM, V56, P1353, DOI 10.1021/jo00004a004; SHAH MA, 1993, J BIOL CHEM, V268, P11573; SILVERMAN RB, 1983, J BIOL CHEM, V258, P4766; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; WIECHELMAN K, 1979, ANAL BIOCHEM, V100, P201; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P14520; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; WISEMAN JS, 1979, BIOCHEMISTRY-US, V18, P427, DOI 10.1021/bi00570a006	32	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11580	11585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099355				2022-12-25	WOS:A1993LF28400022
J	LAW, SF; YASUDA, K; BELL, GI; REISINE, T				LAW, SF; YASUDA, K; BELL, GI; REISINE, T			G(I-ALPHA-3) AND G(O-ALPHA) SELECTIVELY ASSOCIATE WITH THE CLONED SOMATOSTATIN RECEPTOR SUBTYPE-SSTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NEOCORTICAL NEURONS; RIBONUCLEIC-ACID; CALCIUM CURRENTS; G-PROTEIN	The interaction of the SRIF receptor subtype SSTR2 with pertussis toxin-sensitive G proteins was investigated using an immunoprecipitation approach employing peptide-directed antisera against G(ialpha) and G(oalpha). Antisera directed against either the COOH terminus of G(ialpha) or G(oalpha) uncoupled SSTR2-G protein complexes from CHO cells stably expressing the cloned receptor indicating that both G proteins form complexes with SSTR2. Chinese hamster ovary cells primarily express G(ialpha3) and G(oalpha2) immunoreactivity, with much lower levels of the other pertussis toxin-sensitive G proteins. Antiserum against G(ialpha3) uncoupled SSTR2/G protein complexes to a similar extent as G(1alpha) common antiserum while antisera against G(ialpha1) and G(ialpha2) did not. These findings indicate that SSTR2 expressed in Chinese hamster ovary cells predominantly associates with G(ialpha3) and G(oalpha2). In HEK 293 cells which endogenously express low densities of SSTR2 and similar levels of G(ialpha1) and G(ialpha3) immunoreactivity but no G(oalpha), only antiserum directed against G(ialpha3) immunoprecipitated SSTR2-G protein complexes, indicating that in these cells SSTR2 primarily associates with G(ialpha3). SRIF can not inhibit forskolin-stimulated cAMP formation in wild-type HEK 293 cells nor in HEK 293 cells transfected with SSTR2. In contrast, SRIF can inhibit cAMP formation in HEK 293 cells expressing the cloned SRIF receptor SSTR3, which requires the presence of G(ialpha1) to functionally couple to adenylyl cyclase. The lack of efficient association of SSTR2 with G(ialpha1) may be the cause of its inability to mediate inhibition of cAMP formation. Differences in the G protein-coupling domains of the cloned SRIF receptors may be responsible for their differences in G protein association and ability to effect various signaling pathways.	UNIV PENN,SCH MED,DEPT PHARMACOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP CELL BIOL,PHILADELPHIA,PA 19104; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Pennsylvania; University of Pennsylvania; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago					NIDDK NIH HHS [DK20595] Funding Source: Medline; NIMH NIH HHS [MH45533, MH48518] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, P30DK020595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048518] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; LAW S, 1991, J BIOL CHEM, V268, P17885; LAW SF, 1992, MOL PHARMACOL, V42, P398; MAHY N, 1988, J PHARMACOL EXP THER, V247, P390; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; Patel Y. C., 1992, Society for Neuroscience Abstracts, V18, P448; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; RAYNOR K, 1991, MOL PHARMACOL, V40, P248; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	22	149	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10721	10727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098703				2022-12-25	WOS:A1993LD46600006
J	AHRENS, PB				AHRENS, PB			ROLE OF TARGET-CELL GLYCOPROTEINS IN SENSITIVITY TO NATURAL-KILLER-CELL LYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; MURINE TUMOR-CELLS; MEDIATED LYSIS; ICAM-1 CD54; GLYCOSYLATION; CARBOHYDRATE; ASSOCIATION; KIFUNENSINE; BINDING; FAMILY	Natural killer cells select targets for lysis based on target cell glycoproteins. Compared to controls, K-562 cells treated with kifunensine, an inhibitor of Golgi mannosidase I, accumulate more high mannose-type asparagine-linked oligosaccharide, Man9GlcNAc2, and bind more concanavalin A, an oligomannosyl binding lectin. In addition, natural killer cell lysis of kifunensine-treated cells increases 34% over that of controls. Increased sensitivity to lysis occurs after treatment with other N-glycan processing inhibitors that promote accumulation of high mannose-type glycosides (deoxymannojirimycin and swainsonine). In addition, kifunensine-treated cells form more effector:target conjugates. Monoclonal antibodies to the adhesion molecule LFA-1 and its ligand ICAM-1 reduce lysis of control targets but are less effective in blocking lysis of kifunensine-treated cells. K-562 cells bind anti-ICAM-1 but not anti-LFA-1, and this binding does not change after kifunensine treatment. These data demonstrate conclusively a role for asparagine-linked oligosaccharides in the human natural killer cell:target interaction. The presence of high mannose-type glycans on K-562 cells correlates with increased binding of effectors and a greater susceptibility to lysis. These results support the idea that target cell N-glycosides influence the NK-target interaction mediated by adhesion molecules such as ICAM-1.			AHRENS, PB (corresponding author), MED COLL WISCONSIN, DEPT BIOCHEM, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.				NATIONAL CANCER INSTITUTE [R29CA046956] Funding Source: NIH RePORTER; NCI NIH HHS [CA46956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHRENS PB, 1987, J BIOL CHEM, V262, P7575; AHRENS PB, 1988, BIOCHIMIE, V70, P1619, DOI 10.1016/0300-9084(88)90297-0; ANUMULA KR, 1991, EUR J BIOCHEM, V195, P269, DOI 10.1111/j.1432-1033.1991.tb15703.x; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BEELEY JG, 1985, GLYCOPROTEINS PROTEO, P256; BLANCHARD DK, 1990, INT J CANCER, V45, P312; BONAVIDA B, 1987, ADV EXP MED BIOL, V184, P179; DENNIS JW, 1985, CANCER RES, V45, P6034; DENNIS JW, 1984, J CELL BIOL, V99, P1034, DOI 10.1083/jcb.99.3.1034; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELBEIN AD, 1983, METHOD ENZYMOL, V98, P135; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; ISHIKAWA M, 1988, CANCER RES, V48, P665; KAYAKIRI H, 1989, J ORG CHEM, V54, P4015, DOI 10.1021/jo00278a003; KOSHIYAMA I, 1969, ARCH BIOCHEM BIOPHYS, V130, P370, DOI 10.1016/0003-9861(69)90046-0; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEVVY GA, 1966, BIOCHIM BIOPHYS ACTA, V130, P150, DOI 10.1016/0304-4165(66)90017-1; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; NESSER J, 1985, GLYCOCONJUGATE J, V2, P355; NESTEL FP, 1984, J NATL CANCER I, V73, P483, DOI 10.1093/jnci/73.2.483; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; RODER JC, 1979, P NATL ACAD SCI USA, V76, P1405, DOI 10.1073/pnas.76.3.1405; RONIN C, 1986, J BIOL CHEM, V261, P7287; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; TIMONEN T, 1990, INT J CANCER, V46, P1035, DOI 10.1002/ijc.2910460615; TIMONEN T, 1988, J IMMUNOL, V141, P1041; WERKMEISTER JA, 1983, INT J CANCER, V32, P71, DOI 10.1002/ijc.2910320112; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOSHIMA H, 1982, J BIOCHEM, V91, P233, DOI 10.1093/oxfordjournals.jbchem.a133680	38	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					385	391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093244				2022-12-25	WOS:A1993KE60300059
J	CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G				CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G			DNA POLYMORPHISMS AND CONDITIONS FOR SSCP ANALYSIS OF THE 20 EXONS OF THE RET PROTOONCOGENE	ONCOGENE			English	Note							SINGLE BASE SUBSTITUTIONS; POINT MUTATIONS; PROTOONCOGENE; MISMATCHES; LINE	Recently identified mutations affecting different domains of the RET proto-oncogene are associated with Multiple Endocrine Neoplasia type 2A (MEN 2A) and type 2B (MEN 2B), familial and sporadic Medullary Thyroid Carcinomas (MTC) and Hirschsprung disease (HSCR). In order to facilitate the screening for RET mutations, and to study possible genotype-phenotype correlations, we established exon-intron junctions and extended the intronic sequences flanking the 20 exons of this gene. This made it possible to design primers and to develop PCR conditions useful for SSCP analysis of the whole RET coding sequence. Nine conformational variants were observed which after sequencing turned out to be 8 silent mutations and a conservative amino acid substitution. Restriction analysis performed on DNA samples from unrelated controls confirmed the polymorphic nature of six of these nucleotide changes and made it possible to estimate the frequency of the corresponding alleles.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV GRONINGEN,DEPT MED GENET,9713 AW GRONINGEN,NETHERLANDS	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Groningen			Bocciardi, Renata/J-8577-2016; Ceccherini, Isabella/P-8195-2014; Bolino, Alessandra/O-2933-2013; Barone, Virginia/K-8782-2015; Pasini, Barbara/AHI-2004-2022; Nijveen, Harm/L-2272-2014; Ronchetto, Patrizia/AAA-7742-2020; Seri, Marco/A-4339-2014	Bocciardi, Renata/0000-0001-8415-3802; Ceccherini, Isabella/0000-0001-8732-1955; Barone, Virginia/0000-0001-8794-9291; Pasini, Barbara/0000-0002-4373-1212; Nijveen, Harm/0000-0002-9167-4945; Bolino, Alessandra/0000-0002-8980-4878; Hofstra, Robert/0000-0001-7498-3829; Ronchetto, Patrizia/0000-0002-2606-3398; Seri, Marco/0000-0003-2425-2176				BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LO YMD, 1992, NUCLEIC ACIDS RES, V20, P1005, DOI 10.1093/nar/20.5.1005; MAHAFFEY SM, 1990, J PEDIATR SURG, V25, P101, DOI 10.1016/S0022-3468(05)80172-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	26	159	162	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3025	3029						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084609				2022-12-25	WOS:A1994PG82200032
J	SANKARAM, MB; JONES, JD				SANKARAM, MB; JONES, JD			MODE OF MEMBRANE INTERACTION OF WILD-TYPE AND MUTANT SIGNAL PEPTIDES OF THE ESCHERICHIA-COLI OUTER-MEMBRANE PROTEIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; ACIDIC PHOSPHOLIPIDS; HYDROPHOBIC REGION; LEADER REGION; SEQUENCE; TRANSLOCATION; BINDING; EXPORT; LABEL; INTERFACE	The membrane insertion potentials of the signal peptide of the outer membrane protein A (OmpA) from Escherichia coli and two peptides corresponding to functionally impaired mutant OmpA signal sequences were examined using spin label electron spin resonance (ESR) spectroscopy. The wild-type OmpA signal peptide, WT, a deletion mutant lacking the amino acid stretch 6-9, Delta 6-9, and a substitution mutant with the isoleucine residue at position 8 replaced by asparagine, I8N, were incorporated into mixed lipid vesicles containing negatively charged 1-palmitoyl-2-oleoyl phosphatidylglycerol (POPG) and zwitterionic 1-palmitoyl-2-oleoyl phosphatidylethanolamine (POPE). Spin-labeled derivatives of phosphatidylglycerol and phosphatidylethanolamine containing a nitroxide moiety at the 12th position in the sn-2 acyl chain, 12-PGSL and 12-PESL, respectively, were employed for the ESR experiments. The 12-PGSL and 12-PESL exhibited two-component spectra in the presence of the WT and Delta 6-9, but not when I8N was present. Using difference spectroscopy, the number of POPG and POPE molecules associated with an ordered lipid layer surrounding the peptides was estimated. The results suggest that WT exists as a transmembrane monomer in the membrane. The Delta 6-9 mutant signal peptide appears to exist either as a transmembrane aggregate or partially inserted into the acyl chain region. The substitution mutant, I8N, has a most probable location near the membrane surface. Among these variants of the OmpA signal peptide, the ability to adopt a transmembrane monomeric orientation correlates well with the export activity.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Virginia					NIGMS NIH HHS [GM34962, GM13341, GM14628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962, F32GM013341, R01GM014628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; Barany G, 1979, PEPTIDES           A, V2, P1; BATENBURG AM, 1988, J BIOL CHEM, V263, P4202; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BROPHY PJ, 1977, FEBS LETT, V84, P92, DOI 10.1016/0014-5793(77)81064-8; BROTHERUS JR, 1981, BIOCHEMISTRY-US, V20, P5261, DOI 10.1021/bi00521a026; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; DEVRIJE T, 1989, EUR J BIOCHEM, V180, P385; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DIERSTEIN R, 1985, J BIOL CHEM, V260, P5919; DRYLAND A, 1986, J CHEM SOC P1, V1, P125; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; ERICKSON BW, 1976, PROTEINS, V2, P225; GE MT, 1993, BIOPHYS J, V65, P2106, DOI 10.1016/S0006-3495(93)81255-4; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; HORVATH LI, 1988, BIOCHEMISTRY-US, V27, P46, DOI 10.1021/bi00401a009; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10156; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KNOWLES PF, 1979, BIOCHEMISTRY-US, V18, P4480, DOI 10.1021/bi00588a005; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsh D., 1982, LIPID PROTEIN INTERA, V2, P53; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; RYBA NJP, 1987, BIOCHEMISTRY-US, V26, P3234, DOI 10.1021/bi00385a045; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SANKARAM MB, 1989, BIOCHEMISTRY-US, V28, P9699, DOI 10.1021/bi00451a024; SANKARAM MB, 1994, BIOPHYS J, V66, P1959, DOI 10.1016/S0006-3495(94)80989-0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23477	23483						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089113				2022-12-25	WOS:A1994PQ34500018
J	CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA				CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA			CLONING AND CHARACTERIZATION OF NOVEL RAT AND MOUSE LOW-MOLECULAR-WEIGHT CA2+-DEPENDENT PHOSPHOLIPASE-A(2)S CONTAINING 16 CYSTEINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHRITIC SYNOVIAL-FLUID; SEQUENCE; EXPRESSION; VENOM; FORMS	A novel rat 4.4-kilobase (kb) cDNA encoding a low molecular weight Ca2+-dependent phospholipase A(2) (PLA(2)) and its murine homologue were cloned. The rat and mouse cDNA predict a mature protein of 130 amino acids (M(r) = 14, 763) preceded by a 28-amino acid prepro-peptide. The deduced amino acid sequences encode a protein containing 16 cysteines which distinguishes them from both mammalian group I and II PLA(2)s and the recently described group of mammalian PLA(2)s containing 12 cysteines. A rat RNA blot hybridized with the rat cDNA exhibited an abundant 2.3-kb and a less abundant 5-kb transcript in testis. When the rat cDNA was expressed using an Epstein-Barr virus-based vector in human 293s cells, PLA(2) activity accumulated in the culture medium. Conditioned medium optimally hydrolyzed the phospholipids of [1-C-14]oleate-labeled Escherichia coli at neutral to alkaline pH with 1-7 mM Ca2+. In assays with individual substrates, L-alpha-1-stearoyl-2-arachidonyl phosphatidylinositol was hydrolyzed more efficiently than L-alpha-1-palmitoyl-2-oleoyl phosphatidylcholine, L-alpha-1-palmitoyl-2-arachidonyl phosphatidylcholine, or L-alpha-1-palmitoyl-2-arachidonyl phosphotidylethanolamine.	INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Incyte			Chen, Ju/E-5579-2011	Tischfield, Jay/0000-0003-3217-8287	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030171] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30171] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHEN J, 1994, J BIOL CHEM, V269, P2365; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ELLIS L, 1977, TESTIS, V4, P289; ELLIS LC, 1981, J ANDROL, V2, P94; ELLIS LC, 1981, ARCH ANDROLOGY, V6, P283, DOI 10.3109/01485018108987539; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; HAFS HD, 1974, PROSTAGLANDINS, V8, P417, DOI 10.1016/0090-6980(74)90120-8; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HEMSWORTH PH, 1977, PROSTAGLANDINS, V13, P933, DOI 10.1016/0090-6980(77)90223-4; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RONKKO S, 1992, INT J ANDROL, V15, P62, DOI 10.1111/j.1365-2605.1992.tb01115.x; Sambrook J, 1989, MOL CLONING LABORATO; SEILHAMER JJ, 1989, J CELL BIOCHEM, V39, P327, DOI 10.1002/jcb.240390312; SEILHAMER JJ, 1989, J BIOCHEM, V106, P38, DOI 10.1093/oxfordjournals.jbchem.a122815; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; WOLF RA, 1985, J BIOL CHEM, V260, P7295	25	110	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23018	23024						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083202				2022-12-25	WOS:A1994PQ16400021
J	SUDHAKAR, K; LOE, S; YONETANI, T; VANDERKOOI, JM				SUDHAKAR, K; LOE, S; YONETANI, T; VANDERKOOI, JM			FLUORESCENT DERIVATIVES OF HUMAN HEMOGLOBIN - DIFFERENCES IN INTERACTION OF THE PORPHYRIN WITH THE PROTEIN BETWEEN THE ALPHA-SUBUNIT AND BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALT HYBRID HEMOGLOBINS; NUCLEAR MAGNETIC-RESONANCE; HORSERADISH-PEROXIDASE; CYTOCHROME-C; FE-HIS; SPECTRA; OXYGEN; SPECTROSCOPY; MYOGLOBIN; BINDING	The fluorescence properties of porphyrin were compared in protoporphyrin-protoheme hybrid hemoglobins (Hb) in which the protohemes (Fe) in either the alpha or beta subunits were substituted with protoporphyrin IX, alpha(P)(2) beta(Fe)(2)-Hb and alpha(Fe)(2) beta(P)(2)-Hb, respectively. The fluorescence lifetimes of the porphyrin in these hybrid derivatives are shorter than for the tetra-substituted protoporphyrin Hb, indicating that there is energy transfer from the porphyrin to the heme. The energy transfer resulted in only similar to 20% diminution of donor fluorescence, thereby allowing for the examination by fluorescence of the interaction of porphyrin with a given subunit peptide chain. Fluorescence line narrowing spectroscopy, a high resolution fluorescence technique that involves laser excitation, produced vibrationally resolved emission spectra in which the zero phonon lines were separated from a broadened background consisting of phonon wings. Resolved spectra were obtained in the temperature range of 5-50 K; above 70 K the spectra were unresolved. By changing the excitation frequency the mean energy of the 0,0 transition, characterizing the separation in energy between the ground and excited states, can be determined. For both derivatives a bimodal distribution was seen, indicating that more than one conformation of molecules was present. The distribution of 0,0 transition energies of the porphyrin in the beta-chain in alpha(Fe)(2) beta(P)(2)-Hb was shifted to lower energy relative to the a chain in alpha(P)(2) beta(P)(2)-Hb, whereas the excited state molecules in the two subunits had very little difference in vibrational energy. These data point to the same configuration of the porphyrins in the two sites, but differences in the electric field for the alpha and beta subunits.	UNIV PENN,SCH MED,JOHNSON RES FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048130] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM48130] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGIOLILLO PJ, 1982, PHOTOCHEM PHOTOBIOL, V36, P133, DOI 10.1111/j.1751-1097.1982.tb04354.x; ANNI H, 1994, BIOCHEMISTRY-US, V33, P3475, DOI 10.1021/bi00178a003; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Douzou P., 1977, CRYOBIOCHEMISTRY INT; FIDY J, 1989, BIOCHEMISTRY-US, V28, P7531, DOI 10.1021/bi00445a006; FIDY J, 1991, LIGHT IN BIOLOGY AND MEDICINE, VOL 2, P367; FIDY J, 1989, J PHYS CHEM-US, V93, P2253, DOI 10.1021/j100343a014; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FUJII M, 1993, J BIOL CHEM, V268, P15386; GIBSON QH, 1985, J BIOL CHEM, V260, P4126; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HOLTOM GR, 1986, CHEM PHYS LETT, V131, P44, DOI 10.1016/0009-2614(86)80514-0; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; KAMINAKA S, 1989, J AM CHEM SOC, V111, P3787, DOI 10.1021/ja00193a004; KAPOSI AD, 1992, P NATL ACAD SCI USA, V89, P11371, DOI 10.1073/pnas.89.23.11371; KAPOSI AD, 1993, J PHYS CHEM-US, V97, P6317; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1460, DOI 10.1021/bi00704a022; MORRIS RJ, 1984, J BIOL CHEM, V259, P6701; OLSON JS, 1971, J BIOL CHEM, V246, P5919; PERSONOV RI, 1969, SOV PHYS DOKL, V13, P1033; PERSONOV RI, 1983, SPECTROSCOPY EXCITAT, P555; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; VANDERKOOI JM, 1993, TRENDS BIOCHEM SCI, V18, P71, DOI 10.1016/0968-0004(93)90155-G; VANDERKOOI JM, 1985, BIOCHEMISTRY-US, V24, P7931, DOI 10.1021/bi00348a013; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673; VOELKER S, 1979, CHEM PHYS LETT, V61, P421, DOI 10.1016/0009-2614(79)87141-9; WEATHERALL DJ, 1978, METABOLIC BASIS INHE, P1508; ZOLLFRANK J, 1991, BIOPHYS J, V59, P305, DOI 10.1016/S0006-3495(91)82224-X; ZOLLFRANK J, 1991, J CHEM PHYS, V95, P3134, DOI 10.1063/1.461780	31	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23095	23101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083211				2022-12-25	WOS:A1994PQ16400032
J	WEISSHART, K; KUO, AA; HWANG, CBC; KUMURA, K; COEN, DM				WEISSHART, K; KUO, AA; HWANG, CBC; KUMURA, K; COEN, DM			STRUCTURAL AND FUNCTIONAL-ORGANIZATION OF HERPES-SIMPLEX VIRUS-DNA POLYMERASE INVESTIGATED BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 REVERSE-TRANSCRIPTASE; ACCESSORY PROTEIN COMPLEX; EXONUCLEASE ACTIVE-SITE; RIBONUCLEASE-H ACTIVITY; BINDING PROTEIN; CRYSTAL-STRUCTURE; C-TERMINUS; GENETIC-CHARACTERIZATION; HUMAN CYTOMEGALOVIRUS; PHOSPHONOACETIC ACID	The 1235 residue herpes simplex virus DNA polymerase is a prototype alpha-like DNA polymerase and also an antiviral drug target. To investigate its organization, we mapped favored cleavage sites for seven proteases and identified three major classes of stable proteolytic fragments: 70-85-kDa N-terminal fragments, 50-70-kDa fragments that start near residues 600-700, and 12-kDa C-terminal fragments. In coimmunoprecipitation experiments, the first two classes of fragments remained associated; thus, cleavage in the center of the protein did not resolve structurally separate domains. In contrast, the 12-kDa C-terminal fragments did not remain associated with other fragments, suggesting a small separable C-terminal domain. The 70-85-kDa N-terminal fragments contained 3'-5' exonuclease and ribonuclease H activities; however, cleavage at the center of the molecule or near the C terminus appeared to destroy DNA polymerase activity. All three major classes of fragments bound DNA in DNA-cellulose chromatography and Southwestern blot analyses. The C-terminal fragments bound the viral polymerase processivity factor, UL42. The results map activities to regions of herpes simplex virus polymerase and suggest a model for its organization that may be pertinent to other DNA polymerases.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCRR NIH HHS [SO7 RR05381] Funding Source: Medline; NIAID NIH HHS [UO1 AI26077, R01 AI19838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026077, R01AI019838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DIGARD P, 1990, J BIOL CHEM, V265, P17393; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORSKY DI, 1988, J VIROL, V62, P3224, DOI 10.1128/JVI.62.9.3224-3232.1988; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GIBBS JS, 1985, P NATL ACAD SCI USA, V82, P7969, DOI 10.1073/pnas.82.23.7969; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; HALL JD, 1986, DNA-J MOLEC CELL BIO, V5, P281, DOI 10.1089/dna.1986.5.281; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HWANG CBC, 1992, J VIROL, V66, P1774, DOI 10.1128/JVI.66.3.1774-1776.1992; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBSEN H, 1979, EUR J BIOCHEM, V45, P623; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KLENOW H, 1971, EUR J BIOCHEM, V22, P371, DOI 10.1111/j.1432-1033.1971.tb01554.x; KNOPF CW, 1990, EUR J BIOCHEM, V191, P263, DOI 10.1111/j.1432-1033.1990.tb19119.x; KNOPF CW, 1987, J GEN VIROL, V68, P1429, DOI 10.1099/0022-1317-68-5-1429; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINBACH SS, 1989, BIOCHIM BIOPHYS ACTA, V1008, P281, DOI 10.1016/0167-4781(89)90017-1; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LINDBORG B, 1992, ANTIVIR CHEM CHEMOTH, V3, P223, DOI 10.1177/095632029200300405; LURAIN NS, 1992, J VIROL, V66, P7146, DOI 10.1128/JVI.66.12.7146-7152.1992; Maniatis T., 1982, MOL CLONING; MARCY AI, 1990, NUCLEIC ACIDS RES, V18, P1207, DOI 10.1093/nar/18.5.1207; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MURPHY M, 1989, J GEN VIROL, V70, P2357, DOI 10.1099/0022-1317-70-9-2357; OSTRANDER M, 1980, BIOCHIM BIOPHYS ACTA, V609, P232, DOI 10.1016/0005-2787(80)90234-8; POWELL KL, 1977, J VIROL, V24, P618, DOI 10.1128/JVI.24.2.618-626.1977; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; QUINN JP, 1985, NUCLEIC ACIDS RES, V13, P8143, DOI 10.1093/nar/13.22.8143; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1990, GENETICS, V124, P213; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; SCHENCK P, 1988, J GEN VIROL, V69, P99, DOI 10.1099/0022-1317-69-1-99; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; SPANOS A, 1983, METHOD ENZYMOL, V91, P263; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; SULLIVAN V, 1993, ANTIMICROB AGENTS CH, V37, P19, DOI 10.1128/AAC.37.1.19; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TADDIE JA, 1991, J VIROL, V65, P869, DOI 10.1128/JVI.65.2.869-879.1991; TADDIE JA, 1993, J VIROL, V67, P4323, DOI 10.1128/JVI.67.7.4323-4336.1993; TENNEY DJ, 1993, J VIROL, V67, P543, DOI 10.1128/JVI.67.1.543-547.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990; WEISSHART K, 1988, EUR J BIOCHEM, V174, P707, DOI 10.1111/j.1432-1033.1988.tb14155.x; WEISSHART K, 1993, P NATL ACAD SCI USA, V90, P1028, DOI 10.1073/pnas.90.3.1028; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	75	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22788	22796						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077231				2022-12-25	WOS:A1994PQ16300051
J	HAUSDORFF, SF; FRANGIONI, JV; BIRNBAUM, MJ				HAUSDORFF, SF; FRANGIONI, JV; BIRNBAUM, MJ			ROLE OF P21(RAS) IN INSULIN-STIMULATED GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PC12 CELLS; RECEPTOR SUBSTRATE-1; RAS PROTEINS; P21RAS; DIFFERENTIATION; MICROINJECTION; ACTIVATION; INHIBITION; SIGNAL	The proto-oncogene p21(ras) has been implicated as an essential intermediate in several actions of the hormone insulin. This study examines the role of p21(ras) in the signaling pathways by which insulin increases hexose transport in differentiated 3T3-L1 adipose cells, a model system for study of the metabolic effects of the hormone on a physiological target tissue, Introduction of constitutively activated p21(ras(G12V)) by microinjection into 3T3-L1 adipocytes stimulated the expression of the ubiquitous glucose transporter, GLUT1, in the absence of insulin. Moreover, introduction of dominant inhibitory forms of p21(ras) or neutralizing antibodies directed against p21(ras) blocked the insulin induced increase in GLUT1 expression. In contrast, microinjection of activating or inhibitory forms of p21(ras)had no effect on translocation of the ''insulin-responsive'' glucose transporter, GLUT4, to the cell surface. These results indicate that p21(ras) mediates the insulin-induced increase in GLUT1 expression in 3T3-L1 adipocytes but is not involved in the translocation of GLUT4 that leads to acute increases in glucose transport.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School				Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519, F32DK008714] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK08714, DK39519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; YANG J, 1992, J BIOL CHEM, V267, P10393	34	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21391	21394						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063767				2022-12-25	WOS:A1994PK97300001
J	CHANG, ZF; HUANG, DY; HSUE, NC				CHANG, ZF; HUANG, DY; HSUE, NC			DIFFERENTIAL PHOSPHORYLATION OF HUMAN THYMIDINE KINASE IN PROLIFERATING AND M-PHASE-ARRESTED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; POTENT INHIBITOR; PURIFICATION; PROTEINS; ENZYME; GENE; STAUROSPORINE; CYCLE	The expression of cytosolic human thymidine kinase (TK) occurs in a cell cycle-dependent manner. Here, we show that TK is hyperphosphorylated during the M phase in several human cell lines. Our data from characterizing TK phosphorylation in proliferating and M phase-arrested HeLa cells suggest that the polypeptide of TR is differentially phosphorylated during the progression of the cell cycle. TK in the M phase-arrested HeLa cells was found to have a 10-fold lower affinity for its substrate, thymidine, than in the proliferating cells. We propose that phosphorylation of TK by the mitotic kinase(s) may provide an attenuating mechanism to prevent unnecessary synthesis of dTTP at the time of mitosis.			CHANG, ZF (corresponding author), CHANG GUNG COLL MED & TECHNOL, DEPT BIOCHEM, 259 WEN HWA 1 RD, TAYUAN 3333, TAIWAN.							ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; BRONZERT DA, 1981, CANCER RES, V41, P604; CHANG ZF, 1993, J BIOL CHEM, V268, P1266; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GAN TE, 1983, J BIOL CHEM, V258, P7000; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; ITO M, 1990, J BIOL CHEM, V265, P6954; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; LEE LS, 1976, J BIOL CHEM, V251, P2600; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; NOBURY C, 1992, ANNU REV BIOCHEM, V61, P441; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	26	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21249	21254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063748				2022-12-25	WOS:A1994PC40300066
J	PANAYOTOVAHEIERMANN, M; LOO, DDF; LOSTAO, MP; WRIGHT, EM				PANAYOTOVAHEIERMANN, M; LOO, DDF; LOSTAO, MP; WRIGHT, EM			SODIUM D-GLUCOSE COTRANSPORTER CHARGE MOVEMENTS INVOLVE POLAR RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SMALL-INTESTINE; VOLTAGE-CLAMP; NA+/GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; XENOPUS-OOCYTES; CLONING; EXPRESSION; SIMILARITY; CHANNELS; CDNA	Na+-dependent glucose transporters (SGLT1) exhibit transient carrier currents with a time constant (tau) of 2-20 ms, and the charge transfer (Q) fits the Boltzmann equation. There is a 60-mV negative displacement in the tau/V and Q/V curves between the human and rabbit SGLT1 proteins, and the initial goal was to identify the charges responsible for these differences in kinetics. We have focused on residue 176 in putative transmembrane helix 4 (M4) because this is an aspartic acid in rabbit and asparagine in human. Asp-176 in rabbit SGLT1 was replaced with asparagine and alanine residues, and the wild-type and mutant proteins were expressed in Xenopus laevis oocytes. A two-electrode voltage clamp was used to measure the kinetics of charge transfer. There was no difference between the wild-type and D176N, but there was a 60-mV negative shift in the tau/V and Q/V curves with D176A. This suggests that polar residues at position 176 play an important role in determining charge transfer, probably by electrostatic bonding to a neighboring polar residue in the membrane domain of the protein. The similarity between rabbit SGLT1 and the D176N mutant further indicates that other membrane residues account for the difference between rabbit and human SGLT1. There were only modest changes in the steady-state Na+/glucose cotransport kinetics between wild-type and D176A mutant transporters in the voltage range +50 to -50 mV. Model simulations show that the mutation alters the rate constants for conformational changes of the unloaded transporter. Phlorizin, a specific competitive inhibitor of sugar transport, has a lower affinity for the D176A mutant than for SGLT1. This indicates that polar residues at position 176 hydrogen bond with the -OH group on the B-phenyl ring of the inhibitor.			PANAYOTOVAHEIERMANN, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.		Lostao, M. Pilar/AAW-4238-2021; Lostao, M. Pilar/ABH-4714-2020	Lostao, M. Pilar/0000-0002-7319-3451; Lostao, M. Pilar/0000-0002-7319-3451	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK019567] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44602, DK19567] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; DIEDRICH DF, 1990, METHOD ENZYMOL, V191, P755; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KONG CT, 1993, J BIOL CHEM, V268, P1509; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P	18	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21016	21020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063719				2022-12-25	WOS:A1994PC40300033
J	CARRAWAY, CAC; CARVAJAL, ME; LI, YQ; CARRAWAY, KL				CARRAWAY, CAC; CARVAJAL, ME; LI, YQ; CARRAWAY, KL			ASSOCIATION OF P185(NEU) WITH MICROFILAMENTS VIA A LARGE GLYCOPROTEIN COMPLEX IN MAMMARY-CARCINOMA MICROVILLI - EVIDENCE FOR A MICROFILAMENT-ASSOCIATED SIGNAL TRANSDUCTION PARTICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR-CELL MICROVILLI; FACTOR RECEPTORS; A431 CELLS; ASCITES ADENOCARCINOMA; MORPHOLOGICAL-CHANGES; PHOSPHOLIPASE-C; TYROSINE KINASE; MEMBRANE; REORGANIZATION	The protein product of the neu (proto)oncogene P185neu is an analog of the epidermal growth factor receptor. Immunoblot analyses of cell surface fractions (microvilli) from the ascites 13762 rat mammary adenocarcinoma indicate that these cells contain p185neu but not epidermal growth factor receptor. Phalloidin shift velocity sedimentation analysis indicated that essentially all of the microvillar p185 co-migrated with microvillar microfilament cores when extractions were performed under microfilament-stabilizing conditions. Fractionation studies of these microvilli indicated that the association of p185 with the microfilament core is mediated by its stable interaction with a previously described transmembrane complex (TMC), composed minimally of at least four glycoproteins, a 58-kDa cytoplasmic membrane protein, and actin (Carraway, C. A. C., Jung, G., and Carraway, K. L. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 430-434). A fraction of the p185 co-purifies with a large (>2 x 10(6) kDa) complex of the TMC glycoproteins on gel filtration of microvilli, microfilament cores, or microvillar membranes in buffer containing 1 M KCl at pH 9.5, which are conditions required for the dissociation of actin from the complex. We propose that p185-containing TMC serves as a signal transduction particle at the surface of the 13762 cells and may be a prototype for similar microfilament-associated signal-transducing complexes in other cells.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33136	University of Miami	CARRAWAY, CAC (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,R-629,MIAMI,FL 33136, USA.				NATIONAL CANCER INSTITUTE [P30CA014395, R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395, CA 52498] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY C A C, 1992, P123; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1983, CELL MOTIL CYTOSKEL, V3, P491, DOI 10.1002/cm.970030516; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CHINKERS M, 1981, J CELL BIOL, V88, P422, DOI 10.1083/jcb.88.2.422; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; DEFIZE LHK, 1989, J CELL BIOL, V107, P939; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JUNG G, 1986, J CELL BIOCHEM, V28, P243; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KING AC, 1982, J BIOL CHEM, V257, P3053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LIU YC, 1989, J BIOL CHEM, V264, P1208; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TODARO GJ, 1990, CANCER BIOL, V1, P257; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YE XH, 1989, EXP CELL RES, V182, P160, DOI 10.1016/0014-4827(89)90288-7	40	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5582	5587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095497				2022-12-25	WOS:A1993KR82200037
J	KOLLER, KJ; LIPARI, MT; GOEDDEL, DV				KOLLER, KJ; LIPARI, MT; GOEDDEL, DV			PROPER GLYCOSYLATION AND PHOSPHORYLATION OF THE TYPE-A NATRIURETIC PEPTIDE RECEPTOR ARE REQUIRED FOR HORMONE-STIMULATED GUANYLYL CYCLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PORCINE BRAIN; ATRIAL; ACTIVATION; FAMILY; SYSTEM; FORM; CNP	The natriuretic peptide receptor type A (NPR-A) is a receptor-guanylyl cyclase whose cytoplasmic enzymatic activity is stimulated by atrial natriuretic peptide binding to the extracellular domain. NPR-A expressed in COS cells is heterogeneously glycosylated, and the more highly glycosylated protein is also phosphorylated. Upon hormone binding, dephosphorylation occurs from both serine and threonine residues, probably within the kinase homology domain of NPR-A, and may be involved with receptor desensitization. Using site-specific mutations in the kinase homology domain of NPR-A, we have identified several residues that are important for regulating the guanylyl cyclase activity of NPR-A. Some of these amino acids are probably essential for maintaining the proper tertiary structure of the intracellular domain, and others may form loops that allow for binding of ATP, which is required for proper enzymatic activity. The site-specific mutants which have greatly reduced enzymatic activity are not phosphorylated and are incompletely glycosylated. These results suggest a correlation between phosphorylation and complete glycosylation of NPR-A and that both are required for hormone-induced enzymatic activity.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								ATLAS SA, 1987, ATRIAL HORMONES OTHE, P53; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JEWETT JRS, 1993, IN PRESS EMBO J; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1992, J BIOL CHEM, V267, P21691; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; POTTER LR, 1992, J BIOL CHEM, V267, P14531; RAMARAO CS, 1988, J BIOL CHEM, V263, P1524; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; ULLRICH A, 1984, NATURE, V309, P416; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581	28	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5997	6003						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095500				2022-12-25	WOS:A1993KR82200095
J	HALL, PA; MCKEE, PH; MENAGE, HD; DOVER, R; LANE, DP				HALL, PA; MCKEE, PH; MENAGE, HD; DOVER, R; LANE, DP			HIGH-LEVELS OF P53 PROTEIN IN UV-IRRADIATED NORMAL HUMAN SKIN	ONCOGENE			English	Note							DNA POLYMERASE-ALPHA; NUCLEAR ANTIGEN PCNA; CELL-PROLIFERATION; REPAIR SYNTHESIS; GENE; DAMAGE; MUTATIONS; AGENTS; FORM	Exposure of normal adult human skin to doses of UV irradiation that induced mild sunburn resulted in the rapid appearance of p53 protein in the epidermis and superficial dermal fibroblasts. Immunohistological analysis with a panel of antibodies established that while p53 staining was not seen in normal skin it appeared within 2h of UV exposure. The level of p53 immunostaining peaked at 24h and returned to undetectable levels within 360h. The induction of proliferating cell nuclear antigen (PCNA) (which is required for both DNA replication and repair) followed a similar spatial and temporal pattern to p53. The UV irradiation did not induce a mitotic response or the replication-associated antigens DNA polymerase alpha or Ki67. The accumulation of high levels of p53 and PCNA in response to UV doses to which many human populations are routinely exposed provides strong support for a model in which normal p53 acts as part of the DNA damage response in vertebrate cells. Such a model is consistent with the profound tumour-suppressor function of the p53 gene, the high rate of p53 mutation in neoplasia and the exceptionally high tumour susceptibility of p53-deficient mice.	UMDS,DEPT PHOTOBIOL,LONDON SE1 7EH,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; ICRF,HISTOPATHOL UNIT,LONDON WC1A 7BE,ENGLAND	University of London; King's College London; University of Dundee	HALL, PA (corresponding author), UMDS,DEPT HISTOPATHOL,ST THOMASS CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREEMAN SE, 1987, J INVEST DERMATOL, V88, P430, DOI 10.1111/1523-1747.ep12469778; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GARMYN M, 1991, LAB INVEST, V65, P471; GERDES J, 1991, AM J PATHOL, V138, P867; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HALL PA, 1988, J PATHOL, V154, P223, DOI 10.1002/path.1711540305; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HAWK JLM, 1982, SCI PHOTOMECHANISMS, P246; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P23; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIJZEWIJK JJ, 1989, ACTA DERM-VENEREOL, V69, P512; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIM CS, 1992, J CUTAN PATHOL, V19, P302, DOI 10.1111/j.1600-0560.1992.tb01366.x; SLATER SD, 1992, HISTOPATHOLOGY, V20, P237, DOI 10.1111/j.1365-2559.1992.tb00962.x; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WASEEM NH, 1990, J CELL SCI, V96, P121; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	37	722	728	0	34	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					203	207						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093810				2022-12-25	WOS:A1993KN00500025
J	MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK				MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK			EFFICIENT INDUCTION OF FIBROSARCOMAS BY V-JUN REQUIRES MUTATIONS IN THE DNA-BINDING REGION AND THE TRANSACTIVATION DOMAIN	ONCOGENE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; FOS; TRANSFORMATION; ONCOGENE; AP-1; DELTA	v-jun is the transforming gene of ASV 17, a retrovirus isolated from a spontaneous chicken fibrosarcoma. There are three mutations in the viral Jun protein (v-Jun) as compared to its cellular progenitor c-Jun: a deletion in the transactivation domain (called delta) and two amino acid substitutions in and near the DNA binding region. The effect of each of these mutations on fibrosarcoma development is described. All three mutations contribute towards tumor formation, and their cumulative effect makes v-Jun more tumorigenic compared to Jun proteins that carry only one or two of the mutations. Viruses rescued from tumors induced by c-Jun carrying the two amino acid substitutions in the DNA binding region have increased transforming and tumorigenic potential. These increases are probably due to further mutations that result in the expression of a rearranged Jun protein. Taken together the results show that the evolution of the c-Jun oncoprotein to an efficient carcinogen requires mutations in the transactivation and DNA binding regions.	NLVF, MICROBIAL GENE THERAPY LAB, AS, NORWAY; UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; TULARIK INC, San Francisco, CA 94080 USA	University of Southern California	MORGAN, IM (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1989, New Biologist, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2793	2797						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084584				2022-12-25	WOS:A1994PG82200004
J	BERNI, R; MALPELI, G; FOLLI, C; MURRELL, JR; LIEPNIEKS, JJ; BENSON, MD				BERNI, R; MALPELI, G; FOLLI, C; MURRELL, JR; LIEPNIEKS, JJ; BENSON, MD			THE ILE-84-]SER AMINO-ACID SUBSTITUTION IN TRANSTHYRETIN INTERFERES WITH THE INTERACTION WITH PLASMA RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL AMYLOIDOTIC POLYNEUROPATHY; CRYSTAL-STRUCTURE; HEREDITARY AMYLOIDOSIS; PREALBUMIN VARIANTS; THYROID-HORMONE; INDIANA SWISS; PRE-ALBUMIN; RESOLUTION; THYROXINE; CRYSTALLIZATION	In plasma the thyroid hormone-binding protein transthyretin (TTR) forms a tight complex with the specific retinol carrier retinol-binding protein (RBP). The ILe-84 --> Ser mutation and several other point mutations in TTR are associated with familial amyloidotic polyneuropathy, which is characterized by extracellular depositions of amyloid fibrils mainly consisting of mutated TTRs. The interactions with human REP of recombinant human normal and Ser-84 TTRs were investigated by monitoring the fluorescence anisotropy of REP-bound retinol. A nearly negligible affinity of the recombinant Ser-84 TTR for RBP was found. This result indicates the participation of a region on the outer surface of TTR that comprises Ile-84 in the recognition of RBP. In preliminary studies the Ser-84 TTR was the only one among several amyloidogenic variant TTRs to display negligible interaction with RBP. Therefore, in general a substantially altered binding of TTR to RBP is not associated with familial amyloidotic polyneuropathy. Instead, the altered binding of Ser-84 TTR to RBP appears to be responsible for an abnormal plasma transport of RBP. The recombinant normal TTR exhibits binding properties, in its interaction with human RBP, approximately similar to those of TTR purified from human plasma. Two independent and equivalent RBP binding sites on recombinant normal TTR are characterized by a dissociation constant of about 0.4 mu M.	INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	BERNI, R (corresponding author), UNIV PARMA,FAC SCI,INST BIOCHEM SCI,VIALE SCI,I-43100 PARMA,ITALY.			Malpeli, Giorgio/0000-0002-2996-2903; Berni, Rodolfo/0000-0002-1839-0479	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042111, R01DK034881] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00750] Funding Source: Medline; NIDDK NIH HHS [NIDDK-42111, NIDDK-34881] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AQUIST J, 1992, J MOL GRAPHICS, V10, P120; BENSON MD, 1983, ARTHRITIS RHEUM, V26, P1493, DOI 10.1002/art.1780261211; BENSON MD, 1992, J INTERN MED, V232, P525, DOI 10.1111/j.1365-2796.1992.tb00632.x; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1993, FASEB J, V7, P1179, DOI 10.1096/fasebj.7.12.8375617; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BERNI R, 1985, ANAL BIOCHEM, V150, P273, DOI 10.1016/0003-2697(85)90510-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; GOODMAN DS, 1972, J LIPID RES, V18, P338; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HERBERT J, 1986, NEUROLOGY, V36, P90; JARVIS JA, 1994, BIOCHEMISTRY-US, V33, P33, DOI 10.1021/bi00167a005; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MCCUTCHEN SL, 1993, BIOCHEM BIOPH RES CO, V197, P415, DOI 10.1006/bbrc.1993.2495; MURRELL JR, 1992, J BIOL CHEM, V267, P16595; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; PETERSON PA, 1971, J BIOL CHEM, V246, P34; REFETOFF S, 1986, J CLIN ENDOCR METAB, V63, P1432, DOI 10.1210/jcem-63-6-1432; ROSEN HN, 1993, J CLIN ENDOCR METAB, V77, P370, DOI 10.1210/jc.77.2.370; STEINRAUF LK, 1991, BIOCHEM BIOPH RES CO, V179, P804, DOI 10.1016/0006-291X(91)91888-J; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TRAGARDH L, 1980, J BIOL CHEM, V255, P9243; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; WALLACE MR, 1988, AM J HUM GENET, V43, P182; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P24873; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	37	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23395	23398						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089102				2022-12-25	WOS:A1994PQ34500004
J	PERLMAN, JH; LAAKKONEN, L; OSMAN, R; GERSHENGORN, MC				PERLMAN, JH; LAAKKONEN, L; OSMAN, R; GERSHENGORN, MC			A MODEL OF THE THYROTROPIN-RELEASING-HORMONE (TRH) RECEPTOR-BINDING POCKET - EVIDENCE FOR A 2ND DIRECT INTERACTION BETWEEN TRANSMEMBRANE HELIX-3 AND TRH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEAR MAGNETIC-RESONANCE; PROTEIN-COUPLED RECEPTORS; LIGAND-BINDING; POINT MUTATION; CELLS; SPECIFICITY; AFFINITY; DOMAINS	The receptor for thyrotropin-releasing hormone (TRH) is a member of the seven-transmembrane-spanning, GTP-binding protein-coupled receptor family. We showed that tyrosine at position 106 in transmembrane helix 3 of the TRH receptor directly binds the ring carbonyl of the pyroglutamyl moiety of TRH (Perlman, J. H., Thaw, C. N., Laakkonen L., Bowers, C. Y., Osman, R., and Gershengorn, M. C. (1994) J. Biol. Chem. 269, 1610-1613). We now show that asparagine at position 110 of transmembrane helix 3 directly interacts with the ring N-H of the TRH pyroglutamyl moiety. Based on these findings and evidence that two transmembrane arginines are important in binding, we developed a three-dimensional model of the TRH receptor binding pocket using molecular modeling and simulation programs. The model places the binding pocket for TRH within the transmembrane domains of the receptor and predicts that multiple hydrogen-bonding interactions are involved in binding TRH. To our knowledge, this is the first model, at an atomic level of detail, of the interaction of a peptide ligand with a GTP-binding protein-coupled receptor.	CORNELL UNIV,COLL MED,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10021; NEW YORK HOSP,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Cornell University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036, K11DK002101] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02101, DK43036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; DESLAURIERS R, 1973, FEBS LETT, V31, P59, DOI 10.1016/0014-5793(73)80073-0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONZEL B, 1975, NATURE, V256, P750, DOI 10.1038/256750a0; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; GAO JL, 1993, J BIOL CHEM, V268, P25395; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOREN HJ, 1977, MOL PHARMACOL, V13, P606; IMAI A, 1987, METHOD ENZYMOL, V141, P100; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MERY L, 1994, J BIOL CHEM, V269, P3457; METCALF G, 1989, THYROTROPIN RELEASIN; MONTAGUT M, 1974, BIOPOLYMERS, V13, P2615, DOI 10.1002/bip.1974.360131216; NAGAYAMA Y, 1991, J BIOL CHEM, V266, P14926; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERLMAN JH, 1993, T ASSOC AM PHYSICIAN, V106, P162; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; SURYANARAYANA S, 1993, MOL PHARMACOL, V44, P111; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; UNKEFER CJ, 1983, INT J PEPT PROT RES, V22, P582; VALE W, 1971, ENDOCRINOLOGY, V89, P1485, DOI 10.1210/endo-89-6-1485; Vale W, 1973, Front Neuroendocrinol, V0, P375; VICAR J, 1979, FEBS LETT, V97, P275, DOI 10.1016/0014-5793(79)80101-5; WALKER P, 1994, J BIOL CHEM, V269, P2863; XIE YB, 1990, J BIOL CHEM, V265, P21411; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; YANG JH, 1994, BIOCHEM BIOPH RES CO, V198, P999, DOI 10.1006/bbrc.1994.1142; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021	37	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23383	23386						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089099				2022-12-25	WOS:A1994PQ34500001
J	YANG, PF; MAJOR, D; RUTISHAUSER, U				YANG, PF; MAJOR, D; RUTISHAUSER, U			ROLE OF CHARGE AND HYDRATION IN EFFECTS OF POLYSIALIC ACID ON MOLECULAR-INTERACTIONS ON AND BETWEEN CELL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULES; NCAM; IDENTIFICATION; REGULATOR; INSULIN; NEURONS; GROWTH	Previous studies have shown that the polysialic acid (PSA) moiety associated with the neural cell adhesion molecule (NCAM) has strong antiadhesive properties that can influence a variety of cell-cell interactions. Based on the size and structure of this long linear homopolymer, we have proposed that the activity of PSA results from its physical properties. In the present study, the premise that the charge and hydration properties of PSA underlie its effects on membrane vesicle aggregation is investigated through the manipulation of ionic strength. The results establish that the antiadhesive properties of PSA are accentuated at low ionic strength, where charge and hydration cause expansion of the polymer size, and are absent at high ionic strengths, where the polymer size collapses. These large effects of PSA on aggregation were shown not to result from changes in the osmolarity of the solvent or from the relatively small effect of ionic strength on the intrinsic functional properties of the adhesion receptors. In addition to this influence on overall membrane-membrane interaction, PSA was found to have a highly localized and ionic strength sensitive effect on the binding of monoclonal antibodies to NCAM. Together these results suggest that the charge and hydration properties of PSA can impede both molecular interactions between apposing membranes and more direct contact of NCAM with other proteins at the cell surface.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018369, R37HD018369] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER; NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD18369] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHESON A, 1988, J CELL BIOL, V106, P479, DOI 10.1083/jcb.106.2.479; ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BALAZS EA, 1951, J POLYM SCI, V6, P665, DOI 10.1002/pol.1951.120060517; BETTELHEIM FA, 1970, BIOL POLYELECTROLYTE, P131; CLELAND RL, 1968, BIOPOLYMERS, V6, P1519, DOI 10.1002/bip.1968.360061102; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; CONWAY BE, 1972, REV MACROMOLECULAR C, P114; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; FINNE J, 1985, TRENDS BIOCHEM SCI, V10, P129, DOI 10.1016/0968-0004(85)90274-9; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HAHN HJ, 1974, J BIOL CHEM, V249, P5275; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACOBSON B, 1954, J COLL SCI IMP U TOK, V9, P36, DOI 10.1016/0095-8522(54)90083-5; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; PLEKONEN S, 1988, J BACTERIOL, V170, P2642; Rathjen F. G, 1991, SEMIN NEUROSCI, V3, P297, DOI 10.1016/1044-5765(91)90047-R; REED CE, 1989, BIOPOLYMERS, V28, P1981, DOI 10.1002/bip.360281114; ROARK EF, 1992, DEVELOPMENT, V114, P973; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; RUTISHAUSER U, 1991, RECEPTORS EXTRACELLU, P132; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; TANFORD C, 1965, PHYSICAL CHEM MACROM; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WARREN L, 1959, J BIOL CHEM, V234, P1971; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487	39	111	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23039	23044						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083205				2022-12-25	WOS:A1994PQ16400024
J	CESARMAN, GM; GUEVARA, CA; HAJJAR, KA				CESARMAN, GM; GUEVARA, CA; HAJJAR, KA			AN ENDOTHELIAL-CELL RECEPTOR FOR PLASMINOGEN TISSUE-PLASMINOGEN ACTIVATOR (T-PA) .2. ANNEXIN II-MEDIATED ENHANCEMENT OF T-PA-DEPENDENT PLASMINOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING; GLU-PLASMINOGEN; PROTEINS; SURFACE; IDENTIFICATION; EXPRESSION; SEQUENCE; FAMILY; INACTIVATION; PROTEOLYSIS	In the preceding paper (Hajjar, K. A., Jacovina, A. T., and Chacko, J. (1994) J. Biol. Chem. 269, 21191-21197), we identified a M(r) = 40,000 endothelial cell receptor for tissue plasminogen activator (t-PA) and plasminogen (PLG) as the calcium- and phospholipid-binding protein, annexin II (Arm-II). Here, we examined the effect of Ann-II on t-PA-dependent plasminogen activation in a purified system. Purified native Ann-II bound t-PA, plasminogen, and plasmin with high affinity (K-d = 25 nM, 161 nM, and 75 nM, respectively). At fixed plasminogen concentrations, preincubation with purified native Ann-II was associated with an similar to 21-fold increase in the rate of Glu-PLG activation and an similar to 14-fold increase in activation of Lys-PLG. Three irrelevant proteins had no effect on plasmin formation, while fibrinogen increased the rate of Glu-PLG activation by similar to 4-fold. Annexin-II-mediated enhancement of t-PA-dependent plasminogen activation was 90-95% inhibited by epsilon-aminocaproic acid or by pretreatment of Ann-II with carboxypeptidase B, indicating a carboxyl-terminal lysine-dependent interaction. Kinetic analyses revealed that Ann-II conferred an similar to 60-fold increase in catalytic efficiency upon t-PA-dependent activation of either Glu-PLG or Lys-PLG. Thus, Ann-II-mediated assembly of plasminogen and t-PA may promote and localize constitutive plasmin generation on the surface of the blood vessel wall.	CORNELL UNIV, COLL MED, DEPT PEDIAT, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, P50HL018828, R01HL042493] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42493, HL 18828, HL 46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN B, 1986, BLOOD, V68, P1280; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; APLIN JD, 1982, BIOCHIM BIOPHYS ACTA, V694, P375, DOI 10.1016/0304-4157(82)90003-X; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; BRODER CC, 1991, J BIOL CHEM, V266, P4922; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; COLIGAN JE, 1984, J BIOL CHEM, V259, P3944; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; GEIGER M, 1984, J BIOL CHEM, V259, P2976; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARKUS G, 1978, J BIOL CHEM, V253, P733; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGUYEN G, 1992, J BIOL CHEM, V267, P6249; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; OMAR MN, 1987, J BIOL CHEM, V262, P9750; OTTER M, 1991, J BIOL CHEM, V266, P13931; OTTO U, 1982, EUR J BIOCHEM, V123, P63; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUSELL J, 1979, J BIOL CHEM, V254, P2296; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; STRICKER RB, 1986, BLOOD, V68, P275; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; VIRJI MAG, 1980, P NATL ACAD SCI-BIOL, V77, P875, DOI 10.1073/pnas.77.2.875; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	50	294	300	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21198	21203						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063741				2022-12-25	WOS:A1994PC40300058
J	CHEN, MY; DEVREOTES, PN; GUNDERSEN, RE				CHEN, MY; DEVREOTES, PN; GUNDERSEN, RE			SERINE-113 IS THE SITE OF RECEPTOR-MEDIATED PHOSPHORYLATION OF THE DICTYOSTELIUM G-PROTEIN ALPHA-SUBUNIT G-ALPHA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; NUCLEOTIDE-BINDING; KINASE-C; INTACT HEPATOCYTES; ADENYLATE-CYCLASE; HUMAN-PLATELETS; MUTAGENESIS; TRANSDUCIN; ACTIVATION; MUTANTS	The G protein alpha-subunit G alpha 2 is essential to the developmental program of Dictyostelium. G alpha 2 is transiently phosphorylated on a serine residue(s) following stimulation with extracellular cAMP (Gundersen, R. E., and Devreotes, P. N. (1990) Science 248, 591-593). To aid in defining the function of cu-subunit phosphorylation, we identified the site of G alpha 2 phosphorylation. Comparison of the isoelectric points (pI) of the phosphorylated and nonphosphorylated forms indicated that a single mole of phosphate is added to G alpha 2. Cleavage at tryptophan residues and immunoprecipitation with a specific peptide antibody localized the phosphorylated serine in the N-terminal 119 residues. Analysis of a series of G alpha 1 and G alpha 2 chimeras further confined the site between amino acids 33 and 215. Site-directed mutagenesis of serines between amino acids 33 and 119 produced two mutants that were not phosphorylated, S45A and S113A. Ser(113) was identified as the site by sequential Edman degradation of P-32-radiolabeled G alpha 2 digested with endoproteinase Glu-C. We have expressed the G alpha 2 mutants S113A, S113I, S113T, and S113D in a G alpha 2 null cell line to examine the function of phosphorylation.	UNIV MAINE, DEPT BIOCHEM MICROBIOL & MOLEC BIOL, ORONO, ME 04469 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	University of Maine System; University of Maine Orono; Johns Hopkins University				CHEN, MEI-YU/0000-0002-5765-9178	NIGMS NIH HHS [GM28007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD R, 1993, PRACTICAL GUIDE PROT, P103; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIULIAN GG, 1985, FED PROC, V44, P686; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KONIJN TM, 1987, METHOD CELL BIOL, V28, P283; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; ROOS W, 1976, FEBS LETT, V68, P170, DOI 10.1016/0014-5793(76)80429-2; SAGIEISENBERG R, 1989, TRENDS BIOCHEM SCI, V14, P355, DOI 10.1016/0968-0004(89)90001-7; Sambrook J, 1989, MOL CLONING LABORATO; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20925	20930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063709				2022-12-25	WOS:A1994PC40300020
J	RAVI, N; MOORE, V; LLOYD, SG; HALES, BJ; HUYNH, BH				RAVI, N; MOORE, V; LLOYD, SG; HALES, BJ; HUYNH, BH			MOSSBAUER CHARACTERIZATION OF THE METAL-CLUSTERS IN AZOTOBACTER-VINELANDII NITROGENASE VFE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; KLEBSIELLA-PNEUMONIAE NITROGENASE; CIRCULAR-DICHROISM SPECTROSCOPY; X-RAY ABSORPTION; MOFE-PROTEIN; VANADIUM NITROGENASE; P-CLUSTERS; CLOSTRIDIUM-PASTEURIANUM; ELECTRONIC-PROPERTIES; EPR SPECTROSCOPY	The VFe protein of alternative nitrogenase, isolated from Azotobacter vinelandii, strain LS15 and designated as Av1', has been investigated by Mossbauer spectroscopy. The Mossbauer spectrum of the dithionite-reduced Av1', recorded at 4.2 K with a 60-millitesla magnetic field applied parallel to the gamma-beam, is a superposition of three spectral components: 1) a complex spectrum (the M component) with magnetic hyperfine structures attributed to the paramagnetic FeV cofactor, 2) a component (the P component) consisting of three quadrupole doublets identifiable as the Fe2+, D, and S doublets similar to those observed for the P cluster pairs in MoFe proteins, and 3) a minor (4% of total absorption) quadrupole doublet attributable to adventitiously bound iron. The observed 4.2-K parameters for the Fe2+ (Delta E(Q) = 2.99 mm/s and delta = 0.64 mm/s), D (Delta E(Q) = 0.75 mm/s and delta = 0.63 mm/s), and S (Delta E(Q) = 1.2 mm/s and delta = 0.65 mm/s) iron sites and their temperature dependence are very similar to those observed for the P cluster pairs in the conventional MoFe proteins. Similar to those of the MoFe protein, strong field spectra indicate that these doublets are associated with a diamagnetic system. Their percent absorption intensities (Fe2+/D/S = 13.0:32.2:6.8) determined at 4.2 K after the removal of the contributions from the adventitiously bound iron are comparable to those of the P cluster pairs in MoFe proteins. These observations established that Av1' also contains P cluster pairs that are identical, in both composition and quantity, to those of the MoFe proteins; i.e. each molecule contains two P cluster pairs and each pair is formed by two Fe2+, five D, and one S iron sites. Considering that 52% absorption of the P component corresponding to two 8Fe clusters, the remaining 48% absorption determined for the M component is consistent with two 7Fe-containing FeV cofactors/molecule of Av1'. The fact that both P cluster pairs are found in the diamagnetic states implies that the S = 3/2 and S = 1/2 signals detected in earlier EPR measurements are associated with the FeV cofactor and suggests a spin mixture for the FeV cofactor in the dithionite-reduced Av1'.	EMORY UNIV, ROLLINS RES CTR, DEPT PHYS, ATLANTA, GA 30322 USA; LOUISIANA STATE UNIV, DEPT CHEM, BATON ROUGE, LA 70803 USA	Emory University; Louisiana State University System; Louisiana State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033965] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33965] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBER JM, 1987, NATURE, V325, P372, DOI 10.1038/325372a0; BURGESS BK, 1993, ACS SYM SER, V535, P144; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CARNEY MJ, 1987, INORG CHEM, V26, P719, DOI 10.1021/ic00252a016; CEN W, 1993, J AM CHEM SOC, V115, P9515, DOI 10.1021/ja00074a016; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN J, 1993, J AM CHEM SOC, V115, P5509, DOI 10.1021/ja00066a019; CHRISTOU G, 1982, J AM CHEM SOC, V104, P2820, DOI 10.1021/ja00374a021; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; DUNHAM WR, 1985, EUR J BIOCHEM, V146, P497, DOI 10.1111/j.1432-1033.1985.tb08679.x; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; GEORGE GN, 1988, J AM CHEM SOC, V110, P4057, DOI 10.1021/ja00220a066; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; HUYNH BH, 1979, BIOCHIM BIOPHYS ACTA, V576, P192, DOI 10.1016/0005-2795(79)90497-5; JOHNSON MK, 1981, BIOCHIM BIOPHYS ACTA, V671, P61, DOI 10.1016/0005-2795(81)90094-5; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1988, J BIOL CHEM, V263, P19412; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MORNINGSTAR JE, 1987, J AM CHEM SOC, V109, P6854, DOI 10.1021/ja00256a051; MORNINGSTAR JE, 1987, BIOCHEMISTRY-US, V26, P1975; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; ROBINSON AE, 1984, BIOCHEM J, V219, P495, DOI 10.1042/bj2190495; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1980, BIOCHEM J, V191, P449, DOI 10.1042/bj1910449; SMITH BE, 1974, BIOCHEM J, V137, P169, DOI 10.1042/bj1370169; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; VENTERS RA, 1986, J AM CHEM SOC, V108, P3487, DOI 10.1021/ja00272a054; WATT GD, 1981, BIOCHEMISTRY-US, V20, P7272, DOI 10.1021/bi00528a034; WOLFF TE, 1980, J AM CHEM SOC, V102, P4694, DOI 10.1021/ja00534a023; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, EUR J BIOCHEM, V35, P401, DOI 10.1111/j.1432-1033.1973.tb02852.x	39	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20920	20924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063708				2022-12-25	WOS:A1994PC40300019
J	SEVERINOV, K; FENYO, D; SEVERINOVA, E; MUSTAEV, A; CHAIT, BT; GOLDFARB, A; DARST, SA				SEVERINOV, K; FENYO, D; SEVERINOVA, E; MUSTAEV, A; CHAIT, BT; GOLDFARB, A; DARST, SA			THE SIGMA-SUBUNIT CONSERVED REGION-3 IS PART OF 5'-FACE OF ACTIVE-CENTER OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FUNCTIONAL TOPOGRAPHY; PROMOTER RECOGNITION; MASS-SPECTROMETRY; AFFINITY; CONTACTS; PROTEINS	Ribonucleotide analogs bound in the initiating site of Escherichia coli RNA polymerase holoenzyme in open promoter complexes were cross-linked to the beta and sigma(70) subunits. Using Limited proteolysis and chemical degradation, the cross-link site in sigma(70) was mapped to a segment between amino acids GLu(508) and Met(561) containing the C-terminal part of conserved region 3. This result, when reconciled with genetic data on the interaction of sigma(70) conserved regions 2 and 4 with the -10 and -35 promoter regions, respectively, allows us to model the orientation of the sigma(70) subunit domains within the open promoter complex.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA	Rockefeller University			Severinov, Konstantin/C-8545-2016	Fenyo, David/0000-0001-5049-3825	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BERNHARD SL, 1986, BIOCHEMISTRY-US, V25, P5914, DOI 10.1021/bi00368a012; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Burgess R.R., 1987, RNA POLYM REGULATION, P3; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1981, FEBS LETT, V130, P23, DOI 10.1016/0014-5793(81)80657-6; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KUHNKE G, 1987, EMBO J, V6, P507, DOI 10.1002/j.1460-2075.1987.tb04782.x; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OSUMIDAVIS PA, 1987, BIOCHIM BIOPHYS ACTA, V910, P130, DOI 10.1016/0167-4781(87)90065-0; PRICE NT, 1991, FEBS LETT, V282, P253, DOI 10.1016/0014-5793(91)80489-P; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992	25	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20826	20828						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063697				2022-12-25	WOS:A1994PC40300006
J	OFFRINGA, R; BIERER, BE				OFFRINGA, R; BIERER, BE			ASSOCIATION OF CD2 WITH TUBULIN - EVIDENCE FOR A ROLE OF THE CYTOSKELETON IN T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; HUMAN LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAIN; BRAIN MICROTUBULES; MOLECULAR-CLONING; ANTIGEN RECEPTOR; BINDING PROTEIN; SURFACE	In addition to the antigen-specific T cell receptor, a number of other T cell surface molecules contribute to T cell adhesion and activation. CD2 is a 50-kDa glycoprotein found on the surface of human T lymphocytes which plays a role in T cell adhesion and stimulation. The intracellular mechanisms by which CD2 functions are, however, not fully defined. Here we show that the T cell surface molecule CD2 physically interacts with tubulin. This interaction appears to involve the membrane-proximal part of the cytoplasmic domain of the CD2 molecule, suggesting that CD2 binds to the tubulin fraction previously shown to be present in membranes. Stimulation of T cells with activating pairs of anti-CD2 antibodies, capable of initiating lymphokine production and T cell proliferation, disrupts the CD2-tubulin complexes, suggesting that the dynamic interaction of CD2 with tubulin may play a role in T cell activation.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL, DANA 1610B,44 BINNEY ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028554, R01AI028554] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACHVAROFF RJ, 1980, P NATL ACAD SCI-BIOL, V77, P4979, DOI 10.1073/pnas.77.8.4979; BERNIERVALENTIN F, 1983, J CELL BIOL, V97, P209, DOI 10.1083/jcb.97.1.209; BEST D, 1981, ANAL BIOCHEM, V114, P281, DOI 10.1016/0003-2697(81)90481-4; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BIERER BE, 1990, J IMMUNOL, V144, P785; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BROTTIER P, 1985, J IMMUNOL, V135, P1624; BROWN MH, 1989, NATURE, V339, P551, DOI 10.1038/339551a0; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; HAGMANN J, 1980, J BIOL CHEM, V255, P2659; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HAHN WC, 1991, J IMMUNOL, V147, P14; HARLOW E, 1988, ANTIBODIES LABORATOR; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; JIN YJ, 1990, J IMMUNOL, V144, P647; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KAMOUN M, 1981, J EXP MED, V153, P207, DOI 10.1084/jem.153.1.207; KELLY WG, 1983, J CELL BIOL, V97, P1191, DOI 10.1083/jcb.97.4.1191; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; MAKNI H, 1991, J IMMUNOL, V146, P2522; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING, V3; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PLUNKETT ML, 1986, J IMMUNOL, V136, P4181; QUILLEN M, 1985, J CELL BIOL, V101, P2345, DOI 10.1083/jcb.101.6.2345; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; van der Eb A J, 1980, Methods Enzymol, V65, P826	44	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4979	4988						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095265				2022-12-25	WOS:A1993KP88400064
J	MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR				MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR			DELETION MAPPING OF CHROMOSOME 8P IN PROSTATE-CANCER BY FLUORESCENCE IN-SITU HYBRIDIZATION	ONCOGENE			English	Note							INSITU HYBRIDIZATION; COLORECTAL-CANCER; ALLELIC LOSS; ADENOCARCINOMA; ABERRATIONS; CARCINOMA; CELLS; LOCI; RETINOBLASTOMA; ONCOGENES	Double-target fluorescence in situ hybridization (FISH) was applied to 42 cases of prostate cancer and seven cases of histologically proven benign prostate hyperplasia for the detection of structural aberrations of chromosome 8. Cosmid probes for two chromosome 8p loci (LPL/8p22 and D8S7/8p23) were used in 34 specimens of malignant tumors obtained by the touch biopsy technique. Deletion was defined as when the number of cosmid signals was lower than the number of centromere signals in more than 35% of all nuclei observed. In total; thirty of the 42 (71%) specimens demonstrated any type of 8p deletion. Out of the 34 cases in which deletion mapping could be evaluated, distal deletion (D8S7) was detected in 17 (50%), of which 10 also showed deletion of LPL. Deletion of LPL was detected in 18 cases (53%), of which 8 (24%) retained the D8S7 (interstitial deletion). When the deletion pattern was graded as (1) no deletion (2) partial deletion (either D8S7 or LPL deleted) and (3) both deletions, the degree of deletion was well correlated with the tumor grade (P = 0.0009) and with stage (P = 0.0072, Fisher's Exact test). These data support the hypothesis that tumor suppressor gene(s) may be located in the chromosomal region 8p22, hence 8p deletions may play a crucial role in the pathogenesis of prostate cancer.	KAROLINSKA HOSP,DEPT UROL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT MED RADIOBIOL,STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM,SWEDEN; DEUTSCH KREBSFORSCHUNGSZENTRUM,HEIDELBERG,GERMANY; YAMAGUCHI UNIV,SCH MED,DEPT UROL,UBE,YAMAGUCHI 755,JAPAN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Yamaguchi University			Matsuyama, Hideyasu/AAC-7487-2020	Matsuyama, Hideyasu/0000-0001-5607-7769				ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1993, CANCER-AM CANCER SOC, V71, P1179, DOI 10.1002/1097-0142(19930201)71:3+<1179::AID-CNCR2820711442>3.0.CO;2-B; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; EMI M, 1992, CANCER RES, V52, P5368; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MATSUMURA K, 1992, CANCER RES, V52, P3474; MATSUYAMA H, 1994, IN PRESS CANCER GENE; MCNEAL JE, 1986, LANCET, V1, P60; Mostofi FK, 1973, INT CLASSIFICATION T; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STILGENBAUER S, 1993, BLOOD, V81, P2118; TRIBUKAIT B, 1989, RAPID FLOW CYTOMETRY; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114	28	81	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3071	3076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084616				2022-12-25	WOS:A1994PG82200040
J	NILSSON, P; MEHLE, C; REMES, K; ROOS, G				NILSSON, P; MEHLE, C; REMES, K; ROOS, G			TELOMERASE ACTIVITY IN-VIVO IN HUMAN-MALIGNANT HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							TRANSFERASE-ACTIVITY; HUMAN FIBROBLASTS; IDENTIFICATION; REDUCTION; RNA	In somatic cells, each DNA replication round gives a shortening of the telomere ends as a consequence of incomplete lagging strand synthesis. Telomeres are essential for chromosomal integrity and extensive telomere length reduction is associated with increased instability of the genome. In germ line cells and in established cell lines, telomerase activity maintains the length of the telomeres by de novo synthesis of telomeric repeats, in humans (T(2)AG(3))(n). Recently, it was for the first time shown the existence of telomerase activity in human ovarian carcinomas. In the present study we show that telomerase activation can also occur in human hematopoietic tumor cells in vivo. Cell extracts from 19 cases with leukemia, lymphoma and myeloma were tested for telomerase activity using an in vitro assay with (T(2)AG(3))(3) or permutations of this sequence as primers. Eight cases demonstrated an RNAse A sensitive ability to add new nucleotides to the human telomere sequence. Nine acute leukemias were tested telomerase negative. Our data demonstrate that telomerase activation in vivo seems to be a common event in B cell neoplasias with a mature immunophenotype like non-Hodgkin's lymphoma and myeloma, in contrast to acute leukemias of B, T or myeloid cell origin. Telomere length evaluation indicated no marked differences between samples with or without telomerase activity which could argue for a telomere length independent mechanism for telomerase activation in at least some cases.	UMEA UNIV, DEPT PATHOL, S-90187 UMEA, SWEDEN	Umea University								ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCAFFREY R, 1975, NEW ENGL J MED, V292, P775, DOI 10.1056/NEJM197504102921504; MEHLE C, 1994, CANCER RES, V54, P236; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8	20	98	104	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3043	3048						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084612				2022-12-25	WOS:A1994PG82200035
J	SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS				SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS			P53 GENE-MUTATIONS IN BREAST CANCERS IN MIDWESTERN US WOMEN - NULL AS WELL AS MISSENSE-TYPE MUTATIONS ARE ASSOCIATED WITH POOR-PROGNOSIS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR CARCINOMAS; MOLECULAR EPIDEMIOLOGY; SKIN; OCCUR; AMPLIFICATION; PATTERN	We determined the pattern of mutations in exons 2-11 and adjacent intronic regions in breast cancers from Midwestern US white women. Twenty-one mutations were detected in 53 tumors (39.6%). Comparisons of the pattern of mutations within exons 5-9 showed that the frequency of missense mutations (44%) was lower in breast cancers of US Midwestern women than in most tumor types including breast cancers in other populations. Compared to breast cancers reported in a Scottish population, US women had a high frequency of microdeletion mutations (P = 0.006) and a low frequency of G:C-->T:A transversions (P = 0.046). These findings suggest that environmental or endogenous factors contribute to p53 mutagenesis in mammary tissue to different extents among different populations. With a median follow-up of 19 months, the presence of a mutation was associated with shorter time to disease recurrence (P = 0.05) and shorter survival (P = 0.003). Putative dominant negative missense-type mutations (missense and in-frame microdeletions; P = 0.001) and null mutations (hemizygous nonsense and frameshift mutations; P = 0.007) were equally ominous. Thus, tumors with missense p53 mutations resulting in overexpression of a dysfunctional but otherwise intact protein have a clinical outcome similar to tumors with null mutations resulting in a truncated or garbled protein.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BLASZYK H, 1994, IN PRESS HUMAN MUT; BORING CC, 1994, CA-CANCER J CLIN, V43, P7; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; COLES C, 1992, CANCER RES, V52, P5291; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ELLEDGE RM, 1993, BREAST CANCER RES TR, V27, P95, DOI 10.1007/BF00683196; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KANJILAL S, 1993, CANCER RES, V53, P2961; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRESS S, 1992, CANCER RES, V52, P6400; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Osborne CK, 1991, BREAST DIS, P301; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; THORLACIUS S, 1993, CANCER RES, V53, P1637; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; 1991, STAT XACT VER 2 0	33	70	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2869	2875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084591				2022-12-25	WOS:A1994PG82200012
J	ROLDAN, ERS; MURASE, T				ROLDAN, ERS; MURASE, T			POLYPHOSPHOINOSITIDE-DERIVED DIACYLGLYCEROL STIMULATES THE HYDROLYSIS OF PHOSPHATIDYLCHOLINE BY PHOSPHOLIPASE-C DURING EXOCYTOSIS OF THE RAM SPERM ACROSOME - EFFECT IS NOT MEDIATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN-NEUTROPHILS; ZONA PELLUCIDA; MONOACYLGLYCEROL LIPASE; FERTILIZATION INVITRO; SUBSEQUENT EXOCYTOSIS; SIGNAL TRANSDUCTION; LINKED DIGLYCERIDES; RABBIT SPERMATOZOA; PLASMA-MEMBRANES	In ram spermatozoa, treatment with the ionophore A23187 and Ca2+ led to an increase in total diacylglycerol mass and to exocytosis of the acrosomal granule. If sperm cells were prelabeled with [H-3]palmitic acid, stimulation with A23187/Ca2+ resulted in the generation of [H-3]diacylglycerols with a mixture of saturated and unsaturated fatty acids. When cells were prelabeled with 1-O-[H-3]octadecylglycerophosphocholine, stimulation led to the generation of [H-3]alkylacylglycerol. No rise in [H-3]diacyl- or [H-3]alkylacylphosphatidic acid was detected under these conditions. Moreover, no changes in the mass of phosphatidic acid have been previously noted under similar conditions. Thus, these results indicate that diradylglycerols are generated via phospholipase C (PLC). Increases in diradylglycerols were paralleled by rises in monoacyl- or monoalkylglycerols labeled at position 1, but not in free [H-3]palmitic acid or [H-3]octadecanol, implying that, unlike somatic cells, spermatozoa catabolize diradylglycerols via a a-diglyceride lipase, Activation of PLC appears to be effected by phosphoinositide-derived diacylglycerol: exposure to Mg2+, a cation known to inhibit phosphoinositide hydrolysis, resulted in less PLC activity upon stimulation, and addition of exogenous 1,2-diacylglycerols enhanced the enzyme's activity. However, 1,3-diacylglycerol and alkylacylglycerol also stimulated PLC activity, suggesting that the effect is unlikely to be mediated via protein kinase C. Since diradylglycerols are known to be essential in the molecular sequence leading to membrane fusion in mammalian spermatozoa, these results suggest that their generation via PLC constitutes a fundamental event during acrosomal exocytosis in response to physiological agonists.			ROLDAN, ERS (corresponding author), BIOTECHNOL & BIOL SCI RES COUNCIL,BABRAHAM INST,DEPT DEV & SIGNALLING,CAMBRIDGE CB2 4AT,ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AITKEN RJ, 1984, J ANDROL, V5, P321; ALLEN AC, 1992, J NEUROCHEM, V58, P1130, DOI 10.1111/j.1471-4159.1992.tb09372.x; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BASS DA, 1988, J BIOL CHEM, V263, P19610; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONI LT, 1985, J BIOL CHEM, V260, P819; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CROSS NL, 1988, BIOL REPROD, V38, P235, DOI 10.1095/biolreprod38.1.235; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DAWSON WD, 1987, J CELL PHYSIOL, V132, P104, DOI 10.1002/jcp.1041320114; DOMINO SE, 1989, J BIOL CHEM, V264, P9412; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FORD DA, 1989, J BIOL CHEM, V264, P13818; FRASER LR, 1982, J ANDROL, V3, P412; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HINKOVSKAGALCHEV V, 1992, MOL REPROD DEV, V33, P281, DOI 10.1002/mrd.1080330308; LEE C, 1991, J BIOL CHEM, V266, P22837; LLANOS MN, 1993, BIOL REPROD S1, V48, P106; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; Mann T., 1981, PHYSL BIOCH INVESTIG, P495; MELENDREZ C, 1993, BIOL REPRODUCTION S1, V48, P107; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NEILL AR, 1973, J REPROD FERTIL, V34, P279, DOI 10.1530/jrf.0.0340279; NIKOLOPOULOU M, 1985, BIOCHIM BIOPHYS ACTA, V815, P486, DOI 10.1016/0005-2736(85)90377-3; NOMURA H, 1986, BIOCHEM BIOPH RES CO, V140, P1143, DOI 10.1016/0006-291X(86)90754-0; ORAND MG, 1987, DEV BIOL, V119, P551, DOI 10.1016/0012-1606(87)90058-3; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PARKS JE, 1987, BIOL REPROD, V37, P1249, DOI 10.1095/biolreprod37.5.1249; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; RIDER LG, 1988, J IMMUNOL, V140, P200; RINDLISBACHER B, 1987, BIOCHIM BIOPHYS ACTA, V905, P349, DOI 10.1016/0005-2736(87)90463-9; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P108, DOI 10.1016/0005-2760(93)90273-C; ROLDAN ERS, 1994, BIOCHEM J, V297, P225, DOI 10.1042/bj2970225; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1993, BIOCHEM SOC T, V21, P284, DOI 10.1042/bst0210284; ROLDAN ERS, 1990, BIOCHEM BIOPH RES CO, V172, P8, DOI 10.1016/S0006-291X(05)80165-2; ROLDAN ERS, 1988, BIOCHEM BIOPH RES CO, V155, P901, DOI 10.1016/S0006-291X(88)80581-3; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P48, DOI 10.1016/0005-2760(93)90048-E; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; SELIVONCHICK DP, 1980, BIOCHIM BIOPHYS ACTA, V618, P242, DOI 10.1016/0005-2760(80)90030-2; SHAMSBORHAN G, 1981, GAMETE RES, V4, P407, DOI 10.1002/mrd.1120040506; SHEARS SB, 1993, INTRACELLULAR MESSEN, P315; SHEIKHNEJAD RG, 1986, J BIOL CHEM, V261, P7544; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; XIA T, 1992, BIOCHIM BIOPHYS ACTA, V1126, P327, DOI 10.1016/0005-2760(92)90248-T; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893	55	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23583	23589						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089126				2022-12-25	WOS:A1994PQ34500032
J	CHALBOS, D; GALTIER, F				CHALBOS, D; GALTIER, F			DIFFERENTIAL EFFECT OF FORM-A AND FORM-B OF HUMAN PROGESTERONE-RECEPTOR ON ESTRADIOL-DEPENDENT TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; HUMAN ESTROGEN-RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; GENE-EXPRESSION; CDNA SEQUENCES; CHICK OVIDUCT; MCF7 CELLS; BINDING; CLONING; RNA	In addition to stimulation of the target gene fatty-acid synthetase, the synthetic progestin R5020 strongly inhibited estradiol-induced pS2 and cathepsin D mRNA levels in MCF7 human breast cancer cells as shown by Northern blot analysis. Inhibition was half-maximal with 30 pM R5020, and the antiprogestin RU486 had only a weak effect. Two human progesterone receptor isoforms have been described; isoform A is a truncated form of isoform B and lacks the 164 N-terminal amino acids. We hypothesized that the two isoforms could have a differential capacity to transrepress estrogen-induced responses. Therefore, in MDA-MB231 cells containing no progesterone and estrogen receptors, we transiently transfected progesterone receptor expression vectors coding for form B (hPR1 or hPR0) or form A (hPR2) along with the estrogen receptor expression vector HEO. We show that R5020 inhibited estradiol-induced transcription of the pS2-CAT reporter plasmid only in cells selectively expressing isoform B. The same results were obtained when progesterone receptor isoforms were overexpressed in MCF7, Ishikawa, HeLa, or NIH-3T3 cells. Transrepression was dependent on the promoter context since the extent of inhibition by isoform B was higher when evaluated with pS2 or cathepsin D nonpalindromic estrogen-responsive element-mediated transcription than with the perfect palindromic form of the vitellogenin gene. Isoform A was inefficient regardless of the reporter construct used. Inhibition varied with the isoform ratio, and isoform B had a dominant effect, with >70% inhibition measured in cells transfected with the same amount of both progesterone receptor iso forms. Progestin repressed only one of the two transcription activation functions of the estrogen receptor, AF-2, which corresponds to the hormone-binding domain. We conclude that differential expression of progesterone receptor isoforms could be responsible for a tissue-specific inhibition of estrogen target genes by progestins.	INSERM,U148,F-34090 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	CHALBOS, D (corresponding author), UNIV MONTPELLIER,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE.							ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; ALEXIEVAFIGUSCH J, 1980, CANCER, V46, P2369, DOI 10.1002/1097-0142(19801201)46:11<2369::AID-CNCR2820461111>3.0.CO;2-3; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BARDON S, 1985, J CLIN ENDOCR METAB, V50, P692; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BOYD PA, 1979, BIOCHEMISTRY-US, V18, P3685, DOI 10.1021/bi00584a008; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CONNEELY OM, 1987, MOL ENDOCRINOL, V1, P517, DOI 10.1210/mend-1-8-517; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; JOYEUX C, 1990, J CLIN ENDOCR METAB, V70, P1438, DOI 10.1210/jcem-70-5-1438; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LOOSFELT H, 1984, J BIOL CHEM, V259, P4196; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1985, BREAST CANCER RES TR, V6, P213, DOI 10.1007/BF01806771; MESTER I, 1974, NATURE, V250, P776, DOI 10.1038/250776a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1992, J BIOL CHEM, V267, P10882; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; Sambrook J, 1989, MOL CLONING LABORATO; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SHYAMALA G, 1990, ENDOCRINOLOGY, V126, P2882, DOI 10.1210/endo-126-6-2882; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; VIGNON F, 1983, J CLIN ENDOCR METAB, V56, P1124, DOI 10.1210/jcem-56-6-1124; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62	41	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23007	23012						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083200				2022-12-25	WOS:A1994PQ16400019
J	JENNINGS, GT; SECHI, S; STEVENSON, PM; TUCKEY, RC; PARMELEE, D; MCALISTERHENN, L				JENNINGS, GT; SECHI, S; STEVENSON, PM; TUCKEY, RC; PARMELEE, D; MCALISTERHENN, L			CYTOSOLIC NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE - ISOLATION OF RAT CDNA AND STUDY OF TISSUE-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE MAMMARY-GLAND; NADP+; MITOCHONDRIAL; PURIFICATION; SEQUENCE; PROTEINS; DNA; OVARY	Immunoscreening and DNA hybridization were used to isolate a 1.72-kilobase pair cDNA encoding cytosolic NADP(+)-dependent isocitrate dehydrogenase from a rat liver, lambda gt11 cDNA library. The identity of the cDNA was confirmed by comparison of the deduced amino acid sequence with sequences of peptides obtained from purified ovarian cytosolic isocitrate dehydrogenase. The 1.72-kilobase pair cDNA sequence translated into a protein of 414 amino acid residues with a molecular mass of 46,681 Da. The amino acid sequence contains a tripeptide (AKL) at the COOH terminus which represents a possible peroxisomal targeting sequence. The deduced amino acid sequence of the rat liver cytosolic isocitrate dehydrogenase showed 70 and 59% identity with sequences reported for NADP(+)-dependent isocitrate dehydrogenases from porcine mitochondria and yeast cytosol respectively. Northern blot analysis demonstrated a 13-fold increase in expression of cytosolic NADP(+)-dependent isocitrate dehydrogenase mRNA during the gonadotropin-induced development of the immature rat ovary. In comparative studies, the cytosolic and mitochondrial isocitrate dehydrogenase mRNAs were found to differ in size (2.2 and 1.8 kilobases, respectively) and to be differentially expressed in various tissues of the rat. Distinct digestion patterns were also obtained in Southern blot analysis of rat genomic DNA.	UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20894	University of Western Australia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	JENNINGS, GT (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Tuckey, Robert/H-5983-2014	Tuckey, Robert/0000-0002-5022-4729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN RL, 1966, J DAIRY SCI, V49, P1533, DOI 10.3168/jds.S0022-0302(66)88132-8; CARLIER MF, 1973, EUR J BIOCHEM, V37, P341, DOI 10.1111/j.1432-1033.1973.tb02993.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FARRELL HM, 1987, J DAIRY SCI, V70, P781, DOI 10.3168/jds.S0022-0302(87)80074-7; FARRELL HM, 1980, ARCH BIOCHEM BIOPHYS, V204, P551, DOI 10.1016/0003-9861(80)90067-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINT APF, 1970, BIOCHEM J, V117, P73, DOI 10.1042/bj1170073; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HENDERSON NS, 1968, ANN NY ACAD SCI, V151, P429, DOI 10.1111/j.1749-6632.1968.tb11906.x; HOGEBOOM GH, 1950, J BIOL CHEM, V186, P417; HUH TL, 1993, BIOCHEM J, V292, P705, DOI 10.1042/bj2920705; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; JENNINGS GT, 1991, EUR J BIOCHEM, V198, P621, DOI 10.1111/j.1432-1033.1991.tb16059.x; JENNINGS GT, 1990, BIOCHIM BIOPHYS ACTA, V1034, P219, DOI 10.1016/0304-4165(90)90080-G; KLINKEN SP, 1977, EUR J BIOCHEM, V81, P327, DOI 10.1111/j.1432-1033.1977.tb11955.x; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LOFTUS TJ, 1994, IN PRESS BIOCHEMISTR; LOWENSTEIN JM, 1962, BIOCHIM BIOPHYS ACTA, V56, P385, DOI 10.1016/0006-3002(62)90587-5; PLAUT GWE, 1983, BIOCHIM BIOPHYS ACTA, V760, P300, DOI 10.1016/0304-4165(83)90177-0; PLAUT GWE, 1970, CURR TOP CELL REGUL, V2, P1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORROSH BS, 1992, PLANT MOL BIOL, V20, P801, DOI 10.1007/BF00027151; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SURGUCHOV AP, 1987, TRENDS BIOCHEM SCI, V12, P335, DOI 10.1016/0968-0004(87)90157-5; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; UDVARDI MK, 1993, PLANT MOL BIOL, V21, P739, DOI 10.1007/BF00027108; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105	32	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23128	23134						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083215				2022-12-25	WOS:A1994PQ16400037
J	LAWSON, JH; KALAFATIS, M; STRAM, S; MANN, KG				LAWSON, JH; KALAFATIS, M; STRAM, S; MANN, KG			A MODEL FOR THE TISSUE FACTOR PATHWAY TO THROMBIN .1. AN EMPIRICAL-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; COAGULATION FACTOR-VII; FACTOR-XI; FACTOR-IX; FACTOR-V; BLOOD-COAGULATION; HUMAN-PROTHROMBIN; EXTRINSIC PATHWAY; ANTITHROMBIN-III; HAGEMAN-FACTOR	The activation of prothrombin, factor V, factor VIII, factor IX, and factor X by the tissue factor factor Wa complex, in vitro, in a system in which each precursor protein was present at plasma concentration, was evaluated using a combination of activity assays, immunoblots, active site blots, and autoradiography. The thrombin generation curves observed were distinctly nonlinear and typically displayed a time lag in which little or no thrombin was observed. This was followed by an almost linear propagation phase of thrombin formation. The lag was a function of tissue factor/factor VIIa con centration and represented primarily the interval of fac tor V and factor VIII activation. The postlag propagation phase of thrombin generation was nearly independent of the initial activator (factor VIIa or tissue factor) concentration over a 10(3)-fold range in factor VIIa-tissue factor concentration. Maximum thrombin generation rates were observed when less than 1% of the factor IX and X present was activated but when nearly 100% activation of the cofactors, factor V and factor VIII, was achieved. Analyses of the activation pattern of factor V indicated that the cofactor is activated by both factor Xa and thrombin which are formed at low levels during the lag phase of the reaction. When the initial reaction mixture contained factor Va instead of factor V, the lag was substantially reduced. When factor V was deleted from the reaction mixture, no thrombin formation was observed. When either factor VIII or factor IX was deleted from the reaction system, the propagation phase of thrombin formation (at 5 pM tissue factor-factor VIIa complex) was only one third that observed for reactions which contained factor VIII and factor IX. The addition of factor XI to the experimental system increased the rate of thrombin formation by 15% during the propagation phase but had no effect upon the lag phase of the reaction. Our data suggest that normal hemostasis may be initiated by the factor VIIa-tissue factor complex and support the concept of multiple feedback reactions which amplify and propagate the hemostatic response.	UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594, P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL46703, T32HL07594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BRUNNEE T, 1993, BLOOD, V81, P580; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; Colman RW, 1987, HEMOSTASIS THROMBOSI; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HATHAWAY WE, 1965, BLOOD-J HEMATOL, V26, P521, DOI 10.1182/blood.V26.5.521.521; HEDNER U, 1983, J CLIN INVEST, V71, P1836, DOI 10.1172/JCI110939; HEDNER U, 1988, LANCET, V2, P1193; HOAK JC, 1966, LANCET, V2, P884; HOYER LW, 1981, BLOOD, V58, P1; JANCO RL, 1985, BLOOD, V65, P545; Jesty J, 1976, Methods Enzymol, V45, P95; KANE WH, 1981, J BIOL CHEM, V256, P1002; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MILLER BC, 1985, BLOOD, V65, P845; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MORRISSEY JH, 1993, BLOOD, V81, P734; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RAO LVM, 1993, BLOOD, V81, P2600; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; ROBERTS HR, 1987, HEMOSTASIS THROMBOSI, P162; ROSING J, 1985, BLOOD, V65, P1557, DOI 10.1182/blood.V65.6.1557.bloodjournal6561557; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; Schmaier AH, 1987, HEMOSTASIS THROMBOSI, P18; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SEELER RA, 1972, MED CLIN N AM, V56, P119; SHAPIRO SS, 1966, THROMB DIATH HAEMOST, V16, P469, DOI 10.1055/s-0038-1655603; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SIDI A, 1978, J UROLOGY, V119, P528, DOI 10.1016/S0022-5347(17)57537-0; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; THOMPSON AR, 1986, BLOOD, V67, P565; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACY PB, 1982, BLOOD, V60, P59; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WATZKE HH, 1991, J CLIN INVEST, V88, P1685, DOI 10.1172/JCI115484; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	74	231	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23357	23366						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083241				2022-12-25	WOS:A1994PQ16400069
J	SKIBA, PJ; KEESLER, GA; TABAS, I				SKIBA, PJ; KEESLER, GA; TABAS, I			INTERFERON-GAMMA DOWN-REGULATES THE LIPOPROTEIN(A)/APOPROTEIN(A) RECEPTOR ACTIVITY ON MACROPHAGE FOAM CELLS - EVIDENCE FOR DISRUPTION OF LIGAND-INDUCED RECEPTOR RECYCLING BY INTERFERON-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; MONOCYTE-DERIVED MACROPHAGES; HUMAN ATHEROSCLEROTIC PLAQUE; SMOOTH-MUSCLE CELLS; TRANSFERRIN RECEPTOR; DEGRADATION; EXPRESSION; APOLIPOPROTEIN(A); BETA	Cholesterol loading of macrophages, such as occurs in atheroma foam cells, has recently been shown to upregulate a novel receptor activity that mediates the internalization and degradation of the atherogenic lipoprotein, lipoprotein(a) (Lp(a)), and its protein moiety, apoprotein(a), (apo(a)). Herein, the regulation of this receptor activity by macrophage activation and interferon-gamma (IFN-gamma) was investigated. Compared with control foam cells, I-125-recombinant-apo(a) (r-apo(a)) degradation assayed after 5 h of incubation was 3-6-fold less in foam cells derived from thioglycollate- or concanavalin A elicited mouse peritoneal macrophages. In vitro treatment of foam cells derived from resident mouse peritoneal macrophages or from human monocyte derived macrophages with IFN-gamma also led to a substantial decrease in the ability of these cells to degrade I-125-r-apo(a); similar results were obtained with I-125-Lp(a). In contrast, IFN-gamma-treated foam cells that were incubated for 10 min with I-125-r-apo(a) and then chased for 2 h in the absence of ligand degraded similar amounts of I-125-r-apo(a)as untreated foam cells. To reconcile these data, we hypothesized that the apo(a) receptor activity undergoes ligand-induced recycling and that IFN-gamma disrupts this recycling. To test this idea, control and IFN-gamma-treated foam cells were incubated for 10 min with unlabeled r-apo(a), and then I-125-r-apo(a) receptor activity was assayed at various times thereafter. Untreated foam cells showed clear evidence of ligand-induced recycling of the apo(a) receptor activity, whereas recycling was markedly diminished in the IFN-gamma-treated foam cells. Thus, by disrupting ligand-induced receptor recycling, IFN-gamma leads to down-regulation of the foam cell Lp(a)/apo(a) receptor activity. Since T cells are known to be present in atherosclerotic lesions, these findings raise the possibility that the degradation by atheroma foam cells of Lp(a) and other possible ligands for the receptor may be reversibly regulated by IFN-gamma.	COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT CELL BIOL & ANAT,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009001, T32HL007343, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL-07343, HL-21006, F32HL-09001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EMERSON EE, 1988, AM J PATHOL, V130, P369; FONG LG, 1990, J BIOL CHEM, V265, P11751; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOWN AM, 1986, AM J PATHOL, V191, P207; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HABERLAND ME, 1992, J BIOL CHEM, V267, P4143; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAMILTON TA, 1984, CELL IMMUNOL, V89, P478, DOI 10.1016/0008-8749(84)90348-4; HANSSON GK, 1989, AM J PATHOL, V135, P169; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; INNERARITY TL, 1982, ARTERIOSCLEROSIS, V2, P114, DOI 10.1161/01.ATV.2.2.114; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KARNOVSKY ML, 1978, J IMMUNOL, V121, P809; KEESLER GA, 1994, ARTERIOSCLER THROMB, V14, P1337, DOI 10.1161/01.ATV.14.8.1337; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KREMPLER F, 1984, J LIPID RES, V25, P283; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LIBBY P, 1991, LAB INVEST, V64, P5; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1992, J EXP BIOL, V172, P39; MOKENA T, 1985, J CLIN INVEST, V75, P624; MUNRO JM, 1987, HUM PATHOL, V18, P375; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SMITH CW, 1972, EXP CELL RES, V73, P394, DOI 10.1016/0014-4827(72)90063-8; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	46	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23059	23067						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083207				2022-12-25	WOS:A1994PQ16400027
J	TOH, Y; PENCIL, SD; NICOLSON, GL				TOH, Y; PENCIL, SD; NICOLSON, GL			A NOVEL CANDIDATE METASTASIS-ASSOCIATED GENE, MTA1, DIFFERENTIALLY EXPRESSED IN HIGHLY METASTATIC MAMMARY ADENOCARCINOMA CELL-LINES - CDNA CLONING, EXPRESSION, AND PROTEIN ANALYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; CANCER METASTASIS; SH3 DOMAINS; KINASE-C; RAT; SITES; DIVERSIFICATION; PHOSPHORYLATION; PURIFICATION; DEGRADATION	To understand the genes involved in breast cancer invasion and metastasis, we analyzed a novel candidate metastasis-associated gene, mta1, which was isolated by differential cDNA library screening using the 13762NF rat mammary adenocarcinoma metastatic system. Northern blot analyses showed that the mRNA expression level of the mta1 gene was 4-fold higher in the highly metastatic cell line MTLn3 than in the nonmetastatic cell line MTC.4. The mta1 gene was expressed in various normal rat organs, especially in the testis, suggesting its essential normal function. The mRNA expression levels of the human homologue of this gene also correlated with the metastatic potential in two human breast cancer metastatic systems. The full-length mta1 cDNA sequence contained an open reading frame encoding a protein of 703 amino acid residues, and sequence analysis by data base homology search indicated that mta1 is a novel gene. The Mta1 protein contained several possible phosphorylation sites, and a proline-rich amino acid stretch at the carboxyl-terminal end completely matched the consensus sequence for the src homology 3 domain-binding motif. Using antibodies raised against glutathione S-transferase-Mta1 fusion protein or a synthetic oligopeptide, Western blots showed that the mo lecular mass of the Mta1 protein was similar to 80 kDa, and the levels of the Mta1 protein also correlated with the metastatic potential, results similar to those obtained from the Northern analyses. Thus, the novel gene mta1 may encode a molecule that is functional in normal cells as well as in breast cancer invasion and metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [NCI R35-CA44342, NCI R01-CA63045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts B., 1989, MOL BIOL CELL; ATNIP KD, 1987, BIOCHEM BIOPH RES CO, V146, P996, DOI 10.1016/0006-291X(87)90746-7; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BRUNNER N, 1993, CANCER RES, V53, P3229; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DEAR TN, 1989, CANCER RES, V49, P5323; DEAR TN, 1989, CANCER RES, V48, P5208; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LaBiche R A, 1992, In Vivo, V6, P317; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MUSCHEL R, 1988, CARCINOGENESIS, V9, P705, DOI 10.1093/carcin/9.5.705; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1992, CANCER RES, V146, P996; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLSON GL, 1988, BREAST CANCER RES TR, V12, P167, DOI 10.1007/BF01805938; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1991, J CELL BIOCHEM, V46, P277, DOI 10.1002/jcb.240460402; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; NIEDERBERGER CS, 1993, WORLD J UROL, V11, P120; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; PHILLIPS SM, 1990, J NATL CANCER I, V82, P199, DOI 10.1093/jnci/82.3.199; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REN R, 1993, NATURE, V259, P1157; Sambrook J, 1989, MOL CLONING LABORATO; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; TOH Y, 1994, IN PRESS GENE AMST; WENG Z, 1993, J BIOL CHEM, V268, P14958; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG RD, 1991, INVAS METAST, V11, P204	41	309	364	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22958	22963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083195				2022-12-25	WOS:A1994PQ16400011
J	TABAS, I; ZHA, XH; BEATINI, N; MYERS, JN; MAXFIELD, FR				TABAS, I; ZHA, XH; BEATINI, N; MYERS, JN; MAXFIELD, FR			THE ACTIN CYTOSKELETON IS IMPORTANT FOR THE STIMULATION OF CHOLESTEROL ESTERIFICATION BY ATHEROGENIC LIPOPROTEINS IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACYL-COENZYME-A; MOUSE PERITONEAL-MACROPHAGES; HAMSTER OVARY CELLS; ADP-RIBOSYLATING TOXINS; NIEMANN-PICK DISEASE; LEYDIG TUMOR-CELLS; PLASMA-MEMBRANE; INTRACELLULAR-TRANSPORT; TRANSFERASE-ACTIVITY	Stimulation of intracellular cholesterol esterification, which is catalyzed by the enzyme acyl-coenzyme A: cholesterol O-acyltransferase (ACAT), by atherogenic lipoproteins in macrophages is a key step in the ability of these cells to store lipoprotein-cholesterol and in the eventual development of atheroma foam cells. Herein, we provide evidence that the actin cytoskeleton plays an important role in the stimulation of cholesterol esterification by atherogenic lipoproteins in macrophages. When the actin cytoskeleton of cultured mouse peritoneal macrophages was disrupted by treatment with cytochalasin D or Clostridial C2 toxin, the ability of beta very low density lipoprotein (beta-VLDL) to stimulate cholesterol esterification was decreased 3-6-fold, even under conditions in which beta-VLDL protein degradation, cholesteryl ester hydrolysis, or net cholesterol delivery to the cells was matched. Esterification of cellular phospholipids and triglycerides was not affected by this treatment. Cytochalasin D treatment of macrophages also inhibited the ability of acetyl-low density lipoprotein, another foam cell-forming lipoprotein, to stimulate cholesterol esterification, but stimulation of cholesterol esterification by 25-hydroxycholesterol was not inhibited by cytochalasin D. Cytochalasin D was found to inhibit neither the exit of beta-VLDL derived cholesterol from lysosomes nor the ability of beta-VLDL to down-regulate endogenous cholesterol synthesis. From these data we conclude that an intact actin cytoskeleton is necessary for efficient stimulation of cholesterol esterification by atherogenic lipoproteins in macrophages. Although the exact function of actin in the cholesterol esterification pathway remains to be determined, our data rule out a general role for actin in intracellular cholesterol trafficking or maintenance of ACAT enzyme activity. Rather, we speculate that actin filaments play a role in specific cellular entry processes of atherogenic lipoproteins and/or in establishing transport or contact between the plasma membrane cholesterol substrate pool and the ACAT enzyme in macrophages.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University	TABAS, I (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032, USA.		Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-21006, HL-39703] Funding Source: Medline; NIDDK NIH HHS [DK-27083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL039703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; AMANUMA K, 1986, VIRCHOWS ARCH A, V410, P231; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BROWN MS, 1986, SCIENCE, V232, P32; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CORTESE F, 1978, J CELL BIOL, V77, P507, DOI 10.1083/jcb.77.2.507; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; ROSS AC, 1984, J BIOL CHEM, V259, P815; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUCKLING KE, 1985, J LIPID RES, V26, P647; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1986, J BIOL CHEM, V261, P3147; XU XX, 1991, J BIOL CHEM, V266, P17040	51	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22547	22556						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077203				2022-12-25	WOS:A1994PQ16300018
J	WOYNAROWSKA, B; SKRINCOSKY, DM; HAAG, A; SHARMA, M; MATTA, K; BERNACKI, RJ				WOYNAROWSKA, B; SKRINCOSKY, DM; HAAG, A; SHARMA, M; MATTA, K; BERNACKI, RJ			INHIBITION OF LECTIN MEDIATED OVARIAN TUMOR-CELL ADHESION BY SUGAR ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; GALACTOSIDE-BINDING LECTIN; ASN-LINKED OLIGOSACCHARIDES; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; ENDOGENOUS LECTINS; LUNG COLONIZATION; CANCER-CELLS; GALAPTIN; DIFFERENTIATION	Adhesion of A-121 human ovarian carcinoma cells to extracellular matrix is partly mediated via interaction between galaptin, an endogenous beta-galactoside-binding lectin present in extracellular matrix, and specific cell surface carbohydrate receptors identified as lysosomal associated membrane proteins, lamp-1 and lamp-2. In this study, we report that adhesion of human ovarian carcinoma cells to polystyrene plates coated with polymerized human splenic galaptin can be inhibited by polyclonal antibodies raised against lamp-1 and lamp-2 molecules and by pretreatment of A-121 human ovarian carcinoma cells with glucosamine analogs: 2-acetamido-1,4,6-tri-O-acetyl-3-deoxy-3-fluoro-alpha-D-glucopyranose (3-F-GlcNAc) and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-alpha-D-glucopyranose (4-F-GlcNAc). A 48-h exposure of A-121 cells to individual sugar analogs, or to a combination of the two, resulted in a concentration-dependent inhibition of cellular attachment to polymerized galaptin. Both drugs inhibited glycoprotein biosynthesis as measured by cellular incorporation of labeled [H-3]glucosamine and [H-3]fucose with negligible effects on [H-3]thymidine and [H-3]leucine incorporation and cell growth. As a result of drug action on glycoprotein biosynthesis, an alteration in the structure of the galaptin receptor was noted by indirect immunofluorescence and Western blot analysis. Moreover, probing gels of cell extracts with anti-lamp antibodies or Datura stramonium lectin demonstrated significant changes in the reactivity and pattern of glycoprotein staining, suggesting an effect of sugar analogs on the glycosylation of various cellular receptor molecules. The greatest change was observed when tumor cells were exposed to a combination of the two sugar analogs. These studies suggest that specific endogenous lectins and their surface receptors play a role in tumor cell adhesion and perhaps metastasis and may serve as suitable targets for therapeutic exploitation.	ROSWELL PK CANC INST, DEPT EXPTL THERAPEUT, BUFFALO, NY 14263 USA; ROSWELL PK CANC INST, DEPT GYNECOL ONCOL, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA042898, P01CA013038, R01CA035329] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA 13038, NCI CA 35329, NCI CA 42898] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; AHMED H, 1992, Journal of Molecular Recognition, V5, P1, DOI 10.1002/jmr.300050102; ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; ALLEN HJ, 1987, TUMOR BIOL, V8, P218, DOI 10.1159/000217525; ALLEN HJ, 1991, TUMOR BIOL, V12, P52, DOI 10.1159/000217688; AMOS B, 1990, J BIOL CHEM, V265, P19192; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BERGMAN F, 1966, ACTA OBSTET GYN SCAN, V45, P211, DOI 10.3109/00016346609158447; BLADIER D, 1989, ARCH BIOCHEM BIOPHYS, V269, P433, DOI 10.1016/0003-9861(89)90127-6; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CATT JW, 1985, J CELL SCI, V73, P347; CRICKARD K, 1989, GYNECOL ONCOL, V32, P163, DOI 10.1016/S0090-8258(89)80028-9; DRICKAMER K, 1989, CIBA F SYMP, V145, P45; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRABAYASHI K, 1970, AM J OBSTET GYNECOL, V106, P492, DOI 10.1016/0002-9378(70)90031-1; HUANG J, 1992, ONCOL RES, V4, P507; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOTAN R, 1988, ANN NY ACAD SCI, V551, P385, DOI 10.1111/j.1749-6632.1988.tb22372.x; LOTAN R, 1988, J CELL BIOCHEM, V37, P107, DOI 10.1002/jcb.240370110; LOTAN R, 1985, CANCER RES, V45, P4349; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MEROMSKY L, 1986, CANCER RES, V46, P5270; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; OZEKI Y, 1993, GLYCOCONJUGATE J, V10, P271, DOI 10.1007/BF01209960; PLATT D, 1992, J NATL CANCER I, V84, P438, DOI 10.1093/jnci/84.6.438; RAZ A, 1987, INT J CANCER, V39, P353, DOI 10.1002/ijc.2910390314; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; RAZ A, 1984, EMBO J, V3, P2979, DOI 10.1002/j.1460-2075.1984.tb02244.x; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SHARMA M, 1993, CARBOHYD RES, V240, P85, DOI 10.1016/0008-6215(93)84174-5; SHARMA M, 1990, CARBOHYD RES, V198, P205, DOI 10.1016/0008-6215(90)84293-4; SKRINCOSKY DM, 1993, CANCER RES, V53, P2667; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WOYNAROWSKA B, 1989, CANCER RES, V49, P5598; WOYNAROWSKA B, 1993, GLYCOCONJUGATE J, V10, P249, DOI 10.1007/BF01209896; WOYNAROWSKA B, 1985, BIOCHIM BIOPHYS ACTA, V825, P199, DOI 10.1016/0167-4781(85)90104-6; WOYNAROWSKA B, 1990, P AM ASSOC CANC RES, V31, P65; YOUAKIM A, 1989, CANCER RES, V49, P6889	50	69	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22797	22803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077232				2022-12-25	WOS:A1994PQ16300052
J	GARNIER, M; BOUJRAD, N; OGWUEGBU, SO; HUDSON, JR; PAPADOPOULOS, V				GARNIER, M; BOUJRAD, N; OGWUEGBU, SO; HUDSON, JR; PAPADOPOULOS, V			THE POLYPEPTIDE DIAZEPAM-BINDING INHIBITOR AND A HIGHER AFFINITY MITOCHONDRIAL PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR SUSTAIN CONSTITUTIVE STEROIDOGENESIS IN THE R2C LEYDIG TUMOR-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; HORMONE-STIMULATED STEROIDOGENESIS; RAT ADRENAL-CORTEX; ACTIVATOR POLYPEPTIDE; STEROID-BIOSYNTHESIS; CHOLESTEROL; IDENTIFICATION; PROTEINS; PEPTIDE; CYCLOHEXIMIDE	The polypeptide diazepam binding inhibitor (DBI) and drug ligands for the mitochondrial peripheral-type benzodiazepine receptor (PBR) have been shown to regulate cholesterol transport, the rate determining step in steroidogenesis, in hormone-responsive steroidogenic cells including the MA-10 Leydig tumor cells. The present study was designed to characterize the role of DBI and PBR in the R2C rat Leydig tumor constitutive steroid-producing cell model. Both DBI and PBR were present in R2C cells. R2C cell treatment with a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to DBI, but not sense, resulted in the reduction of DBI levels and a concomitant dramatic decrease of the amount of progesterone produced. These observations strongly suggested that DBI was important in maintaining constitutive steroidogenesis in R2C cells. Radioligand binding assays revealed the presence of a single class of PBR binding sites with an affinity 10 times higher (K-d similar to 0.5 nM) than that displayed by the MA-10 PBR (K-d similar to 5 nM). Photolabeling of R2C and MA-10 cell mitochondria with the photoactivatable PBR ligand [H-3] 1-(2-fluoro-5-nitrophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide showed that the M(r) 18,000 PBR protein was specifically labeled. This indicates that the R2C cells express a PBR protein which has properties similar to the MA-10 PBR. Chemical crosslinking studies of purified metabolically radiolabeled DBI to mitochondria provided direct evidence that DBI specifically binds to the M(r) 18,000 PBR protein. Moreover, DBI and a PBR synthetic ligand were able to increase steroid production in isolated R2C cell mitochondria which express the 5 nM affinity receptor. However, mitochondrial PBR binding was increased by 6-fold upon addition of the post-mitochondrial fraction, suggesting that a cytosolic factor modulates the binding properties of PBR in R2C cells and is responsible for the 0.5 nM affinity receptor seen in intact cells. In conclusion, these data demonstrate that DBI plays a key role in maintaining R2C constitutive steroidogenesis by binding to the mitochondrial higher affinity PBR which promotes a continuous supply of cholesterol to the inner mitochondrial side chain cleavage cytochrome P450.	GEORGETOWN UNIV, MED CTR, DEPT CELL BIOL, WASHINGTON, DC 20007 USA; RES GENET INC, HUNTSVILLE, AL 35801 USA	Georgetown University			BOUJRAD, Noureddine/L-1367-2015; Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	NICHD NIH HHS [HD-01031] Funding Source: Medline; NIDDK NIH HHS [DK-43358] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043358] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELSON D, 1966, METABOLIS, V15, P242, DOI 10.1016/0026-0495(66)90022-9; AMSTERDAM A, 1991, ENDOCRINOLOGY, V129, P503, DOI 10.1210/endo-129-1-503; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BARNEA ER, 1989, MOL CELL ENDOCRINOL, V64, P155, DOI 10.1016/0303-7207(89)90141-X; BERCOVICI JP, 1981, J CLIN ENDOCR METAB, V53, P1291, DOI 10.1210/jcem-53-6-1291; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; BOUJRAD N, 1993, 1993 END SOC ANN M L; BOUJRAD N, 1994, IN PRESS ENDOCRINOLO; BOVOLIN P, 1990, REGUL PEPTIDES, V29, P267, DOI 10.1016/0167-0115(90)90089-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AS, 1992, MOL CELL ENDOCRINOL, V83, P1, DOI 10.1016/0303-7207(92)90189-D; BROWN AS, 1991, BIOCHEM BIOPH RES CO, V180, P609; CAVALLARO S, 1992, P NATL ACAD SCI USA, V89, P10598, DOI 10.1073/pnas.89.22.10598; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHAUDHARY LR, 1988, BIOCHIMIE, V70, P1799, DOI 10.1016/0300-9084(88)90041-7; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FREEMAN DA, 1987, ENDOCRINOLOGY, V120, P124, DOI 10.1210/endo-120-1-124; GARNIER M, 1994, MOL PHARMACOL, V45, P201; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; GUARNERI P, 1992, P NATL ACAD SCI USA, V89, P5118, DOI 10.1073/pnas.89.11.5118; GUIDOTTI A, 1990, BIOCHEM J, V265, P928, DOI 10.1042/bj2650928; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; Hall P.F., 1988, P975; HALL PF, 1988, INT CONGR SER, V799, P253; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; KIMURA T, 1986, J STEROID BIOCHEM, V25, P711, DOI 10.1016/0022-4731(86)90299-2; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCNAMARA BC, 1989, ARCH BIOCHEM BIOPHYS, V275, P53, DOI 10.1016/0003-9861(89)90349-4; MERTZ LM, 1989, J BIOL CHEM, V264, P15274; MOCCHETTI I, 1986, P NATL ACAD SCI USA, V83, P7221, DOI 10.1073/pnas.83.19.7221; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PON LA, 1986, J BIOL CHEM, V261, P6594; RITTA MN, 1989, NEUROENDOCRINOLOGY, V49, P262, DOI 10.1159/000125126; SHIN SI, 1968, ENDOCRINOLOGY, V82, P614, DOI 10.1210/endo-82-3-614; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; WARD JA, 1960, J CLIN ENDOCR METAB, V20, P1622, DOI 10.1210/jcem-20-12-1622; WOOD CL, 1985, J BIOL CHEM, V260, P1243; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075; YANG WH, 1974, CANCER RES, V34, P2440	51	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22105	22112						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071335				2022-12-25	WOS:A1994PE09800030
J	HARTMANN, G; WEIDNER, KM; SCHWARZ, H; BIRCHMEIER, W				HARTMANN, G; WEIDNER, KM; SCHWARZ, H; BIRCHMEIER, W			THE MOTILITY SIGNAL OF SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR MEDIATED THROUGH THE RECEPTOR TYROSINE KINASE MET REQUIRES INTRACELLULAR ACTION OF RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPITHELIAL-CELLS; GENE; IDENTIFICATION; PURIFICATION; DIFFERENTIATION; PHOSPHORYLATION; INVASIVENESS; TRANSDUCTION; HEPATOCYTES; ANTAGONIST	Scatter factor/hepatocyte growth factor (SF/HGF) has various biological effects upon different cells, i.e. induces increased motility and proliferation as well as invasiveness and morphogenesis. The signals given to epithelial cells by SF/HGF are all mediated through the Met receptor tyrosine kinase (Weidner, K. M., Sachs, M., and Birchmeier, W. (1993) J. Cell Biol. 111, 145-154) suggesting that signal diversity is due to the interplay of different downstream pathways. It has also been shown that SF/HGF activates the protooncogene product Ras, i.e. stimulates guanine nucleotide exchange. In order to examine whether Ras is involved in mediating the dissociation and motility signal of SF/HGF to epithelial cells, we have expressed in Madin-Darby canine kidney cells the dominant-negative N17Ras under the control of a modified metallothionein promoter. Induced expression of N17Ras by the addition of Zn2+ clearly prevented dissociation of the cells by SF/HGF. These data indicate that the Ras pathway is indeed essential to mediate the motility signal of SF/HGF-Met to the cell-cell adhesion system and the cytoskeleton of epithelial cells.	MAX PLANCK INST ENTWICKLUNGSBIOL,D-72076 TUBINGEN,GERMANY	Max Planck Society	HARTMANN, G (corresponding author), MAX DELBRUCK CENTRUM MOLEK MED,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							BARDELLI A, 1992, ONCOGENE, V7, P973; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FALETTO DL, 1993, HEPATOCYTE GROWTH FA, P107; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LONGATI P, 1994, ONCOGENE, V9, P49; MCGLADE J, 1993, EMBO J, V12, P3077; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	45	167	177	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21936	21939						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071312				2022-12-25	WOS:A1994PE09800004
J	PURMAL, AA; LAMPMAN, GW; POURMAL, EI; MELAMEDE, RJ; WALLACE, SS; KOW, YW				PURMAL, AA; LAMPMAN, GW; POURMAL, EI; MELAMEDE, RJ; WALLACE, SS; KOW, YW			URACIL DNA N-GLYCOSYLASE DISTRIBUTIVELY INTERACTS WITH DUPLEX POLYNUCLEOTIDES CONTAINING REPEATING UNITS OF EITHER TGGCCAAGCU OR TGGCCAAGCTTGGCCAAGCU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-V; DIFFUSION-DRIVEN MECHANISMS; RESTRICTION ENDONUCLEASE; PROTEIN TRANSLOCATION; ECORI ENDONUCLEASE; NACL CONCENTRATION; NUCLEIC-ACIDS; PROCESSIVITY; RECOGNITION	Uracil DNA N-glycosylase (UDG) has been used as a model enzyme to test a novel universal approach to discriminate between two possible enzymatic mechanisms of specific site location in DNA, processive (DNA-scanning mechanism) and distributive (random diffusion-mediated mechanism). Two double-stranded concatemeric polynucleotides of defined length (440-480 nucleotides) containing deoxyuridine at either every 10th or 20th nucleotide in the DNA chain were prepared by the ligation of self complementary 10- or 20-mer oligodeoxyribonucleotides. Incubation of these polynucleotides with Escherichia coli UDG, followed by thermal breakage of the abasic sites, formed fragments that were multiples of either the 10- or the 20-mer. Since the processive and distributive mechanisms of uracil removal by UDG would be very different, the fragment distribution, generated at each time interval during the UDG reaction, should be unique. To show this, we developed a computer model illustrating both possible mechanisms of UDG functioning. The distribution of DNA fragments experimentally generated during the time course of the UDG reaction was compared with the results of the computer programs that modeled the distributive and processive mechanisms. The data indicated that uracil removal, catalyzed by UDG, is consistent with a distributive model.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; UNIV ILLINOIS,CTR COMPUTAT,MAT RES LAB,URBANA,IL 61801	University of Vermont; University of Illinois System; University of Illinois Urbana-Champaign				Wallace, Susan S./0000-0002-3906-0321	NCI NIH HHS [CA 33657] Funding Source: Medline; NIGMS NIH HHS [GM 37216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033657, R01CA033657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; DOLINNAYA NG, 1986, VESTN MOSK U KHIM+, V27, P520; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HAMILTON RW, 1989, J BIOL CHEM, V264, P17422; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; LANGOWSKI J, 1983, NUCLEIC ACIDS RES, V11, P501, DOI 10.1093/nar/11.2.501; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; NARDONE G, 1986, J BIOL CHEM, V261, P2128; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; VERSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; YOLOV AA, 1985, MOL BIOL REP, V10, P173, DOI 10.1007/BF00778525	18	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22046	22053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071327				2022-12-25	WOS:A1994PE09800021
J	SAWAYA, PL; LUSE, DS				SAWAYA, PL; LUSE, DS			2 MEMBERS OF THE HNF-3 FAMILY HAVE OPPOSITE EFFECTS ON A LUNG TRANSCRIPTIONAL ELEMENT - HNF-3-ALPHA STIMULATES AND HNF-3-BETA INHIBITS ACTIVITY OF REGION-I FROM THE CLARA CELL SECRETORY PROTEIN (CCSP) PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN; RABBIT UTEROGLOBIN; TRANSGENIC MICE; 5'-FLANKING REGION; A GENE; EXPRESSION; BINDING; IDENTIFICATION; RAT; EPITHELIUM	Region I of the Clara cell secretory protein (CCSP; also called CC10) promoter contains at least three functional factor binding sites, an upstream HNF-3 site and a downstream overlapping AP-1/HNF-3 site (Sawaya, P. L., Stripp, E. R., Whitsett, J. A., and Luse, D. S. Mol. Cell. Biol. (1993) 13, 3860-3871). Fragments containing -320/ +58 of the rat CCSP promoter were mutagenized to eliminate one or two factor binding sites in region I, cloned into a luciferase reporter cassette, and assayed for activity by transfection into cultured lung (H441) cells. We found that the HNF-3 sites alone can account for the activity of region I in H441 cells. The activity of the two HNF-3 sites is synergistic; this effect depends on the presence of an upstream factor binding site. We had shown previously that H441 cells contain exclusively the HNF-3 alpha form of HNF-3, whereas HeLa cells have essentially no HNF-3. Co-transfection of an HNF-3 alpha expression plasmid with a CCSP reporter containing four copies of region I in HeLa cells stimulated CCSP activity 4-fold, whereas co expression of HNF-3 beta inhibited activity 8-fold. HNF-3 beta was also inhibitory to region I expression in H441 cells, but to a lesser extent than in HeLa cells, presumably because of the high levels of HNF-3 alpha already present in H441 cells. We have thus identified a gene regulatory element through which two members of the HNF-3 transcription factor family, HNF-3 alpha and HNF-3 beta, exert opposite effects.			SAWAYA, PL (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANG SL, 1993, DEVELOPMENT, V119, P1301; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN Q, 1992, AM J PHYSIOL, V262, pL662, DOI 10.1152/ajplung.1992.262.6.L662; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS MJ, 1978, LAB INVEST, V38, P648; EVANS MJ, 1986, AM J PATHOL, V123, P126; GAIL DB, 1983, AM REV RESPIR DIS, V127, P366; GAO E, 1993, J BIOL CHEM, V268, P19697; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; HACKETT BP, 1992, P NATL ACAD SCI USA, V89, P9079, DOI 10.1073/pnas.89.19.9079; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; JACOB GA, 1994, J BIOL CHEM, V269, P3655; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; MANTILE G, 1993, J BIOL CHEM, V268, P20343; MASSARO R, 1989, LUNG CELL BIOL; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RYSECK RP, 1991, ONCOGENE, V6, P533; SAWAYA PL, 1993, MOL CELL BIOL, V13, P38608; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Wolf Markus, 1992, Human Molecular Genetics, V1, P371, DOI 10.1093/hmg/1.6.371; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	30	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22211	22216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071346				2022-12-25	WOS:A1994PE09800046
J	THINAKARAN, G; SISODIA, SS				THINAKARAN, G; SISODIA, SS			AMYLOID PRECURSOR-LIKE PROTEIN-2 (APLP2) IS MODIFIED BY THE ADDITION OF CHONDROITIN SULFATE GLYCOSAMINOGLYCAN AT A SINGLE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; ALZHEIMERS-DISEASE; HEPARAN-SULFATE; CELL-SURFACE; BETA-PROTEIN; MAMMALIAN-CELLS; NEUROFIBRILLARY TANGLES; MESSENGER-RNA; IDENTIFICATION; EXPRESSION	beta-Amyloid, the principal component of senile plaques in individuals with Alzheimer's disease, is derived from larger integral membrane glycoproteins, termed amyloid precursor proteins (APP). APP is a member of a family of proteins that includes the amyloid precursor-like proteins APLP1 and APLP2. The present study examines the metabolism of mouse APLP2 in cultured mammalian cells. We report that in stably transfected Chinese hamster ovary and transiently transfected African green monkey kidney (COS-1) cells, APLP2 is modified by glycosaminoglycan (GAG) addition. The sensitivity of GAG-modified APLP2 to digestion with chondroitinase AC indicates that chondroitin sulfate (CS) chains are the preponderant GAG on APLP2. CS GAG modification of APLP2 occurs in a region with little homology to APP. Contained within this heterologous region is a predicted CS modification site, ENEGSGMAEQ (APLP2 residues 610-619); APLP2 polypeptides harboring a serine-to-alanine substitution at position 614 fail to undergo CS GAG modification. Our observation that APLP2 is modified by a pathway distinct from APP suggests that the two molecules may be functionally divergent.	JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NINDS NIH HHS [NS 20471, NS AG 05146] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KISILEVSKY R, 1989, NEUROBIOL AGING, V10, P499, DOI 10.1016/0197-4580(89)90109-7; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KONIG G, 1992, J BIOL CHEM, V267, P10804; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PERLMUTTER LS, 1990, BRAIN RES, V508, P13, DOI 10.1016/0006-8993(90)91111-S; PERRY G, 1991, J NEUROSCI, V11, P3679; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIOI J, 1993, NEUROSCI LETT, V154, P121, DOI 10.1016/0304-3940(93)90186-O; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SNOW AD, 1989, ACTA NEUROPATHOL, V78, P113, DOI 10.1007/BF00688198; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TANZI RE, 1988, MOL BIOL ALZHEIMERS, P95; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; WANG R, 1991, J BIOL CHEM, V266, P16960; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I	60	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22099	22104						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071334				2022-12-25	WOS:A1994PE09800029
J	DITTMER, J; GEGONNE, A; GITLIN, SD; GHYSDAEL, J; BRADY, JN				DITTMER, J; GEGONNE, A; GITLIN, SD; GHYSDAEL, J; BRADY, JN			REGULATION OF PARATHYROID HORMONE-RELATED PROTEIN (PTHRP) GENE-EXPRESSION - SP1 BINDS THROUGH AN INVERTED CACCC MOTIF AND REGULATES PROMOTER ACTIVITY IN COOPERATION WITH ETS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; CONTROL REGION; PEPTIDE GENE; HTLV-I; C-ETS; GROWTH	We have previously shown that mutations in the GGAA core motif of the Ets1 binding site, EBSI, or deletion of EBSI, reduced basal and Tax, transactivation of the PTHrP P2 promoter. Here we demonstrate that, in addition to EBSI, a CACCC-like motif located between -53 and -58 is required for full basal activity of this promoter in Jurkat T-cells. Site-specific mutations in the CACCC motif decreased promoter activity approximately 5-fold. In an effort to identify transcription factors that bind to the CACCC element, we found that purified human Sp1, as well as Sp1 in HeLa nuclear extract, can specifically bind to a DNA probe that corresponds to the PTRrP-specific sequence between -94 and -34. Gel shift competition studies and DNase I footprinting analyses revealed that Sp1 specifically interacts with the CACCC motif. In the presence of Ets1, the mobility of the Sp1-specific gel shift complex with the PTHrP DNA decreased. DNase I footprint analysis of this gel shift complex showed an extended footprint over both the Sp1 and the Ets1 binding site, demonstrating that Sp1 and Ets1 form a ternary complex with the PTRrP DNA. Cotransfection of an Ets1 and Sp1 expression vector into Drosophila Schneider cells demonstrated that Sp1 can functionally cooperate with Ets1 to transactivate the PTHrP promoter. We conclude from these data that Ets1 and Sp1 can cooperatively regulate PTHrP P2 promoter activity.	NCI,MOLEC VIROL LAB,BETHESDA,MD 20892; CTR UNIV ORSAY,INST CURIE,BIOL SECT,F-91405 ORSAY,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Dittmer, Juergen/G-1160-2011; GHYSDAEL, Jacques/F-3377-2013					ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BURTON PBJ, 1992, FEBS LETT, V305, P228, DOI 10.1016/0014-5793(92)80674-6; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; EJIMA E, 1993, BLOOD, V81, P1017; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1993, EUR J BIOCHEM, V218, P195, DOI 10.1111/j.1432-1033.1993.tb18365.x; IKEDA K, 1993, ENDOCRINOLOGY, V132, P2551, DOI 10.1210/en.132.6.2551; INOUE D, 1993, J BIOL CHEM, V268, P1670; INSOGNA KL, 1989, J CLIN INVEST, V83, P1057, DOI 10.1172/JCI113947; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1993, CLIN INVEST MED, V16, P395; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI X, 1993, CANCER RES, V53, P2980; LI X, 1994, J BIOL CHEM, V269, P6263; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MORI N, 1993, JPN J CANCER RES, V84, P425, DOI 10.1111/j.1349-7006.1993.tb00153.x; NUMATA N, 1991, NEW BIOL, V3, P896; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; SACCHI N, 1988, LEUKEMIA, V2, P12; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YASUDA T, 1989, J BIOL CHEM, V264, P7720	55	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21428	21434						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063775				2022-12-25	WOS:A1994PK97300009
J	GUFFANTI, AA; KRULWICH, TA				GUFFANTI, AA; KRULWICH, TA			OXIDATIVE-PHOSPHORYLATION BY ADP+ P-I-LOADED MEMBRANE-VESICLES OF ALKALIPHILIC BACILLUS-FIRMUS OF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; ESCHERICHIA-COLI; ATP SYNTHESIS; PROTON; SYNTHASE; SURFACE; OXIDASE; ALCALOPHILUS; HYPOTHESIS; RESISTANCE	ATP synthesis in ADP + P-i-loaded membrane vesicles of the facultative alkaliphile Bacillus firmus OF4 at an external pH of 10.5 did not depend upon the presence of cell wall polymers, e.g. as a proton barrier or sequestration device. Upon energization with ascorbate plus phenazine methosulfalte, vesicles at pH(out), = 7.5 generated an electrochemical proton gradient (Delta p) of -160 mV, acid and positive out, whereas at pH(out) = 10.5, the Delta p was -40 mV, alkaline and positive out. Nonetheless, ATP synthesis was more rapid at the more alkaline pH value, especially in the presence of 200 mM K2SO4, which markedly lowered the surface potential. No synthesis was observed upon abolition of the hp. Respiration-derived transmembrane potentials (Delta psi) energized ATP synthesis much better-than an equally large diffusion potential. The diffusion potential failed to energize ATP synthesis above pH 9.5. When hp, all in the form of a Delta psi was titrated downward at either pH 7.8 or 9.5, ATP synthesis by the latter vesicles was much less adversely affected in the Delta p range of -150 to -50 mV, supporting the existence of a sparing, non-chemiosmotic energy component at high pH.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028454] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIGMS GM28454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONO R, 1992, BIOCHEM J, V285, P99, DOI 10.1042/bj2850099; AONO R, 1983, J GEN MICROBIOL, V129, P1083; AONO R, 1990, BIOCHEM J, V266, P933; ASHWELL G, 1957, METHOD ENZYMOL, V3, P73, DOI 10.1016/S0076-6879(57)03350-9; CHIANG G, 1987, BIOCHEMISTRY-US, V26, P4911, DOI 10.1021/bi00390a003; CLEJAN S, 1989, J BACTERIOL, V171, P1744, DOI 10.1128/jb.171.3.1744-1746.1989; COLE HA, 1967, BIOCHIM BIOPHYS ACTA, V143, P445, DOI 10.1016/0005-2728(67)90050-3; Cramer W.A., 1990, ENERGY TRANSDUCTION; DAVIDSON EA, 1957, METHOD ENZYMOL, V8, P52; GUFFANTI AA, 1981, BIOCHIM BIOPHYS ACTA, V635, P619, DOI 10.1016/0005-2728(81)90118-3; GUFFANTI AA, 1985, ARCH BIOCHEM BIOPHYS, V239, P327, DOI 10.1016/0003-9861(85)90695-2; GUFFANTI AA, 1991, J GEN MICROBIOL, V137, P2375, DOI 10.1099/00221287-137-10-2375; GUFFANTI AA, 1992, J BIOL CHEM, V267, P9580; GUPTE SS, 1991, BIOCHIM BIOPHYS ACTA, V1069, P131, DOI 10.1016/0005-2736(91)90114-N; GUTMAN M, 1993, BIOCHEMISTRY-US, V32, P2942, DOI 10.1021/bi00063a003; HAINES TH, 1983, P NATL ACAD SCI-BIOL, V80, P160, DOI 10.1073/pnas.80.1.160; HEBERLE J, 1990, FEBS LETT, V277, P277, DOI 10.1016/0014-5793(90)80864-F; HEISE R, 1993, FEMS MICROBIOL LETT, V112, P261, DOI 10.1111/j.1574-6968.1993.tb06460.x; HICKS DB, 1991, J BACTERIOL, V173, P5010, DOI 10.1128/jb.173.16.5010-5016.1991; HICKS DB, 1986, J BIOL CHEM, V261, P2896; HOFFMANN A, 1991, EUR J BIOCHEM, V201, P467, DOI 10.1111/j.1432-1033.1991.tb16304.x; IVEY DM, 1992, RES MICROBIOL, V143, P467, DOI 10.1016/0923-2508(92)90092-3; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KATES M, 1993, LIPIDS, V28, P877, DOI 10.1007/BF02537494; KITADA M, 1989, J BACTERIOL, V171, P1879, DOI 10.1128/jb.171.4.1879-1884.1989; KITADA M, 1987, J BACTERIOL, V169, P5761, DOI 10.1128/jb.169.12.5761-5765.1987; KOCH AL, 1986, J THEOR BIOL, V120, P73, DOI 10.1016/S0022-5193(86)80018-2; KRULWICH TA, 1989, J BIOENERG BIOMEMBR, V21, P663, DOI 10.1007/BF00762685; KRULWICH TA, 1992, J BIOENERG BIOMEMBR, V24, P587, DOI 10.1007/BF00762351; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALPRESS FH, 1981, NATURE, V289, P335, DOI 10.1038/289335b0; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1961, BIOL REV CAMB PHILOS, V41, P451; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; QIU ZH, 1992, BIOCHEMISTRY-US, V31, P3297, DOI 10.1021/bi00127a036; QUIRK PG, 1991, BIOCHIM BIOPHYS ACTA, V1058, P131, DOI 10.1016/S0005-2728(05)80229-4; QUIRK PG, 1993, J BIOL CHEM, V268, P678; ROBERTSON DE, 1983, J BIOL CHEM, V258, P1039; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; SLATER EC, 1987, EUR J BIOCHEM, V166, P489, DOI 10.1111/j.1432-1033.1987.tb13542.x; SONE N, 1990, J BIOCHEM-TOKYO, V107, P597, DOI 10.1093/oxfordjournals.jbchem.a123092; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; STOCK JB, 1977, J BIOL CHEM, V252, P7850; STURR MG, 1994, J BACTERIOL, V176, P3111, DOI 10.1128/jb.176.11.3111-3116.1994; TSSIE J, 1990, BIOCHEMISTRY-US, V29, P59; TSUCHIYA T, 1976, J BIOL CHEM, V251, P5315; VANDERLAAN JC, 1991, APPL ENVIRON MICROB, V57, P901, DOI 10.1128/AEM.57.4.901-909.1991; VONWACHENFELDT C, 1992, FEMS MICROBIOL LETT, V100, P91, DOI 10.1016/0378-1097(92)90194-S; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6; ZARITSKY A, 1981, J MEMBRANE BIOL, V63, P215, DOI 10.1007/BF01870983; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	53	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21576	21582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063796				2022-12-25	WOS:A1994PK97300031
J	DUVALJOBE, C; PARMELY, MJ				DUVALJOBE, C; PARMELY, MJ			REGULATION PLASMINOGEN ACTIVATION BY HUMAN U937 PROMONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; RECEPTOR-BOUND UROKINASE; HUMAN-MONOCYTES; PRO-UROKINASE; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; HUMAN-PLASMA; BINDING; GROWTH; MACROPHAGE	Urokinase-type plasminogen activator (uPA) is initially produced by cells as a single-chain precursor (pro-uPA), which can be cleaved by the serine protease plasmin to form the two-chain molecule uPk This latter protease efficiently converts the inactive zymogen plasminogen into plasmin. Cell surface binding of both pro-uPA and plasminogen is known to enhance the rate of plasminogen activation. It has been postulated that this may be due, in part, to an enhanced plasmin-mediated feedback activation of pro-uPA. This study directly demonstrates the enhancement by cells of this feedback. activation loop by showing that uPA is generated more rapidly from pro-uPA and plasminogen in the presence of human promonocytic U937 cells than it is under fluid-phase conditions. Moreover, the enhanced activation of pro-uPA and plasminogen observed in the presence of cells was significantly less susceptible to inhibition by alpha(2)-antiplasmin. Finally, the presence of cells not only potentiated the production of plasmin, as measured using a plasmin-specific peptide substrate, it also potentiated the cleavage of a natural protein substrate, I-125-labeled recombinant interferon-gamma, even in the presence of alpha(2)-antiplasmin or alpha(2)-macroglobulin. These results demonstrate that cell-associated plasmin mediates a positive feedback amplification of plasminogen activation and thereby potentiates the proteolysis of natural plasmin substrates, even in the presence of plasma protease inhibitors.	UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [P01CA054474] Funding Source: NIH RePORTER; NCI NIH HHS [CA54474] Funding Source: Medline; NCRR NIH HHS [RR05373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		COLLEN D, 1972, J CLIN INVEST, V51, P1310, DOI 10.1172/JCI106927; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; GYETKO MR, 1993, J LEUKOCYTE BIOL, V53, P598, DOI 10.1002/jlb.53.5.598; GYETKO MR, 1992, J LEUKOCYTE BIOL, V51, P256, DOI 10.1002/jlb.51.3.256; HALL SW, 1991, J BIOL CHEM, V266, P12329; HART PH, 1991, BLOOD, V77, P841; HORVAT RT, 1988, INFECT IMMUN, V56, P2925, DOI 10.1128/IAI.56.11.2925-2932.1988; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1989, BLOOD, V73, P1864; LORTAT-JACOB H, 1990, CR ACAD SCI III-VIE, V311, P143; LOSKUTOFF DJ, 1978, J CELL PHYSIOL, V96, P361, DOI 10.1002/jcp.1040960312; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANNELL R, 1987, BLOOD, V69, P22; PARMELY MJ, 1993, J INTERFERON RES, V13, P397, DOI 10.1089/jir.1993.13.397; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VASSALLI JD, 1977, J EXP MED, V145, P429, DOI 10.1084/jem.145.2.429; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WALKER JE, 1982, THROMB HAEMOSTASIS, V47, P265; WUN TC, 1982, J BIOL CHEM, V257, P7262	42	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21353	21357						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063761				2022-12-25	WOS:A1994PC40300079
J	HJELMSTAD, RH; MORASH, SC; MCMASTER, CR; BELL, RM				HJELMSTAD, RH; MORASH, SC; MCMASTER, CR; BELL, RM			CHIMERIC ENZYMES - STRUCTURE-FUNCTION ANALYSIS OF SEGMENTS OF SN-1,2-DIACYLGLYCEROL CHOLINE-ETHANOLAMINEPHOSPHOTRANSFERASE AND ETHANOLAMINEPHOSPHOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPT1 GENE-PRODUCTS; SACCHAROMYCES-CEREVISIAE; PHOSPHOGLYCERATE KINASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CHOLINEPHOSPHOTRANSFERASE; RECEPTOR; BINDING; CPT1; DEHYDROGENASE	The Saccharomyces cerevisiae CPT1 and EPT1 genes represent structural genes that encode distinct choline- and choline/ethanolaminephosphotransferases, respectively. To explore the function of linear segments of these enzymes, a series of 14 EPT1-CPT1 chimeric gene constructs and the parental wild-type genes were expressed in a cpt1 ept1 double null mutant background completely devoid of phosphoamino alcohol transferase activity. Eleven of the chimeric genes expressed functional enzymes. The CDP-amino alcohol and sn-1,2-diacylglycerol (DAG) substrate specificities and essential phospholipid cofactor requirements of the parental and chimeric enzymes were investigated using a mixed micellar assay system. Chimeric enzymes exhibited a pattern of CDP-amino alcohol affinities that defined a structural domain sufficient to confer CDP-amino alcohol specificity. When wild-type enzymes were investigated using a chemically defined series of DAGs, each possessed a distinct characteristic pattern of utilization. Chimeric enzymes exhibited DAG acyl chain specificity profiles that either conformed to parental wild-type patterns or represented novel substrate specificities. Correlation of these outcomes with their underlying structural modifications permitted the assignment of an internal, linear region of 218 amino acids sufficient to confer DAG acyl chain specificity; this region contained three predicted transmembrane segments. Neither wildtype enzyme showed significant acyl chain selectivity with respect to phospholipid activation when a homologous series of chemically defined phosphatidylcholines were employed, suggesting that enzyme recognition of the fatty acyl moieties of the DAG substrate and phospholipid activator is fundamentally different. Analysis of chimeric enzymes dependence on phospholipid activators suggested the involvement of discontinuous protein segments participating in the interaction with phospholipid cofactors.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				McMaster, Christopher/0000-0003-0822-5776	NIGMS NIH HHS [GM20015] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BLOTSTEIN R, 1993, J BIOL CHEM, V268, P10654; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; EXTON JH, 1990, J BIOL CHEM, V265, P1; GETHER U, 1993, J BIOL CHEM, V268, P7893; HEGUY A, 1993, J BIOL CHEM, V268, P10490; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P272; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLLAND JP, 1980, J BIOL CHEM, V255, P2596; HOSAKA K, 1987, EUR J BIOCHEM, V162, P7, DOI 10.1111/j.1432-1033.1987.tb10533.x; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; MCALLISTER G, 1993, FEBS LETT, V324, P81, DOI 10.1016/0014-5793(93)81537-A; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; PALTAUF K, 1992, MOL CELLULAR BIOL YE, P415; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; White D.A., 1973, FORM FUNCTION PHOSPH; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	33	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20995	21002						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063717				2022-12-25	WOS:A1994PC40300030
J	MOOREFIELD, B; ROEDER, RG				MOOREFIELD, B; ROEDER, RG			PURIFICATION AND CHARACTERIZATION OF HUMAN TRANSCRIPTION FACTOR IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RNA GENE; INTERNAL CONTROL REGION; INDIVIDUAL ZINC FINGERS; TATA-BINDING PROTEIN; POLYMERASE-III; XENOPUS-LAEVIS; MULTIPLE FACTORS; ALTERED LEVELS; FACTOR TFIIIA; 5S-RNA GENE	The 5S gene-specific transcription factor, TFIIIA, was purified approximately 35,000-fold from HeLa cell extracts using a combination of conventional and affinity chromatographic methods. A single polypeptide of apparent molecular mass 42-kDa cofractionates with both 5S DNA binding and 5S transcription activities, and was conclusively identified as human TFIIIA by its ability to direct specific 5S gene transcription in vitro following elution and renaturation from SDS-polyacrylamide gels. The DNase I protection pattern of the purified human factor on a human 5S gene is similar to the pattern previously observed with Xenopus TFIIIA. A Xenopus 5S gene, but not a yeast 5S gene, is able to effectively compete for binding of the human factor. In addition, we report a previously undetected immunological cross-reactivity between human and Xenopus TFIIIA. hTFIIIA is recognized specifically both by polyclonal antisera raised against Xenopus laevis TFIIIA as well as by a monoclonal antibody generated against the amphibian protein. These observations indicate that human TFIIIA is structurally related to the Xenopus oocyte factor and that the previous inability to detect human TFIIIA by immunological methods is due primarily to the low abundance of this factor in HeLa cell extracts.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NCI NIH HHS [CA09673, 5R35 CA42567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRABKIN HJ, 1985, J BIOL CHEM, V260, P5596; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; EMERSON BM, 1984, J BIOL CHEM, V259, P7926; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GASKINS CJ, 1989, NUCLEIC ACIDS RES, V17, P781, DOI 10.1093/nar/17.2.781; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KIM SH, 1990, GENE DEV, V4, P1602, DOI 10.1101/gad.4.9.1602; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; KRAMER A, 1983, J BIOL CHEM, V258, P1915; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1985, MOL CELL BIOL, V5, P40, DOI 10.1128/MCB.5.1.40; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MARTIN PL, 1985, THESIS WASHINGTON U; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; PELHAM H, 1981, P NATL ACAD SCI USA, V76, P1760; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SEIFART KH, 1989, J BIOL CHEM, V264, P1702; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHASTRY BS, 1984, J BIOL CHEM, V259, P1373; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WALDSCHMIDT R, 1990, EUR J BIOCHEM, V194, P167, DOI 10.1111/j.1432-1033.1990.tb19441.x; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WINGENDER E, 1984, EMBO J, V3, P1761, DOI 10.1002/j.1460-2075.1984.tb02043.x; WU C, 1988, GENETIC ENG, V10, P67; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	57	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20857	20865						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063702				2022-12-25	WOS:A1994PC40300011
J	NAVARRE, C; CATTY, P; LETERME, S; DIETRICH, F; GOFFEAU, A				NAVARRE, C; CATTY, P; LETERME, S; DIETRICH, F; GOFFEAU, A			2 DISTINCT GENES ENCODE SMALL ISOPROTEOLIPIDS AFFECTING PLASMA-MEMBRANE H+-ATPASE ACTIVITY OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; PROTON-TRANSLOCATING ATPASE; AMINO-ACID SEQUENCE; CHROMOSOME-III; DNA-SEQUENCE; YEAST; PHOSPHOLAMBAN; PROTEINS; PUMP; PURIFICATION	A small proteolipid called PMP1 is associated with yeast plasma membrane RC-ATPase (Navarre, C., Ghislain, M., Leterme, S., Ferroud, C., Dufour, J,-P., and Goffeau, A (1992) J. Biol. Chem. 267, 6425-6428). We have identified a second Saccharomyces cerevisiae plasma membrane proteolipid gene by hybridization with a PMP1 probe. The sequence of the corresponding gene, called PMP2, is 92% identical to the PMP1 gene sequence. PMP2 encodes a 43-amino acid polypeptide that can be extracted from the membrane with chloroform/methanol. The two proteolipids differ at residue 21, which is an alanine in PMP1 and a serine in PMP2. The two PMP genes are similarly expressed in the wild-type strain, and no modification of the level of transcription of one PMP gene is detected in a strain deleted of the other. A regulatory function of the proteolipids is indicated by the observation that a strain lacking both PMP genes and no longer containing plasma membrane proteolipids displays a lower V-max of the plasma membrane H+-ATPase activity.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; STANFORD UNIV, DEPT GENET, STANFORD, CA 94301 USA	Universite Catholique Louvain; Stanford University								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOLLE PA, 1992, YEAST, V8, P205, DOI 10.1002/yea.320080306; COLLINS JH, 1987, BIOCHEMISTRY-US, V26, P8665, DOI 10.1021/bi00400a026; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1993, YEAST, V9, P691, DOI 10.1002/yea.320090703; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KIM HW, 1990, J BIOL CHEM, V265, P1702; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; NAVARRE C, 1992, J BIOL CHEM, V267, P6425; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PULLMAN ME, 1976, METHOD ENZYMOL, V6, P277; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCARBOROUGH GA, 1984, J BIOL CHEM, V259, P9109; SCARBOROUGH GA, 1992, MOL CELL BIOCHEM, V114, P49; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; TADA M, 1992, ANN NY ACAD SCI, V671, P92, DOI 10.1111/j.1749-6632.1992.tb43787.x; TADA M, 1988, METHOD ENZYMOL, V157, P107; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	40	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21262	21268						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063750				2022-12-25	WOS:A1994PC40300068
J	RUAN, KH; LI, P; KULMACZ, RJ; WU, KK				RUAN, KH; LI, P; KULMACZ, RJ; WU, KK			CHARACTERIZATION OF THE STRUCTURE AND MEMBRANE INTERACTION OF NH2-TERMINAL DOMAIN OF THROMBOXANE A(2) SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ENDOPLASMIC-RETICULUM; PHOSPHOLIPID-VESICLES; CIRCULAR-DICHROISM; GROWTH-HORMONE; CYTOCHROME-P-450; TOPOLOGY; CONFORMATION; REDUCTASE; PROTEINS	Thromboxane A(2) synthase (TXAS), a member of the cytochrome P450 superfamily, is believed to be anchored to the endoplasmic reticulum membrane by hydrophobic portions of its NH2-terminal domain. Two hydrophobic peptides, corresponding to potential membrane-anchor segments of the NH2-terminal region of TXAS (residues 1-36, designated LP1 and residues 33-60, designated LP2) were synthesized, and their secondary structure and ability to insert in a lipid bilayer were characterized. The conformation of the synthetic peptides were analyzed in organic and membrane (bilayer) environments. Circular dichroism spectroscopy indicated that both segments adopt structures with significant alpha-helical content in a hydrophobic environment. For the LP1 peptide, the helical content was maximal with 60% trifluoroethanol, whereas 20% trifluoroethanol maximized the helix content for the LP2 peptide. The interaction of several NH2-terminal peptides with a lipid bilayer was determined by reconstitution of these peptides into lipid vesicles composed of phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine. Both the LP1 and LP2 peptides bound strongly to the defined lipid vesicles, but peptides corresponding to residues 1-15 and 33-36 were not incorporated into the lipid vesicles. The results indicate that TXAS has two distinct membrane-anchor segments, comprising residues 16-33 and 37-60 in its NH2-terminal domain.	UNIV TEXAS,VASC BIOL RES CTR,HOUSTON,TX 77030	University of Texas System	RUAN, KH (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,6431 FANNIN ST,HOUSTON,TX 77030, USA.		Wu, Kenneth Kun-Yu/B-1070-2010					BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; Catty D., 1988, ANTIBODIES, V1, P19; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLORE GM, 1986, J MOL BIOL, V191, P553, DOI 10.1016/0022-2836(86)90147-6; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; GUT J, 1982, J BIOL CHEM, V257, P7030; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KUNZ BC, 1985, BIOCHEMISTRY-US, V24, P2889, DOI 10.1021/bi00333a011; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LI SC, 1993, J BIOL CHEM, V268, P22975; MADDEN TD, 1983, BIOCHEMISTRY-US, V22, P1970, DOI 10.1021/bi00277a036; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OHASHI K, 1992, J BIOL CHEM, V267, P789; RUAN KH, 1993, J BIOL CHEM, V268, P19483; RUAN KH, 1990, P NATL ACAD SCI USA, V87, P6156, DOI 10.1073/pnas.87.16.6156; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SMITH R, 1989, BIOPHYS J, V56, P307, DOI 10.1016/S0006-3495(89)82677-3; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; ZHANG YZ, 1984, BIOCHEMISTRY-US, V23, P5616, DOI 10.1021/bi00318a036; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20938	20942						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063711				2022-12-25	WOS:A1994PC40300022
J	GALANOPOULOU, AS; KENT, G; RABBANI, SN; SEIDAH, NG; PATEL, YC				GALANOPOULOU, AS; KENT, G; RABBANI, SN; SEIDAH, NG; PATEL, YC			HETEROLOGOUS PROCESSING OF PROSOMATOSTATIN IN CONSTITUTIVE AND REGULATED SECRETORY PATHWAYS - PUTATIVE ROLE OF THE ENDOPROTEASES FURIN, PC1, AND PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPEPTIDE CONVERTING ENZYME; MONOBASIC SITES; CELLS; PROHORMONE; SOMATOSTATIN; CLEAVAGE; SEQUENCE; KEX2; RAT; PREPROSOMATOSTATIN	Mammalian prosomatostatin (PSS) is cleaved at a dibasic Arg-Lys site to produce somatostatin-14 (SS-14) and at monobasic Arg and Lys sites to yield SS-28 and PSS(1-10) (antrin), respectively. Furin, PC1, and PC2 are three recently discovered mammalian endoproteases localized either to the constitutive (furin) or regulated (PC1, PC2) secretory pathways. In this study we have compared the heterologous processing of PSS in transiently transfected endocrine (AtT-20 pituitary) and nonendocrine (COS-7 monkey kidney, PC12 pheochromocytoma) tumor cells. We have correlated the efficiency of processing of PSS to SS-14, SS-28, and PSS(1-10) with (i) secretion through the constitutive or regulated pathways; (ii) endogenous expression of mRNA for furin, PC1, and PC2; and (iii) exogenous expression of PC1 and PC2 in cells that do not contain these enzymes in order to delineate the putative role of these enzymes in mediating PSS cleavage at dibasic and monobasic sites and to localize the proteolytic events to specific compartments of the secretory pathways. COS-7 and PC12 cells expressed only furin, secreted constitutively, and processed PSS preferentially at monobasic sites to SS-28 (40-43%) and antrin (27-29%). Processing, however, was inefficient as suggested by large amounts of unprocessed PSS. In contrast, AtT-20 cells showed regulated secretion, expressed all three endoproteases (with high levels of PCI), and processed PSS efficiently to mainly SS-14. PCI, but not PC2, exogenously coexpressed with PSS in COS-7 cells produced significant conversion to SS-14 but not SS-28. This study shows that PSS is capable of monobasic cleavage in the constitutive secretory pathway. Such processing could be mediated by a furin-like enzyme but is relatively inefficient. PC1 can effect dibasic cleavage of PSS whereas PC2 is without influence on PSS processing at least within the constitutive secretory pathway. Although monobasic and dibasic processing of PSS in COS-7 cells correlates with furin-like and PC1 activity, respectively, the relative inefficiency of such processing suggests that compartmentalization of proteolytic events in secretory vesicles or other more specific endoproteases may be required.	ROYAL VICTORIA HOSP, DEPT MED, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA; ROYAL VICTORIA HOSP, DEPT NEUROL & NEUROSURG, MONTREAL H3A 1A1, QUEBEC, CANADA; MCGILL UNIV, FRASER LABS, MONTREAL H3A 1A1, QUEBEC, CANADA; MONTREAL NEUROL HOSP & INST, MONTREAL H3A 2B4, QUEBEC, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ARGOS P, 1983, J BIOL CHEM, V258, P8788; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENOIT R, 1984, BRAIN RES, V311, P23, DOI 10.1016/0006-8993(84)91394-5; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BENOIT R, 1990, METABOLISM, V39, P22, DOI 10.1016/0026-0495(90)90202-N; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLON JM, 1990, PROG CLIN BIOL RES, V342, P10; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MCDONALD JK, 1987, J HISTOCHEM CYTOCHEM, V35, P155, DOI 10.1177/35.2.2878951; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; ORCI L, 1985, CELL, V42, P67; PATEL YC, 1988, J BIOL CHEM, V263, P745; PATEL YC, 1985, SOMATOSTATIN, P71; PRADAYROL L, 1980, FEBS LETT, V109, P55, DOI 10.1016/0014-5793(80)81310-X; RABBANI SN, 1990, ENDOCRINOLOGY, V126, P2054, DOI 10.1210/endo-126-4-2054; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D F, 1980, Ann N Y Acad Sci, V343, P1, DOI 10.1111/j.1749-6632.1980.tb47238.x; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WARREN TG, 1984, CELL, V39, P547, DOI 10.1016/0092-8674(84)90461-6; WETSEL WC, 1992, 74TH ANN M END SOC S; ZINGG HH, 1982, J CLIN INVEST, V70, P1101, DOI 10.1172/JCI110698	48	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6041	6049						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095501				2022-12-25	WOS:A1993KR82200100
J	LEIBER, D; JASPER, JR; ALOUSI, AA; MARTIN, J; BERNSTEIN, D; INSEL, PA				LEIBER, D; JASPER, JR; ALOUSI, AA; MARTIN, J; BERNSTEIN, D; INSEL, PA			ALTERATION IN GS-MEDIATED SIGNAL TRANSDUCTION IN S49 LYMPHOMA-CELLS TREATED WITH INHIBITORS OF MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CYCLIC-AMP ACCUMULATION; PROTEIN ALPHA-SUBUNIT; ADENYLATE-CYCLASE; REGULATORY PROTEIN; BINDING; STIMULATION; MYRISTOYLATION; MONOPHOSPHATE; ASSOCIATION	We have assessed the possible interaction between the microtubular component of the cytoskeleton and signal transducing GTP-binding (G) proteins by examining the ability of colchicine and vinblastine (two microtubule disrupters) to alter G(s) and G(i) protein activity in S49 lymphoma cells. Treatment of wild type S49 cells with colchicine and vinblastine increased beta-adrenergic agonist- and prostaglandin (PG) E1-stimulated formation of cAMP. The microtubular inhibitor nocodazole also enhanced isoproterenol-stimulated cAMP accumulation, whereas the inactive analog of colchicine, beta-lumicolchicine, did not have this action. Based on data obtained with wild type, cyc-, and UNC S49 cells, we determined that enhancement in cyclic AMP accumulation is proximal to the catalytic (C) unit of adenylylcyclase, distal to hormone receptors, and seems to be located on G(s). Treatment with colchicine increased guanosine 5'-(gamma-thio)triphosphate-stimulated accumulation of cAMP in permeabilized wild type cells. The increase in activity of G(s) appeared not to result from a change in the intracellular concentration of GTP. Treatment of cells with colchicine or vinblastine also increased the amount of the alpha(s)-C complex, as assessed by the binding of [H-3]forskolin to intact cells at 37-degrees-C. In contrast to the observed effect on G(s), treatment of wild type S49 cells with colchicine failed to modify the degree of inhibition of cAMP formation produced by somatostatin, which acts via the activation of G(i). These data suggest that microtubules regulate the ability of G(s) to interact with and activate the catalyst of adenylylcyclase.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, 0636, LA JOLLA, CA 92093 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA	University of California System; University of California San Diego; Stanford University				Bernstein, Daniel/0000-0001-7761-5853				ALOUSI AA, 1991, FASEB J, V5, P2300, DOI 10.1096/fasebj.5.9.1650314; BARBER R, 1980, 2ND MESSENGERS PHOSP, V12, P59; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRANN MR, 1987, FEBS LETT, V222, P191, DOI 10.1016/0014-5793(87)80218-1; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DOKHAC L, 1983, BIOCHEM PHARMACOL, V32, P2535, DOI 10.1016/0006-2952(83)90015-1; DULIS BH, 1980, J BIOL CHEM, V255, P1043; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; Guidotti A, 1990, Adv Exp Med Biol, V268, P135; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAGMANN J, 1980, J BIOL CHEM, V255, P2659; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; INSEL PA, 1978, NATURE, V273, P471, DOI 10.1038/273471a0; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN LC, 1985, MOL PHARMACOL, V29, P16; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RASENICK MM, 1985, MICROTUBULES MICROTU, P313; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1977, J BIOL CHEM, V252, P5761; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; YAN K, 1990, GWUMC DEPT, P163; ZOR U, 1983, ENDOCR REV, V4, P1	31	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3833	3837						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095044				2022-12-25	WOS:A1993KN53300010
J	BRAIDOTTI, G; BORTHWICK, IA; MAY, BK				BRAIDOTTI, G; BORTHWICK, IA; MAY, BK			IDENTIFICATION OF REGULATORY SEQUENCES IN THE GENE FOR 5-AMINOLEVULINATE SYNTHASE FROM RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; PORPHOBILINOGEN DEAMINASE GENE; MESSENGER-RNA; CHLORAMPHENICOL ACETYLTRANSFERASE; DIHYDROFOLATE-REDUCTASE; HOUSEKEEPING GENE; MAMMALIAN-CELLS; X-CHROMOSOME; DNA; PROMOTER	The housekeeping enzyme 5-aminolevulinate synthase (ALAS) regulates the supply of heme for respiratory cytochromes. Here we report on the isolation of a genomic clone for the rat ALAS gene. The 5'-flanking region was fused to the chloramphenicol acetyltransferase gene and transient expression analysis revealed the presence of both positive and negative cis-acting sequences. Expression was substantially increased by the inclusion of the first intron located in the 5'-untranslated region. Sequence analysis of the promoter identified two elements at positions -59 and -88 bp with strong similarity to the binding site for nuclear respiratory factor 1 (NRF-1). Gel shift analysis revealed that both NRF-1 elements formed nucleoprotein complexes which could be abolished by an authentic NRF-1 oligomer. Mutagenesis of each NRF-1 motif in the ALAS promoter gave substantially lowered levels of chloramphenicol acetyltransferase expression, whereas mutagenesis of both NRF-1 motifs resulted in the almost complete loss of expression. These results establish that the NRF-1 motifs in the ALAS promoter are critical for promoter activity. NRF-1 binding sites have been identified in the promoters of several nuclear genes encoding mitochondrial proteins concerned with oxidative phosphorylation. The present studies suggest that NRF-1 may co-ordinate the supply of mitochondrial heme with the synthesis of respiratory cytochromes by regulating expression of ALAS. In erythroid cells, NRF-1 may be less important for controlling heme levels since an erythroid ALAS gene is strongly expressed and the promoter for this gene apparently lacks NRF-1 binding sites.	UNIV ADELAIDE,DEPT BIOCHEM,GEN POB 498,ADELAIDE,SA 5001,AUSTRALIA; HEART RES INST,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Adelaide; University of Sydney; Heart Research Institute								BAWDEN MJ, 1987, NUCLEIC ACIDS RES, V15, P8563, DOI 10.1093/nar/15.20.8563; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BORTHWICK IA, 1984, EUR J BIOCHEM, V144, P95, DOI 10.1111/j.1432-1033.1984.tb08435.x; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BROOKER JD, 1980, EUR J BIOCHEM, V106, P17; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHINGMAN AC, 1992, J BIOL CHEM, V267, P6999; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSEN AJ, 1990, MOL PHARMACOL, V38, P486; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JACOB WF, 1989, J BIOL CHEM, V264, P20371; KAPPAS A, 1989, METABOLIC BASIS INHE, V6, P1305; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V14, P1379, DOI 10.1093/nar/14.3.1379; Maniatis T., 1982, MOL CLONING; MAY BK, 1990, MOL BIOL MED, V7, P405; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORTHEMANN W, 1983, FEBS LETT, V161, P319, DOI 10.1016/0014-5793(83)81033-3; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROMANA M, 1987, NUCLEIC ACIDS RES, V15, P7343, DOI 10.1093/nar/15.18.7343; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P701; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	41	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1109	1117						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8093450				2022-12-25	WOS:A1993KG07700054
J	LADU, MJ; FALDUTO, MT; MANELLI, AM; REARDON, CA; GETZ, GS; FRAIL, DE				LADU, MJ; FALDUTO, MT; MANELLI, AM; REARDON, CA; GETZ, GS; FRAIL, DE			ISOFORM-SPECIFIC BINDING OF APOLIPOPROTEIN-E TO BETA-AMYLOID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL ALZHEIMER-DISEASE; RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; PEPTIDE; BRAIN; EXPRESSION; ALLELE; CELLS	Apolipoprotein E (apoE), particularly the e4 allele, is genetically linked to the incidence of Alzheimer's disease, ApoE is present in the extracellular senile plaques and intracellular neurofibrillary tangles associated with Alzheimer's disease. In vitro, apoE has been shown to bind beta-amyloid (A beta), an amyloidogenic proteolytic product of amyloid precursor protein. To analyze the interaction of A beta and apoE, we used Western immunoblotting of human A beta-(1-40)-peptide incubated with conditioned medium from HEK-293 cells transfected with either human apoE3 or apoE4 (products of the e3 and e4 alleles, respectively) cDNA. Nonreducing SDS-polyacrylamide gel electrophoresis revealed the presence of an similar to 45-kDa complex with both A beta and apoE immunoreactivity. The level of the apoE3 A beta complex was similar to 20-fold greater than that of the apoE4.A beta complex. This apoE isoform-specific binding pattern was maintained from pH 5.0 to 9.0, from 2 min to 24 h of peptide incubation, and at concentrations of apoE from 5 to 100 mu g/ml and of A beta from 10 mu M to 1 mM. The higher level of apoE3 binding to A beta is in contrast to previously published data using purified apoE (Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L.-M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8098-8102). Factors responsible for the isoform-specific interactions between apoE and A beta will require further study before the apparent discrepancy between these data can be reconciled.	ABBOTT LABS,DIV PHARMACEUT PROD,NEUROSCI DISCOVERY,DEPT 47U,ABBOTT PK,IL 60064; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	Abbott Laboratories; University of Chicago				LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008833, P50HL015062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL15062, 1F32 HL08833-01] Funding Source: Medline; NIA NIH HHS [AG10481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PITAS RE, 1987, J BIOL CHEM, V262, P14352; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WOLF BB, 1992, AM J PATHOL, V141, P37; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	26	465	479	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23403	23406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089103				2022-12-25	WOS:A1994PQ34500006
J	MAEDA, N; LI, H; LEE, D; OLIVER, P; QUARFORDT, SH; OSADA, J				MAEDA, N; LI, H; LEE, D; OLIVER, P; QUARFORDT, SH; OSADA, J			TARGETED DISRUPTION OF THE APOLIPOPROTEIN C-III GENE IN MICE RESULTS IN HYPOTRIGLYCERIDEMIA AND PROTECTION FROM POSTPRANDIAL HYPERTRIGLYCERIDEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; EMBRYONIC STEM-CELLS; TRIGLYCERIDE-RICH LIPOPROTEINS; A-IV EXPRESSION; TRANSGENIC MICE; PREMATURE ATHEROSCLEROSIS; APO-CIII; LIPASE; ACID; HYPERCHOLESTEROLEMIA	Using gene targeting in embryonic stem cells, we have generated mice lacking apolipoprotein C-III (ApoC-III). Homozygous mutant animals show absence of ApoC-III protein and no expression of ApoC-III mRNA in the liver or in the intestine. Expression of the neighboring genes, coding for apolipoprotein A-I and apolipoprotein A-IV, are not altered in the liver but are reduced in the intestine. This suggests that these three genes share a tissue-specific element for intestinal expression and that insertion of an additional promoter for the neomycin-resistant gene into the locus affects interaction between the tissue-specific element and the promoter of the individual gene. Fasted plasma triglyceride levels in the homozygous mutants are reduced to about 70% of normal, while heterozygotes have values intermediate between those of the homozygous mutants and wild types. Plasma levels of total cholesterol and of high density lipoprotein cholesterol in homozygotes are consistently lower than those in normal mices but the reduction does not reach statistical significance. A fat meal test showed that postprandial hypertriglyceridemia is abolished in homozygotes lacking ApoC-III. The homozygous mutants also clear chylomicrons faster than wild type controls. These data indicate that ApoC-III modulates the catabolism of triglyceride-rich lipoproteins and plays a role in the postprandial management of triglycerides.	DUKE UNIV,MED CTR,DURHAM,NC 27705; VET AFFAIRS HOSP,DEPT MED,DURHAM,NC 27705	Duke University	MAEDA, N (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL 42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BOLLMAN JL, 1948, J LAB CLIN MED, V33, P1348; BREWER HB, 1974, J BIOL CHEM, V249, P4975; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DOLE VP, 1962, PHYSIOL REV, V42, P674, DOI 10.1152/physrev.1962.42.4.674; FRANCE DS, 1989, J LIPID RES, V30, P1997; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG SZ, 1986, J BIOL CHEM, V261, P2368; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KARATHANASIS SK, 1987, P NATL ACAD SCI USA, V84, P7198, DOI 10.1073/pnas.84.20.7198; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; LAUER SJ, 1991, ARTERIOSCLEROSIS, V11, pA1390; LENICH C, 1988, J LIPID RES, V29, P755; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LIU MS, 1994, J BIOL CHEM, V269, P11417; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; QUARFORDT SH, 1991, HEPATOLOGY, V14, P911, DOI 10.1002/hep.1840140526; REUE K, 1993, J LIPID RES, V34, P893; REUE K, 1991, J BIOL CHEM, V266, P12715; Sambrook J, 1989, MOL CLONING LABORATO; SCHOTZ MC, 1970, J LIPID RES, V11, P68; SHEHEE WR, 1993, P NATL ACAD SCI USA, V90, P3177, DOI 10.1073/pnas.90.8.3177; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; SKOW LC, 1983, CELL, V34, P1043, DOI 10.1016/0092-8674(83)90562-7; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WALSH A, 1993, J LIPID RES, V34, P617; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS SC, 1989, J BIOL CHEM, V264, P19009; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; WINDLER E, 1980, J BIOL CHEM, V255, P5475; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	39	265	286	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23610	23616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089130				2022-12-25	WOS:A1994PQ34500036
J	MANZI, AE; HIGA, HH; DIAZ, S; VARKI, A				MANZI, AE; HIGA, HH; DIAZ, S; VARKI, A			INTRAMOLECULAR SELF-CLEAVAGE OF POLYSIALIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; LONG OLIGOSACCHARIDE SEGMENT; ENDO-N-ACETYLNEURAMINIDASE; PROKARYOTIC-DERIVED PROBES; GROUP-B; NEISSERIA-MENINGITIDIS; SIALIC ACIDS; CAPSULAR POLYSACCHARIDE; POLY(SIALIC ACID)	Polysialic acid (PSA) is an unusual homopolymer of sialic acid (Sia) found on a limited number of animal glycoproteins and in the capsules of certain pathogenic bacteria. The biological properties of PSA are known to vary markedly with the length of the polymer. We confirm here that while the primary linkage unit of PSA (Sia alpha 2-8Sia) is more stable than commoner Sia linkages, PSA with >3 Sia units is substantially more labile. A ''limit digest'' of PSA yields fragments of degree of polymerization (DP) = 2 and 3 and little monomeric Sia, In keeping with this, the fragmentation of PSA of DP 4 is non-random, with the internal glycosidic bond being more labile than those at the two ends. The accelerated breakdown of PSA involves an intramolecular mechanism that is not explained by lactone formation, cation effects, or specific secondary structural features. However, it is dependent upon the intactness of internal carboxyl groups, which have an anomalously high pK(a). Thus, the instability of PSA appears to result from intramolecular self-cleavage of the glycosidic bonds of internal Sia units, in which the adjacent carboxyl group with a high pK(a) acts as a proton donor for general acid catalysis. This lability of PSA is seen under mildly acidic conditions that can be encountered in various physiological and pathological situations and thus has potential implications for neuronal adhesion, embryogenesis, and bacterial pathogenicity.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Díaz, Sandra/ABE-7349-2020	Díaz, Sandra/0000-0003-0012-4612	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; CAPON B, 1963, TETRAHEDRON LETT, P911; CROSSIN KL, 1984, J CELL BIOL, V99, P1848, DOI 10.1083/jcb.99.5.1848; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; DEVI SJN, 1991, INFECT IMMUN, V59, P732, DOI 10.1128/IAI.59.2.732-736.1991; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; FIFE TH, 1972, ACCOUNTS CHEM RES, V5, P264, DOI 10.1021/ar50056a002; FINNE J, 1985, J BIOL CHEM, V260, P1265; FRANCK RW, 1992, BIOORG CHEM, V20, P77, DOI 10.1016/0045-2068(92)90028-2; HALBERSTADT JB, 1993, ANAL BIOCHEM, V209, P136, DOI 10.1006/abio.1993.1093; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HIGA HH, 1988, J BIOL CHEM, V263, P8872; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; INOUE M, 1992, BIOCHEMISTRY-US, V31, P5545, DOI 10.1021/bi00139a017; Jennings H J, 1978, Methods Enzymol, V50, P39; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; KABAT EA, 1988, J EXP MED, V168, P699, DOI 10.1084/jem.168.2.699; KARKAS JD, 1964, J BIOL CHEM, V239, P949; KATCHALSKY A, 1947, J POLYM SCI, V2, P432, DOI 10.1002/pol.1947.120020409; Kern W, 1938, Z PHYS CHEM A-CHEM T, V181, P249; KEY B, 1990, J CELL BIOL, V110, P1729, DOI 10.1083/jcb.110.5.1729; KING EJ, 1965, ACID BASE EQUILIBRIA, P218; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; LIFELY MR, 1981, CARBOHYD RES, V94, P193, DOI 10.1016/S0008-6215(00)80717-X; MATTHEWS PM, 1989, ARCH NEUROL-CHICAGO, V46, P994, DOI 10.1001/archneur.1989.00520450064020; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MEYER FB, 1988, ANN NY ACAD SCI, V522, P502; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; Mooser G., 1992, ENZYMES, P187; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; POSNER JB, 1967, NEW ENGL J MED, V277, P605, DOI 10.1056/NEJM196709212771201; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SHUKLA AK, 1982, H-S Z PHYSIOL CHEM, V363, P255, DOI 10.1515/bchm2.1982.363.1.255; Siesjo B K, 1986, Adv Neurol, V44, P813; SIESJO BK, 1993, PROG BRAIN RES, V96, P23; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SILVER RP, 1984, J BACTERIOL, V157, P568, DOI 10.1128/JB.157.2.568-575.1984; SIMNOT ML, 1984, CHEM ENZYME ACTION, P389; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TROY FA, 1987, METHOD ENZYMOL, V138, P169; TROY FA, 1979, ANNU REV MICROBIOL, V33, P519, DOI 10.1146/annurev.mi.33.100179.002511; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VAUPEL P, 1989, CANCER RES, V49, P6449; VIMR ER, 1985, J BACTERIOL, V164, P845, DOI 10.1128/JB.164.2.845-853.1985; VIMR ER, 1992, J BACTERIOL, V174, P6191, DOI 10.1128/JB.174.19.6191-6197.1992; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WARREN L, 1959, J BIOL CHEM, V234, P1971; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P851, DOI 10.1021/bi00217a039; YU RK, 1970, J LIPID RES, V11, P506; ZUBER C, 1992, J BIOL CHEM, V267, P9965	60	66	69	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23617	23624						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089131				2022-12-25	WOS:A1994PQ34500037
J	ODA, T; HEANEY, C; HAGOPIAN, JR; OKUDA, K; GRIFFIN, JD; DRUKER, BJ				ODA, T; HEANEY, C; HAGOPIAN, JR; OKUDA, K; GRIFFIN, JD; DRUKER, BJ			CRKL IS THE MAJOR TYROSINE-PHOSPHORYLATED PROTEIN IN NEUTROPHILS FROM PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P210 BCR-ABL; PHILADELPHIA-CHROMOSOME; CELL-LINE; ONCOGENE; GENE; TRANSFORMATION; PRODUCT	The Philadelphia chromosome (Ph(1)), detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosome 9 and 22 that fuses Bcr-encoded sequences upstream of exon 2 of c-Abl. This oncogene produces a fusion protein, p210(bcr-abl), in which the Abl tyrosine kinase activity is elevated. Using anti-phosphotyrosine immunoblotting, we have compared the pattern of phosphotyrosine-containing proteins from freshly prepared neutrophils of patients in the stable phase of CML to normal controls. The only consistent difference was the presence of a 39-kDa tyrosine-phosphorylated protein in 18 out of 18 neutrophil samples from CML patients that was not seen in normal controls. This same protein, as assessed by two-dimensional anti-phosphotyrosine immunoblotting, was also present in cell lines expressing p210(bcr-abl), including K562 cells. Using K562 cells as a source of protein, the 39-kDa protein was purified and identified by microsequencing as CrkI, an SH2/SH3 adaptor protein related to the crk oncogene of the avian sarcoma virus, CT10. A direct interaction between CrkI and Abl has also been shown using a yeast two-hybrid screen.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Oregon Health & Science University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Oda, Tsukasa/ABI-1855-2020	Druker, Brian/0000-0001-8331-8206; Oda, Tsukasa/0000-0002-8941-161X	NCI NIH HHS [CA 36167, CA 34183, CA 01422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034183, R37CA036167, R01CA036167, K08CA001422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; NOWELL PC, 1960, SCIENCE, V132, P1497; PEGORARO L, 1983, J NATL CANCER I, V70, P447; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1990, CANCER CELL-MON REV, V2, P284; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TEHNOEVE J, 1994, ONCOGENE, V8, P2469; TENHOEVE J, 1994, CANCER RES, V54, P2563; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	30	243	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22925	22928						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083188				2022-12-25	WOS:A1994PQ16400004
J	SULLIVAN, TA; USCHMANN, B; HOUGH, R; LEBOY, PS				SULLIVAN, TA; USCHMANN, B; HOUGH, R; LEBOY, PS			ASCORBATE MODULATION OF CHONDROCYTE GENE-EXPRESSION IS INDEPENDENT OF ITS ROLE IN COLLAGEN SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO CHONDROCYTES; MESSENGER-RNA LEVELS; HUMAN-SKIN FIBROBLASTS; GROWTH FACTOR-I; ALKALINE-PHOSPHATASE; EXTRACELLULAR-MATRIX; CARTILAGE MATRIX; COORDINATE REGULATION; OSTEOBLAST PHENOTYPE; LIPID-PEROXIDATION	During development and fracture repair, endochondral bone formation is preceeded by an orderly process of chondrocyte hypertrophy and cartilage matrix calcification. Analysis of calcifying versus noncalcifying cartilage has identified several differences in matrix proteins; among these are appearance of a novel collagen, type X, and decreased synthesis of type II collagen, the major component of cartilage matrix. In addition, there is a marked increase in alkaline phosphatase, an enzyme expressed at high levels in all mineralizing tissues. Cultured chondrocytes can be induced to undergo these changes in gene expression and to produce calcified matrix by exposure to ascorbic acid. The mechanism by which ascorbate produces these changes has been examined by analyzing the effect of the vitamin on prehypertrophic chick embryo sternal chondrocytes. Nuclear run-on assays demonstrated that ascorbate alters mRNA levels in chondrocytes by changing the transcription rates. The fact that marked changes in mRNA levels require 1-2 days of ascorbate exposure suggested that the effect of this vitamin on gene transcription may be secondary to other, earlier ascorbate-induced effects. Since cells cultured with ascorbate produce a collagen-enriched matrix, we examined the hypothesis that transcriptional changes were secondary to altered cell-matrix interactions. Chondrocytes were cultured after attachment to tissue culture plastic, in suspension, or on plates coated with collagen type I. Comparison of alkaline phosphatase activity with and without ascorbate addition demonstrated that under all of these conditions, induction of enzyme was dependent on the presence of ascorbate. When plates containing ascorbate conditioned chondrocyte matrix were used as substrate for naive chondrocytes, the cells continued to require ascorbate for induction of high levels of alkaline phosphatase and type X collagen mRNA Addition of the hydroxylation inhibitor, 3,4-dehydroproline, caused marked inhibition of collagen secretion as well as accumulation of underhydroxylated collagens within the cells. However, even in the presence of this inhibitor ascorbate was effective in inducing elevated alkaline phosphatase and type X collagen. These results indicate that the ability of ascorbate to induce chondrocyte hypertrophy does not depend on production of a collagen-rich matrix.	UNIV PENN, SCH DENT MED, DEPT BIOCHEM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Leboy, Phoebe/A-1062-2007		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040075] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40075] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BALLOCK RT, 1993, DEV BIOL, V158, P414, DOI 10.1006/dbio.1993.1200; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERGSTEN P, 1994, J BIOL CHEM, V269, P1041; BOHME K, 1992, J CELL BIOL, V116, P1035, DOI 10.1083/jcb.116.4.1035; CHOJKIER M, 1989, J BIOL CHEM, V264, P16957; DANIEL JC, 1984, J CELL BIOL, V99, P1960, DOI 10.1083/jcb.99.6.1960; DARR D, 1993, ARCH BIOCHEM BIOPHYS, V307, P331, DOI 10.1006/abbi.1993.1596; ENOMOTO M, 1993, EXP CELL RES, V205, P276, DOI 10.1006/excr.1993.1087; Fell HB, 1929, BIOCHEM J, V23, P767, DOI 10.1042/bj0230767; FRANCESCHI RT, 1992, NUTR REV, V50, P65; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; GEESIN JC, 1988, J INVEST DERMATOL, V90, P420, DOI 10.1111/1523-1747.ep12460849; GEESIN JC, 1993, EXP CELL RES, V206, P283, DOI 10.1006/excr.1993.1148; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; Gould BS, 1942, AM J PHYSIOL, V135, P0485, DOI 10.1152/ajplegacy.1941.135.2.485; GRINNELL F, 1989, EXP CELL RES, V181, P483, DOI 10.1016/0014-4827(89)90105-5; HABUCHI H, 1985, J BIOL CHEM, V260, P3029; HAJEK AS, 1977, J EXP ZOOL, V200, P377, DOI 10.1002/jez.1402000308; HARADA S, 1991, J BONE MINER RES, V6, P903; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MEIER S, 1978, J ULTRA MOL STRUCT R, V65, P48, DOI 10.1016/S0022-5320(78)90021-7; NANDAN D, 1990, J CELL BIOL, V110, P1673, DOI 10.1083/jcb.110.5.1673; OCONNER JL, 1992, BIOTECHNIQUES, V12, P238; OYAMADA I, 1990, ARCH BIOCHEM BIOPHYS, V276, P85, DOI 10.1016/0003-9861(90)90013-O; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; PETERKOFSKY B, 1991, AM J CLIN NUTR, V54, pS1135, DOI 10.1093/ajcn/54.6.1135s; PHILLIPS CL, 1992, ARCH BIOCHEM BIOPHYS, V295, P397, DOI 10.1016/0003-9861(92)90533-3; ROSS R, 1962, J CELL BIOL, V12, P533, DOI 10.1083/jcb.12.3.533; SALPETER MM, 1991, AM J CLIN NUTR, V54, pS1184; SCHWARZ RI, 1993, NUTRITION GENE EXPRE, P483; SUZUKI H, 1993, BIOCHEM PHARMACOL, V46, P186, DOI 10.1016/0006-2952(93)90365-4; WHITSON SW, 1992, J BONE MINER RES, V7, P727; WHYTE MP, 1989, BONE MINERAL RES, V6, P175; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1993, J BIOL CHEM, V268, P25084; Wuthier R.E., 1985, CHEM BIOL MINERALIZE, P113	44	55	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22500	22506						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077198				2022-12-25	WOS:A1994PQ16300012
J	RYDEL, TJ; YIN, ML; PADMANABHAN, KP; BLANKENSHIP, DT; CARDIN, AD; CORREA, PE; FENTON, JW; TULINSKY, A				RYDEL, TJ; YIN, ML; PADMANABHAN, KP; BLANKENSHIP, DT; CARDIN, AD; CORREA, PE; FENTON, JW; TULINSKY, A			CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; CRYSTAL-STRUCTURE; FIBRINOGEN; BINDING; SITE; PROTEIN; HIRUDIN; THROMBOMODULIN; CHYMOTRYPSIN	In an effort to prepare crystals and determine the structure of alpha-thrombin complexed to a synthetic peptide inhibitor (MDL-28050) of the hirudin 54-65 COOH-terminal region, it was discovered that the crystals were not those of the complex but of gamma-thrombin. Gel electrophoresis studies revealed that autolytic degradation had occurred prior to crystallization. NH2-terminal sequence analysis of these autolytic fragments confirmed the gamma-thrombin product (cleavages at Arg(75)-Tyr(76) and/or Arg(77A)-Asn(78), and Lys(149E)-Gly(150); chymotrypsinogen numbering) with a minor amount of another autolysis product, beta-thrombin (first two cleavages only). The final structure has an R-factor of 0.156 for 7.0-2.5-Angstrom data, and includes 186 water molecules. A comparison of gamma-thrombin with the thrombin structure in the alpha-thrombin-hirugen complex revealed that the two structures agreed well (r.m.s.Delta = 0.39 Angstrom for main chain atoms). These structures possess uninhibited active sites where the disposition of the catalytic triad residues is nearly identical. The electron density in the vicinity of the gamma-thrombin cleavage regions is poor, and only becomes well defined several residues prior to and after the actual cleavage sites. The extensive disorder evoked by beta-cleavage(s) in the Lys(70)-Glu(80) loop region indicates that this part of the molecule is severely disrupted by autolysis and is the reason exosite functions are dramatically impaired in beta- and gamma-thrombin. Since autolysis did not lead to a major reorganization of the folded structure of alpha-thrombin, the likely structural features of the interaction of thrombin substrate with thrombin enzyme during beta-cleavage have been modeled by docking the exosite region of one molecule at the active site of another.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MARION MERRELL DOW INC, DEPT MOLEC GENET, CINCINNATI, OH 45215 USA; PROCTER & GAMBLE CO, MIAMI VALLEY LABS, DIV CORP RES, CINCINNATI, OH 45239 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA; ALBANY MED COLL, DEPT PHYSIOL & CELL BIOL, ALBANY, NY 12208 USA; ALBANY MED COLL, DEPT BIOCHEM MOLEC BIOL, ALBANY, NY 12208 USA	Michigan State University; Dow Chemical Company; Procter & Gamble; State University of New York (SUNY) System; Wadsworth Center; Albany Medical College; Albany Medical College					NHLBI NIH HHS [HL 13160, HL43229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043229, R01HL013160] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; BROWER MS, 1987, BLOOD, V69, P813; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DAVEY MG, 1968, BIOCHIM BIOPHYS ACTA, V165, P490, DOI 10.1016/0304-4165(68)90230-4; ESMON CT, 1986, ANN NY ACAD SCI, V485, P215, DOI 10.1111/j.1749-6632.1986.tb34583.x; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FENTON JW, 1979, CHEM PHYSL HUMAN PLA, P151; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, P43; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KAWABATA S, 1985, J BIOCHEM, V97, P325, DOI 10.1093/oxfordjournals.jbchem.a135057; KRSTENANSKY JL, 1990, THROMB HAEMOSTASIS, V63, P208; LEWIS SD, 1987, BIOCHEMISTRY-US, V26, P7597, DOI 10.1021/bi00398a010; LORAND L, 1977, CHEM BIOL THROMBIN, P311; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MATTHEWS DA, 1977, J BIOL CHEM, V252, P8875; QIU XY, 1992, BIOCHEMISTRY-US, V31, P11689, DOI 10.1021/bi00162a004; QIU XY, 1993, J BIOL CHEM, V268, P20318; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; RYDEL TJ, 1991, THESIS MICHIGAN STAT; SEEGERS W H, 1975, Seminars in Thrombosis and Hemostasis, V1, P211; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SONDER SA, 1984, BIOCHEMISTRY-US, V23, P1818, DOI 10.1021/bi00303a037; SONDER SA, 1986, CLIN CHEM, V32, P934; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; WITTING JI, 1991, THROMB RES, V63, P473, DOI 10.1016/0049-3848(91)90235-O	42	46	51	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22000	22006						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071320				2022-12-25	WOS:A1994PE09800014
J	MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B				MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B			ONCOGENE AMPLIFICATION IN HUMAN GLIOMAS - A MOLECULAR CYTOGENETIC ANALYSIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; MALIGNANT HUMAN GLIOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; GENE AMPLIFICATION; CHROMOSOMAL-ABNORMALITIES; HUMAN GLIOBLASTOMA; DNA-AMPLIFICATION; SOLID TUMORS; CELL-LINES	Nine cases of malignant gliomas were selected for the presence of double minutes (dmin) or homogeneously staining regions (hsr) detected by conventional cytogenetics. Analyses were performed on fresh (2 cases) or xenografted (5 cases) tumors or both (2 cases). A modified comparative genomic hybridization technique (mCGH) was applied exhibiting a single amplified locus in 8 tumors and 4 amplified loci in one tumor. Recurrent sites of amplification were detected in 7p11-p12 (5 cases) and 1q32.1 (2 cases). Signals were also observed in 4q11-q12, 5p15.1, 7q31, 8q24.1 and 9p2 in one tumor each. Southern blotting demonstrated that the genes for EGFR (epidermal growth factor receptor), PDGFRA (platelet derived growth factor receptor alpha), MET and MYC oncogenes were involved in 7p11-p12, 4q11-q12, 7q31 and 8q24.1 amplifications, respectively. These amplifications were found by ill situ hybridization on tumor spreads, in dmin or episomes for EGFR, dmin for PDGFRA and MET, and hsr and dmin for MYC genes. Other mCGH signals, for which no target genes could be proposed, were confirmed by chromosome paintings on tumor metaphases. In one of the tumors, the coamplification of DNA from 5p15.1 and 9p2 bands in the same dmin was demonstrated.	CEA,DSV DPTE LCG,F-92265 FONTENAY ROSES,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE	CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	MULERIS, M (corresponding author), INST CURIE,CNRS,BIOL SECT,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BIGNER SH, 1990, CANCER RES, V50, P8017; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, ISI ATLAS-BIOCHEM, V1, P333; BIGNER SH, 1987, CANCER GENET CYTOGEN, V29, P165, DOI 10.1016/0165-4608(87)90045-8; BIGNER SH, 1984, HEREDITAS, V101, P103, DOI 10.1111/j.1601-5223.1984.tb00455.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FLEMING TP, 1992, CANCER RES, V52, P4550; FULLER GN, 1992, MUTAT RES, V276, P299, DOI 10.1016/0165-1110(92)90016-3; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; MULERIS AM, IN PRESS GENES CHROM; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PRUCHON E, IN PRESS CANCER GENE; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SPEICHER MR, 1993, HUM MOL GENET, V2, P1907; THIEL G, 1992, CANCER GENET CYTOGEN, V58, P109, DOI 10.1016/0165-4608(92)90095-P; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WAHL GM, 1989, CANCER RES, V49, P1333; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WULCH KJ, 1979, INT HISTOLOGICAL CLA, V21; WULLICH B, 1993, EUR J CANCER, V29A, P1991, DOI 10.1016/0959-8049(93)90460-W; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0	43	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2717	2722						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058336				2022-12-25	WOS:A1994PC05400033
J	SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP				SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP			IN-VITRO PHOSPHORYLATION OF CAVEOLIN-RICH MEMBRANE DOMAINS - IDENTIFICATION OF AN ASSOCIATED SERINE KINASE-ACTIVITY AS A CASEIN KINASE II-LIKE ENZYME	ONCOGENE			English	Article							TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; GROWTH-FACTOR; CELL-SURFACE; 3T3-L1 CELLS; INSULIN; PROTEIN; BINDING; DIFFERENTIATION	Caveolae are flask-shaped micro-invaginations associated with the plasma membrane of a wide variety of cell types. Caveolin, an integral membrane component of caveolae, was first identified as the major phosphoprotein whose phosphorylation was elevated in v-Src transformed cells. As both v-Src transformation and elevated caveolin phosphorylation were dependent on membrane attachment of v-Src, it has been suggested that caveolin is a critical target in v-Src transformation. Although an increase in tyrosine phosphorylation of caveolin was evident, the increase in caveolin phosphorylation was predominantly on serine residues. In accordance with these in vivo observations, isolated caveolin-rich membrane domains undergo phosphorylation in vitro predominantly on serine and contain an unidentified serine kinase activity. Here, we have identified this serine kinase activity as a casein kinase II-like enzyme, since the phosphorylation of caveolin-rich membrane domains is stimulated and inhibited by known effecters of casein kinase II (poly-L-lysine, endogenous polyamines, and a casein kinase II inhibitor peptide), but is unaffected by modulators of other known kinases. In support of these observations, caveolin contains a consensus sequence for casein kinase II phosphorylation in its cytoplasmic N-terminal domain (Ser-88). A peptide containing this sequence inhibits the in vitro phosphorylation of caveolin-rich membrane domains, while many other peptides derived from the N-terminal domain of caveolin do not affect phosphorylation. Caveolin-rich membrane domains were also a substrate for exogenously added purified casein kinase II, but not casein kinase I. Finally, immunoblotting of these domains with an antibody directed against the alpha and alpha' subunits of casein kinase II reveals two bands with apparent molecular weights consistent with the known molecular weights of the alpha and alpha' subunits of casein kinase II. As casein kinase II appears to play a role in mitogenic signalling events and casein kinase II activators (endogenous polyamines) are required for v-Src transformation, our results may have implications for understanding the mechanism of v-Src oncogenesis.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,DEPT PEDIAT GASTROENTEROL,DIV MUCOSAL IMMUNOL,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047618, R37DK047618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47618] Funding Source: Medline; NIGMS NIH HHS [GM-50443, GM-49516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1993, J CELL BIOL, V124, P307; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TELLEZ R, 1992, FEBS LETT, V308, P113, DOI 10.1016/0014-5793(92)81255-K; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S	36	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2589	2595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058322				2022-12-25	WOS:A1994PC05400018
J	KYSELOVIC, J; LEDDY, JJ; RAY, A; WIGLE, J; TUANA, BS				KYSELOVIC, J; LEDDY, JJ; RAY, A; WIGLE, J; TUANA, BS			TEMPORAL DIFFERENCES IN THE INDUCTION OF DIHYDROPYRIDINE RECEPTOR SUBUNITS AND RYANODINE RECEPTORS DURING SKELETAL-MUSCLE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; MYOGENIC CELL-LINE; SARCOPLASMIC-RETICULUM; RELEASE CHANNEL; BETA-SUBUNIT; TRANSVERSE TUBULES; ELECTRICAL-ACTIVITY; GENE-EXPRESSION; CHARGE MOVEMENT; MESSENGER-RNAS	The expression of the dihydropyridine (DHP) and ryanodine receptors in skeletal muscle was investigated during development of rat myotubes in culture as well as during embryonic and postnatal development in the rat. Through the use of specific gene probes, antibodies and radioligand binding ([H-3]PN 200-110 (DHP) and [H-3]ryanodine), we identified a significant difference between the time course of appearance of the DHP receptor and the ryanodine receptor during muscle development. Although the number of DHP receptors dramatically increased at early stages of development (up to day 7 in tissue culture and day 20 postnatal), increase in the ryanodine receptor density occurred comparatively later at day 10 in culture and day 30 postnatal. This process was associated with parallel changes in the expression of the mRNA encoding the alpha(1), alpha(2) and beta subunits of the DHP receptor and the skeletal muscle ryanodine receptor. The genes encoding the DHP receptor subunits were activated in a temporally distinct manner during development. The increase in beta subunit transcript appeared and plateaued first, at the onset of myoblast fusion and day 16 embryonic. This was followed closely by an increase in expression of the mRNAs for alpha(1) and alpha(2) subunits which coincided with the sharp rise in the DHP receptor density. Ryanodine receptor gene expression was induced well after the DHP receptor gene expression had plateaued. The temporal appearance of the polypeptides comprising the DHP receptor subunits and the ryanodine receptor paralleled the induction of the genes encoding these receptors. These results imply that gene expression is a major mechanism that contributes to the regulation of DHP and ryanodine receptor numbers during muscle development. The temporal differences in the induction of the genes encoding the DHP receptor subunits and the ryanodine receptor suggests that these genes are under the control of distinct endogenous factors. These differences in expression of the DHP receptor and the ryanodine receptor may contribute to the different mechanisms of excitation-contraction coupling in immature versus adult skeletal muscle.	UNIV OTTAWA, FAC MED, DEPT PHARMACOL, OTTAWA K1H 8M5, ON, CANADA	University of Ottawa			Wigle, J.t./G-2005-2014; Kyselovic, Jan/H-4858-2016	Wigle, J.t./0000-0002-4985-7684; Kyselovic, Jan/0000-0001-9208-5352				ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BEAM KG, 1988, J GEN PHYSIOL, V91, P799, DOI 10.1085/jgp.91.6.799; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BIEL M, 1991, EUR J BIOCHEM, V200, P81, DOI 10.1111/j.1432-1033.1991.tb21051.x; BISHOPRIC JH, 1992, HEART CARDIOVASCULAR, P1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BOLAND R, 1974, J BIOL CHEM, V249, P612; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; COGNARD C, 1992, PFLUG ARCH EUR J PHY, V422, P207, DOI 10.1007/BF00370424; COGNARD C, 1993, DEVELOPMENT, V117, P1153; COLMAN H, 1993, DEV BIOL, V156, P1, DOI 10.1006/dbio.1993.1054; DANGAIN J, 1991, CAN J PHYSIOL PHARM, V69, P1294, DOI 10.1139/y91-190; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FLUCHER BE, 1993, DEV BIOL, V160, P135, DOI 10.1006/dbio.1993.1292; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FRANZINIARMSTRONG C, 1991, DEV BIOL, V146, P353, DOI 10.1016/0012-1606(91)90237-W; GONOI T, 1988, J PHYSIOL-LONDON, V401, P617, DOI 10.1113/jphysiol.1988.sp017183; GUTIERREZ LM, 1991, J BIOL CHEM, V266, P16387; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; HUGHES SM, 1993, NATURE, V364, P485, DOI 10.1038/364485a0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; JORGENSEN AO, 1977, J CELL BIOL, V74, P287, DOI 10.1083/jcb.74.1.287; KELLY AM, 1971, J CELL BIOL, V49, P335, DOI 10.1083/jcb.49.2.335; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1992, J MUSCLE RES CELL M, V13, P394, DOI 10.1007/BF01738035; LAWRENCE JC, 1981, J BIOL CHEM, V256, P6213; LYTTON J, 1991, HEART CARDIOVASCULAR, P1203; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MURPHY BJ, 1990, CAN J PHYSIOL PHARM, V68, P1389, DOI 10.1139/y90-211; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; OFFORD J, 1989, NEURON, V2, P1447, DOI 10.1016/0896-6273(89)90190-6; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OTSU K, 1990, J BIOL CHEM, V265, P13472; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROMEY G, 1989, P NATL ACAD SCI USA, V86, P2933, DOI 10.1073/pnas.86.8.2933; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SCHIAFFINO S, 1969, J CELL BIOL, V41, P855, DOI 10.1083/jcb.41.3.855; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SHERMAN SJ, 1982, J GEN PHYSIOL, V80, P753, DOI 10.1085/jgp.80.5.753; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SUNAHARA RK, 1990, ANAL BIOCHEM, V185, P143, DOI 10.1016/0003-2697(90)90269-F; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1; VARADI G, 1989, FEBS LETT, V250, P515, DOI 10.1016/0014-5793(89)80787-2; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WANG JP, 1993, J BIOL CHEM, V268, P20974; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINTER B, 1993, J BIOL CHEM, V268, P9869; YUAN SH, 1991, J CELL BIOL, V112, P289, DOI 10.1083/jcb.112.2.289; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	80	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21770	21777						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063821				2022-12-25	WOS:A1994PK97300059
J	ZHUANG, HM; PATEL, SV; HE, TC; SONSTEBY, SK; NIU, ZT; WOJCHOWSKI, DM				ZHUANG, HM; PATEL, SV; HE, TC; SONSTEBY, SK; NIU, ZT; WOJCHOWSKI, DM			INHIBITION OF ERYTHROPOIETIN-INDUCED MITOGENESIS BY A KINASE-DEFICIENT FORM OF JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; INTERFERON-ALPHA/BETA; RECEPTOR; INTERLEUKIN-3; PHOSPHORYLATION; ACTIVATION; EXPRESSION; INCLUDES	Receptors for a variety of hematopoietins, interferons alpha/beta and gamma, and growth hormone have recently been shown to mediate rapid, ligand dependent activation of the Janus-type cytosolic protein-tyrosine kinases Jak1, Jak2, and/or tyk-2. This finding extends relatedness among class I and II cytokine receptors to a functional context and provides an initially satisfying mechanistic analogy to protein-tyrosine kinase encoding receptors of the epidermal growth factor/platelet-derived growth factor/insulin family Through the construction and expression of a kinase deficient form of Jak2 (JK2 Delta VIII) in interleukin-3 (IL-3)/erythropoietin (Epo)-dependent DAER cells, we have tested whether activation of Jak2 is required for induced mitogenesis via these class I cytokine receptors. Ectopic expression of JK2 Delta VIII inhibited Epo- and IL-3-induced activation of endogenous wild-type Jak2, transiently attenuated IL-3-dependent growth, and essentially abrogated Epo-induced proliferation in this model system. These dominant-negative effects provide the first direct experimental evidence for an essential role for Janus kinase activation in mitogenesis and suggest that distinct effectors may mediate IL-3-induced versus Epo-induced pathways.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,DEPT VET SCI,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NHLBI NIH HHS [R01HL44491] Funding Source: Medline; PHS HHS [K04H203042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1229; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PAN CX, 1993, J BIOL CHEM, V268, P25818; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREURS J, 1992, INT REV CYTOL, V137B, P121; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YANG XJ, 1993, J NEUROSCI, V13, P3006; ZHU XY, 1994, J BIOL CHEM, V269, P5518	37	121	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21411	21414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063772				2022-12-25	WOS:A1994PK97300006
J	DUVE, H; JOHNSEN, AH; SCOTT, AG; EAST, P; THORPE, A				DUVE, H; JOHNSEN, AH; SCOTT, AG; EAST, P; THORPE, A			[HYP(3)]MET-CALLATOSTATIN - IDENTIFICATION AND BIOLOGICAL PROPERTIES OF A NOVEL NEUROPEPTIDE FROM THE BLOWFLY CALLIPHORA-VOMITORIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELEASING HORMONE; ADULT DIPLOPTERA-PUNCTATA; LUTEINIZING-HORMONE; MET-ENKEPHALIN-ARG6-GLY7-LEU8-LIKE PEPTIDES; FUNCTIONAL-SIGNIFICANCE; PROLYL 4-HYDROXYLASE; LEUCOPHAEA-MADERAE; LOCUSTA-MIGRATORIA; NEURONAL PATHWAYS; CORPORA ALLATA	A novel, hydroxyproline-containing neuropeptide, Gly-Pro-Hyp-Tyr-Asp-Phe-Gly-Met-NH2, designated [Hyp(3)]Met-callatostatin, has been identified from extracts of heads of the blowfly Calliphora vomitoria. The peptide is a naturally occurring hydroxylated analogue of Met-callatostatin, a previously identified allatostatin-like peptide, and is present to the extent of 20% of the nonhydroxylated form. In bioassays, both forms of the peptide show allatostatic activity by inhibiting juvenile hormone synthesis and release in the cockroaches Periplaneta americana, Diploptera punctata, and Blattella germanica (IC50 = 100 pM-10 nM). They do not, however, influence juvenile hormone bisepoxide synthesis and release in the blowfly. In flies, [Hyp(3)]Met-callatostatin inhibits the peristaltic movements of the hindgut, showing a biphasic response (IC50 = 0.5 pM and 0.5 mu M) compared with the monophasic response of Met-callatostatin (IC50 = 100 nM). Immunocytochemical studies with Met-callatostatin antisera provide the cytological basis for a myoinhibitory role in the gut since the axons of immunoreactive neurons in the abdominal ganglion project to the ileum. There are also endocrine cells in the midgut that, by releasing the peptides into the hemolymph, would allow the Met-callatostatins to fulfill a neurohormonal role on muscles of the gut and heart. In contrast, there are no Met-callatostatin neural pathways from the brain to the corpus allatum, the gland that produces juvenile hormone. NH2-terminal degradation of Met-callatostatins incubated with the hemolymph of P. americana results in cleavage of the Pro-Tyr bond giving the pentapeptide Tyr-Asp-Phe Gly-Met-NH2 as a degradation product. In contrast, the Hyp-Tyr bond resists cleavage. With hemolymph from C. vomitoria, no immunoassayable degradation product has been observed with either peptide.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, SCH BIOL SCI, LONDON E1 4NS, ENGLAND; STATE UNIV HOSP COPENHAGEN, DEPT CLIN BIOCHEM, DK-2100 COPENHAGEN, DENMARK; CSIRO, DIV ENTOMOL, CANBERRA, ACT 2601, AUSTRALIA	University of London; Queen Mary University London; University of Copenhagen; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			East, Peter/C-2352-2009					ADAMS E, 1977, J BIOL CHEM, V252, P7591; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; DONLY BC, 1993, P NATL ACAD SCI USA, V90, P8807, DOI 10.1073/pnas.90.19.8807; DUVE H, 1993, P NATL ACAD SCI USA, V90, P2456, DOI 10.1073/pnas.90.6.2456; DUVE H, 1989, CELL TISSUE RES, V258, P147, DOI 10.1007/BF00223154; DUVE H, 1990, CELL TISSUE RES, V259, P147, DOI 10.1007/BF00571439; DUVE H, 1994, CELL TISSUE RES, V276, P367, DOI 10.1007/BF00306122; DUVE H, 1988, CELL TISSUE RES, V251, P399, DOI 10.1007/BF00215849; DUVE H, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P91; DUVE H, 1992, P NATL ACAD SCI USA, V89, P2326, DOI 10.1073/pnas.89.6.2326; DUVE H, 1991, REGUL PEPTIDES, V35, P145, DOI 10.1016/0167-0115(91)90477-X; ENJYOJI K, 1988, FEBS LETT, V238, P1, DOI 10.1016/0014-5793(88)80212-6; GAUTRON JP, 1992, BIOCHEM BIOPH RES CO, V189, P1368, DOI 10.1016/0006-291X(92)90225-A; GAUTRON JP, 1992, MOL CELL ENDOCRINOL, V85, P99, DOI 10.1016/0303-7207(92)90129-T; GAUTRON JP, 1991, NEUROCHEM INT, V18, P221, DOI 10.1016/0197-0186(91)90189-K; GRIMMELIKHUIJZEN CJP, 1992, AM ZOOL, V32, P1; HOLMAN GM, 1991, INSECT BIOCHEM, V21, P107, DOI 10.1016/0020-1790(91)90070-U; HOLMAN GM, 1991, ACS SYM SER, V453, P40; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P31, DOI 10.1016/0742-8413(87)90043-0; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KATO H, 1988, FEBS LETT, V1, P252; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; MAIER M, 1988, FEBS LETT, V232, P395, DOI 10.1016/0014-5793(88)80778-6; MATSUMOTO S, 1989, INSECT BIOCHEM, V19, P277, DOI 10.1016/0020-1790(89)90073-5; MINDROIU T, 1988, BIOCHEM BIOPH RES CO, V152, P519, DOI 10.1016/S0006-291X(88)80068-8; PIULACHS MD, 1992, COMP BIOCHEM PHYS A, V102, P477, DOI 10.1016/0300-9629(92)90197-X; PRATT GE, 1989, BIOCHEM BIOPH RES CO, V163, P1243, DOI 10.1016/0006-291X(89)91111-X; PRATT GE, 1991, P NATL ACAD SCI USA, V88, P2412, DOI 10.1073/pnas.88.6.2412; SCHOOFS L, 1993, INSECT BIOCHEM MOLEC, V23, P859, DOI 10.1016/0965-1748(93)90104-Z; STAY B, 1992, CELL TISSUE RES, V270, P15, DOI 10.1007/BF00381875; STERNBERGER LA, 1974, IMMUNOCYTOCHEMISTRY; TALBO G, 1991, EUR J BIOCHEM, V195, P495, DOI 10.1111/j.1432-1033.1991.tb15730.x; WEAVER RJ, 1994, COMP BIOCHEM PHYS C, V107, P119, DOI 10.1016/1367-8280(94)90018-3; WEAVER RJ, 1991, J INSECT PHYSIOL, V37, P111, DOI 10.1016/0022-1910(91)90096-I; WOODHEAD AP, 1989, P NATL ACAD SCI USA, V86, P5997, DOI 10.1073/pnas.86.15.5997	36	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21059	21066						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063725				2022-12-25	WOS:A1994PC40300039
J	MERTZ, PM; DEWITT, DL; STETLERSTEVENSON, WG; WAHL, LM				MERTZ, PM; DEWITT, DL; STETLERSTEVENSON, WG; WAHL, LM			INTERLEUKIN 10 SUPPRESSION OF MONOCYTE PROSTAGLANDIN-H SYNTHASE-2 - MECHANISM OF INHIBITION OF PROSTAGLANDIN-DEPENDENT MATRIX METALLOPROTEINASE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE COLLAGENASE PRODUCTION; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; CYTOKINE PRODUCTION; B-CELLS; ACTIVATED MACROPHAGES; ALVEOLAR MACROPHAGES; INTERFERON-GAMMA; GENE-EXPRESSION; CYCLOOXYGENASE	Monocytes/macrophages are associated with chronic inflammatory lesions, such as periodontal disease and rheumatoid arthritis, in which there is extensive connective tissue destruction. Stimulation of human monocytes results in the production of matrix metalloproteinases (MMPs) via a prostaglandin E(2) (PGE(2))-cAMP-dependent pathway. Modulation of many monocyte functions by interleukin 10 (IL-10) suggested that this cytokine may influence the signal transduction pathway leading to the production of MMPs by monocytes. Preincubation of monocytes with IL-10 for 1 h prior to stimulation with ConA resulted in significant inhibition of prostaglandin H synthase-2 (PGHS-2, the inducible form of prostaglandin synthase). In contrast, PGHS-1, the constitutive PGHS, was not affected by IL-10. Suppression of PGHS-2 mRNA and protein levels was detected at 1 ng/ml of IL-10 with maximal inhibition at 20 ng/ml Nuclear run-on transcription assays performed on monocytes exposed to ConA or the combination of ConA and IL-10 indicated that IL-10 treatment suppressed PGHS-2 expression at the level of transcription. Attenuation of PGHS-2 by IL-10 was accompanied by decreased prostaglandin production, including PGE(2). The decrease in prostaglandin production was primarily related to the effect of IL-10 on PGHS-2 since the release of arachidonic acid was unaffected by this cytokine. The inhibition of PGE(2) production by IL-10 resulted in the suppression of mRNA and protein for interstitial collagenase and 92-kDa type IV collagenase/ gelatinase (gelatinase B). This conclusion is supported by the ability of exogenously added PGE(2) or dibutyryl cAMP to restore the production of MMPs in IL-10-treated monocytes. Additionally, PGHS-2 was also restored by PGE(2) or dibutyryl cAMP, indicating that PGHS-2 is regulated through a PGE(2)-cAMP amplification pathway. These data add further support to the anti-inflammatory properties of IL-10.	NCI,PATHOL LAB,EXTRACELLULAR MATRIX PATHWAY SECT,BETHESDA,MD 20892; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Michigan State University	MERTZ, PM (corresponding author), NIDR,IMMUNOL LAB,CELLULAR IMMUNOL SECT,9000 ROCKVILLE PIKE,BLDG 30,RM 325,BETHESDA,MD 20892, USA.		Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808				ANDREWS HJ, 1990, ARTHRITIS RHEUM, V33, P1733, DOI 10.1002/art.1780331119; BEAN AGD, 1993, INFECT IMMUN, V61, P4937, DOI 10.1128/IAI.61.11.4937-4939.1993; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOTTOMS GD, 1992, J AM VET MED ASSOC, V200, P1842; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CRYER B, 1992, ARCH INTERN MED, V152, P1145, DOI 10.1001/archinte.152.6.1145; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FU JY, 1990, J BIOL CHEM, V265, P16737; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOWARD M, 1992, J CLIN IMMUNOL, V12, P61; ISHIDA H, 1993, CELL IMMUNOL, V148, P371, DOI 10.1006/cimm.1993.1119; ISHIDA H, 1992, J EXP MED, V175, P1213, DOI 10.1084/jem.175.5.1213; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUJUBU DA, 1987, ONCOGENE, V1, P257; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LEE SH, 1992, J BIOL CHEM, V267, P25934; MALEFYT RD, 1991, J EXP MED, V174, P1209; MCCARTHY JB, 1980, J IMMUNOL, V124, P2405; MEADE EA, 1993, J LIPID MEDIATOR, V6, P119; NIIRO H, 1992, LYMPHOKINE CYTOK RES, V11, P209; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; RALPH P, 1992, J IMMUNOL, V148, P808; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUDA T, 1990, CELL IMMUNOL, V129, P228, DOI 10.1016/0008-8749(90)90200-B; VELDE AAT, 1992, J IMMUNOL, V149, P4048; WACHER MP, 1990, J IMMUNOL METHODS, V126, P239, DOI 10.1016/0022-1759(90)90156-P; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL LM, 1984, ARCH BIOCHEM BIOPHYS, V230, P661, DOI 10.1016/0003-9861(84)90447-8; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WAHL LM, 1990, J IMMUNOL, V144, P3518; WAHL LM, 1987, CELL IMMUNOL, V105, P411, DOI 10.1016/0008-8749(87)90088-8; WAHL LM, 1977, P NATL ACAD SCI USA, V74, P4955, DOI 10.1073/pnas.74.11.4955; WAHL LM, 1991, CURRENT PROTOCOLS IM; WAHL LM, 1981, MANUAL MACROPHAGE ME, P423; WAHL SM, 1987, J IMMUNOL, V139, P1342; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	62	176	179	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21322	21329						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063757				2022-12-25	WOS:A1994PC40300075
J	ZHENG, XX; ROSENBERG, LE; KALOUSEK, F; FENTON, WA				ZHENG, XX; ROSENBERG, LE; KALOUSEK, F; FENTON, WA			GROEL, GROES, AND ATP-DEPENDENT FOLDING AND SPONTANEOUS ASSEMBLY OF ORNITHINE TRANSCARBAMYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-FAECALIS; MITOCHONDRIAL PROTEIN; BOVINE LIVER; RAT-LIVER; CHAPERONIN; PURIFICATION; BINDING; HSP60; CARBOXYLASE	When purified rat liver ornithine transcarbamylase (OTC), a trimer of 36 kDa subunits, was denatured in 6 M guanidine hydrochloride and then diluted 50-100-fold, no activity was recovered, and the OTC subunits aggregated. In contrast, when the chaperonin groEL was included in the dilution buffer, OTC did not aggregate but instead comigrated in a sucrose density gradient with the groEL oligomer, indicating that a complex had been formed. Upon addition of the co-chaperonin groES and ATP to the isolated OTC-groEL complex, OTC monomers were folded, released, and assembled into active trimer. Neither groES nor ATP alone was sufficient to release active OTC from groEL The extent of recovery of activity was proportional to the concentration of the complex, reaching approximately 80-90% at monomer concentrations above 0.6 muM. At low complex concentrations, kinetic studies revealed an initial lag in the reconstitution reaction, suggesting that assembly is the rate-limiting step under these conditions. We could trap folded, released, inactive OTC monomers at early times that assembled into active trimers with longer incubation. A nonhydrolyzable ATP analog could release bound OTC from groEL in the presence of groES, but the OTC monomers were not competent for assembly. These data show that recovery of OTC activity in vitro can be efficiently directed by the bacterial chaperonins in the presence of ATP and suggest that the mechanism of reconstitution involves ATP and groES-dependent folding and release of OTC monomers from groEL, followed by spontaneous assembly of trimers.	YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 09527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KALOUSEK F, 1984, J BIOL CHEM, V259, P5392; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARSHALL M, 1972, J BIOL CHEM, V247, P1654; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522	31	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7489	7493						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096512				2022-12-25	WOS:A1993KV14100095
J	JAKOB, U; GAESTEL, M; ENGEL, K; BUCHNER, J				JAKOB, U; GAESTEL, M; ENGEL, K; BUCHNER, J			SMALL HEAT-SHOCK PROTEINS ARE MOLECULAR CHAPERONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EHRLICH ASCITES TUMOR; ESCHERICHIA-COLI; BAKERS-YEAST; EXPRESSION; HSP27; CELLS	Small heat shock proteins (sHsp) with a molecular mass of 15-30 kDa are ubiquitous and conserved. Up to now their function has remained enigmatic. Increased expression under heat shock conditions and their protective effect on cell viability at elevated temperatures suggest that they may have a function in the formation or maintenance of the native conformation of cytosolic proteins. To test this hypothesis we studied the influence of murine Hsp25, human Hsp27, and bovine alpha-B-crystallin (an eye lens protein homologous to sHsps) on the unfolding and refolding of citrate synthase and alpha-glucosidase in vitro. Here we show that all sHsps investigated act as molecular chaperones in these folding reactions. At stoichiometric amounts they maximally prevent the aggregation of citrate synthase and alpha-glucosidase under heat shock conditions and stabilize the proteins. Furthermore, they promote the functional refolding of these proteins after urea denaturation similar to GroE and Hsp90. The interaction both with unfolding and refolding proteins seems to be ATP-independent.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,O-1115 BERLIN,GERMANY	University of Regensburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Buchner, Johannes/0000-0003-1282-7737				ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; DEJONG WW, 1988, J BIOL CHEM, V263, P4141; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOELL-NEUGEBAUER B, 1991, Biochemistry, V30, P11609, DOI 10.1021/bi00114a001; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; KOPETZKI E, 1989, MOL GEN GENET, V216, P149, DOI 10.1007/BF00332244; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; OESTERREICH S, 1990, BIOMED BIOCHIM ACTA, V49, P219; PAYOT P, 1975, EUR J BIOCHEM, V63, P263; PIATGORSKY, 1989, FASEB J, V3, P1933; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SPECTOR NL, 1992, J IMMUNOL, V148, P277; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEST SM, 1988, BIOCHEM J, V251, P135, DOI 10.1042/bj2510135; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAHI W, 1992, PROTEIN SCI, V1, P522; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	31	1127	1182	1	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1517	1520						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093612				2022-12-25	WOS:A1993KH62000005
J	GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV				GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV			HIGH-FREQUENCY OF MUTATOR PHENOTYPE IN HUMAN PROSTATIC ADENOCARCINOMA	ONCOGENE			English	Article							NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; GENETIC INSTABILITY; CARCINOMA; P53; MUTATIONS; CELLS; SUPPRESSION; ASSOCIATION	Mutator phenotype of nucleotide repeats has been implicated to be involved in human cancer and other diseases. This type of instability may be the direct result of DNA replication and/or repair errors. To examine mutator phenotype during the development of human prostate cancer, we undertook this study to screen 57 patients with prostatic adenocarcinoma for possible mutator phenotype at 18 microsatellite marker loci on 12 chromosomes (3p, 5q, 6p, 7p, 8p, 10q, 11p, 13q, 16q, 17p, 18q and Xq) Overall, in 37 of 57 patients, we have found positive mutator phenotype in at least one of the loci analysed. A significantly greater number of cases mere found to be positive for this phenotype among the poorly differentiated than the moderately- and well-differentiated prostatic adenocarcinomas. Our data suggest that mutator phenotype may play an important role in the development and progression of human prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHIARODO A, 1991, CANCER RES, V51, P2498; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GAO X, 1993, CANCER RES, V53, P2723; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISAACS WB, 1991, CANCER RES, V51, P4716; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STEVENBOVA G, 1993, CANCER RES, V53, P3869; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	34	78	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2999	3003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084604				2022-12-25	WOS:A1994PG82200027
J	YAMAIZUMI, M; SUGANO, T				YAMAIZUMI, M; SUGANO, T			UV-INDUCED NUCLEAR ACCUMULATION OF P53 IS EVOKED THROUGH DNA-DAMAGE OF ACTIVELY TRANSCRIBED GENES INDEPENDENT OF THE CELL-CYCLE	ONCOGENE			English	Article							TUMOR-ANTIGEN; COCKAYNE SYNDROME; SV40-TRANSFORMED CELLS; ATAXIA-TELANGIECTASIA; ULTRAVIOLET-RADIATION; TRANSFORMED-CELLS; ALPHA-AMANITIN; T-ANTIGEN; PROTEIN; REPAIR	Induction of p53 in u.v.-irradiated primary human fibroblasts was monitored by immunostaining and Western blotting. Minimum u.v. doses required for induction of nuclear accumulation of p53 (minimum response dose: MRD) were estimated in various cells with different DNA repair capacities. The MRD in repair deficient xeroderma pigmentosum (XP) group A cells is eightfold lower than in normal cells, indicating that nuclear accumulation of p53 is related to DNA repair capacity. Cells from patients with another u.v. sensitive disorder, Cockayne syndrome (CS), which have normal repair capacity for the overall genome but have a specific defect in preferential repair of lesions in active genes, have the same low MRD as of XP-A cells. Furthermore, the MRD in XP-C cells, which have normal preferential repair but have defects in overall genome repair, is as high as that of normal cells. DNA damage induced by X-ray is repaired at similar rates in normal, XP and CS cells. In contrast to u.v.-irradiation, the minimum dose of X-rays that induces nuclear accumulation of p53 is the same in these cells. Inhibition of transcription with alpha-amanitin evokes nuclear accumulation of p53 both in normal cells and in XP cells. These results strongly suggest that u.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes. Nuclear accumulation of p53 is observed in any phase of the cell cycle at both low and high u.v. doses.			YAMAIZUMI, M (corresponding author), KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN.							AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEAVER J, 1989, METABOLIC BASIS INHE, P2948; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDBERG EC, 1985, DNA REPAIR, P503; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1992, NATURE, V358, P17; LEHMANN AR, 1977, CANCER RES, V37, P904; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1983, EMBO J, V2, P1633, DOI 10.1002/j.1460-2075.1983.tb01637.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	40	234	235	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2775	2784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084582				2022-12-25	WOS:A1994PG82200002
J	MANN, DM; ROMM, E; MIGLIORINI, M				MANN, DM; ROMM, E; MIGLIORINI, M			DELINEATION OF THE GLYCOSAMINOGLYCAN-BINDING SITE IN THE HUMAN INFLAMMATORY RESPONSE PROTEIN LACTOFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FIBROBLAST GROWTH-FACTOR; HUMAN LACTOTRANSFERRIN; AFFINITY; RECEPTOR; HEPARIN; DOMAIN; CELLS; IDENTIFICATION; TRANSFERRINS	Lactoferrin is an iron-binding protein which is synthesized by mucosal epithelium and neutrophils and released by these cells in response to inflammatory stimuli. It promotes neutrophil aggregation and manifests iron-dependent and -independent antimicrobial properties in vitro. Since lactoferrin binds to glycosaminoglycans (GAGs) and sulfated polysaccharides can inhibit its clearance in vivo and in vitro, we sought to examine its interaction with the GAGs chondroitin sulfate and heparin. Amino-terminal sequencing of proteolytic fragments of human lactoferrin that were fractionated by GAG chromatography suggested that the aminoterminal 6 kDa of the secreted protein mediates its interaction with GAGs. Synthetic peptides were used to show that the first 33 residues of human lactoferrin can bind well to solid-phase or solution-phase GAGs. The first 33 residues bound fluoresceinamine-labeled heparin with an IC50 (611 nM) which approximated that of the intact protein (124 nM). In contrast, when the first six residues (GRRRRS) were removed from this peptide, it then bound poorly to heparin (IC50 = 49 mu M). Our results suggest that the GRRRRS sequence at the amino terminus of human lactoferrin acts synergistically with an RKVR sequence at positions 28-31 to form the predominate functional GAG-binding site of human lactoferrin. Molecular modeling of the crystalline structure of lactoferrin supports a synergistic activity between these two sites since it shows that they juxtapose each other on the surface of the folded protein. Solid docking calculations indicate that they can form a cationic cradle as a binding site for chondroitin sulfate.			MANN, DM (corresponding author), AMER RED CROSS,DEPT BIOCHEM,JH HOLLAND LAB,ROCKVILLE,MD 20855, USA.							AMBRUSO DR, 1981, J CLIN INVEST, V67, P352, DOI 10.1172/JCI110042; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ARFORS KE, 1993, J LAB CLIN MED, V121, P201; BARTAL L, 1987, PEDIATR RES, V21, P54, DOI 10.1203/00006450-198701000-00013; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BLACKBERG L, 1980, FEBS LETT, V109, P180, DOI 10.1016/0014-5793(80)81081-7; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CROUCH SPM, 1992, BLOOD, V80, P235; DAY CL, 1993, J MOL BIOL, V232, P1084, DOI 10.1006/jmbi.1993.1462; GAHR M, 1991, J LEUKOCYTE BIOL, V49, P427, DOI 10.1002/jlb.49.5.427; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; Grant David, 1992, Biochemical Society Transactions, V20, p361S; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1993, 66TH SCI SESS AM HEA, P49; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HUTCHENS TW, 1989, BIOCHIM BIOPHYS ACTA, V999, P323; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; IYER S, 1993, EUR J CLIN NUTR, V47, P232; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LEGRAND D, 1992, BIOCHEMISTRY-US, V31, P9243, DOI 10.1021/bi00153a018; MCABEE DD, 1991, J BIOL CHEM, V266, P23624; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; OSEAS R, 1981, BLOOD, V57, P939; RIDER CC, 1992, BIOCHEM SOC T, V20, P291, DOI 10.1042/bst0200291; SANCHEZ L, 1992, ARCH DIS CHILD, V67, P657, DOI 10.1136/adc.67.5.657; STOWELL KM, 1991, BIOCHEM J, V276, P349, DOI 10.1042/bj2760349; TRUMPLER U, 1989, EUR J CLIN MICROBIOL, V8, P310, DOI 10.1007/BF01963459; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VANTRAPPEN G, 1993, LANCET, V341, P730, DOI 10.1016/0140-6736(93)90495-3; WIGHT TN, 1993, CELL BIOL EXTRACELLU, P45; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINTER WT, 1978, J MOL BIOL, V125, P1, DOI 10.1016/0022-2836(78)90251-6; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069; ZOU S, 1992, COMP BIOCHEM PHYS B, V103, P889, DOI 10.1016/0305-0491(92)90210-I; ZUCALI JR, 1989, BLOOD, V74, P1531	42	201	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23661	23667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089135				2022-12-25	WOS:A1994PQ34500043
J	COLE, DG; SAXTON, WM; SHEEHAN, KB; SCHOLEY, JM				COLE, DG; SAXTON, WM; SHEEHAN, KB; SCHOLEY, JM			A SLOW HOMOTETRAMERIC KINESIN-RELATED MOTOR PROTEIN PURIFIED FROM DROSOPHILA EMBRYOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN KINESIN; DRIVEN MICROTUBULE MOTILITY; SEA-URCHIN EGGS; MITOTIC SPINDLE; HEAVY-CHAIN; CHROMOSOME SEGREGATION; ASPERGILLUS-NIDULANS; PEPTIDE ANTIBODIES; FISSION YEAST; GENE	Pan-kinesin peptide antibodies (Cole, D. G., Cande, W. Z., Baskin, R. J., Skoufias, D. A., Hogan, C. J., and Scholey, J. M. (1992) J. Cell Sci. 101, 291-301; Sawin, K. E., Mitchinson, T J., and Wordeman, L. G. (1992) J. Cell Sci. 101, 303-313) were used to identify and isolate kinesin-related proteins (KRPs) from Drosophila melanogaster embryonic cytosol. These KRPs cosedimented with microtubules (MTs) polymerized from cytosol treated with AMP-PNP (adenyl-5'-yl imidodiphosphate), and one of them, KRP(130), was further purified from ATP eluates of the embryonic MTs. Purified KRP(130) behaves as a ho motetrameric complex composed of four 130-kDa polypeptide subunits which displays a ''slow'' plus-end directed motor activity capable of moving single MTs at 0.04 +/- 0.01 mu m/s. The 130-kDa subunit of KRP(130) was tested for reactivity with monoclonal and polyclonal antibodies that are specific for various members of the kinesin superfamily. Results indicate that the KRP(130) subunit is related to Xenopus Eg5 (Sawin, K. E., Le Guellec, K. L., Philippe, M., Mitchinson, T. J. (1992) Nature 359, 540-543), a member of the BimC subfamily of kinesins. Therefore, KRP(130) appears to be the first Drosophila KRP, and the first member of the BimC subfamily in any organism, to be purified from native tissue as a multimeric motor complex.	INDIANA UNIV, INST MOLEC & CELLULAR BIOL, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	COLE, DG (corresponding author), UNIV CALIF DAVIS, MOLEC & CELLULAR BIOL SECT, DAVIS, CA 95616 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295, R01GM046376] Funding Source: NIH RePORTER; NIAMS NIH HHS [IF32AR08173] Funding Source: Medline; NIGMS NIH HHS [GM46376, GM46295, R01 GM046295, R01 GM046295-09] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BUSTER D, 1991, J CELL SCI, P109; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1992, J CELL SCI, V101, P291; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, P NATL ACAD SCI USA, V88, P4424, DOI 10.1073/pnas.88.10.4424; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; HOWARD J, 1993, METHOD CELL BIOL, V39, P137, DOI 10.1016/S0091-679X(08)60167-3; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; Pereira Andrea, 1994, V13, P269; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	47	156	164	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22913	22916						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083185				2022-12-25	WOS:A1994PQ16400001
J	HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			THE CATALYTIC SUBUNIT OF BOVINE BRAIN PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE IS A NOVEL TYPE OF SERINE ESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; FACTOR RECEPTOR; SIALIC ACIDS; PAF-ACETHER; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; PHOSPHOLIPIDS; PURIFICATION; CLONING; IDENTIFICATION; NEUTROPHILS	Platelet-activating factor (PAF) acetylhydrolase is the key enzyme in PAF inactivation. We recently purified one isoform of the enzyme from a bovine brain soluble fraction and revealed it as a heterotrimeric enzyme consisting of 29-, 30-, and 45-kDa subunits. Among them, the 29-kDa subunit possesses an active serine residue since diisopropyl fluorophosphate (DFP), an inhibitor of the enzyme, labeled only this subunit (Hattori, M., Arai, H., and Inoue, K. (1993) J. Biol. Chem. 268, 18748-18753). In the current study, we cloned the cDNA for the 29-kDa catalytic subunit. The predicted sequence of 232 amino acids is unique and is not homologous with those of any other proteins reported so far. When transfected into either Escherichia coli or COS7 cells, the cDNA produced PAF acetylhydrolase activity in both types of cells, indicating that this subunit alone is enough for catalysis. The recombinant 29-kDa protein was also inhibited and labeled by DFP. Furthermore, we isolated and sequenced the [H-3]DFP-labeled peptide fragment, revealing that Ser(47) is the active serine residue. The sequence surrounding it is different from the consensus sequence of the serine esterase family. Interestingly, the sequence of about 30 amino acids located 6 residues downstream from the active serine site exhibits significant homology to the first transmembrane region of the PAF receptor. These data demonstrate that the catalytic subunit of brain PAF acetylhydrolase is a novel type of serine esterase.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT HLTH CHEM, BUNKYO KU, TOKYO 113, JAPAN; SUNTORY INST BIOMED RES, SHIMAMOTO 618, OSAKA, JAPAN	University of Tokyo; Suntory Holdings Ltd			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				BLANK ML, 1981, J BIOL CHEM, V256, P175; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DEMOPOULOS H, 1977, OXYGEN PHYSL FUNCTIO, P49; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; INOUE K, 1994, J LIPID MEDIAT CELL, V10, P13; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KORTH R, 1993, LIPIDS, V28, P193, DOI 10.1007/BF02536639; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MAIN AR, 1964, SCIENCE, V144, P992, DOI 10.1126/science.144.3621.992; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	34	120	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23150	23155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083218				2022-12-25	WOS:A1994PQ16400040
J	MALATHI, K; GANESAN, K; DATTA, A				MALATHI, K; GANESAN, K; DATTA, A			IDENTIFICATION OF A PUTATIVE TRANSCRIPTION FACTOR IN CANDIDA-ALBICANS THAT CAN COMPLEMENT THE MATING DEFECT OF SACCHAROMYCES-CEREVISIAE STE12 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY ACID PROTEINASE; SIGNAL TRANSDUCTION; FILAMENTOUS GROWTH; YEAST; DNA; GENES; DOMAINS; MUTAGENESIS; INDUCTION; PATHWAY	We have isolated an acid proteinase-related gene, ACPR, from Candida albicans using a partial clone (Ganesan, K., Banerjee, A., and Datta, A. (1991) Infect. Immun. 59, 2972-2977) as a probe. Sequencing of the full-length gene revealed an open reading frame that can encode a protein of 699 amino acids. The deduced NH2-terminal amino acid sequence did not correspond with that determined from the purified secretory acid proteinase; however, the encoded protein is antigenically related to secretory acid proteinase and has a putative active site for acid proteinase. Interestingly, the amino acid sequence of the NH2-terminal 215 residues of Acprp is highly similar to the DNA binding domain of Ste12p of Saccharomyces cerevisiae. Gel retardation experiments showed that this region of Acprp, like Ste12p, could bind to S. cerevisiae pheromone response elements, suggesting that Acprp has a function similar to Ste12p. Chimeric constructs composed of S. cerevisiae STE12 and C. albicans ACPR genes complemented the mating defect of S. cerevisiae a or cu ste12 mutants. Our results suggest the presence of a signal transduction system in C. albicans similar to that of S. cerevisiae mating pathway.	JAWAHARLAL NEHRU UNIV, SCH LIFE SCI, NEW DELHI 110067, INDIA	Jawaharlal Nehru University, New Delhi					NIAID NIH HHS [R15 AI089518, R15 AI089518-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI089518] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BANERJEE A, 1991, J GEN MICROBIOL, V137, P2455, DOI 10.1099/00221287-137-10-2455; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA A, 1989, ADV MICROB PHYSIOL, V30, P53; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANESAN K, 1991, INFECT IMMUN, V59, P2972, DOI 10.1128/IAI.59.9.2972-2977.1991; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Odds FC., 1988, CANDIDA CANDIDOSIS; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUCHEL R, 1981, BIOCHIM BIOPHYS ACTA, V659, P99, DOI 10.1016/0005-2744(81)90274-6; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS M, 1990, CURR GENET, V17, P487, DOI 10.1007/BF00313076; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SPENCER JFT, 1988, YEAST PRACTICAL APPR, P65; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Staib F, 1965, Sabouraudia, V4, P187; STAIB F, 1969, MYCOPATH MYCOL APPL, V37, P345, DOI 10.1007/BF02129881; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WHITEWAY M, 1992, P NATL ACAD SCI USA, V89, P9410, DOI 10.1073/pnas.89.20.9410; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584	42	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22945	22951						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083193				2022-12-25	WOS:A1994PQ16400009
J	SONG, HY; DUNBAR, JD; DONNER, DB				SONG, HY; DUNBAR, JD; DONNER, DB			AGGREGATION OF THE INTRACELLULAR DOMAIN OF THE TYPE-1 TUMOR-NECROSIS-FACTOR RECEPTOR DEFINED BY THE 2-HYBRID SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR TNF RECEPTOR; MOLECULAR-CLONING; 2-HYBRID SYSTEM; BINDING; PROTEIN; ACTIVATION; ALPHA; BETA; INHIBITION; ANTIBODIES	The yeast-based two hybrid system has been used to determine whether oligomerization of the intracellular domain of the 55-kDa type 1 tumor necrosis factor (TNF) receptor may occur during TNF action. This assay depends upon reconstitution of the function of the GAIA transcriptional activator through interaction of a protein fused to the GAL4 DNA binding domain with a protein fused to the transcriptional activation domain of GAL4. Fusion of the type 1 TNF receptor intracellular domain with the DNA binding domain and the transactivation domain of GAL4 led to activation of the lacZ indicator gene, demonstrating interaction of the receptor intracellular domain with itself. A HeLa cell cDNA Library was searched for proteins that interact with the intracellular domain of the type 1 TNF receptor. A protein corresponding to amino acids 329-426 in the type 1 TNF receptor intracellular domain was identified by this screen. The aggregation domain was further defined by testing the ability of deletion mutants of the type 1 TNF receptor intracellular region to interact with the complete intracellular domain. These experiments map the aggregation domain to a sequence of amino acids previously shown to be responsible for mediating TNF-induced cytotoxicity. These results suggest that aggregation of type 1 TNF receptor intracellular domains may be important in TNF signal transduction.	INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITOH N, 1993, J BIOL CHEM, V268, P10932; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KWON BS, 1987, P NATL ACAD SCI USA, V84, P2896, DOI 10.1073/pnas.84.9.2896; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Miller J.H., 1972, EXPT MOL GENETICS; OLD LJ, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P1; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WONG GHW, 1992, J IMMUNOL, V149, P3550	38	62	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22492	22495						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077196				2022-12-25	WOS:A1994PQ16300010
J	ISMAILOV, II; MCDUFFIE, JH; SARIBANSOHRABY, S; JOHNSON, JP; BENOS, DJ				ISMAILOV, II; MCDUFFIE, JH; SARIBANSOHRABY, S; JOHNSON, JP; BENOS, DJ			CARBOXYL METHYLATION ACTIVATES PURIFIED RENAL AMILORIDE-SENSITIVE NA+ CHANNELS IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-TRANSPORT; ALDOSTERONE ACTION; APICAL MEMBRANE; K+-ATPASE; PROTEIN; KIDNEY; A6; VASOPRESSIN; EPITHELIA; SUBUNIT	The early increase in luminal membrane Na+ permeability by aldosterone in Na+-reabsorbing epithelia is attributed to an increase in the open probability (and number) of preexisting amiloride sensitive Na+ channels, Carboxyl methylation reactions are involved, but the mechanism of action is unknown. We report that the 90-95-kDa polypeptide subunit of a purified renal Na+ channel protein can be specifically carboxymethylated and that this biochemical reaction, in the presence of guanosine 5'-3-O-(thio)triphosphate, leads directly to an increase in channel activity. Further, we show that protein kinase A-mediated phosphorylation can synergistically activate these channels. We suggest that renal Na+ channels have multiple biochemical regulatory inputs and that post-translational modifications underlie the increases in luminal membrane Na+ channel activity produced by aldosterone and vasopressin in Na+-reabsorbing epithelia.	FREE UNIV BRUSSELS, PHYSIOL & PHYSIOPATHOL LAB, B-1070 BRUSSELS, BELGIUM; UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, PITTSBURGH, PA 15213 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ISMAILOV, II (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINDELS RJM, 1988, BIOCHIM BIOPHYS ACTA, V972, P320, DOI 10.1016/0167-4889(88)90208-X; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX M, 1991, ALDOSTERONE FUNDAMEN, P249; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; GARTY H, 1986, J MEMBRANE BIOL, V90, P193, DOI 10.1007/BF01870126; GINGRAS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P261, DOI 10.1016/0005-2736(91)90196-F; GINGRAS D, 1993, AM J PHYSIOL, V265, pF316, DOI 10.1152/ajprenal.1993.265.2.F316; GIRARDET M, 1986, AM J PHYSIOL, V251, pF662, DOI 10.1152/ajprenal.1986.251.4.F662; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDLER JS, 1969, J CLIN INVEST, V48, P823, DOI 10.1172/JCI106040; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; JOHNSON JP, 1992, PHARMACOL THERAPEUT, V53, P1, DOI 10.1016/0163-7258(92)90042-X; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KIM SD, 1984, METHOD ENZYMOL, V106, P295; LAZORICK K, 1985, J MEMBRANE BIOL, V86, P69, DOI 10.1007/BF01871612; LIEN EL, 1975, BIOCHEMISTRY-US, V14, P2749, DOI 10.1021/bi00683a030; LING BN, 1900, MOL CELL BIOL, V99, P141; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; OH YS, 1993, PROTEIN EXPRES PURIF, V4, P312, DOI 10.1006/prep.1993.1040; OHARA A, 1993, AM J PHYSIOL, V264, pC352, DOI 10.1152/ajpcell.1993.264.2.C352; PERKINS FM, 1981, AM J PHYSIOL, V241, pC154, DOI 10.1152/ajpcell.1981.241.3.C154; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; RODRIGUEZ HJ, 1981, AM J PHYSIOL, V241, pF186, DOI 10.1152/ajprenal.1981.241.2.F186; ROSSIER BC, 1989, CURR TOP MEMBR TRANS, V34, P167; Rossier BC, 1992, KIDNEY PHYSL PATHOPH, P1373; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SCHAFER JA, 1990, AM J PHYSIOL, V258, pF199, DOI 10.1152/ajprenal.1990.258.1.F199; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; YAMANE HK, 1989, J BIOL CHEM, V264, P20100	42	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22193	22197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071343				2022-12-25	WOS:A1994PE09800043
J	PARTHASARATHY, N; GOLDBERG, IJ; SIVARAM, P; MULLOY, B; FLORY, DM; WAGNER, WD				PARTHASARATHY, N; GOLDBERG, IJ; SIVARAM, P; MULLOY, B; FLORY, DM; WAGNER, WD			OLIGOSACCHARIDE SEQUENCES OF ENDOTHELIAL-CELL SURFACE HEPARAN-SULFATE PROTEOGLYCAN WITH AFFINITY FOR LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FIBROBLAST GROWTH-FACTOR; RECEPTOR-RELATED PROTEIN; FREE-FATTY-ACIDS; STRUCTURAL CHARACTERIZATION; NITROUS-ACID; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION; DOMAIN	Lipoprotein lipase (LpL) catalyzes the hydrolysis of triglycerides in plasma lipoproteins at the luminal surface of the vascular endothelium. This enzyme is bound via electrostatic interactions to heparan sulfate (HS). The specific endothelial cell surface HS oligosaccharide sequences that are necessary for binding of LpL to HS have not been characterized. To identify this LpL-binding oligosaccharide sequence, oligosaccharides were isolated from bovine aortic endothelial cell-derived HS and assessed for LpL binding properties. Endothelial HS chains that were isolated from endothelial total cell-associated proteoglycans were deacetylated by complete hydrazinolysis, cleaved with nitrous acid (pH 4.5), and reduced with [H-3]NaBH4. The resulting fragments composed of N-sulfated glucosamine-rich oligosaccharides terminating with [H-3]2,5-anhydromannitol (AMan(R)) were chromatographed on a LpL-Sepharose column. A high affinity decasaccharide was isolated and characterized. Disaccharide analysis of this decasaccharide indicated that it yielded only the disaccharide IdceA(2-SO4)-->AMan(R)(6-SO4) on treatment with nitrous acid at low pH. Therefore, the sequence of the LpL-binding decasaccharide is [IdceA(2-SO4)alpha 1-4GlcNSO(4)(6-SO4)alpha 1-4](4)- IdceA(2-SO4)alpha 1-4AMan(R)(6-SO4) and is distinct from those that bind antithrombin and basic fibroblast growth factor. Partial depolymerization of endothelial HS chains with hydrazine/high pH nitrous acid treatment gave rise to lipase-binding oligosaccharides larger than decasaccharide. However, further complete depolymerization of these oligosaccharides resulted in only a high affinity decasaccharide composed of repeating disaccharide units of [IdceA(2-SO4)alpha 1-4GlcNSO(4)(6-SO4)]. These results indicate that the decasaccharide is the active fragment that binds to LpL with high affinity. Molecular modeling studies of the decasaccharide indicate that it presents a linear array of negatively charged sulfate groups that may adopt a favorable disposition to bind to peptide region(s) comprised of basic amino acid residues of LpL with high affinity.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA; NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND	Wake Forest University; Wake Forest Baptist Medical Center; Columbia University; National Institute for Biological Standards & Control					NHLBI NIH HHS [HL-45095, HL-07115-19, HL-45848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045848, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CHAPPELL DA, 1992, J BIOL CHEM, V267, P14168; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EDGE ASB, 1985, ARCH BIOCHEM BIOPHYS, V240, P560, DOI 10.1016/0003-9861(85)90063-3; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FORSTER MJ, 1993, BIOPOLYMERS, V33, P575, DOI 10.1002/bip.360330407; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; GURNBULL JE, 1992, J BIOL CHEM, V267, P10337; HATA A, 1993, J BIOL CHEM, V268, P8447; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MULDER M, 1993, J BIOL CHEM, V268, P9369; MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P161, DOI 10.1016/0005-2760(90)90291-5; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIMADA K, 1981, BIOCHIM BIOPHYS ACTA, V710, P117; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	54	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22391	22396						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071367				2022-12-25	WOS:A1994PE09800070
J	TAPPING, RI; SYROID, DE; CAPONE, JP				TAPPING, RI; SYROID, DE; CAPONE, JP			UPSTREAM INTERACTIONS OF FUNCTIONAL MAMMALIAN TRANSFER-RNA GENE-TRANSCRIPTION COMPLEXES PROBED USING A HETEROLOGOUS DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; SACCHAROMYCES-CEREVISIAE; LAC-REPRESSOR; CONTROL REGIONS; 5-S RNA; OPERATOR; SUBUNIT; INVITRO; TFIIIB; EXPRESSION	An oligonucleotide containing the recognition site-for the Escherichia coli lac repressor was inserted at various positions in the 5' flanking region of a human serine tRNA gene, and the consequences of binding lac repressor on in vitro transcription by RNA polymerase III were investigated. lac repressor prebound to operator sites centered at positions -9, -15, -35, and -37 upstream of the mature tRNA coding region completely inhibited transcription by interfering with the formation or stability of transcription complexes. lac repressor also inhibited transcription of tDNA derivatives containing operator sites at -9 and -15 when added following assembly of transcription complexes or during ongoing synthesis, but had no effects on the other tDNA derivatives if added subsequent to complex assembly. lac repressor prebound at position -43 and -46 partially inhibited transcription and redirected initiation to sites farther downstream. These effects required the continued presence of bound repressor protein. Our findings demonstrate that the human RNA polymerase III transcription complex extends at least 35 nucleotides upstream of the coding region and suggest that the spatial constraints imposed by a protein bound this far upstream can alter start site selection. Moreover, the flanking region encompassing the transcription start site remains accessible to DNA-binding proteins following assembly of the initiation complex and throughout multiple rounds of transcription.	MCMASTER UNIV,HLTH SCI CTR,DEPT BIOCHEM,HAMILTON L8N 3Z5,ON,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba								BARKLEY MD, 1980, OPERON, P177; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CAPONE JP, 1988, DNA-J MOLEC CELL BIO, V7, P459, DOI 10.1089/dna.1.1988.7.459; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGERMANN T, 1987, ANAL BIOCHEM, V162, P466, DOI 10.1016/0003-2697(87)90422-2; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; FOWLKES DM, 1980, CELL, V22, P405, DOI 10.1016/0092-8674(80)90351-7; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; OEI SL, 1990, J BIOL CHEM, V265, P7485; OHSHIMA Y, 1975, J MOL BIOL, V91, P515, DOI 10.1016/0022-2836(75)90277-6; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SHARP S, 1983, J BIOL CHEM, V258, P2440; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; SYROID DE, 1992, MOL CELL BIOL, V12, P4271, DOI 10.1128/MCB.12.10.4271; TAPPING RI, 1993, NUCLEIC ACIDS RES, V21, P4476, DOI 10.1093/nar/21.19.4476; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; WORMINGTON WM, 1981, CELL, V24, P809, DOI 10.1016/0092-8674(81)90106-9; ZINGSHEIM HP, 1977, J MOL BIOL, V115, P565, DOI 10.1016/0022-2836(77)90171-1	44	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21812	21819						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063824				2022-12-25	WOS:A1994PK97300064
J	JOHNSON, RS; OHGURO, H; PALCZEWSKI, K; HURLEY, JB; WALSH, KA; NEUBERT, TA				JOHNSON, RS; OHGURO, H; PALCZEWSKI, K; HURLEY, JB; WALSH, KA; NEUBERT, TA			HETEROGENEOUS N-ACYLATION IS A TISSUE-SPECIFIC AND SPECIES-SPECIFIC POSTTRANSLATIONAL MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; COLLISION-INDUCED DISSOCIATION; TANDEM MASS-SPECTROMETRY; CATALYTIC SUBUNIT; BINDING PROTEIN; ALPHA-SUBUNIT; FATTY-ACIDS; TERMINUS; PEPTIDES; MYRISTOYLTRANSFERASE	Heterogeneous N-terminal glycine acylation recently has been reported for two proteins involved in visual signal transduction. Similar N-acylations have typically involved only myristate; however, none of the previously examined proteins were isolated from retinas. To determine whether heterogeneous N-acylation is tissue-specific or protein sequence specific, the N-terminal modifications of the catalytic subunit of cAMP-dependent protein kinase, partially purified from bovine retinas, heart, and brain tissues, were characterized. Using tandem mass spectrometry and liquid chromatography coupled directly to an electrospray mass spectrometer, we found only myristate at the N termini of catalytic subunits from brain and heart tissue, whereas the N termini of the retina-derived subunits were heterogeneously acylated in a manner similar to recoverin and transducin. Thus it appears that the nature of N-terminal glycine acylation is determined by the cell or tissue type in which it is located, and not by the sequence of the modified protein. We also examined the N-acylation of recoverin purified from human retinas, as well as transducin purified from frog retinas, to determine if heterogeneous acylation of retinal proteins is a uniquely bovine phenomenon. Interestingly, human recoverin was modified by the same family of fatty acids found on the bovine retinal proteins, while frog transducin was modified homogeneously not with myristate, but with a doubly unsaturated (C14:2) fatty acyl group.	UNIV WASHINGTON,DEPT BIOCHEM SJ70,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NEI NIH HHS [F32EYO6450-02, EYO6641, R01 EY006641] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006450, R01EY006641] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Beavo J A, 1974, Methods Enzymol, V38, P299; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MOSCARELLO MA, 1992, J BIOL CHEM, V267, P9779; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	26	71	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21067	21071						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063726				2022-12-25	WOS:A1994PC40300040
J	WASSERMAN, RA; WANG, JC				WASSERMAN, RA; WANG, JC			MECHANISTIC STUDIES OF AMSACRINE-RESISTANT DERIVATIVES OF DNA TOPOISOMERASE-II - IMPLICATIONS IN RESISTANCE TO MULTIPLE ANTITUMOR DRUGS TARGETING THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL-LINE; HYDROPHILIC CARBOXYL-TERMINUS; HUMAN-LEUKEMIA-CELLS; DROSOPHILA-MELANOGASTER; ESCHERICHIA-COLI; POINT MUTATION; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; SACCHAROMYCES-CEREVISIAE; CATALYTIC ACTIVITY; FISSION YEAST	Wild-type yeast DNA topoisomerase II and three of its amsacrine-resistant derivatives L475A/L480P, L475A/ R476G, and A642G, named according to amino acid changes at the codons specified, were overexpressed and purified. Because cells expressing several mutant enzymes missing portions of the carboxyl-terminal domain of the wild-type enzyme were previously found to exhibit amsacrine resistance, a carboxyl-terminal truncation protein Top2(1-1166), which lacks the last 263 amino acids of the wild-type enzyme, was also overexpressed and purified. These purified enzymes were used in the measurement of the turnover numbers of the DNA-dependent hydrolysis of ATP, the transport of one DNA segment through another, and the effects of amsacrine, teniposide or Ca(II) on the formation of the enzyme-DNA covalent intermediate. The results of these studies indicate that mutations leading to cellular resistance to amsacrine may occur by several different mechanisms, including reduction of the nuclear concentration and attenuation of the intrinsic catalytic steps of the enzyme. The significance of this underpinning mechanistic diversity of drug resistance and its relation to the simultaneous development of cellular resistance to chemically distinct drugs that target DNA topoisomerase II are discussed.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NATIONAL CANCER INSTITUTE [R01CA047958] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA47958] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDOH T, 1993, MOL BIOL DNA TOPOISO; BECK WT, 1991, DNA TOPOISOMERASES C, P445; BERRY DE, 1992, J ORG CHEM, V57, P420, DOI 10.1021/jo00028a002; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; Danks M K, 1989, Cancer Commun, V1, P101; DANKS MK, 1993, CANCER RES, V53, P1373; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DEFFIE AM, 1989, CANCER RES, V49, P6879; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, CANCER RES, V49, P2578; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FERGUSON PJ, 1988, CANCER RES, V48, P5956; FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028; GLISSON B, 1986, CANCER RES, V46, P1939; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HANCOCK R, 1990, MOL BASIS CHEMOTHERA, P119; HARKER WG, 1991, BIOCHEMISTRY-US, V30, P9953, DOI 10.1021/bi00105a020; HINDS M, 1991, CANCER RES, V51, P4729; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1991, CANCER RES, V51, P4909; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; JENSEN PB, 1990, CANCER RES, V50, P3311; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; LEE MS, 1992, J MOL BIOL, V223, P837, DOI 10.1016/0022-2836(92)90245-F; LI CJ, 1993, J BIOL CHEM, V268, P22463; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU L, 1994, DNA TOPOISOMERASES T; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Macdonald T. L., 1991, DNA TOPOISOMERASES C, P199; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1992, CANCER RES, V52, P4467; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PATEL S, 1993, BRIT J CANCER, V67, P456, DOI 10.1038/bjc.1993.87; POTMESIL M, 1987, NATL CANCER I MONOGR, V4, P1; POTMESIL M, 1987, NATL CANCER I MONOGR, V4, P105; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Ross W E, 1988, Important Adv Oncol, P65; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SINHA BK, 1988, CANCER RES, V48, P5096; SPIRIDONIDIS CA, 1989, CANCER RES, V49, P644; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; TANABE K, 1991, CANCER RES, V51, P4903; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WASSERMAN RA, 1994, CANCER RES, V54, P1795; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YOSHIDA H, 1993, ANTIMICROB AGENTS CH, V37, P839, DOI 10.1128/AAC.37.4.839; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	69	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20943	20951						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063712				2022-12-25	WOS:A1994PC40300023
J	AMICHE, M; DUCANCEL, F; MOR, A; BOULAIN, JC; MENEZ, A; NICOLAS, P				AMICHE, M; DUCANCEL, F; MOR, A; BOULAIN, JC; MENEZ, A; NICOLAS, P			PRECURSORS OF VERTEBRATE PEPTIDE ANTIBIOTICS DERMASEPTIN-B AND ADENOREGULIN HAVE EXTENSIVE SEQUENCE IDENTITIES WITH PRECURSORS OF OPIOID-PEPTIDES DERMORPHIN, DERMENKEPHALIN, AND DELTORPHINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIBIAN SKIN; HIGH-AFFINITY; SIGNAL-SEQUENCE; XENOPUS-LAEVIS; MESSENGER-RNA; CDNA SEQUENCE; SELECTIVITY; BIOSYNTHESIS; DEGRADATION; SECRETIONS	The dermaseptins are a family of broad spectrum antimicrobial peptides, 27-34 amino acids long, involved in the defense of the naked skin of frogs against microbial invasion. They are the first vertebrate peptides to show lethal effects against the filamentous fungi responsible for severe opportunistic infections accompanying immunodeficiency syndrome and the use of immunosuppressive agents. A cDNA library was constructed from skin poly(A(+)) RNA of the arboreal frog Phyllomedusa bicolor and screened with an oligonucleotide probe complementary to the COOH terminus of dermaseptin b. Several clones contained a full-length DNA copy of a 443-nucleotide mRNA that encoded a 78-residue dermaseptin b precursor protein. The deduced precursor contained a putative signal sequence at the NH2 terminus, a 20-residue spacer sequence extremely rich (60%) in glutamic and aspartic acids, and a single copy of a dermaseptin b progenitor sequence at the COOH terminus. One clone contained a complete copy of adenoregulin, a 33-residue peptide reported to enhance the binding of agonists to the A1 adenosine receptor. The mRNAs encoding adenoregulin and dermaseptin b were very similar: 70 and 75% nucleotide identities between the 5'- and 3'-untranslated regions, respectively; 91% amino acid identity between the signal peptides; 82% identity between the acidic spacer sequences; and 38% identity between adenoregulin and dermaseptin b. Because adenoregulin and dermaseptin b have similar precursor designs and antimicrobial spectra, adenoregulin should be considered as a new member of the dermaseptin family and alternatively named dermaseptin b II. Preprodermaseptin b and preproadenoregulin have considerable sequence identities to the precursors encoding the opioid heptapeptides dermorphin, dermenkephalin, and deltorphins. This similarity extended into the 5'-untranslated regions of the mRNAs. These findings suggest that the genes encoding the four preproproteins are all members of the same family despite the fact that they encode end products having very different biological activities. These genes might contain a homologous export exon comprising the 5'-untranslated region, the 22-residue signal peptide, the 20-24-residue acidic spacer, and the basic pair Lys-Arg.	CENS,DEPT INGN & ETUD PROT,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay	AMICHE, M (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,BIOACTIVAT PEPTIDES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		AMICHE, Mohamed/R-3684-2018; Nicolas, Pierre/C-7908-2009					ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; AUBERTHOMAY M, 1991, REV FR AQUA HERPETOL, V4, P121; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; ERSPAMER V, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90343-2; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P113; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; KUCHLER K, 1989, EUR J BIOCHEM, V179, P281, DOI 10.1111/j.1432-1033.1989.tb14552.x; LAZARUS LH, 1989, J BIOL CHEM, V264, P3047; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; MOR A, 1991, Journal de Mycologie Medicale, V1, P216; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; SAGAN S, 1989, J BIOL CHEM, V264, P17100; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; STEPHEN D, 1990, NUCLEIC ACIDS RES, V18, P7463, DOI 10.1093/nar/18.24.7463; TERRY AS, 1988, J BIOL CHEM, V263, P5745; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WAINHOBSON S, 1981, GENE, V13, P355, DOI 10.1016/0378-1119(81)90015-9; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	40	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17847	17852						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8074751				2022-12-25	WOS:A1994NV42200017
J	LEHOTZKY, A; TELEGDI, M; LILIOM, K; OVADI, J				LEHOTZKY, A; TELEGDI, M; LILIOM, K; OVADI, J			INTERACTION OF PHOSPHOFRUCTOKINASE WITH TUBULIN AND MICROTUBULES - QUANTITATIVE-EVALUATION OF THE MUTUAL EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MUSCLE PHOSPHOFRUCTOKINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRUCTURAL PROTEINS; GLYCOLYTIC-ENZYMES; SELF-ASSOCIATION; SKELETAL-MUSCLE; BINDING; PURIFICATION; DISSOCIATION; MODULATION	The linked equilibria involved in the binding of phosphofructokinase (EC 2.7.1.11, ATP:D-fructose-6-phosphate 1-phosphotransferase) to tubulin and microtubules were studied at high ionic strength in vitro. The concentration-dependent dissociation of phosphofructokinase was analyzed in the absence and presence of tubulin or microtubules, and the binding of kinase to the tubulin dimer and microtubules was compared. Enzyme activity of phosphofructokinase was inhibited by both tubulin and microtubules: the relative inhibition increased with decreasing enzyme concentration. The complex formation between phosphofructokinase and tubulin was demonstrated by means of fluorescent anisotropy. Concentration-dependent copelleting of the kinase with taxol-stabilized microtubules revealed binding of the enzyme to microtubules as well as phosphofructokinase-enhanced pelleting of microtubules. The binding data agree with the enzyme kinetic findings that the inactive dissociated forms of phosphofructokinase (monomer-dimer) are involved in the heterologous complex formation. Microtubule reorganization (bundle formation) by phosphofructokinase was established by turbidity measurements and sedimentation experiments. The binding data are consistent with a simple molecular model for the interactions in phosphofructokinase-tubulin/microtubules systems.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, POB 27, H-1518 BUDAPEST, HUNGARY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences			Lehotzky, Attila/B-1837-2009; Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872; Ovadi, Judit/0000-0002-3420-682X; Attila, Lehotzky/0000-0001-5235-1812				BOSCA L, 1985, J BIOL CHEM, V260, P2100; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CLARKE F, 1983, ACTIN STRUCTURE FUNC; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; COLLINS CA, 1991, METHOD ENZYMOL, V196, P246; DAVIDSON M, 1983, BIOCHEM J, V214, P703, DOI 10.1042/bj2140703; DEFARIA JB, 1978, DEV BIOL, V65, P547, DOI 10.1016/0012-1606(78)90051-9; DURRIEU C, 1987, MOL CELL BIOCHEM, V74, P55; FOE LG, 1984, ARCH BIOCHEM BIOPHYS, V228, P503, DOI 10.1016/0003-9861(84)90016-X; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; HESTERBERG LK, 1982, BIOCHEMISTRY-US, V21, P216, DOI 10.1021/bi00531a003; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; KAHN A, 1980, PEDIATR RES, V14, P1162, DOI 10.1203/00006450-198011000-00003; KELETI T, 1989, PROG BIOPHYS MOL BIO, V53, P105, DOI 10.1016/0079-6107(89)90016-3; KNULL HR, 1990, STRUCTURAL ORG ASPEC; KRIEGEL T, 1986, STUD BIOPHYS, V113, P247; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1989, ALLOSTERIC ENZYMES; LILLING G, 1990, INT J BIOCHEM, V22, P857, DOI 10.1016/0020-711X(90)90289-F; LIOU RS, 1980, BIOCHEMISTRY-US, V19, P2684, DOI 10.1021/bi00553a022; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LUTHER MA, 1985, BIOCHEMISTRY-US, V24, P2463, DOI 10.1021/bi00331a011; LUTHER MA, 1986, BIOCHEMISTRY-US, V25, P7931, DOI 10.1021/bi00372a022; MAYR GW, 1987, METHOD ENZYMOL, V139, P745; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; NA GC, 1985, METHOD ENZYMOL, V117, P459; OROSZ F, 1987, BIOCHEM BIOPH RES CO, V147, P1121, DOI 10.1016/S0006-291X(87)80186-9; OVADI J, 1982, BIOCHEMISTRY-US, V21, P6375, DOI 10.1021/bi00268a009; OVADI J, 1978, EUR J BIOCHEM, V90, P499, DOI 10.1111/j.1432-1033.1978.tb12629.x; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; OVADI J, 1986, BIOCHEM BIOPH RES CO, V135, P852, DOI 10.1016/0006-291X(86)91006-5; RAWITCH AB, 1972, J BIOL CHEM, V247, P680; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; Sokal RR, 1969, BIOMETRY, P204; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; TAYLOR JF, 1948, J BIOL CHEM, V173, P591; THRASHER JR, 1981, J BIOL CHEM, V256, P7844; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TORNHEIM K, 1976, J BIOL CHEM, V251, P7322; TSAI MY, 1973, J BIOL CHEM, V248, P785; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9	43	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10888	10894						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098705				2022-12-25	WOS:A1993LD46600029
J	VAANDRAGER, AB; SCHULZ, S; DEJONGE, HR; GARBERS, DL				VAANDRAGER, AB; SCHULZ, S; DEJONGE, HR; GARBERS, DL			GUANYLYL CYCLASE-C IS AN N-LINKED GLYCOPROTEIN RECEPTOR THAT ACCOUNTS FOR MULTIPLE HEAT-STABLE ENTEROTOXIN-BINDING PROTEINS IN THE INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ESCHERICHIA-COLI; ADENINE-NUCLEOTIDES; EXPRESSION; TOXIN; GLYCOSYLATION; ACTIVATION; TRANSPORT; MEMBRANE; CLEAVAGE	Guanylyl cyclase C (GC-C) is a newly discovered receptor found in the intestine, and possibly in other epithelia, that binds bacterial heat-stable enterotoxins (STa). The receptor has now been stably expressed in human embryonic 293 cells, which do not normally contain the receptor. Cyclic GMP concentrations are elevated 40-fold in response to 1 muM STa, and membranes obtained from the overproducing cells contain GC-C activity that can be stimulated about 9-fold by STa alone and an additional 1.4- to 2-fold by a combination of ATP and STa. The ATP effect does not appear to be due to enzyme activation, but instead to protection of GC-C against inactivation. Antibody raised against the carboxyl-terminal sequence of GC-C identified two major proteins (M(r) 140,000 and 160,000) in 293 cells expressing GC-C. Both proteins bound to wheat germ lectin-Sepharose, and N-glycosidase F treatment converted both forms to a single M(r) 120,000 protein, the size predicted from amino acid composition. The addition of high concentrations of tunicamycin to 293-GC-C cells also reduced the M(r) to 120,000, indicating that GC-C is an N-linked glycoprotein. When rat intestinal membranes or 293-GC-C cells were cross-linked with I-125-labeled STa, the major I-125-labeled protein complexes had M(r) ranging between 45,000 and 80,000. On immunoblots of rat intestinal membranes treated with a reducing agent, 3 major proteins of M(r) 65,000, 85,000, and 140,000 were specifically recognized by a GC-C antibody. However, under nonreducing conditions one major GC-C related protein appeared at a higher position (M(r) 230,000). Its mobility was reduced in the presence of STa, similar to rGC-C expressed in 293 cells. These data indicate that at least part of the lower M(r) STa-binding proteins found in intestinal extracts represent proteolytic products of GC-C.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; ERASMUS UNIV, FAC MED, DEPT BIOCHEM, 3000 DR ROTTERDAM, NETHERLANDS	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Erasmus University Rotterdam				Vaandrager, Arie/0000-0001-9394-9239				CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DATEMA R, 1987, PHARMACOL THERAPEUT, V33, P221, DOI 10.1016/0163-7258(87)90066-0; DEJONGE HR, 1975, FEBS LETT, V53, P237, DOI 10.1016/0014-5793(75)80028-7; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P190; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FIELD M, 1989, NEW ENGL J MED, V321, P800; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; IVENS K, 1990, INFECT IMMUN, V58, P1817, DOI 10.1128/IAI.58.6.1817-1820.1990; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUNO T, 1986, J BIOL CHEM, V261, P1470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT A, 1980, ANAL BIOCHEM, V106, P199, DOI 10.1016/0003-2697(80)90138-4; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THOMPSON MR, 1985, ANAL BIOCHEM, V148, P26, DOI 10.1016/0003-2697(85)90623-2; THOMPSON MR, 1990, J RECEPTOR RES, V10, P97, DOI 10.3109/10799899009064660; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986	31	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2174	2179						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093618				2022-12-25	WOS:A1993KH62000101
J	CHEN, HC; WANG, LM; BANERJEE, S				CHEN, HC; WANG, LM; BANERJEE, S			ISOLATION AND CHARACTERIZATION OF THE PROMOTER REGION OF HUMAN NM23-H1, A METASTASIS SUPPRESSOR GENE	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN BREAST-CARCINOMA; MESSENGER-RNA; GOOD PROGNOSIS; EXPRESSION; CANCER; OVEREXPRESSION; AMPLIFICATION; ASSOCIATION; PRODUCT	Allelic deletions in the nm23, a metastasis suppressor gene, are known to occur in neuroblastomas, breast and colorectal carcinomas. Down-regulation of nm23 expression has been reported in various rodent and human tumor cells with high metastasis phenotype. Colorectal tumors showed overexpression of nm23. To elucidate the regulatory mechanisms of nm23, we isolated, cloned and sequenced the presumptive regulatory DNA fragment spanning the 5' region of the human nm23-H1 gene. The region's nucleotide sequence shows the presence of motifs typical for transcriptional elements such as TFIID, AP-1 and CTF/NF1. A common transcription initiation site is located at - 136 upstream from the first ATG codon in placenta tissue, in breast, colorectal, prostate tumor cell lines and in primary colorectal tumor. Multiple transcription start sites were identified in tumor cell lines and colorectal tumor. When the promoter element was linked to a reporter gene, chloramphenicol acetyltransferase (CAT) and transfected in human 2fTGH cells, strong CAT activity was detected, which also showed that the presence of AP-1 and CTF/NF1 elements are essential for promoter activity. A detailed study of the structure and function of the promoter element of the nm23-H1 gene will help in understanding the regulatory mechanisms of nm23 expression and its role in tumor progression, especially in metastasis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BACKER JM, 1993, ONCOGENE, V8, P497; BEVILACQUA G, 1989, CANCER RES, V49, P5185; CLARK GM, 1991, CANCER RES, V51, P944; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FLORENES VA, 1992, CANCER RES, V52, P6088; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HONOKI K, 1993, CANCER RES, V53, P5038; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LASKO M, 1992, CELL GROWTH DIFFER, V3, P876; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; Maniatis T, 1989, DECONTAMINATION DILU; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RADINSKY R, 1992, CANCER RES, V52, P5808; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKINNER A, 1993, ONCOGENE, V8, P3393; STAHL JA, 1991, CANCER RES, V51, P445; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; WANG LM, 1993, CANCER RES, V53, P717	36	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2905	2912						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084595				2022-12-25	WOS:A1994PG82200016
J	GALANG, CK; DER, CJ; HAUSER, CA				GALANG, CK; DER, CJ; HAUSER, CA			ONCOGENIC RAS CAN INDUCE TRANSCRIPTIONAL ACTIVATION THROUGH A VARIETY OF PROMOTER ELEMENTS, INCLUDING TANDEM C-ETS-2 BINDING-SITES	ONCOGENE			English	Article							NF-KAPPA-B; C-JUN ACTIVITY; GENE-EXPRESSION; PROTEIN-KINASE; SIGNAL TRANSDUCTION; REQUIRES RAF-1; DOMAIN; CELLS; PHOSPHORYLATION; TRANSACTIVATION	Oncogenic Ras activates the transcription of a variety of viral and cellular genes through promoter elements consisting of two closely linked binding sites for transcription factors from several distinct families. To better understand what constitutes a promoter oncogene response element (ORE), various transcription factor binding site configurations were inserted into a reporter gene, and transactivation by oncogenic Ras was measured by cotransfection assays in NIH3T3 cells. We show that a single copy of two closely linked binding sites for either AP-1, Ets, NF-kappa B, or single closely linked Ets and AP-1 binding sites, are sufficient to confer at least 10-fold transactivation by similar amounts of oncogenic Ras. Single binding sites for these factors, or several other pairings of binding sites, are not sufficient to confer Ras responsiveness. The effect of altered ORE binding site spacing and orientation was systematically analysed, and limited flexibility was observed. The novel observation that two adjacent c-Ets-2 binding sites are sufficient to act as an ORE, indicates that Ets family proteins are a target of the Ras pathway distinct from AP-1. This ORE also mediates equivalent transactivation by c-Ets-2, and mutant OREs show a parallel decrease in Ras and c-Ets-2 responsiveness. Together, these data help to define transcriptional targets of the Ras signal transduction pathway.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Der, Channing/0000-0002-7751-2747	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028525] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NICHD NIH HHS [HD28525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COFFER P, 1994, ONCOGENE, V9, P911; DER CJ, 1988, ONCOGENE, V3, P105; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HERBOMEL P, 1990, New Biologist, V2, P1063; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETH A, 1993, ONCOGENE, V8, P1783; SIF S, 1993, ONCOGENE, V8, P2501; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	53	129	130	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2913	2921						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084596				2022-12-25	WOS:A1994PG82200017
J	LACHAAL, M; MORONSKI, C; LIU, HZ; JUNG, CY				LACHAAL, M; MORONSKI, C; LIU, HZ; JUNG, CY			BREFELDIN-A INHIBITS INSULIN-INDUCED GLUCOSE-TRANSPORT STIMULATION AND GLUT4 RECRUITMENT IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; CELL-SURFACE; RECEPTOR INTERNALIZATION; ORGANELLE STRUCTURE; PLASMA-MEMBRANE; OKADAIC ACID; BETA-COP; TRANSLOCATION; ENDOSOMES; PROTEIN	GLUT4, the major insulin-responsive glucose transporter isoform in rat adipocytes, rapidly recycles between an intracellular pool and the plasma membrane in the basal and insulin-stimulated states. To gain insight into the route of this GLUT4 recycling, we studied the effects of brefeldin A (BFA) on glucose transport and glucose transporter subcellular distribution in rat adipocytes in the absence and in the presence of insulin. 3-O-Methyl-D-glucose equilibrium exchange measurements revealed that BFA inhibits insulin-stimulated glucose transport by as much as 80%, whereas the inactive BFA analog, B36, was without effect. The inhibition was reversible and was a saturable function of BFA concentration with an apparent K-i of less than 1 mu M. In the absence of insulin, on the other hand, BFA caused a slight (up to 2-fold) increase in glucose transport. Subcellular fractionation and semiquantitative immunoblotting analysis revealed that BFA inhibits insulin-induced redistribution of GLUT4 from microsomes to the plasma membranes, with a dose dependence similar to that for glucose transport inhibition. BFA also caused a slight increase in the plasma membrane GLUT4 level in the absence of insulin. BFA did not affect the subcellular distribution of GLUT1 in these experiments. These findings strongly suggest that GLUT4 recycling in rat adipocytes involves a BFA-sensitive, coat protein-mediated, membrane budding step, which is distinct between the constitutive and the insulin induced pathways.	SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	LACHAAL, M (corresponding author), VET ADM MED CTR, BIOPHYS LAB, BUFFALO, NY 14215 USA.				NIDDK NIH HHS [DK17736] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAMKE H, 1991, J BIOL CHEM, V266, P24829; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLADHAUG IP, 1988, J BIOL CHEM, V263, P12199; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JACOBS DB, 1984, J CLIN INVEST, V74, P1679, DOI 10.1172/JCI111584; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOW SH, 1991, J BIOL CHEM, V266, P17729; MARTZ A, 1986, J BIOL CHEM, V261, P3606; OKA Y, 1985, J BIOL CHEM, V260, P9435; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEIN BS, 1986, J BIOL CHEM, V261, P319; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	32	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23689	23693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089139				2022-12-25	WOS:A1994PQ34500047
J	BALBIN, M; HALL, A; GRUBB, A; MASON, RW; LOPEZOTIN, C; ABRAHAMSON, M				BALBIN, M; HALL, A; GRUBB, A; MASON, RW; LOPEZOTIN, C; ABRAHAMSON, M			STRUCTURAL-CHARACTERIZATION AND FUNCTIONAL-CHARACTERIZATION OF 2 ALLELIC VARIANTS OF HUMAN CYSTATIN-D SHARING A CHARACTERISTIC INHIBITION SPECTRUM AGAINST MAMMALIAN CYSTEINE PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C AMYLOID ANGIOPATHY; EGG-WHITE CYSTATIN; HUMAN WHOLE SALIVA; ESCHERICHIA-COLI; ALZHEIMER-DISEASE; CHICKEN CYSTATIN; APOLIPOPROTEIN-E; CATHEPSIN-H; IDENTIFICATION; GENE	Human cystatin D is a novel member of the cystatin superfamily of cysteine proteinase inhibitors present in saliva and tears. Two alleles of the cystatin D gene (CST5), encoding protein variants with either Cys or Arg as residue 26 in their 122-residue polypeptide chains, are present in the population. Expression of the two alleles was investigated by immunochemical analyses of the secreted cystatin D in saliva from individuals homozygous for each of the two alleles, with results demonstrating that both are expressed at similar levels. The inhibitory characteristics of the two cystatin D variants were studied, by determination of dissociation equilibrium constants (K-i) for their complexes with papain and with the mammalian cysteine proteinases, cathepsins B, H, L, and S. The results demonstrate that 1) cystatin D has a characteristic inhibition profile since it does not inhibit cathepsin B (K-i > 1 mu M), and when compared to cystatin C and all other known cystatins it is a much poorer inhibitor of cathepsin L (mean K-i 25 nM) but binds cathepsin H and S relatively tightly (mean K-i values of 8.5 and 0.24 nM, respectively); and 2) the inhibitory activities of the two cystatin D variants are not significantly different, demonstrating that the presence of an extra cysteine residue in the cystatin D molecule affects neither the stability nor the functional activity of the inhibitor, thus explaining the widespread distribution of the Cys(26)-cystatin D encoding allele in the population. The inhibitory properties displayed by cystatin D suggest that it has a function in saliva as inhibitor of either endogenous or exogenous enzymes with cathepsin S- or H-like properties.	UNIV LUND HOSP, DEPT CLIN CHEM, S-22185 LUND, SWEDEN; UNIV OVIEDO, FAC MED, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM, BLACKSBURG, VA 24061 USA	Lund University; Skane University Hospital; University of Oviedo; Virginia Polytechnic Institute & State University			Balbín, Milagros/I-4206-2015; Abrahamson, Magnus/CAG-9507-2022; Lopez-Otin, Carlos/AAB-2106-2020	Balbín, Milagros/0000-0001-5325-0407; Lopez-Otin, Carlos/0000-0001-6964-1904; Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1994, IN PRESS METHODS ENZ, V244; BALBIN M, 1993, HUM GENET, V90, P668; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1984, BIOCHEM BIOPH RES CO, V120, P631, DOI 10.1016/0006-291X(84)91302-0; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BJORCK L, 1990, J VIROL, V64, P941; BJORK I, 1992, FEBS LETT, V299, P66, DOI 10.1016/0014-5793(92)80102-M; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS AR, 1991, ANTIMICROB AGENTS CH, V35, P2444, DOI 10.1128/AAC.35.11.2444; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; Davis LG, 1986, BASIC METHODS MOL BI, P42; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; FREIJE JP, 1993, CYTOGENET CELL GENET, V62, P29, DOI 10.1159/000133438; GARCIA JA, 1993, PLANT MOL BIOL, V22, P697, DOI 10.1007/BF00047410; HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; ISEMURA S, 1987, J BIOCHEM-TOKYO, V102, P693, DOI 10.1093/oxfordjournals.jbchem.a122107; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KORANT BD, 1985, BIOCHEM BIOPH RES CO, V127, P1072, DOI 10.1016/S0006-291X(85)80054-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; OLAFSSON I, 1990, SCAND J CLIN LAB INV, V50, P85, DOI 10.3109/00365519009091569; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; SCHNITTGER S, 1993, GENOMICS, V16, P50, DOI 10.1006/geno.1993.1139; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; XIE B, 1992, AM J HUM GENET, V50, P1046; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3	49	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23156	23162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083219				2022-12-25	WOS:A1994PQ16400041
J	KHACHIGIAN, LM; FRIES, JWU; BENZ, MW; BONTHRON, DT; COLLINS, T				KHACHIGIAN, LM; FRIES, JWU; BENZ, MW; BONTHRON, DT; COLLINS, T			NOVEL CIS-ACTING ELEMENTS IN THE HUMAN PLATELET-DERIVED GROWTH-FACTOR B-CHAIN CORE PROMOTER THAT MEDIATE GENE-EXPRESSION IN CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; SMOOTH-MUSCLE CELLS; ALTERNATIVELY SPLICED EXON; TRANSCRIPTION FACTOR NF-E2; LEUCINE ZIPPER PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; PDGF-B; SIS GENE; REGULATORY ELEMENTS	Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant constitutively expressed by a variety of normal and transformed cells. Transient transfection and deletion analysis of the human c-sis proto-oncogene in cultured vascular endothelial cells revealed a minimal core promoter region extending 82 base pairs upstream from the TATA box. Two novel and functional cis-acting elements were identified within the core that share considerable sequence homology with consensus binding elements for transacting factors of the ETS class and those involved in AP-1 complexes. Deletion or mutation of either the ETS-like site or the AP-1-like site resulted in significant attenuation in the ability of the core to drive transcription. Electrophoretic mobility shift assays revealed that proteins from bovine aortic and human umbilical vein endothelial nuclear extracts bound to these elements in a specific manner and that both sites were essential for protein binding. Ferguson analysis predicted a combined molecular mass of 153 kDa for these proteins. In addition, transient transfection, gel shift, and DNase I footprint analysis were used to identify a functional Sp1 binding site downstream of these elements in the core promoter By localizing the functional cis-acting elements in the PDGF-B promoter, it may be possible to elucidate the normal transcriptional control of the gene, as well as the mechanisms that activate it in pathologic settings.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV EDINBURGH, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Edinburgh; University of Edinburgh			Fries, Jochen/AAM-5999-2020; Khachigian, Levon/AAZ-7458-2020	Fries, Jochen/0000-0003-2054-6345; Bonthron, David/0000-0001-8132-8179; Khachigian, Levon/0000-0003-3446-0323	NHLBI NIH HHS [HL 45462, HL 35716] Funding Source: Medline; PHS HHS [P01 36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BARTRAM CR, 1984, BLOOD, V63, P223; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BONTHRON DT, 1991, GENOMICS, V10, P287, DOI 10.1016/0888-7543(91)90515-G; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CALDERON TM, 1992, CELL IMMUNOL, V143, P118, DOI 10.1016/0008-8749(92)90010-M; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COLLINS T, 1987, AM J PATHOL, V126, P7; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; FRIES JWU, 1993, AM J PATHOL, V143, P725; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAJJAR KA, 1987, J EXP MED, V166, P235, DOI 10.1084/jem.166.1.235; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HOHEISEL J, 1986, NUCLEIC ACIDS RES, V14, P3605, DOI 10.1093/nar/14.8.3605; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAETZEL DM, 1993, BIOFACTORS, V4, P71; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P7478; KHACHIGIAN LM, 1993, PLATELETS, V4, P304, DOI 10.3109/09537109309013233; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MAY G, 1991, J BIOL CHEM, V266, P3052; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NAWROTH PP, 1993, TRANSPLANT P, V25, P2052; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; ORCHARD K, 1992, NUCLEIC ACIDS RES, V20, P5429, DOI 10.1093/nar/20.20.5429; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RAO VN, 1992, ONCOGENE, V7, P2335; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SUZUKI H, 1989, AM J PATHOL, V134, P35; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	82	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22647	22656						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077216				2022-12-25	WOS:A1994PQ16300032
J	ZHENG, YW; RIEGLER, J; WU, J; YEN, TSB				ZHENG, YW; RIEGLER, J; WU, J; YEN, TSB			NOVEL SHORT TRANSCRIPTS OF HEPATITIS-B VIRUS-X GENE DERIVED FROM INTRAGENIC PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL REPLICATION; TRANS-ACTIVATION; III-PROMOTERS; EXPRESSION; PROTEIN; INITIATION; ENHANCER; CELLS; TRANSACTIVATION; IDENTIFICATION	The hepatitis B virus X gene encodes a transcriptional trans-activator that appears essential for viral replication in the infected liver. It has been shown by others that at least two X protein products, initiating at different in-frame ATG codons within the X open reading frame, are necessary for full trans-activating function. Yet, previous studies have demonstrated only a full-length X gene transcript that extends 5' of the first ATG codon in the X open reading frame. In this communication, we present evidence for the existence of shorter X gene transcripts, whose heterogeneous 5' ends straddle the second ATG codon of the X open reading frame. These transcripts are not degradation products of the full-length X gene transcripts but rather arise from an independent promoter. Furthermore, immunofluorescence and functional analyses reveal that active X proteins are translated from these transcripts. Therefore, there appears to be a previously undescribed promoter embedded within the X open reading frame that can give rise to functionally important transcripts.	VET AFFAIRS MED CTR, SERV ANAT PATHOL, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, CTR LIVER, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco								AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BLUM HE, 1991, J VIROL, V65, P1836, DOI 10.1128/JVI.65.4.1836-1842.1991; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; FAKTOR O, 1990, ONCOGENE, V5, P867; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUO WT, 1991, VIROLOGY, V181, P630, DOI 10.1016/0042-6822(91)90896-J; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLINGER FB, 1990, VIROLOGY, P2171; HUANG ZM, 1993, J VIROL, V67, P7032, DOI 10.1128/JVI.67.12.7032-7040.1993; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LIN KH, 1991, BIOTECHNIQUES, V11, P748; NAKATAKE H, 1993, VIROLOGY, V195, P305, DOI 10.1006/viro.1993.1381; SAMBROOK J, MOL CLONING LABORATO; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; SCHEK N, 1991, ONCOGENE, V6, P1735; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WU XN, 1993, J VIROL, V67, P5833, DOI 10.1128/JVI.67.10.5833-5842.1993; YAGINUMA K, 1993, J VIROL, V67, P2559, DOI 10.1128/JVI.67.5.2559-2565.1993; YEN TSB, 1993, SEMIN VIROL, V4, P33; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZHOU DX, 1990, J BIOL CHEM, V265, P20731; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	35	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22593	22598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077209				2022-12-25	WOS:A1994PQ16300024
J	SAWYER, JT; LUKACZYK, T; YILLA, M				SAWYER, JT; LUKACZYK, T; YILLA, M			DITHIOTHREITOL TREATMENT INDUCES HETEROTYPIC AGGREGATION OF NEWLY SYNTHESIZED SECRETORY PROTEINS IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; PLASMA-PROTEINS; IMMUNOGLOBULIN; CALCIUM; HEMAGGLUTININ; BIOSYNTHESIS; RECEPTOR; EXPORT; GOLGI	To analyze the importance of the endoplasmic reticulum oxidizing state for the folding and aggregation of newly made polypeptides, we have incubated intact HepG2 hepatoma cells in the presence of dithiothreitol. When dithiothreitol-treated cells were extracted under nondenaturing conditions immunoprecipitates of newly synthesized albumin showed a complex polypeptide profile. Using direct and sequential immunoprecipitation protocols we identified eight other polypeptide chains, transferrin, plasminogen, ceruloplasmin, cu,macroglobulin, the three fibrinogen chains, and haptoglobin, that were among the proteins co-immunoprecipitated with albumin. The heterotypic aggregates are larger than several hundred kilodaltons and are stabilized by noncovalent interactions. Of the 10 polypeptide chains we examined, only one, alpha(1)-antitrypsin, failed to aggregate. This protein is distinguished from the others by the absence of disulfide bonds, We propose a model in which the function of the oxidizing conditions of the endoplasmic reticulum is to promote the rapid formation of disulfide bonds that stabilize adhesive domains in a buried state, thus preventing ''global'' heterotypic aggregation of newly synthesized chains.			SAWYER, JT (corresponding author), SUNY BUFFALO, DEPT BIOL SCI, 109 COOKE HALL, BUFFALO, NY 14260 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ANDERSON L, 1977, P NATL ACAD SCI USA, V74, P5421, DOI 10.1073/pnas.74.12.5421; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; COLAU B, 1984, DNA-J MOLEC CELL BIO, V3, P327, DOI 10.1089/dna.1.1984.3.327; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; HILLE A, 1989, J BIOL CHEM, V264, P13460; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIM PS, 1991, J BIOL CHEM, V266, P12412; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MORGAN EH, 1985, J BIOL CHEM, V260, P4793; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETERS T, 1982, J BIOL CHEM, V257, P8847; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	30	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22440	22445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071373				2022-12-25	WOS:A1994PE09800077
J	TAMURA, K; NAMEKI, N; HASEGAWA, T; SHIMIZU, M; HIMENO, H				TAMURA, K; NAMEKI, N; HASEGAWA, T; SHIMIZU, M; HIMENO, H			ROLE OF THE CCA TERMINAL SEQUENCE OF TRNA(VAL) IN AMINOACYLATION WITH VALYL-TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; GLUTAMINYL-TRANSFER RNA; TYROSYL-TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; ESCHERICHIA-COLI; IDENTITY DETERMINANTS; BACILLUS-STEAROTHERMOPHILUS; COGNATE SYNTHETASE; ACCEPTOR ACTIVITY; TRANSFER RNA(TYR)	All known tRNAs have a universal CCA sequence at the 3'-terminal. To study the role of this terminal sequence in the aminoacylation process, base substitutions were introduced into a transcript of Escherichia coli valine tRNA and the effects on the aminoacylation activity with valyl-tRNA synthetase were evaluated. Substitution of the terminal adenosine residue at position 76 by C or U caused a 5-7-fold decrease of valine charging activity in V-max/K-m, while substitution by G resulted in about a 300-fold decrease. In addition, these mutations gave rise to an appreciable level of misaminoacylation with threonine. ATP hydrolysis activity during threonylation was lower in the terminal adenosine mutants than in the wild-type. Mutations introduced at positions 75 and 74 also caused threonylation instead of reducing valylation, albeit to a much smaller extent. These results indicate that the CCA sequence, especially the base portion of the terminal adenosine residue, plays an important role not only in aminoacylation efficiency with valine but also in preventing misaminoacylation by hydrolyzing misactivated threonyl-tRNA(Val).	HIROSAKI UNIV,FAC SCI,DEPT BIOL,HIROSAKI 036,AOMORI,JAPAN; INST SPACE & ASTRONAUT SCI,SAGAMIHARA,KANAGAWA 229,JAPAN	Hirosaki University; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS)			Nameki, Nobukazu/H-1764-2013; Himeno, Hyouta/E-8703-2010					ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CHAKRABURTTY K, 1975, NUCLEIC ACIDS RES, V2, P1793, DOI 10.1093/nar/2.10.1793; CHU WC, 1991, BIOCHEMISTRY-US, V30, P1655, DOI 10.1021/bi00220a031; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FREIST W, 1987, EUR J BIOCHEM, V169, P33, DOI 10.1111/j.1432-1033.1987.tb13577.x; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P9081, DOI 10.1093/nar/15.21.9081; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HECK JD, 1988, J BIOL CHEM, V263, P868; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; IGLOI GL, 1977, BIOCHEMISTRY-US, V16, P1696, DOI 10.1021/bi00627a027; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; KERN D, 1979, BIOCHEMISTRY-US, V18, P5819, DOI 10.1021/bi00593a011; KIM HY, 1993, P NATL ACAD SCI USA, V90, P11553, DOI 10.1073/pnas.90.24.11553; KIRSCHENBAUM AH, 1976, BIOCHEM BIOPH RES CO, V70, P258, DOI 10.1016/0006-291X(76)91136-0; KUCAN Z, 1971, NATURE-NEW BIOL, V232, P177, DOI 10.1038/newbio232177a0; LABOUZE E, 1989, J MOL BIOL, V205, P729, DOI 10.1016/0022-2836(89)90317-3; LAGERKVI.U, 1967, J BIOL CHEM, V242, P3021; MAELICKE A, 1974, EUR J BIOCHEM, V43, P617, DOI 10.1111/j.1432-1033.1974.tb03449.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MURAMATSU T, 1992, NUCLEOS NUCLEOT NUCL, V11, P719, DOI 10.1080/07328319208021736; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; NISHIMURA S, 1967, BIOCHIM BIOPHYS ACTA, V142, P133, DOI 10.1016/0005-2787(67)90522-9; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY KL, 1967, BIOCHEMISTRY-US, V6, P2847, DOI 10.1021/bi00861a027; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1973, J BIOL CHEM, V248, P1341; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1977, BIOCHEMISTRY-US, V16, P4256, DOI 10.1021/bi00638a020; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SHIMIZU M, 1992, J MOL EVOL, V35, P436; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; SPRINZL M, 1972, EUR J BIOCHEM, V25, P262, DOI 10.1111/j.1432-1033.1972.tb01692.x; SPRINZL M, 1973, EUR J BIOCHEM, V34, P306, DOI 10.1111/j.1432-1033.1973.tb02759.x; TAMURA K, 1991, BIOCHEM BIOPH RES CO, V177, P619, DOI 10.1016/0006-291X(91)91833-X; Tamura K, 1991, J Mol Recognit, V4, P129, DOI 10.1002/jmr.300040404; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; URETSKY SC, 1968, J BIOL CHEM, V243, P306; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; VONDERHAAR F, 1975, P NATL ACAD SCI USA, V72, P1378; WARD DC, 1969, J BIOL CHEM, V244, P3243	70	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22173	22177						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071341				2022-12-25	WOS:A1994PE09800040
J	DEVLIN, J; KEEN, AJ; KNOWLES, MA				DEVLIN, J; KEEN, AJ; KNOWLES, MA			HOMOZYGOUS DELETION MAPPING AT 9P21 IN BLADDER-CARCINOMA DEFINES A CRITICAL REGION WITHIN 2CM OF IFNA	ONCOGENE			English	Note							ALLELIC LOSSES; SHORT ARM; CHROMOSOME-9; CANCER; MELANOMA	We have screened 165 cases of primary transitional cell carcinoma of the bladder for loss of heterozygosity of markers on chromosome 9. High density deletion mapping was then carried out on a panel of 16 tumours with partial deletions of 9p using 15 microsatellite markers. Seven tumours had hemizygous deletions which included small interstitial losses and large terminal deletions. Homozygous deletions of one or more markers were identified in the remaining 9 tumours. By comparing the limits of hemi- and homozygous deletions in these tumours we have defined a single common region of 2cM flanked by IFNA and D9S171.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED,SURREY RH8 0TL,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P1; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MERLO A, 1994, CANCER RES, V54, P2322; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; POVEY S, 1994, IN PRESS ANN HUM GEN; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; STADLER WM, 1994, CANCER RES, V54, P2060; TSAI YC, 1990, CANCER RES, V50, P44; VANDERRIET P, 1994, CANCER RES, V54, P1156	27	66	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2757	2760						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058343				2022-12-25	WOS:A1994PC05400041
J	REABAN, ME; LEBOWITZ, J; GRIFFIN, JA				REABAN, ME; LEBOWITZ, J; GRIFFIN, JA			TRANSCRIPTION INDUCES THE FORMATION OF A STABLE RNA-CENTER-DOT-DNA HYBRID IN THE IMMUNOGLOBULIN-ALPHA SWITCH REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR TRIPLEX FORMATION; SUPERCOILED PLASMID DNA; C-MYC GENE; HELICAL DNA; H-DNA; STRANDED POLYNUCLEOTIDES; RECA PROTEIN; SEQUENCES; RECOMBINATION; INDUCTION	We previously showed that the in vitro transcription of a negatively supercoiled plasmid containing the murine IgA switch region caused the formation of fewer supercoiled conformers of the plasmid due to the presence of a stable RNA.DNA hybrid. Here, we demonstrate that the RNA.DNA hybrid is approximately 140 nucleotides, and it forms regardless of the initial topological state of the transcription template. Transcription of the switch region in a relaxed closed circular plasmid generates positively supercoiled plasmid conformers that revert to their original relaxed state when treated with RNase H. conformers that have incorporated a stable RNA transcript are also observed when nicked circular and linear plasmids containing the IgA switch sequences are transcribed with P-32-labeled nucleotide triphosphates. Once formed, the RNA.DNA hybrid is stable to both thermal and superhelical stress, tolerating temperatures in excess of 95 degrees C and restraining approximately 12 positive supercoils in the plasmid.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT BIOL MOLEC,RIDGEFIELD,CT 06877; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Boehringer Ingelheim; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI 23694] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023694] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS SM, 1991, FOCUS, V13, P56; ARNOTT S, 1973, NATURE-NEW BIOL, V244, P99, DOI 10.1038/newbio244099a0; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; CHEN FM, 1991, BIOCHEMISTRY-US, V30, P4472, DOI 10.1021/bi00232a014; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; GAGO F, 1989, FEBS LETT, V242, P270, DOI 10.1016/0014-5793(89)80483-1; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1991, NUCLEIC ACIDS RES, V19, P4267, DOI 10.1093/nar/19.15.4267; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REABAN ME, 1990, NATURE, V351, P447; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; Singer B., 1983, MOL BIOL MUTAGENS CA; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAGIL G, 1986, EMBO J, V5, P1719, DOI 10.1002/j.1460-2075.1986.tb04416.x	42	107	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21850	21857						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063829				2022-12-25	WOS:A1994PK97300069
J	TREJO, J; MASSAMIRI, T; DENG, TL; DEWJI, NN; BAYNEY, RM; BROWN, JH				TREJO, J; MASSAMIRI, T; DENG, TL; DEWJI, NN; BAYNEY, RM; BROWN, JH			A DIRECT ROLE FOR PROTEIN-KINASE-C AND THE TRANSCRIPTION FACTOR JUN/AP-1 IN THE REGULATION OF ALZHEIMERS BETA-AMYLOID PRECURSOR PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DNA-BINDING; TRANSGENIC MICE; MESSENGER-RNA; PHORBOL ESTER; GROWTH-FACTOR; RECEPTOR ACTIVATION; FOS PROTEINS; FACTOR AP-2; JUN	Overexpression of the beta-amyloid precursor protein gene (beta-APP) may contribute to the abnormal generation of beta-amyloid protein in Alzheimer's disease. We demonstrate using a human glial cell line (1321N1) that activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (PMA) increases beta-APP mRNA levels, induces known components of the transcription factor activator protein-1 (AP-1), and increases protein-DNA binding activity to AP-1 sequences within the beta-APP promoter. A beta-APP promoter-luciferase reporter gene is transcriptionally activated by PMA, as well as by expression of constitutively activated PKC or by expression of c-Jun. Further characterization suggests that the distal but not the proximal AP-1 recognition site binds nuclear proteins regulated by PKC, and that the AP-1 binding activity is likely to be composed of Jun-Jun homodimers rather than Jun-Fos heterodimers. Additional studies demonstrate that a single copy of the distal AP-1 site fused to a heterologous promoter is sufficient to confer a response to PMA. Mutagenesis of this site in the beta-APP promoter renders it unresponsive to c-Jun and attenuates transcriptional activation by PMA. We suggest that cellular mediators that activate PKC, particularly those that induce significant increases in c-Jun, may up-regulate expression of the beta-APP gene and consequently affect production and processing of this protein.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92093 USA; MOLEC THERAPEUT INC, MILES RES CTR, West Haven, CT 06516 USA	University of California System; University of California San Diego; University of California System; University of California San Diego				TREJO, JOANN/0000-0003-4405-6228	NIA NIH HHS [AG00216] Funding Source: Medline; NIGMS NIH HHS [GM 36927] Funding Source: Medline; NINDS NIH HHS [NS27580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027580] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWJI NN, 1990, J MOL NEUROSCI, V2, P19, DOI 10.1007/BF02896922; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDHU FA, 1991, J BIOL CHEM, V266, P21331; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TREJO J, 1991, J BIOL CHEM, V266, P7876; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	62	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21682	21690						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063812				2022-12-25	WOS:A1994PK97300048
J	CROUSE, BR; YANO, T; FINNEGAN, MG; YAGI, T; JOHNSON, MK				CROUSE, BR; YANO, T; FINNEGAN, MG; YAGI, T; JOHNSON, MK			PROPERTIES OF THE IRON-SULFUR CENTER IN THE 25-KILODALTON SUBUNIT OF THE PROTON-TRANSLOCATING NADH-QUINONE OXIDOREDUCTASE OF PARACOCCUS-DENITRIFICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; SITE-DIRECTED MUTAGENESIS; AMINO-ACID SEQUENCE; 2FE-2S FERREDOXIN; ESCHERICHIA-COLI; RESONANCE RAMAN; UBIQUINONE OXIDOREDUCTASE; 24-KDA SUBUNIT; COMPLEX-I; CLOSTRIDIUM-PASTEURIANUM	The 25-kDa subunit of the proton-translocating NADH-quinone oxidoreductase (NDH-1) of Paracoccus denitrificans has been expressed in Escherichia coli and purified to homogeneity. EPR studies of the reduced recombinant protein indicated that the expressed subunit contains a single [2Fe-2S] cluster (Yano, T., Sled', V. D., Ohnishi, T., and Yagi, T. (1994) Biochemistry 33, 494-499). In this report, the electronic, magnetic, and vibrational properties of the [2Fe-2S](2+,+) center have been investigated by the combination of absorption, circular dichroism, variable-temperature magnetic circular dichroism, electron paramagnetic resonance, and resonance Raman spectroscopies and compared with a range of simple [2Fe-2S]-containing proteins. The results are consistent with coordination by two cysteinyl residues at both the reducible and nonreducible iron sites and reveal a striking similarity between the properties of the [2Fe-2S] cluster in the P. denitrificans NDH-1 25-kDa subunit and those of the subclass of ferredoxin-type [2Fe-2S] centers typified by Clostridium pasteurianum 2Fe ferredoxin. The four cyteines residues involved in cluster ligation in these proteins have been tentatively identified based on sequence homology considerations.	UNIV GEORGIA, DEPT CHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Scripps Research Institute					NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [R01-GM51962, R01-GM33712] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM051962] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCHER CD, 1993, P NATL ACAD SCI USA, V90, P9877, DOI 10.1073/pnas.90.21.9877; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BERTRAND P, 1985, BIOCHIM BIOPHYS ACTA, V831, P261, DOI 10.1016/0167-4838(85)90044-5; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CARDENAS J, 1976, BIOCHIM BIOPHYS ACTA, V434, P244, DOI 10.1016/0005-2795(76)90056-8; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; CHOMYN A, 1989, CURR GENET, V16, P117, DOI 10.1007/BF00393404; CUPP JR, 1988, J BIOL CHEM, V263, P17418; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DERVARTANIAN DV, 1979, BIOCHIM BIOPHYS ACTA, V194, P548; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; FEE JA, 1984, J BIOL CHEM, V259, P124; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; FU WG, 1992, J BIOL CHEM, V267, P15502; FUJINAGA J, 1993, BIOCHEM BIOPH RES CO, V194, P104, DOI 10.1006/bbrc.1993.1791; GERBER NC, 1990, BIOCHEM BIOPH RES CO, V169, P1016, DOI 10.1016/0006-291X(90)91995-5; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAMILTON CL, 1989, J BIOL CHEM, V264, P11605; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Hardy R. W. F., 1965, NONHEME IRON PROTEIN, P275; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATEFI Y, 1985, ENZYMES BIOL MEMBR, P1; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; JOHNSON MK, 1988, ACS SYM SER, V372, P326; JOHNSON MK, 1994, IN PRESS ENCY INORGA; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN R, 1992, J BIOL CHEM, V267, P25625; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MEINHARDT SW, 1987, J BIOL CHEM, V262, P9147; MEYER J, 1986, BIOCHEMISTRY-US, V25, P6054, DOI 10.1021/bi00368a033; NISHIKIMI M, 1988, BIOCHEM BIOPH RES CO, V157, P914, DOI 10.1016/S0006-291X(88)80961-6; PILKINGTON SJ, 1989, BIOCHEMISTRY-US, V28, P3257, DOI 10.1021/bi00434a021; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; STEINRUCKE P, 1993, FEMS MICROBIOL LETT, V104, P83, DOI 10.1111/j.1574-6968.1993.tb05865.x; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; STOUTHAMER AH, 1992, ANTON LEEUW INT J G, V61, P1, DOI 10.1007/BF00572119; STOUTHAMER AH, 1991, J BIOENERG BIOMEMBR, V23, P163, DOI 10.1007/BF00762216; TA DT, 1992, J BIOL CHEM, V267, P11120; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; VONBAHRLINDSTROM H, 1983, EUR J BIOCHEM, V134, P145; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; WERTH MT, 1992, FEBS LETT, V299, P1, DOI 10.1016/0014-5793(92)80086-V; XU XM, 1992, BIOCHEMISTRY-US, V31, P6925, DOI 10.1021/bi00145a009; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAGI T, 1990, BIOCHEMISTRY-US, V29, P5515, DOI 10.1021/bi00475a015; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1992, BIOCHIM BIOPHYS ACTA, V1101, P181, DOI 10.1016/S0005-2728(05)80014-3; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; Yano T., 1993, Biological Chemistry Hoppe-Seyler, V374, P820	67	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21030	21036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063721				2022-12-25	WOS:A1994PC40300035
J	SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M				SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M			THE UTEROGLOBIN PROMOTER TARGETS EXPRESSION OF THE SV40 T-ANTIGEN TO A VARIETY OF SECRETORY EPITHELIAL-CELLS IN TRANSGENIC MICE	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; RABBIT UTEROGLOBIN; GENE REGION; HORMONAL-REGULATION; RIBONUCLEIC-ACID; RAT; PROTEIN; LUNG; TRANSCRIPTION; ENDOMETRIUM	Adenocarcinomas derived from the lining epithelia of various organs are the most common malignant tumors in human pathology and about 50% are hormone dependent. The tissue-specific and hormally regulated expression of the rabbit uteroglobin gene is secretory epithelial cells could provide a means of establishing in vivo models for a variety of human tumors originating from such tissues. We have generated trangenic mice inheriting a hybrid gene containing 4.7 kb of the rabbit uteroglobin 5'-flanking sequences fused to the SV40 T antigen encoding region. All transgenic founders examined exhibited bronchio-alveolar adenocarcinomas, probably due to expression of the transgene in Clara cells. Most founders also developed tumors of the submandibular salivary gland, and adenocarcinomas of the stomach. Adenocarcinomas and dysplasias in epithelial cells of the male and female genital tract were found in single founders. Immunohistochemical analysis showed that T antigen expression interfered with stable maintenance of the differentiated phenotype as documented by expression of the endogenous uteroglobin gene. One founder gave rise to a mouse Line, UT7.1. Transgenic descendants of UT7.1 developed lung adenocarcinomas and, depending on the genetic background, exhibited tumors of the stomach, the salivery gland and the pancreas. Sporadically male descendants developed prostatic adenocarcinoma whereas females developed dysplasias and adenocarcinomas of the uterus and the oviduct. Thus, the UT7.1 mouse line could be a useful model for several epithelial neoplasias.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; FRAUNHOFER INST TOXIKOL & MOLEK BIOL,D-30625 HANNOVER 41,GERMANY; UNIV MARBURG,MED ZENTRUM PATHOL,D-35033 MARBURG,GERMANY	Philipps University Marburg; Fraunhofer Gesellschaft; Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				BEATO M, 1978, J REPROD FERTIL, V53, P305; BEATO M, 1983, REGULATION GENE EXPR, P151; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1975, CELL TISSUE RES, V165, P1; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEHARO MSL, 1985, BIOCHEM J, V225, P255; DEHARO MSL, 1988, BIOCHEM J, V250, P647, DOI 10.1042/bj2500647; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DEMAYO FJ, 1991, MOL ENDOCRINOL, V5, P311, DOI 10.1210/mend-5-3-311; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HEINS B, 1981, MOL CELL ENDOCRINOL, V17, P71; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; HOGAN B, 1986, MANIPULATING MOUSE E; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; JEFFERY PK, 1983, AM REV RESPIR DIS, V128, P14; KAY E, 1972, BIOCHIM BIOPHYS ACTA, V271, P436, DOI 10.1016/0005-2795(72)90219-X; KIRCHNER C, 1976, CELL TISSUE RES, V170, P415, DOI 10.1007/BF00219420; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; KULKA U, 1993, MUTAGENESIS, V8, P193, DOI 10.1093/mutage/8.3.193; KURMAN RJ, 1987, ENDOMETRIAL CARCINOM; Maniatis T., 1982, MOL CLONING; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NOSKE IG, 1976, BIOL REPROD, V15, P704, DOI 10.1095/biolreprod15.5.704; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PAUL D, 1988, EXP CELL RES, V175, P334; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SAVOURET JF, 1980, J BIOL CHEM, V255, P4131; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; Suske Guntram, 1992, Gene Expression, V2, P339; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WIEHLE RD, 1990, ONCOGENE, V5, P787	41	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2805	2815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084586				2022-12-25	WOS:A1994PG82200006
J	WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP				WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP			EVOLUTIONARY CONSERVATION OF THE EPS8 GENE AND ITS MAPPING TO HUMAN-CHROMOSOME 12Q23-Q24	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; SIGNALING PROTEINS; SH3 DOMAINS; IDENTIFICATION; PURIFICATION; SUBSTRATE; BINDS; CELLS	We have previously isolated the coding sequence for a novel substrate for tyrosine kinases, eps8, from NIH3T3 fibroblasts. Eps8 was phosphorylated in vivo by several receptor tyrosine kinases (RTKs) and, upon overexpression, was able to enhance EGFR-mediated mitogenic signaling in NIH3T3 cells. To gain understanding of eps8 function as well as its role in normal and neoplastic proliferation, we cloned the human eps8 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. In addition to a previously identified SH3 domain, the predicted amino acid sequence of human eps8 revealed a non-random distribution of prolines, clustered in a way to suggest SH3-binding sites and a putative PH domain. Eps8 was expressed in all epithelial and fibroblastic lines examined and in some, but not all, hematopoietic cells. An essential function of eps8 in cell growth regulation was underscored by its conservation during evolution, where eps8-related sequences were detected as early as in Saccaromyces cerevisiae. Finally, the human EPS8 locus was mapped to chromosome 12q23-q24.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; ATENEO FEDERICIANO, FAC MED & CHIRURG, DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL, NAPLES, ITALY; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; REGINA ELENA INST CANC RES, MOLEC PATHOL & IMMUNOL LAB, ROME, ITALY; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro			Young, Richard A/F-6495-2012; Di Fiore, Pier Paolo/K-2130-2012	Young, Richard A/0000-0001-8855-8647; Di Fiore, Pier Paolo/0000-0002-2252-0950	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAIG IW, 1993, 1992 CHROM COORD M, P402; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3228; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MITELMAN F, 1993, 1992 CHROM COORD M, P700; MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OZISIK YY, 1993, CANCER GENET CYTOGEN, V69, P35, DOI 10.1016/0165-4608(93)90109-Y; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOUTEN HC, 1989, BLOOD, V73, P2149; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STREHL S, 1993, CANCER GENET CYTOGEN, V71, P94, DOI 10.1016/0165-4608(93)90207-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	35	29	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3057	3061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084614				2022-12-25	WOS:A1994PG82200037
J	YOKOTA, H; FERNANDEZSALGUERO, P; FURUYA, H; LIN, KM; MCBRIDE, OW; PODSCHUN, B; SCHNACKERZ, KD; GONZALEZ, FJ				YOKOTA, H; FERNANDEZSALGUERO, P; FURUYA, H; LIN, KM; MCBRIDE, OW; PODSCHUN, B; SCHNACKERZ, KD; GONZALEZ, FJ			CDNA CLONING AND CHROMOSOME MAPPING OF HUMAN DIHYDROPYRIMIDINE DEHYDROGENASE, AN ENZYME ASSOCIATED WITH 5-FLUOROURACIL TOXICITY AND CONGENITAL THYMINE URACILURIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE FLUOROURACIL TOXICITY; DIHYDROTHYMINE DEHYDROGENASE; FAMILIAL PYRIMIDINEMIA; CANCER-PATIENTS; HUMAN-LIVER; RAT-LIVER; PIG-LIVER; DEFICIENCY; PURIFICATION; PROTEINS	The pig and human dihydropyrimidine dehydrogenase (DPD) cDNAs were cloned and sequenced. The pig enzyme, expressed in Escherichia coli, catalyzed the reduction of uracil, thymine, and 5-fluorouracil with kinetics approximating those published for the enzyme purified from mammalian liver. DPD could be expressed in significant quantities only when uracil was added to the bacterial growth medium. The pig and human enzymes contained 1025 amino acids and calculated M(r) = 111,416 and 111,398, respectively. Conserved domains corresponding to a possible NADPH binding site and FAD binding site were found in the NH2-terminal half of the proteins and two motifs of putative [4Fe-4S] binding sites were found near to the carboxyl terminus of the enzyme. The latter corresponds to the labile COOH-terminal fragment previously shown to contain the iron sulfur centers. A sequence encompassing a peptide corresponding to the uracil binding site was found between the NADPH/FAD-containing NH2-terminal portion of the protein and the iron-sulfur binding sites near to the COOH terminus. Thus, the DPD appears to be derived from at least three distinct domains. The DPYD gene was localized to the centromeric region of human chromosome 1 between 1p22 and q21.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892; THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fernandez-Salguero, Pedro M./J-8437-2014	Fernandez-Salguero, Pedro M./0000-0003-2839-5027				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAKKEREN JAJM, 1984, CLIN CHIM ACTA, V140, P247, DOI 10.1016/0009-8981(84)90206-7; BERGER R, 1984, CLIN CHIM ACTA, V141, P227, DOI 10.1016/0009-8981(84)90014-7; BROCKSTEDT M, 1990, J INHERITED METAB DI, V12, P121; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002; DUPUIS A, 1991, BIOCHEMISTRY-US, V30, P2954, DOI 10.1021/bi00225a032; DURAN M, 1985, J INHERITED METAB DI, V14, P367; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEMING RA, 1993, EUR J CANCER, V29A, P740; FLEMING RA, 1992, CANCER RES, V52, P2899; FUJIMOTO S, 1991, J NUTR SCI VITAMINOL, V37, P89, DOI 10.3177/jnsv.37.89; GOLDBERG JA, 1988, BRIT J CANCER, V57, P186, DOI 10.1038/bjc.1988.39; GREM JL, 1990, CANC CHEMOTHERAPY PR, P180; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HARRIS BE, 1990, CANCER RES, V50, P197; HEGGIE GD, 1987, CANCER RES, V47, P2203; HOUYAU P, 1993, J NATL CANCER I, V85, P1602, DOI 10.1093/jnci/85.19.1602; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU ZH, 1992, J BIOL CHEM, V267, P17102; LYSS AP, 1993, CANCER INVEST, V11, P239, DOI 10.3109/07357909309024846; MCBRIDE O, 1982, P NATL ACAD SCI USA, V83, P130; MCBRIDE OW, 1982, NATURE, V300, P773, DOI 10.1038/300773a0; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; PODSCHUN B, 1993, J BIOL CHEM, V268, P3407; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; SCHMITT U, 1994, IN PRESS J INORG BIO; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; VANGENNIP AH, 1993, CLIN CHEM, V39, P380; VANGENNIP AH, 1989, ADV EXP MED BIOL, V253, P111; Wadman S K, 1984, Adv Exp Med Biol, V165 Pt A, P109; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILCKEN B, 1985, J INHERIT METAB DIS, V8, P115, DOI 10.1007/BF01811485; YAMANO S, 1989, BIOCHEMISTRY-US, V28, P7340, DOI 10.1021/bi00444a029	44	114	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23192	23196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083224				2022-12-25	WOS:A1994PQ16400046
J	DAVISSALINAS, J; SAPORITOIRWIN, SM; DONOVAN, FM; CUNNINGHAM, DD; VANNOSTRAND, WE				DAVISSALINAS, J; SAPORITOIRWIN, SM; DONOVAN, FM; CUNNINGHAM, DD; VANNOSTRAND, WE			THROMBIN RECEPTOR ACTIVATION INDUCES SECRETION AND NONAMYLOIDOGENIC PROCESSING OF AMYLOID BETA-PROTEIN PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MESSENGER-RNA; NEXIN-II; MOLECULAR-CLONING; HUMAN PLATELETS; CELL-ADHESION; DOMAIN; PHOSPHORYLATION; INHIBITOR; CLEAVAGE	The amyloid beta-protein (A beta) and protease nexin-2/ amyloid beta-protein precursor (PN-2/A beta PP) are major constituents of senile plaques and cerebrovascular deposits in individuals with Alzheimer's disease and related disorders. It has been suggested that the coagulation protease thrombin may process A beta PP in a manner leading to the formation of A beta. Here we investigated the effects of thrombin on the secretion and processing of PN-2/A beta PP and the production of A beta in a cellular system. Incubation of glioblastoma cells with thrombin (1-5 nM) resulted in the accumulation of abnormally processed, carboxyl-terminal-truncated forms of secreted PN-2/ A beta PP (approximate to 85 kDa) in the culture medium. Higher concentrations of thrombin (>10 nM) also increased the levels of secreted PN-2/A beta PP in cultured untransfected glioblastoma cells and glioblastoma cells that were stably transfected to overproduce the 695 isoform of A beta PP. Increased secretion of PN-2/A beta PP required the proteolytic activity of thrombin, was induced by activation of the thrombin receptor by agonist peptides, and required activation of protein kinase C. Incubation of the untransfected and transfected glioblastoma cells with thrombin led to decreased levels of soluble A beta in the culture medium consistent with previously suggested mechanisms regarding the secretion of PN-2/A beta PP. Although the present studies suggest that thrombin does not directly contribute to A beta formation, its proteolysis of secreted PN-2/A beta PP may disrupt regions near the carboxyl terminus of the secreted proteins that account for their neuroprotective and cell adhesive properties.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine			Galgiani, John/GLT-7012-2022		NHLBI NIH HHS [HL49566] Funding Source: Medline; NIA NIH HHS [AG00538, AG0096-11] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538, T32AG000096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V66, P184; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GARDELLA JE, 1990, BIOCHEM BIOPH RES CO, V173, P1292, DOI 10.1016/S0006-291X(05)80927-1; GARDELLA JE, 1992, LAB INVEST, V67, P303; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG DT, 1992, J BIOL CHEM, V267, P20831; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG R, 1991, J BIOL CHEM, V266, P16960	51	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22623	22627						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077213				2022-12-25	WOS:A1994PQ16300028
J	SZABO, G; GRAY, MC; HEWLETT, EL				SZABO, G; GRAY, MC; HEWLETT, EL			ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS PRODUCES ION CONDUCTANCE ACROSS ARTIFICIAL LIPID BILAYERS IN A CALCIUM-DEPENDENT AND POLARITY-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI HEMOLYSIN; AUREUS ALPHA-TOXIN; STAPHYLOCOCCUS-AUREUS; ANTHRAX TOXIN; MEMBRANES; ACTIVATION; DIPHTHERIA; CHANNELS; PROTEIN; CELLS	Adenylate cyclase toxin (AC toxin) from Bordetella pertussis enters target cells to produce supraphysiologic levels of cAMP and, by a cAMP-independent process, is hemolytic. In the present study, we show for the first time that this toxin also produces ion-permeable, cation-selective pores in phospholipid bilayers. The resulting membrane conductance is absolutely calcium-dependent, as are the intoxication and hemolytic activities. It is strongly affected by the polarity and magnitude of the membrane potential and enhanced by the presence of negatively charged phospholipid. AC toxins from two mutants, BPDE386 and BPD377, which are defective in toxin activity, produce little or no conductance. Finally, evaluation of the current-voltage relationships and the concentration dependence of pore formation and of hemolysis reveal a greater than 3rd power dependence, suggesting that a multimer of AC toxin, probably consisting of three or more holotoxin molecules, is involved in pore formation.	UNIV VIRGINIA,SCH MED,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia				gray, mary/0000-0003-4441-5905				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; CLERC P, 1986, ANN INST PASTEUR MIC, V137A, P267, DOI 10.1016/S0769-2609(86)80033-3; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CONFER DL, 1984, ADV CYCLIC NUCL PROT, V17, P183; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; FINKELSTEIN A, 1990, J PHYSIOLOGY PARIS, V84, P188; GALGIANI JN, 1988, INFECT IMMUN, V56, P751, DOI 10.1128/IAI.56.4.751-755.1988; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HACKETT M, 1994, IN PRESS SCIENCE; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEWLETT EL, 1976, P NATL ACAD SCI USA, V73, P1926, DOI 10.1073/pnas.73.6.1926; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAN BL, 1984, BIOPHYS J, V45, P102, DOI 10.1016/S0006-3495(84)84126-0; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; MENESTRINA G, 1989, BIOSCIENCE REP, V9, P465, DOI 10.1007/BF01117049; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SZABO G, 1969, J MEMBRANE BIOL, V1, P346, DOI 10.1007/BF01869788; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1986, PROTEIN CARBOHYDRATE, P433	39	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22496	22499						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077197				2022-12-25	WOS:A1994PQ16300011
J	BROCK, TG; PAINE, R; PETERSGOLDEN, M				BROCK, TG; PAINE, R; PETERSGOLDEN, M			LOCALIZATION OF 5-LIPOXYGENASE TO THE NUCLEUS OF UNSTIMULATED RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES; INTRACELLULAR-LOCALIZATION; MEMBRANE TRANSLOCATION; LEUKOTRIENE PRODUCTION; ARACHIDONIC-ACID; HUMAN-LEUKOCYTES; PROTEIN; PROLIFERATION; BIOSYNTHESIS; DIFFERENTIATION	Arachidonate metabolism by 5-lipoxygenase (5-LO) coincides with the translocation of the enzyme from a soluble to a pelletable fraction in thoroughly disrupted granulocytic cells. While immunoelectron microscopy has identified the nuclear membrane as the site at which 5-LO, as well as 5-LO activating protein (FLAP), are localized in activated cells, the locale of soluble 5-LO in unstimulated cells could not be established by this technique. We asked whether the nucleus might also be the site for soluble 5-LO in unstimulated cells, and utilized rat basophilic leukemia (RBL) cells as model granulocytic cells to address this question. Using three different techniques to disrupt cells while leaving nuclei intact (mild nitrogen cavitation, Dounce homogenization, and detergent lysis), immunoblot analysis indicated abundant 5-LO in isolated nuclei. Within purified nuclei, 5-LO existed in two pools: a soluble pool that was readily released upon nuclear disruption and a bound pool that was not removed by 300 mM NaCl treatment. In all cases, 5-LO was also found in cytosolic and non-nuclear membrane fractions. Indirect immunofluorescent microscopy confirmed the presence of abundant 5-LO within the nucleus with minimal extranuclear signal in most cells. However, a minority of cells, characterized by condensed chromatin, showed no nuclear-associated staining with increased cytoplasmic staining for 5-LO. This suggested that some of the cytosolic 5-LO found by cell fractionation resulted from these dividing cells. When the contribution from dividing cells was minimized, either by overnight serum deprivation or by isolating cytoplasts of nucleus-containing cells, 5-LO was prominent in the nuclear fraction but negligible in the cytosolic fraction. In contrast to this distribution in RBL cells, 5-LO in unstimulated human neutrophils was predominantly cytosolic, by both immunoblot and immunofluorescence analyses. In both RBL cells and human neutrophils, FLAP was localized at the nuclear membrane and the endoplasmic reticulum. These data provide the first evidence for the localization of 5-LO in unstimulated granulocytic cells. The finding that a substantial proportion of enzyme is localized within the nucleus of unstimulated RBL cells suggests potentially novel roles for 5-LO or its products within the nucleus.	VET AFFAIRS MED CTR,ANN ARBOR,MI 48109	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BROCK, TG (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047391, R01HL050496, K08HL002415] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL50496, KO8 HL02415, R01 HL47391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLURU D, 1993, J LEUKOCYTE BIOL, V54, P269, DOI 10.1002/jlb.54.4.269; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CAMPBELL A, 1986, NUCLEAR STRUCTURES I, P86; COCHRAN FR, 1989, BIOCHEM BIOPH RES CO, V161, P1327, DOI 10.1016/0006-291X(89)91388-0; COFFEY M, 1992, J BIOL CHEM, V267, P570; DUGAS B, 1990, J IMMUNOL, V145, P3406; FERRERI NR, 1986, J IMMUNOL, V136, P4188; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; HAINES KA, 1986, BIOCHEM J, V233, P583, DOI 10.1042/bj2330583; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEIKAUF GD, 1990, AM J PHYSIOL, V259, pL255, DOI 10.1152/ajplung.1990.259.4.L255; LEPLEY RA, 1994, J BIOL CHEM, V269, P2627; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; PASQUALE D, 1993, EXP HEMATOL, V21, P1361; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; RABIER MJ, 1993, J INVEST DERMATOL, V100, P132, DOI 10.1111/1523-1747.ep12462780; REID GK, 1990, J BIOL CHEM, V265, P19818; REN W, 1992, CALCIFIED TISSUE INT, V50, P372, DOI 10.1007/BF00301636; RICHTER JD, 1992, NUCLEAR TRAFFICKING, P89; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SERRERO G, 1992, ENDOCRINOLOGY, V131, P2545, DOI 10.1210/en.131.6.2545; STANKOVA J, 1992, BIOCHEM J, V282, P625; STENKE L, 1993, BLOOD, V81, P352; WANG YL, 1993, J BIOL CHEM, V268, P5899; WIGLER MH, 1975, BIOCHEM BIOPH RES CO, V63, P669, DOI 10.1016/S0006-291X(75)80436-0; WILLIAMS JD, 1986, J IMMUNOL, V136, P642; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; WU SH, 1993, J LAB CLIN MED, V122, P703	41	134	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22059	22066						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071328				2022-12-25	WOS:A1994PE09800023
J	GUO, LN; DIXON, RA; PAIVA, NL				GUO, LN; DIXON, RA; PAIVA, NL			CONVERSION OF VESTITONE TO MEDICARPIN IN ALFALFA (MEDICAGO-SATIVA L) IS CATALYZED BY 2 INDEPENDENT ENZYMES - IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF VESTITONE REDUCTASE AND 7,2'-DIHYDROXY-4'-METHOXYISOFLAVANOL DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; STRESS RESPONSES; PTEROCARPAN SYNTHASE; BIOSYNTHESIS; PHYTOALEXINS; ELICITATION	Pterocarpan phytoalexins are antimicrobial compounds in leguminous plants. The final step of pterocarpan biosynthesis, conversion of vestitone to medicarpin, was thought to be catalyzed by a single enzyme ''pterocarpan synthase.'' We have shown that the pterocarpan synthase activity observed in crude extracts of alfalfa suspension cell cultures is the sum of two independent enzymatic activities: vestitone reductase, which catalyzes the NADPH-dependent reduction of vestitone to 7,2'-dihydroxy-4'-methoxyisoflavanol (DMI), and DMI dehydratase, which catalyzes loss of water and closure of an ether ring to form medicarpin. The first enzyme, vestitone reductase, was purified 1,840-fold to homogeneity by a 5-step procedure. Purified vestitone reductase showed a single band on SDS-polyacrylamide gel electrophoresis with an estimated molecular mass of 38 kDa. The native molecular mass measured by gel filtration was shown to be 34 kDa, indicating that vestitone reductase is a monomer. Vestitone reductase has strict substrate stereo specificity for (3R)-vestitone with a K-m value of 45 mu M. The second enzyme, DMI dehydratase, was partially purified 962-fold. DMI dehydratase had a native molecular mass of 38 kDa as estimated by gel filtration and a K-m value of 5 mu M for DMI. Both enzymes have a temperature optimum of 30 degrees C and a pH optimum of 6.0. The discovery of vestitone reductase and DMI dehydratase will facilitate future genetic manipulation of pterocarpan biosynthesis.	SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA	Noble Research Institute								BLESS W, 1988, FEBS LETT, V235, P47, DOI 10.1016/0014-5793(88)81231-6; BLOUNT JW, 1992, PHYSIOL MOL PLANT P, V41, P333, DOI 10.1016/0885-5765(92)90020-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWICK PM, 1977, PHYTOCHEMISTRY, V16, P93, DOI 10.1016/0031-9422(77)83020-3; DEWICK PM, 1988, FLAVONOIDS ADV RES 1, P125; DIXON RA, 1992, RECENT ADV PHYTOCHEM, V26, P91; FAHRENDORF T, 1993, ARCH BIOCHEM BIOPHYS, V305, P509, DOI 10.1006/abbi.1993.1454; FISCHER D, 1990, PHYTOCHEMISTRY, V29, P2879, DOI 10.1016/0031-9422(90)87096-D; HIGGINS VJ, 1972, PHYSIOL PLANT PATHOL, V2, P289, DOI 10.1016/0048-4059(72)90012-4; Ingham J. L., 1982, Phytoalexins., P21; JORRIN J, 1990, PLANT PHYSIOL, V92, P447, DOI 10.1104/pp.92.2.447; KESSMANN H, 1990, PLANT PHYSIOL, V94, P227, DOI 10.1104/pp.94.1.227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OBERHOLZER M E, 1977, Tetrahedron Letters, V13, P1165; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; PAIVA NL, 1991, PLANT MOL BIOL, V17, P650; PREISIG CL, 1990, PLANT PHYSIOL, V94, P1444, DOI 10.1104/pp.94.3.1444; SCHUMACHER HM, 1987, PLANT CELL REP, V6, P410, DOI 10.1007/BF00272770; Segel I, 1975, ENZYME KINETICS; SMITH DA, 1986, PHYTOCHEMISTRY, V25, P979, DOI 10.1016/S0031-9422(00)81542-3; Stoessl A., 1982, Phytoalexins., P133; STREITWIESER A, 1976, INTRO ORGANIC CHEM, P593; VANETTEN HD, 1989, ANNU REV PHYTOPATHOL, V27, P143, DOI 10.1146/annurev.py.27.090189.001043; WOODWARD MD, 1982, PHYTOCHEMISTRY, V21, P1401	24	60	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22372	22378						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071365				2022-12-25	WOS:A1994PE09800067
J	WADAKIYAMA, Y; KIYAMA, R				WADAKIYAMA, Y; KIYAMA, R			PERIODICITY OF DNA BEND SITES IN HUMAN EPSILON-GLOBIN GENE REGION - POSSIBILITY OF SEQUENCE-DIRECTED NUCLEOSOME PHASING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-HYPERSENSITIVE SITES; C-MYC GENE; CHROMATIN STRUCTURE; ELECTROPHORETIC MOBILITY; ESCHERICHIA-COLI; PROTEIN-BINDING; CURVED DNA; TRANSCRIPTION; UPSTREAM; INITIATION	Analysis by the circular permutation assay of the human epsilon-globin gene region revealed that the DNA bend sites were located every 682.5 +/- 132.0 base pairs on average, separating the region into domains. Among 10 major and 1 minor bend sites mapped in the region, the transcription initiation and termination sites of the epsilon-globin gene were located close to the bend sites, and the first and the second exons of the epsilon-globin gene were separated from the third exon by another site. The bend sites were also located anterior to the two Alu family sequences. Short poly(dA).poly(dT) tracts typical for DNA bending were not always present in the sites. Fine mapping of a bend site having no poly(dA).poly(dT) tracts with concatenated oligonucleotides and analysis by S1 nuclease nicking assay indicated that the unusual structure, a base slippage or a partial tripler DNA structure, formed by a polypurine-polypyrimidine sequence in the region is the basis of bending. The bend sites were mapped in the promoter region (within similar to 300 base pairs from the cap site) of the human beta-globin and in c-myc and erythropoietin receptor genes, as well as in the mouse beta(maj)-globin gene. The conservation and the periodicity of the bend sites in the noncoding region suggest the active role of the sites that is a signal for nucleosome phasing.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	WADAKIYAMA, Y (corresponding author), NIPPON MED COLL,DEPT PHYSIOL,BUNKYO KU,1-1-5 SENDAGI,TOKYO 113,JAPAN.							ALLAN M, 1983, CELL, V35, P187; AMBROSE C, 1990, J MOL BIOL, V214, P875, DOI 10.1016/0022-2836(90)90342-J; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BODNAR JW, 1987, NUCLEIC ACIDS RES, V15, P1835, DOI 10.1093/nar/15.4.1835; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BUSHEL P, 1990, MOL CELL BIOL, V10, P1199, DOI 10.1128/MCB.10.3.1199; CALLADINE CR, 1991, J MOL BIOL, V221, P981, DOI 10.1016/0022-2836(91)80187-Y; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; CONSTANZO G, 1990, J MOL BIOL, V216, P363; ESTRARTIADIS S, 1980, CELL, V21, P653; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GRIFFIN LC, 1989, SCIEBNCE, V245, P67; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HUTCHISON N, 1985, CELL, V43, P471, DOI 10.1016/0092-8674(85)90177-1; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; NOGUCHI CT, 1991, BLOOD, V78, P2548; PENG CK, 1992, NATURE, V356, P168, DOI 10.1038/356168a0; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; van Holde KE., 1989, SPRINGER SERIES MOL; VOGT P, 1990, HUM GENET, V84, P301; VOGT P, 1986, CHROMOSOMA, V94, P459, DOI 10.1007/BF00292755; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P11532; WALKER PR, 1987, J BIOL CHEM, V262, P12223; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; WU JC, 1980, J MOL BIOL, V142, P363, DOI 10.1016/0022-2836(80)90277-6; ZHU JD, 1984, NUCLEIC ACIDS RES, V12, P9191, DOI 10.1093/nar/12.23.9191	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22238	22244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071350				2022-12-25	WOS:A1994PE09800050
J	WANG, W; HIMES, RH; DENTLER, WL				WANG, W; HIMES, RH; DENTLER, WL			THE BINDING OF A CILIARY MICROTUBULE PLUS-END BINDING-PROTEIN COMPLEX TO MICROTUBULES IS REGULATED BY CILIARY PROTEIN-KINASE AND PHOSPHATASE-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; DEPENDENT PHOSPHORYLATION; CAPPING STRUCTURES; EPITHELIAL-CELLS; XENOPUS EGGS; MAP KINASE; RAT-BRAIN; TUBULIN; INHIBITOR; TETRAHYMENA	Using a human autoimmune CREST antiserum, we identified a 97-kDa polypeptide at the plus ends of Tetrahymena ciliary microtubules and an antigen associated with mammalian kinetochores (Miller, J. M., Wang W., Balczon, R., and Dentler, W. L. (1990) J. Cell. Biol. 110, 703-714). The ciliary protein is part of a 1,500-2,000-kDa complex that can be released from ciliary microtubules and from in vitro assembled brain microtubules with ATP and ATP gamma S (Wang, W., Suprenant, K. A., and Dentler, W.L. (1993) J. Biol. Chem. 268, 24796-24807). Here we show that the ATP-dependent release of the 97-kDa protein from microtubules is inhibited, in a concentration-dependent manner by calf intestine phosphatase and by the protein kinase inhibitor 6-dimethylaminopurine. Sodium orthovanadate, a phosphotyrosine phosphatase inhibitor, stimulated the ATP-dependent release of the 97-kDa protein from microtubules. Therefore, the ciliary fraction contains both protein kinase and phosphatase activities, and selective inhibition of these activities is necessary for the ATP-dependent binding and release of the 97-kDa protein from microtubules. When incubated with [gamma-P-32]ATP, a portion of the 97-kDa protein is phosphorylated as are several other polypeptides associated with it. ATP sensitivity requires a low molecular weight heat-stable factor associated with axonemes. These results suggest that the association of the 97-kDa protein with microtubules is regulated by protein phosphorylation by axoneme-associated kinases and phosphatases.	UNIV KANSAS, DEPT PHYSIOL & CELL BIOL, LAWRENCE, KS 66045 USA; UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	University of Kansas; University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032556] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAPLOW M, 1992, Current Opinion in Cell Biology, V4, P58, DOI 10.1016/0955-0674(92)90059-L; CHAO W, 1992, BIOCHEM J, V288, P777, DOI 10.1042/bj2880777; CHENG HC, 1986, J BIOL CHEM, V261, P989; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; Dentler W.L., 1990, P31; DENTLER WL, 1987, INT REV CYTOL, P391; DEPENNART H, 1993, DEV BIOL, V157, P170, DOI 10.1006/dbio.1993.1121; DIAZNIDO J, 1990, J NEUROCHEM, V54, P211, DOI 10.1111/j.1471-4159.1990.tb13303.x; DUBE F, 1991, DEV BIOL, V146, P473, DOI 10.1016/0012-1606(91)90248-2; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GORBSKY GJ, 1992, MOL BIOL CELL S, V3, P344; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GURLAND G, 1993, P NATL ACAD SCI USA, V90, P8827, DOI 10.1073/pnas.90.19.8827; HIRANOOHNISHI J, 1989, J BIOCHEM, V105, P858, DOI 10.1093/oxfordjournals.jbchem.a122766; HOSHI M, 1992, EUR J BIOCHEM, V203, P43, DOI 10.1111/j.1432-1033.1992.tb19825.x; JOHNSON KA, 1992, J CELL BIOL, V119, P1605, DOI 10.1083/jcb.119.6.1605; KADOWAKI T, 1985, J BIOL CHEM, V260, P4016; LEFEBVRE PA, 1978, J CELL BIOL, V78, P8, DOI 10.1083/jcb.78.1.8; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MILLER JM, 1990, J CELL BIOL, V110, P703, DOI 10.1083/jcb.110.3.703; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; NICKLAS RB, 1993, J CELL SCI, V104, P961; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; POCCIA D, 1990, EXP CELL RES, V188, P226, DOI 10.1016/0014-4827(90)90164-6; RAO PN, 1989, J CELL SCI, V93, P63; RIME H, 1989, DEV BIOL, V133, P169, DOI 10.1016/0012-1606(89)90308-4; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SUPRENANT KA, 1988, J CELL BIOL, V107, P2259, DOI 10.1083/jcb.107.6.2259; SUPRENANT KA, 1985, P NATL ACAD SCI USA, V82, P6908, DOI 10.1073/pnas.82.20.6908; TASH JS, 1989, CELL MOTIL CYTOSKEL, V14, P332, DOI 10.1002/cm.970140303; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VOGEL J, 1991, BIOL BULL, V181, P340, DOI 10.1086/BBLv181n2p340; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; WANG W, 1993, J BIOL CHEM, V268, P24796; WICHE G, 1989, BIOCHEM J, V259, P1; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; ZERNICKAGOETZ M, 1993, EXP CELL RES, V207, P189, DOI 10.1006/excr.1993.1179; ZHENG B, 1991, J BIOL CHEM, V266, P10031; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	50	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21460	21466						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063779				2022-12-25	WOS:A1994PK97300014
J	BECKER, TC; BELTRANDELRIO, H; NOEL, RJ; JOHNSON, JH; NEWGARD, CB				BECKER, TC; BELTRANDELRIO, H; NOEL, RJ; JOHNSON, JH; NEWGARD, CB			OVEREXPRESSION OF HEXOKINASE-I IN ISOLATED ISLETS OF LANGERHANS VIA RECOMBINANT ADENOVIRUS - ENHANCEMENT OF GLUCOSE-METABOLISM AND INSULIN-SECRETION AT BASAL BUT NOT STIMULATORY GLUCOSE-LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; PANCREATIC-ISLETS; HEXOSE METABOLISM; DIABETES-MELLITUS; CLONED CDNA; BETA-CELLS; INHIBITION; MICE	Glucose metabolism and glucose-stimulated insulin secretion are thought to be controlled at the level of glucose phosphorylation in pancreatic islet beta-cells. In the current study we have investigated the importance of glucose phosphorylation by using recombinant adenovirus as a gene delivery system for isolated rat islets. Treatment of islets with a virus containing the cDNA encoding the Escherichia coli beta-galactesidase gene (AdCMV-beta GAL) resulted in efficiencies of gene transfer of 70.3 +/- 2.5 and 61.2 +/- 2.2% in two independent experiments. Treatment of islets with a virus containing the cDNA encoding rat hexokinase I (AdCMV-HKI) resulted in a 10.7-fold increase in immunodetectable hexokinase protein and a similar increase in enzyme activity. A large percentage of the overexpressed hexokinase activity was associated with a cell fraction enriched in mitochondria. These changes in enzyme level were accompanied by a 2-fold increase in insulin release and [5-H-3] glucose usage at basal glucose concentrations (3 mM). The rate of glucose usage at 20 mM glucose and the magnitude of the insulin secretory response to this stimulatory level of the sugar were unchanged relative to control islets. Overexpression of hexokinase I in isolated islets therefore creates a phenotype of elevated basal insulin release similar to that seen in islets from obese and insulin-resistant mammals. The discrepancy between the large increase in hexokinase activity and the small increase in glucose usage and insulin release may indicate, however, that other steps in glucose metabolism become rate-limiting after only modest increases in glucose-phosphorylating activity.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582, R01DK046492, R37DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42582, DK46492] Funding Source: Medline; NIGMS NIH HHS [2T3-GM08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCROFT SJH, 1981, ISLETS LANGERHANS BI, P117; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; FERBER S, 1994, J BIOL CHEM, V269, P11523; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GIROIX MH, 1984, BIOCHEM J, V223, P447, DOI 10.1042/bj2230447; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HEIMBERGH, 1993, EMBO J, V12, P2873; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; McCrory W.J., 1988, VIROLOGY, V163, P614; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; PFEIFER MA, 1981, AM J MED, V70, P579, DOI 10.1016/0002-9343(81)90579-9; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RASSCHAERT J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P353, DOI 10.1016/0005-2728(90)90040-B; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; VOSSMCCOWAN ME, 1994, J BIOL CHEM, V269, P15814; WILSON JE, 1984, REGULATION CARBOHYDR, P45	25	152	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21234	21238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063745				2022-12-25	WOS:A1994PC40300063
J	MOLLICONE, R; REGUIGNE, I; KELLY, RJ; FLETCHER, A; WATT, J; CHATFIELD, S; AZIZ, A; CAMERON, HS; WESTON, BW; LOWE, JB; ORIOL, R				MOLLICONE, R; REGUIGNE, I; KELLY, RJ; FLETCHER, A; WATT, J; CHATFIELD, S; AZIZ, A; CAMERON, HS; WESTON, BW; LOWE, JB; ORIOL, R			MOLECULAR-BASIS FOR LEWIS ALPHA(1,3/1,4)-FUCOSYL-TRANSFERASE GENE DEFICIENCY (FUT3) FOUND IN LEWIS-NEGATIVE INDONESIAN PEDIGREES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; BLOOD-GROUP ANTIGENS; FUCT-III GENE; FUCOSYL-TRANSFERASE; EXPRESSION; INDIVIDUALS; ANTIBODIES; ABO; ALPHA-3-FUCOSYLTRANSFERASES; HETEROGENEITY	The Le(a) and Le(b) human blood group antigens are synthesized in tissues producing exocrine secretions; they also circulate in plasma, where they are adsorbed by erythrocytes. They are synthesized by two fucosyltransferases, encoded by Lewis (FUT3) and secretor (FUT2) loci. This genetic model has been challenged because some erythrocyte Lewis-negative individuals express Lewis antigens in saliva. To define the molecular basis of this apparent discrepancy, we sequenced FUT3 in Lewis-negative individuals. We identified two single base pair changes. One, termed L1, yields a Leu-20 --> Arg substitution in the enzyme's transmembrane domain. When expressed in COS-7 cells, enzyme substrate affinities are essentially identical to those of wild type. However, the mutant enzyme is found at substantially reduced levels in transfected cells. This suggests that the L1 mutation may alter the Golgi membrane anchoring of the enzyme. It was found alone in double dose in 10 of30 erythrocyte Lewis-negative individuals, nine of whom express Lewis antigens in saliva. Therefore, L1 can account for erythrocyte/saliva-discrepant Lewis typing results. The L2 mutation creates an ILe-356 --> Lys change in the enzyme's catalytic domain and inactivates the enzyme. It was found in double dose in 18 of 19 individuals bearing the double erythrocyte and salivary Lewis deficiency and can account for this phenotype.	RED CROSS BLOOD TRANSFUS SERV, SYDNEY, NSW 2000, AUSTRALIA; INDONESIAN RED CROSS SOC, CENT BLOOD TRANSFUS SERV, JAKARTA 10002, INDONESIA; UNIV N CAROLINA, DEPT PEDIAT, DIV HEMATOL ONCOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	Australian Red Cross Blood Service; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	MOLLICONE, R (corresponding author), INSERM, U178, BATIMENT, 16 AVE PAUL VALLIANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		/L-2667-2019		NIGMS NIH HHS [GM47455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRESEN PH, 1948, ACTA PATHOL MIC SC, V25, P728; BERGER SL, 1987, GUIDE MOL CLONING TE, P709; BJORK S, 1987, J BIOL CHEM, V262, P6758; BROADBERRY RE, 1991, HUM HERED, V41, P290, DOI 10.1159/000154015; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CEPPELLINI R., 1955, RIV 1ST SIEROTEROP ITAL, V30, P431; CHIA D, 1985, CANCER RES, V45, P435; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; FRANCOIS A, 1986, VOX SANG, V50, P227, DOI 10.1111/j.1423-0410.1986.tb04887.x; GOOD AH, 1992, VOX SANG, V62, P180, DOI 10.1111/j.1423-0410.1992.tb01195.x; HENRY S, 1994, IN PRESS VOX SANG, V67; HENRY SM, 1993, VOX SANG, V65, P62, DOI 10.1111/j.1423-0410.1993.tb04527.x; HIRANO K, 1987, J NATL CANCER I, V79, P1261; JOHNSON PH, 1993, GLYCOCONJUGATE J, V10, P152, DOI 10.1007/BF00737712; KODA Y, 1993, BLOOD, V82, P2915; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LIN M, 1994, VOX SANG, V66, P137, DOI 10.1111/j.1423-0410.1994.tb00296.x; MANDEL U, 1991, VOX SANG, V61, P205, DOI 10.1111/j.1423-0410.1991.tb00947.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, TRANSFUS CLIN BIOL, V1, P91, DOI 10.1016/S1246-7820(94)80002-2; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOURANT AE, 1946, NATURE, V158, P237, DOI 10.1038/158237c0; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; ORIOL R, 1992, APMIS, V100, P28; ORNTOFT TF, 1991, BLOOD, V77, P1389; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VOS GH, 1967, ACTA GENET STAT MED, V17, P495; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	38	115	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20987	20994						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063716				2022-12-25	WOS:A1994PC40300029
J	MENKHAUS, M; ULLRICH, C; KLUGE, B; VATER, J; VOLLENBROICH, D; KAMP, RM				MENKHAUS, M; ULLRICH, C; KLUGE, B; VATER, J; VOLLENBROICH, D; KAMP, RM			STRUCTURAL AND FUNCTIONAL-ORGANIZATION OF THE SURFACTIN SYNTHETASE MULTIENZYME SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE PHOSPHODIESTERASE; BACILLUS-SUBTILIS; POLYACRYLAMIDE GELS; BIOSYNTHESIS; PROTEINS; ACID; IDENTIFICATION; ACYLPEPTIDES; INHIBITORS; QUANTITIES	By gel filtration of a crude extract of Bacillus subtilis ATCC 21332 and OKB 105, the multienzyme system that forms the lipoheptapeptide surfactin was separated into three enzyme fractions, E1, E2, and E3. E1, which appeared near the exclusion limit of the column, activates all amino acid components of surfactin as aminoacyladenylates and thioesters according to the thioester mechanism. In addition, a leucine-activating enzyme (E2) and an acyltransferase (E3) were detected that show molecular masses of approximately 160 and 40 kDa, respectively. The surfactin synthetase multienzyme system was reconstituted by complementation of all three enzyme fractions, yielding high rates of lipopeptide formation. E1 is composed of two multifunctional polypeptides (E1A and E1B) with molecular masses of 460 and 435 kDa, respectively, that can be separated by high-resolution anion-exchange chromatography on Pharmacia Mono Q. E1A binds L-Glu and L-Leu in a molar ratio of 1:2, whereas E1B incorporates L-Val, L-Asp, and L-Leu in a molar ratio of 1:1:1. The hydroxy fatty acid moiety is contributed by the acyltransferase accepting the hydroxy fatty acid coenzyme A thioester as substrate. The transfer of the hydroxy fatty acid to E1A and the formation of the hydroxyacyl-L-glutamate intermediate are the initiation steps in the biosynthesis of surfactin. The amino acid-activating enzyme components E1A, E1B, and E2 have been highly purified and partially characterized.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY; TECH UNIV BERLIN,FACHBEREICH CHEM & BIOTECHNOL 3,W-1000 BERLIN 65,GERMANY	Technical University of Berlin; Technical University of Berlin				Vater, Joachim/0000-0002-4478-4244				ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; BAUMGART F, 1991, BIOCHEM BIOPH RES CO, V177, P998, DOI 10.1016/0006-291X(91)90637-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GILHUUSMOE CC, 1970, FEBS LETT, V7, P287, DOI 10.1016/0014-5793(70)80183-1; HOSONO K, 1983, J ANTIBIOT, V36, P674, DOI 10.7164/antibiotics.36.674; HOSONO K, 1983, J ANTIBIOT, V36, P667, DOI 10.7164/antibiotics.36.667; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P1669, DOI 10.1080/00021369.1969.10859524; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P973, DOI 10.1080/00021369.1969.10859409; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P971, DOI 10.1080/00021369.1969.10859408; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P1523, DOI 10.1080/00021369.1969.10859499; KANDA M, 1978, J BIOCHEM, V84, P435, DOI 10.1093/oxfordjournals.jbchem.a132144; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laland S G, 1973, Essays Biochem, V9, P31; LAPIDOT Y, 1967, J LIPID RES, V8, P142; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; Loeffler W., 1990, FORUM MIKROBIOL, V3, P156; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P1770, DOI 10.1128/jb.173.5.1770-1778.1991; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PUGH EL, 1965, J BIOL CHEM, V240, P4727; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; VATER J, 1986, PROG COLLOID POLYM S, V72, P12; VATER J, 1989, BIOL ACTIVE MOL, P27; Warburg O., 1942, BIOCHEM Z, V310, P384; YAMADA M, 1968, J BIOCHEM, V63, P59, DOI 10.1093/oxfordjournals.jbchem.a128748; YAMADA M, 1969, J BIOCHEM, V66, P529, DOI 10.1093/oxfordjournals.jbchem.a129178; Zimmer T L, 1975, Methods Enzymol, V43, P567	35	73	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7678	7684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096516				2022-12-25	WOS:A1993KW97900017
J	ALTIERI, DC; PLESCIA, J; PLOW, EF				ALTIERI, DC; PLESCIA, J; PLOW, EF			THE STRUCTURAL MOTIF GLYCINE-190-VALINE-202 OF THE FIBRINOGEN-GAMMA CHAIN INTERACTS WITH CD11B CD18 INTEGRIN (ALPHA-M-BETA-2, MAC-1) AND PROMOTES LEUKOCYTE ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOAM CELLS; HUMAN-NEUTROPHILS; HUMAN-MONOCYTES; RECEPTOR; BINDING; MACROPHAGES; RECOGNITION; ATHEROGENESIS; ASSOCIATION; ANTIBODIES	The leukocyte-restricted integrin CD11b/CD18 (alpha(M)beta2, Mac-1) is a receptor for fibrinogen on stimulated monocytes and neutrophils. At variance with platelet alpha(IIb)beta3 or endothelial cell alpha(v)beta3 integrins, CD11b/CD18 interacts with a approximately 30-kDa plasmic fragment D (D30) of fibrinogen that lacks the Arg-Gly-Asp sequences in the Aalpha chain and the carboxyl terminus of the gamma chain. Using epitope-mapped antibodies and synthetic peptidyl mimicry, we have now identified a unique linear sequence in fibrinogen that mediates ligand binding to CD11b/CD18. Anti-fibrinogen antibodies directed to the gamma chain region 95-264 inhibited I-125-fibrinogen or I-125-D30 binding to chemoattractant-stimulated neutrophils or monocytic THP-1 cells in a dose-dependent fashion. Partially overlapping synthetic peptides reproducing this gamma chain region were tested for their ability to inhibit fibrinogen binding to leukocytes. A synthetic peptide designated P1, duplicating gamma chain Gly190-Val202, inhibited I-125-fibrinogen binding to stimulated neutrophils or THP-1 cells and blocked adhesion of these cells to immobilized fibrinogen in a dose-dependent fashion. Increasing concentrations of P1 inhibited I-125-fibrinogen binding to isolated CD11b/CD18 in a cell-free system. Consistent with genuine peptidyl mimicry, I-125-P1 bound saturably to THP-1 cells in a reaction inhibited by molar excess of unlabeled peptide, fibrinogen, or D30. Finally, immobilized P1 effectively supported adhesion of THP-1 cells in a CD11b/CD18-dependent manner. These data suggest that the fibrinogen gamma chain region Gly190-Val202 functions as a minimal recognition sequence for the leukocyte integrin CD11b/CD18. Given the participation of fibrinogen:leukocyte interaction in inflammation and atherogenesis, antagonists based on this unique structural motif would effectively interfere with aberrant leukocyte adhesion mechanisms without affecting Arg-Gly-Asp-directed vascular integrins.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, INST IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R01HL043773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38292, R01 HL-43773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1990, J IMMUNOL, V145, P662; AQEL NM, 1985, J PATHOL, V146, P197, DOI 10.1002/path.1711460306; ARNAOUT MA, 1990, BLOOD, V75, P1037; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COLVIN RB, 1979, J CLIN INVEST, V63, P1302, DOI 10.1172/JCI109425; COLVIN RB, 1975, J EXP MED, V142, P1377, DOI 10.1084/jem.142.6.1377; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; EZEKOWITZ RAB, 1984, J EXP MED, V159, P244, DOI 10.1084/jem.159.1.244; FAIR DS, 1981, J BIOL CHEM, V256, P8018; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HOGG N, 1983, J EXP MED, V157, P473, DOI 10.1084/jem.157.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHERMAN LA, 1977, J EXP MED, V145, P76, DOI 10.1084/jem.145.1.76; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STARY HC, 1987, ATHEROSCLEROSIS, V64, P91, DOI 10.1016/0021-9150(87)90234-6; TREZZINI C, 1988, BIOCHEM BIOPH RES CO, V156, P477, DOI 10.1016/S0006-291X(88)80866-0; TREZZINI C, 1991, BRIT J HAEMATOL, V77, P16, DOI 10.1111/j.1365-2141.1991.tb07942.x; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	34	173	177	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1847	1853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093615				2022-12-25	WOS:A1993KH62000055
J	ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ				ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ			INHIBITION OF TUMORIGENICITY OF A MURINE SQUAMOUS-CELL CARCINOMA (SCC) CELL-LINE BY A PUTATIVE TUMOR-SUPPRESSOR GENE ON HUMAN-CHROMOSOME-7	ONCOGENE			English	Article							IDENTIFICATION; EXPRESSION; DELETION; CANCER; NEUROFIBROMATOSIS; HETEROZYGOSITY; CLONING; DISEASE; HYBRIDS; GROWTH	Alterations in oncogenes and tumor suppressor genes (TSG) are considered to be critical steps in oncogenesis. However information on putative TSG involved in the developement of squamous cell carcinomas (SCC) is very limited. In this study we confirmed the existence of a tumor suppressor gene (TSG) on human chromosome 7 (hchr 7) that suppresses the tumorigenicity of squamous cell carcinomas (SCCs). We injected seven clones of CH72 cells (a murine SCC-derived cell line) bearing a hchr 7 (CH72/hchr 7) introduced by microcell fusion, two clones bearing human chromosome 12 (CH72/hchr 12) and parental CH72 cells into athymic Balb/c nude mice. The sizes of the tumors were determined twice a week until tumors reached 12 mm diameter. In situ hybridization for centromeric repetitive sequences of the transferred chromosomes were performed on the cell lines injected and the tumors arising after the injection. Southern blots and polymerase chain reaction (PCR) amplifications of near terminal sequences and (CA) microsatellite repeats were done to test the integrity of the introduced chromosomes. Five out of seven CH72/ hchr 7 clones had a twofold and threefold longer latency periods than CH72 cells. The remaining CH72/hchr 7 clones (MF 6 and 13 no. 4) had latency periods similar to that of parental CH72; MF 6 had a deletion in the introduced chromosome 7 involving q31.3-q31.3, whereas the other hybrid (MF 13 no. 4) seemed to have an intact hchr 7. Tumor-derived cells from CH72/hchr 7 hybrids with a delayed latency had lost centromeric and telomeric sequences of Chr 7. In constrast, tumors derived from the MF 6 and MF 13 no. 4 as well as the CH72/hchr 12 clones retained the introduced human chromosome as shown by chromosome 7 or 12 centromeric and telomeric sequences. These results indicate that the tumorigenicity of CH72 murine SCC cells was suppressed by hchr 7 and that the CH72/hchr 7 regain the tumorigenic phenotype after loss of the introduced chromosome, suggesting the presence of a TSG on hchr 7.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV RES,SMITHVILLE,TX 78957; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI,JAPAN; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Texas System; UTMD Anderson Cancer Center; Tottori University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V1, pCH2; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CONTI CJ, 1988, CANCER RES, V48, P435; CONWAY K, 1992, CANCER RES, V52, P6487; DORNISKELLER H, 1987, CELL, V51, P319; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HANSEN MF, 1987, CANCER RES, V47, P5518; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; NEUMAN WL, 1992, BLOOD, V79, P1501; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; OSLO P, 1992, CANCER GENET CYTOGEN, V59, P73; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHANNON KM, 1992, BLOOD, V79, P1311; TANAKA K, 1990, SCIENCE, V247, P568; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZAR JH, 1992, BIOSTATISTICAL ANAL, pCH16	37	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2817	2825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084587				2022-12-25	WOS:A1994PG82200007
J	CHOU, HF; PASSAGE, M; JONAS, AJ				CHOU, HF; PASSAGE, M; JONAS, AJ			REGULATION OF LYSOSOMAL SULFATE TRANSPORT BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RAT-LIVER LYSOSOMES; EMBRYO HEART-CELLS; CYSTINE TRANSPORT; CALCIUM-TRANSPORT; LIPID-COMPOSITION; PLASMA-MEMBRANE; LEVEL; TRIIODOTHYRONINE; MITOCHONDRIA	Sulfate transport was examined in rat liver lysosomes that were isolated from thyroid hormone-treated, thyroidectomized, and control animals. Sulfate uptake was significantly decreased in lysosomes from animals that had received intraperitoneal T-3 (3,5,3'-triiodothyronine) at a dose of 20 mu g/100 g body weight. The effect of T-3 was maximal by 24 h post-injection and resulted in marked decreases in both V-max (control: 155 +/- 33 pmol/unit of beta-hexosaminidase/30 s versus T-3 treated: 24 +/- 7 pmol/unit of beta-hexosaminidase/30 s) and K-m (control: 213 +/- 34 mu M versus T-3 treated: 92 +/- 6 mu M). Thyroidectomy was associated with a significant increase in V-max (control: 250 pmol/unit of beta-hexosaminidase/30 s versus thyroidectomized: 564 pmol/unit of beta-hexosaminidase/30 s), while K-m was not significantly affected. The effect of thyroid hormone on lysosomal sulfate transport appeared to be relatively specific. In contrast to its effect on sulfate transport, T-3 treatment had no effect on the uptake of either glucose or N-acetylglucosamine by rat liver lysosomes. Lysosomal pH, acidification in response to Mg/ATP, and the specific activities of alpha-L-iduronidase, beta-hexosaminidase, beta-D-glucosidase, and acid phosphatase were unaffected by T-3 administration. Incubation of T-3 with lysosomes from control animals had little or no effect on sulfate transport. Treatment of isolated lysosomes with either protein kinase A or alkaline phosphatase resulted in modest stimulation of transport. Thus, T-3 does not appear to regulate transport by either direct interaction with the lysosomal transporter or protein kinase A-mediated phosphorylation. The exact mechanism for the inhibitory effect of T-3 on lysosomal sulfate transport remains to be determined.			CHOU, HF (corresponding author), UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, DEPT PEDIAT, DIV MED GENET, E4, TORRANCE, CA 90502 USA.				NIDDK NIH HHS [DK44220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADENOCHJONES P, 1973, NATURE-NEW BIOL, V242, P123, DOI 10.1038/newbio242123a0; CHOPRA IJ, 1972, J LAB CLIN MED, V80, P729; CHOU HF, 1992, BIOCHEM MED METAB B, V48, P179, DOI 10.1016/0885-4505(92)90064-6; DEGIOVANNI R, 1992, PHYSIOL CHEM PHYS M, V24, P271; DETER RL, 1971, J CELL BIOL, V48, P473, DOI 10.1083/jcb.48.3.473; ESPINOSA RE, 1984, AM J PHYSIOL, V246, pF133, DOI 10.1152/ajprenal.1984.246.2.F133; FAAS FH, 1981, BIOCHEM J, V193, P845, DOI 10.1042/bj1930845; GOLDFINE ID, 1975, ENDOCRINOLOGY, V96, P802, DOI 10.1210/endo-96-3-802; GOLDFINE ID, 1975, ENDOCRINOLOGY, V96, P1030, DOI 10.1210/endo-96-4-1030; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1133, P89, DOI 10.1016/0167-4889(91)90245-S; HALL CW, 1978, METHOD ENZYMOL, V50, P455; HARPER GS, 1988, J BIOL CHEM, V263, P9320; HERD PA, 1978, ARCH BIOCHEM BIOPHYS, V188, P220, DOI 10.1016/0003-9861(78)90375-2; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JADOT M, 1989, BIOCHEM J, V262, P981, DOI 10.1042/bj2620981; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; JONAS AJ, 1983, J BIOL CHEM, V258, P1727; JONAS AJ, 1986, BIOCHEM J, V236, P671, DOI 10.1042/bj2360671; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PANIN L E, 1990, Problemy Endokria, V36, P62; PASQUINI JM, 1980, BIOCHEM J, V186, P127, DOI 10.1042/bj1860127; PILARSKA M, 1991, BIOCHIM BIOPHYS ACTA, V1068, P167, DOI 10.1016/0005-2736(91)90206-N; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; ROBINSON R, 1993, J BIOL CHEM, V268, P22119; ROSA F, 1971, J ULTRA MOL STRUCT R, V34, P205, DOI 10.1016/S0022-5320(71)80068-0; RUBINACCI A, 1992, BIOCHEM MED METAB B, V48, P235, DOI 10.1016/0885-4505(92)90070-F; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; SEGAL J, 1989, ENDOCR RES, V15, P619, DOI 10.3109/07435808909036355; SEGAL J, 1977, ENDOCRINOLOGY, V101, P1468, DOI 10.1210/endo-101-5-1468; SEGAL J, 1977, ENDOCRINOLOGY, V101, P150, DOI 10.1210/endo-101-1-150; SEGAL J, 1977, ENDOCRINOLOGY, V101, P143, DOI 10.1210/endo-101-1-143; SEGAL J, 1989, ENDOCRINOLOGY, V124, P2755, DOI 10.1210/endo-124-6-2755; SHAPIRA G, 1989, BIOCH GENETICS LAB M, P28; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SMITH TJ, 1982, J CLIN INVEST, V70, P1066, DOI 10.1172/JCI110694; SZEGO CM, 1974, EUR J BIOCHEM, V46, P377, DOI 10.1111/j.1432-1033.1974.tb03630.x; TENENHOUSE HS, 1991, AM J PHYSIOL, V261, pF420, DOI 10.1152/ajprenal.1991.261.3.F420; VAVRINKOVA H, 1971, BIOCHIM BIOPHYS ACTA, V231, P320; Weissmann B, 1978, Methods Enzymol, V50, P141; WELLS WW, 1981, LYSOSOMES LYSOSOMAL, P21; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; ZAHLTEN RN, 1972, P NATL ACAD SCI USA, V69, P800, DOI 10.1073/pnas.69.4.800	44	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23524	23529						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089119				2022-12-25	WOS:A1994PQ34500024
J	COUVE, A; GERST, JE				COUVE, A; GERST, JE			YEAST SNC PROTEINS COMPLEX WITH SEC9 - FUNCTIONAL INTERACTIONS BETWEEN PUTATIVE SNARE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY PATHWAY; FUSION; FAMILY; IDENTIFICATION; EXOCYTOSIS; SYNTAXIN; VESICLES; DOCKING	Yeast possess two homologs of the synaptobrevin family of vesicle-associated proteins that are proposed to be involved in membrane recognition and to act as receptors for components of the fusion machinery in neurons. We have previously described the yeast homologs, Snc1 and Snc2, and demonstrated that they localize to secretory vesicles and are required for normal secretion. Yeast lacking Snc protein expression accumulate post-Golgi transport vesicles that contain secretory proteins. Therefore, Snc proteins are essential for the fusion of carrier vesicles with the plasma membrane, and this property appears to have been conserved in evolution. We have now examined whether Snc proteins interact with other components of the late secretory pathway in yeast. Here we show that Snc proteins form a tight genetic and physical interaction with a plasma membrane protein, Sec9. Sec9 is the yeast equivalent of SNAP-25, a second receptor protein from neurons that has been shown to interact with synaptobrevin. We suggest, then, that recognition of the plasma membrane by secretory vesicles may involve the formation of a Snc-Sec9 complex and that this interaction has evolved as a fundamental step in secretory processes.	CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			couve, andres/I-2249-2013	couve, andres/0000-0003-4216-8672				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1994, IN PRESS CELL; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GRIFF LC, 1992, J BIOL CHEM, V91, P257; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SALAMINEN A, 1987, CELL, V49, P527; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	27	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23391	23394						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089101				2022-12-25	WOS:A1994PQ34500003
J	ZHEN, RG; KIM, EJ; REA, PA				ZHEN, RG; KIM, EJ; REA, PA			LOCALIZATION OF CYTOSOLICALLY ORIENTED MALEIMIDE-REACTIVE DOMAIN OF VACUOLAR H+-PYROPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; SUBSTRATE-BINDING SUBUNIT; HIGHER-PLANT TONOPLAST; MOLECULAR-CLONING; PROTEINS; MEMBRANE; ATPASE; PURIFICATION; KINETICS; SEQUENCE	The vacuolar H+-pyrophosphatase (V-PPase) of plant cells is subject to substrate (Mg2PPi)-protectable, free PPi-potentiated irreversible inhibition by the sulfhydryl reagent N-ethylmaleimide (NEM). inhibition by NEM ap proximates pseudo-first order kinetics and double-log plots of the first order rate constant for inactivation versus NEM concentration yield a straight line relationship with a slope of approximately unity. Since NEM and the membrane-impermeant cysteine reagent 3-(N-male-imidylpropionyl)biocytin (MPB) inhibit the V-PPase with similar kinetics and compete for a common binding site on the M(r) = 66,000 substrate-binding subunit, a single residue located in a cytosolically disposed extramembranous domain is inferred to undergo covalent modification in both cases. Selective labeling of the V-PPase of vacuolar membrane vesicles with [C-14]NEM, purification of the M(r) = 66,000 subunit, and its digestion with V8 protease generates multiple peptide fragments. Of the bands identified after electrophoresis of the digests on Tris-Tricine gels, only one, migrating at M(r) = 14,000 (V8(14K)), contains C-14 label. Gas phase sequence analysis of this band after electrotransfer to Immobilon P-SQ yields two overlapping sequences (V8(14K2) and V8(14K2)) which unambiguously align with the carboxyl-terminal segment of the M(r) = 66,000 subunit. Both V8(14K1) and V8(14K2) encompass only 1 cysteine residue at position 634 which is conserved between the V-PPases from Arabidopsis thaliana, Beta vulgaris (isoforms 1 and 2), and Hordeum vulgare. On the basis of these findings, the strict conservation of the sequence of the V-PPase from multiple plant sources, and the identical kinetics of interaction of the enzymes from Vigna and Beta with NEM and MPB, Cys(634) of putative hydrophilic loop X is concluded to be the cytosolically oriented residue whose alkylation by maleimides is responsible for inactivation of the V-PPase. The significance of these results with respect to earlier speculations concerning the identity of the catalytic site and topology of the V-PPase is discussed.	UNIV PENN,DEPT BIOL,INST PLANT SCI,PHILADELPHIA,PA 19104	University of Pennsylvania								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BAYER EA, 1987, ANAL BIOCHEM, V161, P262, DOI 10.1016/0003-2697(87)90450-7; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARLOWE E, 1988, ANTIBODIES LABORATOR; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KIM Y, 1994, IN PRESS PLANT PHYSL; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGH RA, 1992, PLANT PHYSIOL, V100, P1698, DOI 10.1104/pp.100.4.1698; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Matsudaira P, 1989, PRACTICAL GUIDE PROT; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; REA PA, 1986, PLANT PHYSIOL, V81, P126, DOI 10.1104/pp.81.1.126; REA PA, 1992, TRENDS BIOCHEM SCI, V12, P146; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TANAKA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1110, DOI 10.1006/bbrc.1993.1164; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671	34	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23342	23350						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083239				2022-12-25	WOS:A1994PQ16400067
J	CALABRO, A; HASCALL, VC				CALABRO, A; HASCALL, VC			EFFECTS OF BREFELDIN-A ON AGGRECAN CORE PROTEIN-SYNTHESIS AND MATURATION IN RAT CHONDROSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CARTILAGE PROTEOGLYCAN; CULTURED CHONDROCYTES; ARTICULAR-CARTILAGE; BIOSYNTHESIS; CYCLOHEXIMIDE; FIBRONECTIN; EXPRESSION; CISTERNAE; COMPLEX	In this paper, the effects of the fungal metabolite, brefeldin A, on the synthesis and maturation of aggrecan core protein precursor were studied in rat chondrosarcoma chondrocytes. The aggrecan core protein precursor was partially identified in total protein pools isolated from cell extracts based on its selective cleavage at a single site by the restriction protease factor Xa. During a 2-h labeling period with [H-3]serine as precursor, brefeldin A inhibited the synthesis of mature aggrecan from its aggrecan core protein precursor consistent with an inhibition of chondroitin sulfate chain elongation and sulfation as described in the accompanying paper (Calabro, A., and Hascall, V. C. (1994) J. Biol Chem. 269, 22764-22770). This inhibition is presumably the result of the disruption of vesicular transport by brefeldin A, which isolates the aggrecan core protein precursor at the level of the trans-Golgi cisternae from the enzymes for chondroitin sulfate chain elongation and sulfation located in the trans-Golgi network. Brefeldin A also inhibited the exocytosis of all radiolabeled secretory proteins from the cell layer into the medium compartment, which is also consistent with the disruption of vesicular transport attributed to this metabolite. Although total protein synthesis was inhibited by 12% in the presence of brefeldin A, the aggrecan core protein precursor accumulated within the cell layer indicating that the inhibition of chondroitin sulfate synthesis by brefeldin A was not the result of a lack of aggrecan core protein precursor. When the brefeldin A block was removed and cultures chased in the presence of cycloheximide to prevent new protein synthesis, vesicular transport through the cell was re-established and chondroitin sulfate chains were added to a large proportion of the aggrecan core protein precursor that had accumulated during the brefeldin A block. These results suggest that the machinery for chondroitin sulfate synthesis and for protein exocytosis, that were disrupted by brefeldin A treatment, recover after removal of the brefeldin A, even in the presence of cycloheximide, and that the structures involved in these processes reassemble from previously existing proteins. Interestingly, two other proteins with the same relative abundance as the aggrecan core protein precursor were observed. An similar to 10 kDa protein with the characteristics of the fibronectin subunit, and an unidentified similar to 150-kDa protein which was efficiently cleaved by the protease Xa enzyme.	NIDR,BONE RES BRANCH,PROTEOGLYCAN CHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BURTONWURSTER N, 1989, ARCH BIOCHEM BIOPHYS, V269, P32, DOI 10.1016/0003-9861(89)90084-2; BURTONWURSTER N, 1988, BIOCHEM BIOPH RES CO, V154, P1088, DOI 10.1016/0006-291X(88)90252-5; BURTONWURSTER N, 1989, BIOCHEM BIOPH RES CO, V165, P782, DOI 10.1016/S0006-291X(89)80034-8; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; KIMURA JH, 1981, J BIOL CHEM, V256, P7890; KIMURA JH, 1981, J BIOL CHEM, V256, P4368; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL D, 1981, BIOCHEM J, V196, P521, DOI 10.1042/bj1960521; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370	17	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22771	22778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077229				2022-12-25	WOS:A1994PQ16300049
J	MATSUOKA, Y; CHEN, SY; COMPANS, RW				MATSUOKA, Y; CHEN, SY; COMPANS, RW			A SIGNAL FOR GOLGI RETENTION IN THE BUNYAVIRUS G1 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUNTA-TORO VIRUS; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MEMBRANE-SPANNING DOMAIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; INTRACELLULAR-TRANSPORT; ENVELOPE GLYCOPROTEIN; CYTOPLASMIC DOMAINS; PROTEIN-TRANSPORT; COMPLEX	The G1 and G2 glycoproteins of Punta Toro virus, a member of the bunyaviruses, are targeted to the Golgi complex, where viral budding occurs. We found that the G1 protein, when expressed in the absence of G2, is also targeted to the Golgi complex. A series of G1 proteins truncated at the carboxyl-terminal region was constructed, and the localization of the expressed proteins was examined. It was found that the proteins expressed from constructs with partial deletions in the cytoplasmic domain were transported to the Golgi complex at a significantly slower rate than G1. Although a major fraction of these proteins was eventually transported to the Golgi complex, they did not exhibit as clearly defined a pattern of accumulation as G1, but rather appeared to be distributed throughout the endoplasmic reticulum as well as the Golgi complex. The proteins expressed from constructs lacking most of the cytoplasmic domain and, in some cases, part of the transmembrane domain sequences as well were transported to the cell surface. We have also constructed chimeric proteins with the envelope protein of a murine leukemia virus (MCFenv), which is efficiently transported to the plasma membrane. A MCF G1 chimera that contained the G1 transmembrane and cytoplasmic domains was found to be efficiently retained in the Golgi complex, and a construct that contained only the G1 transmembrane domain was also partially retained in the Golgi complex. Thus, the transmembrane domain as well as a portion of the cytoplasmic domain adjacent to the transmembrane domain are apparently crucial for Golgi retention of the G1 protein.	EMORY UNIV, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV HUMAN RETROVIROL, BOSTON, MA 02115 USA	Emory University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NCI NIH HHS [NCI CA-18611] Funding Source: Medline; NIAID NIH HHS [NIAID AI-12680] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012680, R37AI012680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; ARMSTRONG J, 1991, J CELL SCI, V98, P567; BURKE J, 1992, J BIOL CHEM, V267, P24433; CHEN SY, 1991, VIROLOGY, V183, P351, DOI 10.1016/0042-6822(91)90148-5; CHEN SY, 1991, J VIROL, V65, P5902, DOI 10.1128/JVI.65.11.5902-5909.1991; CHEN SY, 1991, J VIROL, V65, P1427, DOI 10.1128/JVI.65.3.1427-1439.1991; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IHARA T, 1985, VIROLOGY, V144, P246, DOI 10.1016/0042-6822(85)90321-6; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KILPATRICK DR, 1987, J BIOL CHEM, V262, P16116; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MANIATIS T, 1986, MOL CLONING; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MATSUOKA Y, 1991, CURR TOP MICROBIOL, V169, P161; MATSUOKA Y, 1988, VIROLOGY, V167, P251, DOI 10.1016/0042-6822(88)90075-X; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MURPHY F A, 1973, Intervirology, V1, P297, DOI 10.1159/000148858; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; PESONEN M, 1982, J VIROL, V41, P390, DOI 10.1128/JVI.41.2.390-400.1982; Pettersson R F, 1991, Curr Top Microbiol Immunol, V170, P67; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PINTER A, 1979, J VIROL, V30, P157, DOI 10.1128/JVI.30.1.157-165.1979; PINTER A, 1984, VIROLOGY, V136, P196, DOI 10.1016/0042-6822(84)90259-9; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SCHMALJOHN C S, 1990, P1175; SMITH JF, 1982, VIROLOGY, V121, P61, DOI 10.1016/0042-6822(82)90118-0; STEPHENS EB, 1988, ANNU REV MICROBIOL, V42, P489; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	49	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22565	22573						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077205				2022-12-25	WOS:A1994PQ16300020
J	LEIPER, JM; BAYLISS, JD; PEASE, RJ; BRETT, DJ; SCOTT, J; SHOULDERS, CC				LEIPER, JM; BAYLISS, JD; PEASE, RJ; BRETT, DJ; SCOTT, J; SHOULDERS, CC			MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN, THE ABETALIPOPROTEINEMIA GENE-PRODUCT, MEDIATES THE SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS FROM HETEROLOGOUS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; HEP-G2 CELLS; TRANSLOCATION; DEGRADATION; DISTINCT; CLEAVAGE; ABILITY	Apolipoprotein (apo) B is an obligatory component of triglyceride-rich lipoproteins. In the rare autosomal recessive disorder abetalipoproteinemia (ABL), no triglyceride-rich lipoproteins are secreted. Mutations in the gene encoding the 97-kDa subunit of a microsomal triglyceride transfer protein (MTP) cause ABL (Sharp, D., Blinderman, L., Combs, K. A., Klenzle, B., Ricci, B., Wager-Smith, K., Gil, C. M., Turck, C. W, Bouma, M. E., Rader, D. J., Aggerbeck, L. P., Gregg, R. E., Gordon, D. A., and Wetterau, J. R. (1993) Nature 365, 65-69; Shoulders, C. C., Brett, D. J., Bayliss, J. D., Narcisi, T. M., Jarmuz, k, Grantham, T. T., Leoni, P. R. D., Bhattacharya, S., Pease, R. J., Cullen, P. M., Levi, S., Byfield, P. G. H., Purkiss, P., and Scott, J. (1993) Hum. Mol. Genet. 2, 2109-2116). Here we have examined whether MTP is both necessary and sufficient to mediate the secretion of apoB-containing lipoproteins from cells that do not normally express either of these proteins. Carboxyl-terminal truncated forms of apoB, apoB17, and apoB41 on the centile system were expressed in COS-1 cells. ApoB17 was secreted whereas apoB41 was unable to traverse the secretory pathway. Cotransfection of apoB41 and MTP promoted the secretion of apoB41 as a buoyant lipoprotein particle with a modal density of 1.15 g/ml. When cotransfected COS-1 cells were cultured under conditions that increase the secretion of apoB100 from HepG2 cells, secretion of apoB41 was similarly increased. N-Acetyl-leucyl-leucyl-norleucinal (ALLN), a calpain I inhibitor, abolished intracellular degradation of apoB41 and increased secretion 2.5-fold. Oleate, a substrate for triglyceride synthesis, reduced degradation from 50 to 19% and increased secretion by 2.5 fold. The effects of ALLN and oleate were additive. We conclude that the secretion of apoB from COS-1 cells cotransfected with apoB and MTP is determined by the competitive processes of lipoprotein assembly and intracellular degradation in the endoplasmic reticulum and that MTP is the only tissue-specific component, other than apoB, required for the secretion of apoB-containing lipoproteins.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,LONDON W12 0NN,ENGLAND	Imperial College London								BOREN J, 1990, J BIOL CHEM, V265, P10556; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONFAVA S, 1987, J BIOL CHEM, V262, P8944; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WHITE AL, 1992, J BIOL CHEM, V267, P15657; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; 1992, INT J CARDIOL S1, V37, pS1	23	152	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21951	21954						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071315				2022-12-25	WOS:A1994PE09800008
J	RUFFJAMISON, S; ZHONG, Z; WEN, ZL; CHEN, K; DARNELL, JE; COHEN, S				RUFFJAMISON, S; ZHONG, Z; WEN, ZL; CHEN, K; DARNELL, JE; COHEN, S			EPIDERMAL GROWTH-FACTOR AND LIPOPOLYSACCHARIDE ACTIVATE STAT3 TRANSCRIPTION FACTOR IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; SH3 DOMAINS; RECEPTOR; PROTEINS; KINASES; ELEMENTS; BINDING	Previous studies demonstrated that the intraperitoneal injection of epidermal growth factor (EGF) into mice resulted in the appearance, within minutes, of several tyrosine-phosphorylated proteins in liver nuclei. Two of these proteins have been identified as the transcription factors p91/p84 (Stat1 alpha/1 beta) (Ruff-Jamison, S., Chen, K., and Cohen, S. (1993) Science 261, 1733-1736). We have now identified, by Western blotting and immunoprecipitation, an additional EGF-modulated transcription factor, Stat3. We find that Stat3 is tyrosine-phosphorylated and present in mouse liver nuclei following either EGF or lipopolysaccharide administration. Gel shift analyses show that Stat3 is capable of specifically binding the SIE (a DNA sequence present in the c-fos promoter). Three active SIE binding complexes (SIF A, B, and C) exist in the nucleus after the administration of EGF: one complex that contains Stat3, one that contains Stat1, and a third complex that appears to contain both proteins. Only one active SIE binding complex, containing Stat3, was detected after the administration of lipopolysaccharide.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Vanderbilt University; Rockefeller University					NCI NIH HHS [CA09582] Funding Source: Medline; NICHD NIH HHS [HD-00700] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000700] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	23	140	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21933	21935						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071311				2022-12-25	WOS:A1994PE09800003
J	RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH				RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH			BIOLOGICAL-ACTIVITIES OF A PUTATIVE TRUNCATED HEPATITIS-B VIRUS-X GENE-PRODUCT FUSED TO A POLYLYSIN STRETCH	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; HEPATOCELLULAR-CARCINOMA; DNA-SEQUENCES; MAMMALIAN-CELLS; PLASMID DNA; MOUSE CELLS; VIRAL-DNA; PROTEIN; TRANSFORMATION; TRANSFECTION	Truncated transcripts terminating within the HBx frame have been recognized previously in tumor and liver tissue of HCC patients. In this study biological activities of a predicted truncated HBx fused to a polysin stretch (HBtx-polylysin) and of full length HBx were compared in NIH3T3 cells transfected with respective cDNA plasmids. Transactivation of a co-transfecting reporter gene and influence on neo' DNA mediated transformation to G418 resistance were determined. In comparison to full length HBx the data indicate for HBtx-polylysin a lower transactivating capacity and as judged by the yield of colonies on a solid surface, a lower capacity to stimulate neo(r) DNA mediated transformation. In soft agar the outgrowth into G418 resistant colonies was dependent on co-transfecting HBx cDNA. In providing this condition HBtx-polylysin had a much higher relative activity than full length HBx. Large cointegrants consisting of the plasmids carrying truncated HBx cDNA and neo(r) DNA respectively were identified by chromosomal in situ hybridization. Based on Southern blot analyses extended concatemeres of the HBx cDNA plasmid constituted a main part of the cointegrants. Expression of truncated HBx cDNA was followed on the RNA and the protein level. The presence of this cDNA could be correlated to a compact spindle like cell appearance, its loss after prolonged passaging in the absence of G418 to a concomitant reversion to the phenotype of the NIH3T3 cell. Interspersed selection for G418 resistance stabilized the morphologically transformed phenotype. These results provide a basis to manipulate expression of truncated HBx and to recognize thereby processes leading to transformation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT VIRUS WECHSELWIRKUNGEN,D-69009 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT ORG KOMPLEXER GENOME,D-69009 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)				Hilger, Christiane/0000-0001-9455-5442				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHOT C, 1981, LANCET, V2, P765; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HARNES BD, 1984, TRANSCRIPTION TRANSL; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLST A, 1988, CELL, V52, P355; IMAZEKI F, 1987, HEPATOLOGY, V7, P753, DOI 10.1002/hep.1840070423; KESSLER C, 1990, BIOL CHEM H-S, V371, P917, DOI 10.1515/bchm3.1990.371.2.917; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KLEIN R, 1991, VIRUS GENES, V5, P157, DOI 10.1007/BF00571930; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUPPER H, 1984, EXPRESSION FOOT MOUT, P222; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; POURCEL C, 1982, J VIROL, V42, P100, DOI 10.1128/JVI.42.1.100-105.1982; PULM W, 1985, MOL CELL BIOL, V5, P295; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SCHEK N, 1991, ONCOGENE, V6, P1735; SHAFRITZ DA, 1981, HEPATOLOGY, V1, P1, DOI 10.1002/hep.1840010102; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	40	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2613	2621						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058325				2022-12-25	WOS:A1994PC05400021
J	KIM, PS; ARVAN, P				KIM, PS; ARVAN, P			HORMONAL-REGULATION OF THYROGLOBULIN EXPORT FROM THE ENDOPLASMIC-RETICULUM OF CULTURED THYROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; THYROID EPITHELIAL-CELLS; SECRETORY PROTEINS; EXOCRINE PANCREAS; BINDING-PROTEIN; PEPTIDE-BINDING; SHOCK; HEMAGGLUTININ; GLYCOPROTEIN; EXPRESSION	To understand how the endoplasmic reticulum (ER) of the thyrocyte remains flexible to physiologic changes in the load of exportable proteins, we have examined hormonally-induced increments in thyroglobulin (Tg) flux and pool size in the ER, the relationship between kinetics of Tg folding and ER export, and steady-state levels of molecular chaperones. Tg production was increased greater-than-or-equal-to 5-fold by chronic exposure to thyrotropin (TSH), and greater-than-or-equal-to 25-fold by exposure to a mixture of TSH, insulin, transferrin, and hydrocortisone (4H). In TSH-grown cells Tg assembly was accelerated, specifically involving early folding intermediates that lead to a compact monomer. Accelerated dissociation of nascent Tg from the binding protein, BiP, was observed in parallel. TSH exposure was accompanied by modest increases in ER chaperones as well as accelerated Tg export from the thyrocyte ER. However, in 4H-grown thyrocytes, although there were further increases in ER chaperones, monomer maturation was slowed and the association between nascent Tg and BiP was prolonged. Nevertheless, export from the ER remained accelerated, indicating that exit from the ER must include other regulated steps that occur after the folding of exportable proteins. Thus, protein folding may not necessarily be the rate-limiting step in the export of newly synthesized proteins from the ER.	BETH ISRAEL HOSP,DIV ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CELL & DEV BIOL PROGRAM,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002113, T32DK007516, R01DK040344, R29DK040344, R01DK107516] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40344, DK02113, DK07516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BIEGER W, 1976, CELL TISSUE RES, V170, P203; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DUNN JT, 1992, WERNER INGBARS THYRO, P98; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; ERRICK JE, 1985, THYROGLOBULIN PROTHY, P271; FIELD JB, 1992, WERNER INGBARS THYRO, P276; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; INGBAR SH, 1987, MOL BIOL APPROACHES, P43; KAMG HS, 1991, J BIOL CHEM, V266, P5643; KASAMBALIDES EJ, 1985, J CELL PHYSIOL, V123, P283, DOI 10.1002/jcp.1041230220; KIM P, 1991, CELL BIOL CHEM, V115, P407; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEELE G, 1985, J BIOL CHEM, V260, P926; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WAGAR G, 1974, ACTA ENDOCRINOL-COP, V77, P64, DOI 10.1530/acta.0.0770064; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WOLFFE AP, 1986, FEBS LETT, V176, P8; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	45	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4873	4879						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095263				2022-12-25	WOS:A1993KP88400049
J	ALSHAWI, MK; SENIOR, AE				ALSHAWI, MK; SENIOR, AE			CHARACTERIZATION OF THE ADENOSINE-TRIPHOSPHATASE ACTIVITY OF CHINESE-HAMSTER P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; NUCLEOTIDE-BINDING-SITES; COLI PROTON-ATPASE; BIOCHEMICAL-CHARACTERIZATION; MEMBRANE GLYCOPROTEIN; MITOCHONDRIAL ATPASE; ESSENTIAL TYROSINE; BETA-SUBUNIT; PROTEINS; INHIBITION	A multidrug-resistant Chinese hamster ovary cell line (CR1R12) was obtained which constitutively expresses P-glycoprotein, up to 32% by weight of plasma membrane protein. CR1R12 plasma membranes had high, drug-activated ATPase activity referable to P-glycoprotein. The specific ATPase activity in the presence of verapamil was calculated to be approximately 9 mumol/min/mg (=21 s-1) at 37-degrees-C, pH 7.4. K(M) ATP was 1.4 mM, and ADP and 5'-adenylyl imidodiphosphate were competitive inhibitors with K(i) values 0.35 and 0.44 mM, respectively. 2'-dATP was a good substrate, GTP and ITP were real but poor substrates, and ADP and AMP were not hydrolyzed. Optimal pH for ATP hydrolysis was 7.3. MgATP was the preferred substrate, and CaATP was hydrolyzed very weakly. 7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) covalantly labeled the P-glycoprotein, and incorporation of 1.1 mol of NBD-Cl/mol of P-glycoprotein gave 100% inactivation. ATP protected against NBD-Cl inactivation. N-Ethylmaleimide was a potent inhibitor in the absence of ATP, and in its presence significant protection from inhibition could be achieved. Vanadate and fluoroaluminate were also strong inhibitors. The plasma membranes from CR1R12 cells should provide material for purification and reconstitution of P-glycoprotein and for screening of potential ''multidrug-reversal'' reagents by enzymic assay.			ALSHAWI, MK (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.							ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BECHHANSEN NT, 1976, J CELL PHYSIOL, V88, P23, DOI 10.1002/jcp.1040880104; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; BISHOP JE, 1988, J BIOL CHEM, V263, P1886; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CABANTCHIK IZ, 1975, J BIOL CHEM, V250, P5130; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CANTLEY LC, 1978, BIOCHEMISTRY-US, V17, P418, DOI 10.1021/bi00596a006; Chabner B. A., 1982, CANCER PRINCIPLES PR, P156; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; EBEL RE, 1975, J BIOL CHEM, V250, P191; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENDICOTT JA, 1991, J DNA SEQUENCE, V2, P89; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FENG Y, 1992, J BIOL CHEM, V267, P5817; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FORTE JG, 1975, GASTROENTEROLOGY, V69, P175; Georges E, 1990, Adv Pharmacol, V21, P185, DOI 10.1016/S1054-3589(08)60343-9; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GIBSON SL, 1983, CANCER RES, V43, P4191; Gottesman M M, 1987, Methods Enzymol, V151, P113, DOI 10.1016/S0076-6879(87)51012-6; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1988, J NATL CANCER I, V80, P506, DOI 10.1093/jnci/80.7.506; HAMADA H, 1988, CANCER RES, V48, P4926; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMMES GG, 1971, BIOCHIM BIOPHYS ACTA, V233, P580, DOI 10.1016/0005-2736(71)90156-8; HARPER F, 1978, CAN J BIOCHEM CELL B, V56, P565, DOI 10.1139/o78-086; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; IM WB, 1985, J BIOL CHEM, V260, P9452; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LIN SH, 1989, J BIOL CHEM, V264, P14408; LING V, 1992, CANCER-AM CANCER SOC, V69, P2603, DOI 10.1002/1097-0142(19920515)69:10<2603::AID-CNCR2820691034>3.0.CO;2-E; Linnett P E, 1979, Methods Enzymol, V55, P472; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; PANET R, 1970, EUR J BIOCHEM, V14, P440, DOI 10.1111/j.1432-1033.1970.tb00308.x; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; RAY TK, 1976, BIOCHIM BIOPHYS ACTA, V443, P451, DOI 10.1016/0005-2736(76)90465-X; RICHARDS DE, 1977, J MEMBRANE BIOL, V35, P113, DOI 10.1007/BF01869943; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROBINSON JD, 1974, BIOCHIM BIOPHYS ACTA, V341, P232, DOI 10.1016/0005-2744(74)90084-9; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STURR MG, 1990, ARCH MICROBIOL, V155, P22, DOI 10.1007/BF00291269; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALLICK ET, 1978, J BIOL CHEM, V253, P8778; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	72	240	241	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4197	4206						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095047				2022-12-25	WOS:A1993KN53300059
J	BOULUKOS, KE; ZIFF, EB				BOULUKOS, KE; ZIFF, EB			ADENOVIRUS 5 E1A PROTEINS DISRUPT THE NEURONAL PHENOTYPE AND GROWTH-FACTOR RESPONSIVENESS OF PC12 CELLS BY A CONSERVED REGION 1-DEPENDENT MECHANISM	ONCOGENE			English	Article							INTERMEDIATE FILAMENT PROTEIN; RETINOBLASTOMA GENE-PRODUCT; HUMAN CYCLIN-A; TRK PROTOONCOGENE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; FACTOR RECEPTORS; TERMINAL REGION; KINASE-ACTIVITY; NGF RECEPTOR	Expression in PC12 cells of adenovirus 5 E1a proteins dramatically changes cell morphology and disrupts neuronal differentiation. We demonstrate that the nerve growth factor (NGF) receptors, p140trk and p75NGFR, as well as the epidermal growth factor receptor are undetectable in E1a-expressing PC12 cells. This correlates with a repression of mRNAs for the chromaffin- and neuronal-specific proteins, tyrosine hydroxylase and peripherin, while more ubiquitously expressed genes remain unaffected. One possible mechanism of E1a action could thus be the repression of a coordinately regulated group of chromaffin- and/or neuronal-specific genes. Furthermore, we show that E1a conserved region 1, which binds p105Rb and p300, is necessary for this E1a-dependent effect. This indicates that cellular proteins interacting with E1a conserved region 1 may be implicated in growth arrest, expression of neuron-specific functions and orderly differentiation of PC12 cells in response to NGF.	NYU HOSP, HOWARD HUGHES MED INST, DEPT BIOCHEM, 1ST AVE, NEW YORK, NY 10016 USA; NYU HOSP, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; GIORDANO A, 1991, ONCOGENE, V6, P481; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARUYAMA K, 1987, ONCOGENE, V1, P361; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	53	50	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					237	248						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093977				2022-12-25	WOS:A1993KN00600002
J	HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C				HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C			INFREQUENT MUTATION OF P53 GENE IN HEPATITIS-B VIRUS POSITIVE PRIMARY HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Note							C VIRUS; BREAST-CANCER; LIVER-CANCER; LUNG-CANCER; ALLELE LOSS; CELL-LINES; CHROMOSOME-17; FREQUENT; TAIWAN; HETEROZYGOSITY	Somatic mutation of the p53 oncogene/anti-oncogene allele has been shown to be involved in many different human solid tumors. Recently, there have been reports that p53 mutations are found to occur at high frequency (50%) in aflatoxin-related human primary hepatocellular carcinomas (HCC) (Hsu et al., 1991 Nature, vol 350, p. 427; Bressac et al., 1991 Nature, vol 350, p. 429). Most strikingly, a hotspot G to T mutation at amino acid position 249 was identified. These reports appear to contradict our earlier publications that although p53 mutation is found frequently in human HCC cell lines, it is rarely found in primary tumors. In this paper, we have further examined 20 different primary HCC samples (17 were hepatitis B surface antigen positive) and their adjacent nontumorous tissues, using restriction fragment length polymorphism (RFLP) analyses. Clear loss of heterozygosity (LOH) was found in only 3 out of 20 samples. All three samples were also found to carry a point mutation within the remaining p53 allele. None of these mutations was found to be at the proposed aflatoxin hotspot of amino acid 249. All three point mutations are of somatic origin. Ten samples, randomly chosen from the remaining 17 LOH negative HCC tumors, were analyzed further by DNA sequencing and Western blot analyses. No point mutations of p53 were found. Taken together with our previous report (Hosono et al., 1991, Oncogene vol 6, p. 237-243), we conclude that p53 mutation occurs infrequently, only approximately 18%, in HBV-positive primary hepatomas from Taiwan. Furthermore, p53 mutation appears to be acquired later in tumor development at least in some HCC samples.	UNIV TEXAS,MED BRANCH,SCH MED,DEPT PATHOL,GALVESTON,TX 77550; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Texas System; University of Texas Medical Branch Galveston; National Taiwan University			Shih, Chiaho/S-7017-2018		NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48198, KO4 CA01399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; CHIBA I, 1990, ONCOGENE, V5, P1603; DAVIDOFF AM, 1991, J SURG ONCOL, V48, P260, DOI 10.1002/jso.2930480409; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FUJIMOTO Y, 1992, CANCER RES, V52, P1044; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; LAI MY, 1991, PARIS PASTEUR I M HE, P142; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1991, CANCER RES, V51, P49; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; WALKER GJ, 1991, CANCER RES, V51, P4367; WANG WL, 1991, CANCER RES, V51, P4971; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YU MW, 1991, CANCER RES, V51, P5621; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	41	80	81	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					491	496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093978				2022-12-25	WOS:A1993KN00600029
J	KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D				KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D			P56/P53(LYN) TYROSINE KINASE ACTIVATION IN MAMMALIAN-CELLS TREATED WITH MITOMYCIN-C	ONCOGENE			English	Article							DNA-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; NITROGEN-MUSTARD; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; PHOSPHORYLATION; MECHANISM; P34CDC2; DAMAGE	The present studies have examined the effects of mitomycin C (MMC), a genotoxic alkylating agent, on the activation of Src-like protein tyrosine kinases in HL-60 myeloid leukemia cells. The results demonstrate no detectable induction of p59/(fyn) or pp60(c-src) activity. The response of HL-60 cells to MMC however was associated with rapid activation of p56/p53(lyn). Similar findings were obtained with other alkylating agents such as nitrogen mustard and cis-platinum. Activation of p56/p53(lyn) was associated with increased autophosphorylation on tyrosine and sensitivity to the tyrosine kinase inhibitors herbimycin A and genistein. Studies with a glutathione S-transferase-Lyn fusion protein were performed to explore the potential significance of p56/p53(lyn) activation. Analysis of the adsorbates demonstrates interaction of Lyn with the cell cycle regulatory protein, p34(cdc2). Coimmunoprecipitation studies further confirmed the association of p56/p53(lyn) and p34(cdc2) in MMC-treated cells. We also demonstrate that p34(cdc2) undergoes increased phosphorylation on tyrosine following MMC exposure and that p56/p53(lyn) phosphorylates the Tyr-15 site of p34(cdc2)in vitro. These findings indicate that the cellular response to MMC includes activation of p56/p53(lyn) and that this event may contribute to signals transduced by the DNA damage-dependent mitotic checkpoint.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA019589] Funding Source: NIH RePORTER; NCI NIH HHS [CA19589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P592; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BHUYAN BK, 1992, CANCER RES, V52, P5687; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRANO AV, 1979, MUTAT RES, V63, P175, DOI 10.1016/0027-5107(79)90114-3; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUSRE L, 1989, CHEM-BIOL INTERACT, V71, P63, DOI 10.1016/0009-2797(89)90090-2; EWIG RAG, 1977, CANCER RES, V37, P2114; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTLEY JA, 1992, NUCLEIC ACIDS RES, V20, P3175, DOI 10.1093/nar/20.12.3175; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KHARBANDA S, 1994, CANCER RES, V54, P1412; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LOCK RB, 1990, CANCER RES, V50, P3761; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; UEHARA Y, 1989, CANCER RES, V49, P780; WONG TW, 1984, J BIOL CHEM, V259, P8505; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	50	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084605				2022-12-25	WOS:A1994PG82200028
J	GRADIN, K; WHITELAW, ML; TOFTGARD, R; POELLINGER, L; BERGHARD, A				GRADIN, K; WHITELAW, ML; TOFTGARD, R; POELLINGER, L; BERGHARD, A			A TYROSINE KINASE-DEPENDENT PATHWAY REGULATES LIGAND-DEPENDENT ACTIVATION OF THE DIOXIN RECEPTOR IN HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; NUCLEAR TRANSLOCATOR PROTEIN; AH-RECEPTOR; GLUCOCORTICOID RECEPTOR; MESSENGER-RNA; HSP90; GENE; EXPRESSION; PHOSPHORYLATION	Signal transduction by dioxin is mediated by the intracellular basic helix-loop-helix dioxin receptor which, in its ligand-activated state, binds to target DNA as a heteromeric complex with the partner factor Arnt. In contrast, the repressed form of the receptor is a complex with hsp90 which appears to maintain the receptor in an inducible conformation. In human keratinocytes dioxin receptor activation has previously been shown to depend on phosphorylation processes. To further dissect mechanisms regulating dioxin receptor function the importance of tyrosine phosphorylation was investigated by the use of specific tyrosine kinase inhibitors. Here we report that the inhibitor genistein inhibited dioxin-dependent induction of expression of the target gene cytochrome P-450IA1. This effect wits rapid and reversible and did not lead to altered levels of dioxin receptor protein. Analyses of dioxin receptor or Arnt fusion proteins that function independently of one another showed that the target for genistein action was the dioxin receptor, and, more specifically, a region of the receptor harboring its ligand-binding domain. In addition, function of an unrelated transactivator, the glucocorticoid receptor, was inhibited by genistein while a truncated form lacking the ligand-binding domain was not. A common denominator between the Ligand-binding domains of both receptors is their ability to interact with hsp90. Importantly, co-immunoprecipitation experiments showed that genistein inhibited ligand-induced release of hsp90 from the glucocorticoid receptor, Thus, the interaction of these transactivators with hsp90 may be regulated by a tyrosine kinase dependent pathway.	KAROLINSKA INST, NOVUM, DEPT MED NUTR, S-14157 HUDDINGE, SWEDEN	Karolinska Institutet	GRADIN, K (corresponding author), KAROLINSKA INST, NOVUM, CTR NUTR & TOXICOL, S-14157 HUDDINGE, SWEDEN.							AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DENIS M, 1988, J BIOL CHEM, V263, P18520; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GRADIN K, 1993, J BIOL CHEM, V268, P4061; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; MARKOVITS J, 1989, CANCER RES, V49, P5111; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOYER ML, 1993, J BIOL CHEM, V268, P22933; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKINO ST, 1992, J BIOL CHEM, V267, P6991; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1991, MOL PHARMACOL, V39, P20; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1988, J BIOL CHEM, V263, P267; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; REINERS JJ, 1991, PROG CLIN BIOL RES, V369, P123; REINERS JJ, 1992, BIOCHEM BIOPH RES CO, V186, P970, DOI 10.1016/0006-291X(92)90841-8; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J, 1989, MOL CLONING LABORATO; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; STRUHL K, 1990, CURRENT PROTOCOLS MO; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	58	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23800	23807						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089152				2022-12-25	WOS:A1994PQ34500063
J	FARVER, O; WHERLAND, S; PECHT, I				FARVER, O; WHERLAND, S; PECHT, I			INTRAMOLECULAR ELECTRON-TRANSFER IN ASCORBATE OXIDASE IS ENHANCED IN THE PRESENCE OF OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTAL-STRUCTURE; PULSE-RADIOLYSIS; ZUCCHINI; FORMS	Intramolecular electron transfer from the type 1 copper center to the type 3 copper(II) pair is induced in the multi-copper enzyme, ascorbate oxidase, following pulse radiolytic reduction of the type 1 Cu(II) ion. In the presence of a slight excess of dioxygen over ascorbate oxidase, interaction between the trinuclear copper center and O-2 is observed even with singly reduced ascorbate oxidase molecules. Under these conditions, the rate constant for intramolecular electron transfer from type 1 Cu(I) to type 3 Cu(II) increases 5-fold to 1100 +/- 300 s(-1) (20 degrees C, pH 5.8) as compared to that of the same process under anaerobic conditions. This observation constitutes evidence for control of the internal electron transfer process by one of its substrates. The structural and functional significance of these findings are discussed.	WASHINGTON STATE UNIV,DEPT CHEM,PULLMAN,WA 99164; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Washington State University; Weizmann Institute of Science	FARVER, O (corresponding author), ROYAL DANISH SCH PHARM,DEPT PHYS CHEM,2 UNIV PARKEN,DK-2100 COPENHAGEN,DENMARK.			Wherland, Scot/0000-0003-1699-5594; Pecht, Israel/0000-0002-1883-9547				ANDREASSON LE, 1976, BIOCHIM BIOPHYS ACTA, V483, P370; Bevington PR, 1969, DATA REDUCTION ERROR; BRANDEN R, 1978, BIOCHIM BIOPHYS ACTA, V524, P297, DOI 10.1016/0005-2744(78)90166-3; BRUNORI M, 1992, FEBS LETT, V314, P191, DOI 10.1016/0014-5793(92)80972-J; FARVER O, 1992, P NATL ACAD SCI USA, V89, P8283, DOI 10.1073/pnas.89.17.8283; FARVER O, 1976, BIOCHEM BIOPH RES CO, V73, P494, DOI 10.1016/0006-291X(76)90734-8; FARVER O, 1978, FEBS LETT, V94, P383, DOI 10.1016/0014-5793(78)80983-1; FARVER O, 1993, J INORG BIOCHEM, V51, P14; FARVER O, 1992, J AM CHEM SOC, V114, P5664; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; KRONECK PMH, 1982, ADV CHEM SER, V220, P223; KYRITSIS P, 1993, J CHEM SOC DALTON, P731, DOI 10.1039/dt9930000731; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MARCHESINI A, 1979, EUR J BIOCHEM, V101, P65, DOI 10.1111/j.1432-1033.1979.tb04217.x; MEISEL D, 1975, J PHYS CHEM-US, V79, P1503, DOI 10.1021/j100582a004; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, EUR J BIOCHEM, V209, P597, DOI 10.1111/j.1432-1033.1992.tb17325.x; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P4619, DOI 10.1021/bi00232a037; NAKAMURA T, 1968, J BIOCHEM-TOKYO, V64, P189, DOI 10.1093/oxfordjournals.jbchem.a128879; NAKAMURA T, 1968, J BIOCHEM-TOKYO, V64, P267, DOI 10.1093/oxfordjournals.jbchem.a128890; Pecht I., 1984, COPPER PROTEINS COPP, V1, P183; Rheinhammar B., 1984, COPPER PROTEINS COPP, V3, P1; TOLLIN G, 1993, BIOCHIM BIOPHYS ACTA, V1183, P309, DOI 10.1016/0005-2728(93)90232-5	27	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22933	22936						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083190				2022-12-25	WOS:A1994PQ16400006
J	PINGOUD, V; ZINCK, R; HIPSKIND, RA; JANKNECHT, R; NORDHEIM, A				PINGOUD, V; ZINCK, R; HIPSKIND, RA; JANKNECHT, R; NORDHEIM, A			HETEROGENEITY OF TERNARY COMPLEX FACTORS IN HELA-CELL NUCLEAR EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; ETS-RELATED PROTEIN; C-FOS PROMOTER; GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; AFFINITY PURIFICATION; FACTOR P62TCF; ELK-1; SRF	Ternary complex factors (TCFs) interact with the serum response factor and DNA containing the c-fos serum response element to form a ternary complex that mediates induction of c-fos. TCF activities were partially purified from HeLa cell nuclear extracts by DNA-cellulose and anion-exchange chromatography followed by two-dimensional gel electrophoresis. Four different protein spots (p60(TCF), p62(TCF), p62.5(TCF), and p64(TCF)) show renaturable TCF activity. One, p62(TCF), was indistinguishable from the Ets protein Elk-1 in gel shift analyses, while none of the HeLa TCFs resembled the other cloned TCFs, SAP-1a and SAP-1b. In two-dimensional gel analysis, Elk-1, SAP-1a, and SAP-1b, displayed different pI and M(r) values and in vitro synthesized Elk-1 comigrated with the p62(TCF) spot. Both reacted with Elk-1 specific antisera, as did the major proportion of TCF activity present in HeLa crude extracts. We conclude that p62(TCF) is composed of Elk-1, whereas the identities of the other identified TCFs (p60(TCF), P62.5(TCF), and p64(TCF)) are still unknown.			PINGOUD, V (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,KONSTANTY GUTSCHOW STR 8,D-30625 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIPSKIND RA, 1994, IN PRESS GENES DEV; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JANKNECHT R, 1992, GENE, V121, P321, DOI 10.1016/0378-1119(92)90137-E; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RAO VN, 1992, ONCOGENE, V7, P65; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHROTER H, 1989, NUCLEIC ACIDS RES, V17, P6415, DOI 10.1093/nar/17.15.6415; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23310	23317						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083237				2022-12-25	WOS:A1994PQ16400063
J	TU, CK; CHEN, X; REN, XL; LOGRASSO, PV; JEWELL, DA; LAIPIS, PJ; SILVERMAN, DN				TU, CK; CHEN, X; REN, XL; LOGRASSO, PV; JEWELL, DA; LAIPIS, PJ; SILVERMAN, DN			INTERACTIONS OF ACTIVE-SITE RESIDUES AND CATALYTIC ACTIVITY OF HUMAN CARBONIC-ANHYDRASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIDE HYDRATION ACTIVITY; BOVINE SKELETAL-MUSCLE; DIRECTED MUTAGENESIS; MECHANISM; EXPRESSION; WATER; PHENYLALANINE-198; HISTIDINE-64; ENHANCEMENT; REPLACEMENT	To elucidate the interactions between residues found in the active-site cavity of human carbonic anhydrase III, we have prepared a series of single and double mutants with Lys-64, Arg-67, and Phe-198 replaced with Ala, Asp, Glu, His, and Leu. Rates of catalysis were determined using O-18 exchange between CO2 and water measured by mass spectrometry and initial velocity measured by stopped-flow spectrophotometry. Replacement of these residues resulted in increases in k(cat)/K-m for CO2 hydration as much as 200-fold and increases in the pK(a), of the zinc-bound water by as much as 3.5 units. We conclude that the effect of replacements made at positions 64, 67, and 198 were in general additive for k(cat)/K-m for CO2 hydration, indicating that there is no interaction between these sites that affects the catalytic interconversion of CO2 and HCO3-. One notable exception is the antagonism exhibited by the double mutant of human carbonic anhydrase III containing Glu-64 and Leu-198. The data also show that one source of the large enhancement of k(cat)/K-m for the mutant containing Asp-198 in human carbonic anhydrase III is the presence of both Asp-198 and Lys-64; when Lys-64 was replaced with Ala, a reduction of catalytic activity was observed. These results provide an additional view of the independent interactions of amino acids that affect the catalytic pathway of isozyme III, the least active of the known carbonic anhydrase isozymes.	UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida				Jewell, David/0000-0001-5931-7588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHEN X, 1993, BIOCHEMISTRY-US, V32, P7861, DOI 10.1021/bi00082a004; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ENGBERG P, 1984, FEBS LETT, V170, P326, DOI 10.1016/0014-5793(84)81337-X; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; FORSMAN C, 1988, FEBS LETT, V229, P360, DOI 10.1016/0014-5793(88)81156-6; GEERS C, 1991, CARBONIC ANHYDRASES, P227; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; LLOYD J, 1986, GENE, V41, P233, DOI 10.1016/0378-1119(86)90103-4; LOGRASSO PV, 1991, BIOCHEMISTRY-US, V30, P8463, DOI 10.1021/bi00098a025; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; REN X, 1988, EUR J BIOCHEM, V173, P73, DOI 10.1111/j.1432-1033.1988.tb13968.x; REN X, 1991, EUR J BIOCHEM, V210, P417; REN XL, 1988, BIOCHIM BIOPHYS ACTA, V953, P79, DOI 10.1016/0167-4838(88)90011-8; ROWLETT RS, 1991, J BIOL CHEM, V266, P933; SANYAL G, 1982, MOL PHARMACOL, V22, P211; SEGEL IH, 1975, ENZYME KINETICS, P150; SILVERMAN DN, 1979, J AM CHEM SOC, V101, P6734, DOI 10.1021/ja00516a040; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SIMONSSON I, 1982, EUR J BIOCHEM, V123, P29, DOI 10.1111/j.1432-1033.1982.tb06494.x; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; TU CK, 1986, J BIOL CHEM, V261, P100; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TU CK, 1983, J BIOL CHEM, V258, P8867; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221	38	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23002	23006						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083199				2022-12-25	WOS:A1994PQ16400018
J	WARD, LD; HOWLETT, GJ; DISCOLO, G; YASUKAWA, K; HAMMACHER, A; MORITZ, RL; SIMPSON, RJ				WARD, LD; HOWLETT, GJ; DISCOLO, G; YASUKAWA, K; HAMMACHER, A; MORITZ, RL; SIMPSON, RJ			HIGH-AFFINITY INTERLEUKIN-6 RECEPTOR IS A HEXAMERIC COMPLEX CONSISTING OF 2 MOLECULES EACH OF INTERLEUKIN-6, INTERLEUKIN-6 RECEPTOR, AND GP-130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; HUMAN IL-6; PURIFICATION; EXPRESSION; TRANSDUCER; CLONING; BINDING; GP130	The high affinity human interleukin-6 (IL-6) receptor complex consists of IL-6 and two membrane-associated receptor components, the IL-6 receptor (alpha-subunit) and the high affinity converter and signal transducing molecule, gp-130 (beta-subunit). Recombinant IL-6 and the extracellular (''soluble'') components of the IL-6 receptor (sIL-6R) and gp-130 (sgp-130) have been prepared in order to investigate the stoichiometry and binding of these components in the low affinity (IL-6.sIL-6R) and high affinity (IL-6 sIL-6R.sgp-130) IL-6 receptor complexes. Using a combination of size-exclusion chromatography and analytical ultracentrifugation analysis, in the low affinity receptor complex, IL-6 was shown to bind sIL-6R in a stoichiometric ratio of 1:1, whereas the high affinity ternary complex is hexameric consisting of two molecules each of IL-6, sIL-6R, and sgp-130. This is the first direct demonstration of a higher order arrangement for receptor cytokine interactions that exhibit both high and low affinity complexes.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LUDWIG INST CANC RES MELBOURNE,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA; TOSOH CORP,AYASE,KANAGAWA 252,JAPAN	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; Tosoh Corporation			Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DALLESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS R, 1993, J BIOL CHEM, V268, P6581; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; MAY LT, 1991, J BIOL CHEM, V266, P9950; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WARD LD, 1992, BIOCHEM INT, V26, P559; WARD LD, 1994, TECHNIQUES PROTEIN C, V5; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YET MG, 1993, BLOOD, V82, P1713, DOI 10.1182/blood.V82.6.1713.bloodjournal8261713; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	24	214	217	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23286	23289						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083235				2022-12-25	WOS:A1994PQ16400059
J	PEREZMARTIN, J; TIMMIS, KN; DELORENZO, V				PEREZMARTIN, J; TIMMIS, KN; DELORENZO, V			COREGULATION BY BENT DNA - FUNCTIONAL SUBSTITUTIONS OF THE INTEGRATION HOST FACTOR SITE AT SIGMA(54)-DEPENDENT PROMOTER PU OF THE UPPER-TOL OPERON BY INTRINSICALLY CURVED SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPPER PATHWAY OPERON; ESCHERICHIA-COLI; PSEUDOMONAS-PUTIDA; BACTERIOPHAGE-MU; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATOR; KLEBSIELLA-PNEUMONIAE; CHROMOSOMAL INSERTION; FACTOR PROTEIN; BINDING-SITES	The role of integration host factor (IHF) in the regulation of the sigma(54)-dependent promoter Pu of the TOL plasmid of Pseudomonas putida has been examined. We have selected in vivo insertions of intrinsically curved DNA that restore the responsiveness of an IHF-binding site deletion variant of Pu to the cognate activator of the system, XylR. We found five Pu derivatives which had inserted a core sequence with 6 phased [A](6) tracts, flanked by different lengths of DNA at the location of the former IHF site. They displayed 40-100% of the activity of Pu, were independent of IHF, and maintained the overall geometry of the wild-type promoter. The induction patterns of Pu, compared to those of hybrid promoters, were virtually indistinguishable. This supports the notion that, in native conditions, IHF co-regulates the system by providing a structural aid for promoter architecture and not by interacting directly with the RNA polymerase, as it has been suggested with other known IHF-dependent promoters.	CSIC, CTR INVEST BIOL, E-28006 MADRID, SPAIN; GESELL BIOTECHNOL FORSCH MBH, NATL RES CTR BIOTECHNOL, D-38124 BRAUNSCHWEIG, GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Gesellschaft fur Biotechnologische Forschung mbH			Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1993, MOL GEN GENET, V239, P281, DOI 10.1007/BF00281629; ABRIL MA, 1991, J BIOL CHEM, V266, P15832; ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; ALAZARD R, 1992, MOL MICROBIOL, V6, P1707, DOI 10.1111/j.1365-2958.1992.tb00895.x; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, J BACTERIOL, V175, P6902, DOI 10.1128/jb.175.21.6902-6907.1993; DELORENZO V, 1988, FEMS MICROBIOL LETT, V50, P17, DOI 10.1016/0378-1097(88)90203-0; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DIXON R, 1986, MOL GEN GENET, V203, P129, DOI 10.1007/BF00330393; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMA MJ, 1992, MOL MICROBIOL, V6, P1715, DOI 10.1111/j.1365-2958.1992.tb00896.x; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; HARAYAMA S, 1989, GENETICS BACTERIAL D, P154; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; INOUYE S, 1983, J BACTERIOL, V155, P1192, DOI 10.1128/JB.155.3.1192-1199.1983; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; Maniatis T., 1982, MOL CLONING; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; SANTERO E, 1992, J MOL BIOL, V227, P602, DOI 10.1016/0022-2836(92)90211-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	51	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22657	22662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077217				2022-12-25	WOS:A1994PQ16300033
J	ELIAS, JA; ZHENG, T; EINARSSON, O; LANDRY, M; TROW, T; REBERT, N; PANUSKA, J				ELIAS, JA; ZHENG, T; EINARSSON, O; LANDRY, M; TROW, T; REBERT, N; PANUSKA, J			EPITHELIAL INTERLEUKIN-11 - REGULATION BY CYTOKINES, RESPIRATORY SYNCYTIAL VIRUS, AND RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; ALVEOLAR MACROPHAGES; CELL-LINE; NEUTRAL ENDOPEPTIDASE; AIRWAY RESPONSIVENESS; TOLUENE DIISOCYANATE; MOLECULAR-CLONING; IL-6 PRODUCTION; EXPRESSION	Interleukin-11 (IL-11) is a pleotropic cytokine with effects that overlap with IL-6. To determine if IL-11 is produced by epithelial cells, we determined whether human alveolar A549 cells and airway 9HTE cells produce IL-11. We also determined whether retinoic acid (RA) altered this II-11 production. Unstimulated cells produced low levels of IL-11, while IL-1, transforming growth factor (TGF-beta(1)), and respiratory syncytial virus (RSV) stimulated IL-11 protein production and mRNA accumulation in a time- and dose dependent fashion. IL-1 and TGF-beta(1) also interacted in a synergistic, and presumedly transcriptional, fashion since they augmented A549 cell IL-11 protein production and mRNA accumulation without altering IL-11 mRNA half-life. In contrast, IL-4 only weakly stimulated, and IL-7, hepatocyte growth factor, and herpes simplex virus Type 2 did not stimulate, IL-11 production. RA did not alter the IL-11 production of unstimulated or RSV infected cells. It did, however, inhibit rIL-1-stimulated and synergistically augment TGF-beta-stimulated IL-11 production. Thus, IL-1, TGF-beta, and RSV stimulate epithelial-like cell IL-11 production, and RA regulates these inductive processes in a stimulus-specific fashion.	YALE UNIV,SCH MED,DEPT LAB MED,NEW HAVEN,CT 06510; W HAVEN VET ADM HOSP,RES SERV,W HAVEN,CT 06516; CASE WESTERN RESERVE UNIV,SCH MED,CTR AIRWAY DIS,DEPT INTERNAL MED,CLEVELAND,OH 44106	Yale University; Case Western Reserve University	ELIAS, JA (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE MED SECT,333 CEDAR ST,105 LCI,NEW HAVEN,CT 06510, USA.				NHLBI NIH HHS [HL-36708, HL-41216] Funding Source: Medline; NIAID NIH HHS [AI-34953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036708, R01HL041216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1991, EOSINOPHILS BIOL CLI, P33; AHERNE W, 1970, J CLIN PATHOL, V23, P7, DOI 10.1136/jcp.23.1.7; ALLEGRA L, 1989, EUR RESP J S, V2, P460; ANDERSON KC, 1992, BLOOD, V80, P2797; BARNES PJ, 1991, AM REV RESPIR DIS, V143, pS28, DOI 10.1164/ajrccm/143.3_Pt_2.S28; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; BRUNO E, 1991, EXP HEMATOL, V19, P378; CHYTIL F, 1992, AM J PHYSIOL, V262, pL517, DOI 10.1152/ajplung.1992.262.5.L517; COYLE AJ, 1993, AM REV RESPIR DIS, V147, P896, DOI 10.1164/ajrccm/147.4.896; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; ELIAS JA, 1991, J IMMUNOL, V146, P3437; ELIAS JA, 1990, J IMMUNOL, V145, P161; ELIAS JA, 1994, J IMMUNOL, V152, P2421; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JETTEN AM, 1991, AM J PHYSIOL, V260, pL361, DOI 10.1152/ajplung.1991.260.6.L361; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; KALB TH, 1991, AM J RESP CELL MOL, V4, P320, DOI 10.1165/ajrcmb/4.4.320; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KOTLOFF RM, 1990, AM J RESP CELL MOL, V3, P497, DOI 10.1165/ajrcmb/3.5.497; KOYAMA S, 1991, J IMMUNOL, V147, P972; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MATTOLI S, 1991, J CELL PHYSIOL, V149, P260, DOI 10.1002/jcp.1041490212; MCINTOSH K, 1990, RESPIRATORY SYNCYTIA, P1045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; MUSASHI M, 1991, BLOOD, V78, P1448; NADEL JA, 1991, AM REV RESPIR DIS, V143, pS33, DOI 10.1164/ajrccm/143.3_Pt_2.S33; NAKANE T, 1990, J IMMUNOL, V145, P260; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; NETTESHEIM P, 1990, ENVIRON HEALTH PERSP, V85, P317, DOI 10.2307/3430692; NEY U M, 1987, Dermatologica (Basel), V175, P93; NILES RM, 1990, AM J RESP CELL MOL, V2, P365, DOI 10.1165/ajrcmb/2.4.365; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; PAINE R, 1993, J IMMUNOL, V150, P4561; PANUSKA JR, 1990, J CLIN INVEST, V86, P113, DOI 10.1172/JCI114672; PANUSKA JR, 1992, AM REV RESPIR DIS, V145, P934, DOI 10.1164/ajrccm/145.4_Pt_1.934; PANUSKA JR, 1990, AM J PHYSIOL, V259, pL396, DOI 10.1152/ajplung.1990.259.6.L396; PATTERSON PH, 1993, CELL, V72, pS123; PAUL SR, 1992, LEUKEMIA RES, V16, P247, DOI 10.1016/0145-2126(92)90062-C; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL SR, 1992, INT J CELL CLONING, V10, P135, DOI 10.1002/stem.5530100303; QUESNIAUX VFJ, 1992, RES IMMUNOL, V143, P385, DOI 10.1016/S0923-2494(05)80071-9; ROBERTS NJ, 1986, J EXP MED, V163, P511, DOI 10.1084/jem.163.3.511; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; SALARI H, 1989, AM J RESP CELL MOL, V1, P245, DOI 10.1165/ajrcmb/1.3.245; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SIDELL N, 1991, J IMMUNOL, V146, P3809; SMITH BT, 1977, AM REV RESPIR DIS, V115, P285; SMITH SM, 1990, AM J RESP CELL MOL, V2, P59, DOI 10.1165/ajrcmb/2.1.59; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; UCHIDA DA, 1993, AM REV RESPIR DIS, V147, P982, DOI 10.1164/ajrccm/147.4.982; VILLANI A, 1991, J BIOL CHEM, V266, P5472; WOOD CR, 1992, J CELL BIOCHEM     S, V16, P93; WRIGHT GP, 1976, SYSTEMIC PATHOLOGY, P270; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211	67	130	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22261	22268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071352				2022-12-25	WOS:A1994PE09800053
J	HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF				HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF			RARE VARIANT (GLU TO LYS) IN THE LEUCINE-ZIPPER REGION OF CHOP (GADD153)	ONCOGENE			English	Note							GENE; TRANSCRIPTION; LIPOSARCOMA; PROTEIN; FUSION	CHOP (GADD153) has been shown to be a dominant negative inhibitor of specific transcription factors. Direct sequencing of the gene, amplified from the DNA of a Li-Fraumeni family index case (liposarcoma, breast cancer) revealed a constitutional variant within the coding region. This alteration, though not responsible for the Li-Fraumeni phenotype, resulted in a glutamic acid to lysine switch within the leucine zipper domain, at a residue conserved between CHOP and its potential target molecules and between the human and hamster sequences. The variant created a Tag I restriction fragment length polymorphism (RFLP) facilitating screening. Analysis of 159 breast tumour DNA samples detected two encoding variant alleles (tumour and constitutional DNA).	CHRISTIE CRC RES CTR,CRC,PAEDIAT & FAMILIAL RES GRP,MANCHESTER,LANCS,ENGLAND		HEIGHWAY, J (corresponding author), CHRISTIE CRC RES CTR,PATERSON INST CANC RES,CRC,DEPT CANC GENET,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439	9	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2737	2738						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058339				2022-12-25	WOS:A1994PC05400037
J	LOGRASSO, PV; CORNELLHENNON, S; BOETTCHER, BR				LOGRASSO, PV; CORNELLHENNON, S; BOETTCHER, BR			CLONING, EXPRESSION, AND CHARACTERIZATION OF HUMAN APOLIPOPROTEIN(A) KRINGLE IV37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMINOGEN KRINGLE-4; CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; LYSINE-BINDING SITE; OMEGA-AMINO ACIDS; T7 RNA-POLYMERASE; RISK FACTOR; MYOCARDIAL-INFARCTION; LP(A) LIPOPROTEIN; ESCHERICHIA-COLI	A portion of kringle IV37 (KIV37) of apolipoprotein (a), (apo(a)), was polymerase chain reaction-cloned from human liver cDNA The protein product of this clone was expressed in Escherichia coli as a poly histidine fusion protein. Based on recovery of purified fusion apo(a) KIV37 protein expression levels were estimated to be 10 mg/g of E. coli cell paste. Mass spectral analysis showed the molecular mass of fusion apo(a) KIV37 to be 12,260 +/- 1 daltons. Almost all fusion apo(a) KIV37 was expressed as inclusion bodies and had to be refolded. Fusion apo(a) KIV37 was isolated from the inclusion bodies and purified by lysine-Sepharose affinity chromatography by eluting with 0.2 M epsilon-aminocaproic acid. The fusion protein was treated with thrombin to yield a homogeneous, functional apo(a) KIV37 domain composed of 92 amino acids having a molecular mass of 10,510 +/- 1 daltons. N-terminal protein sequencing and amino acid analysis have confirmed the sequence and composition of apo(a) KIV37. The molar extinction coefficient, epsilon, apo(a) KIV37 was determined to be 3.1. x 10(4) M(-1) cm(-1), and the pI was measured to be 6.7 +/- 0.1. In addition, the dissociation constants, K-d, for a series of 11 lysine analogs have been determined by measuring the change in intrinsic fluorescence of apo(a) KIV37 upon saturable binding with these compounds. K-d values ranged from 4.2 +/- 0.9 mu M for trans-4-(aminomethyl)cyclohexanecarboxylic acid to 4.6 +/- 0.4 mM for L-arginine. Apo(a) KIV37 binds to plasmin-treated fibrinogen with an EC(50) value of 14 +/- 1.2 mu M and prevents the binding of Lp(a) to plasmin-treated fibrinogen with an IC50 value of 16 +/- 6 mu M. Lp(a) binds to the plasmin-treated fibrinogen surface-with an EC(50) value of approximately 1.0 +/- 0.3 nM. These studies demonstrate that apo(a) KIV37 Can be expressed at high levels, refolded properly, and used as a fully functional lysine-binding domain. In addition, these results also demonstrate that apo(a) KIV37 provides the major interaction of Lp(a) with fibrinogen. One additional weak binding site in Lp(a) is adequate to describe overall Lp(a) binding to fibrinogen.	SANDOZ PHARMACEUT CORP,PRECLIN RES,DEPT ATHEROSCLEROSIS & VASC BIOL,E HANOVER,NJ 07936	Novartis; Sandoz								ALBERS JJ, 1977, J LIPID RES, V18, P331; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BARBIR M, 1992, LANCET, V340, P1500, DOI 10.1016/0140-6736(92)92756-6; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1558, DOI 10.1161/01.ATV.13.11.1558; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CASTELLINO FJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P312, DOI 10.1016/0003-9861(86)90589-8; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DESMARAIS RL, 1993, CIRCULATION, V88, P272; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DIEKSTALL F, 1987, OPHTHALMOLOGIE, V84, P369; DURRINGTON PN, 1988, LANCET, V1, P1070; EZRATTY A, 1993, BIOCHEMISTRY-US, V32, P4628, DOI 10.1021/bi00068a021; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HAMSTEN A, 1987, LANCET, V2, P3; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HEARN JA, 1992, AM J CARDIOL, V69, P736, DOI 10.1016/0002-9149(92)90497-M; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; HOOVERPLOW JL, 1993, BIOCHEMISTRY-US, V32, P13681, DOI 10.1021/bi00212a037; HOWARD GC, 1993, LAB INVEST, V69, P373; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JURGENS G, 1993, CIRCULATION, V88, P169; KEMP P, 1994, J CELL BIOCH SA, V18, P279; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; LI ZG, 1992, PROTEIN EXPRES PURIF, V3, P212, DOI 10.1016/1046-5928(92)90017-Q; LLINAS M, 1985, J BIOSCIENCE, V8, P121, DOI 10.1007/BF02703971; LOGRASSO PV, 1993, ARCH BIOCHEM BIOPHYS, V307, P193, DOI 10.1006/abbi.1993.1578; LOSCALZO J, 1987, J CLIN INVEST, V78, P1112; MARTH E, 1982, ANN NUTR METAB, V26, P56, DOI 10.1159/000176544; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MIYATA M, 1992, CIRCULATION, V86, P54; MOLITERNO DJ, 1993, CIRCULATION, V88, P935, DOI 10.1161/01.CIR.88.3.935; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; Muller H M, 1992, Ger J Ophthalmol, V1, P338; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; NAKAMURA CE, 1985, BIOCHEMISTRY-US, V24, P1364, DOI 10.1021/bi00327a014; NIELSEN PR, 1993, BIOCHEMISTRY-US, V32, P13019, DOI 10.1021/bi00211a010; NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6; PARRA HJ, 1987, CLIN CHEM, V33, P721; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; PFAFFINGER D, 1993, BIOCHIM BIOPHYS ACTA, V1225, P107, DOI 10.1016/0925-4439(93)90130-S; RAMESH V, 1987, J MOL BIOL, V198, P481, DOI 10.1016/0022-2836(87)90295-6; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RHOADS GG, 1978, AM J EPIDEMIOL, V108, P350, DOI 10.1093/oxfordjournals.aje.a112631; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANU AM, 1993, BIOCHEM PHARMACOL, V46, P1675, DOI 10.1016/0006-2952(93)90570-M; SCANU AM, 1993, J CLIN INVEST, V91, P283, DOI 10.1172/JCI116182; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SIMON DI, 1993, CURR OPIN CARDIOL, V8, P814, DOI 10.1097/00001573-199309000-00015; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTONTYRRELL K, 1994, STROKE, V25, P44, DOI 10.1161/01.STR.25.1.44; THEWES T, 1987, BIOCHIM BIOPHYS ACTA, V912, P254, DOI 10.1016/0167-4838(87)90096-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYRRELL J, 1992, J INTERN MED, V232, P349, DOI 10.1111/j.1365-2796.1992.tb00596.x; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; VALI Z, 1982, J BIOL CHEM, V257, P2104; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; WILLIAMS JK, 1993, ARTERIOSCLER THROMB, V13, P548, DOI 10.1161/01.ATV.13.4.548; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030; YIYI Z, 1993, CHINESE MED J, V106, P597; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	81	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21820	21827						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063825				2022-12-25	WOS:A1994PK97300065
J	CRIVELLONE, MD				CRIVELLONE, MD			CHARACTERIZATION OF CBP4, A NEW GENE ESSENTIAL FOR THE EXPRESSION OF UBIQUINOL-CYTOCHROME-C REDUCTASE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; YEAST NUCLEAR GENE; COENZYME QH2-CYTOCHROME-C REDUCTASE; PRE-MESSENGER-RNA; DNA-SEQUENCE; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; 14-KDA SUBUNIT; 11-KDA SUBUNIT; PROTEIN	Nuclear respiratory deficient mutants of Saccharomyces cerevisiae have been screened for lesions in genes affecting ubiquinol-cytochrome c reductase activity. In the present study we describe a new gene, CBP4, whose encoded product is absolutely essential for the activity and expression of the respiratory enzyme. We have cloned and sequenced CBP4, which encodes a 20-kDa protein having no obvious homology to any known protein. cbp4 mutants are unable to respire due to specific loss of ubiquinol-cytochrome c reductase activity. cbp4 mutants demonstrate a pleiotropic reduction in the steady state levels of four subunits of ubiquinol-cytochrome c reductase, namely core 4, core 5, the Rieske protein and cytochrome b. Cytochrome b is not spectrally visible in the mutants, although transcription and translation of the apoprotein is normal. Antiserum prepared against a trpE/CBP4 gene fusion react with an 18.4-kDa mitochondrial protein in wild type yeast, but the protein is not found in a mutant containing a deletion of 86% of the CBP4 coding region. CBP4 protein is tightly associated with the mitochondrial membrane as evidenced by the association of the protein with the membrane fraction following carbonate extraction. The phenotype of cbp4 mutants is similar to that of cbp3 mutants. CBP3 encodes a second protein essential for ubiquinol-cytochrome c reductase activity. We found that loss of CBP3 protein does not affect the membrane stability or steady state concentration of CBP4 protein. A double mutant containing a deletion in both CBP3 and CBP4 was constructed. Our study shows that the phenotype of the double mutant is identical to the phenotypes of the individual single mutants.			CRIVELLONE, MD (corresponding author), SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA.							ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; Berden J.A., 1988, MOL BASIS BIOMEMBRAN, P195; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DEHAAN M, 1984, EUR J BIOCHEM, V138, P169; DIECKMANN CL, 1983, METHOD ENZYMOL, V97, P355; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KATAN MB, 1976, EUR J BIOCHEM, V65, P95, DOI 10.1111/j.1432-1033.1976.tb10393.x; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAARSE AC, 1987, EUR J BIOCHEM, V165, P419, DOI 10.1111/j.1432-1033.1987.tb11455.x; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; Maniatis T, 1989, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHAELIS U, 1988, MOL GEN GENET, V214, P263, DOI 10.1007/BF00337720; MUROFF I, 1990, EMBO J, V9, P2765, DOI 10.1002/j.1460-2075.1990.tb07464.x; NOBREGA FG, 1980, J BIOL CHEM, V255, P9828; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PILLAR T, 1983, J BIOL CHEM, V258, P7954; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUBIN MS, 1973, J BIOL CHEM, V248, P4269; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHMIDT RJ, 1983, J CELL BIOL, V96, P1451, DOI 10.1083/jcb.96.5.1451; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; SCHOPPINK PJ, 1987, ADV MEMBRANE BIOCH B, P129; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SIDHU A, 1982, J BIOL CHEM, V257, P7879; TZAGOLOFF A, 1990, UCLA SYM BI, V133, P71; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1988, PHILOS T ROY SOC B, V319, P107, DOI 10.1098/rstb.1988.0035; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1980, BIOL CHEM ORGANELLE, P1; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; WU M, 1989, J BIOL CHEM, V264, P11122	56	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21284	21292						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063753				2022-12-25	WOS:A1994PC40300071
J	MORTON, ME; CASSIDY, TN; FROEHNER, SC; GILMOUR, BP; LAURENS, RL				MORTON, ME; CASSIDY, TN; FROEHNER, SC; GILMOUR, BP; LAURENS, RL			ALPHA(1) AND ALPHA(2) CA2+ CHANNEL SUBUNIT EXPRESSION IN HUMAN NEURONAL AND SMALL-CELL CARCINOMA-CELLS	FASEB JOURNAL			English	Article						LAMBERT-EATON SYNDROME; CALCIUM CHANNEL; NEUROBLASTOMA	EATON MYASTHENIC SYNDROME; SENSITIVE CALCIUM-CHANNEL; MEMBRANE ACTIVE ZONES; MOTOR-NERVE TERMINALS; LUNG-CARCINOMA; MONOCLONAL-ANTIBODY; OMEGA-CONOTOXIN; TUMOR-CELLS; IGG; ALPHA-1-SUBUNIT	Monoclonal antibodies that recognize skeletal muscle dihydropyridine-sensitive calcium channel subunits were used to identify similar proteins in neuronal and small cell carcinoma cell lines. alpha(1)-related proteins were detected by FACS analysis on the surface of human neuroblastoma (IMR 32) and small cell carcinoma (DMS 273 and DMS 114) cell lines. alpha(1)-like polypeptides from these cells were isolated and partially characterized. The polypeptides exhibit an M(r) similar to that of the L-type channel alpha(1) subunit and are recognized by two distinct anti-alpha(1) mAbs. The data provide biochemical evidence for structural similarities between the alpha(1) subunit of small cell carcinoma and neuronal cell lines. Similarly, an alpha(2)-like protein was characterized from these cells. Because alpha(2) is a subunit shared by many subtypes of calcium channels, these data suggest that subunits other than the pore-forming alpha(1) subunit may play an important role in etiology of Lambert-Eaton syndrome. We demonstrate directly that small cell carcinoma and a cell line derived from peripheral neurons share L-type calcium channel-related proteins and a protein common to many voltage-gated calcium channel subtypes. These data support a model that proposes that cross-reactivity of anti-tumor cell antibodies with presynaptic elements, possibly calcium channels, plays a role in the development of Lambert-Eaton syndrome.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03756; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	Dartmouth College; University of North Carolina; University of North Carolina Chapel Hill	MORTON, ME (corresponding author), COLL HOLY CROSS,DEPT BIOL,WORCESTER,MA 01610, USA.							BALL ED, 1987, CANCER RES, V47, P6556; BERGH J, 1985, AM J CLIN PATHOL, V84, P1; COHEN MW, 1991, J NEUROSCI, V11, P1032; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; FUKUNAGA H, 1982, MUSCLE NERVE, V5, P686, DOI 10.1002/mus.880050905; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LAMBERT EH, 1982, MUSCLE NERVE, V5, pS39; LAMBERT EH, 1971, ANN NY ACAD SCI, V183, P183, DOI 10.1111/j.1749-6632.1971.tb30750.x; LANG B, 1981, LANCET, V2, P224; LANG B, 1989, ANN NEUROL, V25, P265, DOI 10.1002/ana.410250310; LANG B, 1983, J PHYSIOL-LONDON, V344, P335, DOI 10.1113/jphysiol.1983.sp014943; LOGIN IS, 1987, ANN NEUROL, V22, P610, DOI 10.1002/ana.410220509; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MORTON ME, 1987, J BIOL CHEM, V262, P11904; MORTON ME, 1988, J BIOL CHEM, V263, P613; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; PANCRAZIO JJ, 1989, CANCER RES, V49, P5901; PEERS C, 1990, J PHYSIOL-LONDON, V421, P293, DOI 10.1113/jphysiol.1990.sp017945; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SEAGAR MJ, 1993, BIOCHEM SOC T, V21, P423, DOI 10.1042/bst0210423; SHER E, 1990, CANCER RES, V50, P3892; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; TAPIA FJ, 1981, LANCET, V1, P808; TISCHLER AS, 1977, J PATHOL, V122, P153, DOI 10.1002/path.1711220306; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4	32	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1994	8	11					884	888		10.1096/fasebj.8.11.8070639	http://dx.doi.org/10.1096/fasebj.8.11.8070639			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PC885	8070639				2022-12-25	WOS:A1994PC88500013
J	SKACH, WR; CALAYAG, MC; LINGAPPA, VR				SKACH, WR; CALAYAG, MC; LINGAPPA, VR			EVIDENCE FOR AN ALTERNATE MODEL OF HUMAN P-GLYCOPROTEIN STRUCTURE AND BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; STOP TRANSFER; BACTERIAL TRANSPORT; PRION PROTEIN; SEQUENCE; MEMBRANE; ORIENTATION; INVITRO; GLYCOSYLATION; ANTIBODIES	We have studied the transmembrane topology of human P-glycoprotein (MDR1) using protein chimeras in Xenopus oocytes and full-length native protein in a cell-free translation system. We find both in vivo and in vitro, that the peptide region between putative transmembrane helices (TM) 8 and 9 resides in the endoplasmic reticulum lumen not in the cytosol as predicted. The topology of the carboxyl-terminal half of MDR1 therefore appears distinct from the homologous amino-terminal half in which the corresponding region between TM2 and TM3 is cytosolic. Thus, topogenic sequences encoded in the homologous amino and carboxyl domains of MDR1 direct fundamentally different events in biogenesis of the two halves of MDR1. We conclude that the transmembrane topology of MDR1, an important member of the ATP binding cassette (ABC) transporter superfamily, is not as predicted and should be revised.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CASTILLO G, 1990, P NATL ACAD SCI USA, V87, P4737, DOI 10.1073/pnas.87.12.4737; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1991, BIOCH BASIS MULTIDRU; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KATZ FN, 1979, J CELL BIOL, V80, P416, DOI 10.1083/jcb.80.2.416; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SKACH WR, 1992, INTRACELLULAR TRAFFI, P19; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	28	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6903	6908						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096508				2022-12-25	WOS:A1993KV14100019
J	PAHL, HL; SCHEIBE, RJ; ZHANG, DE; CHEN, HM; GALSON, DL; MAKI, RA; TENEN, DG				PAHL, HL; SCHEIBE, RJ; ZHANG, DE; CHEN, HM; GALSON, DL; MAKI, RA; TENEN, DG			THE PROTOONCOGENE PU.1 REGULATES EXPRESSION OF THE MYELOID-SPECIFIC CD11B PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA FUSES; LUCIFERASE REPORTER GENE; TRANSCRIPTION FACTOR; PUTATIVE ONCOGENE; RAR-ALPHA; DIFFERENTIATION; CELLS; SPI-1; TRANSLOCATION; MACROPHAGE	The myeloid integrin CD11b is expressed selectively on the surface of mature monocytes, macrophages, granulocytes, and natural killer cells. Tissue-specific and developmentally regulated expression of CD11b is controlled at the level of mRNA transcription, and recent characterization of the human CD11b promoter indicates that the first 92 bp of 5'-flanking DNA are sufficient to direct tissue-specific expression of a reporter gene. Here we show that the sequence AAAAGGAGAAG at base pair -20 of the CD11b promoter binds the proto-oncogene PU.1 in vitro and that mutation of this site significantly reduces the ability of the CD11b promoter to direct expression of a reporter gene in myeloid cells but not in nonmyeloid cells. PU.1 may thus represent a major determinant of the myeloid expression of CD11b.	BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,RES E 219,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Sanford Burnham Prebys Medical Discovery Institute			Pahl, Heike/AGM-5260-2022; Galson, Deborah L./E-9370-2010	Galson, Deborah L./0000-0002-2045-8807; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline; NIAID NIH HHS [AI30656] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LARRICK JW, 1980, J IMMUNOL, V125, P6; Maxam A M, 1980, Methods Enzymol, V65, P499; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; ROBERTS WM, 1992, BLOOD, V79, P586; ROSMARIN AG, 1989, BLOOD, V73, P131; ROSMARIN AG, 1992, BLOOD, V79, P2598; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; TODD RF, 1981, J IMMUNOL, V126, P1435; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	30	299	301	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5014	5020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095266				2022-12-25	WOS:A1993KP88400068
J	SAMAMA, P; COTECCHIA, S; COSTA, T; LEFKOWITZ, RJ				SAMAMA, P; COTECCHIA, S; COSTA, T; LEFKOWITZ, RJ			A MUTATION-INDUCED ACTIVATED STATE OF THE BETA(2)-ADRENERGIC RECEPTOR - EXTENDING THE TERNARY COMPLEX MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; AGONIST BINDING; CYCLASE; PROTEIN; PHOSPHORYLATION; EXPRESSION; KINASE; LIGAND	We have replaced the C-terminal portion of the third intracellular loop of the beta2-adrenergic receptor (residues 266-272) with the homologous region of the alpha1B-adrenergic receptor. In a fashion analogous to the reciprocal mutations of the alpha1B receptor previously described (Cotecchia, S., Exum, S., Caron, M. G., and Lefkowitz, R. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2896-2900), this conservative substitution leads to agonist-independent activation of adenylyl cyclase. In addition, the constitutively active mutant receptor exhibits: (i) an increased affinity for agonists (even in the absence of guanine nucleotide-binding regulatory protein (G protein)) but not antagonists, with the extent of affinity increase being correlated with the intrinsic activity of the ligand; (ii) an increased potency of agonists for stimulation of adenylyl cyclase; and (iii) an increased intrinsic activity of partial agonists. We document that our experimental findings with the mutant receptor cannot be adequately rationalized within the theoretical framework of the Ternary Complex Model (De Lean, A., Stadel, J. M., and Lefkowitz, R. J. (1980) J. Biol. Chem. 255, 7108-7117) which postulates that receptor activation requires the agonist-promoted formation of an active, ''ternary'' complex of agonist, receptor, and G protein. We show, through extensive computer simulations, that an extended version of this model that includes an explicit isomerization of the receptor (R) to an active state (R*) closely models all our findings for both the mutant and the wild-type receptors. Study of such constitutively active mutant G protein-coupled receptors should help elucidate the molecular nature of the processes involved in receptor activation.	DUKE UNIV,MED CTR,DEPT MED CARDIOL,RM 468,CARL BLDG,RES DR,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; IST SUPER SANITA,FARMACOL LAB,I-00161 ROME,ITALY	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Istituto Superiore di Sanita (ISS)			Lefkowitz, Robert/AAW-2649-2021; costa, tommaso/AAD-3714-2019	costa, tommaso/0000-0002-8729-3357	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [4R37-HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; CARON MG, 1979, J BIOL CHEM, V254, P2923; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; CONTRERAS ML, 1986, J PHARMACOL EXP THER, V237, P165; COSTA T, 1992, MOL PHARMACOL, V41, P549; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EHLERT FJ, 1985, MOL PHARMACOL, V28, P410; FURCHGOTT RF, 1978, FED PROC, V37, P115; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; KENT RS, 1980, MOL PHARMACOL, V17, P14; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PIKE LJ, 1978, MOL PHARMACOL, V14, P370; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; THRON CD, 1973, MOL PHARMACOL, V9, P1; TSAI BS, 1978, MOL PHARMACOL, V14, P540; WREGGET KA, 1984, MOL PHARMACOL, V28, P214	29	1130	1157	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4625	4636						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095262				2022-12-25	WOS:A1993KP88400014
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			FUNCTIONAL CONSEQUENCES OF PROLINE MUTATIONS IN THE PREDICTED TRANSMEMBRANE DOMAIN OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; BACTERIAL TRANSPORT PROTEINS; SARCOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; DEPENDENT TRANSPORT; PHOTOACTIVE ANALOGS; CYSTIC-FIBROSIS; PLASMA-MEMBRANE; CDNA SEQUENCE; MOUSE MDR1	Site-directed mutagenesis was used to investigate whether prolines in the predicted transmembrane domains play essential roles in the function of human P-glycoprotein. Mutant cDNAs in which codons for each of the 13 prolines were changed to alanine were expressed in mouse NIH 3T3 cells and analyzed with respect to their ability to confer resistance to various drugs. Mutations of either Pro223 in transmembrane segment 4 or Pro866 in transmembrane segment 10, drastically reduced the ability of the mutant proteins to confer resistance to colchicine, adriamycin, or actinomycin D, whereas the capacity to confer resistance to vinblastine was retained. These results strongly suggest that residues in putative transmembrane segments 4 and 10, which are found in identical positions when homologous, presumably duplicated, halves of the transporter are aligned, play important roles in recognition of colchicine, adriamycin, and actinomycin D. They may either interact to form a single drug-binding site or form part of two equivalent, but independent, drug-binding sites. The lack of detectable effect of either mutation on vinblastine transport, however, indicates that there are differences in the requirements for binding of various substrates to P-glycoprotein. Mutation of Pro709 in transmembrane segment 7 resulted in a protein unable to confer drug resistance. A change at this position was found to induce a structural aberration, since the major protein product observed in transfected cells had an apparent molecular weight of 150,000, whereas the wild-type enzyme had an apparent molecular weight of approximately 170,000. Mutation of the other 10 prolines yielded protein products with structural and functional characteristics indistinguishable from wild-type P-glycoprotein.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DEVINE SE, 1991, J BIOL CHEM, V266, P4545; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURUNKA PF, 1989, FASEB J, V3, P2583; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; NAITO M, 1988, J BIOL CHEM, V263, P11887; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P17; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA K, 1987, J BIOL CHEM, V262, P505; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YUSA K, 1989, CANCER RES, V49, P5002; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	47	151	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3143	3149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8094081				2022-12-25	WOS:A1993KM16100022
J	LINARDIC, CM; HANNUN, YA				LINARDIC, CM; HANNUN, YA			IDENTIFICATION OF A DISTINCT POOL OF SPHINGOMYELIN INVOLVED IN THE SPHINGOMYELIN CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; PHOSPHOLIPID ASYMMETRY; PLASMA-MEMBRANES; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; KAPPA-B; CERAMIDE; DIFFERENTIATION; CHOLESTEROL	Sphingomyelin (SIM) is a membrane phosphosphingolipid that has recently been identified as a key component of the SM cycle. In this signal transduction pathway, extracellular inducers such as tumor necrosis factor ct cause hydrolysis of membrane SM, resulting in the generation of the lipid second messenger ceramide. Only 10-20% of cellular SM appears to be involved in the SM cycle, raising the possibility of the existence of a unique ''signaling'' pool of SM. The existence and subcellular location of such a pool were investigated, Using bacterial sphingomyelinase from Staphylococcus aureus (bSMase), we first characterized two pools of SIM, identified as an outer leaflet bSMase-sensitive pool and a distinct bSMase-resistant pool. These pools were further characterized by their differential solubility in Triton X-100 and by their kinetics of labeling. The signaling pool of SM was distinguished by the following: 1) resistance to bSMase, 2) solubility in Triton X-100, and 3) delayed labeling kinetics. In subfractionation studies, the signaling pool of SM co-fractionated with the plasma membrane. Since the SM cycle involves a cytosolic sphingomyelinase and the intracellular release of choline phosphate, this pool of SM appears to localize to the inner leaflet of the plasma membrane (or to a closely related compartment). These results identify a unique signaling pool of SM that undergoes significant hydrolysis (20-40%) in response to inducers of the SM cycle.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BAXTER A, 1979, ANAL BIOCHEM, V98, P95, DOI 10.1016/0003-2697(79)90711-5; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; CANONICO PG, 1978, J RETICULOENDOTH SOC, V24, P115; COLLEY CM, 1973, BIOCHIM BIOPHYS ACTA, V307, P74, DOI 10.1016/0005-2736(73)90026-6; CULLIS PR, 1980, BIOCHIM BIOPHYS ACTA, V597, P533, DOI 10.1016/0005-2736(80)90225-4; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ENGSTROEM L, 1961, BIOCHIM BIOPHYS ACTA, V52, P36, DOI 10.1016/0006-3002(61)90901-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG BS, 1976, J VIROL, V20, P658, DOI 10.1128/JVI.20.3.658-663.1976; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GAL AE, 1975, NEW ENGL J MED, V293, P632, DOI 10.1056/NEJM197509252931304; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LENARD J, 1976, P NATL ACAD SCI USA, V73, P391, DOI 10.1073/pnas.73.2.391; LINARDIC CM, 1992, J BIOL CHEM, V267, P14909; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mollby R., 1978, BACTERIAL TOXINS CEL, P367; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PATZER EJ, 1978, J BIOL CHEM, V253, P4544; PORN MI, 1991, BIOCHIM BIOPHYS ACTA, V1093, P7; QUINN P, 1992, BIOCHIM BIOPHYS ACTA, V1124, P95, DOI 10.1016/0005-2760(92)90131-E; RAWYLER AJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P130, DOI 10.1016/0005-2736(83)90325-5; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; ROTHMAN JE, 1976, BIOCHEMISTRY-US, V15, P2361, DOI 10.1021/bi00656a018; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAW JM, 1979, BIOCHEMISTRY-US, V18, P538, DOI 10.1021/bi00570a024; TSAI KH, 1975, NATURE, V253, P554, DOI 10.1038/253554a0; VAN MEER G, 1981, BIOCHEMISTRY-US, V20, P1974, DOI 10.1021/bi00510a037; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; WEITZ G, 1985, BIOCHIM BIOPHYS ACTA, V838, P92, DOI 10.1016/0304-4165(85)90254-5; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	54	164	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23530	23537						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089120				2022-12-25	WOS:A1994PQ34500025
J	PEREZ, HD; VILANDER, L; ANDREWS, WH; HOLMES, R				PEREZ, HD; VILANDER, L; ANDREWS, WH; HOLMES, R			HUMAN FORMYL PEPTIDE RECEPTOR-LIGAND BINDING DOMAIN(S) - STUDIES USING AN IMPROVED MUTAGENESIS/EXPRESSION VECTOR REVEAL A NOVEL MECHANISM FOR THE REGULATION OF RECEPTOR OCCUPANCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CONSTRUCTION; EXPRESSION	Recently, we reported the domain requirements for the binding of formyl peptide to its specific receptor Based on experiments using receptor chimeras, we also postulated an importance for the amino terminal domain of the receptor in ligand binding (Perez, H. D., Holmes, R., Vilander, L., Adams, R., Manzana, W., Jolley, D., and Andrews, W. H. (1993) J. Biol. Chem. 268, 2292-2295). We have begun to perform a detailed analysis of the regions within the formyl peptide receptor involved in ligand binding. To address the importance of the receptor amino-terminal domain, we substituted (or inserted) hydrophilic sequences within the amino terminal domain, expressed the receptors, and determined their ability to bind ligand. A stretch of nine amino acids next to the initial methionine was identified as crucial for receptor occupancy. A peptide containing such a sequence specifically competed binding of the ligand to the receptor. Alanine screen mutagenesis of the second extracellular domain also identified amino acids involved in ligand binding as well as a disulfide bond (Cys(98) to Cys(176)) crucial for maintaining the binding pocket. These studies provide evidence for a novel mechanism involved in regulation of receptor occupancy. Binding of the ligand induces conformational changes in the receptor that result in the aposition of the amino-terminal domain over the ligand, providing a lid to the binding pocket.			PEREZ, HD (corresponding author), BERLEX BIOSCI,DEPT IMMUNOL,15049 SAN PABLO AVE,RICHMOND,CA 94804, USA.							BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Perez H D, 1994, Curr Opin Hematol, V1, P40; PEREZ HD, 1992, J BIOL CHEM, V267, P358; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; QUEHENBERGER O, 1994, FASEB J, V8, pA3960	8	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22485	22487						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077194				2022-12-25	WOS:A1994PQ16300008
J	SEHNKE, PC; PEDROSA, L; PAUL, AL; FRANKEL, AE; FERL, RJ				SEHNKE, PC; PEDROSA, L; PAUL, AL; FRANKEL, AE; FERL, RJ			EXPRESSION OF ACTIVE, PROCESSED RICIN IN TRANSGENIC TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMMUNIS AGGLUTININ; PLANT RIBOSOMES; GENE; PRECURSORS; GALACTOSE; PROTEIN; RNA	The cDNA encoding the plant toxin precursor preproricin was introduced into tobacco via Agrobacterium tumefaciens-mediated gene transfer. Transgenic plants were assayed for type II ribosome-inactivating protein expression and activity. Western blot analysis of soluble leaf extracts using anti-ricin a chain (RTA) antibodies identified 34- and 32-kDa proteins, which were electrophoretically indistinguishable from castor seed RTA. Analysis with anti ricin b-chain (RTB) antibodies identified both a 34-kDa protein major band, which co-migrated with castor seed RTB, and a 30-kDa protein minor band. Enzyme-linked immunoassay of the transgenic leaf extracts with anti-RTA and anti-RTE indicated microgram per gram production on a fresh weight basis of soluble extractable recombinant ricin. Sugar binding enzyme-linked immunoassay employing an immobilized glycoprotein, asialofetuin, and anti-RTE antibodies confirmed the characteristic type II ribosome-inactivating protein galactose binding lectin activity of the recombinant ricin. The enzymatic activity of recombinant ricin was characterized for cell-free translation inhibition, as well as for overall cytotoxicity. A 50% inhibitory dose of 3 x 10(-11) nl was observed for the immunoreactive leaf extract material using a rabbit reticulocyte translation inhibition assay, while a 50% lethal dose of 1 x 10(-12) hr was calculated with human T-lymphotropic virus-1 infected leukemic T-cells.	UNIV FLORIDA,DEPT HORT SCI,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; MED UNIV S CAROLINA,CHARLESTON,SC 29425	State University System of Florida; University of Florida; Medical University of South Carolina				Paul, Anna-Lisa/0000-0003-2211-2604; Ferl, Robert/0000-0003-4178-764X	NATIONAL CANCER INSTITUTE [R01CA054116] Funding Source: NIH RePORTER; NCI NIH HHS [CA54116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1979, J BIOL CHEM, V254, P9765; BARBIERI L, 1982, CANCER SURV, V1, P489; BUTTERWORTH AG, 1983, EUR J BIOCHEM, V137, P57, DOI 10.1111/j.1432-1033.1983.tb07795.x; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FOXWELL BMJ, 1985, BIOCHIM BIOPHYS ACTA, V840, P193, DOI 10.1016/0304-4165(85)90119-9; Frankel AE, 1992, GENETICALLY ENG TOXI; HALLING KC, 1985, NUCLEIC ACIDS RES, V13, P8019, DOI 10.1093/nar/13.22.8019; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HIRAIWA N, 1993, PLANT CELL PHYSIOL, V34, P1197; JEFFERSON RA, 1987, EMBO J, V6, P3901; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LOGEMANN J, 1991, J BIOTECHNOL, V10, P305; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; LORD MJ, 1993, POSTTRANSLATIONAL MO, P243; LORD MJ, 1986, PLANT PROTEOLYTIC EN, P69; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; PIATAK M, 1988, ICSU SHORT REP, V8, P62; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; SAMBROOK J, 1989, MOL CLOING LABORATOR; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STOLARZ A, 1991, J PLANT PHYSIOL, V137, P347, DOI 10.1016/S0176-1617(11)80144-6; TAYLOR BE, 1990, FEBS LETT, V273, P144, DOI 10.1016/0014-5793(90)81070-5; VITETTA ES, 1986, J IMMUNOL, V136, P1880; ZENTZ C, 1978, BIOCHIM BIOPHYS ACTA, V536, P18, DOI 10.1016/0005-2795(78)90047-8	28	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22473	22476						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077191				2022-12-25	WOS:A1994PQ16300005
J	WATSON, AJ; KATZ, A; SIMON, MI				WATSON, AJ; KATZ, A; SIMON, MI			A 5TH MEMBER OF THE MAMMALIAN G-PROTEIN BETA-SUBUNIT FAMILY - EXPRESSION IN BRAIN AND ACTIVATION OF THE BETA-2 ISOTYPE OF PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GAMMA-SUBUNITS; ALPHA-SUBUNIT; ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; COILED-COIL; GENE; IDENTIFICATION; STIMULATION	The beta-subunits of the heterotrimeric GTP-binding proteins (G-proteins) are important regulators of G-protein alpha-subunits as well as of certain signal transduction receptors and effectors. We have identified a fifth member of the G-protein beta-subunit family, G beta 5, by molecular cloning. Sequence analysis of recombinant clones revealed an open reading frame of 1,059 base pairs, potentially encoding a protein of 353 amino acids having 53% identity to previously identified G beta-subunit proteins. Northern blot analysis of poly(A)-selected mRNA prepared from different mouse tissues demonstrated that G beta 5 is predominantly expressed in adult brain as two transcripts of 2.3 and 1.75 kilobases. A G beta 5-specific antiserum detected a band of 39.3 kilodaltons on immunoblots of crude membrane proteins isolated from normal mouse brain but not from other tissues. Using a transient cotransfection assay, we showed that a plasmid construct expressing the G beta 5 open reading frame, when coexpressed with different G-protein gamma (G gamma)-subunits, can stimulate the activity of the beta 2 isoform of phosphoinositide-specific phospholipase C (PLC beta 2). The stimulation of PLC beta 2 was most pronounced when G beta 5 was coexpressed with G gamma 2, although activation was observed when G beta 5 was cotransfected with either G gamma 1, G gamma 3, G gamma 5, or G gamma(cone). These results prove that G beta 5 can functionally associate with G gamma proteins and is therefore a bona fide member of the G beta protein family. The rather low level of identity between G beta 5 and the other mammalian G beta-subunits may shed light on structural/sequence elements necessary for G beta protein function.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P495; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RYBA NJP, 1991, BIOCHEM J, V273, P225, DOI 10.1042/bj2730225; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVOORN L, 1990, J MOL BIOL, V213, P17, DOI 10.1016/S0022-2836(05)80118-4; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134	45	214	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22150	22156						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071339				2022-12-25	WOS:A1994PE09800036
J	NAGAO, A; OLSON, JA				NAGAO, A; OLSON, JA			ENZYMATIC FORMATION OF 9-CIS, 13-CIS, AND ALL-TRANS RETINALS FROM ISOMERS OF BETA-CAROTENE	FASEB JOURNAL			English	Note						9-CIS BETA-CAROTENE; CAROTENOID DIOXYGENASE; LIVER; INTESTINE	RETINOIC ACID; VITAMIN-A; CONVERSION; ALPHA	9-cis Retinoic acid is a highly preferred ligand for the nuclear retinoic acid receptor RXR. Although 9-cis retinoic acid can be formed from all-trans retinoic acid in vivo and in vitro, the nature isomerization process has not been defined. Retinoic acid might also be formed biologically from 9-cis beta-carotene, an isomer of beta-carotene commonly found in foods. We have observed that enzyme preparations of rat liver and intestine convert highly purified 9-cis beta-carotene (99.8%) to a mixture of 9-cis, all-trans, and 13-cis retinals. Highly purified all-trans beta-carotene (99.7%) and 13-cis beta-carotene (99%) are primarily converted to all-trans retinal. Several aldehyde dehydrogenases in tissues can convert retinal to retinoic acid. Although the rates of cleavage of 9-cis and 13-cis beta-carotenes are slower than that of the all-trans isomer, the oxidative conversion of 9-cis beta-carotene to 9-cis and all-trans retinals is the first identified enzymatic reaction for the formation of 9-cis retinal in animal tissues.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NCI NIH HHS [CA 46406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA046406, R01CA046406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWAY RJ, 1986, J AGR FOOD CHEM, V34, P409, DOI 10.1021/jf00069a006; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GROENENDIJK GWT, 1980, EUR J BIOCHEM, V106, P119; Hofmann Clementine, 1994, P387; Kouyama T, 1988, Adv Biophys, V24, P123, DOI 10.1016/0065-227X(88)90006-8; KRINSKY NI, 1993, ANN NY ACAD SCI, V691, P167, DOI 10.1111/j.1749-6632.1993.tb26168.x; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1987, AM J CLIN NUTR, V45, P704, DOI 10.1093/ajcn/45.4.704; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; OLSON JA, 1994, MODERN NUTR HLTH DIS, P287; ONEIL CA, 1991, J ASSOC OFF ANA CHEM, V74, P36; RANDO RR, 1994, PURE APPL CHEM, V66, P989, DOI 10.1351/pac199466050989; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; SCHWARTZ SJ, 1992, J CHROMATOGR, V624, P235; THALLER C, 1993, DEVELOPMENT, V118, P957; Underwood BA, 1984, RETINOIDS, P281; VANVLIET T, 1992, NETH J NUTR, V53, P186; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A	24	100	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1994	8	12					968	973		10.1096/fasebj.8.12.8088462	http://dx.doi.org/10.1096/fasebj.8.12.8088462			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PG293	8088462				2022-12-25	WOS:A1994PG29300009
J	AUBERT, S; GOUT, E; BLIGNY, R; DOUCE, R				AUBERT, S; GOUT, E; BLIGNY, R; DOUCE, R			MULTIPLE EFFECTS OF GLYCEROL ON PLANT-CELL METABOLISM - PHOSPHORUS-31 NUCLEAR-MAGNETIC-RESONANCE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE DEPRIVATION; SUSPENSION-CULTURES; BIOCHEMICAL-CHANGES; CARBON; CARBOHYDRATE; PURIFICATION; ENDOSPERM	The effects of glycerol on plant cell metabolism were studied with sycamore (Acer pseudoplatanus L.) cells using (31)p nuclear magnetic resonance spectroscopy. After a long period of sucrose starvation, the addition of 50 mM glycerol to the medium did not restore the original glucose-6-P pool and led to a rapid accumulation of sn-glycerol-3-P in the cytoplasmic compartment. The synthesis of sn-glycerol-3-P was rapid and occurred first at the expense of cytoplasmic P-i. Accumulated sn-glycerol-3-P competitively inhibited glucose-6-phosphate isomerase activity when fructose-6-P was the varied substrate. Such a situation prevented the rapid recycling of triose phosphates back to hexose phosphates and led to an arrest of the functioning of the cytosolic and plastidial pentose phosphate pathways. Under these conditions, the flow of carbon to drive eel respiration derived almost exclusively from glycerol, and this polyalcohol was not used as a source of carbon skeletons for biosynthesis. Glycerol also induced the accumulation of O-phosphohomoserine in the cytoplasmic compartment as long as the cell culture medium contained sucrose. Finally glycerol added to sucrose starved cells stopped the accumulation of phosphocholine (Roby, C., Martin J.-B., Bligny, R., and Douce, R. (1987) J. Biol. Chem. 262, 5000-5007) and prevented a further decline in the uncoupled rate of O-2 consumption by the cells (Journet, E. P., Bligny, R., and Douce, R. (1986) J. Biol. Chem. 261, 3193-3199). These last observations strongly suggest that glycerol prevented the triggering of autophagy induced by sucrose starvation in sycamore cells.	CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,RESONANCE MAGNET BIOL & MED LAB,PCV,F-38054 GRENOBLE 9,FRANCE; LAB PHYSIOL CELLULAIRE VEGETALE,CNRS,URA 576,F-38054 GRENOBLE 9,FRANCE	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)								APREES T, 1980, BIOCH PLANTS, V2, P1; BEISENHERZ G, 1955, METHOD ENZYMOL, V1, P387, DOI 10.1016/0076-6879(55)01062-8; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V3, P1304; BLIGNY R, 1987, METHOD ENZYMOL, V148, P3; BOWSHER CG, 1989, PLANTA, V177, P359, DOI 10.1007/BF00403594; BRAND MD, 1987, BIOL REV, V62, P141, DOI 10.1111/j.1469-185X.1987.tb01265.x; Bryan J. K., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P403; CARNAL NW, 1983, PLANT PHYSIOL, V71, P150, DOI 10.1104/pp.71.1.150; CHALEFF RS, 1978, GENETICS, V89, P723; DORNE AJ, 1987, PLANT PHYSIOL BIOCH, V25, P589; DOUCE R, 1985, PLANT MITOCHONDRIA S, P103; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; Gancedo C., 1989, YEASTS, V3, P205; GEE RW, 1988, PLANT PHYSIOL, V86, P98, DOI 10.1104/pp.86.1.98; GENIX P, 1990, PLANT PHYSIOL, V94, P712; Gilchrist D. G., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P507; GLAUMANN H, 1981, INT REV CYTOL, V73, P149, DOI 10.1016/S0074-7696(08)61288-7; GOUT E, 1992, J BIOL CHEM, V267, P13903; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; HIPPMANN H, 1976, Z PFLANZENPHYSIOL, V79, P408, DOI 10.1016/S0044-328X(76)80160-2; Horecker B. L., 1975, METHOD ENZYMOL, V42, P234; JONES A, 1980, CAN J BOT, V58, P648, DOI 10.1139/b80-082; JOURNET EP, 1986, J BIOL CHEM, V261, P3193; KELLY GJ, 1977, PLANT PHYSIOL, V60, P295, DOI 10.1104/pp.60.2.295; KIRSCH T, 1992, PLANT PHYSIOL, V100, P352, DOI 10.1104/pp.100.1.352; KIYOSAWA K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P251, DOI 10.1016/0005-2736(91)90309-V; LEEGOOD RC, 1988, PLANTA, V176, P117, DOI 10.1007/BF00392487; LERNER HR, 1977, PLANT PHYSIOL, V59, P15, DOI 10.1104/pp.59.1.15; MACDONALD FD, 1983, PHYTOCHEMISTRY, V22, P1141, DOI 10.1016/0031-9422(83)80208-8; MAESTRI E, 1991, PLANT CELL ENVIRON, V14, P613, DOI 10.1111/j.1365-3040.1991.tb01533.x; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; PASCAL NH, 1994, PLANT PHYSL BETHESDA, V103, P1329; PFEFFER PE, 1989, NUCL MAGN RESON, P3; ROBERTS JKM, 1981, BIOCHIM BIOPHYS ACTA, V639, P53, DOI 10.1016/0304-4173(81)90005-7; ROBY C, 1987, J BIOL CHEM, V262, P5000; SIMCOX PD, 1977, PLANT PHYSIOL, V59, P1128, DOI 10.1104/pp.59.6.1128; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; TELEGDI M, 1968, BIOCHIM BIOPHYS ACTA, V159, P227, DOI 10.1016/0005-2744(68)90071-5	40	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21420	21427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063774				2022-12-25	WOS:A1994PK97300008
J	WIECH, H; BUCHNER, J; ZIMMERMANN, M; ZIMMERMANN, R; JAKOB, U				WIECH, H; BUCHNER, J; ZIMMERMANN, M; ZIMMERMANN, R; JAKOB, U			HSC70, IMMUNOGLOBULIN HEAVY-CHAIN BINDING-PROTEIN, AND HSP90 DIFFER IN THEIR ABILITY TO STIMULATE TRANSPORT OF PRECURSOR PROTEINS INTO MAMMALIAN MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; M13 PROCOAT PROTEIN; GLUCOSE-REGULATED PROTEINS; ESCHERICHIA-COLI; PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; SENSITIVE METHOD; STRESS PROTEINS; ATPASE FRAGMENT; MEMBRANE	Ribonucleoparticle-independent transport of precursor proteins into mammalian microsomes is stimulated by 70-kDa heat shock proteins (Hsc70) and an additional cytosolic protein. Here we addressed the question of whether other molecular chaperones can replace Hsc70 in facilitating protein transport into the endoplasmic reticulum. Specifically, we asked if members of the same family of stress proteins, i.e. the microsomal protein immunoglobulin heavy chain binding protein or the bacterial protein DnaK, can substitute for Hsc70. Furthermore, we investigated whether molecular chaperones with a proven role in protein folding and belonging to the other two major families of stress proteins, i.e. Hsp60 or Hsp90, can substitute for Hsc70. We show that none of these stress proteins was able to substitute for Hsc70 in facilitating protein transport into mammalian microsomes. GroEL (the bacterial member of the Hsp60 family) and Hsp90, however, competed with Hsc70 for binding of the non-native precursor protein. Therefore, we conclude that there are both substrate and functional specificity in the action of molecular chaperones.	UNIV GOTTINGEN,ZENTRUM BIOCHEM,BIOCHEM ABT 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY; UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	University of Gottingen; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ANG D, 1991, J BIOL CHEM, V266, P24233; AUSTEN BM, 1984, BIOCHEM J, V224, P317, DOI 10.1042/bj2240317; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1991, J BIOL CHEM, V266, P19565; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOODMAN JM, 1981, CELL, V24, P437, DOI 10.1016/0092-8674(81)90334-2; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KORNBERG A, 1973, NATURE, V7, P680; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Payot P, 1976, EUR J BIOCHEM, V63, P263; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WIECH H, 1987, EMBO J, V6, P1011, DOI 10.1002/j.1460-2075.1987.tb04853.x; Wiech H, 1990, Semin Cell Biol, V1, P55; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	57	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7414	7421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096509				2022-12-25	WOS:A1993KV14100084
J	PANDEY, KN				PANDEY, KN			STOICHIOMETRIC ANALYSIS OF INTERNALIZATION, RECYCLING, AND REDISTRIBUTION OF PHOTOAFFINITY-LABELED GUANYLATE-CYCLASE ATRIAL-NATRIURETIC-FACTOR RECEPTORS IN CULTURED MURINE LEYDIG TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CYCLIC-GMP ACCUMULATION; LOW-DENSITY LIPOPROTEIN; BOVINE ADRENAL-CORTEX; HUMAN-FIBROBLASTS; PEPTIDE RECEPTOR; LIGAND-BINDING; SIGNAL TRANSDUCTION; SOLUBLE RECEPTORS; INSULIN-RECEPTORS	The membrane-bound form of guanylate cyclase represents a biologically active atrial natriuretic factor receptor (GC/ANF-R). Murine Leydig tumor (MA-10) cells predominantly overexpress GC/ANF-R in high density (Pandey, K. N., Pavlou, S. N., and Inagami, T. (1988) J. Biol. Chem. 263, 13406-13413; Pandey, K. N., and Singh, S. (1990) J. Biol. Chem. 265, 12342-12348). Information regarding the post-binding events of GC/ANF-R is obscure. This study presents the kinetics of internalization, recycling, and redistribution of GC/ANF-R in model MA-10 cells. Both the I-125-ANF binding assays and photoaffinity labeling procedures were utilized to label the total, intracellular, and cell surface GC/ANF-R. After the binding of I-125-ANF to GC/ANF-R, this complex was internalized and both the intact and degraded ligands were released into culture media. The distribution of I-125-ANF on the cell surface, in the intracellular compartments, and into culture media provided a dynamic relationship between the rates of I-125-ANF uptake, its degradation, and extrusion. The extent of receptor recycling was measured using tryptic proteolysis of photoaffinity-labeled GC/ANF-R to distinguish cell surface receptors from those that were internalized. A population of GC/ANF-R rapidly recycled (t1/2 = 5 min) from intracellular compartment to plasma membrane. Recycling of GC/ANF-R was impaired by chloroquine, dinitrophenol, and low temperature (22-degrees-C). Furthermore, these studies suggest that dissociation of ANF from the receptor is not required for recycling of internalized GC/ANF-R.			PANDEY, KN (corresponding author), MED COLL GEORGIA, SCH MED, DEPT BIOCHEM & MOLEC BIOL, AUGUSTA, GA 30912 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1984, BIOCHEM BIOPH RES CO, V121, P855, DOI 10.1016/0006-291X(84)90756-3; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERHANU P, 1988, J BIOL CHEM, V263, P5961; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; BUDZIK GP, 1987, BIOCHEM BIOPH RES CO, V144, P422, DOI 10.1016/S0006-291X(87)80527-2; CAHILL PA, 1990, J BIOL CHEM, V265, P21896; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FULLER F, 1988, J BIOL CHEM, V263, P9395; GALARDY RE, 1974, J BIOL CHEM, V249, P3510; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; HAMET P, 1984, BIOCHEM BIOPH RES CO, V123, P515, DOI 10.1016/0006-291X(84)90260-2; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V132, P976, DOI 10.1016/0006-291X(85)91903-5; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; HUNTER WM, 1962, NATURE, V184, P670; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KOH GY, 1992, J BIOL CHEM, V267, P11987; KUNO T, 1986, J BIOL CHEM, V261, P5817; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITMAN DC, 1987, ENDOCRIN METAB CLIN, V16, P79, DOI 10.1016/S0889-8529(18)30496-1; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MARSHALL S, 1985, J BIOL CHEM, V260, P4128; MAXFIELD FR, 1979, NATURE, V277, P661, DOI 10.1038/277661a0; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MISONO KS, 1985, BIOCHEM BIOPH RES CO, V130, P994, DOI 10.1016/0006-291X(85)91713-9; MISONO KS, 1988, BIOCHEM BIOPH RES CO, V152, P658, DOI 10.1016/S0006-291X(88)80089-5; MURTHY KK, 1989, MOL CELL ENDOCRINOL, V67, P195, DOI 10.1016/0303-7207(89)90210-4; NAPIER MA, 1986, ARCH BIOCHEM BIOPHYS, V248, P516, DOI 10.1016/0003-9861(86)90504-7; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; PANDEY KN, 1988, J BIOL CHEM, V263, P13406; PANDEY KN, 1985, ENDOCRINOLOGY, V117, P2120, DOI 10.1210/endo-117-5-2120; PANDEY KN, 1985, BIOCHEM BIOPH RES CO, V133, P800, DOI 10.1016/0006-291X(85)90975-1; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PANDEY KN, 1992, BIOCHEM J, V288, P55, DOI 10.1042/bj2880055; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SCHWARTZ D, 1985, SCIENCE, V229, P397, DOI 10.1126/science.3160114; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; TAKAYANAGI R, 1987, BIOCHEM BIOPH RES CO, V144, P244, DOI 10.1016/S0006-291X(87)80502-8; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; TIETZE C, 1980, BIOCHEM BIOPH RES CO, V93, P1, DOI 10.1016/S0006-291X(80)80237-3; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332	58	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4382	4390						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095048				2022-12-25	WOS:A1993KN53300083
J	ROSENBERG, HF; ACKERMAN, SJ; TENEN, DG				ROSENBERG, HF; ACKERMAN, SJ; TENEN, DG			CHARACTERIZATION OF A DISTINCT BINDING-SITE FOR THE PROKARYOTIC CHAPERONE, GROEL, ON A HUMAN GRANULOCYTE RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; RIBULOSE BISPHOSPHATE CARBOXYLASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI GROEL; RIBULOSEBISPHOSPHATE-CARBOXYLASE; MOLECULAR-CLONING; BACTERIOPHAGE MORPHOGENESIS; MITOCHONDRIAL PROTEIN; ATP HYDROLYSIS; GENE	Although ribonucleases fold into correct tertiary conformation in vitro guided solely by information contained in the primary amino acid sequence (Sela, M., White, F. H., and Anfinsen, C. B. (1957) Science 124, 691-693), it is not clear whether folding of these proteins proceeds unassisted in a complex intracellular environment. We describe here the specific and high affinity binding of groEL, the prokaryotic homolog of the heat shock protein 60 family of molecular chaperones, to recombinant eosinophil cationic protein and eosinophil-derived neurotoxin, two members of the human ribonuclease gene family. We have determined that groEL binds to a unique peptide sequence near the amino terminus of nascent eosinophil cationic protein that includes the first of eight cysteine residues. This binding site functions independently and can confer groEL binding activity on an unrelated carrier protein. GroEL dissociates from the binding site upon addition of ATP and Mg2+; no other cations or cofactors are necessary. These findings suggest the possibility that interaction with a groEL-like molecular chaperone may be a requirement for correct folding and/or translocation of eukaryotic ribonucleases in vivo.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	ROSENBERG, HF (corresponding author), NIAID, HOST DEF LAB, BLDG 10, RM 11N114, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022660, R01AI025230] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02288] Funding Source: Medline; NIAID NIH HHS [AI22660, AI25230] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1993, IN PRESS J IMMUNOL; AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ANG D, 1991, J BIOL CHEM, V266, P24233; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BAINTON DF, 1970, J CELL BIOL, V45, P54, DOI 10.1083/jcb.45.1.54; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; Blackburn P, 1982, ENZYMES, VXV, P317; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P136, DOI 10.1073/pnas.75.1.136; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JARJOUR W, 1990, J EXP MED, V172, P1857, DOI 10.1084/jem.172.6.1857; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MEADOR J, 1991, GENE, V95, P1; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEIN CH, 1992, BIOCHEM J, V283, P137, DOI 10.1042/bj2830137; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; Sierakowska H, 1977, Prog Nucleic Acid Res Mol Biol, V20, P59; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; TALMADGE K, 1981, NATURE, V294, P176, DOI 10.1038/294176a0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TOMONAGA M, 1986, BLOOD, V67, P1433; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WALDINGER D, 1988, BIOL CHEM H-S, V369, P1185, DOI 10.1515/bchm3.1988.369.2.1185; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHANG J, 1988, NUCLEIC ACIDS RES, V16, P6265, DOI 10.1093/nar/16.14.6265; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	72	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4499	4503						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095049				2022-12-25	WOS:A1993KN53300099
J	CHAKRABARTI, R; CHAKRABARTI, D; SOUBA, WW; SCHUSTER, SM				CHAKRABARTI, R; CHAKRABARTI, D; SOUBA, WW; SCHUSTER, SM			INTERACTION OF THE EUKARYOTIC PEPTIDE-CHAIN INITIATION-FACTOR EIF-4A WITH THE SPECIFIC ELEMENTS AT THE 5'-UNTRANSLATED SEQUENCE OF HUMAN ASPARAGINE SYNTHETASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; EUKARYOTIC TRANSLATION INITIATION; 40S RIBOSOMAL-SUBUNITS; SECONDARY STRUCTURE; UNTRANSLATED REGION; PROTEIN-SYNTHESIS; AUG CODONS; BINDING; GENE; EXPRESSION	The resistance of certain tumor cells to the chemotherapeutic agent L-asparaginase has often been found to be associated with the presence of asparagine synthetase activity. In an attempt to study the translational regulation of the asparagine synthetase gene, the 5'-untranslated region of human asparagine synthetase cDNA was mapped by antisense oligonucleotide-mediated hybrid arrest translation in reticulocyte lysate. Three consecutive cis-acting regulatory elements, spanning from -60 to -120 bases from the initiation codon, in the 5'-untranslated region of the asparagine synthetase gene, were identified. T1 RNase footprinting analysis showed that those regulatory elements can be protected from T1 digestion when incubated with reticulocyte lysate. A 46-kDa trans-acting protein factor that interacts with the cis-acting regulatory element of asparagine synthetase mRNA was detected. This 46-kDa protein factor is most likely to be the eucaryotic peptide chain initiation factor eIF-4A as determined by immunoprecipitation experiments using a monoclonal antibody raised against reticulocyte eIF-4A.	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT SURG,GAINESVILLE,FL 32610; UNIV FLORIDA,INTERDISCIPLINARY CTR BIOTECHNOL RES,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT INFECT DIS,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BLAKE KR, 1985, BIOCHEMISTRY-US, V24, P6132, DOI 10.1021/bi00343a015; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; EDERY I, 1984, BIOCHEMISTRY-US, V23, P2456, DOI 10.1021/bi00306a021; EDERY I, 1983, J BIOL CHEM, V258, P1398; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GUPTA KC, 1987, J BIOL CHEM, V262, P7492; GUPTA NK, 1987, TRANSLATIONAL REGULA, P287; HAMMOND ML, 1991, GENE DEV, V5, P1723, DOI 10.1101/gad.5.9.1723; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HONGO S, 1991, DEV BIOL, V145, P338, DOI 10.1016/0012-1606(91)90132-M; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Kessler S W, 1981, Methods Enzymol, V73, P442; KOZAK M, 1980, CELL, V19, P79, DOI 10.1016/0092-8674(80)90390-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1980, CELL, V22, P459, DOI 10.1016/0092-8674(80)90356-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DC, 1981, MOL CELL BIOL, V1, P635, DOI 10.1128/MCB.1.7.635; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LINDER P, 1990, BIOESSAYS, V12, P519, DOI 10.1002/bies.950121103; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MORGAN MA, 1980, BIOCHEMISTRY-US, V19, P5960, DOI 10.1021/bi00567a003; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PAVLAKIS GN, 1980, CELL, V19, P91, DOI 10.1016/0092-8674(80)90391-8; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; RAY BK, 1985, J BIOL CHEM, V260, P7651; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SCHIMMEL P, 1989, CELL, V58, P9, DOI 10.1016/0092-8674(89)90395-4; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; SONENBERG N, 1982, MOL CELL BIOL, V2, P1633, DOI 10.1128/MCB.2.12.1633; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WILLIS D, 1984, J VIROL, V52, P905, DOI 10.1128/JVI.52.3.905-912.1984; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZANG YP, 1989, GENOMICS, V4, P259	54	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1298	1303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8093451				2022-12-25	WOS:A1993KG07700080
J	HASNAIN, S; HIRAMA, T; HUBER, CP; MASON, P; MORT, JS				HASNAIN, S; HIRAMA, T; HUBER, CP; MASON, P; MORT, JS			CHARACTERIZATION OF CATHEPSIN-B SPECIFICITY BY SITE-DIRECTED MUTAGENESIS - IMPORTANCE OF GLU(245) IN THE S2-P2 SPECIFICITY FOR ARGININE AND ITS ROLE IN TRANSITION-STATE STABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOPEPTIDASE ACTIVITIES; PAPAIN	The pH dependence of cathepsin B-catalyzed hydrolyzes is very complex. At least seven dissociable groups are involved in the binding and hydrolysis of 7-amido-4-methyl coumarin and p-nitroaniline (pNA)-based substrates containing a P1 Arg and either a Phe or Arg at the P2 position. By site-directed mutagenesis we show that a previous suggestion, that Arg202 is one of the groups which influences the pH dependence of cathepsin B-catalyzed hydrolysis of the Z-Arg-Arg-pNA substrate, is not valid. However, it was found that Glu245, which has a pK(a) of 5.1 in rat cathepsin B, is responsible for the S2-P2 specificity for Arg-containing substrates and controls the pH dependence of their hydrolysis. Furthermore, the data indicate that Glu245, which forms a hydrogen bond with the guanidinium group of the substrate's P2 Arg, contributes about 1.8 kcal/mol to transition state stabilization in the protonated state and about 0.6 kcal/mol in the deprotonated state. Mutation of Glu245 to Gln results in a 16-fold decrease in k(cat) but does not affect K(m) while cathepsin B has a 7-fold preference for Phe over Arg at the P2 position of a substrate, binding of the aromatic side chain does not appear to be influenced by Glu245.	SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL H3G 1A6,QUEBEC,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3G 1A6,QUEBEC,CANADA	McGill University; McGill University	HASNAIN, S (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,PROT STRUCT & DESIGN SECT,OTTAWA K1A 0R6,ONTARIO,CANADA.							BAJKOWSKI AS, 1983, J BIOL CHEM, V258, P1645; BAJKOWSKI AS, 1983, J BIOL CHEM, V258, P1650; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; EVANS SV, 1992, IN PRESS J MOL GRAPH; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; LEE X, 1990, J BIOL CHEM, V265, P5950; MENGER FM, 1992, BIOCHEMISTRY-US, V31, P5368, DOI 10.1021/bi00138a018; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; POLGAR L, 1987, J BIOL CHEM, V262, P14448; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; VERNET T, 1992, J MOL BIOL, V224, P501, DOI 10.1016/0022-2836(92)91011-D; WILLENBROCK F, 1984, BIOCHEM J, V222, P805, DOI 10.1042/bj2220805; WILLENBROCK F, 1986, BIOCHEM J, V238, P103, DOI 10.1042/bj2380103	16	82	83	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					235	240						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093241				2022-12-25	WOS:A1993KE60300037
J	JANS, DA; JANS, P				JANS, DA; JANS, P			NEGATIVE CHARGE AT THE CASEIN KINASE-II SITE FLANKING THE NUCLEAR-LOCALIZATION SIGNAL OF THE SV40 LARGE T-ANTIGEN IS MECHANISTICALLY IMPORTANT FOR ENHANCED NUCLEAR IMPORT	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; NF-KAPPA-B; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; GENE-PRODUCT; VASOPRESSIN V2-RECEPTOR; BETA-GALACTOSIDASE	Nuclear import of SV40 large T-antigen (T-ag) is completely dependent on the T-ag nuclear localization sequence (amino acids 126-132), but the rate of nuclear import is greatly increased by the additional presence of the N-terminal flanking sequence (amino acids 111-125), which includes a site for casein kinase II (CKII) (Ser(111/112)). The role of this site was investigated by site-directed mutagenesis and analysis of the effects on phosphorylation and on nuclear import at the single cell level using microinjection and quantitative fluorescent techniques. Removal of the CKII site either by substitution of S-111/112 by nonphosphorylatable amino acid residues, or mutation of the Asp-Asp-Glu(113/115) CKII recognition sequence to Asn-Asn-Gln, resulted in nuclear import rates less than 4% wild type, demonstrating that the CKII site was responsible for the enhancement of nuclear import conferred by T-ag amino acids 111-125. The substitution of Asp for Ser(112), the serine preferentially phosphorylated by purified CKII, enhanced nuclear import to about 45% maximal wild type rates. It is concluded that negative charge at the CKII site, normally provided by phosphorylation, is mechanistically important for nuclear transport enhancement. There was no evidence or a direct role for phosphatases or dephosphorylation in the transport process.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOLEC BIOL, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research	JANS, DA (corresponding author), MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ADAM S, 1989, NATURE, V227, P276; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRZIWA A, 1992, J STRUCT BIOL, V109, P168, DOI 10.1016/1047-8477(92)90048-F; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1991, J CELL BIOL, V114, P53, DOI 10.1083/jcb.114.1.53; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KALDERON D, 1984, NATURE, V311, P499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE H Y, 1991, Korean Journal of Genetics, V13, P1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MOLL T, 1991, CELL, V66, P1; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIHS HP, 1989, THESIS U GIESSEN GIE; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSHLOW CA, 1989, CELL, V59, P1167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; TANAKA K, 1992, NEW BIOL, V4, P173; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382	65	89	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2961	2968						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084599				2022-12-25	WOS:A1994PG82200022
J	LOPEZ, JA; WEISMAN, S; SANAN, DA; SIH, T; CHAMBERS, M; LI, CQ				LOPEZ, JA; WEISMAN, S; SANAN, DA; SIH, T; CHAMBERS, M; LI, CQ			GLYCOPROTEIN (GP)-IB-BETA IS THE CRITICAL SUBUNIT LINKING GP-IB-ALPHA AND GP-IX IN THE GP-IB-IX COMPLEX - ANALYSIS OF PARTIAL COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; LEUCINE-RICH GLYCOPROTEINS; HUMAN-PLATELET MEMBRANE; VEIN ENDOTHELIAL-CELLS; THROMBOCYTOPENIC PURPURA; ADHESION MOLECULE; ACID SEQUENCE; DROSOPHILA; RECEPTOR; MUTATION	The glycoprotein (GP) Ib-IX complex is the receptor on platelet surfaces that mediates their adhesion to subendothelium. It comprises three polypeptides (GP Ib alpha, GP Ib beta, GP IX), each of which belongs to a superfamily of proteins containing conserved leucine-rich motifs. In this study, we used Chinese hamster ovary (CHO) cells expressing every combination of two GP Ib-IX complex subunits to demonstrate that GP Ib beta plays an essential role in the synthesis of the heterotrimer by associating with both of the other two subunits. Confocal microscopy demonstrated that GP Ib beta was present in the same cellular locations as GP Ib alpha in CHO alpha beta cells (cells expressing only GP Ib alpha and GP Ib beta) and as GP IX in CHO beta IX cells. The two polypeptides expressed in CHO alpha IX cells did not co-localize. Association between GP Ib alpha and GP Ib beta was demonstrated biochemically on immunoblots of detergent lysates of CHO alpha beta cells; electrophoresis under nonreducing conditions revealed the two subunits to be covalently linked through a disulfide bond. Association of GP Ib alpha and GP Ib beta was further demonstrated by the finding that immunoprecipitations with antibodies against either polypeptide precipitated both. Similarly immunoprecipitations of lysates of CHO beta IX cells with antibodies against GP Ib beta or GP IX precipitated both polypeptides. In contrast, co-immunoprecipitation of the two polypeptides expressed in CHO alpha IX cells could not be demonstrated. Transient expression in CHO cells of GP Ib beta with GP IX yielded higher GP IX levels on the cell membrane than did expression of GP IX alone; supertransfection of CHO alpha IX cells with GP Ib beta also increased GP IX levels on the cell surface.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LOPEZ, JA (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.				NHLBI NIH HHS [HL02463, HL46416] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R29HL046416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH AS, 1988, J CLIN INVEST, V81, P1600, DOI 10.1172/JCI113494; Berndt M C, 1989, Baillieres Clin Haematol, V2, P585, DOI 10.1016/S0950-3536(89)80035-6; BERNDT MC, 1985, BLOOD, V66, P1292; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; DASHTI N, 1983, J LIPID RES, V24, P368; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIEFEL V, 1991, BRIT J HAEMATOL, V79, P256, DOI 10.1111/j.1365-2141.1991.tb04530.x; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; LOPEZ JA, 1992, J BIOL CHEM, V267, P10055; MCMICHAEL AJ, 1981, BRIT J HAEMATOL, V49, P501, DOI 10.1111/j.1365-2141.1981.tb07258.x; MILLER JL, 1992, BLOOD, V79, P439; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; NOMURA S, 1991, ACTA HAEMATOL-BASEL, V86, P25; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; ROTH GJ, 1992, IMMUNOL TODAY, V13, P100, DOI 10.1016/0167-5699(92)90150-6; SPRANDIO JD, 1988, BLOOD, V71, P234; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WARE J, 1990, P NATL ACAD SCI USA, V87, P2026, DOI 10.1073/pnas.87.5.2026; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WRIGHT SD, 1993, BLOOD, V81, P2339	33	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23716	23721						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089142				2022-12-25	WOS:A1994PQ34500051
J	JARROUS, N; KAEMPFER, R				JARROUS, N; KAEMPFER, R			INDUCTION OF HUMAN INTERLEUKIN-1 GENE-EXPRESSION BY RETINOIC ACID AND ITS REGULATION AT PROCESSING OF PRECURSOR TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; EMBRYONAL CARCINOMA-CELLS; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; NUCLEOTIDE-SEQUENCE; IMMUNE INTERFERON; PROTEIN-SYNTHESIS; THYROID-HORMONE; DOWN-REGULATION; HOMEOBOX GENES	Retinoic acid (RA), we show, induces in peripheral blood mononuclear cells a transient wave of newly transcribed, unstable interleukin-1 alpha (IL-1 alpha) and IL-1 beta mRNA. Tumor necrosis factor-alpha mRNA, by contrast, is expressed in multiple waves. IL-1 genes are primary targets for RA. Most IL-1 beta gene transcription induced by RA fails to yield mature mRNA. Instead, precursor transcripts accumulate, detected by ribonuclease protection analysis. The flow of precursors into IL-1 beta mRNA becomes inhibited during induction. When translation is blocked, e.g. by cycloheximide, expression of IL-1 beta mRNA is superinduced by 2 orders of magnitude. Superinduction is dependent on transcription, yet is unaccompanied by increased primary transcription or mRNA stability. Instead, processing of unstable IL-1 beta precursor transcripts into mature mRNA is greatly facilitated. Control is not narrowly localized within precursors: splicing of distinct exons and intron excision are enhanced by cycloheximide. Pre-mRNA processing thus is a limiting step in RA-induced IL-1 beta gene expression. This regulation is specific for RA: when induced by phorbol ester, IL-1 beta gene expression is also superinduced by cycloheximide but that response is accompanied by enhanced mRNA stability. Thus, IL-1 beta gene transcription is induced by RA, yet, unlike for other primary target genes, mRNA expression is regulated at pre-mRNA processing.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT MOLEC VIROL, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Jarrous, Nayef/S-6825-2019	Kaempfer, Raymond/0000-0002-5865-4619				ANIELLO F, 1991, P NATL ACAD SCI USA, V88, P4035, DOI 10.1073/pnas.88.9.4035; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BEUTLER B, 1988, BIOCHEM BIOPH RES CO, V152, P973, DOI 10.1016/S0006-291X(88)80379-6; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLALOCK JE, 1977, P NATL ACAD SCI USA, V74, P5382, DOI 10.1073/pnas.74.12.5382; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DENNERT G, 1984, RETINOIDS, V2, P373; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GEREZ L, 1991, CLIN IMMUNOL IMMUNOP, V58, P251, DOI 10.1016/0090-1229(91)90140-6; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P293; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LE JM, 1987, LAB INVEST, V56, P234; LEBENDIKER MA, 1987, EMBO J, V6, P585, DOI 10.1002/j.1460-2075.1987.tb04794.x; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUMPKIN MD, 1987, SCIENCE, V238, P452, DOI 10.1126/science.2821618; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; MATIKAINEN S, 1991, J IMMUNOL, V147, P162; MILLER WH, 1990, ONCOGENE, V5, P511; NAUSS KM, 1990, METHOD ENZYMOL, V190, P259; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SILVER G, 1990, MOL CELL BIOL, V10, P6765, DOI 10.1128/MCB.10.12.6765; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOBLER A, 1987, BLOOD, V70, P1940; TRECHSEL U, 1985, BIOCHEM J, V230, P339, DOI 10.1042/bj2300339; TRINCHIERI G, 1987, BLOOD, V69, P1218; TURNER M, 1989, J IMMUNOL, V143, P3556; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WILKINSON MF, 1988, EMBO J, V7, P101, DOI 10.1002/j.1460-2075.1988.tb02788.x; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	53	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23141	23149						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083217				2022-12-25	WOS:A1994PQ16400039
J	LUCERO, HA; LEBECHE, D; KAMINER, B				LUCERO, HA; LEBECHE, D; KAMINER, B			ERCALCISTORIN/PROTEIN DISULFIDE-ISOMERASE (PDI) - SEQUENCE DETERMINATION AND EXPRESSION OF A CDNA CLONE ENCODING A CALCIUM STORAGE PROTEIN WITH PDI ACTIVITY FROM ENDOPLASMIC-RETICULUM OF THE SEA-URCHIN EGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALSEQUESTRIN-LIKE PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; AMINO-ACID-SEQUENCE; CYCLIC ADP-RIBOSE; MOLECULAR-CLONING; BINDING-PROTEIN; MESSENGER-RNAS; DEVELOPMENTAL EXPRESSION; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR	Following the purification of a 58-kDa calsequestrin-like protein from the endoplasmic reticulum (ER) of sea urchin eggs (Oberdorf, J. A., Lebeche, D., Head, J. F., and Kaminer, B. (1988) J. Biol. Chem. 263, 6806-6809) and its characterization as a high capacity, low affinity calcium-binding protein (Lebeche, D., and Kaminer, B. (1992) Biochem. J. 287, 741-747), we isolated and sequenced a cDNA encoding for this protein. The deduced 496 amino acids contain a 17-residue NH2-terminal signal peptide, a KDEL COOH-terminal ER retention signal and two thioredoxin like active site domains, -CGHC-, identical with those in protein disulfide isomerase (PDI). The sea urchin egg protein shares a 55% sequence identity with mammalian PDI and its PDI activity is 30% of the activity of rabbit liver PDI. The corresponding mRNA was found in oocytes, mature eggs, embryos, and differentiated tissues of the sea urchin in varying amounts. COS-7 cells transfected with the cDNA, expressed a 58-kDa pro protein immunoreactive to antibodies against the sea urchin egg protein. This molecule appears to have a dual function of calcium storage and PDI activity within the ER. We hence redesignate it ERcalcistorin/PDI (ECaSt/PDI), a protein that is distinct from calsequestrin and calreticulin.	BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118; MARINE BIOL LAB,WOODS HOLE,MA 02543	Boston University; Marine Biological Laboratory - Woods Hole					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020217] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20217] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDHORST BP, 1980, DEV BIOL, V79, P139, DOI 10.1016/0012-1606(80)90079-2; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CUTTING AE, 1990, P NATL ACAD SCI USA, V87, P7953, DOI 10.1073/pnas.87.20.7953; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P383; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIUDICE G, 1972, EXP CELL RES, V72, P90, DOI 10.1016/0014-4827(72)90570-8; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GROSS P. R., 1965, J MOL BIOL, V13, P463; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; KOCH G, 1986, J CELL SCI, V86, P217; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LEBECHE D, 1992, BIOCHEM J, V287, P741, DOI 10.1042/bj2870741; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MONTESANO L, 1989, EUR J BIOCHEM, V186, P421, DOI 10.1111/j.1432-1033.1989.tb15226.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OBERDORF JA, 1986, J CELL BIOL, V102, P2205, DOI 10.1083/jcb.102.6.2205; OBERDORF JA, 1988, J BIOL CHEM, V263, P6806; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; ROLLER RJ, 1989, DEVELOPMENT, V106, P251; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1992, DEV GROWTH DIFFER, V34, P37; SHORROSH BS, 1992, PLANT MOL BIOL, V19, P319, DOI 10.1007/BF00027354; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VANNGUYEN P, 1993, EUR J BIOCHEM, V213, P789; WELLS DE, 1982, DEV BIOL, V92, P557, DOI 10.1016/0012-1606(82)90202-0; WHITAKER M, 1993, DEVELOPMENT, V117, P1; XIE W, 1991, BIOTECHNIQUES, V11, P325	59	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23112	23119						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083214				2022-12-25	WOS:A1994PQ16400035
J	SHI, GY; KLEINKLAUS, AK; MARRION, NV; TRIMMER, JS				SHI, GY; KLEINKLAUS, AK; MARRION, NV; TRIMMER, JS			PROPERTIES OF KV2.1 K+ CHANNELS EXPRESSED IN TRANSFECTED MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING RAT-BRAIN; POTASSIUM CHANNELS; ENDOPLASMIC-RETICULUM; MYELINATED NERVE; SODIUM-IONS; PHOSPHORYLATION; DELETIONS; MEMBRANE; MUSCLE; SQUID	We have transiently expressed the rat Kv2.1 K+ channel polypeptide (pKv2.1) at high levels by transfection of mammalian COS-1 cells. Kv2.1-transfected cells express a molecular mass of 108 kDa pKv2.1, larger than the size of the core polypeptide (95 kDa) predicted from the deduced primary sequence and of pKv2.1 synthesized in cell free or Xenopus oocyte translation systems. The increased size of pKv2.1 in COS-1 cells is due to a posttranslational modification that occurs early (t(1/2) = 5 min) in the biosynthetic transport through the endomembrane system, presumably while the protein resides in the endoplasmic reticulum. The increased size is entirely due to phosphorylation, based on in vivo P-32-labeling and sensitivity to alkaline phosphatase digestion. Immunofluorescent localization of pKv2.1 shows intense surface labeling; no intracellular pools of retained protein are apparent. Immunogold electron microscopy confirms that the expressed polypeptide is found on the cell surface in small clusters or patches of 10-15 gold particles. Cells expressing pKv2.1 exhibit large, voltage-dependent outward currents. The pharmacological properties of the expressed Kv2.1 currents are virtually indistinguishable from those described previously in Xenopus oocytes microinjected with Kv2.1 cRNA, but differences in voltage-dependent properties were observed. High level of expression of functional pKv2.1 in these cells points to the utility of this system for the rapid biochemical, cell biological and electrophysiological analysis of altered forms of pKv2.1, and other members of the K+ channel gene family.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT NEUROBIOL & BEHAV, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NINDS NIH HHS [NS29876] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029876] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIYAR J, 1993, AM J PHYSIOL, V265, pC1571, DOI 10.1152/ajpcell.1993.265.6.C1571; ALMERS W, 1983, J PHYSIOL-LONDON, V336, P261, DOI 10.1113/jphysiol.1983.sp014580; Ausubel FA, 1990, CURRENT PROTOCOLS MO; CAI YC, 1993, J BIOL CHEM, V268, P23720; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; DUBOIS JM, 1981, J PHYSIOL-LONDON, V318, P297; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; FRENCH RJ, 1977, J GEN PHYSIOL, V70, P707, DOI 10.1085/jgp.70.6.707; GILLY WF, 1990, NEURON, V5, P663, DOI 10.1016/0896-6273(90)90220-A; Halliwell J. V., 1990, POTASSIUM CHANNELS S, P348; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HOWE JR, 1992, P ROY SOC B-BIOL SCI, V249, P309, DOI 10.1098/rspb.1992.0120; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LEE BS, 1991, J BIOL CHEM, V266, P11448; Lenn N. J., 1992, Society for Neuroscience Abstracts, V18, P622; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; Maizel JV, 1971, METHOD VIROL, V5, P179; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERNEY TM, 1992, J NEUROPHYSIOL, V68, P756, DOI 10.1152/jn.1992.68.3.756; PEROZO E, 1990, NEURON, V5, P685, DOI 10.1016/0896-6273(90)90222-2; ROBERTS WM, 1986, ANN NY ACAD SCI, V479, P377, DOI 10.1111/j.1749-6632.1986.tb15583.x; ROSS AF, 1987, J BIOL CHEM, V262, P14640; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHWARZ JR, 1971, PFLUG ARCH EUR J PHY, V330, P61, DOI 10.1007/BF00588735; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; TRIMMER JS, 1993, FEBS LETT, V324, P205, DOI 10.1016/0014-5793(93)81394-F; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; WARD GE, 1985, SCIENCE, V227, P768, DOI 10.1126/science.2857502	40	105	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23204	23211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083226				2022-12-25	WOS:A1994PQ16400048
J	STROEBEL, M; GOPPELTSTRUEBE, M				STROEBEL, M; GOPPELTSTRUEBE, M			SIGNAL-TRANSDUCTION PATHWAYS RESPONSIBLE FOR SEROTONIN-MEDIATED PROSTAGLANDIN G/H SYNTHASE EXPRESSION IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLOMERULAR MESANGIAL CELLS; MESSENGER-RNA; H SYNTHASE; ENDOPEROXIDE SYNTHASE; HORMONAL-REGULATION; EXTRACELLULAR ATP; TYROSINE KINASE; PHORBOL ESTER; CYCLOOXYGENASE	Prostaglandin G/H synthase (PGHS) is one of the key enzymes in prostaglandin synthesis. Regulation of the mRNA expression of the two isozymes PGHS-1 and PGHS-2 was investigated in mesangial cells. PGHS-1 was constitutively expressed and not modulated by any of the stimuli used. PGHS-2 was induced by the platelet products serotonin (5-HT) and thromboxane A, (used as its analogue U46619), but not by ATP. Expression of PGHS protein was regulated correspondingly; whereas PGHS-1 protein was constitutively expressed, PGHS-2 protein was virtually absent in unstimulated cells, but could increasingly be induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), 5-HT, or fetal calf serum. Induction of PGHS-2 mRNA was transient with a peak after 2-3 h. Stimulated mRNA levels persisted for more than 6 h when transcription was inhibited by actinomycin D or when translation was inhibited by cycloheximide. As shown by specific inhibitors, 5-HT signal transduction was mediated by 5-HT, receptors, which couple to phospholipase C via pertussis toxin sensitive G-proteins. Induction of PGHS-2 mRNA by 5-HT was dependent on protein kinase C. Down-regulation of the enzyme by prolonged incubation with TPA abolished 5-HT-induced PGHS-2 mRNA expression. Short time activation of protein kinase C by TPA induced PGHS-2 mRNA expression. On the other hand, TPA given immediately before 5-HT decreased the 5-HT-induced PGHS-2 mRNA expression, indicating a negative feedback. The immunosuppressive drug cyclosporin A reduced induction of PGHS-2 mRNA expression by 5-HT, indicating interference with the signaling cascade, most likely with the Ser/Thr phosphatase calcineurin. Involvement of Tyr phosphorylation in 5-HT signaling was shown by the Tyr kinase inhibitor genistein, which inhibited the induction, while the Tyr phosphatase inhibitor vanadate by itself was able to induce PGHS-2 mRNA expression, which was further augmented when vanadate was combined with 5-HT. PGHS-2 mRNA expression is thus tightly regulated in mesangial cells and therefore allows modulation at various levels by physiological and pharmacological stimuli.	UNIV ERLANGEN NURNBERG, DEPT MED 4, D-91054 ERLANGEN, GERMANY	University of Erlangen Nuremberg								CAMERON JS, 1984, ANNU REV MED, V35, P175, DOI 10.1146/annurev.me.35.020184.001135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; ENDLICH K, 1993, KIDNEY INT, V43, P314, DOI 10.1038/ki.1993.49; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HAMON MD, 1991, NEW PHARMACOTHERAPY, P83; HARTNER A, 1994, KIDNEY INT, V45, P1562, DOI 10.1038/ki.1994.206; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1993, EXP NEPHROL, V1, P19; KNAUSS T, 1986, AM J PHYSIOL, V251, pF844, DOI 10.1152/ajprenal.1986.251.5.F844; Korte K., 1993, Clinical and Experimental Obstetrics and Gynecology, V20, P63; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; LOVETT DH, 1983, J IMMUNOL, V130, P1796; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MCNICOL A, 1993, PROSTAG LEUKOTR ESS, V48, P379, DOI 10.1016/0952-3278(93)90118-G; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MENE P, 1992, KIDNEY INT, V41, P554, DOI 10.1038/ki.1992.80; MENE P, 1991, HYPERTENSION, V17, P151, DOI 10.1161/01.HYP.17.2.151; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAVENSTADT H, 1993, BRIT J PHARMACOL, V109, P953, DOI 10.1111/j.1476-5381.1993.tb13713.x; PEROUTKA SJ, 1990, ANN NY ACAD SCI, V600, P104, DOI 10.1111/j.1749-6632.1990.tb16876.x; PIERUCCI A, 1989, ADV EXP MED BIOL, V259, P389; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1993, J BIOL CHEM, V268, P12199; STAHL RAK, 1990, KIDNEY INT, V38, P273, DOI 10.1038/ki.1990.196; STERZEL RB, 1982, KLIN WOCHENSCHR, V60, P1077, DOI 10.1007/BF01715838; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; VARGAS JL, 1989, BIOCHEM J, V258, P33, DOI 10.1042/bj2580033; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WU XB, 1993, J CLIN INVEST, V91, P766, DOI 10.1172/JCI116295; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	47	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22952	22957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083194				2022-12-25	WOS:A1994PQ16400010
J	SYMCOX, MM; CAUTHRON, RD; OGREID, D; STEINBERG, RA				SYMCOX, MM; CAUTHRON, RD; OGREID, D; STEINBERG, RA			ARG-242 IS NECESSARY FOR ALLOSTERIC COUPLING OF CYCLIC AMP-BINDING SITE-A AND SITE-B OF RI-SUBUNIT OF CYCLIC-AMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; NUCLEOTIDE BINDING; MUTATIONS; ACTIVATION; REASSOCIATION; CONSEQUENCES	The functional consequences of Arg-242 to Ser or Lys substitutions in type I alpha regulatory (R) subunits of cAMP-dependent protein kinase were analyzed by using recombinant murine R subunits expressed in Escherichia coli. These mutations arose in cAMP-resistant mutants to S49 mouse lymphoma cells and were shown previously to inhibit cAMP binding to site A, the more amino-terminal of two intrachain cAMP-binding sites. Binding of cAMP to site A of the mutant R subunits could be detected by cAMP-dependent quenching of endogenous tryptophan fluorescence, [H-3]cAMP binding to mutant R subunits with the Arg-242 mutations without or with an inactivating mutation in site B, or biphasic dissociation of [H-3]cAMP from the mutant subunits at low temperature. The mutations reduced site A affinities by about 25-fold, and the reductions were attributable to accelerated rates of cAMP dissociation. While the presence of cAMP in site A retards dissociation of [H-3]cAMP from site B of wild-type R subunits, saturation of site A had little or no effect on dissociation of [H-3]cAMP from site B of the mutant subunits. The predominant effect of the mutations, therefore, was loss of allosteric coupling between the two cAMP-binding sites. A second allosteric interaction, that coupling occupation of site A with a reduced affinity of R for catalytic subunit, was inhibited only partially by these mutations at Arg-242.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV BERGEN,HAUKELAND HOSP,CTR MOLEC MED,N-5021 BERGEN,NORWAY	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Bergen; Haukeland University Hospital					NIDDK NIH HHS [DK37583] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037583, R55DK037583] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; HOUGE G, 1990, J BIOL CHEM, V265, P19507; LAPORTE DC, 1980, J BIOL CHEM, V255, P2343; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1988, J BIOL CHEM, V263, P17397; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SMITH SB, 1981, P NATL ACAD SCI-BIOL, V78, P1591, DOI 10.1073/pnas.78.3.1591; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003	24	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23025	23031						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083203				2022-12-25	WOS:A1994PQ16400022
J	SHIVJI, MKK; EKER, APM; WOOD, RD				SHIVJI, MKK; EKER, APM; WOOD, RD			DNA-REPAIR DEFECT IN XERODERMA-PIGMENTOSUM GROUP-C AND COMPLEMENTING FACTOR FROM HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION NUCLEASE; SIMIAN VIRUS-40 CHROMOSOMES; PREFERENTIAL REPAIR; ACTIVE GENES; GROUP-F; EXTRACTS; CLONING; PROTEIN; MICROINJECTION; FIBROBLASTS	A predominant form of the inherited syndrome xeroderma pigmentosum is genetic complementation group C (XP-C). XP-C cells are defective in DNA nucleotide excision repair in the bulk of the genome but can repair transcribed strands of active genes. An activity that can complement the repair deficiency of extracts from XP-C cells has been purified similar to 2,000-fold from HeLa cells. The factor also increases the unscheduled DNA synthesis of XP-C fibroblasts in vivo after microinjection. Hydrodynamic measurements show that the XP-C complementing factor has a native molecular mass of similar to 160 kDa. The factor binds tightly to single-stranded DNA cellulose, eluting in similar to 1.3 M NaCl. No incision or ATPase activity of the protein alone was detected. XP-C protein is involved in an early stage of repair since its presence was required before the start of gap-filling repair synthesis. In vitro complementation was achieved with naked DNA substrates, and so a primary role in processing chromatin to allow access for repair enzymes seems unlikely. Surprisingly, however, extracts from an XP-C cell line introduced some incisions in UV-irradiated DNA; these were unstable in cell extracts and did not lead to complete repair. The data can be explained by a model in which XP-C factor participates in forming one of the repair incisions flanking DNA damage but not the other. In transcribed DNA, its role is subsumed by RNA polymerase and/or transcription coupling factors.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,CTR GENET MED,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; DEJONGE AJR, 1983, EMBO J, V2, P637, DOI 10.1002/j.1460-2075.1983.tb01477.x; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EKER APM, 1992, MUTAT RES, V274, P211, DOI 10.1016/0921-8777(92)90067-D; GIANNELLI F, 1976, J CELL SCI, V20, P207; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANAWALT PC, 1992, A BENZON S, V35, P231; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; Mansbridge J. N., 1983, UCLA S MOL CELLULAR, VII, P195; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, 1993, J BIOL CHEM, V268, P9105; MATSUKUMA S, 1981, EXP CELL RES, V134, P103, DOI 10.1016/0014-4827(81)90467-5; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; POPANDA O, 1988, J CANCER RES CLIN, V114, P459, DOI 10.1007/BF00391492; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1994, COLD SPRING HARB SYM, V58, P625; YANAGISAWA J, 1992, J BIOL CHEM, V267, P3585	45	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22749	22757						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077226				2022-12-25	WOS:A1994PQ16300046
J	AMLAL, H; PAILLARD, M; BICHARA, M				AMLAL, H; PAILLARD, M; BICHARA, M			NH4+ TRANSPORT PATHWAYS IN CELLS OF MEDULLARY THICK ASCENDING LIMB OF RAT-KIDNEY - NH4+ CONDUCTANCE AND K+NH4+/(H+) ANTIPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; HENLES LOOP; POTASSIUM CONDUCTANCES; BASOLATERAL MEMBRANE; AMMONIUM TRANSPORT; COLLECTING DUCT; RABBIT KIDNEY; INHIBITION; MOUSE; NEPHRONS	To characterize NH4+ transport in the renal medullary thick ascending limb (MTAL), cell pH was monitored with the use of 2',7'-bis(carboxyethyl)-5(6)-carboxyfluoresceine in suspensions of rat MTAL tubules in CO2-free media. Abrupt exposure to NH4Cl led to initial cell alkalinization (NH3 entry) followed by cell acidification due to NH4+ influx. The latter had 1 mu M amiloride- and barium-sensitive components; the barium effect was unchanged when K+ conductances were completely blocked by quinidine, as assessed with the use of the cell membrane potential-sensitive fluorescent probe 3,3'-dipropylthiadicarbocyanine. NH4+ entry-induced depolarization was abolished by 1 mu M amiloride, but it was unaffected by barium. In NH4+-free media, barium, verapamil, and raising of the extracellular K+ concentration alkalinized MTAL cells; imposing an outward directed K+ gradient in Na+-free medium induced cellular acidification, which was abolished by barium and verapamil but not by other K+ channel and Na+/H+ antiport inhibitors (quinidine and 2 mM amiloride). As measured with a K+-selective extracellular electrode, a component of K+ efflux (in presence of furosemide, ouabain, and quinidine) was stimulated by decreasing the extracellular pH from 7.4 to 7.0 and inhibited by barium and verapamil. It was also demonstrated that the K+/H+ antiporter transports NH4+ better than H+ at physiological NH4+ and H+ concentrations. These results demonstrate the presence in MTAL cells of two novel NH4+ transport pathways, amiloride-sensitive NH4+ conductance and barium- and vera pamil-sensitive K+/NH4+(H+) antiport.	UNIV PARIS 06,CTR RECH BIOMED CORDELIERS,INSERM,U356,PHYSIOL & ENDOCRINOL CELLULAIRE RENALE LAB,F-75270 PARIS,FRANCE; HOP BROUSSAIS,F-75674 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								Amlal H., 1992, Journal of the American Society of Nephrology, V3, P771; BINDER HJ, 1986, J MEMBRANE BIOL, V91, P77, DOI 10.1007/BF01870217; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; BONANNO JA, 1991, AM J PHYSIOL, V260, pC618, DOI 10.1152/ajpcell.1991.260.3.C618; BRIVING C, 1988, BIOCHIM BIOPHYS ACTA, V946, P185, DOI 10.1016/0005-2736(88)90391-4; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; BUERKERT J, 1982, J CLIN INVEST, V70, P1, DOI 10.1172/JCI110581; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BUTT AG, 1990, AM J PHYSIOL, V258, pC630, DOI 10.1152/ajpcell.1990.258.4.C630; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; COGAN MG, 1986, KIDNEY, P457; DESIR GV, 1991, BIOCHIM BIOPHYS ACTA, V1067, P38, DOI 10.1016/0005-2736(91)90023-2; DISCALA F, 1992, BRIT J PHARMACOL, V107, P532, DOI 10.1111/j.1476-5381.1992.tb12779.x; DUBOSE TD, 1992, J CLIN INVEST, V90, P1443, DOI 10.1172/JCI116011; DUBOSE TD, 1983, AM J PHYSIOL, V244, pF497, DOI 10.1152/ajprenal.1983.244.5.F497; FROISSART M, 1992, AM J PHYSIOL, V262, pC963, DOI 10.1152/ajpcell.1992.262.4.C963; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GOOD DW, 1985, AM J PHYSIOL, V248, pF459, DOI 10.1152/ajprenal.1985.248.4.F459; GOOD DW, 1990, AM J PHYSIOL, V258, pF1345, DOI 10.1152/ajprenal.1990.258.5.F1345; GOOD DW, 1984, AM J PHYSIOL, V247, pF35, DOI 10.1152/ajprenal.1984.247.1.F35; GOOD DW, 1988, AM J PHYSIOL, V255, pF78, DOI 10.1152/ajprenal.1988.255.1.F78; GRABER M, 1993, AM J PHYSIOL, V265, pF773, DOI 10.1152/ajprenal.1993.265.6.F773; GREGER R, 1990, RENAL PHYSIOL BIOCH, V13, P37; ILLEK B, 1992, AM J PHYSIOL, V263, pC674, DOI 10.1152/ajpcell.1992.263.3.C674; KIKERI D, 1992, J GEN PHYSIOL, V99, P435, DOI 10.1085/jgp.99.3.435; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; PAULAIS M, 1989, J PHYSIOL-LONDON, V413, P315, DOI 10.1113/jphysiol.1989.sp017656; SCHLATTER E, 1992, PFLUG ARCH EUR J PHY, V420, P39, DOI 10.1007/BF00378639; SOLTOFF SP, 1986, AM J PHYSIOL, V250, pC744, DOI 10.1152/ajpcell.1986.250.5.C744; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; TEULON J, 1987, BIOCHIM BIOPHYS ACTA, V905, P125, DOI 10.1016/0005-2736(87)90016-2; TSURUOKA S, 1993, J CLIN INVEST, V92, P1881, DOI 10.1172/JCI116780; VANDEYNSE N, 1992, CELL PHYSIOL BIOCHEM, V2, P37; WATTS BA, 1990, J AM SOC NEPHROL, V1, P660	38	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21962	21971						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071316				2022-12-25	WOS:A1994PE09800010
J	DENNIS, MS; LAZARUS, RA				DENNIS, MS; LAZARUS, RA			KUNITZ DOMAIN INHIBITORS OF TISSUE FACTOR-FACTOR VIIA .1. POTENT INHIBITORS SELECTED FROM LIBRARIES BY PHAGE DISPLAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; FACTOR PATHWAY INHIBITOR; HUMAN GROWTH-HORMONE; BLOOD-COAGULATION; ANTITHROMBIN-III; ESCHERICHIA-COLI; COMPLEX; DNA; PURIFICATION; APROTININ	Potent active-site inhibitors of human tissue factor-Factor VIIa (TF.FVIIa) have been selected from Alzheimer's amyloid beta-protein precursor inhibitor (APPI) Kunitz domain libraries displayed on phage. Eight randomized positions on the extended primary binding loop (P-5 through P-4') and positions 34 and 39 were examined in three separate libraries. Libraries contained from 3.2 x 10(5) to 3.2 x 10(6) potential variants resulting from replacing up to 5 positions with all 20 amino acids. Following 4 rounds of selection against FVIIa associated with immobilized tissue factor (TF), 12 clones from each library were sequenced. Variants were purified by trypsin affinity chromatography and reverse-phase high performance liquid chromatography, and characterized for their ability to inhibit TF.FVIIa chromogenic activity. Measured apparent equilibrium dissociation constants (K-i*) ranged from about 10 to 500 nM. From sequence and activity data, an overall consensus sequence, TF7I-C, was constructed by site-directed mutagenesis. TF7I-C differed from APPI at 4 key residues, T11P, M17L, S19L, and G39Y, and inhibited TF.FVIIa with a K-i* = 1.9 +/- 0.4 nM, which represented an increase in binding affinity of more than 150-fold compared to APPI, At 40 mu M, TF7I-C prolonged the clotting times 3.5-fold in a prothrombin time assay and >10 fold at 7 mu M in an activated partial thromboplastin time assay. Prolongation of the activated partial thromboplastin time correlates with potent inhibition of FXIa (K-i* = 0.8 rm) and plasma Kallikrein (K-i* = 1.2 nM). TF7I-C also inhibited plasmin (K-i* = 40 nM) and FXa (K-i* = 55 nM), but not activated protein C, thrombin, or FXIIa (K-i* >10 mu M each).	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Roche Holding; Genentech								BECKMANN J, 1988, EUR J BIOCHEM, V176, P675, DOI 10.1111/j.1432-1033.1988.tb14330.x; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1993, BLOOD, V82, P1679; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CASTRO M, 1990, FEBS LETT, V267, P207, DOI 10.1016/0014-5793(90)80926-A; CHABBAT J, 1993, THROMB RES, V71, P205, DOI 10.1016/0049-3848(93)90095-6; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; CRONLUND AL, 1992, BIOCHEMISTRY-US, V31, P1685, DOI 10.1021/bi00121a016; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FIORE MM, 1994, J BIOL CHEM, V269, P143; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOSSIAKOFF AA, 1993, BIOCHEM SOC T, V21, P614, DOI 10.1042/bst0210614; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MANN KG, 1993, BLOOD, V82, P1680; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; RAO LVM, 1993, BLOOD, V81, P2600; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; SALVESEN G, 1994, HEMOSTASIS THROMBOSI, P241; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT CF, 1987, BLOOD, V69, P1431; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SINHA S, 1991, J BIOL CHEM, V266, P21011; VANDENBESSELAAR AMH, 1993, THROMB HAEMOSTASIS, V69, P298; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; Wells J. A., 1992, CURR OPIN STRUC BIOL, V2, P597; Williams J W, 1979, Methods Enzymol, V63, P437	53	88	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22129	22136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071337				2022-12-25	WOS:A1994PE09800033
J	ERICKSON, JD; VAROQUI, H; SCHAFER, MKH; MODI, W; DIEBLER, MF; WEIHE, E; RAND, J; EIDEN, LE; BONNER, TI; USDIN, TB				ERICKSON, JD; VAROQUI, H; SCHAFER, MKH; MODI, W; DIEBLER, MF; WEIHE, E; RAND, J; EIDEN, LE; BONNER, TI; USDIN, TB			FUNCTIONAL IDENTIFICATION OF A VESICULAR ACETYLCHOLINE TRANSPORTER AND ITS EXPRESSION FROM A CHOLINERGIC GENE LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYLTRANSFERASE MESSENGER-RNA; VESICLE MONOAMINE TRANSPORTER; INSITU HYBRIDIZATION; PROMOTER REGION; SPINAL-CORD; COMPLETE SEQUENCE; MAMMALIAN-CELLS; RAT; LOCALIZATION; CDNA	The vesicular acetylcholine transporter (VAChT) has been identified and characterized based on the acquisition of high affinity vesamicol binding and proton-dependent, vesamicol sensitive acetylcholine accumulation by a fibroblast cell line transfected with a clone from a rat pheochromocytoma cDNA library encoding this protein. The distribution of VAChT mRNA coincides with that reported for choline acetyltransferase (ChAT), the enzyme required for acetylcholine biosynthesis, in the peripheral and central cholinergic nervous systems. A human VAChT cDNA was used to localize the VAChT gene to chromosome 10q11.2, which is also the location of the ChAT gene. The entire sequence of the human VAChT cDNA is contained uninterrupted within the first intron of the ChAT gene locus. Transcription of VAChT and ChAT mRNA from the same or contiguous promoters within a single regulatory locus provides a previously undescribed genetic mechanism for coordinate regulation of two proteins whose expression is required to establish a mammalian neuronal phenotype.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892; CNRS,NEUROBIOL CELLULAIRE LAB,DEPT NEUROCHIM,F-91190 GIF SUR YVETTE,FRANCE; UNIV MAINZ,DEPT ANAT,W-6500 MAINZ,GERMANY; NCI,FREDERICK CANC RES FACIL,FREDERICK,MD 20797; OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oklahoma Medical Research Foundation	ERICKSON, JD (corresponding author), NIMH,MOLEC NEUROSCI SECT,BETHESDA,MD 20892, USA.			Eiden, Lee/0000-0001-7524-944X	NIGMS NIH HHS [R01 GM038679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ALFONSO A, 1994, IN PRESS J MOL BIOL; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; COHENHAGUENAUER O, 1990, GENOMICS, V6, P374, DOI 10.1016/0888-7543(90)90579-J; DAN Y, 1994, J NEUROBIOL, V25, P336, DOI 10.1002/neu.480250313; DAVIES P, 1976, LANCET, V2, P1403; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HERSH LB, 1993, J NEUROCHEM, V61, P306, DOI 10.1111/j.1471-4159.1993.tb03569.x; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; ISRAEL M, 1994, IN PRESS NEUROCHEM I; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KREJJCI E, 1994, FEBS LETT, V335, P1614; LAUTERBORN JC, 1993, MOL BRAIN RES, V17, P59, DOI 10.1016/0169-328X(93)90073-X; LAWRENCE JB, 1988, CELL, V52, P51; LI YP, 1993, J NEUROCHEM, V61, P748; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MORI N, 1993, MOL BRAIN RES, V17, P101, DOI 10.1016/0169-328X(93)90078-4; OH JD, 1992, NEUROSCIENCE, V47, P807, DOI 10.1016/0306-4522(92)90031-V; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; PERRY EK, 1977, LANCET, V1, P189; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; TOLL L, 1980, J BIOL CHEM, V255, P1787; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; WAINER BH, 1984, NEUROCHEM INT, V6, P163, DOI 10.1016/0197-0186(84)90089-5; WHITTAKER VP, 1988, CHOLINERGIC SYNAPSE; WU DH, 1994, J NEUROCHEM, V62, P1653	41	345	354	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21929	21932						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071310				2022-12-25	WOS:A1994PE09800002
J	ITO, H; TAKAICHI, S; TSUJI, H; TANAKA, A				ITO, H; TAKAICHI, S; TSUJI, H; TANAKA, A			PROPERTIES OF SYNTHESIS OF CHLOROPHYLL-A FROM CHLOROPHYLL-B IN CUCUMBER ETIOPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; PROTEIN COMPLEXES; PHOTOSYSTEM-II; LIGHT; ACCUMULATION; DARKNESS; BIOSYNTHESIS; APOPROTEINS; COTYLEDONS; GABACULINE	Chlorophyll a accumulated when chlorophyllide b was incubated with isolated cucumber etioplasts in the dark. When [C-14]chlorophyllide b was used as the substrate for chlorophyll synthesis, [C-14]chlorophyll a was formed, showing that chlorophyll a was synthesized from the exogenously added chlorophyllide b, not by light-independent reduction of endogenous protochlorophyllide. The reaction studied showed an optimal pH of 7.5 and required both the soluble and membrane fractions of etioplasts together with ATP. Time course experiments showed that chlorophyll a began to accumulate later than chlorophyll b. Chlorophyllide b esterified with geranylgeraniol accumulated first, but there was little accumulation of chlorophyll a with an unhydrogenated prenyl side chain. No chlorophyllide a was detected during incubation. These observations indicate that esterified chlorophyll b was converted to chlorophyll a. This conversion would play an important role in the use of chlorophyll b for the synthesis of chlorophyll a in the reconstruction of photosystems.	NIPPON MED COLL,BIOL LAB,KAWASAKI 211,JAPAN	Nippon Medical School	ITO, H (corresponding author), KYOTO UNIV,FAC SCI,DEPT BOT,KYOTO 60601,JAPAN.		Ito, Hisashi/A-4211-2012; Tanaka, Ayumi/D-9003-2012	Ito, Hisashi/0000-0002-2482-5870; 				ADAMSON H, 1985, PHYSIOL PLANTARUM, V64, P345, DOI 10.1111/j.1399-3054.1985.tb03351.x; ARGYROUDIAKOYUNOGLOU JH, 1982, PLANT PHYSIOL, V70, P1242, DOI 10.1104/pp.70.5.1242; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CORRIVEAU JL, 1986, PLANT SCI, V45, P9, DOI 10.1016/0168-9452(86)90065-8; DUGGAN JX, 1982, PLANT SCI LETT, V27, P137, DOI 10.1016/0304-4211(82)90142-0; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; HARRISON MA, 1992, BIOCHIM BIOPHYS ACTA, V1100, P83, DOI 10.1016/0167-4838(92)90539-P; HOLDEN M, 1961, BIOCHEM J, V78, P359, DOI 10.1042/bj0780359; HOLT AS, 1954, AM J BOT, V41, P710, DOI 10.2307/2438955; IKEGAMI I, 1984, PLANT CELL PHYSIOL, V25, P343; ITO H, 1993, ARCH BIOCHEM BIOPHYS, V306, P148, DOI 10.1006/abbi.1993.1492; KLEIN AO, 1961, J BIOL CHEM, V236, P2544; KOTZABASIS K, 1989, PHYSIOL PLANTARUM, V76, P474, DOI 10.1111/j.1399-3054.1989.tb05465.x; KUPKE DW, 1963, SCIENCE, V140, P49, DOI 10.1126/science.140.3562.49; MELIS A, 1981, BIOCHIM BIOPHYS ACTA, V637, P138, DOI 10.1016/0005-2728(81)90219-X; OMATA T, 1980, PHOTOCHEM PHOTOBIOL, V31, P183, DOI 10.1111/j.1751-1097.1980.tb03702.x; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; RANDO RR, 1977, BIOCHEMISTRY-US, V16, P4604, DOI 10.1021/bi00640a012; RUDIGER W, 1980, EUR J BIOCHEM, V109, P193, DOI 10.1111/j.1432-1033.1980.tb04784.x; RUDOI A B, 1982, Biokhimiya, V47, P733; SCHNEEGURT MA, 1992, BIOCHEMISTRY-US, V31, P11677, DOI 10.1021/bi00162a002; SHEDBALKAR VP, 1991, J BIOL CHEM, V266, P17151; SHIOI Y, 1983, BIOCHIM BIOPHYS ACTA, V756, P127, DOI 10.1016/0304-4165(83)90033-8; SHIOI Y, 1987, ANAL BIOCHEM, V162, P493, DOI 10.1016/0003-2697(87)90425-8; SOLL J, 1983, PLANT PHYSIOL, V71, P849, DOI 10.1104/pp.71.4.849; TAKAICHI S, 1993, ORG MASS SPECTROM, V28, P785, DOI 10.1002/oms.1210280711; TANAKA A, 1981, PLANT PHYSIOL, V68, P567, DOI 10.1104/pp.68.3.567; TANAKA A, 1991, PLANT CELL PHYSIOL, V32, P195, DOI 10.1093/oxfordjournals.pcp.a078064; TANAKA A, 1983, PLANT CELL PHYSIOL, V24, P101, DOI 10.1093/oxfordjournals.pcp.a076502; WALMSLEY J, 1989, PHYSIOL PLANTARUM, V77, P312, DOI 10.1111/j.1399-3054.1989.tb05647.x; WHYTE BJ, 1993, BIOCHEM J, V291, P939, DOI 10.1042/bj2910939	31	43	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22034	22038						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071325				2022-12-25	WOS:A1994PE09800019
J	KATAYAMA, T				KATAYAMA, T			THE MUTANT DNAACOS PROTEIN WHICH OVERINITIATES REPLICATION OF THE ESCHERICHIA-COLI CHROMOSOME IS INERT TO NEGATIVE REGULATION FOR INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; ENZYMATIC REPLICATION; ORIGIN; GENES; EXPRESSION; CLONING; BINDING; SITES; RNA	Initiation of chromosome replication occurs excessively in the dnaAcos mutant at 30 degrees C. DnaAcos protein was purified from an overproducing strain and found to be as active as wild-type DnaA protein in initial synthesis rates of minichromosome replication in vitro at 30 degrees C. However, whereas efficient initiation occurred for only 20 min with wild-type DnaA protein, it continued for 45 min with DnaAcos protein, an indication that DnaAcos protein retained initiation activity for a longer time than wild-type DnaA protein. Also, whereas wild-type DnaA protein is inactivated by ADP binding, DnaAcos protein failed to be inactivated by ADP due to its inability to bind nucleotide. Thus, DnaAcos protein appears to lack negative regulation for its initiation activity. At 42 degrees C, a temperature at which initiation of chromosome replication is normal in the dnaAcos mutant, in vitro DnaAcos protein activity decreased to 25% of that observed at 30 degrees C. This coincident occurrence of normal initiation in vivo and reduced activity is consistent with the idea that negative control of DnaA protein activity is necessary for normal replication.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University				Katayama, Tsutomu/0000-0001-9994-1684				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1987, J BACTERIOL, V169, P3898, DOI 10.1128/jb.169.9.3898-3903.1987; CROOKE E, 1992, J BIOL CHEM, V267, P16779; FAYAT O, 1986, MOL GEN GENET, V202, P435; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; Kornberg A., 1992, DNA REPLICATION; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3526; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; Sambrook J, 1989, MOL CLONING LABORATO; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	33	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22075	22079						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071330				2022-12-25	WOS:A1994PE09800025
J	RICKETTS, D; SUGUMARAN, M				RICKETTS, D; SUGUMARAN, M			1,2-DEHYDRO-N-BETA-ALANYLDOPAMINE AS A NEW INTERMEDIATE IN INSECT CUTICULAR SCLEROTIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLDOPAMINE QUINONE METHIDE; N-BETA-ALANYLDOPAMINE; SARCOPHAGA-BULLATA; SIDE-CHAIN; CUTICLE SCLEROTIZATION; BIOSYNTHESIS; ENZYMES; DERIVATIVES; MECHANISM; OXIDATION	Sclerotization of insect cuticle is an extremely important biochemical process for the successful survival of most insects. N-Acetyldopamine and N-beta-alanyldopamine are two widely used sclerotizing precursors. N-Acetyldopamine is converted by phenoloxidase, quinone isomerase, and quinone methide isomerase to generate the reactive intermediates quinone, quinone methide, and quinone methide imine amide for use in quinone tanning, quinone methide sclerotization, and cw,p sclerotization, respectively. N-beta-Alanyldopamine has been claimed to be used only by phenoloxidase and quinone isomerase for quinone tanning and quinone methide sclerotization thereby attributing biochemical diversity to the coloration and strength of different cuticles. However, we demonstrate here that cuticular enzymes isolated from the larvae of Calliphora possess the capacity to generate 1,2-dehydro-N-beta-alanyldopamine from N-beta- alanyldopamine. Chemical synthesis of 1,2-dehydro-N-beta-alanyldopamine and its further oxidation are reported for the first time. Comparative biochemical studies confirm that both the sclerotizing precursors, N-acetyldopamine and N-beta-alanyldopamine, are used by all three different mechanisms of the unified theory of sclerotization.	UNIV MASSACHUSETTS,DEPT BIOL,BOSTON,MA 02125	University of Massachusetts System; University of Massachusetts Boston					NIAID NIH HHS [R01 AI 14753] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014753] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen S.O., 1990, P133; ANDERSEN SO, 1989, INSECT BIOCHEM, V19, P581, DOI 10.1016/0020-1790(89)90023-1; ANDERSEN SO, 1982, INSECT BIOCHEM, V12, P269, DOI 10.1016/0020-1790(82)90085-3; Andersen Svend Olav, 1991, P123; CHAPMAN DF, 1982, INSECTS STRUCTURE FU, P501; CHRISTENSEN AM, 1991, J AM CHEM SOC, V113, P6799, DOI 10.1021/ja00018a013; DALI H, 1988, ORG PREP PROCED INT, V20, P191, DOI 10.1080/00304948809355808; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; HOPKINS TL, 1982, SCIENCE, V217, P364, DOI 10.1126/science.217.4557.364; KAFLSON P, 1992, NATURE, V195, P183; KRAMER KJ, 1987, ARCH INSECT BIOCHEM, V6, P279, DOI 10.1002/arch.940060406; MORGAN TD, 1987, INSECT BIOCHEM, V17, P255, DOI 10.1016/0020-1790(87)90066-7; SAUL S, 1988, FEBS LETT, V237, P155, DOI 10.1016/0014-5793(88)80191-1; SAUL SJ, 1990, ARCH INSECT BIOCHEM, V15, P237, DOI 10.1002/arch.940150405; SAUL SJ, 1991, ARCH INSECT BIOCHEM, V16, P123, DOI 10.1002/arch.940160205; SAUL SJ, 1989, FEBS LETT, V255, P340, DOI 10.1016/0014-5793(89)81117-2; SAUL SJ, 1989, FEBS LETT, V251, P69, DOI 10.1016/0014-5793(89)81430-9; SAUL SJ, 1990, J BIOL CHEM, V265, P16992; SAUL SJ, 1991, FEBS LETT, V279, P145, DOI 10.1016/0014-5793(91)80270-D; SAUL SJ, 1990, ARCH INSECT BIOCH PH, V15, P255; Sugumaran M., 1988, Advances in Insect Physiology, V21, P179, DOI 10.1016/S0065-2806(08)60124-1; SUGUMARAN M, 1991, FEBS LETT, V293, P4, DOI 10.1016/0014-5793(91)81140-4; SUGUMARAN M, 1989, ARCH INSECT BIOCHEM, V11, P109, DOI 10.1002/arch.940110205; SUGUMARAN M, 1989, ARCH INSECT BIOCHEM, V11, P127, DOI 10.1002/arch.940110206; SUGUMARAN M, 1987, BIOORG CHEM, V15, P194, DOI 10.1016/0045-2068(87)90019-8; SUGUMARAN M, 1987, J BIOL CHEM, V262, P10546; SUGUMARAN M, 1992, ARCH INSECT BIOCHEM, V19, P271, DOI 10.1002/arch.940190406; SUGUMARAN M, 1989, BIOORG CHEM, V17, P443, DOI 10.1016/0045-2068(89)90045-X; SUGUMARAN M, 1989, ARCH INSECT BIOCH PH, V11, P10355; THOMPSON DC, 1992, CHEM-BIOL INTERACT, V86, P129; UMEBACHI Y, 1970, J INSECT PHYSIOL, V16, P1203, DOI 10.1016/0022-1910(70)90210-6	31	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22217	22221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071347				2022-12-25	WOS:A1994PE09800047
J	WINTHER, JR; SORENSEN, P; KIELLANDBRANDT, MC				WINTHER, JR; SORENSEN, P; KIELLANDBRANDT, MC			REFOLDING OF A CARBOXYPEPTIDASE-Y FOLDING INTERMEDIATE IN-VITRO BY LOW-AFFINITY BINDING OF THE PROREGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST CARBOXYPEPTIDASE; PRO-REGION; DENATURED SUBTILISIN; PROTEIN; PROPEPTIDE; CHAPERONE; PEPTIDE; BPN'	Efficient folding of carboxypeptidase Y is dependent on the presence of the proregion. Thus, denatured procarboypeptidase Y, in contrast to the mature enzyme, refolds efficiently in vitro in low ionic strength buffers. Under these conditions denatured mature carboxypeptidase Y forms an inactive, soluble folding intermediate, which has been characterized in the present study. The inactive intermediate can be folded into the active enzyme at a low efficiency (5-10%) by the addition of 0.9 M ammonium sulfate. The refolding is accompanied by pronounced structural changes. As seen for other protease zymogens the isolated proregion from carboxypeptidase Y was found to stimulate refolding without covalent linkage to the mature part. However, the added proregion does not form a stable complex with the native enzyme and requires the presence of 0.9 M ammonium sulfate to exhibit its function. The proregion increases the yield of correctly folded enzyme, and kinetic analysis suggests that this is due to a reduction of the rate of nonproductive folding or aggregation. In addition, the proregion stabilizes carboxypeptidase Y toward thermoinactivation.	CARLSBERG LAB, DEPT CHEM, DK-2500 VALBY, DENMARK		WINTHER, JR (corresponding author), CARLSBERG LAB, DEPT YEAST GENET, GAMLE CARLSBERG VEJ 10, DK-2500 VALBY, DENMARK.		Kielland-Brandt, Morten C./D-2563-2015; Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Kielland-Brandt, Morten/0000-0002-1272-3877				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUJISHIGE A, 1992, J CELL BIOL, V118, P33, DOI 10.1083/jcb.118.1.33; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; HAZEL HB, 1993, J BIOL CHEM, V268, P18002; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RICHARDS FM, 1958, P NATL ACAD SCI USA, V44, P162, DOI 10.1073/pnas.44.2.162; SAEN JL, 1989, NATURE, V341, P462; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; SORENSEN SO, 1994, EUR J BIOCHEM, V220, P19, DOI 10.1111/j.1432-1033.1994.tb18594.x; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	28	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22007	22013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071321				2022-12-25	WOS:A1994PE09800015
J	WONDRAK, EM; SAKAGUCHI, K; RICE, WG; KUN, E; KIMMEL, AR; LOUIS, JM				WONDRAK, EM; SAKAGUCHI, K; RICE, WG; KUN, E; KIMMEL, AR; LOUIS, JM			REMOVAL OF ZINC IS REQUIRED FOR PROCESSING OF THE MATURE NUCLEOCAPSID PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS, TYPE-1, BY THE VIRAL PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MURINE LEUKEMIA-VIRUS; SYNTHETIC PEPTIDE; ESCHERICHIA-COLI; DIMER FORMATION; CIS ELEMENTS; HIV-1; BINDING; RNA; FINGERS; SITE	In human immunodeficiency virus, RNA selection and packaging during assembly involve the two retroviral-type fingers of the nucleocapsid protein that are held in a constrained configuration by coordinated zinc ions, In this report, we demonstrate that the nucleocapsid protein in a metal bound state is resistant to cleavage by the viral protease, but upon removal of zinc ions by chelating agents, it is hydrolyzed within the first zinc finger between Phe-16 and Asn-17. However, 3-nitrosobenzamide and cupric ions, which release zinc through oxidation of the cysteine residues of the finger, render the nucleocapsid protein resistant to cleavage. Since protease inhibitors and 3-nitrosobenzamide restrict processes relating to steps early in infection, the cleavage of the nucleocapsid protein may represent an essential event that can be exploited for the design of novel antiviral agents.	NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702; SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM TOXICOL & CHEM LAB,TIBURON,CA 94920; SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,OCTAMER INC,TIBURON,CA 94920	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; California State University System; San Francisco State University; California State University System; San Francisco State University								ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P87, DOI 10.1016/0006-291X(89)92408-X; MELY Y, 1991, BIOPOLYMERS, V31, P899, DOI 10.1002/bip.360310709; MELY Y, 1993, BIOPHYS J, V65, P1513, DOI 10.1016/S0006-3495(93)81222-0; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; NASHED NT, 1989, BIOCHEM BIOPH RES CO, V163, P1079, DOI 10.1016/0006-291X(89)92331-0; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICH DH, 1985, J MED CHEM, V28, P263, DOI 10.1021/jm00381a001; ROBERTS MM, 1991, PROTEIN ENG, V4, P695, DOI 10.1093/protein/4.6.695; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMMERS MF, 1993, J CELL BIOCHEM, V48, P245; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; VENAUD S, 1992, RES VIROLOGY, V143, P311, DOI 10.1016/S0923-2516(06)80119-6; WONDRAK EM, 1993, FEBS LETT, V333, P21, DOI 10.1016/0014-5793(93)80367-4; WONDRAK EM, 1990, ANAL BIOCHEM, V188, P82, DOI 10.1016/0003-2697(90)90530-M	33	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21948	21950						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071314				2022-12-25	WOS:A1994PE09800007
J	KATZIR, Z; NARDI, N; GEFFEN, I; FUHRER, C; HENIS, YI				KATZIR, Z; NARDI, N; GEFFEN, I; FUHRER, C; HENIS, YI			DYNAMIC INTERACTIONS OF THE ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS WITH COATED PITS - ENHANCED INTERACTIONS OF H2 FOLLOWING ASSOCIATION WITH H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; LYSOSOMAL ACID-PHOSPHATASE; CYTOPLASMIC DOMAIN; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; LATERAL MOBILITY; INTERNALIZATION SIGNALS; MEDIATED ENDOCYTOSIS; INVITRO BINDING; AP-2 SUBUNIT	Lateral mobility studies comparing native and mutated membrane proteins, combined with treatments that alter clatbrin lattice structure, can measure membrane protein-coated pit interactions in intact cells (Fire, E., Zwart, D., Roth, M.G., an Henis, Y.I. (1991) J. Cell Biol. 115, 1585-1594). We applied this approach to study the interactions of the H1 and H2 human asialoglycoprotein receptor subunits with coated pits. The lateral mobilities of singly expressed and coexpressed H1 and H2B (the H2 species that reaches the cell surface) were measured by fluorescence photobleaching recovery. They were compared with mutant proteins, H1(5A) (Tyr-5 replaced by Ala) and H2(5A) (Phe-5 replaced by Ala). While the mobile fraction of H1, H2B, and their mutants were similar, the lateral diffusion rate (measured by D, the lateral diffusion coefficient) was significantly slower for H1, whether expressed alone or with H2B. Coexpression with H1 reduced D of H2B to that of H1. Disruption of the clathrin lattices by hypertonic medium elevated D of H1, H1(5A), H2B, and H2(5A) to the same final level, without affecting their mobile fractions. Cytosol acidification, which retains altered clathrin lattices attached to the membrane and prevents coated vesicle formation, immobilized part of the H1 molecules, reflecting stable entrapment in ''frozen'' coated pits. H1(5A), H2B, and H2(5A) were not affected: however, coexpression of H2B with H1 conferred the sensitivity to cytosol acidification on H2B. Our results suggest that H1 lateral mobility is inhibited by dynamic interactions with coated pits in which Tyr-5 is involved. H2B resembles H1(5A) rather than H1, and its interactions with coated pits are weaker; efficient interaction of H2B with coated pits depends on complex formation with H1.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND	Tel Aviv University; University of Basel				Fuhrer, Christian/0000-0001-8216-8883; Henis, Yoav/0000-0002-1408-3877				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BRANDTZAEG P, 1973, SCAND J IMMUNOL, V2, P273, DOI 10.1111/j.1365-3083.1973.tb02037.x; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; BRETSCHER MS, 1984, CELL, V38, P3, DOI 10.1016/0092-8674(84)90519-1; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CIECHANOVER A, 1983, CELL, V32, P267, DOI 10.1016/0092-8674(83)90517-2; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVOUST J, 1987, EMBO J, V6, P3601, DOI 10.1002/j.1460-2075.1987.tb02691.x; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELSON EL, 1979, J SUPRAMOL STR CELL, V12, P481, DOI 10.1002/jss.400120408; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; FUHRER C, 1994, J BIOL CHEM, V269, P3277; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOPPEL DE, 1981, NATURE, V293, P159, DOI 10.1038/293159a0; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; TANABE T, 1979, J BIOL CHEM, V254, P1038; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WOLF DE, 1980, P NATL ACAD SCI-BIOL, V77, P2043, DOI 10.1073/pnas.77.4.2043	74	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21568	21575						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063795				2022-12-25	WOS:A1994PK97300030
J	VILLANI, G; PILLAIRE, MJ; BOEHMER, PE				VILLANI, G; PILLAIRE, MJ; BOEHMER, PE			EFFECT OF THE MAJOR DNA ADDUCT OF THE ANTITUMOR DRUG CIS-DIAMINEDICHLOROPLATINUM(II) ON THE ACTIVITY OF A HELICASE ESSENTIAL FOR DNA-REPLICATION, THE HERPES-SIMPLEX VIRUS TYPE-1 ORIGIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; HUMAN CELL-EXTRACTS; PLATINUM COMPOUNDS; DUPLEX DNA; INHIBITION; IDENTIFICATION; POLYMERASES; REPAIR; ALPHA; SITE	To determine the effect of the major DNA adduct, the intrastrand d(GpG) cross-link, produced by the antitumor drug cis-diamminedichloroplatinum(II) on the activity of a helicase known to be essential for DNA replication, we have examined its interaction with the origin-binding protein (UL9 protein) of herpes simplex virus type-1. We found that the helicase activity of the UL9 protein is inhibited only when the adduct is present on the template strand along which the protein translocates. This effect was paralleled by a comparable inhibition of the UL9 protein's DNA-dependent ATPase activity. The inhibitory effect of the lesion can be reduced by the addition of the herpes simplex virus type-1 single-stranded DNA-binding protein, ICP8 This stimulatory effect is specific for ICP8 and appears to be the result of the functional and physical interaction that is known to exist between the UL9 protein and ICP8, and not; due to the preferential interaction of ICP8 with the adduct.	STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University	VILLANI, G (corresponding author), CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, 205 ROUTE NARBONNE, F-31077 TOULOUSE, FRANCE.		Pillaire, Marie-Jeanne/P-1579-2014	Pillaire, Marie-Jeanne/0000-0001-6866-7416; Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHU G, 1994, J BIOL CHEM, V269, P787; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; CORDA Y, 1991, BIOCHEMISTRY-US, V30, P222, DOI 10.1021/bi00215a032; CRUTE JJ, 1990, UCLA SYM BI, V127, P327; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELIAS P, 1990, J BIOL CHEM, V265, P17167; FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; HARDER HC, 1970, INT J CANCER, V6, P207, DOI 10.1002/ijc.2910060207; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; HOFFMANN JS, 1989, J BIOL CHEM, V264, P15130; HOWLE JA, 1970, BIOCHEM PHARMACOL, V19, P2757, DOI 10.1016/0006-2952(70)90102-4; HUANG L, 1993, J BIOL CHEM, V268, P26731; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; MAINE IP, 1992, BIOCHEMISTRY-US, V31, P3968, DOI 10.1021/bi00131a012; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; Sambrook J, 1989, MOL CLONING LABORATO; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; VILLANI G, 1993, FEBS LETT, V333, P89, DOI 10.1016/0014-5793(93)80380-D; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	32	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21676	21681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063811				2022-12-25	WOS:A1994PK97300047
J	CHAMBERS, TC; POHL, J; RAYNOR, RL; KUO, JF				CHAMBERS, TC; POHL, J; RAYNOR, RL; KUO, JF			IDENTIFICATION OF SPECIFIC SITES IN HUMAN P-GLYCOPROTEIN PHOSPHORYLATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BACTERIAL TRANSPORT PROTEINS; RESISTANT KB CELLS; MDR GENE FAMILY; MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; CARCINOMA-CELLS; QUANTITIES; SEQUENCES; HOMOLOGY; CHANNELS	Phosphorylation-of P-glycoprotein (Pgp) by protein kinase C occurs on apparently the same sites in vitro and in intact cells (in situ) and is implicated in modulation of Pgp function. The region of the molecule which contains the in vitro phosphorylation sites and two specific sites within this region are now determined by peptide sequencing. Membrane vesicles from multidrug-resistant human KB-V1 cells were incubated with purified protein kinase C and [gamma-P-32]ATP, and Pgp (containing 1 mol of phosphate/mol of protein) was purified to apparent homogeneity. Phosphorylation occurred exclusively on serine residues. Phosphopeptides were generated by digestion with Lys-C endoproteinase or trypsin, partially purified by high performance liquid chromatography, and further purified with strategies developed for individual phosphopeptides. Sequence analysis by Edman degradation and comparison with the deduced amino acid sequence of human (mdr 1) Pgp identified serines 661 and 671, and one or more of serines 667, 675, and 683, as sites of phosphorylation. These sites are clustered in the linker region located between the two homologous halves of Pgp. Our results identify a previously undefined, phosphorylatable domain of Pgp, smaller in size but analogous in location to the R-domain of the cystic fibrosis transmembrane conductance regulator. These data provide a basis for a better understanding of the role of phosphorylation in the mechanism of action and regulation of this important multidrug pump protein.	EMORY UNIV, SCH MED, WINSHIP CANC CTR, MICROCHEM FACIL, ATLANTA, GA 30322 USA	Emory University	CHAMBERS, TC (corresponding author), EMORY UNIV, SCH MED, ROLLINS RES CTR, DEPT PHARMACOL, 1510 CLIFTON RD, ATLANTA, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA036777] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; DEUCHARS KL, 1989, SEMIN ONCOL, V16, P156; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1991, J BIOL CHEM, V266, P4545; ENDICOTT J A, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P367; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GIRARD PR, 1986, J BIOL CHEM, V261, P370; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1987, CANCER RES, V47, P2860; HAN EKH, 1991, J CELL BIOL, V115, pA200; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; MA LD, 1991, J BIOL CHEM, V266, P5593; MCKNIGHT GS, 1977, ANAL BIOCHEM, V78, P86, DOI 10.1016/0003-2697(77)90011-2; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROY SN, 1985, CANCER RES, V45, P3856; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHURR E, 1989, CANCER RES, V49, P2729; SHEN DW, 1986, J BIOL CHEM, V261, P7762; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	38	149	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4592	4595						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095261				2022-12-25	WOS:A1993KP88400007
J	SHATTERS, RG; LIU, Y; KAHN, ML				SHATTERS, RG; LIU, Y; KAHN, ML			ISOLATION AND CHARACTERIZATION OF A NOVEL GLUTAMINE-SYNTHETASE FROM RHIZOBIUM-MELILOTI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PROLINE BIOSYNTHESIS; BRADYRHIZOBIUM-JAPONICUM; NITROGEN-FIXATION; AMMONIUM ASSIMILATION; KLEBSIELLA-AEROGENES; II ACTIVITY; PURIFICATION; PHASEOLI; CLONING; 104A14	Two glutamine synthetases, GSI and GSII, are found in most rhizobia. However, WSU650, a Rhizobium meliloti glnA glnII mutant that lacks both enzymes, can grow without a glutamine supplement in minimal medium that contains both ammonium and glutamate. The bacteria contained a third glutamine synthetase, GSIII, which has been purified and partially characterized. GSIII had considerable glutamine synthetase activity when assayed using a semibiosynthetic (glutamate- and hydroxylamine-dependent) assay, but had no detectable transferase (glutamine- and hydroxylamine-dependent) activity. GSIII was inhibited by ADP and pyrophosphate but not by various nitrogen-containing metabolites that inhibit other GS enzymes. Activity was also inhibited by methionine sulfoximine, a transition state analog, but the concentration needed to inhibit GSIII was 50 to 100 times higher than that needed to inhibit GSI or GSII. GSIII had a K(m) for glutamate of 13.3 mM, for ammonium of 33 mM, and for hydroxylamine of 5.3 mM with a pH optimum of 6.8 and a temperature optimum of 50-degrees-C. The purified protein had related subunits of 46.5 and 49 kDa and a native molecular mass of 355 kDa, indicating the native enzyme was an octamer. Polyclonal antibodies specific for GSIII reacted with a protein of similar molecular weight in Escherichia coli strains that carry R. meliloti glnT on a plasmid. GSIII activity was detected in some of these strains that contained glnT. Extracts of root nodules formed by WSU650 also react with the antibodies.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT BIOCHEM,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT MICROBIOL,PULLMAN,WA 99164	Washington State University; Washington State University; Washington State University; Washington State University				Shatters, Robert/0000-0002-3903-772X; Kahn, Michael/0000-0002-5204-561X				BENDER RA, 1977, J BACTERIOL, V129, P1001, DOI 10.1128/JB.129.2.1001-1009.1977; BRAVO A, 1988, J BACTERIOL, V170, P980, DOI 10.1128/jb.170.2.980-984.1988; CARLSON TA, 1985, J BACTERIOL, V162, P698, DOI 10.1128/JB.162.2.698-703.1985; CARLSON TA, 1987, J BACTERIOL, V169, P5861, DOI 10.1128/jb.169.12.5861-5866.1987; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COVARRUBIAS AA, 1980, PLASMID, V3, P150, DOI 10.1016/0147-619X(80)90106-7; DARROW RA, 1977, BIOCHEM BIOPH RES CO, V78, P554, DOI 10.1016/0006-291X(77)90214-5; DARROW RA, 1980, GLUTAMINE METABOLISM, P139; DEBRUIJN FJ, 1989, J BACTERIOL, V171, P1673, DOI 10.1128/jb.171.3.1673-1682.1989; DONALD RGK, 1984, J BACTERIOL, V158, P1144, DOI 10.1128/JB.158.3.1144-1151.1984; ESPIN G, 1990, MOL GEN GENET, V223, P513, DOI 10.1007/BF00264461; FUCHS RL, 1980, J BACTERIOL, V141, P996, DOI 10.1128/JB.141.2.996-998.1980; Ginsburg A, 1973, ENZYMES GLUTAMINE ME, P9; KAUSH M V, 1984, Biokhimiya, V49, P2012; KUMAR PS, 1990, CURR MICROBIOL, V21, P199, DOI 10.1007/BF02092122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEISTER A, 1980, GLUTAMINE METABOLISM, P4; MORA J, 1980, GLUTAMINE SYNTHETASE; PAHUJA SL, 1982, CHROMATOGRAPHY, V14, P249; Reitzer L.J., 1987, E COLI SALMONELLA CE, P302; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; SALMINEN SO, 1987, J BACTERIOL, V169, P495, DOI 10.1128/jb.169.2.495-499.1987; Sambrook J, 1989, MOL CLONING LABORATO; SHATTERS RG, 1989, J BACTERIOL, V171, P5087, DOI 10.1128/jb.171.9.5087-5094.1989; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; SOMERVILLE JE, 1983, J BACTERIOL, V156, P168, DOI 10.1128/JB.156.1.168-176.1983; SOMERVILLE JE, 1989, J BACTERIOL, V171, P5079, DOI 10.1128/jb.171.9.5079-5086.1989; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V118, P736, DOI 10.1016/0003-9861(67)90412-2	29	40	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					469	475						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093245				2022-12-25	WOS:A1993KE60300072
J	VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H				VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H			ELEVATED EXPRESSION OF THE JUNB PROTOONCOGENE IS ESSENTIAL FOR V-FOS INDUCED TRANSFORMATION OF RAT-1 CELLS	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; C-JUN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; MOLECULAR-CLONING; MOUSE FIBROBLASTS; LEUCINE ZIPPER; GENE; AP-1	We previously described the isolation of non-tumorigenic revertants from mutagenized populations of v-fos-transformed Rat-1 cells (Zarbl et al., 1987). In the present study we examined the possibility that the revertant phenotype resulted from mutations that altered the expression or activities of the c-jun or junB protooncogenes. The results demonstrated that levels of the c-jun mRNA and protein were unchanged in the revertants when compared to the transformed parental cells, and ectopic overexpression of c-jun failed to retransform the revertants. Although one mutant allele was detected in revertant EMS-1-19, overexpression of this mutant allele failed to inhibit v-fos induced cell transformation. Together these results indicated that the revertant phenotype did not result from altered expression or mutations in the c-jun gene. In contrast to the results obtained with c-jun, the levels of junB mRNA and protein were found to be reduced two- or threefold in revertant EMS-1-19. Ectopic overexpression of junB induced transformation of revertant EMS-1-19, but failed to transform Rat-1 cells. Moreover, about 10% of v-fos transformed cells transfected with vectors that express antisense junB mRNA acquired a non-transformed phenotype. Together these results indicate that expression of junB above a threshold level is essential for v-fos-induced transformation of Rat-1 fibroblasts.	MIT, WHITAKER COLL HLTH SCI & TECHNOL, DIV TOXICOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA047571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007020] Funding Source: NIH RePORTER; NCI NIH HHS [CA47571] Funding Source: Medline; NIEHS NIH HHS [2-T32-ES07020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLAN MO, 1991, J CELL BIOCHEM, V46, P199, DOI 10.1002/jcb.240460303; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKUNO H, 1991, ONCOGENE, V6, P1491; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	43	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2969	2976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084600				2022-12-25	WOS:A1994PG82200023
J	SEMENZA, GL; ROTH, PH; FANG, HM; WANG, GL				SEMENZA, GL; ROTH, PH; FANG, HM; WANG, GL			TRANSCRIPTIONAL REGULATION OF GENES ENCODING GLYCOLYTIC-ENZYMES BY HYPOXIA-INDUCIBLE FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; DNA-BINDING ACTIVITY; RAT PYRUVATE-KINASE; ALDOLASE-A GENE; FACTOR-I; NUCLEOTIDE-SEQUENCE; RESPONSE ELEMENTS; ENHANCER ELEMENT; MAMMALIAN-CELLS; 5' REGION	Hypoxia-inducible factor 1 (HIF-1) activates erythropoietin gene transcription in Hep3B cells subjected to hypoxia. HIF-1 activity is also induced by hypoxia in non-erythropoietin-producing cells, suggesting a more general regulatory role. We now report that RNAs encoding the glycolytic enzymes aldolase A (ALDA), phosphoglycerate kinase 1 (PGK1), and pyruvate kinase M were induced by exposure of Hep3B or HeLa cells to inducers of HIF-1 (1% O-2, cobalt chloride, or desferrioxamine), whereas cycloheximide blocked induction of glycolytic RNAs and HIF-1 activity, Oligonucleotides from the ALDA, PGK1, enolase 1, lactate dehydrogenase A, and phosphofructokinase L (PFKL) genes, containing sequences similar to the HIF-1 binding site in the erythropoietin enhancer, specifically bound HIF-1 present in crude nuclear extracts or affinity-purified preparations. Sequences from the ALDA, PFKL, and PGK1 genes containing HIF-1 binding sites mediated hypoxia-inducible transcription in transient expression assays. These results support the role of HIF-1 as a mediator of adaptive responses to hypoxia that underlie cellular and systemic oxygen homeostasis,	JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; FUKASAWA KM, 1987, GENETICS, V116, P99; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HANCE AJ, 1980, J CLIN INVEST, V66, P1258, DOI 10.1172/JCI109977; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; Maniatis T., 1982, MOL CLONING; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MICHELSON AM, 1985, P NATL ACAD SCI USA, V82, P6965, DOI 10.1073/pnas.82.20.6965; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; NOGUCHI CT, 1991, BLOOD, V78, P2548; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PTASHNE KA, 1985, BIOCHIM BIOPHYS ACTA, V844, P19, DOI 10.1016/0167-4889(85)90228-9; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, IN PRESS HEMATOL ONC; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WOLFLE D, 1983, EUR J BIOCHEM, V135, P405, DOI 10.1111/j.1432-1033.1983.tb07667.x	44	1439	1517	6	84	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23757	23763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089148				2022-12-25	WOS:A1994PQ34500057
J	ESTUPINAN, B; SCHRAMM, VL				ESTUPINAN, B; SCHRAMM, VL			GUANOSINE-INOSINE-PREFERRING NUCLEOSIDE N-GLYCOHYDROLASE FROM CRITHIDIA-FASCICULATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; TRYPANOSOMA-CRUZI; HYDROLASE; PURINE; PURIFICATION	Protozoan parasites are incapable of de novo purine biosynthesis and obtain purines by salvage pathways. A nucleoside hydrolase which prefers inosine and uridine as substrates (IU-nucleoside hydrolase) has been characterized and implicated in purine salvage in Crithidia fasciculata (Parkin, D. W., Horenstein, B. A., Abdulah, D. R., Estupinan, B., and Schramm, V. L. (1991) J. Biol. Chem. 31, 20658-20665). Treatment of C. fasciculata with inhibitors of the IU-nucleoside hydrolase did not prevent cell growth, suggesting alternative enzymes. A guanosine-inosine-preferring enzyme (GI-nucleoside hydrolase) has been purified from extracts of C. fasciculata and characterized. The enzyme is an oligomer of M(r) 38,500 subunits. The V-max/K-m for guanosine, inosine, and adenosine are 3.2 x 10(6), 6.2 x 10(6), and 9.8 m(-1) s(-1), respectively. Deoxynucleosides, nucleotides, and pyrimidine nucleosides are poor substrates. The pH profile for K-m is independent of pH, whereas both V-max and V-max/K-m demonstrate that a single protonated base, pK(alpha) 7.7 is required for activity. The transition state inhibitors of IU-nucleoside hydrolase, 1,4-dideoxy-1,4-imino-1-(S)phenyl-D-ribitol (Horenstein, B. A., and Schramm, V. L. (1993) Biochemistry 32, 9917-9925) and p-nitrophenylriboamidrazone (Boutellier, M., Horenstein, B. A., Semenyaka, A., Schramm, V.L., and Ganem, B. (1994) Biochemistry 33, 3994-4000), are unexceptional inhibitors of the GI-nucleoside hydrolase. The enzyme is inhibited by 3-deazaadenosine and 2-iodoadenosine with K-m/K-i values of 145 and 61, respectively. The results demonstrate that this previously uncharacterized enzyme has distinct structure, kinetic, and chemical mechanisms relative to IU-nucleoside hydrolase. Metabolic studies with labeled inosine as the sole purine source indicated that the GI-enzyme is efficient for purine salvage in vivo.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM41916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM041916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUTELLIER M, 1994, BIOCHEMISTRY-US, V33, P3994, DOI 10.1021/bi00179a028; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVIES MJ, 1983, PARASITOLOGY, V87, P211, DOI 10.1017/S0031182000052574; DEWEY VC, 1973, ARCH BIOCHEM BIOPHYS, V157, P380, DOI 10.1016/0003-9861(73)90653-X; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P9917, DOI 10.1021/bi00089a007; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; JAMES DM, 1980, PARASITOLOGY, V81, P383, DOI 10.1017/S0031182000056110; KIDDER GW, 1978, J CELL PHYSIOL, V96, P165, DOI 10.1002/jcp.1040960205; KIDDER GW, 1958, J GEN MICROBIOL, V18, P621, DOI 10.1099/00221287-18-3-621; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; MANIATIS T, 1982, MOL CLONING LABORATO, P458; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MILLER LH, 1992, SCIENCE, V257, P36, DOI 10.1126/science.1621092; MILLER RL, 1984, J BIOL CHEM, V259, P5073; Oppenheimer N. J., 1992, ENZYMES, P453; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006	19	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23068	23073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083208				2022-12-25	WOS:A1994PQ16400028
J	RICHTER, OMH; TAO, JS; TURBA, A; LUDWIG, B				RICHTER, OMH; TAO, JS; TURBA, A; LUDWIG, B			A CYTOCHROME BA(3) FUNCTIONS AS A QUINOL OXIDASE IN PARACOCCUS-DENITRIFICANS - PURIFICATION, CLONING, AND SEQUENCE COMPARISON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; ESCHERICHIA-COLI; UBIQUINOL OXIDASE; TERMINAL OXIDASES; ACETOBACTER-ACETI; BO; BACILLUS; OPERON; MUTANTS; PROTEIN	A quinol oxidase has been purified from the cytoplasmic membrane of Paracoccus denitrificans; its heme composition and CO binding properties identify it as a cytochrome ba(3). On SDS gels, the purified enzyme complex is separated into five polypeptides. Using partial peptide sequence information for subunit II, the gene locus has been cloned and sequenced. In a typical operon pattern, four genes were identified: qoxA, -B, -C, and -D, coding for subunits II, I, III, and IV. DNA-derived amino acid sequence comparisons reveal extensive similarities to other members of the terminal oxidase superfamily.	UNIV FRANKFURT,BIOZENTRUM N200,INST BIOCHEM,DEPT MOLEC GENET,D-60439 FRANKFURT,GERMANY	Goethe University Frankfurt								AEBERSOLD R, 1989, PRACTICAL GUIDE PEPT, P73; AZZI A, 1991, J BIOENERG BIOMEMBR, V23, P161; BARR R, 1971, METHOD ENZYMOL, V23, P344; BECKER M, 1991, FEBS LETT, V291, P331, DOI 10.1016/0014-5793(91)81314-X; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; COX JC, 1978, FEBS LETT, V93, P261, DOI 10.1016/0014-5793(78)81117-X; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; FUKAYA M, 1993, J BACTERIOL, V175, P4307, DOI 10.1128/JB.175.14.4307-4314.1993; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KRANZ RG, 1985, J BACTERIOL, V161, P709, DOI 10.1128/JB.161.2.709-713.1985; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; LUDWIG B, 1992, BIOCHIM BIOPHYS ACTA, V1101, P195, DOI 10.1016/S0005-2728(05)80018-0; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; OERTLING WA, 1994, BIOCHEMISTRY-US, V33, P3128, DOI 10.1021/bi00176a048; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; QUIRK PG, 1993, J BIOL CHEM, V268, P678; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; STEINRUCKE P, 1993, FEMS MICROBIOL LETT, V104, P83, DOI 10.1111/j.1574-6968.1993.tb05865.x; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; STEINRUCKE P, 1991, J BIOENERG BIOMEMBR, V23, P227, DOI 10.1007/BF00762219; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; YUMOTO I, 1993, J BIOCHEM-TOKYO, V114, P88, DOI 10.1093/oxfordjournals.jbchem.a124145	47	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23079	23086						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083210				2022-12-25	WOS:A1994PQ16400030
J	OKAJIMA, TIL; WIGGERT, B; CHADER, GJ; PEPPERBERG, DR				OKAJIMA, TIL; WIGGERT, B; CHADER, GJ; PEPPERBERG, DR			RETINOID PROCESSING IN RETINAL-PIGMENT EPITHELIUM OF TOAD (BUFO-MARINUS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ROD OUTER SEGMENTS; ALL-TRANS-RETINOL; BINDING PROTEIN; VITAMIN-A; VISUAL CYCLE; RHODOPSIN; ISOMERIZATION; REGENERATION; SEPARATION	The formation of 11-cis-[H-3]retinal in the retinal pigment epithelium (RPE) and its release to extracellular medium containing interphotoreceptor retinoid-binding protein (IRBP) were studied in the RPE eyecup of the toad (Bufo marinus). The RPE was labeled with all-trans-[H-3]retinol during an initial 1-h incubation. In phase 2 of the incubation (0-2 h), the extracellular me dium contained initially ligand-free IRBP (0-26 mu M). Retinoids subsequently extracted from the extracellular medium and RPE were analyzed by high performance liquid chromatography and scintillation counting. IRBP increased both the molar amount and specific radioactivity of 11-cis-retinal released by the RPE during phase 2. The molar amount of 11-cis-retinal in the RPE was small relative to that of retinal released with high IRBP. With 21 mu M IRBP and phase 2 incubations of greater than or equal to 10 min, the specific radioactivity of released 11-cis-retinal exceeded that of all-trans retinyl ester in the RPE, The specific radioactivity of 11-cis-retinyl ester was less than that of all-trans-ester, independent of IRBP concentration. The results indicate that IRBP promotes the formation (from all-trans-precursor) as well as the release of 11-cis-retinal and suggest the preferred utilization of recently incorporated and esterified all-trans-retinol in 11-cis-retinal synthesis in a ''last in/first out'' manner.	UNIV ILLINOIS, COLL MED, LIONS ILLINOIS EYE RES INST, DEPT OPHTHALMOL & VISUAL SCI, CHICAGO, IL 60612 USA; NEI, BETHESDA, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					NEI NIH HHS [EY-01792, EY-05494] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001792, R01EY005494] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1982, BIOCHEM BIOPH RES CO, V108, P1601, DOI 10.1016/S0006-291X(82)80091-0; ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, INVEST OPHTH VIS SCI, V26, P273; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERNSTEIN PS, 1987, J BIOL CHEM, V262, P16848; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; DAS SR, 1990, BIOCHEM J, V268, P201, DOI 10.1042/bj2680201; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FURR HC, 1986, J CHROMATOGR, V378, P45, DOI 10.1016/S0378-4347(00)80698-2; HO MTP, 1989, J BIOL CHEM, V264, P928; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; HUBBARD R, 1962, NATURE, V193, P341, DOI 10.1038/193341a0; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; PEPPERBERG DR, 1991, PHOTOCHEM PHOTOBIOL, V54, P1057, DOI 10.1111/j.1751-1097.1991.tb02129.x; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; ROSS AC, 1981, ANAL BIOCHEM, V115, P324, DOI 10.1016/0003-2697(81)90013-0; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; TIMMERS AM, 1991, EXP EYE RES, V52, P129, DOI 10.1016/0014-4835(91)90253-B; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3	30	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21983	21989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071318				2022-12-25	WOS:A1994PE09800012
J	TAKANO, T; HONDA, Z; SAKANAKA, C; IZUMI, T; KAMEYAMA, K; HAGA, K; HAGA, T; KUROKAWA, K; SHIMIZU, T				TAKANO, T; HONDA, Z; SAKANAKA, C; IZUMI, T; KAMEYAMA, K; HAGA, K; HAGA, T; KUROKAWA, K; SHIMIZU, T			ROLE OF CYTOPLASMIC TAIL PHOSPHORYLATION SITES OF PLATELET-ACTIVATING-FACTOR RECEPTOR IN AGONIST-INDUCED DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SMOOTH-MUSCLE CELLS; MAP KINASE KINASE; SIGNAL TRANSDUCTION; GAMMA-SUBUNITS; CDNA CLONING; EXPRESSION; LEUKOCYTES	The platelet-activating factor (PAF) receptor couples with multiple signaling pathways such as activation of phospholipase C, phospholipase A(2), and mitogen-activated protein kinase and the inhibition of adenylate cyclase. The PAF-induced signals are attenuated by repetitive or long standing applications of the agonist (homologous desensitization). To investigate mechanisms underlying the agonist-induced desensitization, we constructed mutant forms of the cloned guinea pig PAF receptor and stably expressed them in Chinese hamster ovary cells. The cells expressing the wild type receptor transiently activated phospholipase C in response to PAF. Intracellular inositol 1,4,5-trisphosphate level and intracellular Ca2+ concentration reached the maximal levels within 20 s and returned to the basal levels in several minutes, even in the continuous presence of the ligand. In contrast, a truncated PAF receptor lacking the carboxyl-terminal cytoplasmic tail induced sustained elevations of inositol 1,4,5-trisphosphate and intracellular Ca2+ concentrations. Similar findings were noted in another mutant, in which the Ser/Thr residues in the carboxyl-terminal tail were substituted with Ala. Both mutant PAF receptors more potently activated the other signals (mitogen-activated protein kinase kinase, arachidonate release, and inhibition of adenylate cyclase) than did the wild type receptor. Thus, while the carboxyl-terminal cytoplasmic tail of the PAF receptor is not required for the forward activation of multiple signals, it does have a critical role for signal attenuation induced by the agonist through phosphate accepters. We also noted that the synthetic peptide of the PAF receptor carboxyl-terminal tail was strongly phosphorylated by the recombinant beta-adrenergic receptor kinase 1, suggesting that it or its relatives might be involved in PAF receptor phosphorylation and homologous desensitization.	UNIV TOKYO,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo								ALI H, 1993, J BIOL CHEM, V268, P24247; BARNES PJ, 1991, TRENDS BIOCHEM SCI, V16, P365, DOI 10.1016/0968-0004(91)90152-L; BITO H, 1994, J BIOL CHEM, V269, P12722; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; CAHO W, 1993, BIOCHEM J, V292, P617; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KOJIMA I, 1986, J BIOL CHEM, V261, P9832; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; MORRISON WJ, 1989, LIFE SCI, V45, P333, DOI 10.1016/0024-3205(89)90143-4; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1989, P SOC EXP BIOL MED, V190, P125; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YAMAZAWA T, 1992, FEBS LETT, V301, P181, DOI 10.1016/0014-5793(92)81243-F; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	41	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22453	22458						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071375				2022-12-25	WOS:A1994PE09800079
J	HAMILTON, JA; CIVELEK, VN; KAMP, F; TORNHEIM, K; CORKEY, BE				HAMILTON, JA; CIVELEK, VN; KAMP, F; TORNHEIM, K; CORKEY, BE			CHANGES IN INTERNAL PH CAUSED BY MOVEMENT OF FATTY-ACIDS INTO AND OUT OF CLONAL PANCREATIC BETA-CELLS (HIT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDUCED INSULIN-SECRETION; ACYL-COA ESTERS; CYTOPLASMIC PH; MALONYL-COA; GLUCOSE; ACTIVATION; METABOLISM; MEMBRANES; CHANNELS	Cells require a constant influx of free fatty acids for lipid resynthesis and metabolic energy. Fatty acids also act as second messengers and modulate channel activities. In the pancreatic beta-cell, fatty acids have both acute and chronic effects on insulin secretion. We show that the addition of fatty acid to pancreatic beta-cells in vitro produces a persistent decrease in intracellular pH, which begins immediately after the addition of fatty acid and has an exponential time course with t(1/2) similar to 60 s. The pH drop can be largely reversed by the addition of albumin. The observed pH effect can be explained by passive diffusion (''flip-flop'') of un-ionized fatty acid across the plasma membrane. Acidification by a fatty acid dimer and alkalinization by an alkylamine also favor the flip-flop mechanism of transport rather than a protein-mediated mechanism. Our method provides for the first time a real-time measurement of fatty acid import into cells. The significant pH change may be important in mediating some of the regulatory effects of fatty acid, such as inhibition of glycolysis.	BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University	HAMILTON, JA (corresponding author), BOSTON UNIV,SCH MED,CTR ADV BIOMED RES,DEPT BIOPHYS,80 E CONCORD ST,BOSTON,MA 02118, USA.		Civelek, Vildan Nur/D-7097-2014; Corkey, Barbara/E-7712-2015	Civelek, Vildan Nur/0000-0002-2942-6609; Hamilton, James/0000-0002-4747-7071; Tornheim, Keith/0000-0002-6235-5128; Corkey, Barbara/0000-0002-5467-1630	NHLBI NIH HHS [HL26335, HL41904] Funding Source: Medline; NIDDK NIH HHS [DK35914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335, R01HL041904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK035914, R37DK035914, R01DK035914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DIPLOCK AT, 1988, BIOCHIM BIOPHYS ACTA, V962, P42, DOI 10.1016/0005-2760(88)90093-8; HAMILTON JA, 1986, P NATL ACAD SCI USA, V83, P82, DOI 10.1073/pnas.83.1.82; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PATRIKIOS IS, 1994, BBA-LIPID LIPID MET, V1212, P225, DOI 10.1016/0005-2760(94)90257-7; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Randle P J, 1966, Recent Prog Horm Res, V22, P1; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; STORCH J, 1991, J BIOL CHEM, V266, P13473; STORCH J, 1990, HEPATOLOGY, V12, P1447, DOI 10.1002/hep.1840120632; STRAZZABOSCO M, 1991, AM J PHYSIOL, V260, pG58, DOI 10.1152/ajpgi.1991.260.1.G58; TAMARITRODRIGUEZ J, 1984, BIOCHEM J, V221, P317, DOI 10.1042/bj2210317; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; UI M, 1966, BIOCHIM BIOPHYS ACTA, V124, P310, DOI 10.1016/0304-4165(66)90194-2; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004	28	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20852	20856						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063701				2022-12-25	WOS:A1994PC40300010
J	MAJANDER, A; FINEL, M; WIKSTROM, M				MAJANDER, A; FINEL, M; WIKSTROM, M			DIPHENYLENEIODONIUM INHIBITS REDUCTION OF IRON-SULFUR CLUSTERS IN THE MITOCHONDRIAL NADH-UBIQUINONE OXIDOREDUCTASE (COMPLEX-I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE DEHYDROGENASE; CELL-FREE SYSTEM; RESPIRATORY-CHAIN; QUINONE OXIDOREDUCTASES; ELECTRON-TRANSFER; OXIDASE COMPLEX; COENZYME-Q; IODONIUM; NEUTROPHILS; ANALOGS	Diphenyleneiodonium (DPI) inhibits the mitochondrial NADH-ubiquinone oxidoreductase (Complex I) on the substrate side of the Fe-S clusters. In the inhibited NADH-supplemented state all of the Fe-S clusters are oxidized, whereas the reduced minus oxidized difference spectrum of the protein-bound FMN can be visualized. It is characterized by troughs at 370 and 450 nm and a small increase of absorbance in the 500-700-nm region. DPI probably reacts irreversibly with FMN, because oxidation of FMN is blocked even after its extraction from the enzyme. Inhibition requires preincubation of enzyme in the presence of NADH and DPI. The lower the NADH/ NAD(+) ratio or the pH, or the higher the NAD(+)/DPI ratio, the more DPI is required for inhibition. NAD(+) and DPI apparently compete for a common site. Both ubiquinone and dichlorophenolindophenol reductase activities are fully blacked by DPI, whereas the ferricyanide reductase activity is inhibited by 75%. Similar results were found with Complex I and two rotenone-insensitive preparations, subcomplex I lambda and the flavoprotein fraction. DPI also inhibits NADH oxidation by bacterial NADH-ubiquinone oxidoreductase-1 (NDH-1) in membranes of Paracoccus denitrificans and Escherichia coli.			MAJANDER, A (corresponding author), UNIV HELSINKI,INST BIOMED SCI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,POB 8,SILTAVUORENPENGER 10,SF-00014 HELSINKI,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Wikstrom, Marten/0000-0002-7527-4415				BANKS DF, 1966, CHEM REV, V66, P243, DOI 10.1021/cr60241a001; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BERINGER FM, 1972, J ORG CHEM, V37, P2484; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DOUSSIERE J, 1991, BIOCHEM BIOPH RES CO, V175, P143, DOI 10.1016/S0006-291X(05)81212-4; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; FINEL M, 1993, J BIOENERG BIOMEMBR, V25, P357, DOI 10.1007/BF00762461; FINEL M, 1994, FEBS LETT, V339, P142, DOI 10.1016/0014-5793(94)80402-8; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HATEFI Y, 1969, J BIOL CHEM, V244, P2350; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hemmerich P, 1971, FLAVINS FLAVOPROTEIN, P83; HORGAN DJ, 1968, J BIOL CHEM, V243, P834; KEAN EA, 1971, J BIOL CHEM, V246, P2346; KRISHNAMOORTHY G, 1988, J BIOL CHEM, V263, P17566; MAJANDER A, 1992, EBEC SHORT REPORTS, V7, P30; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OETTMEIER W, 1994, BIOCHEM SOC T, V22, P213, DOI 10.1042/bst0220213; PALMER G, 1968, J BIOL CHEM, V243, P844; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; RAGAN CI, 1973, J BIOL CHEM, V248, P6876; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; RAITIO M, 1994, IN PRESS BIOCH BIOPH; SHIMOMURA Y, 1989, ARCH BIOCHEM BIOPHYS, V270, P573, DOI 10.1016/0003-9861(89)90539-0; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; Thomson A. J., 1985, METALLOPROTEINS 1, P79; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WAN YP, 1975, BIOCHEM BIOPH RES CO, V63, P11, DOI 10.1016/S0006-291X(75)80003-9; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218	43	172	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21037	21042						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063722				2022-12-25	WOS:A1994PC40300036
J	BAHNSON, TD; PANDOL, SJ; DIONNE, VE				BAHNSON, TD; PANDOL, SJ; DIONNE, VE			CYCLIC-GMP MODULATES DEPLETION-ACTIVATED CA2+ ENTRY IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD GUANYLATE-CYCLASE; PLASMA-MEMBRANE; CALCIUM ENTRY; INOSITOL PHOSPHATES; TUMOR PROMOTER; SMOOTH-MUSCLE; CA-2+ INFLUX; CHANNELS; THAPSIGARGIN; MECHANISM	In the pancreatic acinar cell, hormonal stimulation causes a rise in the intracellular free Ca2+ concentration by activating the inositol 1,4,5-trisphosphate-mediated release of Ca2+ from intracellular stores (Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205). The released Ca2+ is, for the most part, extruded from the cell, necessitating a mechanism for Ca2+ entry and reloading of intracellular Ca2+ stores (Putney, J. W., Jr. (1990) Cell Calcium 11, 611-624; Rink, T. J. (1990) FEBS Lett. 268, 381-385). However, neither the mechanism of depletion-activated Ca2+ entry nor the signal that activates it is known. We report here that a sustained inward current of depletion-activated Ca2+ entry can be measured in pancreatic acinar cells using patch-clamp recording methods. Furthermore, the current can be blocked by an inhibitor of guanylyl cyclase, can be reactivated by 8-bromo-cGMP after inhibition, and can be activated in the absence of Ca2+ depletion by perfusing the cell with cGMP, but not cAMP. Intracellular perfusion with 1,3,4,5-inositol tetrakisphosphate did not activate an inward current, whereas perfusion with 2,4,5-inositol trisphosphate did activate an inward current. We conclude that cGMP may be an intracellular messenger that regulates depletion-activated Ca2+ entry.	VET ADM MED CTR,DEPT MED,DIV GASTROENTEROL,LA JOLLA,CA 92161; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	BAHNSON, TD (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093, USA.							BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1981, MOL CELL ENDOCRINOL, V24, P115, DOI 10.1016/0303-7207(81)90055-1; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOKIN MR, 1953, J BIOL CHEM, V203, P967; HOTH H, 1992, NATURE, V355, P353; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P283; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PANDOL SJ, 1990, CELL CALCIUM, V11, P447; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; WHALLEY R, 1992, MOL BIOL CELL, V3, P373	42	129	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10808	10812						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098704				2022-12-25	WOS:A1993LD46600018
J	THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A				THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A			MODULATION OF DOXORUBICIN RESISTANCE IN MULTIDRUG-RESISTANT CELLS BY LIPOSOMES	FASEB JOURNAL			English	Note						DRUG RESISTANCE; DOXORUBICIN; LIPOSOMES; P-GLYCOPROTEIN; DRUG INTRACELLULAR DISTRIBUTION	P-GLYCOPROTEIN EXPRESSION; BREAST CANCER-CELLS; PLASMA-MEMBRANE; HL-60 CELLS; ENCAPSULATED DOXORUBICIN; GLUTATHIONE TRANSFERASE; VINCRISTINE BINDING; DRUG ACCUMULATION; K562 CELLS; ADRIAMYCIN	In this study, we have confirmed the ability of liposome-encapsulated doxorubicin to modulate drug resistance, as previously observed in CH LZ cells (Thierry et al., Cancer Commun. 1, 311-316, 1989), in two human multidrug-resistant (MDR) cell lines, the breast cancer MCF-7/ADR cell line, and the ovarian carcinoma SKVLB cell line. This effect was specific to MDR cells, as liposomally encapsulated doxorubicin did not enhance cell sensitivity to the drug in the parental cell lines. Cytotoxicity assays demonstrated that empty liposomes in the presence of free doxorubicin (Dox) reversed resistance to the drug at a level that may be higher than that observed when liposome-encapsulated Dox is used. This effect seems to be due to the high affinity of Dox for cardiolipin, one of the liposome components, which leads to the association of the drug and the cardiolipin-containing liposomes in the culture medium before entry into the cells. Neither pretreatment of empty liposomes before drug treatment nor combined incubation of vincristine and empty liposomes alter MDR in CH LZ cells, suggesting that the drug must be encapsulated or complexed to the liposomes to overcome MDR. Because MDR in CH LZ cells does not seem to be related to GSH level, MDR modulation by liposome-encapsulated Dox apparently may not be effected by altering the GSH function. These results suggest that the enhancement of sensitivity of MDR cells using Dox encapsulated in liposomes or complexed with liposomes may be explained by an increase in cell drug incorporation and by an intracellular drug redistribution. Fluorescence confocal microscopy study indicated that Dox is transported and distributed mainly in intracytoplasmic vesicles in SKVLB and MCF-7/ADR cells, whereas in parental cells the drug is located mainly in the nucleus. In addition, presentation of Dox in liposomes modifies the drug distribution pattern in MDR cells by partially shifting the drug to nuclear compartments. Thus, liposome-associated Dox may bypass the vesicular drug transport in MDR cells, resulting in the enhancement of the drug biological activity.	GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,LOMBARDI CANC RES CTR,BIOSTAT & EPIDEMIOL UNIT,WASHINGTON,DC 20007; UNIV TEXAS,MED BRANCH,DEPT RADIAT THERAPY,GALVESTON,TX 77550	Georgetown University; Georgetown University; University of Texas System; University of Texas Medical Branch Galveston	THIERRY, AR (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT RADIAT MED,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		thierry, alain/F-9492-2014					BATIST G, 1986, J BIOL CHEM, V261, P5544; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BRADLEY G, 1989, CANCER RES, V49, P2790; CHABNER BA, 1989, J NATL CANCER I, V81, P910, DOI 10.1093/jnci/81.12.910; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEFFIE AM, 1988, CANCER RES, V48, P3595; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN D, 1990, CANCER RES, V50, P3619; FOJO A, 1985, CANCER RES, V45, P3002; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOTTESMAN MM, 1989, J CLIN ONCOL, V7, P409, DOI 10.1200/JCO.1989.7.4.409; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; HARRIS JR, 1979, INT J RADIAT ONCOL, V5, P1235, DOI 10.1016/0360-3016(79)90645-X; HINDENBURG AA, 1989, CANCER RES, V49, P4607; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOWELL N, 1984, CANCER RES, V44, P4023; KEIZER HG, 1989, CANCER RES, V49, P2988; KLOHS WD, 1988, CANCER RES, V48, P3025; LIU DX, 1989, BIOCHIM BIOPHYS ACTA, V981, P254, DOI 10.1016/0005-2736(89)90035-7; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; NAITO M, 1989, CANCER RES, V49, P1452; NAITO M, 1988, J BIOL CHEM, V263, P11887; NOGAE I, 1989, BIOCHEM PHARMACOL, V38, P519; OUDARD S, 1991, CANCER CHEMOTH PHARM, V28, P259; PAPAHADJ.D, 1974, NATURE, V252, P163, DOI 10.1038/252163a0; QUIAN XD, 1990, CANCER RES, V50, P1132; Roninson, 1991, MOL CELLULAR BIOL MU, P263; SADASIVAN R, 1991, CANCER LETT, V57, P165, DOI 10.1016/0304-3835(91)90211-Y; SEHESTED M, 1989, BRIT J CANCER, V60, P809, DOI 10.1038/bjc.1989.371; SHUMAN H, 1989, BIOTECHNIQUES, V7, P154; SHUURHUIS GJ, 1989, J NATL CANCER I, V81, P1887; Thierry A R, 1989, Cancer Commun, V1, P311; Thierry A. R., 1992, Gene regulation: biology of antisense RNA and DNA., P147; THIERRY AR, 1992, BIOCHEM BIOPH RES CO, V187, P1098, DOI 10.1016/0006-291X(92)91310-M; TREAT J, 1990, J NATL CANCER I, V82, P1706, DOI 10.1093/jnci/82.21.1706; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VERELLE P, 1991, J NATL CANCER I, V83, P111; YANOVICH S, 1989, CANCER RES, V49, P4499	40	101	106	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					572	579		10.1096/fasebj.7.6.8097173	http://dx.doi.org/10.1096/fasebj.7.6.8097173			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8097173				2022-12-25	WOS:A1993KY00900011
J	STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO				STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO			QUANTIFICATION OF ONCOGENE DOSAGE IN TUMORS BY SIMULTANEOUS DUAL-LABEL HYBRIDIZATION	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HUMAN-BREAST CANCER; PROTO-ONCOGENE; MESSENGER-RNA; AMPLIFICATION; QUANTITATION; INT-2; DNA	Gene amplification and allele loss occur in a variety of human tumours and some have prognostic value. Therefore, techniques which facilitate detection and quantification of gene dosage could have wide applicability in cancer research. Using the INT-2 gene as a model system, a quantitative procedure has been developed for measuring gene copy number using dual-label hybridization to DNA dot blots. A probe specific for the INT-2 gene was labelled with [alpha-P-32]dCTP and a probe to beta-actin, the control locus, was labelled with [alpha-S-35]dATP. Flat-bed scintillation counting was used to detect and separate the emissions resulting from each bound probe, and gene dosage was calculated from the ratio of INT-2 to the beta-actin probe compared with the ratio derived from constitutional DNA. Calculated ratios of greater than 1.22 and less than 0.78 indicated gene amplification and allelic loss respectively, at the 99% confidence limit derived from the population of 35 constitutional DNAs. The results were validated by RFLP analysis. It is expected that this technique will permit precise gene dosage quantification in many areas.	UNIV OXFORD,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford								ADNANE J, 1989, ONCOGENE, V4, P1389; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DONOVANPELUSO M, 1991, AM J PATHOL, V138, P835; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LASKEY RA, 1990, RADIOISOTOPES BIOL; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; NEUBAUER A, 1992, ONCOGENE, V7, P1019; Sambrook J, 1989, MOL CLONING LABORATO; TSUDA H, 1989, CANCER RES, V49, P3104; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	15	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093811				2022-12-25	WOS:A1993KN00500029
J	COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G				COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G			ANTISENSE OLIGONUCLEOTIDES SUPPRESS B-CELL LYMPHOMA GROWTH IN A SCID-HU MOUSE MODEL	ONCOGENE			English	Article							NON-HODGKINS LYMPHOMA; T(14-18) CHROMOSOMAL TRANSLOCATION; BCL-2 GENE; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; LEUKEMIA; DISEASE; MICE; PROGRESSION; APOPTOSIS	The t(14;18) translocation is found in the majority follicular lymphomas and some high grade B-cell lymphomas. This is results in deregulation of the BCL-2 gene and appears to play a role in oncogenesis. Various numbers of cells from a cell line derived spontaneously from a patient with B-cell lymphoma bearing the t(14;18) translocation and negative for the Epstein-Barr virus (EBV) were injected by IP, IV, and SC routes into SCID mice. The mice developed lymphoma bearing the t(14;18) translocation with as few as 5 x 10(6) cells within 28 days. This was determined by histological examination. The higher the cell inoculation the more rapidly the lymphoma developed. Engraftment of the tumour cells was determined by PCR for the t(14;18) breakpoint region on peripheral blood samples and could be detected prior to development of overt lymphoma. Having established a lymphoma model the cells were treated with antisense oligonucleotides to the first open reading frame of the BCL-2 gene prior to inoculation of the SCID mice. Control treatments with sense and nonsense oligonucleotides was also performed. At 28 days the sense, nonsense and untreated cell SCID mice had developed lymphoma, however, the antisense treated group failed to develop lymphoma. The findings demonstrate the modelling of B-cell lymphoma bearing the t(14;18) translocation and the ability to modify the lymphoma process with the use of antisense oligonucleotides to the BCL-2 gene. Reduction of the BCL2 protein suppresses the oncogenic potential of these lymphoma cells confirming that it plays an essential role in the development of malignancy.	IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT ONCOL,LONDON EC1 1BB,ENGLAND; ST THOMAS HOSP,DEPT HISTOPATHOL,LONDON SE1 7EH,ENGLAND	Cancer Research UK; University of London; University College London; Cancer Research UK; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust	COTTER, FE (corresponding author), LRF,DEPT HAEMATOL & ONCOL,LONDON WC1N 1EH,ENGLAND.		Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Cowell, John/0000-0002-2079-5950				AMADORI A, 1992, LEUKEMIA, V6, pS23; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; ERSBOLL J, 1989, EUR J HAEMATOL, V42, P155; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARVIN AJ, 1983, CANCER-AM CANCER SOC, V52, P393, DOI 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M; HAGENBEEK A, 1992, LEUKEMIA, V6, P12; HALL PA, 1980, HISTOPATHOLOGY, V13, P149; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUA C, 1988, ONCOGENE RES, V2, P263; KAMELREID S, 1991, BLOOD, V78, P2973; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNOWLES DM, 1989, BLOOD, V73, P1635; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; NGAN BY, 1989, BLOOD, V73, P1735; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZELLA F, 1990, NOUV REV FR HEMATOL, V32, P397; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RISDALL R, 1979, CANCER, V44, P529, DOI 10.1002/1097-0142(197908)44:2<529::AID-CNCR2820440222>3.0.CO;2-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; THOMAS JA, 1993, BLOOD, V81, P3350; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YANO T, 1992, BLOOD, V80, P758	32	190	204	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3049	3055						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084613				2022-12-25	WOS:A1994PG82200036
J	KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H				KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H			HUMAN LTK RECEPTOR TYROSINE KINASE BINDS TO PLC-GAMMA-1, PI3-K, GAP AND RAF-1 IN-VIVO	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; EGF RECEPTOR; PDGF RECEPTOR; PROTEIN; RAS; ASSOCIATION; GRB2	Leukocyte tyrosine kinase (ltk) is a receptor-type tyrosine kinase which is suggested to be expressed in hematopoietic cells and neuronal cells in human. Recently we have cloned a full sized human ltk cDNA which has a 423 amino acid extracellular domain which may bind to unknown ligand(s), and a 415 amino acid cytoplasmic domain which contains a tyrosine kinase domain. To identify the cellular signal transducer proteins binding to the ltk protein, we have analysed the recombinant ltk protein transiently expressed in COS cells. By an in vitro immune complex kinase assay, a major 140 kDa phosphoprotein and other cellular phosphoproteins were co-immunoprecipitated with the 100 kDa ltk protein using anti-ltk monoclonal antibodies. Western blot analysis revealed that the wild-type ltk protein was tyrosine-phosphorylated in vivo and associated with SH2 containing proteins, PLC-gamma 1, p85 subunit of PI3-K and GAP, in vivo. Furthermore, the wild-type ltk protein also binds to a serine/threonine kinase, Raf-1, in vivo. In contrast, none of these signal transducer proteins were associated with a kinase-negative ltk mutant (K544M-ltk) in which methionine at the putative ATP binding site was replaced with lysine. These results suggest that the associations of the ltk protein with those signaling molecules depend on the tyrosine kinase activity of the ltk protein. This is the first detection of cytoplasmic signal transducers that bind to the ltk protein in vivo.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo								BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1773; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2991	2998						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084603				2022-12-25	WOS:A1994PG82200026
J	AVITAHL, N; CALAME, K				AVITAHL, N; CALAME, K			THE C/EBP FAMILY OF PROTEINS DISTORTS DNA UPON BINDING BUT DOES NOT INTRODUCE A LARGE DIRECTED BEND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ENHANCER; TRANSCRIPTIONAL ACTIVATOR PROTEIN; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; LEUCINE ZIPPER; CRYSTAL-STRUCTURE; OPPOSITE ORIENTATIONS; REGULATED EXPRESSION; RNA-POLYMERASE; MINOR-GROOVE	The DNA-bending properties of several C/EBP family proteins, bound to two different sites, have been determined using circular permutation and phasing analyses. All the proteins examined by circular permutation analysis induced a significant distortion in the DNA (40-66 degrees), and this distortion was of the same magnitude at both C/EBP sites. However, phasing analysis revealed that the size of the directed bend induced in the DNA by C/EBP proteins was only 1-4 degrees. Both the magnitude and orientation of the directed bend were affected by the specific sequence of the DNA-binding site. All proteins induced a directed bend of similar magnitude and orientation (toward the minor groove) when bound to the C/EBP site derived from the IgH enhancer, but the induced bend was smaller when the protein was bound to the C/EBP site derived from the V(H)1 promoter. The study also included a heterodimer between Ig/EBP and ATF4. Similar to C/EBP protein homodimers, this heterodimer induces a small directed bend of 4 degrees oriented toward the minor groove when bound to the enhancer derived C/EBP site,	COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University	AVITAHL, N (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044300, R01GM029361] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM44300, R01 GM29361] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; Bellomy G R, 1990, Prog Nucleic Acid Res Mol Biol, V39, P81, DOI 10.1016/S0079-6603(08)60624-8; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BUC H, 1987, RNA POLYMERASE REGUL, P115; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COOPER C, 1992, J IMMUNOL, V149, P3225; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EATON S, 1987, P NATL ACAD SCI USA, V84, P7634, DOI 10.1073/pnas.84.21.7634; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERPPOLA TK, 1993, NUCLEIC ACIDS MOL BI, P70; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAUTENBERGER JA, 1983, GENE, V23, P75, DOI 10.1016/0378-1119(83)90218-4; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PATTERSON TA, 1993, GENE, V132, P83, DOI 10.1016/0378-1119(93)90517-7; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WATERMAN M L, 1990, New Biologist, V2, P621; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	63	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23553	23562						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089123				2022-12-25	WOS:A1994PQ34500028
J	GAMBERUCCI, A; INNOCENTI, B; FULCERI, R; BANHEGYI, G; GIUNTI, R; POZZAN, T; BENEDETTI, A				GAMBERUCCI, A; INNOCENTI, B; FULCERI, R; BANHEGYI, G; GIUNTI, R; POZZAN, T; BENEDETTI, A			MODULATION OF CA2+ INFLUX DEPENDENT ON STORE DEPLETION BY INTRACELLULAR ADENINE-GUANINE NUCLEOTIDE LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ASCITES-TUMOR-CELLS; PANCREATIC-B-CELLS; TARGETED RECOMBINANT AEQUORIN; ISOLATED RAT HEPATOCYTES; CYTOSOLIC FREE CA-2+; INOSITOL PHOSPHATES; PLASMA-MEMBRANE; ACINAR-CELLS; K+ CHANNELS	The effects of a number of metabolic inhibitors on the influx of Ca2+ activated by stimulation of receptors coupled to inositol 1,4,5-trisphosphate generation or by depletion of intracellular Ca2+ stores with thapsigarsn were investigated in four different cell types: Ehrlich ascites tumor cells, Jurkat and HeLa cell lines, and rat hepatocytes. Independently of their chemical structure and site of inhibition, all of these metabolic poisons markedly inhibited Ca2+ influx without significantly affecting Ca2+ release. This inhibition was not due to membrane potential depolarization or to alteration in cytosolic pH but appeared correlated to a drop in the cellular concentration of ATP. The decreases in cellular [ATP] were paralleled by decreases in [GTP] and by increases in [ADP] and [GDP]. The reduction in ATP level necessary to drastically reduce Ca2+ influx was quite small, e.g. a 50% inhibition for a 5% reduction in [ATP], thus within the range of fluctuation presumably occurring under physiological conditions. We suggest that changes in the adenine or guanine nucleotide concentrations may represent an important modulatory mechanism of Ca2+ influx activated by store depletion.	UNIV SIENA, IST PATOL GEN, I-53100 SIENA, ITALY; UNIV PADUA, CNR, CTR STUDY MITOCHONDRIAL PHYSIOL, DEPT BIOMED SCI, I-35121 PADUA, ITALY	University of Siena; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Bánhegyi, Gábor/A-1476-2014					ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTHON B, 1984, FEBS LETT, V167, P19, DOI 10.1016/0014-5793(84)80824-8; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BYGRAVE FL, 1993, BIOCHEM J, V292, P19, DOI 10.1042/bj2920019; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHEEK TR, 1993, J CELL SCI, V105, P913; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DEBETTO P, 1983, J HIGH RES CHROMATOG, V6, P117, DOI 10.1002/jhrc.1240060302; DEYOUNG MB, 1989, METHOD ENZYMOL, V173, P662; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1982, MEMBRANES TUMOR GROW, P527; DUBYAK GR, 1985, J BIOL CHEM, V260, P653; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; FASOLATO C, 1989, J BIOL CHEM, V264, P19630; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINDLAY I, 1988, J MEMBRANE BIOL, V101, P83, DOI 10.1007/BF01872823; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; Moldeus P, 1978, Methods Enzymol, V52, P60; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MONTERO M, 1994, J BIOL CHEM, V269, P3963; OROURKE B, 1992, SCIENCE, V257, P245, DOI 10.1126/science.1321495; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; POZZAN T, 1982, J CELL BIOL, V94, P335, DOI 10.1083/jcb.94.2.335; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1977, J PHYSIOL-LONDON, V268, P139, DOI 10.1113/jphysiol.1977.sp011851; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VINCENT MF, 1982, BIOCHEM J, V202, P117, DOI 10.1042/bj2020117; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911	64	86	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23597	23602						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089128				2022-12-25	WOS:A1994PQ34500034
J	HOPE, HMR; PIKE, LJ				HOPE, HMR; PIKE, LJ			PURIFICATION AND CHARACTERIZATION OF A POLYPHOSPHOINOSITIDE PHOSPHATASE FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIN CAPPING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-NEUTROPHILS; BOVINE BRAIN; INOSITOL TRISPHOSPHATE; A431 CELLS; KINASE-C; ACTIVATION; 4,5-BISPHOSPHATE	A novel membrane-bound polyphosphoinositide phosphatase has been purified 7700-fold from rat brain. A combination of gel filtration chromatography and SDS-polyacrylamide gel electrophoresis indicated that the enzyme is a monomer with a molecular weight of 85,000-90,000. Biochemical analysis of the polyphosphoinositide phosphatase demonstrated that the enzyme utilizes phosphatidylinositol(4)phosphate (PtdIns(4)P), phosphatidylinositol(3)phosphate (PtdIns(3)P), and phosphatidylinositol (4,5)bisphosphate (PtdIns(4,5)P-2) as substrates. In the case of PtdIns(4,5)P-2, the substrate is doubly dephosphorylated to yield PtdIns. The apparent K-m values for PtdIns(4)P and PtdIns(4,5)P-2 are 45 and 5 mu M, respectively. Inositol(1,4)bisphosphate and inositol(1,4,5)trisphosphate neither serve as direct substrates for the polyphosphoinositide phosphatase nor inhibit its activity even at concentrations as high as 100 mu M. Thus, the substrate specificity of the polyphosphoinositide phosphatase is distinct from that of previously identified phosphatases that utilize both inositol phospholipids and soluble inositol phosphates as substrates. The ability of the polyphosphoinositide phosphatase to hydrolyze phosphate from the 3, 4-, or 5-position of the inositol ring suggests that this enzyme may play a key role in maintaining homeostasis among all forms of polyphosphoinositides.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)								ACKERMANN KE, 1987, BIOCHEM J, V242, P517, DOI 10.1042/bj2420517; Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; INHORN RC, 1987, J BIOL CHEM, V262, P15946; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LING LE, 1989, J BIOL CHEM, V264, P5080; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P664; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	62	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23648	23654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089134				2022-12-25	WOS:A1994PQ34500041
J	BATTEY, FD; GAFVELS, ME; FITZGERALD, DJ; ARGRAVES, WS; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK				BATTEY, FD; GAFVELS, ME; FITZGERALD, DJ; ARGRAVES, WS; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK			THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN REGULATES LIGAND-BINDING BY THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; HEYMANN NEPHRITIS; CELL-SURFACE; IN-VITRO; GLYCOPROTEIN; VIVO	A 39-kDa receptor associated protein (RAP) binds and inhibits ligand binding by two members of the low density lipoprotein (LDL) receptor family, gp330 and low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor. To determine if additional members of the LDL receptor family may interact with RAP, Chinese hamster ovary cells were transfected with plasmids directing expression of the very low density lipoprotein (VLDL) receptor cDNA or the LDL receptor cDNA Detergent-soluble extracts from these and normal Chinese hamster ovary cells were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, after which the proteins were transferred to nitrocellulose membranes and incubated with RAP. When detergent extracts from normal cells were incubated with RAP, several polypeptides, including a 130-kDa protein, were observed to bind RAP. In cells transfected with the VLDL receptor cDNA, a substantial increase in RAP binding to the 130-kDa polypeptide was noted. This protein was identified as the VLDL receptor by immunoblotting. The VLDL receptor present in detergent extracts from transfected cells bound to RAP-Sepharose, and a K-D of 0.7 nM for the interaction between RAP and the purified VLDL receptor was determined using enzyme-linked immunosorbant assay. The purified VLDL receptor bound I-125-labeled VLDL, but not I-125-labeled LDL, and the binding of I-125-labeled VLDL was completely inhibited by RAP. Further, RAP inhibited the uptake and degradation of I-125-VLDL by cells overexpressing the VLDL receptor. Thus the VLDL receptor represents the third member of the LDL receptor family whose ligand binding properties are antagonized by RAP. This suggests a common functional role for RAP in modulating ligand binding by members of the LDL receptor family.	AMER RED CROSS,HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV PENN,SCH MED,DEPT OBSTET & GYNAECOL,PHILADELPHIA,PA 19104	American Red Cross; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBATE M, 1993, EUR J CELL BIOL, V61, P139; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOI SY, 1993, J BIOL CHEM, V268, P15804; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOUNNAS MZ, 1994, IN PRESS IN VIVO; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	39	171	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23268	23273						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083232				2022-12-25	WOS:A1994PQ16400056
J	IKEGAMI, S; KOBAYASHI, H; MYOTOISHI, Y; OHTA, S; KATO, KH				IKEGAMI, S; KOBAYASHI, H; MYOTOISHI, Y; OHTA, S; KATO, KH			SELECTIVE-INHIBITION OF EXOPLASMIC MEMBRANE-FUSION IN ECHINODERM GAMETES WITH JASPISIN, A NOVEL ANTIHATCHING SUBSTANCE ISOLATED FROM A MARINE SPONGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; HALENAQUINOL SULFATE; PENTACYCLIC HYDROQUINONES; THEORETICAL CALCULATION; XESTOSPONGIA-SAPRA; HATCHING ENZYME; EGG RECEPTOR; PROTEIN; METALLOENDOPROTEASES; INVOLVEMENT	A specific inhibitor of fertilization of the sea urchin Hemicentrotus pulcherrimus was isolated from the extract of the marine sponge, Jaspis species. Chemical and spectral data of the purified substance, which was designated jaspisin, showed that it is a novel substance with the structure of sodium (E)-5,6-dihydroxystyryl sulfate. Jaspisin at 15 mu g/ml inhibited exoplasmic fusion of the plasma membrane of acrosome-reacted sperm with the plasma membrane of the egg; it did not affect either the acrosome reaction in sperm or the egg cortical reaction, both of which involve endoplasmic membrane fusion events. When a fertilized egg was cultured in jaspisin, the embryo developed through the mesen chymal blastula stage. However, it was unable to hatch from the fertilization envelope, and spiculogenesis, in which cell cell fusion of primary mesenchyme cells is involved, was prevented. Jaspisin at 8.6 mu g/ml inhibited half the activity of hatching enzyme, a kind of Zn2+-dependent metalloendoproteinases. Because Zn2+-activated metalloendoproteinases are suggested to be involved in both sperm egg fusion and fusion of primary mesenchyme cells (Lennarz, W.J., and Strittmatter, W. J. (1991) Biochim. Biophys. Acta 1071, 149-158), one of the possible explanations of the jaspisin effects is that the sulfate inhibits these cellular events through blockage of Zn2+-activated metalloendoproteinases that are involved in membrane fusion processes.	HIROSHIMA UNIV, INSTRUMENT CTR CHEM ANAL, NAKA KU, HIROSHIMA 730, JAPAN; NAGOYA CITY UNIV, COLL GEN EDUC, BIOL LAB, MIZUHO KU, NAGOYA, AICHI 467, JAPAN	Hiroshima University; Nagoya City University	IKEGAMI, S (corresponding author), HIROSHIMA UNIV, FAC APPL BIOL SCI, DEPT APPL BIOCHEM, 1-4-4 KAGAMIYAMA, HIGASHIHIROSHIMA 724, JAPAN.			Ohta, Shinji/0000-0002-1338-5355				CLAPPER DL, 1985, J CELL BIOL, V100, P1817, DOI 10.1083/jcb.100.6.1817; Dan J C, 1970, Adv Morphog, V8, P1; DECKER GL, 1976, DEV BIOL, V53, P115, DOI 10.1016/0012-1606(76)90213-X; EPEL D, 1978, MEMBRANE FUSION, P1; FARACH HA, 1987, J BIOL CHEM, V262, P5483; FOLTZ KR, 1992, J CELL BIOL, V116, P647, DOI 10.1083/jcb.116.3.647; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; Giudice G., 1986, SEA URCHIN EMBRYO DE, P37; GLABE CG, 1977, NATURE, V267, P836, DOI 10.1038/267836a0; HARADA N, 1989, J AM CHEM SOC, V111, P5668, DOI 10.1021/ja00197a025; HINKLEY RE, 1986, DEV BIOL, V118, P148, DOI 10.1016/0012-1606(86)90082-5; IKEGAMI S, 1992, FEBS LETT, V302, P284, DOI 10.1016/0014-5793(92)80460-X; Ishida J., 1936, Annotationes Zoologicae Japonenses, V15, P453; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KOBAYASHI M, 1985, TETRAHEDRON LETT, V26, P3833, DOI 10.1016/S0040-4039(00)89263-1; KOBAYASHI M, 1985, CHEM PHARM BULL, V33, P1305; LEGAGE T, 1989, J BIOL CHEM, V264, P4787; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LONGO FJ, 1973, BIOL REPROD, V9, P149, DOI 10.1093/biolreprod/9.2.149; NOMURA K, 1991, BIOCHEMISTRY-US, V30, P6115, DOI 10.1021/bi00239a005; OKAZAKI K, 1965, EXP CELL RES, V40, P585, DOI 10.1016/0014-4827(65)90236-3; PLATTNER H, 1993, SIGNAL TRANSDUCTION, P19; RAHMAN A, 1986, NUCLEAR MAGNETIC RES; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; ROE JL, 1988, J CELL BIOL, V107, P539, DOI 10.1083/jcb.107.2.539; ROE JL, 1990, J BIOL CHEM, V265, P8704; ROE JL, 1989, EXP CELL RES, V181, P542, DOI 10.1016/0014-4827(89)90110-9; SASAKI H, 1984, DEV BIOL, V101, P125, DOI 10.1016/0012-1606(84)90123-4; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Silverstein R., 1977, SPECTROMETRIC IDENTI; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; VACQUIER VD, 1975, DEV BIOL, V43, P62, DOI 10.1016/0012-1606(75)90131-1; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yeagle P.L, 2016, MEMBRANE CELLS, Vthird, P452; [No title captured]	38	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23262	23267						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083231				2022-12-25	WOS:A1994PQ16400055
J	SHIMIZU, K; KURODA, S; YAMAMORI, B; MATSUDA, S; KAIBUCHI, K; YAMAUCHI, T; ISOBE, T; IRIE, K; MATSUMOTO, K; TAKAI, Y				SHIMIZU, K; KURODA, S; YAMAMORI, B; MATSUDA, S; KAIBUCHI, K; YAMAUCHI, T; ISOBE, T; IRIE, K; MATSUMOTO, K; TAKAI, Y			SYNERGISTIC ACTIVATION BY RAS AND 14-3-3-PROTEIN OF A MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE NAMED RAS-DEPENDENT EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE STIMULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP EXCHANGE PROTEIN; MAP KINASE; XENOPUS-OOCYTES; TYROSINE PHOSPHORYLATION; RAF-1; CELLS; PURIFICATION; EGGS; IDENTIFICATION; EXOCYTOSIS	We have identified, in Xenopus oocyte cytosol, a protein kinase named REKS (Ras-dependent extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase kinase (MER) stimulator), which phosphorylates and activates recombinant ERK2 through recombinant MEK in a recombinant GTP gamma S (guanosine 5'-(3-O-thio)triphosphate)-Ras-dependent manner. We show here that this REKS activity is synergistically enhanced by a combination of mammalian recombinant GTP gamma S-Ki-Ras and 14-3-3 protein purified from rat brain. 14-3-3 protein is known to activate tyrosine and tryptophan hydroxylases, to modulate the protein kinase C activity, to stimulate secretion, and to show phospholipase A(2) activity per se. 14-3-3 protein did not affect the MEK activity. 14-3-3 protein neither interacted with Ki-Ras nor affected the neurofibromin activity to stimulate the GTPase activity of Ki-Ras under the conditions where the recombinant N-terminal fragment of c-Raf-1 inhibited it. These results suggest that 14-3-3 protein has an additional function in the regulation of the Ras-MEK-ERK cascade pathway through the activation of REKS.	NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN; UNIV TOKUSHIMA,FAC PHARMACEUT SCI,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,TOKYO 158,JAPAN; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,NAGOYA,AICHI 46401,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Tokushima University; Tokyo Metropolitan University; Nagoya University	SHIMIZU, K (corresponding author), OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN.		Isobe, Toshiaki/Q-9279-2017; KURODA, SHINYA/G-4961-2014					AITKEN A, 1990, NATURE, V344, P594; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALEST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GUAN C, 1987, GENE, V67, P21; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J, 1989, MOL CLONING LABORATO; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	42	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22917	22920						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083186				2022-12-25	WOS:A1994PQ16400002
J	YUAN, NY; FRIEDMAN, J; WHALEY, BS; CLARK, RB				YUAN, NY; FRIEDMAN, J; WHALEY, BS; CLARK, RB			CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C CONSENSUS SITE MUTATIONS OF THE BETA-ADRENERGIC-RECEPTOR - EFFECT ON DESENSITIZATION AND STIMULATION OF ADENYLYLCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; LYMPHOMA-CELLS; HETEROLOGOUS DESENSITIZATION; WILD-TYPE; PHOSPHORYLATION; IDENTIFICATION; INHIBITION; GS; INTERNALIZATION	Activation of cAMP-dependent protein kinase (cAPK) or protein kinase C (PKC) causes a rapid desensitization of beta(2)-adrenergic receptor (beta AR) stimulation of adenylylcyclase in L cells, which previous studies suggest involves the cAPK/PKC consensus phosphorylation site in the third intracellular loop of the beta AR, RRSSK(263). To determine the role of the individual serines in the cAPK- and PKC-mediated desensitizations, wild type (WT) and mutant beta ARs containing the substitutions, Ser(261) --> Ala, Ser(262) --> Ala, Ser(262) --> Asp, and Ser(261/262) --> Ala, were constructed and stably transfected into L cells. Results showed that serine 262 was the primary site of the cAPK-induced desensitization, whereas either serine 261 or serine 262 was sufficient to confer the 4 beta-phorbol 12 beta-myristate 13 alpha-acetate (PMA)/PKC-mediated desensitization. Coincident stimulation of cAPK and PKC caused an additive desensitization (6-8-fold increase in the EC(50)) which was significantly reduced (80%) only by the double substitution mutation. Quantitative evaluation of the coupling efficiencies and the GTP-shift of the WT and mutant receptors demonstrated that only one of the mutants, Ser(262) --> Ala, was partially uncoupled. The Ser(262) --> Asp mutation did not significantly uncouple, demonstrating that introducing a negative charge did not appear to mimic the desensitized state of the receptor. The beta AR expression level played a critical role in determining the pattern of beta AR desensitization; i.e. while the overall desensitization was unaltered within a large range of beta AR expression level (10-300 fmol/mg), the increase in EC(50) and decrease in V-max were differentially affected by the change in the receptor level.			YUAN, NY (corresponding author), UNIV TEXAS, HLTH SCI CTR, GRAD SCH BIOMED SCI, DEPT PHARMACOL, HOUSTON, TX 77225 USA.				NIGMS NIH HHS [GM31208] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAROVSKY K, 1980, J CYCLIC NUCL PROT, V6, P297; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1991, FEBS LETT, V279, P243, DOI 10.1016/0014-5793(91)80159-Z; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOHNSON JA, 1986, J CYCLIC NUCL PROT, V11, P199; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; PROLL MA, 1992, MOL PHARMACOL, V42, P116; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU SS, 1993, J BIOL CHEM, V268, P337	36	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23032	23038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083204				2022-12-25	WOS:A1994PQ16400023
J	BELL, LM; SOLOMON, KR; GOLD, JP; TAN, KN				BELL, LM; SOLOMON, KR; GOLD, JP; TAN, KN			CYTOPLASMIC TAIL DELETION OF T-CELL RECEPTOR (TCR) BETA-CHAIN RESULTS IN ITS SURFACE EXPRESSION AS GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED POLYPEPTIDE ON MATURE T-CELLS IN THE ABSENCE OF TCR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE AMINO-ACID; ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; GLYCOSYL-PHOSPHATIDYLINOSITOL; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEIN; COMPLEX; DEGRADATION; REQUIREMENTS; RETENTION	Surface expression of the T cell antigen receptor (TCR) in mature T cells requires the association of a variable heterodimer (alpha.beta or gamma.delta) with six invariant CD3 polypeptides (gamma, delta, epsilon-epsilon, zeta-zeta, or zeta-eta). We describe here that deletion of the cytoplasmic tail polypeptide sequence (Lys-Lys-Lys-Asn-Ser) of TCR beta-chain (beta(CT)) results in expression of the truncated beta-chain on the surface of a mature T cell hybridoma line, in the absence of TCR-alpha, as a glycophosphatidylinositol (GPI)-anchored monomeric polypeptide. The GPI-anchored TCR-beta(CT) is not associated with CD3-epsilon and is incapable of conventional signal transduction. Association with TCR-alpha prevents beta(CT) from GPI-linkage formation. The alpha beta(CT) heterodimer binds the CD3 polypeptides, and the resultant TCR alpha beta(CT)/CD3 complex is capable of signal transduction. Our data show that a signal sequence for GPI-linkage formation is present in TCR-beta, and this alternative membrane anchoring mechanism can be utilized by beta-chain polypeptide lacking the CT sequence. We conclude therefore that in the absence of TCR-alpha expression, the beta-chain CT sequence plays an essential function in hindering GPI-Linkage formation, thereby preventing escape of incompletely assembled TCR beta-chain to the cell surface of mature T cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-27983] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027983] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON B, 1988, J BIOL CHEM, V263, P2953; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; COYNE KE, 1993, J BIOL CHEM, V268, P6689; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; Exley M, 1991, Semin Immunol, V3, P283; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P610, DOI 10.1016/0167-5699(93)90201-U; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KAPPLER J, 1983, CELL, V34, P727, DOI 10.1016/0092-8674(83)90529-9; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1985, NATURE, V122, P2491; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; NECKER A, 1991, EUR J IMMUNOL, V21, P3035, DOI 10.1002/eji.1830211220; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; TAN KN, 1988, CELL, V54, P247, DOI 10.1016/0092-8674(88)90557-0; TAN L, 1991, J EXP MED, V173, P1247, DOI 10.1084/jem.173.5.1247; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WHITE J, 1989, J IMMUNOL, V143, P1822; WIENANDS J, 1992, NATURE, V356, P246, DOI 10.1038/356246a0; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67	50	10	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22758	22763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077227				2022-12-25	WOS:A1994PQ16300047
J	DEVIC, E; JOURNOT, L; PANTALONI, C; BOCKAERT, J; AUDIGIER, Y				DEVIC, E; JOURNOT, L; PANTALONI, C; BOCKAERT, J; AUDIGIER, Y			MUTATION OF VALINE RESIDUE UNIQUE TO ALPHA-SUBUNIT OF G(S) ABOLISHES ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; ADENYLATE-CYCLASE; GS-ALPHA; BETA-GAMMA; MEMBRANE ASSOCIATION; MYRISTOYLATION; MUTAGENESIS; TRANSDUCIN; ANCHORAGE; PROTEINS	We recently characterized a decapeptide sequence (residues 367-376) that is important for the membrane association of the activated alpha subunit of G(s). We report here that when this sequence is replaced by the cognate sequence of G(i1) alpha a subunit, the chimeric protein (G(sis)alpha) still interacts with the membrane but cannot be activated, regardless of the mode of activation. Construction of various chimeras demonstrates that the single replacement of valine 367 by threonine, the cognate residue of G(i1) alpha subunit, fully reproduces the loss of activation. Analysis of nucleotide interaction reveals that the mutant V367T G(s) alpha protein poorly binds GDP or GTP. On the other hand, the conservative change of valine to isoleucine does not alter activation. Interestingly, members of the G(s) and G(12) classes have a valine and an isoleucine, respectively, at this position, whereas members of the G(i) or G(q) class contain a threonine residue. The evolutionary relationship between the different classes suggests that the presence of a hydrophobic or a hydrophilic residue is not fortuitous in these alpha subunits and might provide distinctive structural and/or functional properties.	UNIV TOULOUSE 3,CTR DEV BIOL,UMR 9925,F-31068 TOULOUSE,FRANCE; CNRS,CTR PHARMACOL ENDOCRINOL,INSERM,F-34095 MONTPELLIER,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Journot, Laurent/T-9652-2018	Journot, Laurent/0000-0003-3499-8887				AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BOCKAERT J, 1985, EMBO J, V4, P1413, DOI 10.1002/j.1460-2075.1985.tb03795.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; JOURNOT L, 1991, P NATL ACAD SCI USA, V88, P10054, DOI 10.1073/pnas.88.22.10054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631	20	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20899	20904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063706				2022-12-25	WOS:A1994PC40300016
J	ZHONG, FM; SWENDEMAN, SL; POPIK, M; PITHA, PM; SHEFFERY, M				ZHONG, FM; SWENDEMAN, SL; POPIK, M; PITHA, PM; SHEFFERY, M			EVIDENCE THAT LEVELS OF THE DIMERIC CELLULAR TRANSCRIPTION FACTOR CP2 PLAY LITTLE ROLE IN THE ACTIVATION OF THE HIV-1 LONG TERMINAL REPEAT IN-VIVO OR FOLLOWING SUPERINFECTION WITH HERPES-SIMPLEX VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GLOBIN GENE; PROTEINS; PROMOTER; BINDS; DROSOPHILA; ELEMENT; INTERACT; PROVIRUS; REGIONS; SYSTEM	The dimeric transcription factor CP2 binds a sequence element found near the transcription start site of the human immunodeficiency virus (HIV-1) long terminal repeat. Several groups have suggested that cellular factors binding this element might play a role in modulating HIV-1 promoter activity in vivo. For example, induction of latent HIV-1 gene expression in response to superinfection by herpes simplex virus type 1 (HSV-1) or cytomegalovirus is thought to be mediated, in part, by factors binding the CP2 site. In this report we began to examine directly the relationship between CP2 and expression of the HIV-1 promoter. First, we tested what effect HSV-1 infection of T cells had on the cellular levels of CP2. The results showed that HSV-1 infection led to a significant reduction in the level of CP2 DNA binding activity and protein within 20 h. Next, we tested the effect of overexpressing either the wild-type factor or a dominant negative variant of CP2 on HIV-1 promoter activity in vivo. The results showed that CP2 had little effect or slightly repressed HIV-1 promoter activity in vivo. In addition, these expression constructs had little effect on the induction of HIV-1 promoter activity elicited by HSV-1 infection.	CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,GRAD SCH MED SCI,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026123, R37AI026123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037513] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline; NIAID NIH HHS [AI26123] Funding Source: Medline; NIDDK NIH HHS [DK-37513] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BARRY PA, 1990, J VIROL, V64, P2932, DOI 10.1128/JVI.64.6.2932-2940.1990; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KIM CG, 1988, MOL CELL BIOL, V8, P4270, DOI 10.1128/MCB.8.10.4270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; MARGOLIS DM, 1993, VIROLOGY, V192, P370, DOI 10.1006/viro.1993.1046; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VLACH J, 1993, J VIROL, V67, P4427, DOI 10.1128/JVI.67.7.4427-4431.1993; VLACH J, 1992, J VIROL, V66, P3616, DOI 10.1128/JVI.66.6.3616-3623.1992; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776	27	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21269	21276						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063751				2022-12-25	WOS:A1994PC40300069
J	CHAMULITRAT, W; JORDAN, SJ; MASON, RP; SAITO, K; CUTLER, RG				CHAMULITRAT, W; JORDAN, SJ; MASON, RP; SAITO, K; CUTLER, RG			NITRIC-OXIDE FORMATION DURING LIGHT-INDUCED DECOMPOSITION OF PHENYL N-TERT-BUTYLNITRONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; BUTYL-ALPHA-PHENYLNITRONE; SOLUBLE GUANYLATE-CYCLASE; HYDROXYL RADICAL ADDUCT; AQUEOUS-SOLUTIONS; L-ARGININE; TRANSDUCTION MECHANISM; OXIDATIVE DAMAGE; TRAPPING AGENTS; ENZYME-ACTIVITY	Phenyl N-tert-butylnitrone (PBN) is a spin trap commonly employed in free radical research. PBN has been shown to have adverse and beneficial effects on various biological systems. We report here evidence that photolysis (or even ambient light) decomposes PBN to nitric oxide in aqueous solutions. Non-heme and heme proteins have been employed to form nitrosyl complexes, which were detected using EPR spectroscopy. Concomitantly, nitrite formation was detected after light-induced decomposition of PBN. In addition, we found that tert-nitrosobutane and decomposed PBN caused an activation of guanylate cyclase. We propose a mechanism where PBN is decomposed by light to tert-nitrosobutane. The latter compound is, in turn, decomposed to nitric oxide. This study suggests the possibility that PBN or PBN radical adducts may be sources of nitric oxide in biological environments. When using PBN as a spin trap in biological samples, not only is the trapping of reactive free radicals operative, but nitric oxide produced from PBN decomposition may play an important role in altering biological functions.	NIA,GERONTOL RES CTR,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	CHAMULITRAT, W (corresponding author), NIEHS,MOLEC BIOPHYS LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BLASIG IE, 1991, OXIDATIVE DAMAGE & REPAIR, P421; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V184, P1158, DOI 10.1016/S0006-291X(05)80004-X; BOWMAN DF, 1971, J AM CHEM SOC, V93, P6551, DOI 10.1021/ja00753a037; BRADAMANTE S, 1992, J MOL CELL CARDIOL, V24, P375, DOI 10.1016/0022-2828(92)93192-M; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHAMULITRAT W, 1985, J PHYS CHEM-US, V89, P4989, DOI 10.1021/j100269a021; CHARLON V, 1988, BASIC RES CARDIOL, V83, P306, DOI 10.1007/BF01907364; DOCAMPO R, 1981, J BIOL CHEM, V256, P930; Garbers D L, 1979, Adv Cyclic Nucleotide Res, V10, P57; HEARSE DJ, 1987, CIRC RES, V60, P375, DOI 10.1161/01.RES.60.3.375; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HILLE R, 1979, J BIOL CHEM, V254, P2110; HINOJOSA O, 1989, PHOTOCHEM PHOTOBIOL, V49, P1, DOI 10.1111/j.1751-1097.1989.tb04069.x; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1989, SEMIN HEMATOL, V26, P63; JANZEN EG, 1978, J AM CHEM SOC, V100, P2923, DOI 10.1021/ja00477a075; JANZEN EG, 1990, FREE RADICAL RES COM, V9, P325, DOI 10.3109/10715769009145691; JANZEN EG, 1990, FREE RADICAL RES COM, V9, P353, DOI 10.3109/10715769009145694; KALYANARAMAN B, 1991, FEBS LETT, V280, P17, DOI 10.1016/0014-5793(91)80194-8; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; KONOREV EA, 1993, FREE RADICAL BIO MED, V14, P127, DOI 10.1016/0891-5849(93)90003-D; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; LI ASW, 1988, J MAGN RESON, V79, P140, DOI 10.1016/0022-2364(88)90329-0; LION Y, 1982, J PHOTOCHEM, V20, P169, DOI 10.1016/0047-2670(82)85032-6; LOURO SRW, 1981, BIOCHIM BIOPHYS ACTA, V670, P56, DOI 10.1016/0005-2795(81)90048-9; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MASON RP, 1985, J INORG BIOCHEM, V24, P161, DOI 10.1016/0162-0134(85)80008-8; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONTI E, 1991, FREE RADICAL RES COM, V14, P41, DOI 10.3109/10715769109088940; MORENO SNJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P267, DOI 10.1016/0003-9861(88)90127-0; NOVELLI GP, 1990, FREE RADICAL BIO MED, V8, P9, DOI 10.1016/0891-5849(90)90138-9; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SARGENT FP, 1976, CAN J CHEM, V54, P275, DOI 10.1139/v76-041; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; VANIN AF, 1975, STUD BIOPHYS, V49, P13; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; Ziegler DM., 1980, ENZYMATIC BASIS DETO, VI, P201	47	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11520	11527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099352				2022-12-25	WOS:A1993LF28400013
J	SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL				SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL			TOPOISOMERASE-II-ALPHA COAMPLIFICATION WITH ERBB2 IN HUMAN PRIMARY BREAST-CANCER AND BREAST-CANCER CELL-LINES - RELATIONSHIP TO M-AMSA AND MITOXANTRONE SENSITIVITY	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DNA TOPOISOMERASES; PROTEIN OVEREXPRESSION; PROGNOSTIC-SIGNIFICANCE; CHROMOSOME BREAKAGE; DRUG-ACTION; EXPRESSION; GENE; PROLIFERATION; CARCINOMA	Topoisomerase IIalpha (topo IIalpha) is a key enzyme in DNA replication and a target for many anti-cancer drugs. High levels are associated with sensitivity to topoisomerase II inhibitors. Because its chromosome location is similar to erbB2 (17q21-22), which is frequently amplified in breast cancer, co-amplification of these genes was assessed. In 117 primary breast cancers, 25 were amplified for erbB2. Three of these cases showed co-amplification of topo IIalpha. Topo IIbeta was not amplified. Four human breast cancer cell lines were assessed for erbB2 and topo IIalpha co-amplification. They were also analysed for sensitivity to the topoisomerase inhibitors m-AMSA and mitoxantrone. The most sensitive cell line was SKBr3, which was the only one with erbB2 amplification. Topo IIalpha was co-amplified to a similar extent as in tumours. This suggests that patients whose tumours show topo IIalpha amplification should be assessed specifically for therapy with topoisomerase inhibitors.	UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,MOLEC ONCOL LABS,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EPSTEIN RJ, 1989, BIOCHEM BIOPH RES CO, V160, P12, DOI 10.1016/0006-291X(89)91613-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FRICHE E, 1991, CANCER RES, V51, P4213; GLIKIN GC, 1986, EMBO J, V5, P151, DOI 10.1002/j.1460-2075.1986.tb04189.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HINDS M, 1991, CANCER RES, V51, P4729; HOFKER MH, 1985, HUM GENET, V70, P148, DOI 10.1007/BF00273073; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HONG JH, 1990, BIOMED PHARMACOTHER, V44, P41, DOI 10.1016/0753-3322(90)90068-K; HORAK E, 1991, ONCOGENE, V6, P2277; HSIANG YH, 1988, CANCER RES, V48, P3230; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KEITH WN, 1992, IN PRESS GENES CHROM; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LONG BH, 1991, CANCER RES, V51, P5275; NELSON WG, 1987, CANCER RES, V47, P3246; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PENG J, 1988, P NATL ACAD SCI USA, V85, P7177; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PLUMB JA, 1989, CANCER RES, V49, P4435; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROWE TC, 1986, CANCER RES, V46, P2021; SAINTRUF C, 1991, ONCOGENE, V6, P403; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SULLIVAN DM, 1986, BIOCHEMISTRY-US, V25, P2248, DOI 10.1021/bi00356a060; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; 1980, EUR J CANCER, V16, P1313; 1992, LANCET, V339, P71	65	127	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096076				2022-12-25	WOS:A1993KT22000015
J	BLANCO, G; DETOMASO, AW; KOSTER, J; XIE, ZJ; MERCER, RW				BLANCO, G; DETOMASO, AW; KOSTER, J; XIE, ZJ; MERCER, RW			THE ALPHA-SUBUNIT OF THE NA,K-ATPASE HAS CATALYTIC ACTIVITY INDEPENDENT OF THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; FUNCTIONAL EXPRESSION; ADENOSINE-TRIPHOSPHATASE; PLASMA-MEMBRANE; K+-ATPASE; BACULOVIRUS; ION; NA+; PHOSPHORYLATION; TRANSLOCATION	All catalytic activities of the Na,K-ATPase have been ascribed to the alpha-subunit; however, normal activity requires the presence of the beta-subunit. Using recombinant baculoviruses to infect insect cells, we demonstrate that the alpha-subunit, without the beta-subunit, has catalytic activity. During the normal catalytic cycle of the Na,K-ATPase, the alpha-subunit is transiently phosphorylated by ATP at an aspartate residue. This phosphorylation requires Na+, in the presence of K+ the enzyme undergoes rapid dephosphorylation. In contrast, phosphorylation of the independent alpha-subunit by ATP occurs in the presence of Mg2+, does not require Na+ or K+, and is not affected by ouabain. The phosphorylation is, however, inhibited by EGTA and increasing ionic strength. Chemical properties of the alpha-subunit phosphointermediate are consistent with phosphorylation at the normal aspartyl residue. Membranes from cells infected with the recombinant alpha baculovirus exhibit an EGTA-sensitive Mg2(+)-ATPase activity that is not present in the uninfected cells. The Mg2+-ATPase of the alpha-infected cells is reduced under conditions of high ionic strength and completely inhibited by EGTA. Thus the phosphorylation of the unassociated alpha-subunit is representative of the ATPase activity of the enzyme. These results suggest that the alpha-subunit of the Na,K-ATPase can catalyze an activity not normally associated with the enzyme and demonstrate that the beta-subunit plays an important role in conferring normal activity to the enzyme complex.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039746, R01GM039746] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; BARRABIN H, 1990, BIOCHIM BIOPHYS ACTA, V1023, P266, DOI 10.1016/0005-2736(90)90422-K; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; Blanco G, 1988, Prog Clin Biol Res, V268A, P271; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; HOKIN LE, 1965, P NATL ACAD SCI USA, V54, P177, DOI 10.1073/pnas.54.1.177; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; JAISSER F, 1992, ANN NY ACAD SCI, V671, P113, DOI 10.1111/j.1749-6632.1992.tb43789.x; KAWAMURA M, 1991, SOC GEN PHY, V46, P45; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LI ZP, 1992, J BIOL CHEM, V267, P7828; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUTSENKO S, 1992, ANN NY ACAD SCI, V671, P147, DOI 10.1111/j.1749-6632.1992.tb43792.x; Martell A. E., 1977, CRITICAL STABILITY C; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MEDFORD RM, 1991, J BIOL CHEM, V266, P18308; MIRCHEFF AK, 1992, AM J PHYSIOL, V262, pC470, DOI 10.1152/ajpcell.1992.262.2.C470; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; POST RL, 1973, J BIOL CHEM, V248, P6993; SMITH CD, 1992, BIOCHIM BIOPHYS ACTA, V1104, P151, DOI 10.1016/0005-2736(92)90144-B; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7	30	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23420	23425						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089106				2022-12-25	WOS:A1994PQ34500009
J	DOMINSKI, Z; KOLE, R				DOMINSKI, Z; KOLE, R			IDENTIFICATION OF EXON SEQUENCES INVOLVED IN SPLICE-SITE SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN PARTICLE; COMPENSATORY BASE CHANGE; SECONDARY STRUCTURE; ALTERNATIVE 5'; DIFFERENTIAL BINDING; PRECEDING INTRON; DOWNSTREAM EXON; PROTEIN FACTOR; INVITRO	The involvement of exon sequences in splice site selection was studied in vivo in HeLa cells transfected with a series of model three exon-two intron pre-mRNAs which differed only in the sequence of their internal exons. When the majority of the human globin-derived 175-nucleotide internal exon (DUP175) was replaced with a sequence from the yeast URA3 gene (DUP184), the splicing pathway changed from complete inclusion of the internal exon in DUP175 to its predominant skip ping in the DUP184 construct. Skipping of the exon was reversed by increasing the strength of its flanking splicing elements indicating that exon sequences exert their effect only in the presence of relatively weak splicing signals. A series of block mutations in the internal exon of DUP184 showed that a stretch of 6 cytidine nucleotides increased the inclusion of the DUP184 internal exon about 7-fold. Mutations generating purine-rich sequences (AAG and GAAG) at the 3' end of the exon led to complete exon inclusion while stepwise insertion of sequences from the internal exon of DUP175 into the DUP184 background increased exon inclusion 5-fold. Combination of the stretch of cytidines with sequences derived from DUP175 exon resulted in complete exon inclusion indicating that diverse signals within exons may cooperate with each other in affecting splice site selection.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; COOPER TA, 1992, J BIOL CHEM, V267, P5330; COTE GJ, 1992, NUCLEIC ACIDS RES, V20, P2361, DOI 10.1093/nar/20.9.2361; CUNNINGHAM SA, 1991, J MOL BIOL, V217, P265, DOI 10.1016/0022-2836(91)90541-D; DAVIS MG, 1988, BIOTECHNOL APPL BIOC, V10, P6; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; FURDON PJ, 1986, P NATL ACAD SCI USA, V83, P927, DOI 10.1073/pnas.83.4.927; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GRABOWSKI PJ, 1991, MOL CELL BIOL, V11, P5919, DOI 10.1128/MCB.11.12.5919; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; Harper Joan E., 1992, Gene Expression, V2, P19; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MANIATIS T, 1982, MOL CLONING LABORATO, P188; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCKEOWN M, 1990, REGULATION ALTERNATI, P139; Moore M J, 1993, SPLICING PRECURSORS, P303; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PARENT A, 1987, J BIOL CHEM, V262, P11284; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; POTTER H, 1994, CURRENT PROTOCOLS MO; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SCHWARTZ E, 1991, HEMATOLOGY BASIC PRI, P368; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; TURNBULLROSS AD, 1988, NUCLEIC ACIDS RES, V16, P395, DOI 10.1093/nar/16.2.395; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Watakabe Akiya, 1991, Gene Expression, V1, P175; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	81	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23590	23596						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089127				2022-12-25	WOS:A1994PQ34500033
J	LAVERRIERE, AC; MACNEILL, C; MUELLER, C; POELMANN, RE; BURCH, JBE; EVANS, T				LAVERRIERE, AC; MACNEILL, C; MUELLER, C; POELMANN, RE; BURCH, JBE; EVANS, T			GATA-4/5/6, A SUBFAMILY OF 3 TRANSCRIPTION FACTORS TRANSCRIBED IN DEVELOPING HEART AND GUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITIES; FACTOR GATA-1; FACTOR FAMILY; ERYTHROID DEVELOPMENT; REGULATORY GENE; ZINC FINGER; EXPRESSION; EMBRYOS; CELLS; DIFFERENTIATION	We describe experiments which show that: 1) two previously identified members of the GATA family of transcription factors (both of which were originally called GATA-4) correspond to chicken cDNAs for two distinct factors (which we now refer to as cGATA-4 and cGATA-5); 2) another new member of this family corresponds to a third factor designated cGATA-6; 3) each of these mRNAs displays a differential expression pattern. The cGATA-5 gene is initially transcribed in the cardiac crescent prior to formation of the primordial heart tube. Following formation of the primitive heart, cGATA-5 transcripts are evident in both endocardium and myocardium as well as in other lateral plate derivatives. The cGATA-5 gene is also transcribed in the primitive embryonic gut and in late stage embryos is sequentially up-regulated in distinct segments of gastrointestinal epithelia as they undergo terminal differentiation. These studies thus provide novel insights into tissue-specific regulation by GATA-5, as well as into possibly overlapping regulatory functions for these three family members.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; LEIDEN UNIV,DEPT ANAT & EMBRYOL,2300 RC LEIDEN,NETHERLANDS	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Leiden University; Leiden University - Excl LUMC					NATIONAL CANCER INSTITUTE [K11CA001689, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-01689] Funding Source: Medline; PHS HHS [35535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABEL T, 1993, DEVELOPMENT, V119, P623; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AWGULEWITSCH A, 1986, NATURE, V320, P328, DOI 10.1038/320328a0; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DERUITER MC, 1992, ANAT EMBRYOL, V185, P461; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, P NATL ACAD SCI USA, V87, P5331, DOI 10.1073/pnas.87.14.5331; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN Y, 1992, DEV DYNAM, V193, P257, DOI 10.1002/aja.1001930306; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KELLEY C, 1993, DEVELOPMENT, V118, P817; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON MC, 1993, P SOC EXP BIOL MED, V202, P115; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; WINICK J, 1993, DEVELOPMENT, V119, P1055; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1993, BLOOD, V81, P3234	41	481	502	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23177	23184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083222				2022-12-25	WOS:A1994PQ16400044
J	HOLST, BD; GOOMER, RS; WOOD, IC; EDELMAN, GM; JONES, FS				HOLST, BD; GOOMER, RS; WOOD, IC; EDELMAN, GM; JONES, FS			BINDING AND ACTIVATION OF THE PROMOTER FOR THE NEURAL CELL-ADHESION MOLECULE BY PAX-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED BOX GENE; HOMEOBOX-CONTAINING GENE; N-CAM; SMALL-EYE; REGULATORY ELEMENTS; NERVOUS-SYSTEM; DEVELOPING CNS; WILMS-TUMOR; HOMEODOMAIN; MUTATION	The neural cell adhesion molecule (N-CAM), is expressed in definite spatiotemporal patterns during development. To identify factors that may influence place-dependent n-cam gene expression, we have studied the binding and activation of the n-cam promoter by Pax-8, a member of the Pax family of transcription factors. Pax-8 increased n-cam promoter activity 13.4-fold in cellular co-transfection experiments, and a short segment of the promoter (-143 to -15) mediated the response. This region of the n-cam promoter produced a DNA-protein complex when incubated with either extracts from COS-7 cells transfected with the Pax-8 expression vector or a Pax-8/GST fusion protein. Pax-8 bound to the n-cam promoter through two TGCTCC motifs (designated PBS-1 and PBS-2) that resemble paired domain binding sites. Mutation of PBS-1 and PBS-2 eliminated Pax-8 activation of the n-cam promoter. Transfection of N2A neuroblastoma cells with the Pax-8 expression vector resulted in a 5-fold increase in the transcription of the endogenous n-cam gene, The combined results suggest that Pax-8 activates transcription of the n-cam gene through binding of sequences resembling paired domain binding sites in the n-cam promoter. The data raise the possibility that the n-cam promoter may be regulated by other members of the Pax gene family,	Scripps Res Inst, DEPT NEUROBIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Wood, Ian/AAK-9423-2021	Wood, Ian/0000-0003-1886-2533	NIA NIH HHS [AGO9326] Funding Source: Medline; NICHD NIH HHS [HD09635] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009635, R01HD009635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009326] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARTON CH, 1990, BIOCHEM J, V268, P161, DOI 10.1042/bj2680161; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V90, P532; CHEN AS, 1990, MOL CELL BIOL, V10, P3314, DOI 10.1128/MCB.10.7.3314; COLWELL G, 1992, GENOMICS, V14, P875, DOI 10.1016/S0888-7543(05)80108-9; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DANILOFF JK, 1986, J NEUROSCI, V6, P739; EDELMAN GM, 1990, COLD SH Q B, V55, P303; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; GOOMER RS, 1994, IN PRESS P NATL ACAD; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GOULDING MD, 1991, NEURAL DEV DISCUSSIO, V7, P17; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOFFMAN S, 1986, J CELL BIOL, V103, P145, DOI 10.1083/jcb.103.1.145; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; JOSTES B, 1991, MECH DEVELOP, V33, P27; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MAURO VP, 1994, P NATL ACAD SCI USA, V91, P2868, DOI 10.1073/pnas.91.7.2868; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TREISMAN J, 1919, GENESDEV, V5, P4594; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZUBER C, 1990, EUR J CELL BIOL, V51, P313	48	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22245	22252						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071351				2022-12-25	WOS:A1994PE09800051
J	JUI, HY; SUZUKI, Y; ACCILI, D; TAYLOR, SI				JUI, HY; SUZUKI, Y; ACCILI, D; TAYLOR, SI			EXPRESSION OF A CDNA-ENCODING THE HUMAN INSULIN RECEPTOR-RELATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; I RECEPTOR; GROWTH; KINASE; GENE; LEPRECHAUNISM; SPECIFICITY; MUTATIONS; PATIENT; LIGAND	The insulin receptor-related receptor (IRR) gene encodes a protein that is homologous to the receptors for insulin and insulin like growth factor-I (IGF-I). We have cloned a full-length cDNA encoding the human IRR by screening a human kidney cDNA library. The nucleotide sequence of our cDNA is identical to the sequence predicted from the human IRR gene except for the presence of an insertion of 24 base pairs between exons 13 and 14. This insertion was caused by use of an alternative splice acceptor site in the 3' portion of intron 13. Interestingly, this alternative splicing occurs at a position at which alternative splicing of the homologous IGF-I receptor mRNA also occurs. We amplified human kidney IRR by the polymerase chain reaction to quantitate the proportion of transcripts which included the 24-nucleotide sequence between exons 13 and 14. Fewer than 10% of the transcripts contained this additional sequence. We expressed the IRR cDNA lacking the 24-base pair insert in NIH-3T3 cells to study the biosynthesis, tyrosine phosphorylation, and ligand binding properties of the IRR. Like receptors for insulin and IGF-I, the IRR was synthesized as a single polypeptide precursor that underwent proteolytic cleavage and glycosylation to yield an a subunit and a p subunit. However, both subunits of the IRR had smaller apparent molecular mass than the homologous subunits of the insulin receptor (108,000 versus 135,000 for the alpha subunits and 66,000 versus 95,000 for the beta subunits). IRR tyrosine phosphorylation could be stimulated by vanadate plus H2O2, which have been demonstrated previously to increase the phosphotyrosine content of the insulin receptor tyrosine kinase. However, proinsulin, insulin, IGF-I, and IGF-II did not stimulate tyrosine phosphorylation of the IRR. We conclude that these peptides are not the ligands for the IRR.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University								BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITOH N, 1993, J BIOL CHEM, V268, P17983; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KATO H, 1993, J BIOL CHEM, V268, P2655; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVY TR, 1993, ENDOCRINOLOGY, V133, P1803; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; REINHARDT RR, 1993, ENDOCRINOLOGY, V133, P3, DOI 10.1210/en.133.1.3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1989, J BIOL CHEM, V264, P14605; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; YEE D, 1989, J BIOL CHEM, V264, P21439; ZHANG B, 1992, J BIOL CHEM, V267, P18320	26	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22446	22452						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071374				2022-12-25	WOS:A1994PE09800078
J	HACKENG, TM; VANTVEER, C; MEIJERS, JCM; BOUMA, BN				HACKENG, TM; VANTVEER, C; MEIJERS, JCM; BOUMA, BN			HUMAN PROTEIN-S INHIBITS PROTHROMBINASE COMPLEX ACTIVITY ON ENDOTHELIAL-CELLS AND PLATELETS VIA DIRECT INTERACTIONS WITH FACTORS VA AND XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN C4B-BINDING PROTEIN; COAGULATION FACTOR-V; HUMAN FACTOR-VIII; COFACTOR ACTIVITY; THROMBOTIC DISEASE; BLOOD-COAGULATION; CALCIUM-BINDING; HUMAN-PLASMA; FACTOR-IX	Protein S is a vitamin K-dependent non-enzymatic coagulation factor involved in the regulation of activated protein C (APC). In this paper we report an APC-independent anticoagulant function of protein S. We observed an inhibition of prothrombinase activity on endothelial cells and platelets which was half-maximal at physiological concentrations of free protein S in plasma. On endothelial cells, thrombin-cleaved protein S (PSt) as well as protein S in complex with C4b-binding protein (C4BP) inhibited prothrombinase activity to the same extent as protein S did. In solid-phase binding assays, direct binding of protein S and PSt to factor V and factor Va were observed. Protein S-C4BP complex did not bind to factor V or factor Va, implicating that the factor V(a) binding site on protein S is lost by the interaction with C4BP. A direct inhibition of factor Xa activity by protein S was also observed. Incubation of factor Xa with protein S revealed a noncompetitive inhibition of factor Xa by protein S with a K-i of (4.9 +/- 0.8) x 10(-7) M. Both protein S and protein S-C4BP complex were able to inhibit factor Xa to the same extent, whereas PSt had lost its inhib itory activity, This suggests that the conformational change induced by cleavage of the amino-terminal thrombin-sensitive loop results in a loss of a factor Xa binding site on protein S. The inhibitory effect of protein S involves interactions with both factor Va and factor Xa. The interaction of protein S with factor Xa is influenced by cleavage of the thrombin-sensitive loop, whereas C4BP blocks the interaction of protein S with factor Va. Inhibition of the prothrombinase complex by either forms of protein S might be an important mechanism in regulating thrombin generation in blood coagulation. The importance of the APC-independent anticoagulant action of protein S was emphasized by experiments in which the addition of protein S to normal plasma induced a prolongation of clotting time in a dilute activated partial thromboplastin time (dAPTT) assay. Furthermore, inhibition of endogenous protein S by the addition of monoclonal antibodies against protein S to normal plasma, induced a shortening of the clotting time in a dAPTT assay.	UNIV UTRECHT HOSP,DEPT HEMATOL G03647,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center			Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780; Hackeng, Tilman/0000-0003-0142-0843				BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CHANG GTG, 1992, THROMB HAEMOSTASIS, V67, P526; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; FULCHER CA, 1984, BLOOD, V63, P486; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1993, J BIOL CHEM, V268, P3993; HACKENG TM, 1991, THROMB HAEMOSTASIS, V65, P781; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HARRIS KW, 1985, J BIOL CHEM, V260, P2007; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P3642; HESSING M, 1991, EUR J IMMUNOL, V21, P2077, DOI 10.1002/eji.1830210916; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANE SM, 1991, BLOOD COAGUL FIBRIN, V2, P723, DOI 10.1097/00001721-199112000-00005; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MITCHELL CA, 1988, J CLIN INVEST, V82, P2142, DOI 10.1172/JCI113836; NELSON RM, 1992, J BIOL CHEM, V267, P8140; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; SCHOEN P, 1992, BIOCHEM J, V281, P661, DOI 10.1042/bj2810661; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SCHWARZ HP, 1984, BLOOD, V64, P1297; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STERN DM, 1986, J BIOL CHEM, V261, P713; SUGO T, 1986, J BIOL CHEM, V261, P5116; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; TANS G, 1991, BLOOD, V77, P2641; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER FJ, 1986, BIOCHEMISTRY-US, V25, P6305, DOI 10.1021/bi00368a071; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926; WILLEMS C, 1982, EXP CELL RES, V139, P191, DOI 10.1016/0014-4827(82)90332-9	57	157	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21051	21058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063724				2022-12-25	WOS:A1994PC40300038
J	HEIERHORST, J; PROBST, WC; VILIM, FS; BUKU, A; WEISS, KR				HEIERHORST, J; PROBST, WC; VILIM, FS; BUKU, A; WEISS, KR			AUTOPHOSPHORYLATION OF MOLLUSCAN TWITCHIN AND INTERACTION OF ITS KINASE DOMAIN WITH CALCIUM/CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; MOLECULAR CHARACTERIZATION; CAENORHABDITIS-ELEGANS; PROTEIN-KINASES; INSECT FLIGHT; TITIN; MUSCLE; IDENTIFICATION; CALMODULIN; SEQUENCE	An similar to 750-kDa member of the family of giant titin/ twitchin-like myosin-associated proteins was highly purified from muscle of the marine mollusc Aplysia californica. Purified twitchin was able to autophosphorylate on threonine, which demonstrates its protein serine/threonine kinase activity. cDNA sequence analysis of the cloned kinase domain of molluscan twitchin revealed that it is most closely related with the kinase domains of Caenorhabditis elegans twitchin (62% identity) and vertebrate myosin light chain kinases (45% average identity). Analysis of the cDNA sequence further suggested the presence of a potential calmodulin-binding site in a putative autoinhibitory region. The functional activity of this site was demonstrated by the calcium-dependent binding of purified twitchin to immobilized calmodulin and the fact that this interaction could be competed with synthetic peptides deduced from the cDNA sequence. Furthermore, biotinylated calmodulin bound to immobilized twitchin in gel overlay assays with nanomolar affinity (EC(50) congruent to 70 nM). The potential regulation of twitchin by calcium/calmodulin indicates that titin-like molecules may serve dynamic functions during contraction-relaxation cycles in muscle in addition to their functions as cytoskeletal proteins.	NINCDS, NEUROBIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	HEIERHORST, J (corresponding author), CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, BOX 1218, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH36730] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH036730, R01MH036730] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BENIAN GM, 1993, GENETICS, V134, P1097; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GIRI L, 1990, METHOD ENZYMOL, V182, P380; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOROWITS R, 1987, J CELL BIOL, V105, P2217, DOI 10.1083/jcb.105.5.2217; HU DH, 1990, J MUSCLE RES CELL M, V11, P497, DOI 10.1007/BF01745217; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUTCHCROFT JE, 1991, METHOD ENZYMOL, V200, P417; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KRETSINGER RH, 1992, SCIENCE, V258, P50, DOI 10.1126/science.1439768; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; LEI JY, 1994, J BIOL CHEM, V269, P21078; MAROTO M, 1992, J MOL BIOL, V224, P287, DOI 10.1016/0022-2836(92)90994-U; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; NAVE R, 1990, J CELL SCI, V95, P535; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PROBST WC, 1994, IN PRESS P NATL ACAD, V91; Sambrook J, 1989, MOL CLONING LABORATO; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7563; TAN KO, 1993, J BIOL CHEM, V268, P22900; TRINICK J, 1984, J MOL BIOL, V180, P331, DOI 10.1016/S0022-2836(84)80007-8; Trinick J, 1991, CURR OPIN CELL BIOL, V3, P112, DOI 10.1016/0955-0674(91)90173-V; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; Wang Y., 1993, PROTEIN PHOSPHORYLAT, P121	37	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21086	21093						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063728				2022-12-25	WOS:A1994PC40300043
J	LEE, FJS; STEVENS, LA; KAO, YL; MOSS, J; VAUGHAN, M				LEE, FJS; STEVENS, LA; KAO, YL; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF A GLUCOSE-REPRESSIBLE ADP-RIBOSYLATION FACTOR-3 (ARF3) FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; GLUTATHIONE-S-TRANSFERASE; CHOLERA-TOXIN; ESCHERICHIA-COLI; FACTOR-I; SELECTIVE AMPLIFICATION; ENDOPLASMIC-RETICULUM; GENE DISRUPTION; FACTOR-III; GOLGI	ADP-ribosylation factors (ARFs) are highly conserved similar to 20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin, and are believed to participate in vesicular transport in both exocytic and endocytic pathways. Based on size, phylogenetic analysis, amino acid sequence, and gene structure, mammalian ARFs fall into three classes (class I, ARFs 1, 2, 3; class II, ARFs 4, 5; class III, ARF6). Two ARF genes (gamma ARF1, gamma ARF2) are known in Saccharomyces cerevisiae and believed to participate in vesicular trafficking in the Golgi system; the double deletion mutant is not viable. A third yeast ARF (gamma ARF3) cDNA has been cloned by polymerase chain reaction-based procedures. It contains an open reading frame of 549 bases encoding a protein of 183 amino acids, with a deduced amino acid sequence more identical (60%) to that of the class III mammalian ARF than to those of the other two classes (52-56%). The gamma ARF3 protein, however, reacted poorly with antibodies against any of the three classes of mammalian ARFs. In the presence of GTP, recombinant gamma ARF3 protein stimulated cholera toxin catalyzed auto-ADP-ribosylation, gamma ARF3 gene transcription, similar to that of gamma ARF2, was repressed by glucose. As gamma ARF3 was not essential for cell viability and was not required for endoplasmic reticulum to Golgi protein transport, it may provide an opportunity to define an ARF function in another kind of vesicular trafficking.			LEE, FJS (corresponding author), NHLBI, CELLULAR METAB LAB, RM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.			LEE, FANG-JEN/0000-0002-2167-2426				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALPERN JL, 1986, MOL PHARMACOL, V29, P515; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; LEE CM, 1992, J BIOL CHEM, V267, P9028; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LEE FJS, 1992, BIOTECHNIQUES, V13, P844; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; MURTAGH JJ, 1993, BIOCHEMISTRY-US, V32, P6011, DOI 10.1021/bi00074a012; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSAI SC, 1991, P NATL ACAD SCI USA, V88, P5139; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	50	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20931	20937						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063710				2022-12-25	WOS:A1994PC40300021
J	MARIE, J; MAIGRET, B; JOSEPH, MP; LARGUIER, R; NOUET, S; LOMBARD, C; BONNAFOUS, JC				MARIE, J; MAIGRET, B; JOSEPH, MP; LARGUIER, R; NOUET, S; LOMBARD, C; BONNAFOUS, JC			TYR(292) IN THE 7TH TRANSMEMBRANE DOMAIN OF THE AT(1A) ANGIOTENSIN-II RECEPTOR IS ESSENTIAL FOR ITS COUPLING TO PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; LIGAND-BINDING; RAT; EXPRESSION; IDENTIFICATION; VASOPRESSIN; RESIDUES; ACETYLCHOLINE; INHIBITION	An essential role of the conserved Asp(74) in, the coupling of the type 1 angiotensin II (AII) receptor (AT(1)) to phospholipase C has already been reported (Bihoreau, C., Monnot, C., Davies, E., Teutsch, B., Bernstein, K. B., Corvol, P., and Clauser, E. (1993) Proc. Natl. Acad. Sci. U.S. A. 90, 5133-5137). Moreover, preliminary modeling studies have shown that a spatial proximity exists between Asp(74), located in transmembrane domain II, and Tyr(292), located in transmembrane domain VII and conserved in many, but not all, G protein-coupled receptors. We mutated Tyr(292) into Phe and evaluated the pharmacological and activation characteristics of the mutated receptor (Y292F) stably expressed in Chinese hamster ovary cells. This receptor possessed unchanged binding properties for agonist or antagonist peptide ligands compared to the wild-type receptor, while its coupling to phospholipase C was severely impaired. Interestingly, competition binding experiments, using I-125-[Sar(1)]AII as a tracer ligand, showed that the Y292F receptor displayed an increased K-i value for DuP 753, an AT(1)-specific nonpeptide antagonist and a greatly decreased K-i value for the AT(2)-specific ligand CGP 42112A. These pharmacological changes are similar to those observed for the previously reported mutation of Asp(74) into Asn. This apparently symmetrical role of Asp(74) and Tyr(292) is consistent with the hypothesis that an interaction between these two amino acids could be a key event in the molecular processes linking AII recognition and AT(1) receptor activation.	CCIPE,INSERM,U401,F-34094 MONTPELLIER 05,FRANCE; UNIV NANCY 1,CHIM THEOR LAB,F-54506 VANDOEUVRE NANCY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Lorraine								BERGSMA DJ, 1993, MOL PHARMACOL, V44, P277; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BONNAFOUS JC, 1988, BIOCHEM J, V251, P873, DOI 10.1042/bj2510873; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; CHANG RSL, 1990, MOL PHARMACOL, V37, P347; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P2099; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; JI H, 1993, BIOCHEM BIOPH RES CO, V194, P756, DOI 10.1006/bbrc.1993.1886; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Strosberg A D, 1993, Drug Des Discov, V9, P199; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; ZHOU W, 1994, MOL PHARMACOL, V45, P165	36	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20815	20818						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063694				2022-12-25	WOS:A1994PC40300003
J	MINATO, T; WANG, J; AKASAKA, K; OKADA, T; SUZUKI, N; KATAOKA, T				MINATO, T; WANG, J; AKASAKA, K; OKADA, T; SUZUKI, N; KATAOKA, T			QUANTITATIVE-ANALYSIS OF MUTUALLY COMPETITIVE-BINDING OF HUMAN RAF-1 AND YEAST ADENYLYL-CYCLASE TO RAS PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; SACCHAROMYCES-CEREVISIAE; MAP KINASE; TYROSINE KINASE; HA-RAS; GENE; CELLS; TRANSFORMATION; ACTIVATION; ONCOGENE	Ras proteins appear to-have two distinct downstream effecters, adenylyl cyclase in Saccharomyces cerevisiae and a product of raf-1 protooncogene in higher organisms. We found that in vitro activation of adenylyl cyclase by yeast Ras2 and human H-Ras proteins is subject to competitive inhibition by its leucine-rich repeats domain and by the N-terminal regulatory domain of human Raf-1 protein. Kinetic analyses of the inhibition patterns enabled us to determine exact dissociation constants (K-d) of the two polypeptides for Ras2 and H-Ras. The leucine-rich repeats domain bound to the posttranslationally modified Ras2 with the K-d of approximately 13 nM, which was close to the value (7 nM) of the whole adenylyl cyclase. The K-d, of Raf-1 for the modified H-Ras, 3.5 nM, was significantly lower than that for Ras2, 24 nM, whereas adenylyl cyclase bound preferentially to Ras2. Similar inhibition was also observed in vivo by suppression of RAS2(Val-19) dependent heat shock sensitivity and of Ras-dependent cAMP response to glucose upon overexpression of Raf-1 in yeast. These results indicate that the leucine-rich repeats domain contains the Ras protein-binding site and that Raf-1 and adenylyl cyclase, sharing no structural homology with each other, bind to a similar, if not identical, region of Ras with comparable affinities.	KOBE UNIV, SCH MED, DEPT PHYSIOL 2, CHUO KU, KOBE 650, JAPAN	Kobe University								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GUNN C, 1987, GENE, V67, P21; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARSHALL MS, 1993, ONCOGENE, V8, P425; MBONYI K, 1988, MOL CELL BIOL, V8, P3051, DOI 10.1128/MCB.8.8.3051; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; Nielsen Olaf, 1993, Trends in Cell Biology, V3, P60, DOI 10.1016/0962-8924(93)90162-T; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	50	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20845	20851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063700				2022-12-25	WOS:A1994PC40300009
J	KNOWLES, MA; SHAW, ME; PROCTOR, AJ				KNOWLES, MA; SHAW, ME; PROCTOR, AJ			DELETION MAPPING OF CHROMOSOME-8 IN CANCERS OF THE URINARY-BLADDER USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS AND MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							TRANSITIONAL CELL-CARCINOMA; DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; COLORECTAL CANCERS; CLONAL EVOLUTION; GENE; IDENTIFICATION; ADENOCARCINOMAS; LEUKEMIA; LOCUS	We have used a combination of restriction fragment length polymorphism (RFLP) markers and highly informative microsatellite polymorphisms to map a common region of deletion on chromosome 8p in cancers of the urinary bladder. Analysis of loss of heterozygosity (LOH) using microsatellite polymorphisms was shown to be at least as sensitive as detection of RFLPs by Southern blotting. A total of 110 tumours was analysed for loss of heterozygosity (LOH) on 8p and 8q; 109 patients were informative for at least one marker on each chromosome arm and 29 tumours (26%) showed LOH of chromosome 8 markers, 26 of which (25%) showed LOH on 8p. Sixteen tumours (14%) showed LOH on 8q. Thirteen of these also had LOH on 8p. Of the 29 tumours with LOH, five had LOH at all informative loci, indicating loss of an entire copy of chromosome 8. An association was found between high tumour grade and stage and chromosome 8 LOH. Fifty-three per cent of grade 3 muscle-invasive tumours showed LOH compared with 11% of grade 1 non-invasive tumours (0.01 < P < 0.025 and 0.025 < P < 0.05 for grade and stage respectively). Deletion mapping of tumours with chromosome 8 LOH suggests the presence of a suppressor gene(s) for urothelial cancer within a region defined by the loci NEFL and PLAT (8p21 - q11.2). If there is a common target for deletions in bladder and those in hepatocellular and colorectal tumours reported previously, this defines a common region of deletion at 8p21.3.			KNOWLES, MA (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERTI AD, 1988, CANCER GENET CYTOGEN, V34, P101, DOI 10.1016/0165-4608(88)90174-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JIN YS, 1988, CANCER GENET CYTOGEN, V33, P11, DOI 10.1016/0165-4608(88)90043-X; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LEVERGER G, 1988, MED PEDIATR ONCOL, V16, P227, DOI 10.1002/mpo.2950160402; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MITELMAN F, 1981, CANCER GENET CYTOGEN, V4, P197, DOI 10.1016/0165-4608(81)90014-5; MULERIS M, 1986, INT J CANCER, V38, P167, DOI 10.1002/ijc.2910380204; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; PROCTOR AJ, 1991, ONCOGENE, V61, P787; STOLL C, 1979, LEUKEMIA RES, V3, P61, DOI 10.1016/0145-2126(79)90063-8; TAUTZ D, 1990, BIOESSAYS, V12, P44, DOI 10.1002/bies.950120111; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2200; WOOD S, 1991, NUCLEIC ACIDS RES, V19, P6664, DOI 10.1093/nar/19.23.6664-a; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1978, TNM CLASSIFICATION M, P113; 1973, INT HISTOLOGICAL CLA; 1991, CYTOGENET CELL GENET, V58, P1	44	192	194	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1357	1364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097582				2022-12-25	WOS:A1993KY32800029
J	CHARPENTIER, N; PREZEAU, L; CARRETTE, J; BERTORELLI, R; LECAM, G; MANZONI, O; BOCKAERT, J; HOMBURGER, V				CHARPENTIER, N; PREZEAU, L; CARRETTE, J; BERTORELLI, R; LECAM, G; MANZONI, O; BOCKAERT, J; HOMBURGER, V			TRANSFECTED G01-ALPHA INHIBITS THE CALCIUM-DEPENDENCE OF BETA-ADRENERGIC STIMULATED CAMP ACCUMULATION IN C6 GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GLIAL TUMOR-CELLS; ADENYLATE-CYCLASE; GAMMA-SUBUNITS; ALPHA-SUBUNIT; CYCLIC-AMP; RAT; GO; MECHANISM; BRAIN	Increasing evidence indicates that heterotrimeric G proteins, and in particular G(o), regulate ionic channel activities. In order to investigate the role of G(o) proteins in the modulation of the Ca2+ influx, C6 glioma cells were stably transfected with alpha(o1) cDNA. Expression of the G(o1)alpha protein was checked by Bordetella pertussis toxin-catalyzed ADP-ribosylation and Western blots using one- and two-dimensional gel analyses. Three clones were selected based on their degree of G(o1)alpha expression. In alpha(o1)-transfected cells, cAMP accumulations, in response to isoproterenol or forskolin, were lower than in control cells. This inhibitory effect was a function of the amount of expressed G(o1)alpha. In contrast, G(o1)alpha expression was not followed by a significant inhibition of isoproterenol- or forskolin-stimulated adenylyl cyclase activities in particulate fractions. In C6 parental cells, 50-60% of the isoproterenol-induced cAMP accumulation was dependent on external Ca2+ concentration. This Ca2+-dependent cAMP accumulation was related to an induced transient Ca2+ influx. In transfected cells, expression of G(o1)alpha inhibited the Ca2+ influx and the Ca2+-dependent component of isoproterenol-induced cAMP accumulation. In conclusion, beta-adrenergic agonists stimulate an entry of Ca2+ which exerts a positive feedback on cAMP production, and G(o1)alpha blocks this positive feedback by inhibiting the Ca2+ influx.	CNRS,INSERM,RUE CARDONVILLE,F-34094 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Manzoni, Olivier/M-7899-2016; bertorelli, rosalia/A-2989-2012	Manzoni, Olivier/0000-0002-5579-6208; BERTORELLI, Rosalia/0000-0002-7913-3564				ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; BOCKAERT J, 1990, G PROTEINS, P81; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRABET P, 1988, J NEUROSCI, V8, P701; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BRABET P, 1988, BIOCHEM BIOPH RES CO, V152, P1185, DOI 10.1016/S0006-291X(88)80410-8; BROSTROM MA, 1983, MOL PHARMACOL, V23, P399; BROSTROM MA, 1979, J BIOL CHEM, V254, P7548; BROWNING ET, 1974, MOL PHARMACOL, V12, P32; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P6111; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; DOORE BJ, 1975, J BIOL CHEM, V250, P4371; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HOMBURGER V, 1980, J BIOL CHEM, V255, P436; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATADA T, 1982, J BIOL CHEM, V257, P3739; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUCAS M, 1977, MOL PHARMACOL, V13, P314; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARES V, 1981, EXP NEUROL, V71, P154, DOI 10.1016/0014-4886(81)90078-9; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MURPHY PM, 1992, J BIOL CHEM, V267, P883; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OEY J, 1975, NATURE, V257, P317, DOI 10.1038/257317a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROUOT B, 1992, MOL PHARMACOL, V41, P273; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VITKOVIC L, 1988, P NATL ACAD SCI USA, V85, P8296, DOI 10.1073/pnas.85.21.8296; WEISS S, 1985, J NEUROCHEM, V45, P864; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8980	8989						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8097196				2022-12-25	WOS:A1993KX81100087
J	LABORDA, J; SAUSVILLE, EA; HOFFMAN, T; NOTARIO, V				LABORDA, J; SAUSVILLE, EA; HOFFMAN, T; NOTARIO, V			DLK, A PUTATIVE MAMMALIAN HOMEOTIC GENE DIFFERENTIALLY EXPRESSED IN SMALL-CELL LUNG-CARCINOMA AND NEUROENDOCRINE TUMOR-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; DROSOPHILA-MELANOGASTER; BLOOD-COAGULATION; SEQUENCE; NOTCH; PROTEINS; DELTA; ENCODES; CANCER; IDENTIFICATION	Gastrin releasing peptide is mitogenic for mouse Swiss 3T3 fibroblasts and certain human small cell lung carcinoma (SCLC) cells but not for mouse Balb/c 3T3 fibroblasts. To identify new molecules associated with the gastrin releasing peptide-responsive phenotype, clones isolated from a differential cDNA library between Swiss and Balb/c 3T3 fibroblasts were used to screen for their expression in human SCLC cell lines. Using this approach, we have isolated and characterized human and mouse cDNA clones encoding a novel protein. This protein is a putative transmembrane protein belonging to the epidermal growth factor-like superfamily. In vitro transcription and translation studies detect a 42-kDa protein, in agreement with the size predicted from the translated cDNA sequence. This protein (termed Delta-like or dlk) is highly homologous to invertebrate homeotic proteins, including Delta, and Notch, the products of neurogenic loci involved in normal neural differentiation in Drosophila. dlk is expressed in tumors with neuroendocrine features, such as neuroblastoma, pheochromocytoma, and a subset of SCLC cell lines. However, its expression in normal tissues is restricted to the adrenal gland and placenta. These data suggest that dlk may be involved in neuroendocrine differentiation and, because of its cellular location and restricted expression in normal tissues, it may be a potential therapeutic target in neuroendocrine tumors, particularly SCLC.	US FDA,CTR BIOLOG EVALUAT & RES,BETHESDA,MD 20892; GEORGETOWN UNIV,DEPT MED,DIV MED ONCOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	US Food & Drug Administration (FDA); Georgetown University; Georgetown University			/AFP-0764-2022; Laborda, Jorge/L-5726-2014; /AAB-6461-2022	Laborda, Jorge/0000-0002-9210-838X; 				Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAIROCH A, 1990, THESIS U GENEVA GENE; Battey, 1986, BASIC METHODS MOL BI; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CARNEY DN, 1985, CANCER RES, V45, P2913; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAZDAR AF, 1985, CANCER RES, V45, P2924; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HURSH DA, 1987, SCIENCE, V237, P1487, DOI 10.1126/science.3498216; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KOPCZYNSKI CC, 1990, MOL REPROD DEV, V27, P28, DOI 10.1002/mrd.1080270108; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; SHEPHERD JCW, 1990, METHOD ENZYMOL, V188, P180; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	33	193	209	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3817	3820						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095043				2022-12-25	WOS:A1993KN53300006
J	KADOHAMA, T; TSUJI, K; OGAWA, K				KADOHAMA, T; TSUJI, K; OGAWA, K			INDISTINCT CELL-CYCLE CHECKPOINT AFTER UV DAMAGE IN H-RAS-TRANSFORMED MOUSE-LIVER CELLS DESPITE NORMAL P53 GENE-EXPRESSION	ONCOGENE			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA DAMAGE; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GROWTH ARREST; PROTEIN; AMPLIFICATION; INDUCTION	Growth arrest after u.v. damage was investigated in C3H mouse primary cultured hepatocytes, spontaneously immortalized liver epithelial cells and their H-ras-transformed derivatives. All cells except for one of the transformed lines had the wild type p53 gene considered necessary for the G1-S checkpoint. Growth arrest and accumulation of p53 protein with an abnormally-extended half-life were observed after 8 J/m(2) u.v. treatment in primary hepatocytes and immortalized cells, but the arrest was much less evident in H-ras-transformed cells, in spite of the presence of the wild type p53 gene and accumulation of p53. Thus, the signal transduction upstream of p53 in the p53-mediated G1-S checkpoint may be retained in these transformed cell lines, although its downstream signal transduction or a pathway totally independent of this system could be altered. The transformed cells showed a much wider distribution of chromosomal number as compared to normal and immortalized cells, indicating that progression from the immortal to transformed state is associated with chromosomal instability, together with much decrease in the cell cycle checkpoint function.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College				Kadohama, Takayuki/0000-0002-5175-748X				BAARK Y, 1993, EMBO J, V12, P461; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUDA I, 1993, MOL CARCINOGEN, V7, P257, DOI 10.1002/mc.2940070408; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P926; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIMORI H, IN PRESS INT J CANCE; OLSON DC, 1993, ONCOGENE, V8, P2353; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; POPESCU NC, 1972, CYTOGENETICS, V11, P500, DOI 10.1159/000130216; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TISHLER RB, 1993, CANCER RES, V53, P2212; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2845	2852						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084590				2022-12-25	WOS:A1994PG82200010
J	PASTOREK, J; PASTOREKOVA, S; CALLEBAUT, I; MORNON, JP; ZELNIK, V; OPAVSKY, R; ZATOVICOVA, M; LIAO, S; PORTETELLE, D; STANBRIDGE, EJ; ZAVADA, J; BURNY, A; KETTMANN, R				PASTOREK, J; PASTOREKOVA, S; CALLEBAUT, I; MORNON, JP; ZELNIK, V; OPAVSKY, R; ZATOVICOVA, M; LIAO, S; PORTETELLE, D; STANBRIDGE, EJ; ZAVADA, J; BURNY, A; KETTMANN, R			CLONING AND CHARACTERIZATION OF MN, A HUMAN TUMOR-ASSOCIATED PROTEIN WITH A DOMAIN HOMOLOGOUS TO CARBONIC-ANHYDRASE AND A PUTATIVE HELIX-LOOP-HELIX DNA-BINDING SEGMENT	ONCOGENE			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; AMINO-ACID SEQUENCES; HUMAN CELL HYBRIDS; SECONDARY STRUCTURE; NEGATIVE REGULATOR; EXPRESSION; MOTIF; TUMORIGENICITY; TRANSCRIPTION; EFFICIENT	MN is a transmembrane glycoprotein that has been detected in HeLa cells and in some human carcinomas. The expression of MN protein in HeLa cells is regulated by cell density. In HeLa x fibroblast cell. hybrids its expression correlates,vith tumorigenicity. Using a specific monoclonal antibody we have identified a cDNA clone coding for MN. Analysis of the deduced amino acid sequence revealed strong structural homology between the central region of the MN protein and carbonic anhydrases (CA). MN sequence retains the conserved zinc-binding site as well as the enzyme's active center. In accord with these findings, MN protein from HeLa cells was found to bind zinc and to have carbonic anhydrase activity. The N-terminal region of MN shares some similarity with DNA binding proteins of the helix-loop-helix (HLH) family, and the protein was found to have affinity for DNA by DNA-cellulose chromatography. The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors. The fact that MN protein is detectable in several types of human carcinomas, but not in corresponding non-cancerous tissues, suggests its possible role in neoplasia. In addition, the analysis of biological consequences of MN expression of NIH3T3 cells provides the evidence in favour of MN protein involvement in control of cell proliferation and transformation.	FAC AGR SCI GEMBLOUX, DEPT MOLEC BIOL, B-5030 GEMBLOUX, BELGIUM; UNIV BRUSSELS, DEPT MOLEC BIOL, B-1640 RHODE ST GENESE, BELGIUM; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOLEC GENET, IRVINE, CA 92717 USA; UNIV PARIS 06, DEPT BIOL MACROMOLEC, MINERAL CRYSTALLO LAB, F-75252 PARIS 05, FRANCE; UNIV DENIS DIDEROT, F-75252 PARIS 05, FRANCE	University of California System; University of California Irvine; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	PASTOREK, J (corresponding author), SLOVAK ACAD SCI, INST VIROL, BRATISLAVA 84246, SLOVAKIA.		Zaťovičová, Miriam/ABA-3268-2021; Zelnik, Vladimir/AAS-4952-2020; Pastorekova, Silvia/C-6685-2018	Zaťovičová, Miriam/0000-0002-8682-4232; 				ALDRED P, 1991, BIOCHEMISTRY-US, V30, P569, DOI 10.1021/bi00216a035; AUSUBEL FM, 1989, SHORT PROTOCOLS MOL, P387; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODGSON JS, 1991, CARBONIC ANHYDRASES, P398; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIAO SY, 1994, IN PRESS AM J PATHOL; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STEIN CA, 1988, CANCER RES, V48, P2659; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVADA J, 1972, NATURE-NEW BIOL, V240, P124, DOI 10.1038/newbio240124a0; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218	39	445	492	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2877	2888						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084592				2022-12-25	WOS:A1994PG82200013
J	PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV				PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV			CELL-CYCLE PROGRESSION, MORPHOLOGY AND CONTACT INHIBITION ARE REGULATED BY THE AMOUNT OF SV40 T-ANTIGEN IN IMMORTAL HUMAN-CELLS	ONCOGENE			English	Article							HUMAN-FIBROBLASTS	Expression of Simian Virus 40 (SV40) T antigen in human dermal fibroblasts over-rides the normal controls on cell division leading to changes in cellular proliferation and life span. These changes are accompanied by other changes in cell morphology, expression of cell specific functions, and altered cell-cell interactions. In this study, we have examined the effects of different amounts of T antigen on cell cycle progression, life span and morphology in human dermal fibroblasts and demonstrated T antigen to be a concentration dependent regulator of the cell cycle. Using a novel, metal inducible episomal expression vector (p735.6) which produces low basal levels of protein but high (greater than 100-fold) levels of induction, we have compared the effects of low and high levels of T antigen expression in a precrisis and immortalised human line (1BRMT1). The presence of inducing agent led to maximal levels of T antigen expression and resulted in cultures with a high rate of proliferation, an extended in vitro life span, a loss of contact inhibition of growth and a morphology characteristic of SV40-transformed cells. In the absence of inducing agent, read-through of the T antigen gene resulted in low but detectable levels of protein. The reduction in T antigen levels was accompanied by a 50% or greater reduction in the proliferative rate and restoration of cell morphology and contact inhibition similar to that found in non-transfected cells. The results presented here demonstrate that low amounts of T antigen are sufficient to maintain cell viability and prevent the re-expression of the senescent phenotype seen in the absence of T antigen. Similarly, the ability of T antigen to extend the in vitro life span is not dependent on high level expression of T antigen. In contrast, the rate of proliferation of human cells as well as the cell morphology and contact inhibition are dependent on the amount of T antigen present. Many of the cellular effects can be minimised or reversed by reducing T antigen expression.	UNIV SUSSEX,TRAFFORD CTR MED RES,DIV BIOL SCI,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Brighton; University of Sussex								MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; OGRIS E, 1993, ONCOGENE, V8, P1277; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; Sambrook J, 1989, MOL CLONING LABORATO; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SLADEK TL, 1992, ONCOGENE, V7, P1305; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	7	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2897	2904						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084594				2022-12-25	WOS:A1994PG82200015
J	KARLSSON, OP; DAHLQVIST, A; WIESLANDER, A				KARLSSON, OP; DAHLQVIST, A; WIESLANDER, A			ACTIVATION OF THE MEMBRANE GLUCOLIPID SYNTHESIS IN ACHOLESPLASMA-LAIDLAWII BY PHOSPHATIDYLGLYCEROL AND OTHER ANIONIC LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHOLEPLASMA-LAIDLAWII; BILAYER-MEMBRANES; ESCHERICHIA-COLI; PROTEIN; GALACTOSYLTRANSFERASE; PHOSPHOLIPIDS; BIOSYNTHESIS; ADSORPTION; DETERGENTS; CATIONS	In membrane lipids of the prokaryote Acholeplasma laidlawii similar phase equilibria and a nearly constant spontaneous curvature are maintained by an extensive metabolic regulation of especially the major polar lipids monoglucosyldiacylglycerol (MGlcDAG) and diglucosyldiacylglycerol (DGlcDAG), forming nonlamellar and lamellar phases, respectively. A constant surface charge density is maintained by the anionic phospholipid fraction. These lipids are synthesized from phosphatidic acid in two competing pathways. The in vitro synthesis of MGlcDAG and DGlcDAG were totally lost upon delipidation of the membrane proteins by detergent solubilization or solvent extraction of lyophilized cells. Activities were restored by critical concentrations of anionic lipids, but not by bilayer or nonbilayer zwitterionic phospholipids or glucolipids. Phosphatidylglycerol (PG), and to a lesser extent certain other anionic lipids, could activate the synthesis of MGlcDAG in lipid bilayers, whereas the synthesis of DGlcDAG was similarly dependent upon PG only. Two endogenous phosphoglucolipids with no activating potency could partially replace the PG activator for the MGlcDAG synthesis but less so for DGlcDAG formation. A change of inert matrix from phosphatidylcholine to DGlcDAG lowered the apparent cooperativity, but enhanced the efficiency, of activation by PG for both glucolipid synthesizing enzymes, most strongly the synthesis of DGlcDAG. These results indicate that the enzymatic formation of MGlcDAG is regulated by the lipid surface charge density, whereas the consecutive step to DGlcDAG is more dependent upon the specific properties of PG. The modulating effect of the surrounding matrix on the activator efficiencies and cooperativity may constitute part of the bilayer-nonbilayer lipid regulation mechanism.			KARLSSON, OP (corresponding author), UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN.							BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHRISTIANSSON A, 1985, J BIOL CHEM, V260, P3984; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; EFRATI H, 1986, ARCH BIOCHEM BIOPHYS, V248, P282, DOI 10.1016/0003-9861(86)90425-X; EISENBERG M, 1979, BIOCHEMISTRY-US, V18, P5213, DOI 10.1021/bi00590a028; ERIKSSON PO, 1991, BIOCHEMISTRY-US, V30, P4916, DOI 10.1021/bi00234a012; FLEISCHER S, 1967, J CELL BIOL, V32, P193, DOI 10.1083/jcb.32.1.193; GEORGE R, 1989, J BIOL CHEM, V264, P11598; HAUKSSON JB, 1994, IN PRESS BIOCH BIOPH; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P72, DOI 10.1016/0003-2697(83)90651-6; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; LAU A, 1981, BIOCHIM BIOPHYS ACTA, V645, P279, DOI 10.1016/0005-2736(81)90199-1; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LINDBLOM G, 1993, J BIOL CHEM, V268, P16198; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; McElhaney Ronald N., 1992, P231; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; NESKOVIC NM, 1986, J NEUROCHEM, V47, P1412, DOI 10.1111/j.1471-4159.1986.tb00773.x; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; NYSTROM S, 1992, EUR J BIOCHEM, V204, P231, DOI 10.1111/j.1432-1033.1992.tb16629.x; PIERINGER RA, 1968, J BIOL CHEM, V243, P4894; PIKNOVA B, 1993, EUR J BIOCHEM, V218, P385, DOI 10.1111/j.1432-1033.1993.tb18388.x; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Rilfors L., 1984, Biomembranes, V12, P205; RILFORS L, 1987, J BACTERIOL, V169, P830, DOI 10.1128/jb.169.2.830-838.1987; Rilfors L, 1993, Subcell Biochem, V20, P109; SANDERMANN H, 1986, J BIOL CHEM, V261, P6201; SANDERMANN H, 1986, PROGR PROTEIN LIPID, V2, P197; SMITH PF, 1969, J BACTERIOL, V99, P480, DOI 10.1128/JB.99.2.480-486.1969; STEINICK LE, 1980, J BACTERIOL, V143, P1200, DOI 10.1128/JB.143.3.1200-1207.1980; WEBB MS, 1991, BIOCHIM BIOPHYS ACTA, V1060, P133, DOI 10.1016/S0005-2728(09)91002-7; WIESLANDER A, 1977, BIOCHIM BIOPHYS ACTA, V466, P336, DOI 10.1016/0005-2736(77)90229-2; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; WIESLANDER A, 1994, BBA-BIOMEMBRANES, V1191, P331, DOI 10.1016/0005-2736(94)90184-8	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23484	23490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089114				2022-12-25	WOS:A1994PQ34500019
J	STAAB, JF; GINKEL, DL; ROSENBERG, GB; MUNFORD, RS				STAAB, JF; GINKEL, DL; ROSENBERG, GB; MUNFORD, RS			A SAPOSIN-LIKE DOMAIN INFLUENCES THE INTRACELLULAR-LOCALIZATION, STABILITY, AND CATALYTIC ACTIVITY OF HUMAN ACYLOXYACYL HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACYLATES BACTERIAL LIPOPOLYSACCHARIDES; LEUKOCYTE ENZYME; CELLS; EXPRESSION; PROTEINS; BINDING; LIPASE; FAMILY	Acyloxyacyl hydrolase, a leukocyte enzyme that acts on bacterial lipopolysaccharides (LPSs) and many glycerolipids, is synthesized as a precursor polypeptide that undergoes internal disulfide linkage before being proteolytically processed into two subunits. The larger subunit contains an amino acid sequence (Gly-X-Ser-X-Gly) that is found at the active sites of many lipases, while the smaller subunit has amino acid sequence similarity to saposins (sphingolipid activator proteins), cofactors for sphingolipid glycohydrolases. We show here that both acyloxyacyl hydrolase subunits are required for catalytic activity toward LPS and glycerophosphatidylcholine. In addition, mutations that truncate or delete the small subunit have profound effects on the intracellular localization, proteolytic processing, and stability of the enzyme in baby hamster kidney cells. Remarkably, proteolytic cleavage of the precursor protein increases the activity of the enzyme toward LPS by 10-20-fold without altering its activity toward glycerophosphatidylcholine. Proper orientation of the two subunits thus seems very important for the substrate specificity of this unusual enzyme.	UNIV TEXAS, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED SCH, DEPT MICROBIOL, DALLAS, TX 75235 USA; ZYMOGENET INC, SEATTLE, WA 98102 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Zymogenet Inc.					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018188, R01AI018188, R56AI018188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1978, J BIOL CHEM, V253, P1357; Anderson R G, 1986, Methods Enzymol, V129, P201; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHI M, 1993, J IMMUNOL, V151, P959; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MORIMOTO S, 1990, J BIOL CHEM, V265, P2933; MUNFORD RS, 1992, METHOD ENZYMOL, V209, P485; MUNFORD RS, 1992, J BIOL CHEM, V267, P10116; MUNFORD RS, 1990, INT CONGR SER, V923, P305; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0	21	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23736	23742						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089145				2022-12-25	WOS:A1994PQ34500054
J	GORLACH, M; BURD, CG; DREYFUSS, G				GORLACH, M; BURD, CG; DREYFUSS, G			THE DETERMINANTS OF RNA-BINDING SPECIFICITY OF THE HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-C PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICE JUNCTION SEQUENCES; U1 RNA; HNRNP PROTEINS; A-PROTEIN; DOMAIN; PARTICLES; COMPLEXES; COMPONENT; MOTIF	The hnRNP C proteins (C1/C2) are tenacious nuclear pre-mRNA-binding proteins that belong to the large RNP motif family of RNA-binding proteins. This motif identifies an RNA-binding domain (RBD) that consists of a four-stranded antiparallel beta-sheet packed against two cy-helices. Despite considerable information on the structure of the hnRNP C RBD, little is known about its RNA-binding properties. To address this we used in vitro selection/amplification from pools of random sequence RNA to determine the RNA-binding specificity of hnRNP C1. After 8 rounds of selection/amplification nearly all RNAs contained contiguous stretches of at least 5 U residues, and filter-binding assays demonstrated that this sequence constitutes a high-affinity (K-d = 170 nM) binding site for hnRNP C1. The highest affinity we measured for hnRNP C1 was for r(U)(14) (K-d = 14 nM). An RBD-containing peptide fragment of hnRNP C1 (amino acids 2-94) bound oligoribonucleotides containing an hnRNP C1 high-affinity binding site with nearly equal affinity to that of hnRNP C1. Unlike hnRNP C1, however, this peptide also bound oligoribonucleotides that do not contain high-affinity hnRNP C1-binding sites. We identified a region of 10 amino acids, immediately COOH-terminal to the RNP motif (amino acids 95-104), that prevents the minimal RBD from binding nonspecific RNA Ligands. We propose that the highly conserved beta alpha beta beta alpha beta core structure of the RNP motif RBD confers a general RNA binding activity to RNP motif RBDs and that the determinants of RNA-binding specificity reside in the most variable regions, the loops connecting the beta-strands and/or the contiguous NH2 and COOH termini of the RBD.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774; Burd, Christopher/0000-0003-1831-8706				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COHIANCHI F, 1988, J BIOL CHEM, V263, P1063; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1993, MOL BIOL REP, V18, P73, DOI 10.1007/BF00986759; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1994, IN PRESS STRUCTURE F; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHWEMMLE M, 1989, FEBS LETT, V251, P117, DOI 10.1016/0014-5793(89)81439-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	55	145	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23074	23078						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083209				2022-12-25	WOS:A1994PQ16400029
J	RAYCHAUDHURI, D; PARK, JT				RAYCHAUDHURI, D; PARK, JT			A POINT MUTATION CONVERTS ESCHERICHIA-COLI FTSZ SEPTATION GTPASE TO AN ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIVISION GENE-FTSZ; BETA-TUBULIN GENE; DEPENDENT PROTEIN-KINASE; ASPERGILLUS-NIDULANS; FLUORIDE COMPLEXES; BINDING PROTEINS; SEQUENCE; CLONING; SITE; SPECIFICITY	The cell division protein FtsZ, essential to initiate septum formation in Escherichia coli, is a GTPase. The thermosensitive ftsZ84 mutation, which impairs the ability of FtsZ to bind and hydrolyze GTP in vitro, maps to a short glycine-rich FtsZ segment. This region is conserved in eubacterial FtsZ homologs and is strikingly similar to the proposed GTP binding motif in the eukaryotic cytoskeletal protein tubulin. Here we show that in contrast to FtsZ, FtsZ84 protein has a Mg2+-dependent ATPase activity in vitro. This activity, unlike the wild-type GTPase, is specifically inhibited by sodium azide, a known antagonist of F-type ATPases and the bacterial SecA protein translocation ATPase (Oliver, D., Cabelli, R. J., Dolan, K. M., and Jarosik, G. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8227-8231). Conversely, aluminum fluoride abolishes FtsZ GTPase activity but only partially affects FtsZ84 ATPase. Affinity-purified anti-FtsZ antibody blocks FtsZ84 ATPase activity, indicating that this enzymatic function is intrinsic to the mutant protein. This is, to our knowledge, the first example of a missense mutation that converts a GTPase to an ATPase.			RAYCHAUDHURI, D (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111, USA.				NIGMS NIH HHS [GM 40768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BEUVE A, 1992, J MOL BIOL, V225, P933, DOI 10.1016/0022-2836(92)90093-Y; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BURKE M, 1990, FEBS LETT, V262, P185, DOI 10.1016/0014-5793(90)80185-L; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; DAI K, 1994, J BACTERIOL, V176, P130, DOI 10.1128/JB.176.1.130-136.1994; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; FARR GW, 1992, J MOL BIOL, V227, P307, DOI 10.1016/0022-2836(92)90700-T; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLDEN PR, 1993, MOL GEN GENET, V240, P213, DOI 10.1007/BF00277059; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JUNG MK, 1992, CELL MOTIL CYTOSKEL, V22, P170, DOI 10.1002/cm.970220304; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KRAAL B, 1990, EUR J BIOCHEM, V192, P305, DOI 10.1111/j.1432-1033.1990.tb19228.x; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LEE MG, 1983, CELL, V33, P477; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MARGOLIN W, 1994, J BACTERIOL, V176, P2033, DOI 10.1128/jb.176.7.2033-2043.1994; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; RENSLAND H, 1992, THESIS RUPRECHT KARL; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SHABB JB, 1990, J BIOL CHEM, V265, P16031; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YI QM, 1985, GENE, V36, P241; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	46	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22941	22944						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083192				2022-12-25	WOS:A1994PQ16400008
J	TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH			AMINO-ACIDS LYS-ASP-ASP-LYS-PRO-VAL(402) IN THE CA2+-ATPASE OF CARDIAC SARCOPLASMIC-RETICULUM ARE CRITICAL FOR FUNCTIONAL ASSOCIATION WITH PHOSPHOLAMBAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; SITE-SPECIFIC MUTAGENESIS; CALCIUM-TRANSPORT; CA-2+ PUMP; PHOSPHORYLATION; ATPASE; STIMULATION; DOMAIN	Phospholamban interacts with SERCA2 (sarco/endoplasmic reticulum calcium ATPase isoform 2) but not SERCA3. The use of chimeric SERCA2/SERCA3 molecules has revealed that amino acids 336-412 in the phosphorylation domain of SERCA2 are essential for functional association with phospholamban (Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1993) J. Biol. Chem. 268, 2809-2815). When mutations were made in SERCA2 between amino acids 336 and 412 and the mutants were coexpressed with phospholamban, only mutation of amino acids Lys(397) to Val(402) affected phospholamban association with the Ca2+-ATPase. A chimeric Ca2+-ATPase, CH2, was created in which the phosphorylation domain of SERCA2 was replaced with that of SERCA3, disrupting functional interaction with phospholamban. The SERCA3 sequence QGEQLV(402) was then mutated to the corresponding SERCA2 sequence, KDD-KPV402, and to the sequence KGEKPV(402), resulting in restoration of functional interaction with phospholamban, Mutation to KGNKPV(402) or to QGEQPV(402) did not restore functional interaction with phospholamban. These results demonstrate that amino acids Lys(397)-Val(402) comprise the interaction site with phospholamban in SERCA2, and probably also in SERCA1, and that the appropriate balance of charged and hydrophobic residues is an important feature of the interaction.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA; OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOPHYSIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; Osaka University; Osaka University								BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1993, J BIOL CHEM, V268, P11486; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; XU ZC, 1989, J BIOL CHEM, V264, P16644	19	123	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22929	22932						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083189				2022-12-25	WOS:A1994PQ16400005
J	DONG, LM; WILSON, C; WARDELL, MR; SIMMONS, T; MAHLEY, RW; WEISGRABER, KH; AGARD, DA				DONG, LM; WILSON, C; WARDELL, MR; SIMMONS, T; MAHLEY, RW; WEISGRABER, KH; AGARD, DA			HUMAN APOLIPOPROTEIN-E - ROLE OF ARGININE-61 IN MEDIATING THE LIPOPROTEIN PREFERENCES OF THE E3-ISOFORM AND E4-ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN-PLASMA-LIPOPROTEINS; RECEPTOR-BINDING DOMAIN; ALZHEIMERS-DISEASE; AQUEOUS-SOLUTION; E POLYMORPHISM; TYPE-4 ALLELE; E APOPROTEIN; PROTEIN; FIBROBLASTS	Human apolipoprotein (apo) E4 (arginine at residue 112) preferentially associates with very low density lipoproteins (VLDL), and apoE3 (cysteine at 112) associates with high density lipoproteins. It has been postulated that the amino-terminal domain, which contains residue 112, influences the lipoprotein preference by interacting with the carboxyl-terminal domain, which contains the lipid-binding region. To delineate the region in the carboxyl-terminal domain mediating lipoprotein binding and involved in isoform preference, we produced truncated apoE3 and apoE4 variants (terminating at residues 251, 260, 266, or 272) in Escherichia coli and assessed them for lipoprotein association. This analysis suggested that residues 260-272 contain important determinants for complete lipoprotein association and isoform preferences. To determine whether positive charge at residue 112 was an absolute requirement for the apoE4 VLDL preference, we compared the distributions of rabbit apoE (equivalent to apoE3, with cysteine at a position corresponding to 112), canine apoE (arginine at the corresponding site), and cysteamine-treated rabbit apoE (cysteine converted to a positively charged residue). Surprisingly, all distributed like human apoE3, suggesting that positive charge at a position corresponding to 112 was not directly responsible for the isoform preference and that other residues in the aminoterminal domain were involved. To determine which residues were involved, the structure of the apoE4 22-kDa fragment (the amino-terminal two-thirds of the molecule) was determined to 2.5 Angstrom by x-ray crystallography. Compared with the known four-helix bundle structure of apoE3, the only significant differences in the apoE4 structure were that glutamic acid 109 formed a salt bridge with arginine 112 and that the arginine 61 side chain was displaced to a new position. Site-directed mutagenesis of glutamic acid 109 in apoE3 and arginine 61 in apoE4 demonstrated that the position of the arginine 61 side chain in apoE4 was critical in determining apoE4 lipoprotein distribution, suggesting that arginine 61 interacted with the carboxyl-terminal domain to direct binding to VLDL.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,GRAD GRP BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NCRR NIH HHS [RR00083] Funding Source: Medline; NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HERZ J, 1991, J BIOL CHEM, V266, P21232; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LEE BR, 1991, J LIPID RES, V32, P165; LUO CC, 1989, J LIPID RES, V30, P1735; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RALL SC, 1982, J BIOL CHEM, V257, P4171; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGREST JP, 1992, J LIPID RES, V33, P141; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	35	258	272	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22358	22365						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071364				2022-12-25	WOS:A1994PE09800065
J	GRAZIOLI, L; CASERO, D; RESTIVO, A; COZZI, E; MARCUCCI, F				GRAZIOLI, L; CASERO, D; RESTIVO, A; COZZI, E; MARCUCCI, F			TUMOR NECROSIS FACTOR-DRIVEN FORMATION OF DISULFIDE-LINKED RECEPTOR AGGREGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEIN; GROWTH-FACTOR BINDING; FACTOR TNF RECEPTOR; FACTOR-ALPHA; CELL-SURFACE; EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; FACTOR CACHECTIN; PDGF RECEPTOR	We have characterized, by ligand blotting, solubilized tumor necrosis factor receptors (TNFR) from K562 cells. Preparations that had been partially purified by gel filtration chromatography yielded two prominent bands of M(r) 60,000 and 75,000 corresponding to the two known TNFR (types I and II, respectively). In addition to these, types I and II TNFR-related species of M(r) > 100,000 were detected after purification by tumor necrosis factor (TNF)-affinity chromatography, suggesting that TNF had driven receptor aggregation during this step. To test this hypothesis ligand blots were performed on receptor preparations that had been partially purified by gel filtration chromatography and incubated with TNF before electrophoretic separation. Indeed, type II TNFR aggregates, but not type I TNFR aggregates, were generated at optimal TNF concentrations. Formation of type II TNFR aggregates in this last experimental setting and of both type I and type II TNFR aggregates during affinity purification could be prevented if an alkylating agent (N-ethylmaleimide) was added during the TNFR-TNF incubation step. Similar results were obtained when intact K562 cells were incubated with TNF and then analyzed for receptor aggregation; type II TNF receptor aggregates were generated at TNF concentrations ranging from 10(-9) to 10(-10) M and their formation was prevented in the presence of N-ethylmaleimide.			GRAZIOLI, L (corresponding author), PHARMACIA FARMITALIA CARLO ERBA,CTR RIC,ONCOL IMMUNOL RES & DEV,VIA GIOVANNI XXIII 23,I-20014 NERVIANO,ITALY.			marcucci, fabrizio/0000-0002-2977-294X				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; EHRKE MJ, 1988, CANCER IMMUNOL IMMUN, V27, P103; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1992, J BIOL CHEM, V267, P15970; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LIN PH, 1987, BIOCHEMISTRY-US, V26, P731, DOI 10.1021/bi00377a012; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; METZGER H, 1992, J IMMUNOL, V149, P1477; NAKANO Y, 1990, J IMMUNOL, V144, P1935; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; PORTEU F, 1991, J BIOL CHEM, V266, P18864; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1986, INT J CANCER, V38, P126; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH JG, 1990, J INFECT DIS, V162, P1349, DOI 10.1093/infdis/162.6.1349; SMITH RA, 1989, J BIOL CHEM, V264, P14646; SUAN DSR, 1991, J BIOL CHEM, V266, P413; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS DM, 1990, INFECT IMMUN, V58, P1572, DOI 10.1128/IAI.58.6.1572-1576.1990; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	47	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22304	22309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071357				2022-12-25	WOS:A1994PE09800058
J	STEINFORT, J; VANDESTADT, R; BEERTSEN, W				STEINFORT, J; VANDESTADT, R; BEERTSEN, W			IDENTIFICATION OF NEW RAT DENTIN PROTEOGLYCANS UTILIZING C18 CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-CELLS-INVITRO; MATRIX PROTEINS; SULFATE PROTEOGLYCAN; ARTICULAR-CARTILAGE; SIALOPROTEIN-II; GLYCOSAMINOGLYCANS; INCISOR; ENAMEL; MINERALIZATION; COMPONENTS	Although only one small PG has been identified in dentin until now, a preliminary investigation has shown indications of the presence of several new proteoglycans (PGs) in rat incisor dentin. The aim of the present investigation was to isolate and characterize these PGs, which were labeled with S-35 to facilitate the analysis. C18 chromatography resolved five dentin PGs. Based on SDS-polyacrylamide gel electrophoresis, their size varied from 100 to 400 kDa. The core proteins of the first four PGs appeared as 25, 40, 70, and 115 kDa bands. They stained turquoise with Stains Ah but did not stain with Coomassie Brilliant Blue. The core protein of the fifth PG appeared at about 45 kDa. This core protein stained with Coomassie Brilliant Blue but not with Stains All. In all PGs, the glycosaminoglycans consisted mainly of chondroitin 4-sulfate. To investigate their incorporation into predentin (young dentin that is not yet mineralized) and dentin, rat dentin PGs were pulse-labeled by injecting rats with [S-35]sulfate at 5, 28, 55, or 177 h before killing the animals. Radiolabeling of predentin PGs was highest after 5 h and decreased rapidly (76%) over the next 50 h. In dentin PGs, a large percentage (34%) of the final quantity of incorporated S-35 (at 177 h) was already present at 5 h. C18 chromatography of dentin PGs for each of the four time intervals showed similar S-35 distribution patterns representing all five PGs, whereas the predentin appeared to contain mainly the fifth PC;. This study demonstrates the existence of several apparently novel PGs in dentin that can be resolved by the use of a new method. These PGs were found in mineralized dentin and are thought to be rapidly transported toward the mineralization front. Part of the predentin PGs, on the other hand, seems to be lost as mineralization proceeds.	JAN VAN BREEMEN INST,CTR RHEUMATOL & REHABIL,1056 AB AMSTERDAM,NETHERLANDS		STEINFORT, J (corresponding author), UNIV AMSTERDAM,FAC MED,CELL BIOL & HISTOL LAB,ACAD CTR DENT AMSTERDAM,DEPT PERIODONTOL,1105 AZ AMSTERDAM,NETHERLANDS.		Beertsen, Wouter/B-5308-2013	Beertsen, Wouter/0000-0001-5698-5986				BERESFORD JN, 1987, J BIOL CHEM, V262, P17164; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOSKEY AL, 1991, CRIT REV ORAL BIOL M, V2, P369, DOI 10.1177/10454411910020030501; BOSKEY AL, 1989, BONE MINER, V6, P111, DOI 10.1016/0169-6009(89)90044-5; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHOI HU, 1989, J BIOL CHEM, V264, P2876; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FEDARKO NS, 1990, J BIOL CHEM, V265, P12200; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GOLDBERG HA, 1988, J BIOL CHEM, V263, P12092; HJERPE A, 1979, J CHROMATOGR, V171, P339, DOI 10.1016/S0021-9673(01)95313-0; IBARAKI K, 1986, J STOMATOL SOC JPN, V53, P699; Jones S. J., 1984, DENTIN DENTINOGENESI, P81; KENNEDY JS, 1957, J ANAT, V91, P398; KINNE RW, 1987, J BIOL CHEM, V262, P10206; KORVER GHV, 1990, MATRIX, V10, P394, DOI 10.1016/S0934-8832(11)80147-2; LINDE A, 1980, J BIOL CHEM, V255, P5931; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; LINDE A, 1984, DENTIN DENTINOGENESI, V2, P55; LUSSI A, 1988, ARCH ORAL BIOL, V33, P685, DOI 10.1016/0003-9969(88)90124-0; PEARSON CH, 1975, CONNECT TISSUE RES, V3, P195, DOI 10.3109/03008207509152179; PRINCE CW, 1984, BIOCHEM J, V224, P941, DOI 10.1042/bj2240941; RAHEMTULLA F, 1984, BIOCHEM J, V218, P877, DOI 10.1042/bj2180877; RAHEMTULLA F, 1981, 1ST P INT C CHEM BIO, P389; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; STEINFORT J, 1990, J DENT RES, V69, P1287, DOI 10.1177/00220345900690061301; STEINFORT J, 1989, J BIOL CHEM, V264, P2840; SUNDSTROM B, 1971, HISTOCHEMISTRY, V26, P61, DOI 10.1007/BF00307784; TAKAGI M, 1990, J HISTOCHEM CYTOCHEM, V38, P319, DOI 10.1177/38.3.1689334; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; VEIS A, 1989, BIOMINERALISATION, P289; WEINSTOCK A, 1972, J CELL BIOL, V55, P276; Wheeler A.P., 1989, P95; YANAGISHITA M, 1979, J BIOL CHEM, V254, P911; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22397	22404						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071368				2022-12-25	WOS:A1994PE09800071
J	BROWN, JC; JONES, AM				BROWN, JC; JONES, AM			MAPPING THE AUXIN-BINDING SITE OF AUXIN-BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLEOPTILE MEMBRANES; MAIZE COLEOPTILES; PLASMA-MEMBRANE; ACID; PEPTIDE; GROWTH; KDEL	Auxin-binding protein 1 (ABP1) is a putative receptor for the class of plant growth hormones designated auxins of which indole-3-acetic acid (IAA) is the predominant endogenous member. ABP1 is a homodimeric glycoprotein consisting of subunits of 163 amino acid residues. We have performed a structural study of ABP1 that has localized a region along its primary sequence that is involved in hormone binding, We have used the photoaffinity labeling agent, 5-[7-H-3]azidoindole-3-acetic acid (5-[H-3]N(3)IAA), an active auxin analog, to covalently label residues that are within, or near, the auxin-binding site. Photolabeled ABP1 was digested to completion with trypsin, and the resulting peptides were purified by reverse phase high performance liquid chromatography. When 5-[H-3]N(3)IAA was used at a concentration of 0.5 mu M (one order of magnitude below the K-d for 5-N(3)IAA) only one peptide was labeled at a high specific activity, Labeling was blocked by the presence of 50 mu M IAA, indicating that the interaction is specific, Sequence analysis determined that this tryptic fragment was derived from ILe(130) to Leu(145) of ABP1. We suggest that residue Asp(134) is the specific target of the photolabeling and is within 1.48 Angstrom of the postulated hydrophobic platform of the auxin-binding site. We propose that Trp(136) may serve as this hydrophobic platform in the binding site for the aromatic rings of auxins.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill								BARRIERBRYGOO H, 1989, P NATL ACAD SCI USA, V86, P891, DOI 10.1073/pnas.86.3.891; BRINEGAR AC, 1988, P NATL ACAD SCI USA, V85, P5927, DOI 10.1073/pnas.85.16.5927; CHIRIAC A, 1983, EUR J MED CHEM, V18, P507; CLELAND RE, 1987, PHYSL CELL EXPANSION, P18; Davies P. J., 1987, PLANT HORMONES THEIR; EDGERTON MD, 1994, PHYTOCHEMISTRY, V35, P1111, DOI 10.1016/S0031-9422(00)94807-6; JONES AM, 1984, PLANT PHYSIOL, V74, P295, DOI 10.1104/pp.74.2.295; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; JONES AM, 1991, PLANT PHYSIOL, V97, P352, DOI 10.1104/pp.97.1.352; JONES AM, 1989, PLANTA, V179, P409, DOI 10.1007/BF00391088; JONES AM, 1989, P NATL ACAD SCI USA, V86, P6153, DOI 10.1073/pnas.86.16.6153; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; KATEKAR GF, 1979, PHYTOCHEMISTRY, V18, P223, DOI 10.1016/0031-9422(79)80059-X; LOBLER M, 1985, J BIOL CHEM, V260, P9848; MELHADO LL, 1981, PLANT PHYSIOL, V68, P469, DOI 10.1104/pp.68.2.469; MELHADO LL, 1982, PHYTOCHEMISTRY, V21, P2879, DOI 10.1016/0031-9422(80)85060-6; NAPIER RM, 1992, J CELL SCI, V102, P261; NAVE JF, 1984, PLANT PHYSIOL, V74, P1035, DOI 10.1104/pp.74.4.1035; RAKHAMINOVA AB, 1978, BIOCHEMISTRY-MOSCOW+, V43, P639; RAY PM, 1977, PLANT PHYSIOL, V60, P585, DOI 10.1104/pp.60.4.585; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SCHWOB E, 1993, PLANT J, V4, P423, DOI 10.1046/j.1365-313X.1993.04030423.x; SENN AP, 1988, PLANT PHYSIOL, V88, P131, DOI 10.1104/pp.88.1.131; SHIMOMURA S, 1988, PLANTA, V175, P558, DOI 10.1007/BF00393079; THIEL G, 1993, P NATL ACAD SCI USA, V90, P11493, DOI 10.1073/pnas.90.24.11493; VENIS MA, 1992, P NATL ACAD SCI USA, V89, P7208, DOI 10.1073/pnas.89.15.7208; VENIS MA, 1977, PLANTA, V134, P145, DOI 10.1007/BF00384963; VIOLA G, 1991, THESIS U BONN	28	35	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21136	21140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063734				2022-12-25	WOS:A1994PC40300050
J	HOBBIE, L; FISHER, AS; LEE, S; FLINT, A; KRIEGER, M				HOBBIE, L; FISHER, AS; LEE, S; FLINT, A; KRIEGER, M			ISOLATION OF 3 CLASSES OF CONDITIONAL-LETHAL CHINESE-HAMSTER OVARY CELL MUTANTS WITH TEMPERATURE-DEPENDENT DEFECTS IN LOW-DENSITY-LIPOPROTEIN RECEPTOR STABILITY AND INTRACELLULAR MEMBRANE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTOR; DECAY-ACCELERATING FACTOR; FLUID-PHASE ENDOCYTOSIS; O-LINKED GLYCOSYLATION; MEDIATED ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; LDL RECEPTOR; END4 MUTANT; CHOLESTEROL DEPOSITION	Fluorescence-activated cell sorting was used to isolate 19 independent, temperature-sensitive, low density lipoprotein (LDL) receptor-deficient Chinese hamster ovary cell mutants that define three recessive complementation groups, IdlE, ldlF, ldlG. LDL receptor activity, essentially normal at the permissive temperature (34 degrees C), was virtually abolished in the mutants after incubation for 8-12 h at the nonpermissive temperature (39-40.5 degrees C). The mutants died after incubation for >24 h at 39.5 degrees C. These mutants exhibited two striking and unexpected abnormalities that suggest that they define three genes important for general vesicular membrane traffic. First, LDL receptors were degraded abnormally rapidly at the nonpermissive temperature (chloroquine inhibited this degradation in ldlE and ldlG, but not in ldlF). In IdlE cells, the rapid degradation did not require efficient receptor clustering into coated pits and was not observed for all cell surface proteins. This selective degradation may be due to endocytic missorting. Second, the mutants exhibited temperature-sensitive defects in the posttranslational processing and intracellular transport of many membrane-associated and secreted proteins, including the LDL, mannose 6-phosphate/insulin-like growth factor II, and scavenger receptors, the vesicular stomatitis virus G protein and decay accelerating factor. Although the initial synthesis, folding, and processing of precursor forms of these proteins in the endoplasmic reticulum were apparently normal at the nonpermissive temperature, there was either a delay or a block in oligosaccharide processing associated with endoplasmic reticulum to medial Golgi transport at the nonpermissive temperature. This was accompanied by a dramatic inhibition of total soluble protein secretion. The posttranslational processing defects, the instability of cell surface LDL receptors, and the defective protein secretion exhibited by these mutants suggest that the ldlE-G gene products regulate or participate in reactions that are vital for a variety of secretory and endocytic membrane transport processes. This suggestion is strongly supported by our recent observation that a cDNA encoding a component of the coatomer, epsilon-COP, corrects the mutant phenotypes of ldlF cells (Guo, Q., Vasile, E., and Krieger, M. (1994) J. Cell Biol. 125, 1213-1224). Thus, these mutant cells should prove useful for further genetic and biochemical analysis of the mechanisms underlying intracellular membrane traffic.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital								Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCCI M, 1994, IN PRESS SOMATIC CEL; CAIN CC, 1991, J BIOL CHEM, V266, P11746; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; COLBAUGH PA, 1989, J CELL BIOL, V108, P2211, DOI 10.1083/jcb.108.6.2211; COLBAUGH PA, 1988, SOMAT CELL MOLEC GEN, V14, P499, DOI 10.1007/BF01534715; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DERMODY JJ, 1986, MOL CELL BIOL, V6, P4594, DOI 10.1128/MCB.6.12.4594; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Esko J D, 1986, Methods Enzymol, V129, P237; FISHER AS, 1992, THESIS MIT CAMBRIDGE; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOTTLIEB C, 1974, P NATL ACAD SCI USA, V71, P1078, DOI 10.1073/pnas.71.4.1078; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HEARING J, 1989, J CELL BIOL, V108, P339, DOI 10.1083/jcb.108.2.339; HOBBIE LJ, 1989, THESIS MIT CAMBRIDGE; HUGHESRYSER J, 1988, J CELL PHYSL, V135, P277; KAIDEN A, 1991, SOMAT CELL MOLEC GEN, V17, P15, DOI 10.1007/BF01233202; KAO CY, 1992, J CELL BIOL, V117, P701, DOI 10.1083/jcb.117.4.701; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KOHRER K, 1993, J BIOL CHEM, V268, P559; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; KRIEGER M, 1985, TRENDS BIOCHEM SCI, V10, P447, DOI 10.1016/0968-0004(85)90029-5; KRIEGER M, 1978, P NATL ACAD SCI USA, V75, P5052, DOI 10.1073/pnas.75.10.5052; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1991, J CELL PHYSIOL, V147, P215, DOI 10.1002/jcp.1041470205; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMSTROM K, 1991, J BIOL CHEM, V266, P24025; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; PRESLEY JF, 1991, J VIROL, V65, P1332, DOI 10.1128/JVI.65.3.1332-1339.1991; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REDDY P, 1989, J BIOL CHEM, V264, P17329; RESNICK D, 1993, J BIOL CHEM, V268, P3538; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JH, 1989, TRENDS BIOCHEM SCI, V14, P347, DOI 10.1016/0968-0004(89)90170-9; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SEGE RD, 1984, NATURE, V307, P742, DOI 10.1038/307742a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1987, METHOD ENZYMOL, V138, P443; THOMPSON LH, 1975, SOMAT CELL GENET, V1, P187, DOI 10.1007/BF01538547; TIMCHAK LM, 1986, J BIOL CHEM, V261, P14154; WANG RH, 1990, J BIOL CHEM, V265, P20179; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299; ZUBER C, 1991, P NATL ACAD SCI USA, V88, P9818, DOI 10.1073/pnas.88.21.9818	100	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20958	20970						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063714				2022-12-25	WOS:A1994PC40300025
J	LIU, JP; POWELL, KA; SUDHOF, TC; ROBINSON, PJ				LIU, JP; POWELL, KA; SUDHOF, TC; ROBINSON, PJ			DYNAMIN-I IS A CA2+-SENSITIVE PHOSPHOLIPID-BINDING PROTEIN WITH VERY HIGH-AFFINITY FOR PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; AMINO-ACID-SEQUENCE; PHORBOL ESTER; NERVE-TERMINALS; NEUROTRANSMITTER RELEASE; MECHANOCHEMICAL ENZYME; CORTICAL SYNAPTOSOMES; TRANSMITTER RELEASE; INTACT SYNAPTOSOMES; SYNAPTIC VESICLES	Depolarization-induced Ca2+ influx into rat brain synaptosomes induces dephosphorylation of dephosphin, a 96-94-kDa protein kinase C (PKC) substrate recently identified as dynamin I, a protein associated with endocytosis, We characterized purified dynamin I to better understand regulation of its phosphorylation in nerve terminals, Purified dynamin I possessed a very high affinity for PKC but did not fit Michaelis-Menten kinetics. It had an optimum phosphorylation rate of 1.42 +/- 0.02 mu mol/mg/min and a concentration giving half-maximal activity (S-0.5) of 0.14 +/- 0.02 mu M, the highest affinity reported for a PKC substrate protein. Concentrations of dynamin greater than 0.5 mu M inhibited phosphorylation. The stoichiometry was 1.5, indicating more than one phosphorylation site. Dynamin was predominantly associated with the brain particulate fraction under conditions of low ionic strength, and this prevented its phosphorylation by PKC until released by moderate increases in ionic strength (Na+, K+, and Mg2+) or by GTP or ATP. In intact synaptosomes the largest dynamin pool was associated with the particulate fraction, while a smaller pool was cytosolic or extracted with 150 mM NaCl and contained all the phosphorylated protein. Purified dynamin also bound to phospholipid-coated controlled-pore glass beads, but poorly in the presence of NaCl, Mg2+, GTP, or ATP. Ca2+ induced a reversible translocation from the cytosol to the particulate fraction (50% at 183 mu M Ca2+) in brain homogenates, and the purified protein also underwent Ca2+-sensitive translocation to phospholipid coated controlled-pore glass beads. We conclude that dynamin I is a nerve terminal Ca2+-sensitive phospholipid-binding protein with very high sub strate affinity for PKC. We propose that phosphorylation by PKC occurs in the nerve terminal soluble compartment and that Ca2+ may mediate its binding to the particulate fraction, thereby blocking the PKC phosphorylation sites. These properties may contribute to the lack of PKC phosphorylation during depolarization, despite the presence of activated PKC.	JOHN HUNTER HOSP, ENDOCRINE UNIT, NEWCASTLE, NSW 2310, AUSTRALIA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	John Hunter Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313; Liu, Jun-Ping/0000-0001-7442-2116; Powell, Kate/0000-0002-1826-953X				ANDO Y, 1989, J BIOL CHEM, V264, P6948; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEKKER LV, 1990, EUR J PHARM-MOLEC PH, V188, P113, DOI 10.1016/0922-4106(90)90046-Z; DIAZGUERRA MJM, 1988, BIOCHIM BIOPHYS ACTA, V970, P157, DOI 10.1016/0167-4889(88)90174-7; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, PROG BRAIN RES, V69, P273; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; MALHOTRA RK, 1988, J NEUROCHEM, V51, P967, DOI 10.1111/j.1471-4159.1988.tb01834.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MOZIER NM, 1990, EUR J BIOCHEM, V194, P19, DOI 10.1111/j.1432-1033.1990.tb19421.x; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; NORDMANN JJ, 1991, BIOCHEM J, V273, P493, DOI 10.1042/bj2730493; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; ROBINSON PJ, 1991, NEUROSCI RES COMMUN, V9, P167; RODNIGHT R, 1986, J PHYSIOLOGY PARIS, V81, P340; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEISS S, 1989, J NEUROCHEM, V52, P530, DOI 10.1111/j.1471-4159.1989.tb09152.x; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	48	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21043	21050						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063723				2022-12-25	WOS:A1994PC40300037
J	PIEKARZ, RL; COHEN, D; HORWITZ, SB				PIEKARZ, RL; COHEN, D; HORWITZ, SB			PROGESTERONE REGULATES THE MURINE MULTIDRUG RESISTANCE MDR1B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P-GLYCOPROTEIN EXPRESSION; HUMAN ESTROGEN-RECEPTOR; FUNCTIONAL-ANALYSIS; REPORTER GENE; DNA; PROMOTERS; SEQUENCE; CELLS; FORM; ENDOMETRIUM	P-glycoprotein, the product of the multidrug resistance (mdr) gene family, is a major determinant in the development of resistance to a large number of cancer chemotherapeutic agents and is also expressed normally in a variety of mammalian tissues. In rodents during pregnancy, there is a dramatic overproduction of the mdr1b form of P-glycoprotein at the lumenal surface of the secretory epithelium of the gravid uterus (1). An expression vector, mdr1b-CAT, was constructed by fusion of this promoter region to a reporter gene, the bacterial chloramphenicol acetyltransferase (CAT) gene (2). R5020, a progesterone agonist, increased approximately 3-fold the expression of mdr1b-CAT when transfected into T47D cells, a cell line that constitutively expresses the progesterone receptor. A far greater response to R5020 was observed when the cells were co-transfected with an expression vector for the A form of the progesterone receptor, but not the B form. A series of 5'-deleted clones of the mdr1b-CAT construct indicated that the region of responsiveness was located in the first untranslated exon of the gene. Furthermore, sequences from the first exon were able to confer responsiveness to the non-responsive thymidine kinase-CAT vector. This study demonstrates that progesterone specifically regulates the activity of the mdr1b promoter and that this response is directed solely by the A form of the progesterone receptor.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Piekarz, Richard/GXH-9978-2022		NATIONAL CANCER INSTITUTE [K04CA001330, R35CA039821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260] Funding Source: NIH RePORTER; NCI NIH HHS [5P303CA1330, CA 39821] Funding Source: Medline; NIGMS NIH HHS [5T32GM 07260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACRECI RJ, 1990, MOL REPROD DEV, V25, P101; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; AXIOTIS CA, 1991, LAB INVEST, V65, P577; BECKER KF, 1992, HORM METAB RES, V24, P210, DOI 10.1055/s-2007-1003295; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN D, 1991, J BIOL CHEM, V266, P2239; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GURPIDE E, 1991, JNCI-J NATL CANCER I, V83, P405, DOI 10.1093/jnci/83.6.405; HORWITZ KB, 1985, CANCER RES, V45, P167; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KAUPPILA A, 1980, CANCER, V46, P2162, DOI 10.1002/1097-0142(19801115)46:10<2162::AID-CNCR2820461010>3.0.CO;2-V; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARIE JP, 1991, BLOOD, V78, P586; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; SCHNEIDER W, 1991, J STEROID BIOCHEM, V38, P285, DOI 10.1016/0960-0760(91)90099-Q; SCHOTT DR, 1991, BIOCHEMISTRY-US, V30, P7014, DOI 10.1021/bi00242a029; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282	30	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7613	7616						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096515				2022-12-25	WOS:A1993KW97900004
J	HERZOG, CE; TSOKOS, M; BATES, SE; FOJO, AT				HERZOG, CE; TSOKOS, M; BATES, SE; FOJO, AT			INCREASED MDR-1/P-GLYCOPROTEIN EXPRESSION AFTER TREATMENT OF HUMAN COLON-CARCINOMA CELLS WITH P-GLYCOPROTEIN ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; DIFFERENTIATING AGENTS; ADENOCARCINOMA CELLS; DRUG-RESISTANCE; MDR1 GENE; LINES; CDNA; VINBLASTINE; MODULATION; VERAPAMIL	We observed increased levels of mdr-1 mRNA and its protein product P-glycoprotein (Pgp) in the human colon carcinoma cell line, LS 180, and its drug-resistant sublines, LS 180-Ad50 and LS 180-Vb2, after treatment with the Pgp antagonists, verapamil, nifedipine, and cyclosporin A. Increases in mdr-1 RNA were observed within 8 h of the addition of the Pgp antagonists and continued to rise over time. Peak levels were attained after several weeks and were sustained for the duration of treatment up to several months, with a rapid decline in mdr-1 mRNA levels after removal of the Pgp antagonist. Corresponding changes in Pgp were demonstrated with addition and removal of the Pgp antagonists. Increased mdr-1 mRNA was also seen with two other calcium channel blockers, nicardipine and diltiazem, but not with the Pgp antagonists, quinidine and chlorpromazine. Treatment with verapamil or nifedipine was associated with electron microscopic changes consistent with increased differentiation and resulted in increased carcinoembryonic antigen expression, suggesting that the increase in mdr-1 expression was associated with the process of differentiation. Nuclear runoff experiments and inhibition of new RNA synthesis with actinomycin D treatment failed to detect an increase in mdr-1 transcription or stabilization of the mdr-1 mRNA suggesting that the effect of these agents is mediated post-transcriptionally within the nucleus.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bates, Susan/AFP-9514-2022					AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144; BATES SE, 1991, AM J PATHOL, V139, P305; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; CAIRO MS, 1989, CANCER RES, V49, P1063; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2602; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; FOJO A, 1985, CANCER RES, V45, P3002; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GUM JR, 1987, J BIOL CHEM, V262, P1092; HWANG CL, 1989, J BIOL CHEM, V264, P14923; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIZOGUCHI T, 1990, J NATL CANCER I, V82, P1679, DOI 10.1093/jnci/82.21.1679; MURPHY LD, 1990, CANCER COMMUN, V2, P345, DOI 10.3727/095535490820874092; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRESANT CA, 1986, AM J CLIN ONCOL-CANC, V9, P355, DOI 10.1097/00000421-198608000-00016; SCHINKEL AH, 1991, CANCER BIOL, V2, P213; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG LYH, 1992, IN PRESS MOL ENDOCRI; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSOKOS M, 1987, AM J PATHOL, V128, P484; TSURUO T, 1983, CANCER RES, V43, P2267; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004	32	134	137	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2946	2952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8094079				2022-12-25	WOS:A1993KK81500101
J	ZHANG, HY; YOUNG, AP				ZHANG, HY; YOUNG, AP			EXOGENOUS, BUT NOT ENDOGENOUS, GLUCOCORTICOID RECEPTOR INDUCES GLUTAMINE-SYNTHETASE GENE-EXPRESSION IN EARLY STAGE EMBRYONIC RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL RETINA; TRANSCRIPTION FACTOR; MESSENGER-RNA; DNA-BINDING; BETA-GALACTOSIDASE; CELL-INTERACTIONS; FOS JUN; C-JUN; INDUCTION; HORMONE	Although glucocorticoid receptors are present throughout retinal development, the chicken glutamine synthetase (GS) gene becomes hormonally inducible between embryonic day 7.5 (E7.5) and E8. In this report we demonstrate that a transiently expressed GS-chloramphenicol (CAT) fusion gene is subject to temporal control resembling that experienced by the endogenous GS gene during in vitro retinal development. In addition, an enhancer located approximately 2 kilobases upstream of the GS transcription start site renders an SV40-CAT fusion plasmid hormonally inducible in E10, but not E5.5 retina, thereby implicating this element as the mediator of developmentally regulated expression. The enhancer contains a single glucocorticoid-response element juxtaposed to an essential ancillary site. Band shift assays demonstrate that nuclear extracts obtained from E5.5, E10, and E18 retina all contain similar levels of proteins that interact with the ancillary site, suggesting that developmental regulation of the hormonal response does not reflect the timed appearance of an ancillary factor. However, supplying exogenous glucocorticoid receptor through cotransfection is sufficient to produce hormonally inducible expression of the glutamine synthetase-CAT fusion gene in nonresponsive early stage retina. Based on these data, we postulate that the general glucocorticoid signaling pathway is compromised in early stage retina in a manner that is compensated by overexpression of the glucocorticoid receptor.	OHIO STATE UNIV,CTR BIOTECHNOL,182 RIGHTMIRE HALL,1060 CARMACK RD,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL PHARM,DIV PHARMACOL,COLUMBUS,OH 43210	Ohio State University; Ohio State University					NATIONAL EYE INSTITUTE [R01EY005063] Funding Source: NIH RePORTER; NEI NIH HHS [EY05063] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BODINE PV, 1990, J BIOL CHEM, V265, P9544; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; COULOMBRE AJ, 1955, AM J ANAT, V96, P153, DOI 10.1002/aja.1000960106; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KOEHLER DE, 1975, ARCH BIOCHEM BIOPHYS, V170, P102, DOI 10.1016/0003-9861(75)90101-0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LIPPMAN ME, 1974, J BIOL CHEM, V249, P5916; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MOSCONA AA, 1983, CURR TOP DEV BIOL, V18, P155; MOSCONA M, 1979, DIFFERENTIATION, V13, P165, DOI 10.1111/j.1432-0436.1979.tb01579.x; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; PATEJUNAS G, 1987, J CELL BIOCHEM, V35, P205, DOI 10.1002/jcb.240350304; PATEJUNAS G, 1990, J BIOL CHEM, V265, P15280; PU HF, 1990, GENE, V89, P259, DOI 10.1016/0378-1119(90)90014-I; PU HF, 1989, GENE, V81, P169, DOI 10.1016/0378-1119(89)90348-X; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; VARDIMON L, 1988, P NATL ACAD SCI USA, V85, P5981, DOI 10.1073/pnas.85.16.5981; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	46	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2850	2856						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8094078				2022-12-25	WOS:A1993KK81500087
J	TOKUNAGA, F; YAMADA, M; MIYATA, T; DING, YL; HIRANAGAKAWABATA, M; MUTA, T; IWANAGA, S; ICHINOSE, A; DAVIE, EW				TOKUNAGA, F; YAMADA, M; MIYATA, T; DING, YL; HIRANAGAKAWABATA, M; MUTA, T; IWANAGA, S; ICHINOSE, A; DAVIE, EW			LIMULUS HEMOCYTE TRANSGLUTAMINASE - ITS PURIFICATION AND CHARACTERIZATION, AND IDENTIFICATION OF THE INTRACELLULAR SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PIG LIVER TRANSGLUTAMINASE; FIBRIN-STABILIZING FACTOR; TACHYPLEUS-TRIDENTATUS HEMOCYTES; HORSESHOE-CRAB; CROSS-LINKING; INVERTEBRATE FIBRINOGEN; PROCLOTTING ENZYME; FACTOR-XIII; COAGULATION	To investigate further the molecular events of the intracellular coagulation cascade in limulus hemocytes, a transglutaminase (TGase), which may be involved in the formation of a stabilized gel, was purified and characterized. Through the purification procedures consisting of six steps, 1.6 mg of TGase with a specific activity of 940 amine incorporation unit/mg was obtained from 32.4 g of Tachypleus tridentatus hemocytes. The purified TGase gave a single band on SDS-polyacrylamide gel electrophoresis with a molecular mass of 86 kDa, and demonstrated mammalian-type II TGase-like enzymatic properties. The TGase activity was Ca2+-dependent and was inhibited by primary amines, EDTA, and SH-reagents. Moreover, two major potential substrates for TGase were identified in the hemocyte lysate by using dansylcadaverine (DCA) incorporation in the presence of 10 mM CaCl2 and 10 mM dithiothreitol. Of these protein substrates, an 80-kDa protein contained a large number of proline residues, amounting to about 22% of the total amino acids. On the other hand, an 8.6-kDa protein abundantly present in the hemocytes was characterized as a Cys-rich protein consisting of 81 amino acid residues and a calculated molecular mass of 8,671. The entire amino acid sequence of this protein was established. Also, the 8.6-kDa protein was readily cross-linked intermolecularly by TGase, forming multimers as large as pentamers. We speculate that like plasma factor XIIIa, limulus TGase and its two protein substrates in the hemocytes may play an important role in the defense of this animal against invading microorganisms.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,6-10-1 HAKOZAKI,HIGASHI KU,FUKUOKA 812,JAPAN; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Kyushu University; University of Washington; University of Washington Seattle				Tokunaga, Fuminori/0000-0003-3626-9119	NHLBI NIH HHS [HL-16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ANDO H, 1989, AGR BIOL CHEM TOKYO, V53, P2613, DOI 10.1080/00021369.1989.10869735; BROZEN R, 1987, BIOL BULL, V173, P423; CAMPBELLWILKES LK, 1973, THESIS NW U, P763; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG SI, 1977, THROMB HAEMOSTASIS, V38, P182; COLVIN RB, 1989, FIBRONECTIN, P213; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FULLER GM, 1971, BIOCHEMISTRY-US, V10, P1305, DOI 10.1021/bi00784a005; FULLER GM, 1971, BIOCHEMISTRY-US, V10, P1311, DOI 10.1021/bi00784a006; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IWANAGA S, 1986, J PROTEIN CHEM, V5, P255, DOI 10.1007/BF01025424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Lorand L, 1980, Prog Hemost Thromb, V5, P245; LORAND L, 1950, NATURE, V166, P694, DOI 10.1038/166694a0; Lorand L., 1970, METHOD ENZYMOL, V19, P770; MADRAS F, 1979, THROMB HAEMOSTASIS, V42, P734; MANJUNATH R, 1984, BIOCHEM BIOPH RES CO, V121, P400, DOI 10.1016/0006-291X(84)90736-8; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; PEREZPAYA E, 1991, FEBS LETT, V278, P51, DOI 10.1016/0014-5793(91)80081-D; ROTH RI, 1989, THROMB RES, V55, P25, DOI 10.1016/0049-3848(89)90453-2; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SRIMAL S, 1985, J BIOCHEM-TOKYO, V98, P305, DOI 10.1093/oxfordjournals.jbchem.a135283; TAKAGI T, 1984, J BIOCHEM-TOKYO, V95, P1445, DOI 10.1093/oxfordjournals.jbchem.a134752; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; TSAI H, 1981, BIOCHIM BIOPHYS ACTA, V667, P213, DOI 10.1016/0005-2795(81)90082-9; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P522	49	64	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					252	261						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093242				2022-12-25	WOS:A1993KE60300040
J	MISRA, KB; KIM, KC; CHO, SY; LOW, MG; BENSADOUN, A				MISRA, KB; KIM, KC; CHO, SY; LOW, MG; BENSADOUN, A			PURIFICATION AND CHARACTERIZATION OF ADIPOCYTE HEPARAN-SULFATE PROTEOGLYCANS WITH AFFINITY FOR LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FIBROBLAST GROWTH-FACTOR; PHOSPHOLIPASE-C; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; BINDING; DEGRADATION; METABOLISM; PROTEINS	Lipoprotein lipase (LPL)-binding heparan sulfate proteoglycans (HSPGs) were isolated from cell extracts and conditioned media of cultured adipocytes treated with phosphatidylinositol-specific phospholipase C (PIPLC). The methodology employed included anion exchange chromatography, affinity chromatography on LPL Affi-Prep 10 and hydrophobic chromatography. HSPGs were resolved into two distinct fractions on the Octyl-Sepharose CL-4B matrix. Treatment of the eluted fractions with heparinase and heparitinase yielded core proteins of 48.4 and 39 kDa. The 39-kDa core protein is anchored to the cell surface by a glycosyl phosphatidylinositol anchor as evidenced by 1) release of the HSPG with the 39-kDa core protein into media by PIPLC treatment and 2) biosynthetic incorporation of [H-3]ethanolamine and [P-32]orthophosphate into the PIPLC-releasable 39-kDa core protein. PIPLC released 23% of the total heparin-releasable LPL. A similar percentage (24.5%) of the total heparan sulfate chains was released by PIPLC. Over 96% of the total adipocyte heparan sulfate chains bound to LPL Affi-Prep 10 column. The heterogeneity of core proteins of HSPGs with affinity for LPL may provide a structural basis for the multiple fates of LPL on the surface of adipocytes, i.e. internalization, degradation, or recycling to the cell surface and translocation into the medium.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853; CORNELL UNIV,DIV BIOL SCI,ITHACA,NY 14853; EWHA WOMANS UNIV,DEPT PHARMACOL,SEOUL,SOUTH KOREA; COLUMBIA UNIV,DEPT PHYSIOL & CELL BIOPHYS,NEW YORK,NY 10032	Cornell University; Cornell University; Ewha Womans University; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035873, R55GM040083, R01GM040083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14990] Funding Source: Medline; NIGMS NIH HHS [GM-35873, GM-40083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASKIN P, 1992, J CELL PHYSL, V151, P126; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BRAUN JEA, 1991, AM J PHYSIOL, V260, pE477, DOI 10.1152/ajpendo.1991.260.3.E477; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; CAREY DJ, 1989, J CELL BIOL, V108, P1891, DOI 10.1083/jcb.108.5.1891; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHEUNG AH, 1979, ANAL BIOCHEM, V94, P346, DOI 10.1016/0003-2697(79)90371-3; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CUPP M, 1987, J BIOL CHEM, V262, P6383; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; KIM JJ, 1974, J BIOL CHEM, V249, P3091; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1989, BIOCHEM J, V261, P145, DOI 10.1042/bj2610145; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1987, BIOCHEM J, V244, P1; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; PHELPS BM, 1988, SCIENCE, V120, P1780; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; TING AE, 1990, J BIOL CHEM, V265, P5337; VANNIER C, 1989, J BIOL CHEM, V264, P13199; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	47	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23838	23844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089154				2022-12-25	WOS:A1994PQ34500068
J	STEWART, AE; ARFIN, SM; BRADSHAW, RA				STEWART, AE; ARFIN, SM; BRADSHAW, RA			PROTEIN NH2-TERMINAL ASPARAGINE DEAMIDASE - ISOLATION AND CHARACTERIZATION OF A NEW ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ACIDIC NH2 TERMINI; UBIQUITIN PATHWAY; EUKARYOTIC CELLS; DEGRADATION; PURIFICATION; CYCLIN	An apparently unique enzyme, designated protein NH2-terminal asparagine deamidase (PNAD), that specifically converts NH2-terminal asparagine residues of peptide and protein substrates to aspartic acid, has been isolated to homogeneity from porcine liver by an eight-step procedure. PNAD is a relatively low abundance protein, is readily solubilized, and exists as a monomeric species of similar to 33 kDa. PNAD does not act on internal asparagine residues and requires a free N-alpha-amino group. It has reduced or no activity on NH2-terminal asparagine dipeptides and no activity toward free asparagine or asparagine amide. It does not act on any NH2-terminal glutamine substrates. PNAD does not show a strong pH dependence suggesting that the enzyme can act equally well on substrates with ionized or unionized alpha-amino groups. The properties and specificity of PNAD are consistent with those expected for the enzyme required for the ubiquitin-dependent turnover of intracellular proteins that initiate with Met-Asn-. Such proteins should be N-alpha-acetylated on the retained initiator methionine and can subsequently be modified by the removal of N-acetyl methionine by acylaminoacid hydrolase. Conversion of the resulting NH2-terminal asparagine to aspartic acid by PNAD would render the protein susceptible to arginylation, polyubiquitinylation and degradation as specified by the N-end rule.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIDDK NIH HHS [DK-32465] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032465] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW RA, 1989, TRENDS BIOCHEM SCI, V14, P276, DOI 10.1016/0968-0004(89)90063-7; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; EDSALL JT, 1958, BIOPHYSICAL CHEM, P466; ELIAS S, 1990, J BIOL CHEM, V265, P15511; EVERT RF, 1986, ANAL BIOCHEM, V154, P431; GADE W, 1978, J BIOL CHEM, V253, P5012; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	20	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23509	23517						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089117				2022-12-25	WOS:A1994PQ34500022
J	GERMANO, P; GOMEZ, J; KAZANIETZ, MG; BLUMBERG, PM; RIVERA, J				GERMANO, P; GOMEZ, J; KAZANIETZ, MG; BLUMBERG, PM; RIVERA, J			PHOSPHORYLATION OF THE GAMMA-CHAIN OF THE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E BY RECEPTOR-ASSOCIATED PROTEIN-KINASE C-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; TYROSINE KINASE; T-CELL; SIGNAL-TRANSDUCTION; RBL-2H3 CELLS; ZETA-CHAIN; MAST-CELLS; HISTAMINE-RELEASE; PHORBOL ESTER	The gamma chain of the high affinity receptor for immunoglobulin E is a member of the T-cell antigen receptor zeta chain family and a functional subunit common to both T-cell and Fc receptors. Here we report that the gamma chain is phosphorylated on threonine in response to protein kinase C activation. Furthermore, the threonine phosphorylation of the gamma chain correlates with the endocytosis of this receptor. We identified a receptor-associated kinase as the calcium-independent protein kinase C-delta and found that it associates with the carboxyl-terminal cytoplasmic domain of the beta chain. In addition, protein kinase C-delta was the only isozyme capable of phosphorylating the gamma chain in vitro. These findings provide evidence for the functional role of protein kinase C-delta in early signal transduction events in the mast cell and suggest a more general mechanism of activation for receptors that share subunits of the zeta chain family.	NIAMSD,CHEM IMMUNOL SECT,BETHESDA,MD 20892; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; EISEMAN E, 1992, NATURE, V355, P78; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU FT, 1980, J IMMUNOL, V124, P2728; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; OLIVER JM, 1985, J CELL BIOL, V101, P2156, DOI 10.1083/jcb.101.6.2156; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11445; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RA C, 1989, EUR J IMMUNOL, V19, P1771, DOI 10.1002/eji.1830191002; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE JR, 1985, P NATL ACAD SCI USA, V82, P8193, DOI 10.1073/pnas.82.23.8193; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMADA K, 1992, J IMMUNOL, V149, P1031; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x	38	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23102	23107						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083212				2022-12-25	WOS:A1994PQ16400033
J	HAYSTEAD, TAJ; HAYSTEAD, CMM; HU, CB; LIN, TA; LAWRENCE, JC				HAYSTEAD, TAJ; HAYSTEAD, CMM; HU, CB; LIN, TA; LAWRENCE, JC			PHOSPHORYLATION OF PHAS-I BY MITOGEN-ACTIVATED PROTEIN (MAP) KINASE - IDENTIFICATION OF A SITE PHOSPHORYLATED BY MAP KINASE IN-VITRO AND IN RESPONSE TO INSULIN IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE PROTEIN; GLYCOGEN-SYNTHASE; SUBSTRATE RECOGNITION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; S6 KINASE; SUBUNIT; PHOSPHOPROTEIN	PHAS-I is a heat- and acid-stable protein that is phosphorylated on Ser/Thr residues in response to insulin and growth factors. To investigate the phosphorylation of PHAS-I, the protein was expressed in bacteria and purified for use as substrate in protein kinase reactions in vitro. Recombinant PHAS-I was rapidly and stoichiometrically phosphorylated by mitogen-activated protein (MAP) kinase. At saturating MgATP, the K-m and V-max observed with PHAS-I were almost identical to those obtained with myelin basic protein, one of the best MAP kinase substrates. PHAS-I was also phosphorylated at a significant rate by casein kinase II and protein kinase C. To investigate sites of phosphorylation, PHAS-I was digested with collagenase and phosphopeptides were resolved by reverse phase high performance liquid chromatography. Almost all of the phosphate introduced by MAP kinase was recovered in the peptide, Leu-Met-Glu-Cys-Arg-Asn-Ser-Pro-Val-Ala-Lys-Thr. P-32 was released in the seventh cycle of Edman degradation, identifying the Ser (Ser(64)) as the phosphorylated residue. Ser(64) was also phosphorylated in response to insulin in rat adipocytes. We conclude that PHAS-I is a substrate for MAP kinase both in vivo and in vitro. As PHAS-I is one of the most prominent insulin-stimulated phosphoproteins in adipocytes, it may qualify as the major MAP kinase substrate in these cells.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22903	Washington University (WUSTL); University of Virginia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; AVRUCH J, 1982, FED PROC, V41, P2629; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COHEN P, 1983, METHOD ENZYMOL, V99, P243; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENTON RM, 1981, DIABETOLOGIA, V21, P347; DEPAOLIROACH AA, 1981, J BIOL CHEM, V256, P8871; DIGGLE TA, 1991, BIOCHEM J, V279, P545, DOI 10.1042/bj2790545; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; GEER P, 1994, PROTIEN PHOSPHORYLAT, P31; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; ISHIZUKA T, 1989, FEBS LETT, V257, P337, DOI 10.1016/0014-5793(89)81565-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; MAURER MC, 1992, ARCH BIOCHEM BIOPHYS, V298, P561, DOI 10.1016/0003-9861(92)90450-B; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMAKRISHNA S, 1983, BIOCHEM BIOPH RES CO, V117, P758, DOI 10.1016/0006-291X(83)91662-5; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSENWASSER TA, 1990, J BIOL CHEM, V265, P13066; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SEE PY, 1989, PROTEIN STRUCTURE PR, P1; SETH A, 1991, J BIOL CHEM, V266, P23521; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH PK, 1985, ANAL BIOCHEM, V47, P20; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKEDA Y, 1975, J BIOL CHEM, V250, P8943; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; WANG QM, 1994, J BIOL CHEM, V269, P14566; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	48	173	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23185	23191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083223				2022-12-25	WOS:A1994PQ16400045
J	WOLUCKA, BA; MCNEIL, MR; DEHOFFMANN, E; CHOJNACKI, T; BRENNAN, PJ				WOLUCKA, BA; MCNEIL, MR; DEHOFFMANN, E; CHOJNACKI, T; BRENNAN, PJ			RECOGNITION OF THE LIPID INTERMEDIATE FOR ARABINOGALACTAN ARABINOMANNAN BIOSYNTHESIS AND ITS RELATION TO THE MODE OF ACTION OF ETHAMBUTOL ON MYCOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL ARABINOGALACTAN; STRUCTURAL FEATURES; O-ANTIGEN; TUBERCULOSIS; SALMONELLA; SMEGMATIS; RESIDUES; LIPOARABINOMANNAN; POLYSACCHARIDE; INHIBITION	Despite major advances in our understanding of the structure of mycobacterial cell walls, little is known of their biogenesis, and yet they are the site of action of many anti-tuberculosis drugs and implicated in much of the pathology of tuberculosis and leprosy. A family of monoglycosyl polyprenylphosphates was isolated from Mycobacterium smegmatis, containing arabinose, ribose, and mannose. The isoprenoid nature of the lipid components was established by H-1 NMR, and fast atom bombardment mass spectroscopy (FAB-MS) demonstrated the presence of C-50 decaprenyl-P derivatives and smaller amounts of the C-35 octahydroheptaprenyl-P products. The configuration of the mycobacterial decaprenol was established as mono-trans, octa-cis, pointing to carriers of unusual structure. Combined gas chromatography (GC)/MS, FAB-MS/MS, and H-1 MMR allowed characterization of one of the primary components as beta-D-arabinofuranosyl-1-monophosphodecaprenol. Pulse chase metabolic labeling of cells with D-[C-14]glucose indicated that the decaprenyl-P-arabinose is an active intermediate in the biosynthesis of the arabinan of cell wall arabinogalactan and arabinomannan. The identification of poly-prenyl-P-ribose suggests the existence of ribose containing polysaccharides in the cell walls of M. smegmatis or/ and of a novel epimerase in the D-arabinose biosynthetic pathway. Ethambutol, a powerful anti-tuberculosis drug known to inhibit arabinogalactan and arabinomannan biosynthesis, results in the rapid accumulation of decaprenyl-P-arabinose, indicating that the drug interferes with either the transfer of arabinose from the donor or, alternatively, the synthesis of the arabinose acceptor itself.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; POLISH ACAD SCI, INST BIOCHEM & BIOPHYS, PL-02532 WARSAW, POLAND	Colorado State University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	WOLUCKA, BA (corresponding author), UNIV CATHOLIQUE LOUVAIN, DEPT CHEM, BIOCHIM PHYS & BIOPOLYMERES LAB, PL LOUIS PASTEUR, 1-1B, B-1348 LOUVAIN, BELGIUM.		McNeil, Michael/G-3325-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189, R01AI018357, R01AI033706, R22AI018357, R37AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID AI 33706, NIAID AI 30189, NIAID AI 18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1982, EUR J BIOCHEM, V128, P363, DOI 10.1111/j.1432-1033.1982.tb06973.x; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; ANNER B, 1975, ANAL BIOCHEM, V65, P305, DOI 10.1016/0003-2697(75)90514-X; ASPINALL GO, 1972, CAN J BIOCHEM, V50, P575; ASTRAND IM, 1986, EUR J BIOCHEM, V155, P447, DOI 10.1111/j.1432-1033.1986.tb09511.x; BADDILEY J, 1961, BIOCHIM BIOPHYS ACTA, V50, P391, DOI 10.1016/0006-3002(61)90351-1; BADET J, 1988, CARBOHYD RES, V178, P49, DOI 10.1016/0008-6215(88)80101-0; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CUMMINS CS, 1962, J GEN MICROBIOL, V28, P35, DOI 10.1099/00221287-28-1-35; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DAWSON RMC, 1960, BIOCHEM J, V75, P45, DOI 10.1042/bj0750045; FEENEY J, 1967, ANAL BIOCHEM, V20, P1, DOI 10.1016/0003-2697(67)90258-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; HEMMING FW, 1985, GLYCOLIPIDS, P261; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; HONDA S, 1989, ANAL BIOCHEM, V180, P351, DOI 10.1016/0003-2697(89)90444-2; KALLENIUS G, 1989, AM REV RESPIR DIS, V140, P264; KILBURN JO, 1977, ANTIMICROB AGENTS CH, V11, P534, DOI 10.1128/AAC.11.3.534; KILBURN JO, 1981, ANTIMICROB AGENTS CH, V20, P401, DOI 10.1128/AAC.20.3.401; LEZICA RP, 1986, ADV CARBOHYD CHEM BI, V44, P341; LOW P, 1991, J BIOL CHEM, V266, P19250; MANCUSO DJ, 1982, J BACTERIOL, V152, P616; MARYANOFF BE, 1988, TETRAHEDRON, V44, P3093, DOI 10.1016/S0040-4020(01)85941-X; MARYANOFF BE, 1984, J AM CHEM SOC, V106, P7851, DOI 10.1021/ja00337a034; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1987, CARBOHYD RES, V166, P299, DOI 10.1016/0008-6215(87)80065-4; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; NIKAIDO H, 1971, J BACTERIOL, V105, P1073, DOI 10.1128/JB.105.3.1073-1082.1971; NIKAIDO K, 1971, J BIOL CHEM, V246, P3912; SARVAS M, 1971, J BACTERIOL, V105, P1063, DOI 10.1128/JB.105.3.1063-1072.1971; SASAK W, 1977, ARCH BIOCHEM BIOPHYS, V181, P402, DOI 10.1016/0003-9861(77)90245-4; SCHER M, 1968, P NATL ACAD SCI USA, V59, P1313, DOI 10.1073/pnas.59.4.1313; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SCHWARZ RT, 1982, ADV CARBOHYD CHEM BI, V40, P287, DOI 10.1016/S0065-2318(08)60111-0; SEELA F, 1982, LIEBIGS ANN CHEM, P1634; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SILVE G, 1993, ANTIMICROB AGENTS CH, V37, P1536, DOI 10.1128/AAC.37.7.1536; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; TROY FA, 1971, J BIOL CHEM, V246, P118; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WELLBURN AR, 1967, BIOCHEM J, V102, P313, DOI 10.1042/bj1020313; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WOLUCKA BA, 1994, IN PRESS ACTA BIOCH; WRIGHT A, 1971, J BACTERIOL, V105, P927, DOI 10.1128/JB.105.3.927-936.1971; YAMAMORI S, 1978, J BIOL CHEM, V253, P6516; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21621; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; [No title captured]	57	224	232	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23328	23335						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083238				2022-12-25	WOS:A1994PQ16400065
J	CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ				CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ			TRANSCRIPTIONAL REGULATION OF C-JUN EXPRESSION DURING LATE G(1)/S IN NORMAL HUMAN-CELLS IS LOST IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; MESSENGER-RNA; G0/G1 TRANSITION; BINDING PROTEIN; DNA-REPLICATION; FACTOR AP-1; FOS; GENE; ACTIVATION; FIBROBLASTS	Previous results from our laboratory have identified a second peak in steady state levels of c-jun mRNA (in addition to the immediate early induction) which occurs at the G(1)/S border in WI-38 normal human diploid fibroblasts. The present studies were undertaken in an attempt to determine (1) the molecular mechanism responsible for the expression of c-jun in late G(1)/S, (2) the relationship between this second peak of c-jun mRNA expression and the induction of DNA synthesis and (3) whether this cell cycle specific c-jun expression is deregulated in transformed cells. Our results show that the second peak in steady state levels of c-jun mRNA is the result of new transcription during late G(1) and not altered stability of the c-jun mRNA transcribed during G(1). We also show that this second peak of expression still occurs even when DNA synthesis is inhibited by either hydroxyurea or aphidicolin. Thus, the second peak precedes and is independent of DNA synthesis. Finally, we find that while two other normal human fibroblast cell lines exhibit a second peak of c-jun mRNA during late G(1)/S, c-jun expression is not cell cycle-regulated but rather is constitutively expressed in a number of distinct transformed cell lines. Since events occuring throughout G(1) are known to regulate cell growth, our results suggest that the extent of regulation of c-jun expression during G, may affect molecular events which ultimately lead to altered growth control as a result of cellular transformation.	TEMPLE UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANDEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GINSBERG D, 1990, ONCOGENE, V5, P1285; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELVIN WT, 1977, BIOCHEM J, V168, P595, DOI 10.1042/bj1680595; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAI M, 1989, CANCER RES, V49, P5633; SAUVE GL, 1991, DNA SEQUENCE, V1, P13; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SINCLAIR WK, 1967, CANCER RES, V27, P297; SOPRANO KJ, 1992, ANN NY ACAD SCI, V660, P231, DOI 10.1111/j.1749-6632.1992.tb21075.x; STEIN GS, 1984, RECOMBINANT DNA CELL, P107; TAKEISHI K, 1989, J BIOCHEM-TOKYO, V106, P575, DOI 10.1093/oxfordjournals.jbchem.a122898; TAVALI S, 1989, J BIOL CHEM, V264, P7466; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WOODFORD TA, 1988, ANAL BIOCHEM, V171, P166, DOI 10.1016/0003-2697(88)90138-8; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	48	8	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2675	2682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058331				2022-12-25	WOS:A1994PC05400028
J	TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M				TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M			DIFFERENTIAL EXPRESSION AND REGULATION OF CYCLIN D1 PROTEIN IN NORMAL AND TUMOR HUMAN-CELLS - ASSOCIATION WITH CDK4 IS REQUIRED FOR CYCLIN D1 FUNCTION IN G1 PROGRESSION	ONCOGENE			English	Review							HUMAN-DIPLOID FIBROBLASTS; HUMAN BREAST-CANCER; DNA POLYMERASE-DELTA; RETINOBLASTOMA PROTEIN; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53 GENE; SUBUNIT REARRANGEMENT; AUXILIARY PROTEIN; DEPENDENT KINASES	In this study we have surveyed by immunoblotting the protein levels of Cyclin D1, D2, D3 and their catalytic partners, Cdk4 and Cdk6 in normal and transformed human cells. We found that all these proteins were differentially expressed in diploid cells derived from different tissues, in contrast to Cyclin E, Cyclin A and Cdk2 which are ubiquitously expressed. D-type Cyclins were never dramatically overexpressed and often very poorly expressed in tumor cell lines when compared to the levels in their normal counterparts. In contrast, Cdk4 was expressed at high levels in several tumor cell lines and Cdk6 was ectopically expressed in two sarcoma lines, suggesting a possible involvement of these two Cdks in oncogenesis. Interestingly, low levels of Cyclin D1 and D3 proteins always correlated with functional inactivation of the retinoblastoma gene product (pRb). In cells displaying active pRb, Cyclin D1 was found associated with Cdk4 regardless of whether the p53 gene was wild-type or mutant. Microinjection during G1 of Cyclin D1 anti-sense cDNA or anti-Cyclin D1 antibody in these cells arrested the cell cycle in G1. In cells lacking pRb function, Cyclin D1 was dissociated from Cdk4. Microinjection during G1 of Cyclin D1 antisense cDNA or anti-Cyclin D1 antibody in these cells did not affect G1 progression. These results show that (i) in the absence of pRb, Cyclin D1 is expressed at low levels, is dissociated from Cdk4 and becomes dispensable in G1; (ii) Cyclin D1 needs to be associated with its catalytic subunit, Cdk4, to function as a positive regulator of G1 progression.	MITOTIX INC, CAMBRIDGE, MA 02139 USA; UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011	pagano, michele/0000-0003-3210-2442	NCI NIH HHS [CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1992, ONCOGENE, V7, P101; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GLOTZE RM, 1990, NATURE, V349, P132; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANNA Z, 1993, ONCOGENE, V8, P1661; HARPER JW, 1993, CELL, V75, P805; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LOVEC H, 1994, ONCOGENE, V9, P323; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUKAS J, 1994, ONCOGENE, V9, P707; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATSUSHIME H, 1991, COLD SPRING HARBOR S, V56; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1994, IN PRESS GENES DEV; PALMERO I, 1993, ONCOGENE, V8, P1049; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1993, ONCOGENE, V8, P1407; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; STRATTON MR, 1990, ONCOGENE, V5, P1297; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TSAI LH, 1993, DEVELOPMENT, V119, P1029; WASEEM NH, 1990, J CELL SCI, V96, P121; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	103	313	329	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2663	2674						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058330				2022-12-25	WOS:A1994PC05400027
J	WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC				WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC			APOPTOSIS REGULATION BY INTERACTION OF BCL-2 PROTEIN AND RAF-1 KINASE	ONCOGENE			English	Note							EPSTEIN-BARR-VIRUS; CELL-DEATH; PROTOONCOGENE EXPRESSION; RAS; ONCOPROTEIN; ACTIVATION; LINE; PHOSPHORYLATION; ONCOGENES; PROSTATE	The Bcl-2 protein is over-produced in many types of human tumors and suppresses apoptosis induced by a wide-variety of stimuli, including chemotherapeutic drugs and gamma-irradiation. The biochemical mechanism of action of the Bcl-2 protein however remains enigmatic. Here we show that Bcl-2 can be co-immunoprecipitated with the serine/ threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Though analysis of-Raf-1 deletion mutants suggested that the C-terminal half of the protein which contains the catalytic domain is sufficient for co-immunoprecipitation with Bcl-2, Raf-1 does not appear to induce phosphorylation of Bcl-2 protein in 32D.3 and Sf9 cells. Furthermore, a mutant form of Raf-1 that lacks kinase activity could still be co-immunoprecipitated with Bcl-2 in Sf9 cells, suggesting that the interaction of these proteins does not reflect a kinase-substrate relation, Gene transfer experiments using 32D.3 hemopoietic cells demonstrated functional synergy between Bcl-2 and Raf-1 with regards to suppression of apoptosis induced by growth factor withdrawal. Taken together, these observations for the first time functionally link Bcl-2 to a signal transducing protein and suggest that the interaction of the Bcl-2 and Raf-1 proteins may be responsible for their ability to cooperate in the suppression of apoptosis.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; NCI,FREDERICK CANC RES FACIL,TUMOR VIROL LAB,FREDERICK,MD 21702	Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Troppmair, Jakob/0000-0002-0611-3837	NCI NIH HHS [CA-54957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054957] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; CAMPOS I, 1993, BLOOD, V18, P3091; CLEVELAND J, IN PRESS ONCOGENE; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DEJONG D, 1994, CANCER RES, V54, P256; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HANADA M, 1993, BLOOD, V82, P1820; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IKEGAKI B, 1994, CANCER RES, V54, P6; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOCACHE MM, 1990, INTERVIROLOGY, V31, P1; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MARILIO F, 1989, ONCOGENE, V4, P301; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; PEZELLA F, 1993, NEW ENGL J MED, V329, P690; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REY I, 1994, ONCOGENE, V9, P686; SATO T, IN PRESS P NATL ACAD; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	236	245	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2751	2756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058342				2022-12-25	WOS:A1994PC05400040
J	ARCINAS, M; SIZER, KC; BOXER, LM				ARCINAS, M; SIZER, KC; BOXER, LM			ACTIVATION OF C-MYC EXPRESSION BY C-ABL IS INDEPENDENT OF BOTH THE DNA-BINDING FUNCTION OF C-ABL AND THE C-MYC EP SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; CHROMATIN STRUCTURE; TYROSINE KINASE; PROTEIN-BINDING; CELL-CYCLE; V-ABL; GENE; TRANSCRIPTION; INVIVO; ONCOGENES	We have shown by transient transfection assays that c-Abl increases expression of a c-myc promoter construct although to a lesser extent than v-Abl. c-Abl has been reported to bind to a specific DNA sequence, the EP element, in the hepatitis B virus enhancer. A similar sequence exists in the promoter region of the c-myc gene, and we have identified a potential protein binding site in this region by in vivo footprinting. Gel shift analysis demonstrated that the hepatitis B virus enhancer and c-nye sites yield identical complexes. To determine whether c-Abl activates c-myc transcription by binding directly to the promoter region, several experiments were performed. Mutation of the EP site in the c-myc promoter had no effect on transcriptional activation of c-myc by c-Abl. Next, we demonstrated that the DNA binding domain of c-Abl was not required for the transcriptional activation of c-myc. Finally, by Western blot analysis, we have determined that c-Abl is not present in the gel shift complexes formed by either the hepatitis B virus enhancer or c-myc promoter. We conclude that c-Abl activates c-myc transcription indirectly with no requirement for DNA binding by c-Abl. We also find no evidence for the interaction of c-Abl with the EP sequence of either the hepatitis B virus enhancer or the c-myc promoter.	STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL MED, STANFORD, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, IN PRESS ONCOGENE; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BORNKAMM GW, 1988, C MYC DEREGULATION C; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CONKLIN KF, 1984, DNA METHYLATION; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SALUZ HP, 1987, LABORATORY GUIDE GEN; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x	35	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21919	21924						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063836				2022-12-25	WOS:A1994PK97300078
J	EBERT, SN; BALT, SL; HUNTER, JPB; GASHLER, A; SUKHATME, V; WONG, DL				EBERT, SN; BALT, SL; HUNTER, JPB; GASHLER, A; SUKHATME, V; WONG, DL			EGR-1 ACTIVATION OF RAT ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; COMPLETE NUCLEOTIDE-SEQUENCE; MESSENGER-RNA EXPRESSION; ZINC FINGER PROTEIN; TRANSCRIPTION FACTOR; INSITU HYBRIDIZATION; BASAL EXPRESSION; RESPONSE ELEMENT; MAMMALIAN-CELLS; PC12 CELLS	The immediate early gene transcription factor Egr-1 increases luciferase reporter gene activity 3-4-fold when a rat phenylethanolamine N-methyltransferase (PNMT) promoter-luciferase construct and an Egr-1 expression construct are cotransfected into transformed PC12 cells (RS1). Egr-1 also stimulates endogenous PNMT mRNA expression in the RS1 cells. Furthermore, when transfected RS1 cells are treated with dexamethasone, both luciferase and endogenous PNMT mRNA rise an additional 2-fold although dexamethasone does not independently activate transcription from the PNMT promoter. While both Egr-1 sites (-45 and -165 base pairs) in the PNMT promoter appear necessary for maximum luciferase reporter gene expression, the -165 site appears to be the more important for mediating the Egr-1 response. When the upstream site is deleted or either or both sites are mutated in PNMT-reporter gene constructs, Egr-1-induced luciferase activity from the PNMT promoter is significantly reduced. In addition, the incremental activation by dexamethasone is lost when sequences containing the glucocorticoid response element are deleted or when the Egr-1 sites are mutated. In the transfected RS1 cells, a rise in nuclear Egr-1 protein accompanies the rise in endogenous PNMT mRNA. Similarly, reserpine treated rats (10 mg/kg, intraperitoneally), which show an 8-fold elevation in adrenal PNMT mRNA at 6 h postdrug administration, also show a marked rise in Egr-1 protein in adrenal medullary cell nuclei. These studies provide the first direct evidence that a transcription factor, Egr-1, can activate PNMT gene expression and identify PNMT as a novel target gene for Egr-1. Finally, the incremental enhancement of the Egr-1 response by glucocorticoids suggests a potential interaction between Egr-1 and another transcription factor, the glucocorticoid receptor.	STANFORD UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, NANCY PRITZKER LAB DEV & MOLEC NEUROBIOL, STANFORD, CA 94305 USA; BETH ISRAEL HOSP, DIV RENAL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Stanford University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Sukhatme, Vikas/W-2776-2019		NIMH NIH HHS [MH10350, MH39437] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010350, P01MH039437] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AN G, 1992, MOL CELL BIOL, V2, P12628; ANDERSON DJ, 1989, TRENDS NEUROSCI, V12, P83, DOI 10.1016/0166-2236(89)90160-4; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BHAT RV, 1992, J PHARMACOL EXP THER, V263, P343; BHAT RV, 1992, EUR J PHARM-MOLEC PH, V227, P447, DOI 10.1016/0922-4106(92)90165-R; BOHN MC, 1981, DEV BIOL, V82, P1, DOI 10.1016/0012-1606(81)90423-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDHURY K, 1988, EMBO J, V7, P1345, DOI 10.1002/j.1460-2075.1988.tb02950.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CIARANELLO RD, 1975, J NEUROCHEM, V24, P775, DOI 10.1111/j.1471-4159.1975.tb03863.x; DAY ML, 1990, J BIOL CHEM, V265, P15253; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONIS JA, 1993, BIOTECHNIQUES, V15, P786; EVINGER MJ, 1992, CELL MOL NEUROBIOL, V12, P193, DOI 10.1007/BF00712926; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KATAYAMA N, 1993, J NEUROCHEM, V60, P902, DOI 10.1111/j.1471-4159.1993.tb03235.x; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LI Y, 1993, J BIOL CHEM, V268, P3563; LIM RW, 1987, ONCOGENE, V1, P263; MAILLEUX P, 1992, NEUROSCI LETT, V147, P182, DOI 10.1016/0304-3940(92)90590-4; MICHELSOHN AM, 1992, NEURON, V8, P589, DOI 10.1016/0896-6273(92)90285-L; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORATALLA R, 1992, J NEUROSCI, V12, P2609; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; MULLER MT, 1987, J VIROL, V61, P858, DOI 10.1128/JVI.61.3.858-865.1987; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; ROSS ME, 1990, J NEUROSCI, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL ENDOCRINOL, V5, P829, DOI 10.1210/mend-5-6-829; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TISCHLER AS, 1985, LAB INVEST, V53, P486; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WONG DL, 1992, DEV BRAIN RES, V67, P229, DOI 10.1016/0165-3806(92)90223-J; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WONG DL, 1993, MOL BRAIN RES, V18, P107, DOI 10.1016/0169-328X(93)90178-R	61	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20885	20898						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063705				2022-12-25	WOS:A1994PC40300015
J	HANAZAWA, S; TAKESHITA, A; KITANO, S				HANAZAWA, S; TAKESHITA, A; KITANO, S			RETINOIC ACID SUPPRESSION OF C-FOS GENE INHIBITS EXPRESSION OF TUMOR NECROSIS FACTOR-ALPHA-INDUCED MONOCYTE CHEMOATTRACTANT JE/MCP-1 IN CLONAL OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELLS; PROTEIN-1 MCP-1; THYROID-HORMONE; RECEPTOR-ALPHA; LINE MC3T3-E1; GROWTH-FACTOR; X-RECEPTOR; JE GENE; BINDING; BONE	Our previous study (Hanazawa, S., Takeshita, k, Amano, S., Semba, T., Nirazuka, T., Katoh, H., and Kitano, S. (1993) J. Biol. Chem. 268, 9526-9532) demonstrated that tumor necrosis factor-cu (TNF-cu) induces monocyte chemoattractant JE/MCP-1 expression via c-fos and c-jun genes following protein kinase C activation in osteoblastic MC3T3-E1 cells. In the present study, we examined the effect of retinoic acid (RA) on the cytokine-induced JE/MCP-1 expression in the cells. RA significantly inhibited the JE/MCP-1 gene expression by at least 6 h of pretreatment, and the inhibition was pretreatment time-dependent and occurred at the transcriptional level of the JE/MCP-1 gene expression. The RA-induced inhibition of the JE/MCP-1 gene product was also evidenced by both an assay involving immuno-precipitation with JE/MCP-1-specific antiserum and an assay for monocyte chemotaxis. Also, RA stimulated the gene expression of three different subclasses of RA receptor. RA pretreatment transcriptionally suppressed the expression of the c-fos gene but not that of the c-jun gene in TNF-alpha-treated cells. Antisense oligonucleotide to c-fos gene inhibited the cytokine-induced JE/MCP-1 gene expression in the cells. Furthermore, RA inhibited activator protein-1 binding to 12-O-tetradecanoylphorbol 13-acetate-response element (TRE) in the cells treated with TNF-alpha, suggesting that RA acts as a potent negative regulator for activator protein-1 binding activity to TRE in the osteoblastic cells.			HANAZAWA, S (corresponding author), MEIKAI UNIV,SCH DENT,DEPT ORAL MICROBIOL,SAKADO,SAITAMA 35002,JAPAN.							ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIETMAN TR, 1980, P NATL ACAD SCI USA, V77, P2936; BRINCKERHOFF CE, 1983, SCIENCE, V221, P756, DOI 10.1126/science.6308759; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5295; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1175; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HACHICHA M, 1993, ARTHRITIS RHEUM, V36, P26, DOI 10.1002/art.1780360106; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANAZAWA S, 1991, BIOCHEM BIOPH RES CO, V180, P1130, DOI 10.1016/S0006-291X(05)81184-2; JAFFEY P, 1992, CANCER RES, V52, P2384; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Maniatis T., 1982, MOL CLONING; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; MUNDY GR, 1978, NATURE, V275, P132, DOI 10.1038/275132a0; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OHMORI Y, 1988, BIOCHIM BIOPHYS ACTA, V970, P22, DOI 10.1016/0167-4889(88)90218-2; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; SARIBAN E, 1988, BLOOD, V71, P488; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULZ WA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P125, DOI 10.1016/0167-4889(89)90040-2; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAKESHITA A, 1993, J IMMUNOL, V150, P1554; TALMAGE DA, 1992, ONCOGENE, V7, P1837; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VAN DJ, 1989, EUR J IMMUNOL, V19, P2367; VILLIGER PM, 1992, IMMUNOLOGY, V149, P722; YLA HS, 1991, P NATL ACAD SCI USA, V88, P5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	51	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21379	21384						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063765				2022-12-25	WOS:A1994PC40300083
J	KATO, I; SUZUKI, Y; AKABANE, A; YONEKURA, H; TANAKA, O; KONDO, H; TAKASAWA, S; YOSHIMOTO, T; OKAMOTO, H				KATO, I; SUZUKI, Y; AKABANE, A; YONEKURA, H; TANAKA, O; KONDO, H; TAKASAWA, S; YOSHIMOTO, T; OKAMOTO, H			TRANSGENIC MICE OVEREXPRESSING HUMAN VASOACTIVE-INTESTINAL-PEPTIDE (VIP) GENE IN PANCREATIC BETA-CELLS - EVIDENCE FOR IMPROVED GLUCOSE-TOLERANCE AND ENHANCED INSULIN-SECRETION BY VIP AND PHM-27 IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GLUCAGON-SECRETION; DIABETES-MELLITUS; POLYPEPTIDE VIP; MESSENGER-RNA; EXPRESSION; MOUSE; RAT; ISLETS; ALPHA	Vasoactive intestinal peptide (VIP), a 28-amino acid peptide hormone, plays many physiological roles in the peripheral and central nervous systems. It has been proposed that endogenous VIP released from VIP-containing nerves is involved in the regulation of the secretory function of the endocrine pancreas. To test this hypothesis in vivo, we produced transgenic mice carrying the human VIP/peptide histidine methionine 27 (PHM-27) gene under the control of insulin promoter. In immunohistochemical analyses of islets, all the islet beta cells of transgenic mice were intensely stained for both VIP and PHM-27, consistent with the fact that these two peptides are encoded in a single mRNA (Itoh, N., Obata, K., Yanaihara, N., and Okamoto, H. (1983) Nature 304, 547-549). VIP was efficiently secreted from isolated transgenic islets in vitro. The blood glucose assays in free-fed mice indicated that the transgene lowered the blood glucose levels of transgenic mice (128 +/- 4 mg/dl) by about 20% below control levels (155 +/- 6 mg/dl). In the glucose tolerance test, at 60 min after glucose administration, the transgenic blood glucose levels (129 +/- 12 mg/dl) were much lower than control levels (175 +/- 13 mg/dl). The transgenic serum insulin levels at 15 min after glucose administration were 2.5-3.0-fold higher than control levels. The transgene was also effective in ameliorating glucose intolerance of 70% depancreatized mice. These results indicate that VIP and PHM-27 produced from the transgenic beta cells efficiently enhance glucose-induced insulin secretion from beta cells by an autocrine mechanism. These results also suggest that genetic manipulation of islet beta cells by the human VIP/PHM-27 gene or delivery of VIP to beta cells may ultimately provide a valuable approach to enhancing insulin secretion in clinical diabetes.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, AOBA KU, SENDAI 98077, MIYAGI, JAPAN; TOHOKU UNIV, SCH MED, DEPT ANAT, SENDAI 98077, MIYAGI, JAPAN; TOHOKU UNIV, SCH MED, DEPT NEUROSURG, SENDAI 98077, MIYAGI, JAPAN	Tohoku University; Tohoku University; Tohoku University								AHREN B, 1981, DIABETOLOGIA, V20, P54, DOI 10.1007/BF00253818; ANTEUNIS A, 1986, CR ACAD SCI III-VIE, V303, P357; BARBEZAT GO, 1971, SCIENCE, V174, P422, DOI 10.1126/science.174.4007.422; BISHOP AE, 1980, DIABETOLOGIA, V18, P73, DOI 10.1007/BF01228307; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; FAHRENKRUG J, 1987, REGUL PEPTIDES, V18, P51, DOI 10.1016/0167-0115(87)90050-4; GEPTS W, 1985, DIABETIC PANCREAS, P337; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEISTAD DD, 1980, AM J PHYSIOL, V239, pH73, DOI 10.1152/ajpheart.1980.239.1.H73; HOGAN B, 1986, MANIPULATING MOUSE E; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HOLST JJ, 1987, AM J PHYSIOL, V252, pG182, DOI 10.1152/ajpgi.1987.252.2.G182; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; LAMPERTI ED, 1991, MOL BRAIN RES, V9, P217, DOI 10.1016/0169-328X(91)90005-I; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; LUNDBERG JM, 1982, NATURE, V295, P147, DOI 10.1038/295147a0; MAGISTRETTI PJ, 1981, P NATL ACAD SCI-BIOL, V78, P6535, DOI 10.1073/pnas.78.10.6535; MILLER RE, 1981, ENDOCR REV, V2, P471, DOI 10.1210/edrv-2-4-471; NISHIZAWA M, 1985, FEBS LETT, V183, P55, DOI 10.1016/0014-5793(85)80953-4; NOGUCHI M, 1988, TOHOKU J EXP MED, V156, P191, DOI 10.1620/tjem.156.191; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; PFEIFER MA, 1981, AM J MED, V70, P579, DOI 10.1016/0002-9343(81)90579-9; PIPER PJ, 1970, NATURE, V225, P1144, DOI 10.1038/2251144a0; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; SACCHI TB, 1992, PANCREAS, V7, P601, DOI 10.1097/00006676-199209000-00014; SAID S, 1982, VASOACTIVE INTESTINA; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; SAID SI, 1986, J ENDOCRINOL INVEST, V9, P191, DOI 10.1007/BF03348097; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHEBALIN M, 1977, AM J PHYSIOL, V232, pE197, DOI 10.1152/ajpendo.1977.232.2.E197; STEFAN Y, 1982, DIABETES, V31, P694, DOI 10.2337/diabetes.31.8.694; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; SZECOWKA J, 1983, ENDOCRINOLOGY, V112, P1469, DOI 10.1210/endo-112-4-1469; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; UNNO M, 1993, J BIOL CHEM, V268, P15974; WAHL MA, 1993, DIABETOLOGIA, V36, P920, DOI 10.1007/BF02374473; YAMAGAMI T, 1988, ANN NY ACAD SCI, V527, P87; YANAIHARA C, 1986, PEPTIDES, V7, P83, DOI 10.1016/0196-9781(86)90169-5	44	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21223	21228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063743				2022-12-25	WOS:A1994PC40300061
J	THOMPSON, MJ; ROE, MW; MALIK, RK; BLACKSHEAR, PJ				THOMPSON, MJ; ROE, MW; MALIK, RK; BLACKSHEAR, PJ			INSULIN AND OTHER GROWTH-FACTORS INDUCE BINDING OF THE TERNARY COMPLEX AND A NOVEL PROTEIN COMPLEX TO THE C-FOS SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; KINASE-C; TRANSCRIPTIONAL ACTIVATION; FACTOR P62TCF; EXPRESSION; PHOSPHORYLATION; SEQUENCES; DOMAIN; CDNA; IDENTIFICATION	Rapid, transient induction of c-fos transcription follows treatment of cells with insulin and other growth factors. This is mediated through the serum response element (SRE), which binds the serum response factor (SRF), as well as accessory factors such as p62 ternary complex factor. Using a gel shift assay we found that formation of the ternary complex increased transiently within 2 min of insulin or phorbol ester treatment of several insulin-sensitive cell lines. However, mutations that prevented formation of this ternary complex did not inhibit insulin- or phorbol ester-stimulated induction of c-fos transcription in these cell Lines. We also identified a novel SRF-containing multiprotein complex that forms on the SRE within 2 min following insulin, phorbol ester, or other growth factor treatment. Formation of this novel complex, called band 3, occurred rapidly and transiently, with a time course parallel to the induction of c-fos transcription. Band 3 also formed with gamma-actin and zif268/3 SRE probes. Methylation and carboxy ethylation interference analysis, as well as extensive SRE mutagenesis, suggest that only the SRF directly contacts the SRF in forming band 3. Formation of this novel complex appears to involve protein-protein interactions between SRF and other nuclear protein(s) that may play a role in growth factor stimulation of c-fos transcription.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DIV ENDOCRINOL,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [DK07012] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007012] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MANAK JR, 1993, ONCOGENE, V8, P703; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Sprague G F Jr, 1990, Adv Genet, V27, P33; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	46	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21127	21135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063733				2022-12-25	WOS:A1994PC40300049
J	DYE, RB; FINK, SP; WILLIAMS, RC				DYE, RB; FINK, SP; WILLIAMS, RC			TAXOL-INDUCED FLEXIBILITY OF MICROTUBULES AND ITS REVERSAL BY MAP-2 AND TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STRUCTURAL-CHANGES; TUBULIN SHEETS; PROTEINS; INVITRO; CELLS; BRAIN; REMOVAL	When microtubules, ordinarily quite rigid structures, are treated in vitro with the anti-tumor drug taxol, they rapidly develop a wavy appearance and become strikingly flexible. A quantitative measure of their flexibility, the reciprocal statistical length, lambda, increases by an order of magnitude when taxol is bound. Subsequent addition of either of the microtubule-associated proteins MAP-2 or tau causes the flexibility to disappear. It can be restored again by removing the microtubule-associated protein. These results show that taxol changes microtubular structure substantially, probably by weakening the interactions between protofilaments, and that microtubule-associated proteins reverse these effects, possibly by bridging protofilaments. This structural change and the accompanying flexibility may contribute importantly to taxol's cytotoxic activity.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Vanderbilt University				Fink, Stephen/0000-0003-4107-7912	NIGMS NIH HHS [GM-25638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINHANJANI S, 1991, CELL MOTIL CYTOSKEL, V20, P136, DOI 10.1002/cm.970200206; Amos L.A., 1979, MICROTUBULES, P1; AMOS LA, 1991, J CELL SCI, P95; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BERG HC, 1984, J GEN MICROBIOL, V130, P2915; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; EDSON K, 1993, IN PRESS DEVELOPMENT, V117; HEIDEMANN SR, 1990, CELL MOTIL CYTOSKEL, V17, P6, DOI 10.1002/cm.970170103; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Inoue S, 1986, VIDEO MICROSCOPY; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; MCEWEN BF, 1983, J MOL BIOL, V166, P119, DOI 10.1016/S0022-2836(83)80002-3; MIZUSHIMASUGANO J, 1983, BIOCHIM BIOPHYS ACTA, V755, P257, DOI 10.1016/0304-4165(83)90212-X; NAGASHIMA H, 1980, J MOL BIOL, V136, P169, DOI 10.1016/0022-2836(80)90311-3; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RINGEL I, 1991, J PHARMACOL EXP THER, V259, P855; ROBERTS RL, 1982, J IMMUNOL, V129, P2134; ROWINSKY EK, 1988, CANCER RES, V48, P4093; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; SMALHEISER NR, 1991, DEV BRAIN RES, V58, P271, DOI 10.1016/0165-3806(91)90015-B; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEISSHAAR B, 1992, DEVELOPMENT, V116, P1151; WILLIAMS R C JR, 1992, P151; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WINCKLER B, 1991, P NATL ACAD SCI USA, V88, P6033, DOI 10.1073/pnas.88.14.6033; YAMAZAKI S, 1982, BIOL FUNCTIONS MICRO	34	121	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6847	6850						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096507				2022-12-25	WOS:A1993KV14100007
J	PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R				PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R			EXPRESSION OF THE C-ERBB2 GENE IN THE BT474 HUMAN MAMMARY-TUMOR CELL-LINE - MEASUREMENT OF C-ERBB2 MESSENGER-RNA HALF-LIFE	ONCOGENE			English	Article							HUMAN BREAST-CANCER; PROTO-ONCOGENE; GROWTH-FACTOR; EGF-RECEPTOR; C-MYC; HER-2/NEU PROTOONCOGENE; OVARIAN-CANCER; OVEREXPRESSION; LIGAND; ACTIVATION	BT474 and SK-BR-3 mammary adenocarcinoma cells contain eight copies of the c-erbB2 gene but overexpress the mRNA 80 times over the levels measured in normal breast or in the HBL-100 cell line. Using Northern blot analysis and molecular titration based on RNAase protection assay, the decrease in the c-erbB2 mRNA level was monitored in BT474 cells treated with actinomycin D from 1 up to 24 h. The c-erbB2 degradation rate during the first 12 h corresponds to a calculated c-erbB2 mRNA half-life of approximately 7 h. Forty percent of the mRNA present in the cells before treatment remains undegraded after transcription has been blocked for 24 h. Pretreatment with cycloheximide results in complete mRNA degradation in 24 h, suggesting that labile proteins stabilize part of the c-erbB2 mRNA population. Comparison with the c-erbB2 mRNA turnover in HBL100 'normal' cells indicated that the accumulation of the c-erbB2 gene product in the tumor cells is not the result of stabilization of the messenger. Rather, it is correlated with an increased rate of c-erbB2 mRNA transcription as indicated by run-on transcription assays. Both BT474 and SK-BR-3 tumor cell lines were found to synthesize 20-40 times more c-erbB2 mRNA than HBL-100 cells.			PASLEAU, F (corresponding author), UNIV LIEGE,DEPT RADIOIMMUNOL,MOLEC ONCOL LAB,TOUR PATHOL B23,B-4000 SART,BELGIUM.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BERCHUCK A, 1990, CANCER RES, V50, P4087; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DATI C, 1990, ONCOGENE, V5, P1001; DELVENNE CG, 1992, EUR J CANCER, V28A, P700; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; KERN JA, 1990, CANCER RES, V50, P5184; KESAVAN P, 1990, ONCOGENE, V5, P483; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PASLEAU F, 1990, ARCH INT PHYSL BIOCH, V98, P40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PRESS MF, 1990, ONCOGENE, V5, P953; RAYMOND V, 1989, ONCOGENE RES, V5, P1; READ LD, 1990, CANCER RES, V50, P3947; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2179; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEINER DB, 1990, CANCER RES, V50, P421; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	35	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					849	854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096075				2022-12-25	WOS:A1993KT22000005
J	WU, BM; TOMATSU, S; FUKUDA, S; SUKEGAWA, K; ORII, T; SLY, WS				WU, BM; TOMATSU, S; FUKUDA, S; SUKEGAWA, K; ORII, T; SLY, WS			OVEREXPRESSION RESCUES THE MUTANT PHENOTYPE OF L176F MUTATION CAUSING BETA-GLUCURONIDASE DEFICIENCY MUCOPOLYSACCHARIDOSIS IN 2 MENNONITE SIBLINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCURONIDASE DEFICIENCY; HYDROPS-FETALIS; DNA TRANSFECTION; EXPRESSION; VII; CELLS; GENE; PATIENT; PSEUDOGENES; CLONING	Two beta-glucuronidase-deficient Mennonite siblings were found to be homozygous for a mutation in exon 3 of the beta-glucuronidase gene that produces a Leu --> Phe substitution (L176F). The siblings also have the previously described benign polymorphism, P649L. Although their cultured fibroblasts contained 1.5-2.2% of normal beta-glucuronidase activity, transient expression of the L176F/P649L cDNA in COS cells produced nearly as much enzyme activity as the wild-type control cDNA. The L176F/P649L enzyme was as stable as wild-type enzyme following endocytosis by fibroblasts and delivery to lysosomes, but was more labile to heat inactivation at 65 degrees C. To study the mutant enzyme at lower levels of expression, we stably transfected mouse mucopolysaccharidosis type VII cells with the L176F/P649L cDNA and selected single-copy cell lines. Metabolic labeling with [S-35]methionine revealed that cell lines expressing the mutant enzyme activity at low levels (7-10% of the wild type) actually produced the same amount of enzyme protein as the cell lines expressing the more active wild-type enzyme. However, the cell lines expressing four times this much mutant enzyme protein produced 150-200% as much enzyme activity as the cell line expressing the single copy wild-type cDNA These data suggest that overexpression can drive the folding reaction or the self-association of mutant monomers to form active tetramers and, at least partially, correct the beta-glucuronidase deficiency seen at low levels of expression with certain missense mutations.	ST LOUIS UNIV,SCH MED,EA DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104; GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN	Saint Louis University; Gifu University					NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHINSKY DR, 1991, THESIS ST LOUIS U ST; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; ISLAM MR, 1993, J BIOL CHEM, V268, P22627; KOGAN SC, 1990, PCR PROTOCOLS, P288; LEE JES, 1985, AM J DIS CHILD, V139, P57, DOI 10.1001/archpedi.1985.02140030059029; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MA M, 1991, J BIOL CHEM, V266, P10589; MAHURAN DJ, 1991, AM J HUM GENET, V49, P59; MCKUSICK VA, 1988, MENDELIAN INHERITANC, P1626; MILLER RD, 1990, GENOMICS, V7, P280, DOI 10.1016/0888-7543(90)90552-6; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYAZAKI J, 1989, GENE, V79, P269; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NELSON A, 1982, J PEDIATR-US, V101, P574, DOI 10.1016/S0022-3476(82)80707-5; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Sambrook J, 1989, MOL CLONING LABORATO; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SHIPLEY JM, 1993, AM J HUM GENET, V52, P517; SHIPLEY JM, 1991, GENOMICS, V10, P1009, DOI 10.1016/0888-7543(91)90192-H; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SLY WS, 1988, CECIL TXB MED, P1174; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; TOMATSU S, 1991, AM J HUM GENET, V48, P89; TOMATSU S, 1990, GENE, V89, P283, DOI 10.1016/0378-1119(90)90019-N; VERVOORT R, 1993, HUM MUTAT, V2, P443, DOI 10.1002/humu.1380020604; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WU BM, 1993, HUM MUTAT, V2, P446, DOI 10.1002/humu.1380020605	36	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23681	23688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089138				2022-12-25	WOS:A1994PQ34500046
J	LATINKIC, BV; LAU, LF				LATINKIC, BV; LAU, LF			TRANSCRIPTIONAL ACTIVATION OF THE IMMEDIATE-EARLY GENE PIP92 BY SERUM GROWTH-FACTORS REQUIRES BOTH ETS AND CARG-LIKE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; RESPONSE ELEMENT; DNA-BINDING; MEMBRANE DEPOLARIZATION; PROTEIN-SYNTHESIS; FACTOR INDUCTION; PC12 CELLS; EXPRESSION; PROMOTER; SRF	pip92 is an immediate early gene that is transcriptionally activated in mouse 3T3 fibroblasts upon treatment with serum growth factors or the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Here we show that a 73-base pair pip92 promoter fragment located between base pairs 1231 and 1158 upstream of the transcription start site is sufficient to mediate transcriptional activation. This promoter fragment contains two binding sites for transcription factors of the Ets family and a low affinity binding site for the serum response factor. The minimal sequence that mediates serum induction includes at least one copy of the Ets-binding site and a low affinity binding site for the serum response factor. This sequence can interact with at least two proteins in a fibroblast nuclear extract that have binding characteristics of an Ets family protein and a serum response factor-like protein. These proteins can bind the pip92-inducible element simultaneously, thus forming a ternary complex. Furthermore, the same element interacts with recombinant serum response factor and Elk1 proteins individually as well as simultaneously to form a ternary complex. This mode of ternary complex formation is in contrast to the one seen in the promoter of the c-fos protooncogene, where formation of the ternary complex is dependent on the prior assembly of the serum response factor-DNA binary complex. The activation of a number of immediate early genes appears to be mediated through a ternary complex involving members of the Ets family of transcription factors and the serum response factor. We propose that different mechanisms can lead to the formation of such ternary complexes.	UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Latinkic, Branko/0000-0003-4952-123X; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [R01-CA52220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COLECLOUGH C, 1990, P NATL ACAD SCI USA, V87, P1753, DOI 10.1073/pnas.87.5.1753; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LIU SH, 1993, J BIOL CHEM, V268, P21147; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; YOON JK, 1993, J BIOL CHEM, V268, P9148; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	46	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23163	23170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083220				2022-12-25	WOS:A1994PQ16400042
J	LIOTTA, AS; KOLE, HK; FALES, HM; ROTH, J; BERNIER, M				LIOTTA, AS; KOLE, HK; FALES, HM; ROTH, J; BERNIER, M			A SYNTHETIC TRIS-SULFOTYROSYL DODECAPEPTIDE ANALOG OF THE INSULIN-RECEPTOR 1146-KINASE DOMAIN INHIBITS TYROSINE DEPHOSPHORYLATION OF THE INSULIN-RECEPTOR IN-SITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSYL-PROTEIN PHOSPHATASES; GROWTH-FACTOR RECEPTORS; AUTOPHOSPHORYLATION SITES; KINASE-ACTIVITY; HUMAN-PLACENTA; PARTICULATE; PHOSPHORYLATION; PEPTIDE; BETA	A synthetic tris-sulfotyrosyl dodecapeptide (TRDIY-(S)ETDY(S)Y(S)RK-amide), whose primary sequence is identical to the 1142-1153 sequence of the insulin proreceptor, inhibited insulin receptor dephosphorylation in solubilized membranes, and digitonin-permeabilized cells derived from Chinese hamster ovary (CHO) cells expressing high levels of human insulin receptors (CHO/HIRc). It also inhibited the dephosphorylation of a synthetic tyrosine phosphorylated substrate by recombinant PTP-1B, a protein tyrosine phosphatase (PTPase), indicating that it acted via interaction with PTPase(s). A N-stearyl derivative of the peptide caused an similar to 4.5-fold increase in insulin-stimulated receptor autophosphorylation in intact CHO/HIRe cells. The peptide displayed specificity toward tyrosine-class phosphatases only, as it had no effect on the activities of the serine/threonine phosphatases PP-1 and PP-2A, or alkaline phosphatase. The tyrosine sulfate ester bonds of the peptide were stable when incubated with PTP-1B (1 h, 30 degrees C). These data suggest that the sulfotyrosyl peptide functions as a nonhydrolyzable phosphotyrosyl peptide analogue capable of direct interaction with PTPase catalytic domain.	NIA,GERONTOL RES CTR,CLIN PHYSIOL LAB,DIABET UNIT,BALTIMORE,MD 21224; NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University			Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P496; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BRILLON DJ, 1988, ENDOCRINOLOGY, V123, P1837, DOI 10.1210/endo-123-4-1837; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CUSHMAN M, 1992, TETRAHEDRON LETT, V33, P1193, DOI 10.1016/S0040-4039(00)91893-8; DICKENS M, 1991, BIOCHIM BIOPHYS ACTA, V172, P772; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HOIBERG CP, 1969, J AM CHEM SOC, V91, P4273, DOI 10.1021/ja01043a041; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KING MJ, 1988, FEBS LETT, V237, P137, DOI 10.1016/0014-5793(88)80187-X; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P9776; NAKAHARA T, 1988, ANAL BIOCHEM, V154, P194; PENKE B, 1979, 15TH P EUR PEPT S, P582; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SHOELSON SE, 1991, TETRAHEDRON LETT, V32, P6061, DOI 10.1016/0040-4039(91)80753-S; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	34	52	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22996	23001						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	8083198				2022-12-25	WOS:A1994PQ16400017
J	HENDZEL, MJ; SUN, JM; CHEN, HY; RATTNER, JB; DAVIE, JR				HENDZEL, MJ; SUN, JM; CHEN, HY; RATTNER, JB; DAVIE, JR			HISTONE ACETYLTRANSFERASE IS ASSOCIATED WITH THE NUCLEAR MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; CHICKEN ERYTHROCYTES; INSITU HYBRIDIZATION; PARTIAL-PURIFICATION; BASIC PROPERTIES; SODIUM BUTYRATE; NASCENT RNA; ACETYLATION; ORGANIZATION; NUCLEOSOME	Only a small fraction of the adult chicken erythrocyte histones is involved in dynamic acetylation. me have reported previously that the rapidly acetylated and deacetylated H4 histones are primarily associated with the transcriptionally active DNA-enriched chromatin fragments that remain attached to the residual nuclear material following micrococcal nuclease digestion and chromatin solubilization. Furthermore, this nuclear fraction contained most of the histone deacetylase activity. In this study we show that the bulk of the nuclear histone acetyltransferase activity is located with the insoluble residual nuclear material. We demonstrate that in vitro the enzymes associated with the residual nuclear material catalyze reversible acetylation when the endogenous histones of the nuclear skeleton-bound chromatin fragments are used as substrate. Nuclear matrices isolated from adult chicken immature erythrocyte and trout liver nuclei had 60-76% of the nuclear histone acetyltransferase activity. Procedures that solubilized the internal nuclear matrix also resulted in the release of the enzyme from the nuclear matrix. Together, our observations suggest that histone acetyltransferase and deacetylase are associated with the internal nuclear matrix, and one of the functions of these enzymes may be to mediate a dynamic attachment between transcriptionally active chromatin and the nuclear matrix.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG R3E 0W3,MB,CANADA; UNIV CALGARY,FAC MED,DEPT ANAT,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,FAC MED,DEPT BIOCHEM MED,CALGARY T2N 4N1,AB,CANADA	University of Manitoba; University of Calgary; University of Calgary			Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945; Davie, James/0000-0002-0420-6888				ANDREEVA M, 1992, EUR J BIOCHEM, V207, P887, DOI 10.1111/j.1432-1033.1992.tb17121.x; ATTISANO L, 1990, J BIOL CHEM, V265, P3949; BELGRADER P, 1991, J CELL SCI, V98, P281; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BOHM J, 1980, EUR J BIOCHEM, V112, P353, DOI 10.1111/j.1432-1033.1980.tb07212.x; CARTER KC, 1991, J CELL BIOCHEM, V47, P124, DOI 10.1002/jcb.240470205; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CHAN S, 1988, J BIOL CHEM, V263, P15643; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; COVAULT J, 1980, J BIOL CHEM, V255, P9110; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; HASSAN AB, 1994, J CELL SCI, V107, P425; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; IP YT, 1988, J BIOL CHEM, V263, P14044; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KELNER DN, 1984, J BIOL CHEM, V259, P3413; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; RICHARDS RG, 1982, ANAL BIOCHEM, V121, P69, DOI 10.1016/0003-2697(82)90558-9; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; SURES I, 1980, BIOCHEMISTRY-US, V19, P943, DOI 10.1021/bi00546a019; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; van Holde K.E., 1988, CHROMATIN; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WIKTOROWICZ JE, 1982, J BIOL CHEM, V257, P2893; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; ZHANG DE, 1986, BIOCHEM J, V240, P857, DOI 10.1042/bj2400857	58	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22894	22901						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077241				2022-12-25	WOS:A1994PQ16300066
J	UITTENBOGAARD, MN; ARMSTRONG, AP; CHIARAMELLO, A; NYBORG, JK				UITTENBOGAARD, MN; ARMSTRONG, AP; CHIARAMELLO, A; NYBORG, JK			HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX PROTEIN REPRESSES GENE-EXPRESSION THROUGH THE BASIC HELIX-LOOP-HELIX FAMILY OF TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG TERMINAL REPEAT; BETA-POLYMERASE GENE; HTLV-I; REGULATORY ELEMENTS; DNA-BINDING; ENHANCER SEQUENCE; ACTIVATION; TRANSACTIVATION; IDENTIFICATION; STIMULATION	The human T-cell leukemia virus type I (HTLV-I) oncoprotein Tax is a potent activator of viral and cellular gene transcription. Tax does not bind DNA directly but utilizes cellular transcription factors to mediate activation. In this report, we examine the role of the basic helix-loop-helix (bHLH) proteins in Tax deregulation of gene expression, as these proteins play a critical role in progression through the cell cycle and have been implicated in neoplastic disease. We show that the bHLH proteins do not mediate activation, but instead mediate repression of gene expression in the presence of Tax. We further show that a consensus bHLH binding site in the promoter of the beta-polymerase gene, which encodes an enzyme involved in DNA repair, mediates the previously reported repression of beta-polymerase gene expression by Tax. Together, these results suggest that Tax may induce malignant transformation, at least in part, through bHLH-mediated repression of key cellular regulatory genes.	COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA	Colorado State University; Colorado State University			Chiaramello, Anne/AAG-9825-2020	Chiaramello, Anne/0000-0001-8424-0826; Uittenbogaard, Martine/0000-0003-0371-3041	NATIONAL CANCER INSTITUTE [R01CA055035] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA55035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEIMLING P, 1992, ONCOGENE, V7, P257; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOHNLEIN E, 1989, J VIROL, V63, P1578; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HJELLE B, 1991, ARCH PATHOL LAB MED, V115, P440; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	38	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22466	22469						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	8077190				2022-12-25	WOS:A1994PQ16300003
J	BEREZOV, A; IRIARTE, A; MARTINEZCARRION, M				BEREZOV, A; IRIARTE, A; MARTINEZCARRION, M			BINDING TO PHOSPHOLIPID-VESICLES IMPAIRS SUBSTRATE-MEDIATED CONFORMATIONAL-CHANGES OF THE PRECURSOR TO MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION CONTACT SITES; ISOLATED YEAST MITOCHONDRIA; PROTEIN IMPORT MACHINERY; RAT-LIVER MITOCHONDRIA; APOCYTOCHROME-C; MEMBRANE-LIPIDS; OUTER-MEMBRANE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSIT PEPTIDE	Specific labeling of both the mature (mAspAT) and precursor (pmAspAT) forms of rat liver mitochondrial aspartate aminotransferase with three different spectroscopic probes (monobromotrimethylammoniobimane, N-(iodoacetylaminoethyl)-5-naphthalene-1-sulfonic acid, and N-(1-pyrenyl)maleimide) was used to assess the possible conformational consequences of the interaction of a mitochondrial precursor protein with lipid membranes by means of fluorescence spectroscopy. The three probes react with the same cysteine residue causing a partial loss of catalytic activity whose extent depends on the nature of the probe introduced. The fluorescence intensity of the attached probes decreases upon addition of substrates or substrate analogues, indicating that the modified enzymes can undergo the open-closed conformational transitions that accompany catalysis. Both unmodified and labeled precursor proteins bind to negatively charged phospholipid vesicles, whereas the mature enzyme is unable to bind. Binding to liposomes does not affect the fluorescent properties of the attached probes. However, addition of the pseudosubstrate alpha-methylaspartate to liposome-bound precursor fails to induce the characteristic conformational changes observed with the protein free in solution. Furthermore, upon binding to liposomes the precursor protein loses enzymatic activity, and the reactive cysteine residue becomes inaccessible to reaction with thiol reagents. In contrast, the presence of liposomes has no effect on the activity, cysteine reactivity, or syncatalytic conformational transitions of the mature enzyme. It appears that interaction of pmAspAT with negatively charged phospholipids prevents the protein from undergoing the conformational transitions required for catalysis, ''freezing'' the enzyme in a sterically hindered but open-like conformation.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BIRCHMEIER W, 1973, J BIOL CHEM, V248, P1751; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOETTCHER B, 1978, J BIOL CHEM, V253, P4642; CRITZ WJ, 1977, BIOCHEMISTRY-US, V16, P1559, DOI 10.1021/bi00627a005; DEKROON AIPM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P111, DOI 10.1016/0005-2736(91)90199-I; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; EILERS M, 1989, J BIOL CHEM, V264, P2945; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; ENDO T, 1989, J BIOL CHEM, V264, P2951; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GARNIER A, 1993, EUR J BIOCHEM, V216, P763, DOI 10.1111/j.1432-1033.1993.tb18196.x; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GEHRING H, 1978, J BIOL CHEM, V253, P3158; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLICK B, 1991, ANNU REV GENET, V25, P21; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; IRIARTE A, 1984, J BIOL CHEM, V259, P723; IRIARTE A, 1991, INT UNION B, V199, P527; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JANSONIUS JN, 1985, TRANSAMINASES, P109; JENKINS WT, 1960, J BIOL CHEM, V235, P620; JORDI W, 1992, EUR J BIOCHEM, V204, P841, DOI 10.1111/j.1432-1033.1992.tb16703.x; LEENHOUTS JM, 1993, FEBS LETT, V327, P172, DOI 10.1016/0014-5793(93)80164-P; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MARTINEZCARRION M, 1980, ARCH BIOCHEM BIOPHYS, V202, P624, DOI 10.1016/0003-9861(80)90470-1; MARTINEZCARRION M, 1975, ISOZYMES, V2, P567; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MICHUDA CM, 1969, J BIOL CHEM, V244, P5920; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; PETRILLI P, 1977, ESTRATO RENDICONTO 4, V44, P1; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFISTER K, 1985, J BIOL CHEM, V260, P1414; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; PICOT D, 1985, EUR J BIOCHEM, V260, P11414; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REYES AM, 1993, J BIOL CHEM, V268, P22281; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; RIETVELD A, 1984, J BIOL CHEM, V259, P6704; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; SANDMEIER E, 1984, CHEM BIOL ASPECTS B, P117; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STANKEWICZ MJ, 1971, BIOCHEMISTRY-US, V10, P2877; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WELTMAN JK, 1973, J BIOL CHEM, V248, P3173; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323	76	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22222	22229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071348				2022-12-25	WOS:A1994PE09800048
J	MURAKAMI, M; MATSUMOTO, R; AUSTEN, KF; ARM, JP				MURAKAMI, M; MATSUMOTO, R; AUSTEN, KF; ARM, JP			PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1 AND SYNTHASE-2 COUPLE TO DIFFERENT TRANSMEMBRANE STIMULI TO GENERATE PROSTAGLANDIN-D-2 IN MOUSE BONE-MARROW-DERIVED MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONNECTIVE-TISSUE-TYPE; NERVE GROWTH-FACTOR; C-KIT LIGAND; G/H SYNTHASE; COMPLEMENTARY-DNA; MEDIATOR RELEASE; LEUKOTRIENE C-4; MESSENGER-RNA; CDNA CLONING	The view that the two isoforms of prostaglandin-en doperoxide synthase (cyclooxygenase), PGHS-1 and PGHS-2, mediate physiologic and inflammatory processes, respectively, implies separate pathways of arachidonic acid metabolism with different benefits to the host. Functional segregation of these steps in endogenous arachidonic acid metabolism in a single cell in response to different stimuli is now demonstrated. When mouse bone marrow derived mast cells developed in interleukin-3 (IL-3)-containing medium were cultured with c-kit ligand in combination with IL-10 and IL-1 beta, transient expression of PGHS-2 mRNA and protein occurred in a dose- and time-dependent fashion, accompanied by substantial release of prostaglandin D-2 (PGD(2)) into the culture medium from 2 to 10 h. In contrast, induction of PGHS-2 did not mediate an increase in PGD(2) generation in response to stimulation with IgE and antigen. After a longer period of culture, from 24 to 48 h, the expression of PGHS-1 increased, as did the increase in IgE/antigen dependent generation of PGD(2). Dexamethasone, which inhibited the induction of PGHS-2 but not PGHS-1, and a PGHS-2-selective inhibitor suppressed cytokine-induced PGD(2) generation but not IgE-dependent PGD(2) generation. Thus, at a time when both PGHS-1 and PGHS-2 are present in bone marrow-derived mast cells, they function independently by coupling to different stimulus-initiated pathways to PGD(2) generation from endogenously derived arachidonic acid.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R37AI022531, R01AI022531, U19AI031599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DINARELLO CA, 1991, BLOOD, V77, P1627; EKLUND KK, 1993, J IMMUNOL, V151, P4266; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GALLI SJ, 1994, ADV IMMUNOL, V55, P11; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH M, 1992, J IMMUNOL, V149, P2123; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOIKE T, 1993, J IMMUNOL, V151, P359; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LIN LL, 1992, J BIOL CHEM, V267, P23451; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PITTON C, 1988, J IMMUNOL, V141, P2437; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROBIN JL, 1985, J IMMUNOL, V135, P2719; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; URADE Y, 1987, J BIOL CHEM, V262, P3820; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOSHIMOTO T, 1985, P NATL ACAD SCI USA, V82, P8399, DOI 10.1073/pnas.82.24.8399	52	229	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22269	22275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071353				2022-12-25	WOS:A1994PE09800054
J	LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL				LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL			ENHANCED TRANSLATION - A NOVEL MECHANISM OF MDM2 ONCOGENE OVEREXPRESSION IDENTIFIED IN HUMAN TUMOR-CELLS	ONCOGENE			English	Note							WILD-TYPE P53; MONOCLONAL-ANTIBODY; TRANSFORMED-CELLS; SIMIAN VIRUS-40; GENE-EXPRESSION; MUTATIONS; AMPLIFICATION; ANTIGEN; PROTEIN; SARCOMAS	The cellular mdm2 gene, which has potential transforming activity that can be activated by overexpression, is amplified in a significant percentage of human sarcomas and in other mammalian tumors. Proteins encoded by the mdm2 gene can bind to, and inhibit the function of, the protein product of the p53 tumor suppressor gene. As reported here, we have identified human choriocarcinoma cell lines that express high levels of mdm2 proteins as well as the p53 protein. Several lines of evidence demonstrate that the p53 in these tumor cells has a wild-type nucleotide sequence, although the protein exhibits an extended half-life. Further, the more than 100-fold overexpression of mdm2 proteins in these cells cannot be explained by gene amplification, elevated RNA expression, or altered protein stability; rather our data indicate that elevated mdm2 protein levels in these choriocarcinoma cell lines result from enhanced translation. This mechanism has not previously been implicated in the regulation of mdm2 gene expression, and it represents a novel means by which the potential transforming,activity of the mdm2 oncogene could be activated.	UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Landers, John/0000-0001-8084-5043	NATIONAL CANCER INSTITUTE [F32CA060390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050786] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 1F32CA60390] Funding Source: Medline; NHLBI NIH HHS [HL50786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1994, CANCER RES, V54, P794; DVIDOFF AM, 1992, ONCOGENE, V7, P127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; MURPHY M, 1991, J NEUROSCI RES, V30, P475, DOI 10.1002/jnr.490300304; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REIHSAUS E, 1990, ONCOGENE, V5, P137; RUBIO MP, 1993, CANCER RES, V53, P3465; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	44	160	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2745	2750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058341				2022-12-25	WOS:A1994PC05400039
J	KRISHNAN, A; NAIR, PN; JONES, D				KRISHNAN, A; NAIR, PN; JONES, D			ISOLATION, CLONING, AND CHARACTERIZATION OF NEW CHITINASE STORED IN ACTIVE FORM IN CHITIN-LINED VENOM RESERVOIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; ENDOPARASITIC WASP; TRICHOPLUSIA-NI; CHELONUS-SP; PROTEIN; SEQUENCE; EXPRESSION; MELITTIN; CURVIMACULATUS; MASTOPARAN	A 52-kDa protein was purified from the venom gland of an endoparasitic wasp Chelonus sp. near curvimaculatus. The acidic protein (pl 4.8-5.0) was purified, and the NH2-terminal amino acid sequence was determined by direct protein sequencing. A vector-anchored primer and a degenerate primer derived from an 8-amino acid region of the NH2 terminus were used in anchored polymerase chain reaction to generate a probe for screening a cDNA library prepared from mRNA from the venom gland of this wasp. A positive clone of 1596 nucleotides was isolated, sequenced, and found to contain an open reading frame encoding a protein of 483 amino acids. The amino acid sequence encoded in the cDNA clone at the amino terminus was identical to the sequence determined from the purified 52-kDa protein. Comparison of the inferred protein sequence against all of the sequences in the GenBank data base revealed a high degree of similarity to a 62-kDa insect chitinase that is expressed at each molt for the purpose of digesting the chitinous insect cuticle. Two regions that are conserved in a group of chitinases from insects, bacteria and fungi, were also conserved in the wasp 52-kDa protein. The region between amino acid residues 382 and 464 in the 52-kDa wasp chitinase markedly differed in primary sequence from the corresponding region in the 62-kDa insect chitinase, although this region in both the proteins is predicted to have a similar secondary structure predominantly of coils and turns. This region may impart unique structural properties to the 52-kDa chitinase that enables it to exist in an active form in a chitin-lined reservoir without exerting an autotoxic effect to digest the cuticular storage reservoir. Chitinolytic activity occurring in the total venom gland extract was kinetically indistinguishable from that observed for the purified 52-kDa protein, including the substrate concentrations at which maximal velocity and substrate inhibition were reached. The kinetic properties of the 52-kDa wasp chitinase were quite distinct from Serratia marcescens chitinase for both catalytic rate and substrate inhibition.	UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40506	University of Kentucky					NIGMS NIH HHS [GM 33995] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], INTRO PROTEIN STRUCT; ARNOLD K, 1993, MOL BIOCHEM PARASIT, V58, P317, DOI 10.1016/0166-6851(93)90054-2; BLACKWELL J, 1980, J MOL BIOL, V137, P49, DOI 10.1016/0022-2836(80)90156-4; BLUM H, 1987, ELECTROPHORESIS, V10, P333; CHANG CH, 1993, J BIOL CHEM, V268, P4908; ELDEFRAWI ME, 1993, ARCH INSECT BIOCHEM, V22, P25, DOI 10.1002/arch.940220105; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FLETCHER JE, 1993, TOXICON, V31, P669, DOI 10.1016/0041-0101(93)90375-S; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; JONES D, 1986, EXPERIENTIA, V42, P45, DOI 10.1007/BF01975888; JONES D, 1992, J BIOL CHEM, V267, P14871; JONES D, 1986, EXP PARASITOL, V61, P10, DOI 10.1016/0014-4894(86)90129-3; JONES D, 1990, ARCH INSECT BIOCHEM, V13, P95, DOI 10.1002/arch.940130109; Jones Davy, 1993, P227; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KAMEI K, 1989, J BIOCHEM-TOKYO, V105, P979, DOI 10.1093/oxfordjournals.jbchem.a122791; KAWASAKI H, 1970, INSECT BIOCHEM, V1, P130; KIKKAWA S, 1992, FEBS LETT, V305, P237, DOI 10.1016/0014-5793(92)80676-8; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KREIL G, 1980, EUR J BIOCHEM, V111, P49, DOI 10.1111/j.1432-1033.1980.tb06073.x; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELUK J, 1989, TOXICON, V27, P105, DOI 10.1016/0041-0101(89)90410-8; LELUK J, 1989, ARCH INSECT BIOCHEM, V10, P1, DOI 10.1002/arch.940100102; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; SAMAC DA, 1990, PLANT PHYSL ROCKVILL, V93, P904; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR T, 1990, BIOCHIM BIOPHYS ACTA, V1035, P37, DOI 10.1016/0304-4165(90)90170-2; TRONSMO A, 1993, ANAL BIOCHEM, V208, P74, DOI 10.1006/abio.1993.1010; van Marle J., 1986, P17; WARD KA, 1972, J PARASITOL, V58, P546, DOI 10.2307/3278202; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992	38	87	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20971	20976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063715				2022-12-25	WOS:A1994PC40300026
J	ORTH, K; WILLNOW, T; HERZ, J; GETHING, MJ; SAMBROOK, J				ORTH, K; WILLNOW, T; HERZ, J; GETHING, MJ; SAMBROOK, J			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN IS NECESSARY FOR THE INTERNALIZATION OF BOTH TISSUE-TYPE PLASMINOGEN ACTIVATOR-INHIBITOR COMPLEXES AND FREE TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; ENDOTHELIAL-CELLS; MYOCARDIAL-INFARCTION; STRUCTURAL DOMAINS; HIGH-AFFINITY; BINDING; INVIVO; CLEARANCE; SEQUENCE; TURNOVER	Tissue-type plasminogen activator (t-PA) is used as a thrombolytic agent in treatment of myocardial infarction. However, large doses of this agent must be administered in treatment to maintain a thrombolytic state because t-PA is cleared rapidly from circulation. We designed specific ligands to distinguish between two major mechanisms by which t-PA is taken into cells and degraded. One of these mechanisms involves internalization of complexes between t-PA and its cognate inhibitor plasminogen activator inhibitor type-1 (PAI-1); the other mechanism is independent of PAI-1. Using specific inhibitors for low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP), we show that the degradation by hepatocytes of both free t-PA and t-PA.PAI-1 complexes involve the receptor LRP. We demonstrate that fibroblasts degrade both free t-PA (PAI-1-independent) and t-PA complexed with its specific inhibitor PAI-1 (PAI-1-dependent), whereas genetically altered fibroblasts that do not express LRP neither internalize nor degrade these ligands. We also show that a PAI-1-independent, BPA ligand can inhibit the degradation of both free t-PA and t-PA.PAI-1 complexes. We propose LRP is the receptor for both PAI-1-independent and PAI-1-dependent t-PA ligands.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ORTH, K (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017669, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, HL17669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BROWNE MJ, 1990, THROMB RES, V59, P687, DOI 10.1016/0049-3848(90)90429-G; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; GARABEDIAN HD, 1987, J AM COLL CARDIOL, V9, P599, DOI 10.1016/S0735-1097(87)80054-2; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORTON PA, 1989, J BIOL CHEM, V264, P7228; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NILSSON S, 1985, THROMB RES, V39, P511, DOI 10.1016/0049-3848(85)90174-4; NILSSON T, 1984, SCAND J HAEMATOL, V33, P49; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OTTER M, 1991, J BIOL CHEM, V266, P13931; OTTER M, 1992, BIOCHEM J, V284, P545, DOI 10.1042/bj2840545; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; POHL G, 1987, EUR J BIOCHEM, V170, P69, DOI 10.1111/j.1432-1033.1987.tb13668.x; RIJKEN DC, 1990, THROMB RES, P63; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TODD AS, 1959, J PATHOL BACTERIOL, V78, P281, DOI 10.1002/path.1700780131; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERSTRAETE M, 1985, J PHARMACOL EXP THER, V235, P506; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	41	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21117	21122						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063731				2022-12-25	WOS:A1994PC40300047
J	TAN, XL; VARUGHESE, M; WIDGER, WR				TAN, XL; VARUGHESE, M; WIDGER, WR			A LIGHT-REPRESSED TRANSCRIPT FOUND IN SYNECHOCOCCUS PCC-7002 IS SIMILAR TO A CHLOROPLAST-SPECIFIC SMALL-SUBUNIT RIBOSOMAL-PROTEIN AND TO A TRANSCRIPTION MODULATOR PROTEIN ASSOCIATED WITH SIGMA-54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-GREEN-ALGA; NTRA RPON GENE; ESCHERICHIA-COLI; FREMYELLA-DIPLOSIPHON; CHROMATIC ADAPTATION; SEQUENCE-ANALYSIS; SP PCC-7002; CYANOBACTERIUM; EXPRESSION; CLONING	The gene encoding a novel light-repressed transcript (lrtA) contained within a 2.7-kbp EcoRI fragment has been cloned and sequenced from the unicellular cyanobacterium, Synechococcus PCC 7002. Northern analysis indicates that this transcript is synthesized rapidly in the dark, but upon 20 min of illumination, transcript levels fall below detectable limits. An open reading frame was located 378 bases from the start of the transcript which encodes a 21-kDa protein with significant homology to two hitherto different proteins. The protein sequence LrtA showed 37% sequence identity and 58% sequence similarity to the chloroplast-specific small subunit ribosomal protein, S30, and 37% sequence identity and 60% sequence similarity to the reported transcription modulator protein of sigma 54 found in Klebsiella pneumonia and Azotobacter vinelandii. Expression of the lrtA gene product is not detectable within 1 h after placing the cells in the dark, however, within 2.5 min of illumination, [S-35]methionine incorporated into a 21-kDa protein. To a lessor extent, [S-35]methionine incorporation into a 17- and a 14-kDa protein was also seen which was followed by two other recognizable waves of translation at 5 and 10 min. This incorporation was not blocked by rifampicin added to dark-adapted cells prior to illumination. [S-35]Methionine pulsed-labeling experiments suggested that the translation of lrtA occurred only during the first 10 min of reillumination of dark-adapted cells. The loss of initial [S-35]methionine labeling in the light of the 21-kDa protein in a kanamycin-interrupted lrtA gene mutant suggests that the lrtA codes for the 21-kDa protein.	UNIV HOUSTON, DEPT BIOCHEM & BIOPHYS SCI, HOUSTON, TX 77204 USA	University of Houston System; University of Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046297] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46297] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGER DK, 1990, J BACTERIOL, V172, P4399, DOI 10.1128/jb.172.8.4399-4406.1990; BINDER BJ, 1990, J BACTERIOL, V172, P2313, DOI 10.1128/jb.172.5.2313-2319.1990; BISANZSEYER C, 1989, PLANT MOL BIOL, V12, P201, DOI 10.1007/BF00020505; BOTTOMLEY PJ, 1976, ARCH MICROBIOL, V108, P249, DOI 10.1007/BF00454849; BRAND SN, 1992, PLANT MOL BIOL, V20, P481, DOI 10.1007/BF00040607; BRUNS BU, 1989, J BACTERIOL, V171, P901, DOI 10.1128/jb.171.2.901-908.1989; BUSTIS SA, 1993, MOL GEN GENETE, V232, P221; CHEN XG, 1993, J BACTERIOL, V175, P5106, DOI 10.1128/JB.175.16.5106-5116.1993; CHIANG GG, 1992, P NATL ACAD SCI USA, V89, P9415, DOI 10.1073/pnas.89.20.9415; COBLEY JG, 1983, J BACTERIOL, V153, P1486, DOI 10.1128/JB.153.3.1486-1492.1983; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GALLAGHER TF, 1982, EMBO J, V1, P1493, DOI 10.1002/j.1460-2075.1982.tb01345.x; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GROSSMAN AR, 1993, J BACTERIOL, V175, P575, DOI 10.1128/JB.175.3.575-582.1993; INOUYE S, 1989, GENE, V85, P145; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KULIK I, 1991, J BACTERIOL, V173, P1125; LIANG J, 1992, P NATL ACAD SCI USA, V89, P5655, DOI 10.1073/pnas.89.12.5655; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRICK MJ, 1989, MOL MICROBIOL, V3, P1765, DOI 10.1111/j.1365-2958.1989.tb00162.x; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; ORS A, 1981, J MOL BIOL, V147, P217; Pallotta D., 1986, MOL BIOL PHYSARUM PO, P315; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; SCHMIDT J, 1993, BIOCHEM MOL BIOL INT, V29, P25; SINGER RA, 1975, NATURE, V253, P650, DOI 10.1038/253650a0; SMITH S, 1991, GENETIC DATA ENV GDE; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SURANYI G, 1987, J BACTERIOL, V169, P632, DOI 10.1128/jb.169.2.632-639.1987; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOGELMANN TC, 1978, PLANTA, V143, P233, DOI 10.1007/BF00391993; WARRELMANN J, 1992, ARCH MICROBIOL, V158, P107, DOI 10.1007/BF00245213; WIDGER WR, 1991, PHOTOSYNTH RES, V30, P71, DOI 10.1007/BF00042005; ZHOU DX, 1989, MOL GEN GENET, V219, P204, DOI 10.1007/BF00261178	39	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20905	20912						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063707				2022-12-25	WOS:A1994PC40300017
J	PRASADARAO, NV; WASS, CA; HACKER, J; JANN, K; KIM, KS				PRASADARAO, NV; WASS, CA; HACKER, J; JANN, K; KIM, KS			ADHESION OF S-FIMBRIATED ESCHERICHIA-COLI TO BRAIN GLYCOLIPIDS MEDIATED BY SFAA GENE-ENCODED PROTEIN OF S-FIMBRIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOPLASMA-PNEUMONIAE; SULFATED GLYCOLIPIDS; SEQUENCE HOMOLOGY; K-ANTIGEN; BINDING; CELLS; GLYCOSPHINGOLIPIDS; IDENTIFICATION; GANGLIOSIDES; RECOGNITION	In an attempt to further assess the role of S-fimbriae in the pathogenesis of Escherichia coli meningitis, the adherence of E. coli strains with or without S-fimbriae were examined for this study to purified glycolipids using thin layer chromatography overlay assays. Only S-fimbriated E. coli strains bound to sulfatide, seminolipid, galactosyl ceramide, and lactosyl ceramide but not to gangliosides including sialyl neolacto-series and other neutral glycolipids. The binding of S-fimbriated E. coli to sulfatide was temperature dependent (i.e. maximal at 37-degrees-C) and inhibited by S-fimbriae, anti-S-fimbriae, and anti-S-adhesin antibodies as well as by sulfatide, galactosyl ceramide, and lactosyl ceramide. E. coli transformants which lack the sfaA gene from the Sfa gene cluster showed no binding to the glycolipids, while other transformants lacking the adhesin gene sfaS or sfaG or H and mutants obtained by site-directed mutagenesis in the sfaS gene exhibited a similar binding to the glycolipids compared to the parent S-fimbriated strain. A large amount of sulfated glycolipids was demonstrated on brain endothelial cells and the binding of S-fimbriated E. coli to brain endothelial cells was inhibited by these glycolipids. These findings suggest that the binding of S-fimbriated E. coli to brain endothelial cells occurs in part via glycolipids containing terminal Gal(3SO4)beta-1 residues and in part by S-fimbriae protein SfaA. S-adhesin was not involved in the binding of S-fimbriae to these glycolipids.	CHILDRENS HOSP LOS ANGELES, DIV INFECT DIS 51, 4650 SUNSET BLVD, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA; UNIV WURZBURG, INST GENET & MIKROBIOL, W-8700 WURZBURG, GERMANY; MAX PLANCK INST IMMUNBIOL, W-7800 FREIBURG, GERMANY	Children's Hospital Los Angeles; University of Southern California; University of Wurzburg; Max Planck Society					NINDS NIH HHS [R01-NS-26310] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE C, 1988, FEMS MICROBIOL LETT, V51, P153, DOI 10.1111/j.1574-6968.1988.tb02988.x; ALPHEN LV, 1991, INFECT IMMUN, V59, P4473; BANAI M, 1978, INFECT IMMUN, V21, P365, DOI 10.1128/IAI.21.2.365-372.1978; BRENNAN MJ, 1987, INFECT IMMUN, V55, P487, DOI 10.1128/IAI.55.2.487-489.1987; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; CROOK SJ, 1986, BIOCHEMISTRY-US, V25, P7488, DOI 10.1021/bi00371a035; CROSS AS, 1986, J INFECT DIS, V154, P497, DOI 10.1093/infdis/154.3.497; FAROOQUI AA, 1985, MOL CELL BIOCHEM, V66, P87; GEMSKI P, 1980, FEMS LETT, V9, P192; GORSKI F, 1977, FEMS MICROBIOL LETT, V1, P265, DOI 10.1016/0378-1097(77)90070-2; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HU PC, 1976, INFECT IMMUN, V14, P217, DOI 10.1128/IAI.14.1.217-224.1976; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KANNAGI R, 1982, P NATL ACAD SCI-BIOL, V79, P3470, DOI 10.1073/pnas.79.11.3470; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KIM KS, 1992, J CLIN INVEST, V90, P897, DOI 10.1172/JCI115965; KIM KS, 1990, PEDIATR RES, V27, P272; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MARRE R, 1990, INFECT IMMUN, V58, P3434, DOI 10.1128/IAI.58.10.3434-3437.1990; MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462; OPAL S, 1982, INFECT IMMUN, V37, P956, DOI 10.1128/IAI.37.3.956-960.1982; ORSKOV I, 1983, PROG ALLERGY, V33, P80; OTT M, 1988, J BACTERIOL, V170, P3983, DOI 10.1128/jb.170.9.3983-3990.1988; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PARKKINEN J, 1983, BIOCHEM BIOPH RES CO, V111, P456, DOI 10.1016/0006-291X(83)90328-5; PARKKINEN J, 1989, INFECT IMMUN, V57, P2256, DOI 10.1128/IAI.57.7.2256-2259.1989; PARKKINEN J, 1988, J CLIN INVEST, V81, P860, DOI 10.1172/JCI113395; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; ROBERTS DD, 1988, CANCER RES, V48, P3367; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHMOLL T, 1987, FEMS MICROBIOL LETT, V41, P229; SIEGEL JD, 1981, NEW ENGL J MED, V304, P642, DOI 10.1056/NEJM198103123041105; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; TOMKINS DC, 1990, J CLIN INVEST, V85, P1248; VAISANEN V, 1982, LANCET, V1, P192; WESTERLUND B, 1989, FEBS LETT, V243, P199, DOI 10.1016/0014-5793(89)80129-2; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; 1986, EUR J BIOCHEM, V159, P1	45	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10356	10363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098039				2022-12-25	WOS:A1993LB80000058
J	YU, LJ; COHEN, D; PIEKARZ, RL; HORWITZ, SB				YU, LJ; COHEN, D; PIEKARZ, RL; HORWITZ, SB			3 DISTINCT NUCLEAR-PROTEIN BINDING-SITES IN THE PROMOTER OF THE MURINE MULTIDRUG RESISTANCE MDR1B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN PRECURSORS; HEAT-SHOCK FACTOR; NF-KAPPA-B; MAMMALIAN-CELLS; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; J774.2 CELLS; EXPRESSION; DNA	Multidrug resistance in mammalian cells is often associated with the overproduction of a membrane glycoprotein, P-glycoprotein, that is encoded by mdr genes. Multidrug resistance cell lines selected with either vinblastine, colchicine, or taxol from the drug-sensitive murine macrophage-like cell line J774.2 overexpress the mdr1a and/or mdr1b genes, and overproduce P-glycoprotein. To elucidate the mechanisms of mdr1b gene expression, the mdr1b 5'-flanking sequences have been isolated from a normal mouse liver genomic library and analyzed by gel shift and DNase I footprinting assays. These analyses have demonstrated three nuclear protein binding sites, from -82 to -59 (site 1), from -123 to -101 (site 2), and from -272 to -249 (site 3), which interact with proteins present in nuclear extracts from both sensitive and resistant cells. Although site 1 contains a partially conserved AP-2 consensus sequence, our results indicate that the nuclear protein binding to site 1 is not AP-2 protein. The sequence of site 2 is conserved in the murine mdr1a, human mdr1, and hamster pgp1 promoters. Such conservation suggests that this sequence may have an important role in mdr gene expression. The use of a transient chloramphenicol acetyltransferase expression vector containing the basal promoter for herpes simplex virus thymidine kinase (tkCAT) and either site 1 or site 2 or both revealed that the sequences of sites 1 and 2 enhanced tkCAT activity. DNase I footprinting analyses demonstrated that site 3 is recognized by human AP-1 protein, indicating that the nuclear protein binding to this site is an AP-1-like protein. These observations suggest that mdr1b gene expression is mediated by preexisting transcription factors present in sensitive and resistant cells.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Piekarz, Richard/GXH-9978-2022		NCI NIH HHS [CA39821, 5P30CA1330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001330, R35CA039821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN D, 1991, J BIOL CHEM, V266, P2239; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; KOHNO K, 1990, J BIOL CHEM, V265, P19690; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; ROY SN, 1985, CANCER RES, V45, P3856; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927	49	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7520	7526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096513				2022-12-25	WOS:A1993KV14100100
J	DIDONATO, L; DESROSIERS, C; MONTGOMERY, JA; DAVID, F; GARNEAU, M; BRUNENGRABER, H				DIDONATO, L; DESROSIERS, C; MONTGOMERY, JA; DAVID, F; GARNEAU, M; BRUNENGRABER, H			RATES OF GLUCONEOGENESIS AND CITRIC-ACID CYCLE IN PERFUSED LIVERS, ASSESSED FROM THE MASS-SPECTROMETRIC ASSAY OF THE C-13 LABELING PATTERN OF GLUTAMATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-MERCAPTOPICOLINIC ACID; KREBS CYCLE; QUANTITATIVE-ANALYSIS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; INTERMEDIARY METABOLISM; GUINEA-PIG; INVIVO; PYRUVATE; CARBON; NMR	Absolute rates of gluconeogenesis and of the citric acid cycle were assessed in livers isolated from 2,4-h starved rats, perfused with physiological concentrations of [3-C-13]lactate and [3-C-13]pyruvate +/- 0.2 mm octanoate. Calculations are based on (i) the C-13-labeling pattern of glutamate determined by gas chromatography-mass spectrometry combined with isotopomer analysis, (ii) substrate balance, and (iii) equations developed by Magnusson et al. (Magnusson, I., Schumann, W. C., Bartsch, G. E., Chandramouli, V., Kumaran, K., Wahren, J., and Landau, B. R. (1991) J. Biol. Chem. 266, 6975-6984) based on a citric acid cycle model proposed by Katz (Katz, J. (1985) Am. J. Physiol. 248, R391-R399). Glutamate, isolated from liver extracts, is enzymatically or chemically converted to gamma-aminobutyrate, alpha-hydroxyglutarate, isocitrate, and glutamine before mass spectrometric analysis. General equations have been developed (''Appendix I'') to determine the isotopic enrichment of each carbon of glutamate from the isotopic enrichment of fragments obtained from the mass spectra of trimethylsilyl or t-butyldimethylsilyl derivatives of glutamate and of derived compounds (''Appendix II''). In the presence of octanoate, (i) the rate of the citric acid cycle decreases from 0.25 to 0.13 mumol/min x g wet weight which are one-third and one-sixth of the rate of pyruvate carboxylation, and (ii) the rate of gluconeogenesis increases from 0.65 to 0.83 mumol/min x g wet weight. The rate of pyruvate carboxylation is 13 and 34-fold faster than that of pyruvate dehydrogenation in the absence or presence of octanoate, respectively. The rate of oxaloacetate to fumarate interconversion is at least six times greater than that of the citric acid cycle. Our data closely agree with those obtained by Magnusson et al. who used a non-invasive ''chemical biopsy'' of the human liver and support the use of labeled lactate and/or pyruvate for tracing hepatic metabolism in vivo.	UNIV MONTREAL, DEPT BIOCHEM, MONTREAL H3C 3J7, QUEBEC, CANADA; UNIV MONTREAL, DEPT NUTR, MONTREAL H3C 3J7, QUEBEC, CANADA; CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA	Universite de Montreal; Universite de Montreal; Case Western Reserve University			Rosiers, Christine Des/O-6285-2014		NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LW, 1987, ANAL BIOCHEM, V163, P358, DOI 10.1016/0003-2697(87)90236-3; BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V4, P1696; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI DOI 10.1016/B978-0-12-091304-6.50017-3; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; Brunengraber H, 1975, Methods Enzymol, V35, P597, DOI 10.1016/0076-6879(75)35187-2; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHEN RF, 1963, BIOCHEMISTRY-US, V2, P752, DOI 10.1021/bi00904a022; COHEN SM, 1983, J BIOL CHEM, V258, P4294; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; DESAGE M, 1989, BIOMED ENVIRON MASS, V18, P1010, DOI 10.1002/bms.1200181110; DIDONATO L, 1992, FASEB J, V6, pA1520; DIDONATO L, 1990, FASEB J, V4, P708; DITULLIO NW, 1974, BIOCHEM J, V138, P387, DOI 10.1042/bj1380387; GAVINO VC, 1987, J BIOL CHEM, V262, P6735; GOODMAN MN, 1975, BIOCHEM J, V150, P137, DOI 10.1042/bj1500137; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HERRERA M. G., 1966, ADVANC ENZYME REGULAT, V4, P225, DOI 10.1016/0065-2571(66)90017-3; HETENYI G, 1982, FED PROC, V41, P104; JEFFREY FMH, 1991, TRENDS BIOCHEM SCI, V16, P5, DOI 10.1016/0968-0004(91)90004-F; KALDERON B, 1989, AM J PHYSIOL, V257, pE346, DOI 10.1152/ajpendo.1989.257.3.E346; KALHAN SC, 1990, J LAB CLIN MED, V116, P615; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1987, FEBS LETT, V220, P257, DOI 10.1016/0014-5793(87)80916-X; KATZ J, 1979, TECHNIQUES METABOLIC, P1; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KINGDON HS, 1968, BIOCHEMISTRY-US, V7, P2136, DOI 10.1021/bi00846a016; KOEPPE RE, 1959, J BIOL CHEM, V234, P2219; KOSTOS V, 1975, ARCH BIOCHEM BIOPHYS, V171, P459, DOI 10.1016/0003-9861(75)90054-5; KREBS HA, 1965, BIOCHEM J, V94, pC3, DOI 10.1042/bj0940003C; LEE WNP, 1991, STABLE ISOTOPES PEDI, P179; LIU KJM, 1990, J SURG RES, V49, P179, DOI 10.1016/0022-4804(90)90259-5; Lund P., 1974, METHODS ENZYMATIC AN, V4, P1719; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; PRASS RL, 1980, J BIOL CHEM, V255, P5215; ROBINSON BH, 1975, FEBS LETT, V58, P12, DOI 10.1016/0014-5793(75)80214-6; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; ROSIERS CD, 1990, AM J PHYSIOL, V258, pE519; ROSS BD, 1967, BIOCHEM J, V105, P869, DOI 10.1042/bj1050869; RUDERMAN NB, 1971, REGULATION GLUCONEOG, P194; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHERRY AD, 1985, J BIOL CHEM, V260, P9272; SHULMAN GI, 1987, J CLIN INVEST, V80, P387, DOI 10.1172/JCI113084; SOLING HD, 1968, EUR J BIOCHEM, V4, P364, DOI 10.1111/j.1432-1033.1968.tb00220.x; SOLING HD, 1965, KLIN WOCHENSCHR, V43, P914; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; STRUCK E., 1966, ADVANC ENZYME REGULAT, V4, P219, DOI 10.1016/0065-2571(66)90016-1; STRUCK E, 1965, BIOCHEM Z, V343, P107; TEUFEL H, 1967, EUR J BIOCHEM, V2, P182, DOI 10.1111/j.1432-1033.1967.tb00124.x; TSERNG KY, 1991, J BIOL CHEM, V266, P2924; WEINMAN EO, 1957, PHYSIOL REV, V37, P252, DOI 10.1152/physrev.1957.37.2.252; WIELAND OH, 1972, EUR J BIOCHEM, V26, P426, DOI 10.1111/j.1432-1033.1972.tb01783.x; WIELAND OH, 1967, EUR J BIOCHEM, V2, P182; Williamson J R, 1968, Adv Enzyme Regul, V6, P67, DOI 10.1016/0065-2571(68)90008-3; Williamson J R, 1967, Adv Enzyme Regul, V5, P229, DOI 10.1016/0065-2571(67)90019-2; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4607; [No title captured]	65	77	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4170	4180						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095046				2022-12-25	WOS:A1993KN53300056
J	BRUNSCHIER, R; DANNER, M; SECKLER, R				BRUNSCHIER, R; DANNER, M; SECKLER, R			INTERACTIONS OF PHAGE-P22 TAILSPIKE PROTEIN WITH GROE MOLECULAR CHAPERONES DURING REFOLDING INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FOLDING MUTATIONS; RECONSTITUTION; TEMPERATURE; P22; INTERMEDIATE; CARBOXYLASE; AGGREGATION; SUPPRESSION; RHODANESE; SURFACE	Because efficient folding in vivo and reconstitution in vitro of phage P22 tailspike protein is temperature-sensitive, and because a chaperone function of the GroE proteins for tailspike folding in vivo has been suggested by genetic observations, the interactions of purified Escherichia coli GroE proteins with phage P22 tailspikes during refolding in vitro were investigated. At elevated temperature (>30-degrees-C), in the absence of ATP, GroEL effectively trapped refolding tailspike protein and prevented reconstitution. Tail-spike protein was released from GroEL by addition of ATP around 35-degrees-C or without added ATP upon cooling to 25-degrees-C, and native tailspike trimers were formed. In accordance with the cold release, tailspike reconstitution at less-than-or-equal-to 25-degrees-C was unaffected by GroE. No formation of native tailspike trimers was observed, when refolding was initiated at 42-degrees-C in the presence of the GroE proteins and ATP or when tailspike protein was dissociated from a preformed complex with the chaperone by addition of ATP at 42-degrees-C. In contrast to other GroE ligands, the tailspike polypeptide was bound by and released from GroE in similar states of folding, and the presence of GroES in addition to GroEL had no effect on reconstitution yields at any temperature. Thus, the GroE proteins may exhibit widely differing interactions even with proteins showing similarly temperature-sensitive yields of folding.			BRUNSCHIER, R (corresponding author), UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, UNIV STR 31, W-8400 REGENSBURG, GERMANY.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KING J, 1990, N HORIZ TH, P59; King J, 1986, Methods Enzymol, V131, P250; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SECKLER R, 1989, J BIOL CHEM, V264, P11750; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YU MH, 1988, J BIOL CHEM, V263, P1424	26	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2767	2772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8094077				2022-12-25	WOS:A1993KK81500076
J	EMI, M; ASAOKA, H; MATSUMOTO, A; ITAKURA, H; KURIHARA, Y; WADA, Y; KANAMORI, H; YAZAKI, Y; TAKAHASHI, E; LEPERT, M; LALOUEL, JM; KODAMA, T; MUKAI, T				EMI, M; ASAOKA, H; MATSUMOTO, A; ITAKURA, H; KURIHARA, Y; WADA, Y; KANAMORI, H; YAZAKI, Y; TAKAHASHI, E; LEPERT, M; LALOUEL, JM; KODAMA, T; MUKAI, T			STRUCTURE, ORGANIZATION, AND CHROMOSOMAL MAPPING OF THE HUMAN MACROPHAGE SCAVENGER RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; LINKAGE MAP; HYBRIDIZATION; LOCALIZATION; EXPRESSION; PROTEINS; PROMOTER; ELEMENT; RNA	Macrophage scavenger receptors (MSR) mediate the binding, internalization, and processing of a wide range of negatively charged macromolecules. Functional MSR are trimers of two C-terminally different subunits that contain six functional domains. We have cloned an 80-kilobase human MSR gene and localized it to band p22 on chromosome 8 by fluorescent in situ hybridization and by genetic linkage using three common restriction fragment length polymorphisms. The human MSR gene consists of 11 exons, and two types of mRNAs are generated by alternative splicing from exon 8 to either exon 9 (type II) or to exons 10 and 11 (type I). The promoter has a 23-base pair inverted repeat with homology to the T cell element. Exon 1 encodes the 5'-untranslated region followed by a 12-kilobase intron which separates the transcription initiation and the translation initiation sites. Exon 2 encodes a cytoplasmic domain, exon 3, a transmembrane domain, exons 4 and 5, an alpha-helical coiled-coil, and exons 6-8, a collagen-like domain. The position of the gap in the coiled coil structure corresponds to the junction of exons 4 and 5. These results show that the human MSR gene consists of a mosaic of exons that encodes the functional domains. Furthermore, the specific arrangement of exons played a role in determining the structural characteristics of functional domains.	UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; NATL CARDIOVASC CTR,RES INST,DEPT BIOSCI,SUITA,OSAKA 565,JAPAN; NATL INST HLTH & NUTR,DEPT CLIN NUTR,TOKYO,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN; UNIV UTAH,MED CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132	University of Tokyo; National Cerebral & Cardiovascular Center - Japan; National Institute of Health & Nutrition - Japan; National Institutes for Quantum Science & Technology; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HARBERS K, 1984, P NATL ACAD SCI-BIOL, V81, P1504, DOI 10.1073/pnas.81.5.1504; HURST J, 1987, CYTOGENET CELL GENET, V45, P30, DOI 10.1159/000132421; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAITO M, 1991, AM J PATHOL, V139, P1411; NAITO M, 1992, AM J PATHOL, V141, P591; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PROUDFOOT NJ, 1988, TRANSCRIPTION SPLICI, P97; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SPANKS RS, 1987, GENOMICS, V1, P138; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI E, 1990, HUM GENET, V86, P14; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K	31	123	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2120	2125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093617				2022-12-25	WOS:A1993KH62000093
J	CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D				CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D			A SINGLE NUCLEOTIDE SUBSTITUTION AT CODON-31 (SER/ARG) DEFINES A POLYMORPHISM IN A HIGHLY CONSERVED REGION OF THE P53-INDUCIBLE GENE WAF1/CIP1	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; EXPRESSION; INHIBITOR; GROWTH; CELLS; P21	The recently discovered WAF1/CTP1 gene is a mediator of p53 tumor suppressor activity. To analyse WAF1/ CIP1 for possible mutations, polymerase chain reaction (PCR) amplified cDNAs from several tumor cell lines were cloned and sequenced. A single point mutation which changes codon 31 from AGC to AGA (Ser to Arg) was found. This change resulted in the loss of a Bpu1102I and gain of an Esp3I restriction site, allowing for rapid screening of this mutation in human DNAs. Analysis of genomic DNAs from 50 randomly selected individuals revealed that this base pair substitution represents a polymorphism with an allelic frequency of 0.14. Transfection studies demonstrated that the expression of the Arg allele of WAF1/CIP1 was not associated with loss of tumor suppressor activity. Moreover, screening of 22 tumor DNA samples revealed no association between the tumor phenotype and the Arg allele of WAF1/CIP1 (two out of 22 tumor DNAs contained the Arg31 allele). This polymorphism will be a useful molecular marker in the analysis of loss of heterozygosity in human cancers, and further studies using a larger panel of tumors may reveal an association between this polymorphism and specific types of cancer.	NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CHEDID, M (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, J BIOL CHEM, V269, P10753; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1994, IN PRESS ONCOGENE; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAZARSTEWART V, 1993, CANCER RES, V53, P2313; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAKAHASHI T, 1992, CANCER RES, V52, P2340; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	17	110	115	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3021	3024						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084608				2022-12-25	WOS:A1994PG82200031
J	OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP				OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP			THE EWS GENE, INVOLVED IN EWING FAMILY OF TUMORS, MALIGNANT-MELANOMA OF SOFT PARTS AND DESMOPLASTIC SMALL ROUND-CELL TUMORS, CODES FOR AN RNA-BINDING PROTEIN WITH NOVEL REGULATORY DOMAINS	ONCOGENE			English	Article							ETS-RELATED PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAINS; PUTATIVE ONCOGENE SPI-1; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; LEUKEMIA-VIRUS; FLI-1 GENE	The EWS gene, which maps to band q12 of human chromosome 22, is involved in a wide variety of human solid tumors including Ewing sarcoma, related primitive neuroectodermal tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors. In these tumors, the EWS is fused to genes encoding transcriptional activators/repressors, like Fli-1 or erg or ATF 1 or wt1. To better understand the function of the EWS protein, we cloned the EWS cDNA. Sequence analysis of this cDNA revealed differential splicing invoving two exons encoding 72 amino acids. Both alternatively spliced transcripts, EWS and EWS-b, are expressed in a variety of cells. Because EWS proteins contain putative conserved RNA binding motifs, we studied the RNA binding properties of the EWS protein. The EWS-b protein binds to RNA in vitro and, specifically, to poly G and poly U. The RNA binding activity was localized to the carboxy terminal 86 amino acids, which constitute RGG box. Thus the amino terminal domain of EWS (NTD-EWS), which is involved in chromosome translocation may regulate the specificity of RNA binding activity of EWS. An EWS-erg chimeric protein, which is found in Ewing's sarcoma cells, functions as a transcriptional activator. Mutational analysis of EWS-erg chimeric protein revealed that NTD-EWS functions as a regulatory domain for the transcriptional activation properties of EWS-erg chimeric protein.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NCI NIH HHS [CA 58642, CA 57157, CA 51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ICHIKAWAH, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LADANYI M, 1994, CANCER RES, V54, P2837; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHNO T, 1993, CANCER RES, V53, P5859; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	66	168	173	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3087	3097						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084618				2022-12-25	WOS:A1994PG82200042
J	ROLLEY, N; MILNER, J				ROLLEY, N; MILNER, J			SPECIFIC DNA-BINDING BY P53 IS INDEPENDENT OF MUTATION AT SERINE-389, THE CASEIN KINASE-II SITE	ONCOGENE			English	Note							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; ACTIVATION DOMAIN; MUTANT FORMS; CONFORMATION; TRANSCRIPTION; VARIANTS; OLIGOMERIZATION; TRANSFORMATION; COMPLEXES	The best understood function of p53 is that of cell growth suppression and this is likely to involve sequence-specific DNA binding and modulation of gene expression. Casein kinase II phosphorylates the C-terminal serine of p53 (residue 389 for murine p53) and mutation of this site abolishes p53 growth suppressor function. DNA binding by purified p53 is 'activated' by casein kinase II, suggesting that the carboxyl terminus of p53 represents a critical regulatory domain for sequence-specific DNA binding and hence for growth suppressor function. In the present study we have substituted serine 389 with either aspartic acid (mimics phosphoserine and partially conserves p53 suppressor function) or with alanine, a non-phosphorylable residue which abolishes suppressor function (Milne et al., 1992; Nucleic Acids Research 20, 5565-5570). When expressed in vitro p53(ala389) and p53(asp389) were both indistinguishable from wild type p53 on the basis of size fractionation and immunoreactivity with PAb421, PAb246 and PAb1620. Both mutants also exhibited specific binding for the DNA consensus p53-CON. Since p53(ala389) retains the ability to bind DNA and yet is known to lack growth suppressor function we conclude that phosphorylation by casein kinase II is important for p53 growth suppressor function via a mechanism which is ancilliary to p53 sequence-specific DNA binding.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEDCALF EA, 1993, ONCOGENE, V8, P2001; MEEK DW, 1994, IN PRESS SEMINARS CA; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1994, IN PRESS SEMINARS CA, V5; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	41	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3067	3070						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084615				2022-12-25	WOS:A1994PG82200039
J	HANADA, M; NISHIYAMA, K; MIZUSHIMA, S; TOKUDA, H				HANADA, M; NISHIYAMA, K; MIZUSHIMA, S; TOKUDA, H			RECONSTITUTION OF AN EFFICIENT PROTEIN TRANSLOCATION MACHINERY COMPRISING SECA AND THE 3 MEMBRANE-PROTEINS, SECY, SECE, AND SECG (P12)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PREPROTEIN TRANSLOCASE; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; ACIDIC PHOSPHOLIPIDS; SECRETORY PROTEINS; PLASMA-MEMBRANE; ATPASE ACTIVITY; COMPONENTS; PRECURSOR	A cytoplasmic membrane protein, p12, of Escherichia coli was discovered as a new factor that stimulates the protein translocation activity reconstituted with SecA, SecY, and SecE (Nishiyama, K., Mizushima, S., and Tokuda, H. (1993) EMBO J. 12, 3409-3415). Direct involvement of p12 in protein translocation was subsequently demonstrated in vivo by genetic studies, and the name SecG; has been proposed for p12 (Nishiyama, K., Hanada, M., and Tokuda, H. (1994) EMBO J. 13, 3272-3277). To elucidate the role of SecG in protein translocation and to characterize the translocation apparatus comprising these four Sec proteins, the activity of reconstituted proteoliposomes was examined in detail as a function of the amount of each component. SecG markedly stimulated the translocation activity over wide ranges of amounts of the other three Sec proteins, indicating that none of the other three Sec proteins substitutes for the SecG function. Detailed kinetic analyses indicated that the activity of proteoliposomes was dependent on the amount of the SecY.SecE complex when SecG was absent and the amount of the SecY.SecE.SecG complex when the proteoliposomes contained SecG. The translocation activity of the latter complex was significantly higher than that of the former one. finding of SecA to liposomes appreciably increased when they contained both SecY and SecE, whereas the further presence of SecG did not enhance the binding. On the other hand, the ATPase activity of SecA, which was dependent on proOmpA and SecY.SecE-containing proteoliposomes, was significantly enhanced when the proteoliposomes contained SecG, Taken together, these results indicate that SecG enhances the translocation activity of the apparatus after the step of SecA targeting to SecY.SecE.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; Mizushima S., 1992, MEMBRANE BIOGENESIS, P21; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; YAMANE K, 1987, J BIOL CHEM, V262, P2358	31	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23625	23631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089132				2022-12-25	WOS:A1994PQ34500038
J	PANCHAL, RG; CHELEY, S; BAYLEY, H				PANCHAL, RG; CHELEY, S; BAYLEY, H			DIFFERENTIAL PHOSPHORYLATION OF NEURONAL SUBSTRATES BY CATALYTIC SUBUNITS OF APLYSIA CAMP-DEPENDENT PROTEIN-KINASE WITH ALTERNATIVE N-TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEURAL SENSORY NEURONS; STRUCTURAL-CHANGES; HETEROSYNAPTIC FACILITATION; SYNAPTIC FACILITATION; TRANSMITTER RELEASE; MOLECULAR MECHANISM; REGULATORY SUBUNIT; PLASMA-MEMBRANE; CALIFORNICA; MODULATION	cAMP-dependent protein kinase (PKA) is an important participant in neuronal modulation: the ability of neurons to change their properties in response to external stimuli. In Aplysia mechanosensory neurons, PKA plays roles in both short and long term presynaptic facilitation, which is a simple model for learning and memory. PKA in Aplysia is a collection of structurally and functionally diverse regulatory and catalytic (C) subunits. We have argued that this diversity may in part account for the ability of the enzyme to take part in neuronal events that are spatially and temporally separated. Here, we add credence to this hypothesis by showing that C subunits of Aplysia PRA with alternative N termini target different substrates in subcellular fractions from Aplysia neurons, despite their similar actions on synthetic peptide substrates. Purified recombinant C-APL-A N1A1, which has an N terminus that is homologous to the myristylated sequence described in mammals, catalyzes the formation of two phosphoproteins of 24 and 8 kDa more rapidly than C-APL-A N2A1, which has a distinct N terminus weakly related to that of the yeast TPK1 gene product. The 24-kDa phosphoprotein, but not the 8-kDa species, is detected in taxol-stabilized microtubules, suggesting that it is associated with the cytoskeleton. C-APL-A N2A1, in contrast, generates a 55 kDa phosphoprotein that is not observed with C-APL-A N1A1. The 55-kDa species is found in the detergent supernatant of the cytoskeleton fraction. Differential targeting of substrates by C subunits of PKA may therefore contribute to the ability of this kinase to play multiple roles in neuronal modulation.			PANCHAL, RG (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.		Panchal, Rekha/None	Panchal, Rekha/0000-0001-8621-9078; Bayley, Hagan/0000-0003-2499-6116	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026760] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26760] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; AMBRON RT, 1992, J NEUROSCI, V12, P2813; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERNIER L, 1982, J NEUROSCI, V2, P1682; BEUSHAUSEN S, 1990, MOL CELL BIOL, V10, P6775, DOI 10.1128/MCB.10.12.6775; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; CHELEY S, 1991, BIOTECHNIQUES, V10, P730; CHELEY S, 1991, BIOCHEMISTRY-US, V30, P10246, DOI 10.1021/bi00106a024; CHELEY S, 1994, J BIOL CHEM, V269, P2911; CHIN GJ, 1990, BRAIN RES, V508, P265, DOI 10.1016/0006-8993(90)90405-Z; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; DALE N, 1987, J NEUROSCI, V7, P2232; DALE N, 1988, SCIENCE, V239, P282, DOI 10.1126/science.2892269; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; EPPLER CM, 1986, J CELL BIOL, V102, P320, DOI 10.1083/jcb.102.1.320; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOLDSMITH BA, 1992, P NATL ACAD SCI USA, V89, P11481, DOI 10.1073/pnas.89.23.11481; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Luckow Verne A., 1993, Current Opinion in Biotechnology, V4, P564, DOI 10.1016/0958-1669(93)90078-B; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P277; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	57	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23722	23730						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	8089143				2022-12-25	WOS:A1994PQ34500052
J	BEJANIN, S; CERVINI, R; MALLET, J; BERRARD, S				BEJANIN, S; CERVINI, R; MALLET, J; BERRARD, S			A UNIQUE GENE ORGANIZATION FOR 2 CHOLINERGIC MARKERS, CHOLINE-ACETYLTRANSFERASE AND A PUTATIVE VESICULAR TRANSPORTER OF ACETYLCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; CAENORHABDITIS-ELEGANS; MONOAMINE TRANSPORTER; COMPLETE SEQUENCE; ELECTRIC ORGAN; CDNA; EXPRESSION; CLONING; RESERPINE; PROTON	Choline acetyltransferase (ChAT) is the biosynthetic enzyme of acetylcholine. In mammalian tissues, it is encoded by multiple mRNAs with different 5'-ends. This diversity results from the alternative usage of three promoters and from differential splicing events. Here, we show that the first intron of the rat ChAT gene contains an open reading frame that encodes a potential vesicular acetylcholine transporter based on the following criteria. (i) The encoded protein is structurally similar to transporter proteins, the highest identity being found with the vesicular acetylcholine transporters from Torpedo and Caenorhabditis elegans (77 and 56%, respectively, in 352 amino acids). (ii) The corresponding mRNAs exhibit a cholinergic expression profile. Amplification experiments with spinal cord cDNA revealed that at least three mRNAs encode this transporter. Two contain the same 5' non-coding region as two ChAT mRNAs and, therefore, are derived from the ChAT transcription unit by alternative splicing. The third mRNA may be transcribed from an additional internal promoter.	CNRS, GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERAT, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BIGUET NF, 1986, EMBO J, V5, P287, DOI 10.1002/j.1460-2075.1986.tb04211.x; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; CAWTHON RM, 1991, GENOMICS, V9, P446, DOI 10.1016/0888-7543(91)90410-G; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; IBANEZ CF, 1991, J NEUROSCI RES, V29, P163, DOI 10.1002/jnr.490290205; ISRAEL M, 1970, J NEUROCHEM, V17, P1441, DOI 10.1111/j.1471-4159.1970.tb00511.x; JOHNSON RG, 1979, J BIOL CHEM, V254, P963; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MISAWA H, 1992, J BIOL CHEM, V267, P20392; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; WU DH, 1994, J NEUROCHEM, V62, P1653	26	169	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21944	21947						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071313				2022-12-25	WOS:A1994PE09800006
J	NEGRE, E; VOGEL, T; LEVANON, A; GUY, R; WALSH, TJ; ROBERTS, DD				NEGRE, E; VOGEL, T; LEVANON, A; GUY, R; WALSH, TJ; ROBERTS, DD			THE COLLAGEN-BINDING DOMAIN OF FIBRONECTIN CONTAINS A HIGH-AFFINITY BINDING-SITE FOR CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; COMPLEMENT RECEPTOR; CELL-ADHESION; YEAST-CELLS; ADHERENCE; THROMBOSPONDIN; EXPRESSION; MECHANISMS; INFECTIONS; SURFACES	A 30-kDa proteolytic fragment from the gelatin/collagen-binding domain of fibronectin is a potent inhibitor of fibronectin binding to Candida albicans, with a molar inhibition constant equal to that of intact fibronectin. Recombinant and proteolytic fragments from the cell-, the fibrin I-, and the heparin II-binding domains also inhibit fibronectin binding, but are 13-1000-fold less active. In suspension, binding of fibronectin to C. albicans is regulated by growth conditions and is specific, saturable, time-dependent, reversible, and divalent cation-independent. Scatchard plot analyses indicate the presence of high affinity (K-d = 1.3 x 10(-9) M) and low affinity (K-d = 1.2 x 10(-7) M) receptors. Recombinant or proteolytic fragments from four binding domains of fibronectin promote adhesion of C. albicans. A recombinant fragment corresponding to the cell-binding domain but with the sequence Arg-Gly-Asp-Ser deleted promotes C. albicans adhesion and inhibits fibronectin binding to C. albicans with the same activity as the natural sequence. Furthermore, four peptides containing the Arg-Gly-Asp sequence and the peptides CS-1 and Arg-Glu-Asp-Val did not block the binding of fibronectin to C. albicans. Thus, in contrast to the specific binding of soluble fibronectin, recognition of immobilized fibronectin by C. albicans is mediated by several domains of the protein. Interactions with the cell-binding domain are not mediated by the Arg-Gly-Asp or other known recognition sequences as it has been suggested. Binding of fibronectin also did not correlate with C(3)d binding to the avirulent clones of C. albicans strain H-12 or with iC(3)b binding to variants of the strain 4918.	NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA; BIOTECHNOL GEN LTD, IL-76326 REHOVOT, ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; BENDEL CM, 1993, J CLIN INVEST, V92, P1840, DOI 10.1172/JCI116775; BOUCHARA JP, 1990, INFECT IMMUN, V58, P48, DOI 10.1128/IAI.58.1.48-54.1990; BOZZINI S, 1992, EUR J BIOCHEM, V207, P327, DOI 10.1111/j.1432-1033.1992.tb17054.x; BRASSART D, 1991, INFECT IMMUN, V59, P1605, DOI 10.1128/IAI.59.5.1605-1613.1991; BUTLER KM, 1988, PEDIATR CLIN N AM, V35, P543; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CURRY CR, 1971, NEW ENGL J MED, V285, P1221, DOI 10.1056/NEJM197111252852203; DRANSFIELD I, 1991, CHEM IMMUNOL, V50, P13; DUPONT B, 1992, J MED VET MYCOL, V30, P19; EIGENTLER A, 1989, INFECT IMMUN, V57, P616, DOI 10.1128/IAI.57.2.616-622.1989; ELORZA MV, 1985, J GEN MICROBIOL, V131, P2209; FRANZKE S, 1993, INFECT IMMUN, V61, P2662, DOI 10.1128/IAI.61.6.2662-2669.1993; GINSBERG MH, 1991, CHEM IMMUNOL, V50, P75; GUO NH, 1992, J BIOL CHEM, V267, P19349; ISAACS BS, 1989, BIOCHEMISTRY-US, V28, P842, DOI 10.1021/bi00428a065; JAKAB E, 1993, APMIS, V101, P187, DOI 10.1111/j.1699-0463.1993.tb00100.x; KALO A, 1988, J INFECT DIS, V157, P1253, DOI 10.1093/infdis/157.6.1253; KENNEDY MJ, 1992, J MED VET MYCOL, V30, P95; KENNEDY MJ, 1991, FUNGAL SPRORE DISEAS; KLOTZ SA, 1985, INFECT IMMUN, V50, P97, DOI 10.1128/IAI.50.1.97-101.1985; KLOTZ SA, 1993, MICROB PATHOGENESIS, V14, P133, DOI 10.1006/mpat.1993.1014; KLOTZ SA, 1991, J INFECT DIS, V163, P604, DOI 10.1093/infdis/163.3.604; KLOTZ SA, 1992, ANTIMICROB AGENTS CH, V36, P132, DOI 10.1128/AAC.36.1.132; KLOTZ SA, 1990, FEMS MICROBIOL LETT, V68, P249, DOI 10.1016/S0378-1097(05)80049-7; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MCCOURTIE J, 1981, INFECT IMMUN, V32, P1234, DOI 10.1128/IAI.32.3.1234-1241.1981; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLLERT MW, 1993, INFECT IMMUN, V61, P4560, DOI 10.1128/IAI.61.11.4560-4568.1993; OLLERT MW, 1990, INFECT IMMUN, V58, P909, DOI 10.1128/IAI.58.4.909-913.1990; OLSEN I, 1990, ACTA ODONTOL SCAND, V48, P45, DOI 10.3109/00016359009012733; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SKERL KG, 1984, CAN J MICROBIOL, V30, P221, DOI 10.1139/m84-033; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TRONCHIN G, 1991, EUR J EPIDEMIOL, V7, P23, DOI 10.1007/BF00221338; VOGEL T, 1993, ARCH BIOCHEM BIOPHYS, V300, P501, DOI 10.1006/abbi.1993.1068; WERBER MM, 1991, BIOLOGICALS FROM RECOMBINANT MICROORGANISMS AND ANIMAL CELLS, P369; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	41	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22039	22045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	8071326				2022-12-25	WOS:A1994PE09800020
J	LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D				LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D			GATA-BINDING AND SP1-BINDING SITES ARE REQUIRED FOR THE FULL ACTIVITY OF THE TISSUE-SPECIFIC PROMOTER OF THE TAL-1 GENE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; DNA-BINDING PROTEIN; LOOP-HELIX GENE; SCL GENE; CHROMOSOMAL LOCALIZATION; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; CONTROL REGION	The tal-1 gene, which is frequently activated in human T cell acute leukemias (T-ALLs), codes for a protein of the basic helix-loop-helix family (b-HLH) and potentially a transcription factor. In human and murine hematopoiesis tal-1 is expressed during the differentiation of the erythroid, megakaryocytic and mastocytic cell lineages. The expression of tal-1 appears to be comodulated with that of the transcription factor GATA-1 gene, suggesting that the GATA-1 protein may regulate the tal-1 gene activity in these hematopoietic lineages. To get further insights into the molecular mechanisms that control tal-1 expression, we have isolated 5' sequences of the murine gene and compared them to their human counterparts. The 5' flanking sequences from the two genes show several regions of high homology. The alignment of both sequences enabled us to predict that similarly, to the human, the mouse gene contains two alternative first exons (Ia and Ib). Remarkably, in both species, the proximal region of the tissue-specific exon Ia (i.e. gene segment -122 to +1) contains two GATA-motifs (at -65 and -33) and one SP-1 consensus binding site (-59). Mobility shift assays demonstrate that GATA proteins are able to interact with both GATA-motifs in a sequence specific fashion, but with different efficiencies. Moreover transfection studies show that the GATA-1 protein directly mediates tal-1 transcription by interacting with the -122/+1 fragment, defined as a minimal promoter in erythroid cells. Mutagenesis of the promoter establishes that the -33 GATA-binding site present in this fragment is critical for tal-1 expression in erythroid cells, but by itself does not lead to full promoter activity. Indeed, further mutations show that the second -65 GATA-binding site and the binding motif for SP1 (-59) significantly contribute to the overall activity of the proximal tal-1 promoter. Altogether, our data provide evidence that GATA-1 cooperates with the transcription factor SP1 to mediate the erythroid-specific expression of the tal-1 gene.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mathieu, Daniele/G-6092-2012; Bernard, Olivier A./E-5721-2016; Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367; JOULIN, Virginie/0000-0003-1091-7819; Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BORIES JC, 1990, J EXP MED, V171, P75, DOI 10.1084/jem.171.1.75; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HWANG LY, 1993, ONCOGENE, V8, P3043; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOLJ, 1993, MOL CELL BIOL, V13, P4011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P1777; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOUHTON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V58, P777; ORKIN SH, 1992, BLOOD, V80, P575; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	52	63	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2623	2632						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058326				2022-12-25	WOS:A1994PC05400022
J	LEDESMA, MD; BONAY, P; COLACO, C; AVILA, J				LEDESMA, MD; BONAY, P; COLACO, C; AVILA, J			ANALYSIS OF MICROTUBULE-ASSOCIATED PROTEIN-TAU GLYCATION IN PAIRED HELICAL FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; ALZHEIMER-LIKE STATE; ABNORMAL PHOSPHORYLATION; CYTOSKELETAL PROTEINS; NEUROFIBRILLARY TANGLES; ANTIGENIC DETERMINANTS; AXONAL-TRANSPORT; CROSS-LINKING; DISEASE; BRAIN	Alzheimer's disease is typified by the characteristic histopathological lesions of neurofibrillar plaques and tangles. The latter are composed of paired helical filaments (PHFs), the major components of which are modified forms of the microtubule-associated protein tau. The exact nature of these modifications remains unknown, although the presence of hyperphosphorylated tau in PHFs argues strongly that phosphorylation is one of the modifications that result in the polymerization of tau into PHFs. However, hyperphosphorylation alone is insufficient to explain the formation of PHFs. In an attempt to characterize other post-translational modifications of PHF-tau, we have analyzed its glycation. A fraction of PHF tau seems to be glycated in. vivo, whereas soluble tau from either Alzheimer's disease or non-demented human brain is not glycated at all. Purified tau from bovine brain can be efficiently glycated in vitro. Tau glycation is accompanied by a decrease in the tau binding to tubulin. These results support the view that glycation may be one of the modifications hampering the binding of tan to tubulin in Alzheimer's disease, thus facilitating tau aggregation into PHFs.	QUADRANT RES FDN,CAMBRIDGE CB2 2SY,CAMBS,ENGLAND		LEDESMA, MD (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHON,E-28049 MADRID,SPAIN.		Ledesma, Maria Dolores/I-5619-2015; Avila, Jesus/I-2610-2015	Ledesma, Maria Dolores/0000-0002-5679-6891; Avila, Jesus/0000-0002-6288-0571				BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEANCOS JG, 1993, J BIOL CHEM, V268, P7976; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; DEGARCINI EM, 1988, FEBS LETT, V236, P150, DOI 10.1016/0014-5793(88)80304-1; DEGARCINI EM, 1987, J BIOCHEM-TOKYO, V102, P1415, DOI 10.1093/oxfordjournals.jbchem.a122187; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DUBRIN DG, 1986, J CELL BIOL, V103, P2739; EBLE AS, 1983, J BIOL CHEM, V258, P9406; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; FLUCKIGER R, 1984, METHOD ENZYMOL, V106, P77; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GONZALEZ PJ, 1992, NEUROSCIENCE, V50, P491, DOI 10.1016/0306-4522(92)90440-D; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5825; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1992, EUR J BIOCHEM, V203, P43, DOI 10.1111/j.1432-1033.1992.tb19825.x; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IQBAL K, 1986, LANCET, V2, P421; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KUMAR A, 1993, P NATL ACAD SCI USA, V90, P7019, DOI 10.1073/pnas.90.15.7019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1990, J STRUCT BIOL, V105, P46, DOI 10.1016/1047-8477(90)90097-V; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MACIOCE P, 1989, J NEUROCHEM, V53, P1261, DOI 10.1111/j.1471-4159.1989.tb07423.x; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MCLEAN WG, 1992, MOL NEUROBIOL, V6, P225, DOI 10.1007/BF02780555; MIELKE R, 1991, NEUROBIOL AGING, V13, P93; MONNIER VM, 1979, J EXP MED, V150, P1098, DOI 10.1084/jem.150.5.1098; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; NIETO A, 1990, NEUROSCIENCE, V37, P163, DOI 10.1016/0306-4522(90)90201-E; NIETO A, 1991, BIOCHIM BIOPHYS ACTA, V1096, P197, DOI 10.1016/0925-4439(91)90005-T; NOVAK M, 1991, P NATL ACAD SCI USA, V88, P5837, DOI 10.1073/pnas.88.13.5837; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARKMAN DR, 1991, BIOCHEM BIOPH RES CO, V181, P771, DOI 10.1016/0006-291X(91)91257-D; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; TARKKA T, 1993, BIOCHIM BIOPHYS ACTA, V1180, P294, DOI 10.1016/0925-4439(93)90053-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; VITADELLO M, 1985, J NEUROCHEM, V45, P860, DOI 10.1111/j.1471-4159.1985.tb04073.x; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YAMAMOTO H, 1983, J NEUROCHEM, V41, P119	73	286	294	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21614	21619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	8063802				2022-12-25	WOS:A1994PK97300037
J	CRESPO, P; XU, NZ; DANIOTTI, JL; TROPPMAIR, J; RAPP, UR; GUTKIND, JS				CRESPO, P; XU, NZ; DANIOTTI, JL; TROPPMAIR, J; RAPP, UR; GUTKIND, JS			SIGNALING THROUGH TRANSFORMING G-PROTEIN-COUPLED RECEPTORS IN NIH 3T3 CELLS INVOLVES C-RAF ACTIVATION - EVIDENCE FOR A PROTEIN KINASE-C-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; C-RAF-1 PROTEIN; EGF RECEPTOR; V-RAF; TRANSDUCTION; ONCOGENE; EXPRESSION; FAMILY; GENES	We have studied the role of Raf-1 in mitogenesis and cellular transformation induced by G protein-coupled receptors in NIH 3T3 cells transfected with the human m1 muscarinic receptor. We have observed that in m1- expressing NIH 3T3 cells, the cholinergic agonist carbachol induces a dose- and time-dependent shift in the electrophoretic mobility of p72(Raf-1), equivalent to that observed when using phorbol esters or platelet-derived growth factor as stimulants. Phosphoamino acid analysis of slower mobility forms of p72(Raf-1) revealed both phosphoserine and phosphothreonine. Carbachol potently induced c-Raf activity as judged by its in vitro phosphorylating activity using MEK as a substrate. However, induction of Raf-1 kinase activity by carbachol occurred much earlier than changes in its electrophoretic mobility. Raf-1 kinase activation followed a kinetic similar to that exhibited by an epitope-tagged ERK2 protein when coexpressed in the same cells. Conventional protein kinase C (PKC) inactivation by means of sustained phorbol ester treatment or by a new nontoxic PKC-specific inhibitor, GF 109203X, abolished p72(Raf-1) mobility shift induced by carbachol or by phorbol esters. However, c-Raf and ERK2 enzymatic activity in response to carbachol was at least 50-80% PKC-independent. Furthermore, inhibition of PKC failed to affect DNA synthesis or focus formation induced by carbachol in cells expressing mi receptors. In contrast, cotransfection of NIH 3T3 cells with the Raf-1 dominant negative mutant Raf-301 (K375W) drastically decreased the transforming ability of mi receptors. Thus, our findings implicate Raf-1 activation in transformation by G protein-coupled receptors. In addition, our data suggest that activation of p72(Raf-1) and ERK2 by G protein-coupled receptors involves PKC-independent pathways.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Troppmair, Jakob/0000-0002-0611-3837; Crespo, Piero/0000-0003-2825-7783				ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JONES SVP, 1988, MOL PHARMACOL, V34, P421; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STEPHENS EV, 1993, ONCOGENE, V8, P19; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	61	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21103	21109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063729				2022-12-25	WOS:A1994PC40300045
J	HAKIMI, JM; SCOCCA, JJ				HAKIMI, JM; SCOCCA, JJ			BINDING-SITES FOR BACTERIOPHAGE-HP1 INTEGRASE ON ITS DNA SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAEMOPHILUS-INFLUENZAE BACTERIOPHAGE-HP1; HOST ATTACHMENT SITE; TRANSFER-RNA GENES; PHAGE ATT SITE; ESCHERICHIA-COLI; LAMBDA-INTEGRASE; INT PROTEIN; HEMOPHILUS-INFLUENZAE; NUCLEOTIDE-SEQUENCE; STRAND EXCHANGE	The temperate phage HPI integrates its genome into the chromosome of Haemophilus influenzae by site-specific recombination between host and phage DNA segments, the attachment sites. This reaction is promoted by the HP1-encoded integrase. The interactions of HP1 integrase with its DNA substrates have been characterized by DNase I footprinting. Two classes of binding sites were identified. At sites of type I, integrase binding almost completely eliminated cleavage by DNase I; type I sites shared the consensus sequence 5'-AGGGATTTWW. At type II sites, integrase binding produced alternating regions of protection from and enhancement of cleavage, suggesting that binding at these sites distorted the DNA. The consensus sequence for type II sites was 5'-ACTGGCGRTW. Each binding site contained two copies of the relevant consensus. The host attachment site (attB) contains an inverted pair of type I consensus sequences surrounding the strand exchange points. The phage attachment site (attP) includes six binding sites, three of type I and three of type E, distributed along its 500 nucleotide pairs. All type I sites contain two consensus motifs arranged as inverted repeats. One of these surrounds the strand exchange points in this substrate, one is located internally, and the third coincides with the right boundary of the attP sequence. One type II site, consisting of an inverted repeat of two type II consensus motifs, coincides with the left boundary of the attP sequence. The other two type II sites contain directly repeated pairs of the consensus and are internally located.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University								ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOODMAN SD, 1989, J BACTERIOL, V171, P4232, DOI 10.1128/JB.171.8.4232-4240.1989; HAKIMIASTUMIAN J, 1989, J BACTERIOL, V171, P1747; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HAUSER MA, 1990, NUCLEIC ACIDS RES, V18, P5305, DOI 10.1093/nar/18.17.5305; HAUSER MA, 1992, J BACTERIOL, V174, P6674, DOI 10.1128/JB.174.20.6674-6677.1992; HOCHSCHILD A, 1991, METHOD ENZYMOL, V208, P343; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HSU PL, 1980, NATURE, V285, P85, DOI 10.1038/285085a0; HWANG ES, 1990, J BACTERIOL, V172, P4852, DOI 10.1128/jb.172.9.4852-4860.1990; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1993, J BIOL CHEM, V268, P17564; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; Mizuuchi K, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P429; PIERSON LS, 1987, J MOL BIOL, V196, P487, DOI 10.1016/0022-2836(87)90026-X; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; TARTOF KD, 1987, FOCUS, V9, P12; THOMPSON JF, 1989, MOBILE DNA, P1; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WALDMAN AS, 1986, J BACTERIOL, V165, P297, DOI 10.1128/jb.165.1.297-300.1986; WEISBERG RA, 1983, LAMBDA, V2, P211; YU A, 1993, J BACTERIOL, V175, P1239, DOI 10.1128/JB.175.5.1239-1249.1993	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21340	21345						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	8063759				2022-12-25	WOS:A1994PC40300077
J	SUTO, N; IKURA, K; SASAKI, R				SUTO, N; IKURA, K; SASAKI, R			EXPRESSION INDUCED BY INTERLEUKIN-6 OF TISSUE-TYPE TRANSGLUTAMINASE IN HUMAN HEPATOBLASTOMA HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; ACUTE-PHASE PROTEINS; GUINEA-PIG LIVER; GENE-EXPRESSION; CROSS-LINKING; RETINOIC ACID; CELLULAR TRANSGLUTAMINASE; SODIUM-BUTYRATE; CDNA CLONES; FACTOR-II	We examined the effect of interleukin-6 (IL-6) on the expression of transglutaminase in human hepatoblastoma HepG2 cells. Treatment of cells with IL-6 increased their transglutaminase activity in a time- and dose-dependent way. Dexamethasone strengthened the stimulation by IL-6. Half-maximum stimulation of transglutaminase activity in the cells occurred at a dose of 40 pM IL-6 regardless of the presence of dexamethasone. Based on its immunoreactivity, the transglutaminase induced was identified as tissue-type transglutaminase. Immunoblot analysis showed that the increase in transglutaminase activity was related to an increase in the amount of transglutaminase protein. Northern blot analysis with a cDNA probe specific for human tissue-type transglutaminase showed that exposure of HepG2 cells to IL-6 increased the mRNA level of the enzyme, and the increase was detectable 3 h after IL-6 was added. Induction of the mRNA was maximum between 10 and 14 h. The increase in the mRNA level was not blocked by the presence of cycloheximide, suggesting that the increase was independent of protein synthesis. Injections into mice of substances that induce inflammation such as turpentine and lipopolysaccharides increased the liver transglutaminase activity. These results indicated that transglutaminase may be involved in some biological processes in hepatocytes regulated by IL-6 signaling.	KYOTO UNIV,FAC AGR,DEPT FOOD SCI & TECHNOL,KYOTO 606,JAPAN	Kyoto University								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; Birckbichler P J, 1978, Ann N Y Acad Sci, V312, P354, DOI 10.1111/j.1749-6632.1978.tb16813.x; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CHEN HM, 1991, J BIOL CHEM, V266, P2946; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEIGER T, 1988, EUR J IMMUNOL, V18, P717, DOI 10.1002/eji.1830180510; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IKURA K, 1990, FEBS LETT, V268, P203, DOI 10.1016/0014-5793(90)81008-C; IKURA K, 1990, EUR J BIOCHEM, V187, P705, DOI 10.1111/j.1432-1033.1990.tb15357.x; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KANNAGI R, 1982, BIOCHEM BIOPH RES CO, V105, P164, DOI 10.1016/S0006-291X(82)80026-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1987, BIOCHIM BIOPHYS ACTA, V928, P22, DOI 10.1016/0167-4889(87)90081-4; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; NAKAMURA T, 1988, EXP CELL RES, V179, P488, DOI 10.1016/0014-4827(88)90286-8; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NARA K, 1989, J BIOL CHEM, V264, P19308; PIACENTINI M, 1988, BIOCHEM J, V253, P33, DOI 10.1042/bj2530033; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; SHABO Y, 1988, BLOOD, V72, P2070; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SIVE HL, 1984, MOL CELL BIOL, V4, P2723, DOI 10.1128/MCB.4.12.2723; SLIFE CW, 1986, J BIOL CHEM, V261, P3451; SUEDHOFF T, 1990, CANCER RES, V50, P7830; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WEISSENBACH J, 1988, P NATL ACAD SCI USA, V79, P2768	58	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7469	7473						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096510				2022-12-25	WOS:A1993KV14100092
J	IKEDA, Y; FUJII, J; TANIGUCHI, N				IKEDA, Y; FUJII, J; TANIGUCHI, N			SIGNIFICANCE OF ARG-107 AND GLU-108 IN THE CATALYTIC MECHANISM OF HUMAN GAMMA-GLUTAMYL TRANSPEPTIDASE - IDENTIFICATION BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT RENAL GAMMA; TRANSFERASE TRANSPEPTIDASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; PRECURSOR FORM; HEAVY SUBUNIT; AMINO-ACIDS; ACTIVE-SITE; GLUTAMYLTRANSFERASE; KIDNEY	The catalytic properties of wild-type and mutant enzymes produced by expression of cDNA (for gamma-glutamyl transpeptidase) in COS-1 cells were analyzed. Substitutions of Lys-100 to Asn, Glu-102 to Gln, and Arg-112, -139, -147, and -150 to Gln resulted in expression of fully active enzymes. Replacement of Arg- 107 with Gln or His led to complete loss of enzyme activity, whereas substitution to Lys resulted in partial loss of activity, indicating that the positive charge at position 107 is essential for enzyme activity. In the Arg-107-to-Lys mutant, the apparent K(m) for the donor L-gamma-glutamyl-3-carboxy-4-nitroanilide was increased 8.4-fold compared to that of the wild-type enzyme. Although 32% of the wild-type hydrolysis activity was retained in this mutant, the activity could not be enhanced by addition of an acceptor substrate, glycylglycine, indicating that the transpeptidation reaction was specifically prevented. Substitution of Glu-108 to Gln increased the apparent K(m) for glycylglycine 8.5-fold while increasing the apparent K(m) for the donor only 1.6-fold. The apparent V(max) was decreased to 4-5% of wild-type for both substrates. These data suggest that Arg-107 plays a significant role in substrate binding rather than catalysis, and that Glu-108 is an important, although not essential, participant in both acceptor binding and catalysis.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University			Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				ALLISON RD, 1985, METHOD ENZYMOL, V113, P419; ANGELE C, 1989, BIOCHEM BIOPH RES CO, V160, P1040, DOI 10.1016/S0006-291X(89)80107-X; ANGELE C, 1991, CLIN CHEM, V37, P662; BAROUKI R, 1984, J BIOL CHEM, V259, P7970; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; ELCE JS, 1980, BIOCHEM J, V185, P473, DOI 10.1042/bj1850473; FUSHIKI T, 1983, J BIOCHEM-TOKYO, V93, P795, DOI 10.1093/jb/93.3.795; GOODSPEED DC, 1989, GENE, V76, P1, DOI 10.1016/0378-1119(89)90002-4; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; INOUE M, 1977, EUR J BIOCHEM, V73, P335, DOI 10.1111/j.1432-1033.1977.tb11323.x; INOUE M, 1978, BIOCHEM BIOPH RES CO, V82, P1183, DOI 10.1016/0006-291X(78)90311-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNO T, 1983, BIOCHEM BIOPH RES CO, V114, P889, DOI 10.1016/0006-291X(83)90864-1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; MATSUDA Y, 1983, J BIOCHEM-TOKYO, V93, P1427, DOI 10.1093/oxfordjournals.jbchem.a134278; MCINTYRE TM, 1979, J BIOL CHEM, V254, P6499; NASH B, 1982, J BIOL CHEM, V257, P585; PAPANDRIKOPOULOU A, 1989, EUR J BIOCHEM, V183, P693, DOI 10.1111/j.1432-1033.1989.tb21100.x; RAJPERTDEMEYTS E, 1988, P NATL ACAD SCI USA, V85, P8840, DOI 10.1073/pnas.85.23.8840; REED DJ, 1980, BIOCHEM BIOPH RES CO, V94, P1273, DOI 10.1016/0006-291X(80)90557-4; SAKAMURO D, 1988, GENE, V73, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHASTEEN CS, 1983, BIOCHEM BIOPH RES CO, V112, P564, DOI 10.1016/0006-291X(83)91501-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; STOLE E, 1991, J BIOL CHEM, V266, P17850; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V150, P33, DOI 10.1016/0006-291X(88)90482-2; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; SZEWCZUK A, 1965, BIOCHIM BIOPHYS ACTA, V105, P352, DOI 10.1016/S0926-6593(65)80159-X; TANIGUCHI N, 1985, CANCER RES, V45, P5835; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATE SS, 1977, P NATL ACAD SCI USA, V74, P931, DOI 10.1073/pnas.74.3.931; TATE SS, 1985, METHOD ENZYMOL, V113, P400; THOMPSON GA, 1977, J BIOL CHEM, V252, P6792; VISVIKIS A, 1991, P NATL ACAD SCI USA, V88, P7361, DOI 10.1073/pnas.88.16.7361; YOKOSAWA N, 1983, ONCODEV BIOL MED, V4, pC71	41	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3980	3985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8095045				2022-12-25	WOS:A1993KN53300029
J	PINNER, E; KOTLER, Y; PADAN, E; SCHULDINER, S				PINNER, E; KOTLER, Y; PADAN, E; SCHULDINER, S			PHYSIOLOGICAL-ROLE OF NHAB, A SPECIFIC NA+/H+ ANTIPORTER IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-PROTON ANTIPORTER; MEMBRANE-VESICLES; PH HOMEOSTASIS; ION-TRANSPORT; BACTERIA; SYSTEMS; GENE; DELETION; DNA; ANT	The nhaB gene which codes for Na+/H+ antiporter activity in Escherichia coli was recently cloned (Pinner, E., Padan, E., and Schuldiner, S. (1992) J. Biol. Chem. 267, 11064-11068). In order to elucidate the role of nhaB in Na+ and H+ ions physiology and its interaction with nhaA, we generated mutants in which the chromosomal gene has been inactivated by insertion/deletion. A mutant devoid of both nhaA and nhaB is extremely sensitive to Na+ and Li+ at all pH values, and membranes prepared from this strain show no Na+/H+ antiporter activity. As opposed with the DELTAnhaA mutant which contains NhaB, the pH independent Na+/H+ antiporter (Padan, E., Maisler, N., Taglicht, D., Karpel, R., and Schuldiner, S. (1989) J. Biol. Chem. 264, 20297-20302), the DELTAnhaB mutant, containing NhaA, shows Na+/H+ antiporter activity highly dependent on pH. nhaB, in the absence of nhaA, confers a certain tolerance to Na+ which decreases with increasing pH. In the absence of NhaB, NhaA alone confers complete halotolerance under all conditions tested. However, when grown on agar in minimal medium on substrates which are symported with Na+ (proline, serine, and glutamate) at pH 6 and at low Na+ concentrations (<10 mM), DELTAnhaB grows slower than the wild type and its Na+ dependent transport of glutamate and proline is markedly inhibited. Since both of these defects of the DELTAnhaB strain are alleviated upon transformation of the mutant with multicopy plasmid bearing nhaA, we conclude that nhaB is crucial when the level of NhaA activity is growth limiting, when nhaA is not sufficiently induced, and/or when NhaA is not activated.			PINNER, E (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AGMON V, 1987, THESIS HEBREW U JERU; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BECK JC, 1979, ARCH BIOCHEM BIOPHYS, V194, P208, DOI 10.1016/0003-9861(79)90611-8; BOOTH IR, 1985, MICROBIOL REV, V49, P395; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREY RN, 1980, J BIOL CHEM, V255, P39; BREY RN, 1978, BIOCHEM BIOPH RES CO, V83, P1588, DOI 10.1016/0006-291X(78)91403-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1992, IN PRESS ALKALI CATI; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Harold F. M., 1974, CURR TOP MEMBR TRANS, V5, P1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HIROTA N, 1981, FEBS LETT, V32, P278; ISHIKAWA T, 1987, J BIOL CHEM, V262, P7443; IVEY DM, 1991, J BIOL CHEM, V266, P23483; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KRULWICH TA, 1986, J MEMBRANE BIOL, V89, P113, DOI 10.1007/BF01869707; LANYI JK, 1979, BIOCHIM BIOPHYS ACTA, V559, P377, DOI 10.1016/0304-4157(79)90011-X; LeBlanc G, 1988, NA PLUS H PLUS EXCHA, p[103, Na+/H+exchange]; MACDONALD RE, 1977, P NATL ACAD SCI USA, V74, P3167, DOI 10.1073/pnas.74.8.3167; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MARCUS M, 1967, J BACTERIOL, V93, P1409, DOI 10.1128/JB.93.4.1409-1415.1967; Miller J.H., 1972, EXPT MOL GENETICS; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PADAN E, 1992, IN PRESS ALKALI CATI; PINNER E, 1992, ARCH MICROBIOL, V157, P323, DOI 10.1007/BF00248676; PINNER E, 1992, J BIOL CHEM, V267, P11064; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; SCHULDINER S, 1992, IN PRESS ALKALI CATI; SKULACHEV VP, 1987, ION TRANSPORT PROKAR, P131; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, IN PRESS J BIOL CHEM; THELEN P, 1991, J BACTERIOL, V173, P6553, DOI 10.1128/jb.173.20.6553-6557.1991; TOKUDA H, 1992, IN PRESS ALKALI CATI; UNEMOTO T, 1990, BACTERIAL ENERGETICS; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	48	162	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1729	1734						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8093613				2022-12-25	WOS:A1993KH62000036
J	BLOBE, GC; SACHS, CW; KHAN, WA; FABBRO, D; STABEL, S; WETSEL, WC; OBEID, LM; FINE, RL; HANNUN, YA				BLOBE, GC; SACHS, CW; KHAN, WA; FABBRO, D; STABEL, S; WETSEL, WC; OBEID, LM; FINE, RL; HANNUN, YA			SELECTIVE REGULATION OF EXPRESSION OF PROTEIN-KINASE-C (PKC) ISOENZYMES IN MULTIDRUG-RESISTANT MCF-7 CELLS - FUNCTIONAL-SIGNIFICANCE OF ENHANCED EXPRESSION OF PKC-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; PHORBOL ESTERS; LEUKEMIA-CELLS; ADRIAMYCIN; PHOSPHORYLATION; FORMS; RNA	The multidrug resistance (MDR) phenotype induces cross-resistance to many chemotherapeutic agents in cancer cells. Protein kinase C (PKC) has been implicated in the regulation of the MDR phenotype. In order to determine the role of specific PKC isoenzymes in regulating the MDR phenotype, the expression and activity of PKC isoenzymes in the human breast cancer cell line, MCF-7-WT, and an MDR subline, MCF-7-MDR, were examined. The MDR phenotype was associated with a 10-fold increase in calcium-dependent PKC activity as well as a 10-fold decrease in calcium-independent activity. The increase in calcium-dependent activity was due to a selective increase in the expression of PKC alpha as determined by Western blot analysis and hydroxylapatite chromatography. This increase in expression of PKC alpha was regulated at the message level as demonstrated by Northern blot analysis. The decrease in calcium-independent activity was caused by a decrease in the expression of PKC delta and epsilon. The significance of the increase in PKC alpha expression was then demonstrated by a commensurate 11-fold increase in the basal and stimulated phosphorylation of the myristolated alanine-rich C kinase substrate. Phosphorylation of P-glycoprotein, the cellular mediator of the MDR phenotype, was increased >20-fold in the unstimulated MCF-7-MDR cell line and its phosphorylation was further increased 2-fold in response to phorbol 12-myristate 13-acetate. These changes paralleled the increases in P-glycoprotein pump function and the MDR phenotype underscoring the role for PKC alpha in regulating P-glycoprotein phosphorylation and function.	MAX PLANCK GESELL, MAX DELBRUCK LAB, W-5000 COLOGNE 30, GERMANY; NIEHS, MOLEC & INTEGRATED NEUROSCI LAB, RES TRIANGLE PK, NC 27709 USA; DUKE UNIV, DIV HEMATOL ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, DIV GERIATR, DURHAM, NC 27710 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, DEPT CELL BIOL, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27705 USA; CIBA GEIGY AG, DIV PHARMACEUT, DEPT RES, CH-4002 BASEL, SWITZERLAND	Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Novartis			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [U01CA046738] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NCI NIH HHS [5U01-CA-46738] Funding Source: Medline; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCANTARA O, 1991, BLOOD, V77, P1290; AQUINO A, 1990, BIOCHEM BIOPH RES CO, V166, P723, DOI 10.1016/0006-291X(90)90869-O; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; GOLLAPUDI S, 1992, CANCER LETT, V62, P69, DOI 10.1016/0304-3835(92)90200-F; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; HAMADA H, 1987, CANCER RES, V47, P2860; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MA LD, 1991, J BIOL CHEM, V266, P5593; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OBRIAN CA, 1991, BIOCHEM PHARMACOL, V41, P797, DOI 10.1016/0006-2952(91)90083-H; PALAYOOR ST, 1987, BIOCHEM BIOPH RES CO, V148, P718, DOI 10.1016/0006-291X(87)90935-1; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; POSADA J, 1989, CANCER RES, V49, P6634; Posada J A, 1989, Cancer Commun, V1, P285; SCHWARTZ GK, 1991, CANCER RES, V51, P55; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1992, IN PRESS METHODS NEU; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	29	178	183	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					658	664						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093247				2022-12-25	WOS:A1993KE60300099
J	PARK, EA; GURNEY, AL; NIZIELSKI, SE; HAKIMI, P; CAO, Z; MOORMAN, A; HANSON, RW				PARK, EA; GURNEY, AL; NIZIELSKI, SE; HAKIMI, P; CAO, Z; MOORMAN, A; HANSON, RW			RELATIVE ROLES OF CCAAT/ENHANCER-BINDING PROTEIN-BETA AND CAMP REGULATORY ELEMENT-BINDING PROTEIN IN CONTROLLING TRANSCRIPTION OF THE GENE FOR PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; GROWTH-HORMONE GENE; RAT-LIVER LOBULUS; NUCLEAR-PROTEIN; MESSENGER-RNA; RESPONSIVE ELEMENTS; THYROID-HORMONE; TRANSGENIC MICE; C/EBP FAMILY; PROMOTER	The gene for phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) is expressed in a tissue-specific manner in the liver, kidney, and adipose tissue and is regulated by hormones including cAMP and insulin. Previous studies have shown that the CCAAT/enhancer-binding protein alpha (C/EBPalpha) binds to several sites on the PEPCK promoter and activates transcription from the promoter in hepatoma cells. Here, we report that a second member of the C/EBP family, C/EBPbeta, bound to the same sites on the PEPCK promoter. However, C/EBPbeta stimulated transcription primarily through the cAMP-responsive element (CRE), which maps between positions -77 to -94, but not at the more 5'-binding sites. In addition, the nuclear factor-1 site, which is immediately adjacent to the CRE in the PEPCK promoter, was also required for the full response of the promoter to cotransfected C/EBPbeta. In gel mobility assays, antibodies to both C/EBPbeta and the cAMP regulatory element-binding protein (CREB), but not to C/EBPalpha, ''supershifted'' DNA-protein complexes formed between a synthetic CRE oligomer and proteins prepared from rat liver nuclei. C/EBPbeta mRNA was expressed at low levels in both the periportal and pericentral regions of the liver lobule, whereas expression of the gene for C/EBPalpha was confined to the pericentral region of the liver lobule. PEPCK gene transcription is greatest in the periportal region of the liver. CREB also bound to the CRE and stimulated transcription of a PEPCK-CAT vector in the presence of an expression vector for the catalytic subunit of protein kinase A. C/EBPbeta and CREB bound to the CRE with similar affinities, both of which were greater than the affinity of C/EBPalpha. Within 90 min after the administration of dibutyryl cAMP to rats, there was a marked increase in the hepatic concentration of C/EBPbeta mRNA and a decrease in the level of mRNA for C/EBPalpha. These studies indicate that C/EBPbeta can regulate PEPCK gene transcription by acting through the CRE and that C/EBPbeta, together with CREB, may contribute to the cAMP responsiveness of the PEPCK promoter.	CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210; UNIV AMSTERDAM,ANAT & EMBRYOL LAB,AMSTERDAM,NETHERLANDS	Carnegie Institution for Science; HRL Laboratories; University of Amsterdam	PARK, EA (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.		Hakimi, Parvin/AAB-1643-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07319, DK-24451, DK-21859] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V181, P367, DOI 10.1016/S0006-291X(05)81428-7; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHU DTW, 1986, J BIOL CHEM, V261, P6848; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIEBELHAUS DH, 1985, DEV BIOL, V107, P407, DOI 10.1016/0012-1606(85)90322-7; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MOORMAN AFM, 1988, J HISTOCHEM CYTOCHEM, V36, P751, DOI 10.1177/36.7.2898495; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895	44	181	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					613	619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093246				2022-12-25	WOS:A1993KE60300092
J	SINGH, N; MANISCALCO, SJ; FISHER, HF				SINGH, N; MANISCALCO, SJ; FISHER, HF			THE REAL-TIME RESOLUTION OF PROTON-RELATED TRANSIENT-STATE STEPS IN AN ENZYMATIC-REACTION - THE EARLY STEPS IN THE OXIDATIVE DEAMINATION REACTION OF BOVINE LIVER GLUTAMATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETICS	We introduce a novel transient-state kinetic approach which can resolve proton and product time courses into a series of individual steps that comprise the reaction path. We have applied this approach to the oxidative deamination reaction catalyzed by bovine liver glutamate dehydrogenase, measuring both the product (NADPH) and proton time courses at various pH values. The global treatment (over all pH values) resolves the very early portion of this reaction quantitatively and provides a continuous time course for each of the six protonic species. We propose the following mechanism: L-glutamate binds to an open conformation of the enzyme-NADP complex, forming salt bridges between its alpha- and gamma-carboxyl groups and the protonated forms of enzyme lysine residues 114 and 90, respectively. In this position, the alpha-H atom of the substrate is too far from the nicotinamide ring for hydride transfer to occur. In the next step, three events occur in a concerted manner: lysine 126 loses a proton and acquires a single water molecule; the active site cleft closes; bulk water is expelled; the substrate and coenzyme are forced closer together and remain in a nonaqueous environment during the ensuing chemical events, returning to an open conformation only in time to allow the product release steps to occur. Thus, substrate binding accomplishes a number of important tasks which are themselves an integral part of the catalytic mechanism. Combining the novel transient state approach developed here with steady-state kinetic information can produce a detailed mechanistic resolution of otherwise hidden steps.	UNIV KANSAS,MED CTR,SCH MED,DEPT BIOCHEM,MOLEC BIOCHEM LAB,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center	SINGH, N (corresponding author), VET AFFAIRS MED CTR,4801 LINWOOD BLVD,KANSAS CITY,MO 64128, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047108] Funding Source: NIH RePORTER; NCRR NIH HHS [S07 RR 05373] Funding Source: Medline; NIGMS NIH HHS [GM-47108, GM-15188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BROWN A, 1973, BIOCHEMISTRY-US, V12, P4367, DOI 10.1021/bi00746a011; COLEN AH, 1977, BIOCHIM BIOPHYS ACTA, V481, P377, DOI 10.1016/0005-2744(77)90271-6; COLEN AH, 1975, J BIOL CHEM, V250, P5243; DIFRANCO A, 1972, EUR J BIOCHEM, V30, P517; EKLUND H, 1987, PYRIDINE NUCLEOTIDE, V2, P51; FISHER HF, 1988, J BIOL CHEM, V263, P11704; FISHER HF, 1981, NATURE, V292, P271, DOI 10.1038/292271a0; FISHER HF, 1970, BIOCHEM BIOPH RES CO, V41, P601, DOI 10.1016/0006-291X(70)90055-0; FISHER HF, 1992, BIOCHIM BIOPHYS ACTA, V1119, P52, DOI 10.1016/0167-4838(92)90233-4; FISHER HF, 1991, FEBS LETT, V294, P1, DOI 10.1016/0014-5793(91)81329-7; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; FISKIN AM, 1971, BIOCHEMISTRY-US, V10, P2396, DOI 10.1021/bi00788a034; IWATSUBO M, 1967, B SOC CHIM BIOL, V49, P1563; LILLEY KS, 1988, BIOCHEM SOC T, V16, P875, DOI 10.1042/bst0160875; MOORE JW, 1981, KINETICS MECHANISM, P296; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4538, DOI 10.1021/bi00800a030; RICE DW, 1987, BIOCHEM J, V242, P789, DOI 10.1042/bj2420789; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SMITH EL, 1975, ENZYMES, V11, P350; SRINIVASAN R, 1985, BIOCHEMISTRY-US, V24, P618, DOI 10.1021/bi00324a012	21	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					21	28						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8093240				2022-12-25	WOS:A1993KE60300006
